
<html lang="en"     class="pb-page"  data-request-id="4df14cf1-db6f-4d7c-ac31-cbfe152d0b7e"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2021.64.issue-12;pageGroup:string:Publication Pages;article:article:10.1021/acs.jmedchem.1c00100;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy" /></meta><meta name="dc.Creator" content="Wen  Shuai" /></meta><meta name="dc.Creator" content="Guan  Wang" /></meta><meta name="dc.Creator" content="Yiwen  Zhang" /></meta><meta name="dc.Creator" content="Faqian  Bu" /></meta><meta name="dc.Creator" content="Sicheng  Zhang" /></meta><meta name="dc.Creator" content="Duane D.  Miller" /></meta><meta name="dc.Creator" content="Wei  Li" /></meta><meta name="dc.Creator" content="Liang  Ouyang" /></meta><meta name="dc.Creator" content="Yuxi  Wang" /></meta><meta name="dc.Description" content="Microtubules play a crucial role in multiple cellular functions including mitosis, cell signaling, and organelle trafficking, which makes the microtubule an important target for cancer therapy. Des..." /></meta><meta name="Description" content="Microtubules play a crucial role in multiple cellular functions including mitosis, cell signaling, and organelle trafficking, which makes the microtubule an important target for cancer therapy. Des..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 8, 2021" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00100" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00100" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00100" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00100" /></link>
        
    
    

<title>Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00100" /></meta><meta property="og:title" content="Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0018.jpeg" /></meta><meta property="og:description" content="Microtubules play a crucial role in multiple cellular functions including mitosis, cell signaling, and organelle trafficking, which makes the microtubule an important target for cancer therapy. Despite the great successes of microtubule-targeting agents in the clinic, the development of drug resistance and dose-limiting toxicity restrict their clinical efficacy. In recent years, multitarget therapy has been considered an effective strategy to achieve higher therapeutic efficacy, in particular dual-target drugs. In terms of the synergetic effect of tubulin and other antitumor agents such as receptor tyrosine kinases inhibitors, histone deacetylases inhibitors, DNA-damaging agents, and topoisomerase inhibitors in combination therapy, designing dual-target tubulin inhibitors is regarded as a promising approach to overcome these limitations and improve therapeutic efficacy. In this Perspective, we discussed rational target combinations, design strategies, structure–activity relationships, and future directions of dual-target tubulin inhibitors." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00100"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00100">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00100&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00100&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00100&amp;href=/doi/10.1021/acs.jmedchem.1c00100" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 12</span><span class="cit-fg-pageRange">, 7963-7990</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/12" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c02265" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.1c00217" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Wen Shuai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wen Shuai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, Department of Respiratory and Critical Care Medicine, Innovation Center of Nursing Research, National Clinical Research Center for Geriatrics, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, Sichuan, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wen++Shuai">Wen Shuai</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Guan Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Guan Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, Department of Respiratory and Critical Care Medicine, Innovation Center of Nursing Research, National Clinical Research Center for Geriatrics, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, Sichuan, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Guan++Wang">Guan Wang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yiwen Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yiwen Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, Department of Respiratory and Critical Care Medicine, Innovation Center of Nursing Research, National Clinical Research Center for Geriatrics, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, Sichuan, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yiwen++Zhang">Yiwen Zhang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Faqian Bu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Faqian Bu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, Department of Respiratory and Critical Care Medicine, Innovation Center of Nursing Research, National Clinical Research Center for Geriatrics, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, Sichuan, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Faqian++Bu">Faqian Bu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sicheng Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sicheng Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sicheng++Zhang">Sicheng Zhang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0003-3798-7550" title="Orcid link">https://orcid.org/0000-0003-3798-7550</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Duane D. Miller</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Duane D. Miller</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Duane+D.++Miller">Duane D. Miller</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath6">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-6093-0985" title="Orcid link">https://orcid.org/0000-0002-6093-0985</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wei Li</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wei Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States</div></div><span class="conrtib-corresp"><strong>*</strong>(W.L.) Email: <a href="/cdn-cgi/l/email-protection#5c2b30351c2928342f3f72393829"><span class="__cf_email__" data-cfemail="88ffe4e1c8fdfce0fbeba6edecfd">[email protected]</span></a>. Phone: (+1) 901-448-7532.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Li">Wei Li</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath7">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-9522-4474" title="Orcid link">https://orcid.org/0000-0002-9522-4474</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Liang Ouyang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Liang Ouyang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, Department of Respiratory and Critical Care Medicine, Innovation Center of Nursing Research, National Clinical Research Center for Geriatrics, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, Sichuan, China</div></div><span class="conrtib-corresp"><strong>*</strong>(L.O.) Email: <a href="/cdn-cgi/l/email-protection#97f8e2eef6f9f0fbfef6f9f0d7e4f4e2b9f2f3e2b9f4f9"><span class="__cf_email__" data-cfemail="4d2238342c232a21242c232a0d3e2e3863282938632e23">[email protected]</span></a>. Phone: (+86) 159-8234-1940.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Liang++Ouyang">Liang Ouyang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath8">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-5537-8834" title="Orcid link">https://orcid.org/0000-0001-5537-8834</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Yuxi Wang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yuxi Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Biotherapy and Cancer Center, Department of Respiratory and Critical Care Medicine, Innovation Center of Nursing Research, National Clinical Research Center for Geriatrics, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, Sichuan, China</div><div class="loa-info-affiliations-info">Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China</div><div class="loa-info-affiliations-info">Precision Medicine Key Laboratory of Sichuan Province & Precision Medicine Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China</div></div><span class="conrtib-corresp"><strong>*</strong>(Y.W.) Email: <a href="/cdn-cgi/l/email-protection#6c151914051b0d020b2c1f0f1942090819420f02"><span class="__cf_email__" data-cfemail="fb828e83928c9a959cbb88988ed59e9f8ed59895">[email protected]</span></a>. Phone: (+86) 159-8234-1940.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yuxi++Wang">Yuxi Wang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath9">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-4056-5829" title="Orcid link">https://orcid.org/0000-0002-4056-5829</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00100&amp;href=/doi/10.1021%2Facs.jmedchem.1c00100" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 12</span><span class="cit-pageRange">, 7963–7990</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 8, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>19 January 2021</li><li><span class="item_label"><b>Published</b> online</span>8 June 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 June 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00100" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00100</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7963%26pageCount%3D28%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DWen%2BShuai%252C%2BGuan%2BWang%252C%2BYiwen%2BZhang%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D12%26contentID%3Dacs.jmedchem.1c00100%26title%3DRecent%2BProgress%2Bon%2BTubulin%2BInhibitors%2Bwith%2BDual%2BTargeting%2BCapabilities%2Bfor%2BCancer%2BTherapy%26numPages%3D28%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7990%26publicationDate%3DJune%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00100"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1086</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00100" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Wen&quot;,&quot;last_name&quot;:&quot;Shuai&quot;},{&quot;first_name&quot;:&quot;Guan&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Yiwen&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Faqian&quot;,&quot;last_name&quot;:&quot;Bu&quot;},{&quot;first_name&quot;:&quot;Sicheng&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Duane&quot;,&quot;last_name&quot;:&quot;D. Miller&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Liang&quot;,&quot;last_name&quot;:&quot;Ouyang&quot;},{&quot;first_name&quot;:&quot;Yuxi&quot;,&quot;last_name&quot;:&quot;Wang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;08&quot;,&quot;issue&quot;:&quot;12&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;7963-7990&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00100&quot;},&quot;abstract&quot;:&quot;Microtubules play a crucial role in multiple cellular functions including mitosis, cell signaling, and organelle trafficking, which makes the microtubule an important target for cancer therapy. Despite the great successes of microtubule-targeting agents in the clinic, the development of drug resistance and dose-limiting toxicity restrict their clinical efficacy. In recent years, multitarget therapy has been considered an effective strategy to achieve higher therapeutic efficacy, in particular dual-target drugs. In terms of the synergetic effect of tubulin and other antitumor agents such as receptor tyrosine kinases inhibitors, histone deacetylases inhibitors, DNA-damaging agents, and topoisomerase inhibitors in combination therapy, designing dual-target tubulin inhibitors is regarded as a promising approach to overcome these limitations and improve therapeutic efficacy. In this Perspective, we discussed rational target combinations, design strategies, structure–activity relationships, and future directions of&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00100&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00100" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00100&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00100" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00100&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00100" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00100&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00100&amp;href=/doi/10.1021/acs.jmedchem.1c00100" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00100" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00100" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (14 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00100%26sid%3Dliteratum%253Aachs%26pmid%3D34101463%26genre%3Darticle%26aulast%3DShuai%26date%3D2021%26atitle%3DRecent%2BProgress%2Bon%2BTubulin%2BInhibitors%2Bwith%2BDual%2BTargeting%2BCapabilities%2Bfor%2BCancer%2BTherapy%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D12%26spage%3D7963%26epage%3D7990%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/12" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/medium/jm1c00100_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Microtubules play a crucial role in multiple cellular functions including mitosis, cell signaling, and organelle trafficking, which makes the microtubule an important target for cancer therapy. Despite the great successes of microtubule-targeting agents in the clinic, the development of drug resistance and dose-limiting toxicity restrict their clinical efficacy. In recent years, multitarget therapy has been considered an effective strategy to achieve higher therapeutic efficacy, in particular dual-target drugs. In terms of the synergetic effect of tubulin and other antitumor agents such as receptor tyrosine kinases inhibitors, histone deacetylases inhibitors, DNA-damaging agents, and topoisomerase inhibitors in combination therapy, designing dual-target tubulin inhibitors is regarded as a promising approach to overcome these limitations and improve therapeutic efficacy. In this Perspective, we discussed rational target combinations, design strategies, structure–activity relationships, and future directions of dual-target tubulin inhibitors.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34415" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34415" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Microtubules, key components of cytoskeletons in eukaryotic cells, play essential roles in multiple cellular functions such as maintenance of cell morphology, signal transmission, organelle trafficking, cell motility, cell division, and mitosis.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Due to their involvement in these crucial cellular processes, microtubules have become one of the most important drug targets for cancer treatment. Microtubule-targeting agents (MTAs) can disrupt the dynamics and structure of the microtubule, further perturb mitotic spindle formation, arrest the cell cycle in the metaphase/anaphase of mitosis, and induce cell apoptotic death.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Currently, MTAs are one of the most frequently prescribed antitumor chemotherapeutic agents, with several U.S. FDA approved MTAs such as vinca alkaloids and taxanes widely used for the treatment of multiple solid tumors and hematological malignancies.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a></div><div class="NLM_p">However, despite the great successes in cancer treatment, the clinical application of MTAs is hampered by a number of major limitations. One of these limitations is the development of drug resistance.<a onclick="showRef(event, 'ref3 ref5'); return false;" href="javascript:void(0);" class="ref ref3 ref5">(3,5)</a> The main drug-resistant mechanisms related to MTAs are the aberrant expressions of β-tubulin isotypes (especially βIII-tubulin) and membrane-bound drug efflux proteins such as P-glycoprotein (P-gp), which decrease the response rate to MTAs in tumors.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Other important drug-resistant mechanisms include the altered interactions between microtubules and actins, and defects in apoptotic pathways.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Another major issue impeding the clinical success of MTAs is their side effects, such as a high rate of neurological and myeloid toxicity and an increased risk of secondary tumors.<a onclick="showRef(event, 'ref3 ref7'); return false;" href="javascript:void(0);" class="ref ref3 ref7">(3,7)</a> Therefore, extensive efforts are required to develop novel MTAs to circumvent these restrictions and to improve patient survival.</div><div class="NLM_p">In recent years, developing multitarget inhibitors, especially dual-target inhibitors with synergistic effects, has become a new trend in tumor treatment.<a onclick="showRef(event, 'ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10">(8−10)</a> Dual-target drugs are novel chemical entities that can interact with two different drug targets, generally have improved therapeutic efficacy, and have overcome drug resistance compared to single-target agents.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a> On the basis of these concepts, the development of dual-target tubulin inhibitors has attracted considerable interest in both academia and industry in the past decade.</div><div class="NLM_p last">Currently, accumulating evidence has demonstrated that the simultaneous inhibition of tubulin and receptor tyrosine kinases (RTKs), histone deacetylases (HDACs), estrogen receptors (ERs), or topoisomerases displayed superior antitumor activity via a single molecule compared to their parent compounds.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> In this Perspective, we have summarized the research advances of dual-target tubulin inhibitors, focusing on the rational targets selection and the design strategies and analyzing structure–activity relationships (SARs) and the biological activities of dual-target tubulin inhibitors. We hope that this Perspective can provide a summary of the status in the field of dual-target tubulin inhibitors along with potential pathways for further advances.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Microtubule as a Therapeutic Target</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70183" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70183" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2.1.  Structure and Dynamic of Microtubules</h3><div class="NLM_p">Microtubule is a crucial component of cell cytoskeleton in eukaryotes. It is a long, filamentous, cylindrical polymeric tube assembled from 13 parallel protofilaments.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Each protofilament is formed by αβ-tubulin heterodimers that align in a head-to-tail manner. The α- and β-tubulin subunits of microtubules possess a guanosine triphosphate (GTP)-binding region. The GTP bound to the α-tubulin subunit is nonhydrolyzable and non-exchangeable (referred to as the N site), while β-tubulin subunit can bind GTP and guanosine diphosphate (GDP) in a hydrolyzable and exchangeable fashion (referred to as the E site).<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> GTP bound to the E site stabilizes microtubules and promotes their aggregation, while GDP bound to the E site promotes microtubules’ depolymerization.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Microtubules have complex dynamic characteristics including dynamic instability (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) and treadmilling, which are driven by hydrolysis of GTP on the E site.<a onclick="showRef(event, 'ref1 ref17'); return false;" href="javascript:void(0);" class="ref ref1 ref17">(1,17)</a> Dynamic instability is the most characteristic dynamic behavior of microtubules, which is the transition between catastrophes and rescues. It consists of the rate of growth and shortening, and the frequencies of the transition between depolymerization and polymerization (referred to as “rescue”) and from polymerization to depolymerization (referred to as “catastrophe”).<a onclick="showRef(event, 'ref1 ref18'); return false;" href="javascript:void(0);" class="ref ref1 ref18">(1,18)</a> Another dynamic behavior is treadmilling, which is net growth at one end and balanced net shortening at the opposite end of the microtubule without an apparent change in microtubule length.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Collectively, the dynamic behaviors of a microtubule are of paramount importance to cellular biological functions and can be regulated by tubulin isotypes, post-translational modifications, and microtubule-associated proteins.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> By disrupting microtubule dynamics, MTAs can impair the spindle formation in mitosis and induce cell cycle arrest at the G2/M phase and cell apoptosis, which make it an important strategy for cancer treatment.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/medium/jm1c00100_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure and dynamic instability of the microtubule. The dynamic instability of the microtubule is driven by the hydrolysis of GTP on β-tubulin subunits, which enable the microtubule to switch between catastrophe and rescue (α-tubulin, wheat color; β-tubulin, blue).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">On the basis of the effects on microtubule mass at a high concentration, MTAs can be classified as microtubule-stabilizing agents (MSAs) and microtubule-destabilizing agents (MDAs).<a onclick="showRef(event, 'ref3 ref21'); return false;" href="javascript:void(0);" class="ref ref3 ref21">(3,21)</a> MSAs promote tubulin polymerization and MDAs inhibit the polymerization. There are six MTA-binding sites on tubulin, five of which reside on β-tubulin. The pironetin site is the only known site located on α-tubulin (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> MTAs binding to the taxane and laulimalide sites belong to MSAs, and MTAs binding to the vinca, colchicine, maytansine, and pironetin sites are MDAs. Currently, several taxane- and vinca-site inhibitors are approved by the FDA for treatment of multiple cancers.<a onclick="showRef(event, 'ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24">(22−24)</a> Meanwhile, several colchicine-site agents have been evaluated as vascular-disrupting agents (VDAs) in clinical trials for cancer therapy. Compared to other inhibitors, colchicine-site inhibitors are not substrates of P-gp or affected by the overexpression of βIII-tubulin. In addition, they can target tumor vasculatures and disrupt the existing blood vessels.<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25,26)</a> Despite achieving great successes in the clinic, the clinical efficacy of MTAs is limited by the development of drug resistance, dose-limiting toxicity, and poor water solubility. Therefore, developing novel therapeutic strategies that can overcome those limitations is highly significant.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/medium/jm1c00100_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Six binding sites of microtubule-target agents on tubulin (α-tubulin, wheat; β-tubulin, blue).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">2.2.  Synergetic Effects of MTAs and Other Antitumor Agents</h3><div class="NLM_p">The antitumor effects of MTAs combining with other antitumor agents have been extensively explored in the clinic and phenotypic screening. It has been demonstrated that the combination of RTK inhibitors and MTAs showed remarkable clinical perspective. For example, the combination therapy of dual epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor-2 (HER-2) inhibitor Iapatinib and Taxol significantly improved the clinical benefit and objective response rate of HER-2-positive breast cancer patients in phase III clinical trial (NCT00075270).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Similarly, the synergetic effects of paclitaxel and bevacizumab, targeting the VEGF–VEGFR (vascular endothelial growth factor receptor) signaling pathway, were also reported. Interestingly, paclitaxel concentrations in tumor tissue were lower after bevacizumab treatment; however, paclitaxel distributed more homogeneously and was cleared more slowly compared to controls.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> This study suggested that the synergetic effects of the drug combination are not only due to the efficient addition of multiple drugs but also a more favorable distribution of the chemotherapy drugs in tumor tissues.</div><div class="NLM_p">HDACs are crucial epigenetic targets in cancer treatment.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Many studies reported the synergetic effects of HDAC inhibitors combining with MTAs. In 2015, Chao et al. reported the therapeutic effects of combining vincristine and vorinostat (a pan-HDAC inhibitor) in human acute T cell lymphoblastic leukemia cells.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> The results indicated that the combination treatment of vincristine and vorinostat significantly enhanced the vincristine-induced cell death both in vitro and in vivo. Likewise, the combination of HDAC inhibitors and paclitaxel also showed synergetic effects.<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31,32)</a></div><div class="NLM_p">Due to different mechanisms of action, the combination of MTAs and DNA-damaging agents is a frequently used antitumor strategy in the clinic. The cotreatment using a platinum antitumor agent and paclitaxel showed synergetic effects,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> and this combination was established as standard first-line chemotherapy for advanced epithelial ovarian cancer. The synergetic antitumor effects of MTAs and immune checkpoint inhibitors have also been demonstrated. Currently, a combination of pembrolizumab with carboplatin and either paclitaxel or nab-paclitaxel has been approved as the first-line treatment of metastatic squamous non-small-cell lung cancer (NSCLC).<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34,35)</a></div><div class="NLM_p last">In summary, these studies demonstrated that the combination therapy based on MTAs exhibited significant therapeutic superiority. They not only improve antitumor efficacy but also overcome drug resistance, which is a crucial issue for clinical application of MTAs. However, there are some potential drawbacks in drug combination therapies caused by administrations of multiple drugs, such as complex PK profiles and administration dosage regimen, drug–drug interactions, and poor patient compliance.<a onclick="showRef(event, 'ref12 ref36'); return false;" href="javascript:void(0);" class="ref ref12 ref36">(12,36)</a> Therefore, their applications in clinical trials are often limited. Encouragingly, the knowledge of synergetic therapeutic effectiveness of these drug combinations by clinical observations and phenotype screenings promoted the rational combinations of multiple targets for developing dual-target tubulin inhibitors.<a onclick="showRef(event, 'ref37 ref38 ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref37 ref38 ref39 ref40">(37−40)</a></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6">2.3.  Design Strategies of Dual-Target Tubulin Inhibitors</h3><div class="NLM_p">Many research groups have developed multitarget therapeutic strategies, especially dual-target approaches, to address the drawbacks of single-target agents and drug combination therapy. Dual-target drugs not only retain the advantages of combination therapy but also circumvent the limitations of combination therapy. For example, dual-target drugs should have no or lower risks of drug–drug interactions due to one integrated molecule, compared to multiple drugs of combination therapy. Likewise, reducing polypharmacy leads to lower adverse reactions. And simplifying dosage regimens optimizes patient compliance.<a onclick="showRef(event, 'ref10 ref41'); return false;" href="javascript:void(0);" class="ref ref10 ref41">(10,41)</a> Another advantage for dual-target drugs is that they may possess more easily predictable PK profiles compared to multiple drugs used in combination therapy.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Additionally, the development of target-based resistance of dual-target drugs is statistically lower than that of single-target drugs. Dual-target drugs also can overcome compensatory mechanisms which may limit the efficacy of single-target drugs.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Moreover, the development of a dual-target drug may require fewer clinical trials than the combination therapy and have a similar cost and risk to those of a single-target agent.<a onclick="showRef(event, 'ref11 ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref11 ref44 ref45">(11,44,45)</a></div><div class="NLM_p">Rational target combinations are key to clinical successes of dual-target drugs, which may provide synergetic therapeutic efficacy. Designing dual-target drugs for highly related targets is generally easier.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Tubulin is functionally related to many important proteins that are also considered as antitumor targets, such as angiokinases (such as VEGFR), HDAC, katanin, and heat shock protein 90 (Hsp90). The connections of tubulin and these targets have been determined in a variety of studies<a onclick="showRef(event, 'ref12 ref47 ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref12 ref47 ref48 ref49">(12,47−49)</a> which revealed that they can regulate the functions of tubulin. On the basis of functional connections in signaling pathways, it is suggested that their combinations may produce promising synergy. Other important antitumor targets that have no obvious connections to tubulin but show synergetic combination therapy in clinical observations and phenotypic screenings, such as topoisomerases, DNA damaging, and tryptophan-2,3-dioxygenase (TDO)/indoleamine-2,3-dioxygenase (IDO), are also useful cotargets for the design of dual-target tubulin inhibitors. Likewise, the concepts of synthetic lethality, compensatory mechanisms, reverse drug resistance, and interaction networks between proteins also rationalize the target combinations.<a onclick="showRef(event, 'ref43 ref50'); return false;" href="javascript:void(0);" class="ref ref43 ref50">(43,50)</a></div><div class="NLM_p">On the basis of the synergetic effects of dual-target drugs, the development of dual-target tubulin drugs attracted interest from many research groups. Since the design of dual-target drugs is more complicated than that of single-target agents, increased efforts have been made to develop them via diverse strategies. There are generally three design approaches, including drug repurposing, pharmacophore-based combination, and computational approaches.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Drug repurposing is the application of known drugs to new therapeutic areas.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Compared to the traditional drug discovery approaches, drug repurposing is less expensive and has shorter development processes. Many dual-target tubulin inhibitors, especially dual tubulin–kinases inhibitors,<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> were identified through this approach. This suggests that there could be structural similarities between the binding pockets of tubulin and other antitumor targets. The pharmacophore-based approach is also a predominant method for developing dual-target tubulin inhibitors, which can integrate the activities of multiple selective inhibitors into a single molecule.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> This strategy combines main pharmacophores of selected parent inhibitors via linking or merging. The pharmacophore-linked approach is a straightforward strategy by connecting two molecules directly via an appropriate linker. This strategy is easy to perform for designing more potent dual-target inhibitors in the absence of a common pharmacophore between two active molecules. However, the pharmacophore-linked molecules possess a large molecular weight (MW) with potential unfavorable bioavailability and physicochemical properties.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Sometimes, linkers may interfere with the interactions between targets and ligands. Unlike the pharmacophore-linked approach, the pharmacophore-merged approach maximizes the overlapping level of pharmacophores, which is similar to a hybrid design. It requires active molecules to share similar pharmacophores. This strategy leads to smaller MW and simpler chemical structures with better physicochemical properties, which are favorable for further optimization.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> However, certain structural changes in the parent active molecules may result in altered biological activities. Therefore, it is critical to accurately determine the common pharmacophores of both tubulin and other targets for designing viable dual-target tubulin agents.</div><div class="NLM_p last">The application of drug repurposing and pharmacophore-based approaches is based on reported small molecules, which restrict the structural diversity of dual-target tubulin inhibitors. Encouragingly, computational approaches have been applied successfully to accelerate the discovery of dual-target drugs, especially for new targets without reported inhibitors. These approaches are generally classified as ligand-based and structure-based methods, which mainly rely on the availability of target structural information.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> In the discovery of multitarget drugs, computational approaches can predict the new targets of known ligands and identify or optimize new ligands for desired multiple targets. Currently, several studies have reported that these approaches facilitate the development of dual-target tubulin inhibitors with novel scaffolds via docking, pharmacophore studies, and pocket similarity searches.<a onclick="showRef(event, 'ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref55 ref56">(55,56)</a> This strategy enlarges the structural diversity of dual-target tubulin inhibitors. Overall, on the basis of the combination of pharmacophore-based and computational strategies, many dual-target tubulin inhibitors have been identified and showed improved antitumor effects.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">3.  Dual Inhibitors of Tubulin and Other Tumor-Related Targets</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50078" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50078" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">3.1.  Dual Tubulin–RTKs Inhibitors</h3><div class="NLM_p">The combination therapy of MTAs and RTKs (such as VEGFR2, EGFR) inhibitors has shown promising effects for the treatment of various cancer types in clinical trials, including head and neck cancer (NCT00720304 and NCT00049283), hepatocellular carcinoma cancer (NCT00532441 and NCT00553358), breast cancer (NCT01050322 and NCT00367471), and lung cancer (NCT01405079). Accordingly, inspired by the results of combination therapy and the advantages of dual-target drugs strategy, several tubulin–RTK dual inhibitors have been identified.</div><div class="NLM_p">In 2014, Gangjee et al.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> discovered a series of dual VEGFR2–tubulin inhibitors by incorporating the 7-benzyl group of RTK inhibitor <b>2</b> into the pyrrolo[3,2-<i>d</i>]pyrimidine scaffold of tubulin inhibitor <b>1</b> via hybrid design (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A). Among them, compound <b>3</b>·HCl (hydrochloride salt form) displayed potent tubulin polymerization and VEGFR2 inhibitory activities with IC<sub>50</sub> values of 21 μM and 21.3 nM, respectively. 7-Benzyl group is critical for the maintenance of VEGFR2 inhibitory activity, and 4-NCH<sub>3</sub> and 4′-OCH<sub>3</sub> are essential for microtubule and VEGFR2 inhibitory effects. Chicken chorioallantoic membrane analysis indicated that compound <b>3</b>·HCl showed an angiogenesis inhibitory effect (IC<sub>50</sub> = 2.9 μM). Moreover, compound <b>3</b>·HCl showed significant antiproliferative activities against βIII-tubulin-overexpressing HeLa cells and P-gp-overexpressing ADR-RES cells with IC<sub>50</sub> values of 280 and 700 nM, respectively, which indicated that compound <b>3</b>·HCl can circumvent βIII-tubulin- and P-gp-overexpression mediated drug resistance. In MDA-MB-435 and U251 xenograft models and a 4T1 orthotopic breast model, compound <b>3</b>·HCl can significantly inhibit primary tumor growth, reduce tumor vascular density, and suppress lung metastases.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/medium/jm1c00100_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Design and SAR analysis of dual tubulin–RTK inhibitors <b>3</b>, <b>4</b>, <b>7</b>, and <b>8</b>. (A) Design and SAR summaries of dual tubulin–RTK inhibitors based on compounds <b>1</b> and <b>2</b>; (B) design and SAR summaries of dual tubulin–RTK inhibitors based on compounds <b>5</b> and <b>6</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Because multiple angiokinases are coactivated in tumors and redundant inputs trigger the downstream signaling pathway, targeting a single angiokinase is unlikely sufficient for effective tumor treatments. Hence, targeting multiple main angiokinases (such as EGFR, VEGFR, and PDGFR) may be a more effective approach. Accordingly, Gangjee et al.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> further investigated the effects of conformational changes on compound <b>3</b> to develop new molecules that can simultaneously target multiple angiokinases and microtubule (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A). Compound <b>4</b> was 44-fold more potent for inhibition of tubulin polymerization (IC<sub>50</sub> = 0.48 μM) than compound <b>3</b> and significantly inhibited VEGFR, EGFR, and PDGFR-β with IC<sub>50</sub> values of 33, 2.3, and 10.3 nM, respectively. Compound <b>4</b> also showed improved antiproliferative activity against βIII- and P-gp-overexpressing cancer cell lines with IC<sub>50</sub> values of 250 and 70 nM, respectively. The N4- and N5-CH<sub>3</sub> groups are crucial for tubulin polymerization inhibition. The N5-CH<sub>3</sub> group can restrict rotation around the <i>N</i>-phenyl bond, thus providing further conformational rigidity with increased potency. However, further conformational restriction of compound <b>4</b> by incorporation of a tetrahydroquinoline or dihydroindole ring to the 4-position of the head moiety abolished the tubulin inhibitory activity. The replacement of the 2-methyl group with a 2-amino moiety reduced tubulin polymerization inhibitory effects.</div><div class="NLM_p">In another report, Gangjee et al.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> tried to integrate tubulin inhibitory activity of compound <b>5</b> into the existing RTK inhibitor <b>6</b> to obtain tubulin–RTK multiple-target inhibitors (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B). They replaced the 5-substituent in compound <b>5</b> with the 4-NH moiety in compound <b>6</b> and introduced a 6-CH<sub>3</sub> group to compound <b>5</b> to obtain a hybrid furo[2,3-<i>d</i>]pyrimidine scaffold. Among the 2-substitution derivatives, compound <b>7</b> with a 2-methyl group showed significant inhibitory activities against EGFR, VEGFR2, and PDGFR-β with IC<sub>50</sub> values of 68.2, 19.1, and 22.8 nM, respectively. Moreover, compound <b>7</b> inhibited tubulin assembly with an IC<sub>50</sub> value of 1.9 μM. SARs indicated that the <i>N</i>-alkyl group was favorable for the microtubule polymerization inhibition and antiproliferative activity. Compound <b>7</b> can effectively inhibit the growth of βIII- and P-gp-overexpressing cancer cells and reduce in vivo tumor growth and tumor vascularity density, which is more potent than docetaxel. To further improve the antiproliferative activities and explore the biologically active conformation of compound <b>7</b>, this research group synthesized compound <b>8</b> by incorporating N–CH<sub>3</sub> of compound <b>7</b> into a fused bicyclic ring system using a conformational restriction strategy<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B). Compound <b>8</b> displayed improved inhibitory activities against tubulin polymerization (IC<sub>50</sub> = 1.1 μM) and EGFR (IC<sub>50</sub> = 3.4 nM) compared to compound <b>7</b>. However, it also showed slightly reduced VEGFR2 (IC<sub>50</sub> = 33.2 nM) and PDGFR-β (IC<sub>50</sub> = 58.2 nM) inhibition. The tetrahydroquinoline ring system is significantly favorable for EGFR inhibition. Moreover, compound <b>8</b> showed significantly improved cytotoxicity against drug-resistant HeLa and SK-OV-3 cancer cells with IC<sub>50</sub> values of 9.1 and 19.4 nM, respectively.</div><div class="NLM_p">In 2019, Romagnoli et al.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> replaced the 5-aminoindole side chain at the C-4 position of VEGFR2–EGFR dual inhibitor <b>9</b> with the 3,4,5-trimethoxyanilino moiety of tubulin inhibitors <b>10</b> to furnish a series of novel derivatives with thieno[3,2-<i>d</i>]pyrimidine scaffold via a pharmacophore-merged approach (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A). Among them, compound <b>11</b> displayed remarkable tubulin polymerization (IC<sub>50</sub> = 0.71 μM) and EGFR (IC<sub>50</sub> = 30 nM) inhibitory activities but lost the potency toward VEGFR2. It strongly inhibited the phosphorylation of EGFR in a dose-dependent manner in HeLa cells. Compound <b>11</b> exerted powerful antiproliferative activity against a variety of cancer cell lines (IC<sub>50</sub> = 1–20 nM). SAR studies revealed that thieno[3,2-<i>d</i>]pyrimidine scaffold is essential for the antiproliferative effects. Moreover, introducing a CH<sub>3</sub> group to the para-position of the phenyl ring, which is directly linked to the thieno[3, 2-d]pyrimidine core, can improve the biological activities. Replacement of the CH<sub>3</sub> group with halide groups (Cl, Br, and I) or OCH<sub>3</sub> group is also tolerant. Compound <b>11</b> displayed potent in vitro antivascular activity and more potent in vivo antitumor effects than combretastatin A-4 (CA-4) phosphate, with a tumor growth inhibition value of 52.5% at a dose of 7.5 mg/kg.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/medium/jm1c00100_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Design and SAR analysis of dual tubulin–RTK inhibitors <b>11</b>, <b>14</b>, <b>16</b>, and <b>17</b>. (A) Design and SAR summary of dual tubulin–RTK inhibitor <b>11</b>; (B) chemical structure of DW532 (<b>14</b>); (C) chemical structure and modification process of dual tubulin–VEGFR inhibitor <b>16</b>; (D) chemical structure of dual tubulin–EGFR inhibitor <b>17</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Hematoxylin (<b>12</b>), a natural product, displayed the broad-spectrum inhibitory activity of tyrosine kinases and antitumor activities in vitro.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> To target simultaneously microtubule and kinases and decrease the complexity of hematoxylin, Peng et al.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> discovered multiple tyrosine kinases–tubulin inhibitor DW532 (<b>14</b>) on the basis of the structures of hematoxylin and tubulin polymerization inhibitor CA-4 (<b>13</b>) (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B). DW532 can moderately inhibit EGFR (IC<sub>50</sub> = 4.9 μM) and VEGFR2 (IC<sub>50</sub> = 5.5 μM) kinase activities, the ligand-induced phosphorylation of EGFR and VEGFR, and their downstream signaling in A431 human epithelial cancer cells and human umbilical vein endothelial cells. Additionally, DW532 inhibited tubulin polymerization in a dose-dependent manner in vitro and disrupt microtubule networks by destabilizing the microtubule at 10 μM in A549 cancer cells. DW532-induced cell cycle arrest in the G2/M phase and cell apoptotic death, and suppressed angiogenesis in vitro and in vivo.</div><div class="NLM_p">Chekler et al.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> identified a tubulin–VEGFR2 dual inhibitor <b>16</b> with 1,3,4-oxadiazole moiety using weak VEGFR2 dual inhibitor <b>15</b> with triazole moiety as the lead (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C). Compound <b>16</b> exhibited significant inhibitory effects on VEGFR2 and tubulin polymerization with IC<sub>50</sub> values of 0.21 and 1.09 μM, respectively, superior to compound <b>15</b> (VEGFR2, IC<sub>50</sub> = 2.3 μM; tubulin polymerization inhibition, IC<sub>50</sub> > 10 μM). Compound <b>16</b> blocked the cell cycle at G2/M phase due to tubulin polymerization inhibition. It was demonstrated that compound <b>16</b> exhibited no neuropathy or white blood cell depletion at a dose up to 100 mg/kg, and can effectively inhibit the tumor growth via oral administration in a breast cancer model.</div><div class="NLM_p last">Recently, Aouad et al.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> discovered an acyclonucleoside analog <b>17</b> with 1,2,4-triazole moiety (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>D). Compound <b>17</b> displayed similar EGFR inhibitory activity (IC<sub>50</sub> = 86.7 nM) to imatinib (the positive control compound) and moderately suppressed the tubulin polymerization (IC<sub>50</sub> = 10.7 μM). Compound <b>17</b> showed potent antiproliferative activity against multiple cancer cells.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">3.2.  Dual Tubulin–HDACs Inhibitors</h3><div class="NLM_p">HDACs can regulate chromatin remodeling and gene expression.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Targeting HDACs indirectly modulates the function of many targets in cancer therapies including α-tubulin in microtubule, p53, and Hsp90, which makes HDACs important targets in cancer therapy.<a onclick="showRef(event, 'ref47 ref67'); return false;" href="javascript:void(0);" class="ref ref47 ref67">(47,67)</a> Currently, several HDACs inhibitors have been approved by the FDA for the treatment of various cancers, such as vorinostat (SAHA),<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> belinostat,<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> and Panobinostat.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Generally, an HDAC inhibitor consists of a zinc-binding group (ZBG), an appropriate linker, and a capping group.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> HDAC inhibitors can tolerate various capping groups; hence, they often hybridize with other cancer-related target inhibitors for the development of dual-target drugs. Inspired by the synergetic effects of MTAs and HDAC inhibitors in combination therapy and interactions between proteins, many dual tubulin–HDAC inhibitors have been developed to overcome drug resistance and improve antitumor effects.</div><div class="NLM_p">Recently, Liou’s research group<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> used the sulfonamide moiety of ABT751 (<b>18</b>, an oral tubulin polymerization inhibitor) as the capping group, an ethylene linkage as the linker, and benzamide as ZBG to generate a series of dual tubulin–HDAC inhibitors (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, left panel). Compound <b>19</b> significantly inhibited the growth of KB cancer cells (IC<sub>50</sub> = 23 nM), which indicated sulfonamide group at the ortho-position of a stilbene linker and a benzamide as ZBG favor the antiproliferative activity. Removal or translocation or replacement of the methoxy group reduced biological activity. Introducing a nitrogen atom into the ethylene linker generated compound <b>20</b> which showed improved antiproliferative activity (KB cells, IC<sub>50</sub> = 12 nM). Moreover, compound <b>20</b> effectively inhibited HDAC (HDAC1, IC<sub>50</sub> = 1.07 μM; HDAC2, IC<sub>50</sub> = 1.47 μM) and induced changes in microtubule assembly at 0.05 μM. Compound <b>20</b> also exhibited remarkable cytotoxicity against vincristine- and etoposide-resistant KB cancer cells with IC<sub>50</sub> values of 12 and 22 nM, respectively. It triggered cell cycle arrest at the G2/M phase and disrupted microtubule dynamics.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/medium/jm1c00100_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Design and SAR analysis of dual tubulin–HDAC inhibitors with sulfonamide moiety as the capping group and benzamide moiety as ZBG.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2018, this research group fused 1-(arylsulfonyl)indolines scaffold with a benzamide group to obtain compound <b>21</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, right panel).<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> Compound <b>21</b> can significantly inhibit tubulin polymerization (IC<sub>50</sub> = 1.1 μM) and exerted potent inhibitory effects on HDAC1, -2, and -6 with IC<sub>50</sub> values of 0.221, 0.662, and 0.314 μM, respectively. Moreover, compound <b>21</b> upregulated acetylated α-tubulin in A549 cells. SAR studies indicated that the 4-methoxybenzenesulfonyl group is a prerequisite for good antiproliferative activity. The N-substituted benzyl moiety on the C-7 position of indoline and the benzamide group on the C-4 position were also favorable for the antiproliferative activity. The NH–CH<sub>2</sub> linker on the C-7 position was optimal for biological activities. Moreover, the indoline group was favored over the indole group. Compound <b>21</b> showed effective antiproliferative activity toward MDR-positive cell lines with IC<sub>50</sub> values of 64 nM (KB-VIN10), 43 nM (KB-S15), and 46 nM (KB-7D), respectively. In A549 and BJAB tumor xenograft models, compound <b>21</b> showed potent tumor inhibitory activities.</div><div class="NLM_p">Additionally, this research group utilized BPR0L075 (a tubulin polymerization inhibitor) as the capping group and a hydroxamic acid as ZBG to obtain tubulin–HDAC dual inhibitor <b>22</b><a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A). Compound <b>22</b> showed specific inhibition of HDAC6 (IC<sub>50</sub> = 64.5 nM). It also increased the level of acetylated α-tubulin and acetylated histone H3 in PC3 cells and inhibited tubulin polymerization in a dose-dependent manner. The hydroxamic acid moiety on the N1 position is key for the biological activities. Removal of the 6-OCH<sub>3</sub> group or replacement of the 3,4,5-trimethoxybenzoyl moiety caused the loss of cytotoxic activity. Compound <b>22</b> inhibited the tumor growth in human prostate PC3 and multiple myeloma RPMI-8226 xenograft models.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/medium/jm1c00100_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Design and SAR analysis of dual tubulin–HDAC inhibitors <b>22</b> and <b>24</b>. (A) Design and SAR analysis of dual tubulin–HDAC inhibitor <b>22</b> with BPR0L075 as the capping group; (B) design and SAR analysis of dual tubulin–HDAC inhibitor <b>24</b> with <i>iso</i>CA-4 as the capping group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2019, Lamaa et al.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> utilized isocombretastation A-4 (<i>iso</i>CA-4, <b>23</b>, a tubulin polymerization inhibitor) and belinostat as templates to design and synthesize a series of tubulin–HDAC dual inhibitors (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B). Among them, compound <b>24</b> with a hydroxamic acid as ZBG is a potent inhibitor of tubulin assembly and HDAC8 with IC<sub>50</sub> values of 1.5 μM and 340 nM, respectively. Moreover, it increased the acetylation of SMC3 (a substrate of HDAC8) in HT-29 cells and disrupted the spindle formation in K562 cells at 1 nM. Compound <b>24</b> exhibited the best cytotoxicity against multiple cancer cell lines with IC<sub>50</sub> values ranging from 0.4 to 5.1 nM. SARs studies indicated that the length of linkers as three atoms was favorable for the antiproliferative activity. <i>N</i>-Hydroxycinnamamide linker on the meta-position of 1,1-diarylethylene played an important role in the inhibition of tubulin polymerization and HDAC8. The phenyl ring located on ring B is more tolerable than other heterocycles for antitumor activity. Moreover, the presence of hydroxamic acid moiety facilitates water solubility of compound <b>24</b>. Compound <b>24</b> can arrest the cell cycle at the G2/M phase, can induce cell apoptotic death, showed a superior safety profile on normal cells compared to parent compounds, and has a good lipophilic–hydrophilic balance.</div><div class="NLM_p">Zhang et al.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> discovered colchicine-SAHA derivative <b>25</b> with a hydroxamic acid as ZBG on the basis of the pharmacophore-linked approach (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A). Compound <b>25</b> showed moderate HDACs inhibitory activity against HDAC1 (IC<sub>50</sub> = 0.72 μM), HDCA3 (IC<sub>50</sub> = 0.83 μM), and HDCA6 (IC<sub>50</sub> = 0.44 μM) and displayed potent antiproliferative activity in vitro against MCF-7 (IC<sub>50</sub> = 0.948 μM). The four carbon atoms on the linker are optimal for HDAC inhibition. This work suggested that colchicine can be used as the capping group of HDAC inhibitors. To further investigate this type of dual tubulin–HDAC inhibitors, compound <b>26</b> with a benzamide moiety as ZBG was synthesized (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A), which showed moderate HDACs’ inhibitory activity against HDCA1 (IC<sub>50</sub> = 1.5 μM), HDCA2 (IC<sub>50</sub> = 0.19 μM), and HDCA6 (IC<sub>50</sub> = 1.49 μM).<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> The thienyl moiety is favorable for anti-HDAC activity. Moreover, it showed comparable tubulin polymerization inhibition and antiproliferative activity on multiple cancer cell lines with colchicine.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/medium/jm1c00100_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Design and SAR analysis of dual tubulin–HDAC inhibitors <b>25</b>–<b>30</b>. (A) Design and SAR analysis of dual tubulin–HDAC inhibitors with colchicine as the capping group; (B) chemical structures of dual tubulin–HDAC inhibitors with quinazoline skeleton and chalcone derivatives as the capping group; (C) chemical structures of dual tubulin–HDAC inhibitors <b>29</b> and <b>30</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Chen’s group discovered SKLB-23bb (<b>27</b>), a selective HDAC6 inhibitor (IC<sub>50</sub> = 17 nM), using quinazoline scaffold as the capping group and hydroxamic acid as ZBG<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B). However, it showed cytotoxicity against tumor cells independent of HDAC6 status. Further analysis indicated that SKLB-23bb (<b>27</b>) can inhibit tubulin polymerization, and significantly disrupt microtubule assembly at 500 nM in MDA-MB-231, which revealed that it is a dual tubulin–HDAC6 inhibitor. SKLB-23bb (<b>27</b>) can effectively inhibit the growth of various cancer cells (IC<sub>50</sub> = 31–121 nM) and induced cell apoptosis and cell cycle arrest at the G2/M phase. In multiple solid tumor models, oral administration of SKLB-23bb (<b>27</b>) potently inhibited tumor growth.</div><div class="NLM_p">Wang et al.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> reported tubulin–HDAC dual inhibitor <b>28</b> with tubulin polymerization inhibitor chalcone derivative as the capping group and hydroxamic acid as ZBG (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B). <b>28</b> can selectively inhibit HDAC6 and tubulin polymerization with IC<sub>50</sub> values of 470 nM and 54.5 μM, respectively. Moreover, it can inhibit A549 cancer cell proliferation (IC<sub>50</sub> = 0.55 μM), induce cell apoptosis, and arrest the cell cycle at the G2/M phase.</div><div class="NLM_p">In 2019, Schmitt et al.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> discovered dual tubulin–HDAC inhibitors with oxazole-bridged CA-4 analogs as the capping group and hydroxamic acid as ZBG. Among them, compound <b>29</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>C) with a three-carbon linker exhibited optimal tubulin polymerization inhibition and moderate inhibitory effect on HDAC1 (IC<sub>50</sub> = 4 μM). Compound <b>29</b> showed comparable antiproliferative activity against human endothelial hybrid cell line Ea.Hy926 with CA-4 (<b>29</b>, IC<sub>50</sub> = 0.018 μM; CA-4, IC<sub>50</sub> = 0.011 μM), which indicated the potent vascular disruptive activity. It can arrest the cell cycle at the G2/M phase and showed no significant toxicity at high doses (100 mg/kg i.p., 200 mg/kg p.o.) in mice.</div><div class="NLM_p last">Another dual HDAC1/-2–tubulin inhibitor <b>30</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>C) with a benzamide moiety as ZBG was reported by Liou’s group.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> It selectively inhibited HDAC1 and HDAC2 with IC<sub>50</sub> values of 0.218 and 0.407 μM, respectively. It increased the acetylation levels of histone H3 at K9 and H4 at K5/8/12/16 in cells and impaired the tubulin assembly in vitro. Furthermore, compound <b>30</b> exhibited high cytotoxicity to HDACi-sensitive and -resistant cancer gastric cells at low micromolar levels and showed efficient inhibition against the growth of multidrug-resistant MES-SA/Dx5 cancer cells (IC<sub>50</sub> = 9.54 ± 1.55 μM). These results indicated that compound <b>30</b> can counteract drug resistance.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">3.3.  Dual Tubulin–DNA Inhibitors</h3><div class="NLM_p">Platinum(II) (Pt(II)) based complexes, including cisplatin (CDDP), carboplatin, and oxaliplatin, are the most frequently used DNA-damaging anticancer drugs in clinical trials. They can induce cancer cell death by distorting DNA structure.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> Many reports have indicated that the combination of MTAs and platinum(II)-based DNA-damaging agents synergistically inhibited tumor growth and overcame the limitation of drug resistance and toxicity. Hence, the development of microtubule dual-targeting Pt(IV) pro-drugs shows remarkable potentials for the treatment of cancers.</div><div class="NLM_p">Wang’s research group designed and synthesized multiple types of dual-targeting Pt(IV) pro-drugs via the pharmacophore-linked approach (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). They can simultaneously release MTAs and CDDP to exert antitumor effects. In 2016, they identified Pt(II) pro-drug <b>31</b> which can release MTAs CA-4<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A) and disrupt tubulin polymerization by binding to the colchicine site (IC<sub>50</sub> = 7.91 μM). Compound <b>31</b> exhibited better antiproliferative activity than CDDP in HepG-2 cells (IC<sub>50</sub> = 0.35 μM). Additionally, it also displayed excellent cytotoxicity against CDDP drug-resistant SGC-7901 (IC<sub>50</sub> = 1.62 μM) and A549 (IC<sub>50</sub> = 2.77 μM) cell lines, and lower cytotoxicity on LO2 normal cells than CDDP. It also induced cell apoptosis and disrupted mitochondrial function. Compound <b>31</b> showed more potent in vivo antitumor activity than CA-4, but less potent than CDDP and the combination treatment of CDDP and CA-4. To improve biological activities, the novel Pt(II) pro-drugs including CA-4 derivatives were discovered. Among them, compound <b>32</b> showed improved antiproliferative effects on CDDP drug-resistant SK-OV-3 cells with an IC<sub>50</sub> value of 0.35 μM.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> However, compound <b>32</b> showed lower in vivo tumor inhibitory activity compared to CDDP and the combination of CDDP and CA-4, which may be attributed to the difficult cleavage of the strong ether bond. Another Pt(IV) pro-drug <b>33</b> containing CA-4 also showed superior cytotoxic activity against CDDP-resistant A549 cells (IC<sub>50</sub> = 0.17 μM) compared to parent compounds.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> To improve the release of MTAs and thus further improve the in vivo antitumor activity, this research group synthesized Pt(IV) pro-drug <b>35</b> including millepachine derivative <b>33</b><a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B). Compared with CDDP and the combination of CDDP and <b>34</b>, compound <b>35</b> exhibited improved in vivo antitumor activity and lower toxicity. Another Pt(IV) pro-drug <b>37</b> containing a chalcone derivative <b>36</b> was reported by Wang’s group.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> Pro-drug <b>37</b> induced mitochondria-mediated cell apoptosis and inhibited the migration of human umbilical vein endothelial cells. Moreover, both those reports demonstrated that Pt(IV) complexes with CDDP exhibited optimal biological activities compared to those pro-drugs with other Pt-based agents.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/medium/jm1c00100_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Design and SAR analysis of dual tubulin–DNA inhibitors. (A) Design and chemical structures of Pt(IV) pro-drugs with combretastatin A-4; (B) design and chemical structures of Pt(IV) pro-drugs with chalcone derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Overall, developing Pt(IV) anticancer pro-drugs containing a tubulin inhibitor may be a promising approach for cancer therapy.</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">3.4.  Dual Tubulin–Topoisomerase I/II Inhibitors</h3><div class="NLM_p">DNA topoisomerases are nuclear enzymes that catalyze DNA cleavage and relegation and regulate the topological structure of DNA. There are two major classes in topoisomerases: toperisomerase I (topo I) and topoisomerase II (topo II), which can induce transient single-strand or double-strand breaks in DNA double helix by cleaving single or double DNA strands, respectively. They are essential for proliferating cancer cells.<a onclick="showRef(event, 'ref87 ref88'); return false;" href="javascript:void(0);" class="ref ref87 ref88">(87,88)</a> Therefore, topoisomerases are important targets in treatment of multiple cancers. The clinical trials indicated that the combination of MTAs and topo II inhibitors exerted synergetic antitumor effects and acquired some clinical successes. Likewise, the combination treatment of topo I and tubulin inhibitors also showed a synergistic antitumor effect in cancer patients.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> However, there are several challenges. For example, both MTAs and topo II inhibitors are sensitive to overexpression of efflux transporters, which leads to the development of cross-resistance and even failure of treatment.<a onclick="showRef(event, 'ref90 ref91'); return false;" href="javascript:void(0);" class="ref ref90 ref91">(90,91)</a> Moreover, the combination of docetaxel and topo II poison doxorubicin showed high efficacy yet high toxicity in breast cancer treatment due to pharmacokinetic interactions between agents.<a onclick="showRef(event, 'ref91 ref92'); return false;" href="javascript:void(0);" class="ref ref91 ref92">(91,92)</a> Developing dual-target inhibitors with simultaneous inhibitions of microtubule and topoisomerases may be an effective approach to improve the antitumor efficacy. Currently, several dual tubulin–topo I/II inhibitors have been discovered by serendipity or pharmacophore-based approaches and can be regarded as the dual-target leads for further development of novel anticancer agents.</div><div class="NLM_p">Hao et al.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> synthesized novel podophyllotoxin and coumarin conjugators via the pharmacophore-linked approach and evaluated their antitumor activity in vitro (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). Among them, compound <b>38</b> displayed superior cytotoxic activities (IC<sub>50</sub> = 4.9–17.5 μM) compared to etoposide in the tested cancer cell lines. The 1,2,3-triazole-4-methylamine as a linker and introducing a methoxy group or a Br atom to the C-6 position of coumarin moiety are optimal for cytotoxicity. Furthermore, compound <b>38</b> can impair a microtubule network and inhibit topo IIβ via binding to CT DNA. It can induce cell cycle arrest at the G1 phase. Recently, another compound, <b>39</b>, was identified via a similar approach (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>).<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> It is a novel conjugate of podophyllotoxin (a tubulin polymerization inhibitor) and etoposide (a topo II inhibitor), exhibiting the inhibitory potency of microtubule polymerization and topo II. Moreover, compound <b>39</b> can perturb the cell cycle through a dual mechanism of action and showed superior antiproliferative activity compared to two parent compounds.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/medium/jm1c00100_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Design and chemical structures of dual topoisomerase II–tubulin inhibitors with podophyllotoxin moiety via pharmacophore-linked approach.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">YCH337 (<b>40</b>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>A), a novel α-carboline derivative, simultaneously inhibited microtubule and topo II.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> It induced DNA double-stranded breaks and disrupted spindle assembly at 1 μM in HeLa cells. Moreover, YCH337 showed potent cytotoxicity against 19 cancer cell lines with IC<sub>50</sub> values in sub-micromolar levels. It effectively inhibited the growth of drug-resistant KB/VCR, MES-SA/DX5, and HL60/MX2 cancer cell lines with IC<sub>50</sub> values of 0.4, 0.16, and 0.32 μM, respectively. It also showed potent in vivo anticancer activity.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/medium/jm1c00100_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Design and SAR analysis of dual tubulin–topos inhibitors. (A) Chemical structures of dual tubulin–topo II inhibitors <b>40</b>, <b>41</b>, and <b>42</b>; (B) discovery and structures of dual tubulin–topos inhibitors <b>43</b> and <b>44</b>; (C) chemical structures of dual tubulin–topo I inhibitors <b>45</b> and <b>46</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2017, Podolski-Renić et al.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> reported that topo II inhibitor DAT0100 (<b>41</b>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>A) can disrupt tubulin polymerization by binding to the colchicine site and disrupted the normal microtubule organization in multiple cell lines. DTA0100 showed potent antiproliferative activity against MTAs-resistant P-gp-overexpressing DLD1-taxane cancer cells (IC<sub>50</sub> = 0.45 μM), and it can reduce the extent of P-gp-mediated drug efflux. Additionally, in multidrug-resistant cells, DTA0100 can induce tubulin depolymerization, cell cycle disruption, and cell apoptosis. Those results indicated that DTA0100 can surmount the limitation of drug resistance.</div><div class="NLM_p">Verma et al. identified tubulin–topo II dual inhibitor <b>42</b> with 1-(3,4,5-trimethoxybenzyl)naphthalene scaffold (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>A).<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> Compound <b>42</b> can suppress the polymerization of tubulin (IC<sub>50</sub> = 5.65 μM) and exhibited the moderate inhibitory activity of topo II in MCF-7 cells. Moreover, compound <b>42</b> displayed inhibitory effects on HCT116 and induced a cell cycle block at S and G2/M phases. The aminoalkyl chain at the ortho-position was beneficial for its antiproliferative activity. It was well-tolerable and safe up to 300 mg/kg dose in Swiss albino mice.</div><div class="NLM_p">In 2015, Sheng’s research group<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> designed and synthesized the novel derivatives based on evodiamine-inspired scaffolds. Thio-evodiamine derivative <b>43</b> showed moderate topo I and II inhibitory activity (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>B). Moreover, it inhibited the tubulin polymerization with an IC<sub>50</sub> value of 4.5 μM, which is more potent than colchicine (IC<sub>50</sub> = 7.8 μM). It displayed excellent antiproliferative activities against A549, MDA-MB-435, and HCT116 cell lines with IC<sub>50</sub> values of 0.02, <0.003, and <0.003 μM, respectively. In the HCT116 xenograft model, <b>43</b> showed a remarkable inhibitory effect on tumor growth with low toxicity at a dose of 2 mg/kg. Compound <b>43</b> is the first-in-class triple topo I/topo II/tubulin inhibitor. To investigate the systematic SARs of evodiamine, this research group discovered compound <b>44</b> (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>B) with indolopyrazinoquinazolinone scaffold by scaffold hopping.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> Compound <b>44</b> exhibited moderate topo I inhibitory activity, and it can also inhibit tubulin polymerization (IC<sub>50</sub> = 26.3 μM). Compound <b>44</b> induced apoptosis and cell cycle arrest at the G2 phase. It showed strong inhibitory activity on HCT116 cells (IC<sub>50</sub> = 2 nM). Likewise, its quaternary ammonium salt displayed excellent tumor growth inhibition (TGI) with a TGI rate of 66.6% in the HCT116 xenograft model with low toxicity. Also on the basis of a natural product, Ceramella et al.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> discovered novel ellipticine analogue <b>45</b> (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>C) with a benzothienoquinazolinone scaffold, which can inhibit tubulin polymerization and topo I activity. Compared to vinblastine, it showed a more potent antiproliferative effect on MDA-MB-231 (IC<sub>50</sub> = 3.88 μM) and better selectivity against nontumor cell MCF-10A.</div><div class="NLM_p last">In 2020, benzimidazole derivative <b>46</b> (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>C) with a 3,4,5-trimethoxybenzylidene moiety was designed and synthesized through fusing polycyclic core and aryl groups.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> It showed remarkable inhibitory effects on topo Iβ in a nanomolar concentration (IC<sub>50</sub> = 21 nM). 3,4,5-Trimethoxybenzylidene moiety is favorable for topo Iβ inhibitory activity. And <b>46</b> can inhibit HCT-116 cells growth with an IC<sub>50</sub> value of 0.16 μM. At this concentration, <b>46</b> also exerted potent tubulin polymerization inhibitory activity with an inhibitory rate of 67%. Moreover, <b>46</b> caused cell cycle arrest at the G0/G1 phase and induced apoptosis by the upregulation of Bax/Bcl-2 ratio and p53. Finally, <b>46</b> enhance radiosensitizing activity against HCT-116 cells by modulating the chromosomal instability.</div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">3.5.  Dual Tubulin–TDO/IDO Inhibitors</h3><div class="NLM_p">Targeting kynurenine (Kyn) pathways has been considered an attractive strategy in cancer immunotherapies. IDO and TDO catalyze the initial and rate-limiting step of the Kyn pathway.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> IDO and TDO can cause the shortage of tryptophan and accumulation of kynurenine, which can inhibit the activation and proliferation of effector T cells and stimulate regulatory T cells.<a onclick="showRef(event, 'ref103 ref104'); return false;" href="javascript:void(0);" class="ref ref103 ref104">(103,104)</a> Hence, suppressing IDO and TDO can improve the effects of cancer treatment by activating antitumor immunity. Many studies have indicated that the combination of IDO/TDO inhibitors and chemotherapy exerted synergistic antitumor activities in vitro and in vivo.<a onclick="showRef(event, 'ref105 ref106'); return false;" href="javascript:void(0);" class="ref ref105 ref106">(105,106)</a> Accordingly, the combination of tubulin inhibition and IDO/TDO may be an effective immunochemotherapeutic approach for the treatment of cancer.</div><div class="NLM_p">Gou’s research group identified a dual tubulin–TDO inhibitor HT2 (<b>48</b>) by bridging the TDO inhibitor <b>47</b> and CA-4 via an appropriate linker<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>A). HT2 showed tubulin polymerization inhibitory potential superior to that of CA-4 and disrupted the Kyn pathway by suppressing the TDO protein expression in HepG2 cells. It also showed effective antiproliferative activity against four cancer cells with IC<sub>50</sub> values from 36 to 430 nM. The SARs studies indicated that the conjunction of compound <b>47</b> and CA-4 was optimal for biological activities compared to that of other TDO inhibitors and MTAs. A linker containing a triazole unit is also important for the antiproliferative activity. Additionally, HT2(<b>48</b>) can induce cell apoptosis via the mitochondrial pathway, inhibit the migration of HepG2 cells, and improve the immune responses of T cells by releasing TDO inhibitor <b>47</b> in vitro. HT2 (<b>48</b>) displayed improved in vivo inhibitory effects of tumor growth compared to the combination of parent compounds CA-4 and <b>47</b>.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/medium/jm1c00100_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Design and SAR analysis of dual tubulin–TDO/–IDO inhibitors. (A) Design and SARs of dual tubulin–TDO/–IDO inhibitors based on CA-4; (B) chemical structures of dual tubulin–IDO inhibitors <b>51a</b> and <b>51b</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The similar strategy, pharmacophore-linked approach, was used to design and synthesize the dual-functional inhibitor HI5 (<b>50</b>) with the potential to release tubulin inhibitor CA-4 and IDO inhibitor D-MT (<b>49</b>)<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>A). HI5 inhibited the polymerization of tubulin in a dose-dependent manner and impaired the Kyn pathway via inhibiting the protein expression of IDO in HeLa cells. HI5 significantly inhibited the growth of HeLa cells (IC<sub>50</sub> = 0.07 μM), blocked the cell cycle at the G2/M phase, and induced cell apoptosis. Moreover, HI5 can enhance the proliferation of T cells, and show greater tumor growth inhibition than CA-4 in vivo. Likewise, the triazole linker and the conjugation of CA-4 and D-MT are optimal for biological activities.</div><div class="NLM_p last">Recently, tryptamine derivatives <b>51a</b> and <b>51b</b> were identified as tubulin–IDO bifunctional inhibitors based on a C<sub>2</sub>-aroyl/arylimino indoles hybrid<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>B). Compounds <b>51a</b> and <b>51b</b> showed potent tubulin polymerization inhibition (IC<sub>50</sub> is around 5 μM) and inhibited the cellular IDO activity in A549 and MCF-7 cancer cells (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>B).</div></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13">3.6.  Dual Tubulin–Estrogen Receptor Inhibitors</h3><div class="NLM_p">ERs are a branch of nuclear receptors superfamily, which are ligand-activated transcriptional regulators that mediate the effects of the endogenous hormone 17β-estradiol.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> ERs are overexpressed in approximately 75% of breast tumors; hence, ER inhibitors can be used for ER-positive breast tumor therapy.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> Moreover, it was reported that paclitaxel synergizing with ER inhibitor Tamoxifen could improve the antitumor effects in clinical trials.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> Accordingly, developing tubulin–ER dual-target inhibitors is a promising antitumor strategy.</div><div class="NLM_p">To discover new taxane-site modulators with optimal pharmacokinetic profiles and to overcome drug resistance, Lo et al.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> employed the structure-based drug repurposing strategy to discover the pocket similarity between the taxane-binding site and ER (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>A). Then, they predicted several potential selective ER modulators as taxane-site ligands via computational docking. Nocodazole challenge assay and tubulin polymerization assay in vitro indicated that Raloxifene (RAL, <b>52</b>) can enhance microtubule stability, which is similar to MSA paclitaxel. Furthermore, cell-based image assay demonstrated that RAL was capable of competing with SiR–tubulin, a fluorescent paclitaxel conjugate and likely bound directly to the taxane site. Immunofluorescence microscopy and bright-field time-lapse microscopy indicated that RAL caused mitotic spindles misorientation in all mitotic cells. The antiproliferative activity of RAL is independent of the ER status of tumor cells. Overall, this research found that RAL can simultaneously target ER and the taxane site in tubulin and could serve as potential repurposed leads for the treatment of cancers with resistance from taxane-site mutations.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/medium/jm1c00100_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Dual tubulin–ER inhibitors. (A) In silico binding pocket similarity screening, revealing that the selective estrogen receptor modulator RAL can bind to taxane pockets of tubulin, and tubulin polymerization assay and cell-based analysis performed to determine the effects of RAL on microtubule; (B) design and SAR analysis of dual tubulin–ER inhibitor <b>54</b> (α-tubulin, wheat; β-tubulin, blue).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2014, O’Boyle et al.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> developed dual tubulin–ER inhibitors with β-lactam scaffold by incorporating a trimethoxy aryl group into the ER pharmacophore with two phenolic groups in the ligand (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>B). Initially, compound <b>53</b> exhibited potent ER binding affinity with IC<sub>50</sub> values of 1.47 μM (ERα) and 23 μM (ERβ), which indicated that the orientations of phenolic rings at N-1 and C-4 positions are optimal for ER binding affinity. However, compound <b>53</b> showed no antiproliferative activity against MCF-7 at 50 μM. In order to improve antiproliferative activity and maintain ER binding affinity, compound <b>54</b> with α-(hydroxyaryl)methyl substituent at the C-3 position of the β-lactam core was prepared. It showed superior ER binding affinity with IC<sub>50</sub> values of 0.008 μM (ERα) and 0.015 μM (ERβ), and improved antiproliferative activity toward MCF-7 cells (IC<sub>50</sub> = 0.21 μM). The SARs indicated that the replacement of 3,4,5-trimethoxy aryl group was detrimental for ER binding and antiproliferative activity. The smaller substituents at the C-3 position and the introduction of basic pyrrolidine ether substituent to phenyl group at the C-3 position also eliminated the ER binding affinity of compound <b>54</b>. Furthermore, compound <b>54</b> is a tubulin destabilizer, which caused depolymerization of tubulin. Moreover, it caused cell cycle G2/M phase arrest, induced cell apoptotic death, and downregulated the expression of antiapoptotic proteins Bcl-2 and Mcl-2.</div><div class="NLM_p last">These works provided potential dual-functional leads acting simultaneously on two targets related to breast tumor treatment. However, to reduce toxicity and improve antitumor effects, further structural modification of leads is required for confirming the optimal activity ratio of tubulin and ER.</div></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14">3.7.  Dual Tubulin–Phosphoinositide 3-Kinase Inhibitors</h3><div class="NLM_p">PI3K/Akt/mTOR (PI3K being phosphoinositide 3-kinase) signaling pathway possesses diverse biological functions, including the regulation of cellular survival, growth, proliferation, migration, metabolism, and angiogenesis, which is similar to the function of microtubules.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> This pathway is upregulated in multiple cancers; therefore, it is considered as an important antitumor target. The PI3K inhibitors in monotherapy displayed disappointing results in early clinical trials.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> The combination therapy based on PI3K inhibitors has been evaluated in preclinical and clinical trials. It was reported that pan-PI3K inhibitors LY294002 significantly enhanced the cell apoptosis induced by vincristine.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> Moreover, it can resensitize docetaxel-resistant cells to docetaxel.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> In clinical treatment, the combination of PI3K and MTAs was proved to be beneficial.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> Accordingly, these results indicated that the combination of tubulin and PI3K may be an attractive antitumor strategy.</div><div class="NLM_p">BKM120 (<b>55</b>) is one of the most advanced pan-PI3Ks inhibitors in clinical trials.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> It possesses excellent druggable properties and can penetrate the blood–brain barrier (BBB). In addition to PI3K inhibitory activity, BKM120 was reported to have microtubule-destabilizing activity. Bohnacker et al.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> developed BKM120 derivatives MTD147 (<b>56</b>) and PQR309 (<b>57</b>) via minute modification of pyrimidine skeleton, which can selectively inhibit tubulin and PI3K (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>A). X-ray crystal structures indicated that BKM120 can bind to the colchicine site of tubulin as well as the ATP-binding pocket of PI3K. BKM120 and MTD147 formed direct or water-mediated interactions with βVal238, βTyr202, and βGlu200 in tubulin (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5M7E">5M7E</a>; <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>B). The core C–H of BKM120 pointed βMet259, which determined the high binding affinity of BKM120 and tubulin. The PQR309 without core C–H is incapable of binding to tubulin. The cocrystal structure of BKM120 in complex with PI3K revealed that its core nitrogen atom formed interactions with a structural water, which is crucial for the high affinity of BKM120 and PI3K (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3SD5">3SD5</a>; <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>C). MTD147 without core nitrogen atom was unable to bind to PI3K binding pocket. Furthermore, the potent antiproliferative activities of BKM120 depended mainly on microtubule cytotoxic activity rather than through PI3K inhibition.</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/medium/jm1c00100_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Dual tubulin–PI3K inhibitor BKM120 (<b>55</b>). (A) Chemical structures of BKM120 and its derivatives; (B) binding mode of BKM120 in complex with tubulin (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5M7E">5M7E</a>); (C) binding mode of BKM120 in complex with PI3K (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3SD5">3SD5</a>). The hydrogen bonds are highlighted in yellow dashes; the water molecules are highlighted in red spheres.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">3.8.  Dual Inhibitors of Tubulin and Rapidly Accelerated Fibrosarcoma Kinases</h3><div class="NLM_p">Rigosertib (<b>58</b>) is in phase III clinical trials for the treatment of myelodysplastic syndrome (NCT01904682) and is showing excellent growth inhibition of tumor cells in vitro and in vivo with minimal toxicity.<a onclick="showRef(event, 'ref120 ref121'); return false;" href="javascript:void(0);" class="ref ref120 ref121">(120,121)</a> In 2016, Athuluri-Divakar et al.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> revealed that Rigosertib acted as a RAS-mimetic and bound to RAS-binding domains of rapidly accelerated fibrosarcoma (RAF) kinases, which disrupted RAF activation and inhibited the RAS-RAF-MEK pathway. In 2017, Jost et al.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> demonstrated that Rigosertib is a microtubule destabilizer via clusters of regularly interspaced short palindromic repeats (CRISPR) based screening platforms for inhibiting (CRISPRi)/activating (CRISPRa) screening approach (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>). Genetic screening revealed that Rigosertib can destabilize microtubule-associated genes <i>TACC3</i> and <i>KIF2C</i> to exert potent cytotoxicity. Chemical–genetic profiling strategy indicated the similarity between Rigosertib and other MDAs. Rigosertib caused spindle and mitotic defects in human retinal pigment epithelial cells and significantly affected the microtubule growth rate and mitosis catastrophe frequency. Co-crystal structures indicated that Rigosertib can bind to the colchicine site in tubulin (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OV7">5OV7</a>). And it can be stabilized by hydrophobic interactions with the β-tubulin subunit and hydrogen bonds between its amine group and βAsn258 and αThr179. Moreover, the carboxy group of Regosertib forms hydrogen bond interactions with αSer178, βLys352, and βAsn349. Additionally, Rigosertib can also bind to B-RAF RAS-binding domain in two orientations to impede RAS–RAF interactions (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5J18">5J18</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5J2R">5J2R</a>).</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/medium/jm1c00100_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Chemical structure and mechanism of action of Rigosertib. The chemical–genetic strategy was applied to identify the mechanism of action of Rigosertib. The cellular analysis indicated that Rigosertib caused spindle defects and microtubule destabilization. The cocrystal structure of Rigosertib in complex with tubulin demonstrated that Rigosertib can bind to the colchicine site. (α-tubulin, wheat; β-tubulin, blue)</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16">3.9.  Dual Tubulin–Src Inhibitors</h3><div class="NLM_p">Src, a nonreceptor protein tyrosine kinase, is a cellular proto-oncogene of the viral transforming gene, <i>v-Src</i>.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> The dysregulation of Src plays an important role in tumor growth and metastasis.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> Src has emerged as the target of cancer treatment. It was reported that non-ATP-competitive, orally clinical Src inhibitors KX2-391 (<b>59</b>) and KX2-361 (<b>60</b>) can disrupt microtubule stabilization<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>A). KX2-391 and KX2-361 showed significant growth inhibition against a broad spectrum of tumor cells, which was inconsistent with approved Src inhibitors.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> Photoaffinity labeling technology and tubulin polymerization assay indicated that KX2-391 and KX2-361 could bind to the interface of αβ-tubulin heterodimer, and disrupt microtubule polymerization.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> The cocrystal structure of KX2-391 in complex with tubulin revealed that KX2-391 can bind to the colchicine site and form extensive hydrophobic interactions with various residues of β-tubulin.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> The amide and pyridine moieties of KX2-391 formed a water-mediated hydrogen bond interaction with βGlu200 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6KNZ">6KNZ</a>). Additionally, KX2-391 and KX2-361 caused G2/M phase cell cycle arrest, induced mitotic catastrophe, increased cell apoptosis, and decreased cell migration. Preclinical in vivo results indicated that KX2-391 significantly inhibited the primary tumor growth in various animal models. Moreover, KX2-391 showed stronger tumor metastasis inhibition than paclitaxel, which may be attributed to its Src inhibitory activity.<a onclick="showRef(event, 'ref130 ref131 ref132 ref133'); return false;" href="javascript:void(0);" class="ref ref130 ref131 ref132 ref133">(130−133)</a> Similarly, KX2-361 induced 30% long-term complete tumor remission in the animal model, and it has good oral bioavailability (40%) and superior BBB penetration in mice.<a onclick="showRef(event, 'ref126 ref134'); return false;" href="javascript:void(0);" class="ref ref126 ref134">(126,134)</a> Currently, KX2-391 is undergoing phase III clinical trials for the treatment of actinic keratosis with good efficacy and low toxicity (NCT03285477). And KX2-361 is undergoing phase I clinical trials for the treatment of malignant glioblastoma (NCT02326441).</div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/medium/jm1c00100_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Design and SAR analysis of dual tubulin–Src/–c-Met inhibitors. (A) Chemical structures of dual tubulin–Src inhibitors KX2-391 and KX2-361 and the binding mode of KX2-391 in complex with tubulin (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6KNZ">6KNZ</a>); (B) binding modes of dual tubulin–c-Met inhibitor Tivantinib in complex with tubulin (left; PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CB4">5CB4</a>) and c-Met (right; PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3RHK">3RHK</a>), respectively. The hydrogen bonds are highlighted in yellow dashes, and water molecules are highlighted in red spheres.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">3.10.  Dual Tubulin–c-MET Inhibitor</h3><div class="NLM_p last">The hepatocyte growth factor receptor, c-MET, showed aberrant activation due to its mutant or overexpression in tumor cells.<a onclick="showRef(event, 'ref135 ref136'); return false;" href="javascript:void(0);" class="ref ref135 ref136">(135,136)</a> Tivantinib (<b>61</b>) is a non-ATP-competitive c-MET inhibitor, and its antitumor activity was verified in clinical trials.<a onclick="showRef(event, 'ref137 ref138 ref139'); return false;" href="javascript:void(0);" class="ref ref137 ref138 ref139">(137−139)</a> Katayama et al.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> discovered that Tivantinib displayed significant antiproliferative activity against both c-Met addicted and nonaddicted cancer cells, and induced cell cycle arrest at the G2/M phase. Those results indicated that the antitumor activity of Tivantinib was independent of the status of c-MET. Further COMPARE analysis identified the microtubule as the target of Tivantinib. Tivantinib can disrupt the microtubule network and suppress tubulin polymerization. Moreover, Tivantinib can circumvent the ABC transporter-mediated multidrug resistance. The X-ray crystal structure of Tivantinib in complex with tubulin revealed that Tivantinib can bind to the colchicine site in β-tubulin, and it forms H-bond interactions with the residues of βN256 and βA315 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CB4">5CB4</a>, <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>B).<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> The crystal structure of Tivantinib in complex with c-MET kinase domain revealed that Tivantinib bound to a novel pocket of c-MET. The complex formed two canonical H-bond hinge interactions with Met1160 and Pro1158 and formed a water-mediated H-bond interaction with Lys1161 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3RHK">3RHK</a>). As a result, it drove c-MET into an inactive conformation.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> Overall, in addition to c-MET, tubulin is also the target of Tivantinib. Currently, Tivantinib is in phase II/phase III clinical trials for the treatment of multiple cancers in monotherapy or combination with other chemotherapy (NCT01755767, NCT01395758, NCT01447914, and NCT01075048).</div></div><div id="sec3_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18">3.11.  Dual Tubulin–Katanin Modulator</h3><div class="NLM_p">Katanin, a microtubule-severing protein, is essential in dynamic modulation of microtubule structure and orientation in maintaining cellular homeostasis.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> The abnormal expression of katanin has been observed in a variety of tumors, which make katanin a promising antitumor target.<a onclick="showRef(event, 'ref143 ref144'); return false;" href="javascript:void(0);" class="ref ref143 ref144">(143,144)</a> Disrupting the severing activity of katanin can affect the structure of microtubule and thus cause cell apoptotic death, which may overcome the drug-resistant limitation of MTAs.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a></div><div class="NLM_p">With an aim to develop novel antitumor compounds that can both target tubulin and katanin, compound <b>64</b> with imidazo[4,5-<i>c</i>]pyridin-2-one scaffold was identified by fusing the structures of β-lactam-type tubulin polymerization inhibitor <b>62</b><a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> and purine-type katanin activator <b>63</b> based on combination principle<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>A). Compound <b>64</b> suppressed tubulin polymerization with an IC<sub>50</sub> value of 8.4 μM and had a moderate binding affinity to katanin with a <i>K</i><sub>d</sub> value of 12.7 μM, showing higher potency than compound <b>63</b>. Compound <b>64</b> exhibited potent antiproliferative activity against four cancer cells (IC<sub>50</sub> = 0.17–0.40 μM). 1, 6-Diaryl substitution and a carbamoyl substituted on the C-4 position were crucial for the antiproliferative activity, and anchoring 3,4,5-trimethoxyphenyl group on the N-1 position of the imidazo[4,5-<i>c</i>] pyridin-2-one core was also beneficial for the biological activity. Compound <b>64</b> induced cell cycle arrest at the G2/M phase and suppressed the formation of colony and angiogenesis. Furthermore, compound <b>64</b> can significantly inhibit tumor growth in vivo and possesses good pharmacokinetic properties (<i>C</i><sub>max</sub> = 0.58 μg/mL, <i>t</i><sub>1/2</sub> = 9.36 h, and AUC<sub>0–24h</sub> = 2.63 mg·h/mL). Compound <b>64</b> is the first-in-class dual tubulin–katanin modulator, which suggested that the simultaneous inhibition of tubulin and microtubule-associated proteins is an effective approach for cancer therapy.</div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/medium/jm1c00100_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Design and SAR analysis of dual tubulin–katanin/–PARP1/–SphK inhibitors. (A) Design and SARs analysis of dual tubulin–katanin modulator <b>64</b>; (B) binding mode of AMXI-5001 (<b>65</b>) in complex with PARP1 (hydrogen bonds, highlighted in green dashes; stacking interactions, highlighted in blue dashes); (C) chemical structures of dual tubulin–SphK inhibitors SKI-178 (<b>66</b>) and SKI-349 (<b>67</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19">3.12.  Dual Tubulin–Poly(ADP-ribose) Polymerase Inhibitors</h3><div class="NLM_p">Synthetic lethality is an emerging antitumor strategy, which, when referred to the inactivation of either gene individually, has little effect on cell viability but perturbation of both genes simultaneously results in cell death.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> Poly(ADP-ribose) polymerase (PARP) inhibitors verified the synthetic lethal effect in the treatment of BRCA1/-2-deficient breast cancer.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> There are studies to indicate that MTAs impair the trafficking of double-stranded DNA damage repair proteins. They can synergize with PARP inhibitors to perturb the alternative DNA repair pathway, resulting in prolonged and intensive DNA damage, improved cytotoxic activity, overcoming drug resistance, and reduced toxicity. The combination of PARP inhibitor Olaparib and weekly Taxol had controllable toxicity properties and showed preliminary evidence of antitumor effects.<a onclick="showRef(event, 'ref149 ref150 ref151'); return false;" href="javascript:void(0);" class="ref ref149 ref150 ref151">(149−151)</a> Hence, the simultaneous inhibition of PARP and microtubules via a single molecule may provide a potent antitumor efficacy with reduced MTA-induced dose-limiting toxicity and drug resistance. The field of dual tubulin–PARP inhibitors is still underdeveloped. Currently, there is only one example reported.</div><div class="NLM_p last">Lemjabbar-Alaoui et al.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> reported that AMXI-5001 (<b>65</b>) is a PARP1/-2 and microtubule polymerization inhibitor. It can significantly inhibit PARP1 and PARP2 with IC<sub>50</sub> values of 5 and 50 nM, respectively. The cocrystal structure of AMXI-5001 in complex with human PARP1 revealed that the amide tail of AMXI-5001 formed interactions with Asp770 and Arg878 and its aromatic moieties formed stacking interactions with Tyr907 and Tyr896 (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>B). Moreover, AMXI-5001 can disrupt microtubule polymerization by binding to the colchicine site, with an IC<sub>50</sub> value of 0.99 μM. AMXI-5001 exhibited remarkable antiproliferative activity against both BRCA mutant and wild-type tumor cells with IC<sub>50</sub> values ranging from 18 to 26 nM. Oral administration of AMXI-5001 caused the complete regression of existing tumors at a dose of 50 mg/kg in MDA-MB-436 xenografts, which is more efficacious compared to that of MTAs or PARP inhibitors as monotherapy and combination treatment of both agents. Moreover, AMXI-5001 showed favorable metabolic stability, oral bioavailability, and pharmacokinetic properties. Collectively, AMXI-5001 is a promising first-in-class tubulin–PARP dual-target inhibitor, which deserves further investigation as a dual-target antitumor agent.</div></div><div id="sec3_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20">3.13.  Dual Tubulin–Sphingosine Kinases Inhibitors</h3><div class="NLM_p last">Sphingosine kinases (SphKs) catalyze the formation of the sphingosine 1-phosphate, which is crucial for the regulation of various cellular functions. Due to its overexpression in multiple cancers, SphKs have been regarded as potent antitumor targets. SKI-178 (<b>66</b>, <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>C) is a novel SphK1/-2 inhibitor and has broad-spectrum antitumor activity including the activity in drug-resistant cell lines. Hengst et al.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> investigated the effects of SKI-178 on tubulin. SKI-178 can impair microtubule dynamics and inhibit microtubule network polymerization in vitro and in intact cells. Additionally, SKI-178 can induce cell apoptotic death and exert potent antitumor activity in several acute myeloid leukemia models on the basis of a synergistic interaction of two targets. To further improve the cytotoxicity and therapeutic efficacy of SKI-178, SKI-359 (<b>67</b>,<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>C) was identified via modifying the linker moiety and maintaining the substituted phenyl rings of SKI-178 through a structure-guided approach.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> SKI-349 simultaneously inhibited SphK1 (IC<sub>50</sub> = 3 μM) and tubulin polymerization. It displayed potent antiproliferative activity against HL-60- and VCR/HL-60-resistant cell lines with IC<sub>50</sub> values of 22 and 23 nM, respectively. SKI-349 induced cell apoptosis and achieved 100% animal survival at a dose of 1 mg/kg in vivo. These studies bolstered the ongoing demand for the development of tubulin–SphK dual-target inhibitors.</div></div><div id="sec3_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21">3.14.  Dual Tubulin–Hsp90 Inhibitors</h3><div class="NLM_p">Hsp90 is a molecular chaperone, which is involved in the maturation of its client proteins. Many of these client proteins facilitate the process of cancers; therefore, Hsp90 is a viable cancer drug target.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> It has been reported that simultaneously targeting Hsp90 and its client proteins can improve therapeutic efficacy.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> Tubulin is a client protein of Hsp90 and is also an important antitumor target. Currently, several dual tubulin–Hsp90 inhibitors have been reported and exhibited promising antitumor efficacy. These studies provide valuable guidance for the discovery of a new generation of dual tubulin–Hsp90 inhibitors.</div><div class="NLM_p">MDG892 (<b>68</b>, <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>A) with indazole-based scaffold is the first dual tubulin–Hsp90 inhibitor, which is discovered via ligand- and structure-based virtual screening including molecule docking and pharmacophore modeling.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> MDG892 exhibited tubulin depolymerizing effect in a dose-dependent manner. Meanwhile, it can induce the significant degradation of Hsp90 client protein ERα at 200 μM in MCF-7 cells, and this effect was mediated by binding to the ATP-binding site of Hsp90.</div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/medium/jm1c00100_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Design and SAR analysis of dual-target tubulin inhibitors <b>68</b>–<b>76</b>. (A) Chemical structures of dual tubulin–Hsp90 inhibitors <b>68</b>–<b>70</b> and dual tubulin–Cdc20 inhibitor <b>71</b>; (B) design and chemical structure of dual tubulin–PDHK1 inhibitor (<b>72</b>); (C) chemical structures of dual inhibitors of tubulin and FLT3 (<b>73</b>), FTase (<b>74</b>), MK2 (<b>75</b>), and AMPK (<b>76</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Zhang et al.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> discovered a dual tubulin–Hsp90 inhibitor CDBT (<b>69</b>,<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>A) by nanoparticle affinity probe method. CDBT showed moderate tubulin depolymerizing activity, inhibited remarkably the binding of [<sup>3</sup>H]-colchicine in a dose-dependent manner, and caused the mitotic spindle abnormalities at 5 μM in H460 cells. Meanwhile, CDBT induced the degradation of Hsp90 oncogenic client proteins CRAF-1 and ERBB2 and inhibited AKT phosphorylation in H460 cells. In the NSCLC H460 xenograft mouse model, CDBT showed potent tumor growth inhibition with TGI of 62.4% at 30 mg/kg without toxicity to normal tissues. Further investigations<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> revealed that CDBT exhibited comparable antitumor activity against P-gp-overexpressing H460<sub>TaxR</sub> cells (IC<sub>50</sub> = 0.8 μM) and parent H460 cells (IC<sub>50</sub> = 0.7 μM), which indicated that CDBT was not a substrate of P-gp. Likewise, in the H460<sub>TaxR</sub> xenograft model, CDBT inhibited tumor growth (TGI = 60.4%) without obvious toxicity at a dose of 30 mg/kg, which was more potent than paclitaxel (TGI = 40.0%).</div><div class="NLM_p last">On the basis of scaffold hopping, a series of 2-aroylquinoline-5,8-diones were designed and synthesized by Nepali et al.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> Among them, compound <b>70</b> (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>A) showed the greatest tubulin depolymerizing activity (IC<sub>50</sub> = 5.9 μM). Moreover, compound <b>70</b> caused the induction of Hsp70 and the degradation of AKT in HONE-1 cells, which was indicative of the Hsp90 inhibitory activity of compound <b>70</b>. It significantly inhibited the proliferation of three cancer cells with IC<sub>50</sub> values ranging from 0.07 to 0.55 μM.</div></div><div id="sec3_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22">3.15.  Dual Inhibitors of Tubulin and Other Antitumor Targets</h3><div class="NLM_p">Currently, several dual inhibitors of tubulin and other antitumor targets were discovered by serendipity or using typical design strategies, and they showed better biological activities than corresponding single-target molecules. These dual inhibitors can be used as tool compounds to investigate the synergetic interactions of tubulin and other antitumor targets. Alternatively, they can be considered as valuable leads to develop novel dual-target antitumor agents.</div><div class="NLM_p">On the basis of the modification of cell division cycle 20 homologue (Cdc20) specific inhibitor apcin, Huang et al.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> discovered a dual tubulin–Cdc20 inhibitor <b>71</b> (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>A). It showed a similar Cdc20 binding affinity compared to apcin (<b>71</b>, <i>K</i><sub>D</sub> = 119 μM; apcin, <i>K</i><sub>D</sub> = 123 μM). Meanwhile, compound <b>71</b> disrupted the cellular microtubule network at 0.3 μM in HepG2 cells and inhibited the tubulin polymerization. In addition, its cell growth inhibition against seven cancer cell lines (IC<sub>50</sub> = 0.2–1.7 μM) was far superior to apcin. It induced cell apoptosis, arrested the cell cycle at the M phase, and inhibited cell migration and invasion.</div><div class="NLM_p">To improve the therapeutic effect and PK properties of pyruvate dehydrogenase kinase 1 (PDHK1) inhibitor dichloroacetic acid (DCA), Ghinet et al.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> discovered a novel DCA-loaded molecule <b>72</b> by fusing the phenstatin derivative with a monochloroacetic group (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>B). It inhibited remarkably tubulin polymerization with an IC<sub>50</sub> value of 1.3 μM, and showed 2.3-fold greater PDHK1 inhibitory activity than DCA. Additionally, compound <b>72</b> showed optimal antiproliferative activity against 23 cancer cell lines with GI<sub>50</sub> < 10 nM. Compound <b>72</b> is the first-in-class dual tubulin–PDHK1 inhibitor and can be used as a lead to design new antitumor agents.</div><div class="NLM_p">Malik et al.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> identified a dual tubulin–FMS-like tyrosine kinase 3 (FLT3) chalcone <b>73</b> (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>C). It reduced phosphorylation of two key downstream targets of FLT3, namely, signal transducer and activator of transcription 5 (Stat5) and/or extracellular signal-regulated kinase (ERK), which is consistent with the antiproliferative activity toward FLT3-internal tandem duplications (ITDs) mutation cell lines MV-4–11 (IC<sub>50</sub> = 0.24 μM) and MOLM-13 (IC<sub>50</sub> = 0.20 μM). Additionally, chalcone <b>73</b> inhibited the microtubule polymerization in a dose-dependent manner in vitro and caused the complete inhibition of microtubule repolymerization at 5 μM in cells. Compared to parent MOLM-13 cells, it displayed similar inhibitory activity against drug-resistant MOLM-13-Res cells (IC<sub>50</sub> = 0.22 μM), which indicated that chalcone <b>73</b> overcame the FLT3–TKD (tyrosine kinase domain) mediated resistance. It can induce cell apoptotic death through the activation of caspase-3 and PARP.</div><div class="NLM_p">The dual tubulin–farnesyltransferase (FTase) inhibitor <b>74</b> (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>C) was discovered through hybridizing indolizine and phenothiazine.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> Compound <b>74</b> displayed remarkable tubulin polymerization and FTase inhibition with IC<sub>50</sub> values of 1.11 and 0.39 μM, respectively. The SARs indicated that the unsubstituted nitrogen atom of phenothiazine of compound <b>74</b> is important for tubulin polymerization inhibition, and the small substituted groups of indolizine are tolerated for FTase inhibition. Compound <b>74</b> exhibited cancer cell growth inhibition at nanomolar concentrations, especially toward MDA-MB-435 (GI<sub>50</sub> = 19 nM). Compound <b>74</b> is the first dual tubulin–FTase inhibitor, which provided a new perspective for the development of novel antitumor agents.</div><div class="NLM_p">CMPD1 (<b>75</b>,<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>C) is a known non-ATP-competitive mitogen-activated protein kinase (MAPK) activated protein kinase 2 (MK2) inhibitor. However, Gurgis et al.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> discovered that the cytotoxic activities of CMPD1 were independent of MK2 inhibition. Further mechanistic investigations demonstrated that CMPD1 can inhibit tubulin polymerization in a concentration-dependent manner and disturbed mitotic spindle assembly, which indicated that the CMPD1 was a dual tubulin–MK2 inhibitor. In addition, CMPD1 induced cell cycle arrest at the G2/M phase and apoptotic cell death. It showed more potent viability inhibition of glioblastoma cells (EC<sub>50</sub> = 0.6–1.2 μM) than single-target MK2 inhibitor with good selectivity.</div><div class="NLM_p last">Tripodi et al.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> discovered novel β-lactam compound <b>76</b> (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>C), which showed tubulin polymerization inhibitory activity with an IC<sub>50</sub> value of 1.61 μM. Moreover, it can induce phosphorylation of adenosine monophosphate activated protein kinase (AMPK) on Thr172, phosphorylation of p53 on Ser15, and phosphorylation of Raptor on Ser792. Compound <b>76</b> showed promising antiproliferative activity toward HuTu-80 cancer cells with an IC<sub>50</sub> value of 3.05 nM, which is comparable with that of CA-4 (IC<sub>50</sub> = 1.37 nM). And it can induce apoptotic cell death by the activation of caspase-3 and PARP.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">4.  Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04433" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04433" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Microtubules play a major role in crucial cellular functions and are one of the most important chemotherapeutic targets for the treatment of multiple cancers. However, the development of drug resistance and toxicities restrict the applications of MTAs in the clinic. It is urgent that novel strategies be developed to overcome those limitations. In recent years, the development of dual-target tubulin inhibitors modulating multiple cancer-related targets has attracted interests of many research laboratories, and a large number of dual-target tubulin inhibitors have been identified on the basis of a variety of drug discovery strategies. Interestingly, these dual-target tubulin inhibitors exerted a variety of advantages. Well-designed dual-target tubulin inhibitors enhance therapeutic efficacy and overcome drug resistance through synergizing multiple antitumor targets. Another advantage may be the reduction of toxicities against normal human cells and tissues. The reason may be that it is sufficient to achieve good therapeutic efficacy through partially modulating tubulin dynamics and the activity of another synergetic target, and thus dual-target tubulin inhibitors can lead to the reduction of side effects mediated by full inhibitions on the individual targets. Moreover, it may also be due to the high expression of another synergistic target in the tumor tissues; these dual-target tubulin inhibitors can target tumor tissues more accurately, resulting in reduced toxicity against normal tissues and enhancing the therapeutic effects on tumor tissues.<a onclick="showRef(event, 'ref46 ref167'); return false;" href="javascript:void(0);" class="ref ref46 ref167">(46,167)</a> In this Perspective, we summarized the recent advances of dual-target tubulin inhibitors, focused on the rational target selections and the design strategies of dual-target tubulin inhibitors, and analyzed their SARs and biological activities. We hope that this Perspective can provide a substantial foundation for the design of the next generation of dual-target tubulin inhibitors.</div><div class="NLM_p">There are many dual-target tubulin inhibitors discovered by drug repurposing, such as inhibitors that target c-Met, MAPK, PI3K, Src, RAF, ER, and Cdc20. Among them, Tivantinib, BKM120, Raloxifene, Rigosertib, and KX2-391 are already-available antitumor agents with optimized PK and safety properties and currently are still under clinical trials. These examples manifest the advantages of drug repurposing, such as lower development risks. In such cases, determining difunctional activities of known agents is crucial for formulating correct drug scheduling schemes and exploring adverse reactions, particularly in the precision medicine area. Additionally, these studies also indicated that tubulin may have structural similarity with the binding pockets of these targets. Investigating their precise molecular mechanisms of binding to multiple related targets is vital for developing next-generation single-/dual-target inhibitors or avoiding off-target effects. Pharmacophore-based approaches are feasible for the design of dual inhibitors of tubulin and many other targets. When tubulin inhibitors and inhibitors of other targets such as RTKs, ER, and katanin are structurally similar, a merging strategy is optimal. Classically, these kinds of dual-target tubulin inhibitors show greater potential because of the high pharmacophore overlap, which enables preferable drug likeness and pharmacological properties. For the inhibitors targeting other antitumor targets that have little structural similarities with tubulin inhibitors, such as HDAC, topo II, DNA-damaging, and IDO/TDO targets, a linking strategy has mainly been applied to aid the design of more potent dual-target tubulin inhibitors. But larger MW and poor PK properties may lead to lower rates of clinical successes. Most dual-target tubulin inhibitors discovered by pharmacophore-based approaches exhibit more potent therapeutic effects than single MTAs in vitro and in vivo. Unfortunately, none of them enters clinical trials to date. One reason may be that it is still necessary to determine more precise mechanisms of action of these dual-target tubulin inhibitors and try to confirm the most suitable activity ratio toward tubulin and another target. There are currently few publications reporting their human tissue toxicity and in vivo PK properties. Therefore, more studies are demanded to accurately evaluate the in vivo therapeutic mechanism, safety, PK, and pharmacodynamics properties of these dual-target inhibitors for further development as clinical candidates. Moreover, to understand the exact molecular mechanisms of these dual-target tubulin inhibitors acting on tubulin and other targets, the cocrystal structures also need to be resolved. Despite acquiring some successes, drug repurposing and pharmacophore-based approaches restrict the structural diversity of dual-target tubulin inhibitors to a degree. Promisingly, ligand- and structure-based virtual screenings have been used to investigate the dual-target tubulin inhibitors and have facilitated the discovery of the first dual tubulin–Hsp90 inhibitor. In general, it is easier to discover high-quality leads by virtual screenings because these leads usually have small molecular sizes, more favorable physicochemical properties, and novel chemical scaffolds, which are favorable for further structural optimization.</div><div class="NLM_p">Collectively, the development of dual-target tubulin inhibitors has shown considerable potential but is still underdeveloped. The determination of rational target combinations based on cancer relevance and application perspectives is a significant challenge for the development of dual-target tubulin inhibitors. Currently, this was mainly achieved by clinical observations and phenotypic screening on combination therapies. Additionally, optimizing PK and safety profiles is also crucial for clinical success of dual-target tubulin inhibitors. To achieve these requirements, acquiring high-quality dual-target leads with better PK properties is a favorable start. The superior manner is to maximize the overlap of pharmacophores of active parent molecules to obtain smaller dual-functional molecules that possess sufficient space for structural enlargement and modification.<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a> Further PK property optimization of dual-target agents needs to rely on conserving low lipophilicity and avoid excessive structural enlargement.<a onclick="showRef(event, 'ref169 ref170'); return false;" href="javascript:void(0);" class="ref ref169 ref170">(169,170)</a> Unfortunately, due to the requirement of high structural similarity for the pharmacophores of active parent molecules, merging pharmacophores may not always be feasible. Another key issue for dual-target tubulin inhibitors is balancing activities toward multiple targets, achieving high selectivity over undesired targets, and, ultimately, minimizing the toxicity risks. Therefore, more efforts are required for developing novel dual-target tubulin inhibitors with higher therapeutic potentials and drug likeness.</div><div class="NLM_p">Encouragingly, in addition to the aforementioned conventional drug discovery strategies, many new approaches are used for the rational design of dual-target inhibitors. For example, computation-based approaches show extensive prospects in developing novel dual-target tubulin inhibitors. They are feasible for the potentially rational target combinations of dual-target tubulin inhibitors through predicting structural similarity between binding pockets of tubulin and other antitumor targets or signaling network analysis via machine/deep learning.<a onclick="showRef(event, 'ref171 ref172'); return false;" href="javascript:void(0);" class="ref ref171 ref172">(171,172)</a> Furthermore, various structure- and ligand-based approaches have been well-established and widely used, including in silico pharmacophore modeling, docking algorithms, and computation de novo design. They can be applied to identify dual-target leads with novel skeletons and are also viable for the structural modification of dual-target molecules.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> Artificial intelligence (AI) techniques are able to predict the PK properties of dual-target molecules. And the combination of AI and experimental methods can reduce model uncertainties and improve experimental accuracy.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Gene editing approaches and high-quality chemical probes can be used to study the roles of molecular targets in pathologies and correlations between the targets. These approaches are favorable for determining the mechanisms of action of dual-target tubulin inhibitors in cellular level and animal models. Additionally, with the rapid development of X-ray crystallography and cryo-electron microscopy, significant breakthroughs in the structural biology field accelerate the rational design of dual-target drugs.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> Currently, a massive amount of high-resolution structures of ligand–protein complexes including ligands–tubulin complexes<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> has become available and provides detailed views for deciphering the comprehensive molecular mechanism of ligands–protein interactions. These achievements provide the structural basis for the development of dual-target drugs and significantly support structural optimization via structure-based drug discovery.</div><div class="NLM_p last">In summary, the combination of current research advances and innovative drug discovery strategies will provide new insight into the future development of dual-target tubulin inhibitors to improve therapeutic effects and overcome drug resistance.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00100" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40186" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40186" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Li</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-9522-4474" title="Orcid link">https://orcid.org/0000-0002-9522-4474</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#daadb6b39aafaeb2a9b9f4bfbeaf"><span class="__cf_email__" data-cfemail="30475c597045445843531e555445">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Liang Ouyang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, Department of Respiratory
and Critical Care Medicine, Innovation Center of Nursing Research,
National Clinical Research Center for Geriatrics, West China Hospital,
and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, Sichuan, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-5537-8834" title="Orcid link">https://orcid.org/0000-0001-5537-8834</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#1a756f637b747d76737b747d5a69796f347f7e6f347974"><span class="__cf_email__" data-cfemail="127d676b737c757e7b737c75526171673c7776673c717c">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuxi Wang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, Department of Respiratory
and Critical Care Medicine, Innovation Center of Nursing Research,
National Clinical Research Center for Geriatrics, West China Hospital,
and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, Sichuan, China</span>; 
    <span class="hlFld-Affiliation affiliation">Targeted
Tracer Research and Development Laboratory, Institute of Respiratory
Health, Frontiers Science Center for Disease-Related Molecular Network,
West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China</span>; 
    <span class="hlFld-Affiliation affiliation">Precision
Medicine Key Laboratory of Sichuan Province & Precision Medicine
Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-4056-5829" title="Orcid link">https://orcid.org/0000-0002-4056-5829</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#8ff6faf7e6f8eee1e8cffcecfaa1eaebfaa1ece1"><span class="__cf_email__" data-cfemail="82fbf7faebf5e3ece5c2f1e1f7ace7e6f7ace1ec">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wen Shuai</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, Department of Respiratory
and Critical Care Medicine, Innovation Center of Nursing Research,
National Clinical Research Center for Geriatrics, West China Hospital,
and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, Sichuan, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guan Wang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, Department of Respiratory
and Critical Care Medicine, Innovation Center of Nursing Research,
National Clinical Research Center for Geriatrics, West China Hospital,
and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, Sichuan, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yiwen Zhang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, Department of Respiratory
and Critical Care Medicine, Innovation Center of Nursing Research,
National Clinical Research Center for Geriatrics, West China Hospital,
and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, Sichuan, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Faqian Bu</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, Department of Respiratory
and Critical Care Medicine, Innovation Center of Nursing Research,
National Clinical Research Center for Geriatrics, West China Hospital,
and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, Sichuan, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sicheng Zhang</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0003-3798-7550" title="Orcid link">https://orcid.org/0000-0003-3798-7550</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Duane D. Miller</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-6093-0985" title="Orcid link">https://orcid.org/0000-0002-6093-0985</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>W.S., G.W., and Y.Z. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74377" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74377" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Wen Shuai</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=BIO-d7e2772-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Wen Shuai</b> received her Master’s degree in Medicinal Chemistry from China Pharmaceutical University in 2020 and is currently a Ph.D. candidate in the State Key Laboratory of Biotherapy and Cancer Center, Department of Respiratory and Critical Care Medicine, Innovation Center of Nursing Research, National Clinical Research Center for Geriatrics, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University. She is working on the design, synthesis, and biological evaluation of autophagy modulators with potential anticancer activities.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Guan Wang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=BIO-d7e2777-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Guan Wang</b> received his Ph.D. from School of Traditional Chinese Materia Medica, Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University in 2017. Currently, he is an assistant professor at the State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, Innovation Center of Nursing Research, Nursing Key Laboratory of Sichuan Province, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University. His research interests focus on targeted drug design and discovery, pharmaceutical chemistry, and bioinformatics.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Yiwen Zhang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=BIO-d7e2782-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Yiwen Zhang</b> received his B.S. from Sichuan University in 2007 and received his Ph.D. from Sichuan University in 2012. He is currently an associate professor of the State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University. As the project leader, he undertook a NSFC (National Natural Science Foundation of China) project. His research currently focuses on small-molecule drug design and synthesis, especially antitumor agents. He is also interested in drug discovery from natural sources.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Faqian Bu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=BIO-d7e2787-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Faqian Bu</b> is a master’s candidate at the State Key Laboratory of Biotherapy and Cancer Center, Department of Respiratory and Critical Care Medicine, Innovation Center of Nursing Research, National Clinical Research Center for Geriatrics, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University. Her research interest focuses on structural biology and bioinformatics.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Sicheng Zhang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=BIO-d7e2792-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Sicheng Zhang</b> obtained his B.S. degree in Pharmaceutical Engineering at Sichuan University in 2014 and obtained his Ph.D. degree in Organic Chemistry at Huazhong University of Science and Technology in 2017. He is currently a postdoctoral fellow in the Department of Pharmaceutical Sciences at the University of Tennessee Health Science Center (Memphis, TN, USA). His research interests are small-molecule drug discovery for cancer and neurodegenerative diseases.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Duane D. Miller</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=BIO-d7e2797-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Duane D Miller</b> received his Ph.D. degree in Medicinal Chemistry in 1969 at the University of Washington. He began his academic career at The Ohio State University and moved in 1992 to join the University to Tennessee College of Pharmacy. He retired in 2015 and is currently Professor Emeritus at the University of Tennessee Health Science Center. His interest continues to be drug design and synthesis of new drug molecules with a focus on tubulin inhibitors and drugs acting on the androgen receptor. He has drugs in clinical trials for prostate and breast cancers.</p></figure></div><div class="bio" rid="ath7"><figure id="ath7" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Wei Li</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=BIO-d7e2802-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Wei Li</b> received his B.S. degree in Chemical Physics in 1992 at the University of Science & Technology of China. After two years of graduate study in Dalian Institute of Chemical Physics, the Chinese Academy of Sciences, he went to the USA and obtained his Ph.D. degree in Chemistry in 1999 from Columbia University in the City of New York. He has been a faculty member at the University of Tennessee College of Pharmacy (UTCoP) since 1999 and is currently a Distinguished Professor and the Director of the UTCoP Drug Discovery Center. He is also the founder and CSO of SEAK Therapeutics, LLC. His research interests are small-molecule drug discovery and development. He and Dr. Duane Miller have one clinical candidate (VERU-111) currently in clinical trials for metastatic prostate cancer and COVID-19.</p></figure></div><div class="bio" rid="ath8"><figure id="ath8" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Liang Ouyang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=BIO-d7e2807-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Liang Ouyang</b> received his Ph.D. degree in medicinal chemistry from West China School of Pharmacy, Sichuan University, in 2010. He began his academic career in 2012 at the State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, Innovation Center of Nursing Research, Nursing Key Laboratory of Sichuan Province, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University as a professor. His research interests include the identification of novel drug targets in cell death and the structure-based discovery of small-molecule and peptide drugs.</p></figure></div><div class="bio" rid="ath9"><figure id="ath9" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Yuxi Wang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=BIO-d7e2812-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Yuxi Wang</b> received his B.S. from West China School of Pharmacy, Sichuan University, in 2011, and received his Ph.D. from State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University in 2016. Currently, he is a professor at the Department of Respiratory and Critical Care Medicine, Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Frontiers Science Center for Disease-Related Molecular Network, Precision Medicine Research Center, West China Hospital, Sichuan University. His research interests focus on drug design and discovery based on structure biology, especially for two-target/multitarget drugs development. At present, several small molecule compounds are in the stage of preclinical research.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01017" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01017" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by grants from the National Natural Science Foundation of China (Grants 81922064, 82073318, 81803755, and 81874290), the National Major Scientific and Technological Special Project for “Significant New Drugs Development” (Grant 2018ZX09201018-021), the Sichuan Science and Technology Program (Grant 2019YFS0003), and the National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University (Grant Z20201004). W.L. and D.D.M. acknowledge the support from the UTCoP Drug Discovery Center.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">AI</td><td class="NLM_def"><p class="first last">artificial intelligence</p></td></tr><tr><td class="NLM_term">AMPK</td><td class="NLM_def"><p class="first last">AMP-activated protein kinase</p></td></tr><tr><td class="NLM_term">CA-4</td><td class="NLM_def"><p class="first last">combretastatin A-4</p></td></tr><tr><td class="NLM_term">Cdc20</td><td class="NLM_def"><p class="first last">cell division cycle 20 homologue</p></td></tr><tr><td class="NLM_term">CDDP</td><td class="NLM_def"><p class="first last">cisplatin</p></td></tr><tr><td class="NLM_term">CRISPR</td><td class="NLM_def"><p class="first last">clusters of regularly interspaced short palindromic repeats</p></td></tr><tr><td class="NLM_term">DCA</td><td class="NLM_def"><p class="first last">dichloroacetic acid</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">ER</td><td class="NLM_def"><p class="first last">estrogen receptor</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">FLT3</td><td class="NLM_def"><p class="first last">FMS-like tyrosine kinase 3</p></td></tr><tr><td class="NLM_term">FTase</td><td class="NLM_def"><p class="first last">farnesyltransferase</p></td></tr><tr><td class="NLM_term">GDP</td><td class="NLM_def"><p class="first last">guanosine diphosphate</p></td></tr><tr><td class="NLM_term">GTP</td><td class="NLM_def"><p class="first last">guanosine triphosphate</p></td></tr><tr><td class="NLM_term">HDAC</td><td class="NLM_def"><p class="first last">histone deacetylase</p></td></tr><tr><td class="NLM_term">HER-2</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor-2</p></td></tr><tr><td class="NLM_term">Hsp90</td><td class="NLM_def"><p class="first last">heat shock protein 90</p></td></tr><tr><td class="NLM_term">IDO</td><td class="NLM_def"><p class="first last">indoleamine-2,3-dioxygenase</p></td></tr><tr><td class="NLM_term"><i>iso</i>CA-4</td><td class="NLM_def"><p class="first last">isocombretastation A-4</p></td></tr><tr><td class="NLM_term">ITD</td><td class="NLM_def"><p class="first last">internal tandem duplications</p></td></tr><tr><td class="NLM_term">Kyn</td><td class="NLM_def"><p class="first last">kynurenine</p></td></tr><tr><td class="NLM_term">MDA</td><td class="NLM_def"><p class="first last">microtubule-destabilizing agent</p></td></tr><tr><td class="NLM_term">MK2</td><td class="NLM_def"><p class="first last">MAPK-activated protein kinase</p></td></tr><tr><td class="NLM_term">MSA</td><td class="NLM_def"><p class="first last">microtubule-stabilizing agent</p></td></tr><tr><td class="NLM_term">MTA</td><td class="NLM_def"><p class="first last">microtubule-targeting agent</p></td></tr><tr><td class="NLM_term">MW</td><td class="NLM_def"><p class="first last">molecular weight</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">metastatic squamous nonsmall cell lung cancer</p></td></tr><tr><td class="NLM_term">PARP</td><td class="NLM_def"><p class="first last">poly(ADP-ribose) polymerase</p></td></tr><tr><td class="NLM_term">PDGFR</td><td class="NLM_def"><p class="first last">platelet-derived growth factor receptor</p></td></tr><tr><td class="NLM_term">PDHK1</td><td class="NLM_def"><p class="first last">pyruvate dehydrogenase kinase 1</p></td></tr><tr><td class="NLM_term">P-gp</td><td class="NLM_def"><p class="first last">P-glycoprotein</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphoinositide 3-kinase</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">Pt</td><td class="NLM_def"><p class="first last">platinum</p></td></tr><tr><td class="NLM_term">RAF</td><td class="NLM_def"><p class="first last">rapidly accelerated fibrosarcoma</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">SAHA</td><td class="NLM_def"><p class="first last">vorinostat</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SphK</td><td class="NLM_def"><p class="first last">sphingosine kinase</p></td></tr><tr><td class="NLM_term">TDO</td><td class="NLM_def"><p class="first last">tryptophan-2,3-dioxygenase</p></td></tr><tr><td class="NLM_term">topo II</td><td class="NLM_def"><p class="first last">topoisomerase II</p></td></tr><tr><td class="NLM_term">VDA</td><td class="NLM_def"><p class="first last">vascular-disrupting agent</p></td></tr><tr><td class="NLM_term">VEGFR</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor receptor</p></td></tr><tr><td class="NLM_term">ZBG</td><td class="NLM_def"><p class="first last">zinc-binding group</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67718" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67718" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 174 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, L.</span></span> <span> </span><span class="NLM_article-title">Microtubules as a target for anticancer drugs</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">265</span>, <span class="refDoi"> DOI: 10.1038/nrc1317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1038%2Fnrc1317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=15057285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=253-265&author=M.+A.+Jordanauthor=L.+Wilson&title=Microtubules+as+a+target+for+anticancer+drugs&doi=10.1038%2Fnrc1317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubules as a target for anticancer drugs</span></div><div class="casAuthors">Jordan, Mary Ann; Wilson, Leslie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">253-265</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Highly dynamic mitotic-spindle microtubules are among the most successful targets for anticancer therapy.  Microtubule-targeted drugs, including paclitaxel and Vinca alkaloids, were previously considered to work primarily by increasing or decreasing the cellular microtubule mass.  Although these effects might have a role in their chemotherapeutic actions, we now know that at lower concns., microtubule-targeted drugs can suppress microtubule dynamics without changing microtubule mass; this action leads to mitotic block and apoptosis.  In addn. to the expanding array of chem. diverse antimitotic agents, some microtubule-targeted drugs can act as vascular-targeting agents, rapidly depolymg. microtubules of newly formed vasculature to shut down the blood supply to tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRJbrFnzwqjbVg90H21EOLACvtfcHk0liC8hsBNX74kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D&md5=bbbf212e03ffe6763098fc41f21a8158</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc1317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1317%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DM.%2BA.%26aulast%3DWilson%26aufirst%3DL.%26atitle%3DMicrotubules%2520as%2520a%2520target%2520for%2520anticancer%2520drugs%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D253%26epage%3D265%26doi%3D10.1038%2Fnrc1317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prota, A. E.</span></span> <span> </span><span class="NLM_article-title">Microtubule-targeting agents: strategies to hijack the cytoskeleton</span>. <i>Trends Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">776</span>– <span class="NLM_lpage">792</span>, <span class="refDoi"> DOI: 10.1016/j.tcb.2018.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.tcb.2018.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=29871823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpslaksL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=776-792&author=M.+O.+Steinmetzauthor=A.+E.+Prota&title=Microtubule-targeting+agents%3A+strategies+to+hijack+the+cytoskeleton&doi=10.1016%2Fj.tcb.2018.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-Targeting Agents: Strategies To Hijack the Cytoskeleton</span></div><div class="casAuthors">Steinmetz, Michel O.; Prota, Andrea E.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">776-792</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Microtubule-targeting agents (MTAs) such as paclitaxel and the vinca alkaloids are among the most important medical weapons available to combat cancer.  MTAs interfere with intracellular transport, inhibit eukaryotic cell proliferation, and promote cell death by suppressing microtubule dynamics.  Recent advances in the structural anal. of MTAs have enabled the extensive characterization of their interactions with microtubules and their building block tubulin.  We review here our current knowledge on the mol. mechanisms used by MTAs to hijack the microtubule cytoskeleton, and discuss dual inhibitors that target both kinases and microtubules.  We further formulate some outstanding questions related to MTA structural biol. and present possible routes for future investigations of this fascinating class of antimitotic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0akrt04GstbVg90H21EOLACvtfcHk0liC8hsBNX74kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpslaksL0%253D&md5=b6ec960a802f658b3f21e030e687c60e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.tcb.2018.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcb.2018.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26aulast%3DProta%26aufirst%3DA.%2BE.%26atitle%3DMicrotubule-targeting%2520agents%253A%2520strategies%2520to%2520hijack%2520the%2520cytoskeleton%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2018%26volume%3D28%26spage%3D776%26epage%3D792%26doi%3D10.1016%2Fj.tcb.2018.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dumontet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, M. A.</span></span> <span> </span><span class="NLM_article-title">Microtubule-binding agents: a dynamic field of cancer therapeutics</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">790</span>– <span class="NLM_lpage">803</span>, <span class="refDoi"> DOI: 10.1038/nrd3253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1038%2Fnrd3253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=20885410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1akur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=790-803&author=C.+Dumontetauthor=M.+A.+Jordan&title=Microtubule-binding+agents%3A+a+dynamic+field+of+cancer+therapeutics&doi=10.1038%2Fnrd3253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-binding agents: a dynamic field of cancer therapeutics</span></div><div class="casAuthors">Dumontet, Charles; Jordan, Mary Ann</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">790-803</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Microtubules are dynamic filamentous cytoskeletal proteins composed of tubulin and are an important therapeutic target in tumor cells.  Agents that bind to microtubules have been part of the pharmacopoeia of anticancer therapy for decades and until the advent of targeted therapy, microtubules were the only alternative to DNA as a therapeutic target in cancer.  The screening of a range of botanical species and marine organisms has yielded promising new antitubulin agents with novel properties.  In the current search for novel microtubule-binding agents, enhanced tumor specificity, reduced neurotoxicity and insensitivity to chemoresistance mechanisms are the three main objectives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ43DyXjdN7rVg90H21EOLACvtfcHk0liC8hsBNX74kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1akur%252FI&md5=9fc6fd966859785605936ecbe6dca44e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd3253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3253%26sid%3Dliteratum%253Aachs%26aulast%3DDumontet%26aufirst%3DC.%26aulast%3DJordan%26aufirst%3DM.%2BA.%26atitle%3DMicrotubule-binding%2520agents%253A%2520a%2520dynamic%2520field%2520of%2520cancer%2520therapeutics%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D790%26epage%3D803%26doi%3D10.1038%2Fnrd3253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horwitz, S. B.</span></span> <span> </span><span class="NLM_article-title">Taxol<sup>®</sup>: The first microtubule stabilizing agent</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1733</span>, <span class="refDoi"> DOI: 10.3390/ijms18081733</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.3390%2Fijms18081733" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVWgurvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1733&author=C.+H.+Yangauthor=S.+B.+Horwitz&title=Taxol%C2%AE%3A+The+first+microtubule+stabilizing+agent&doi=10.3390%2Fijms18081733"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Taxol: the first microtubule stabilizing agent</span></div><div class="casAuthors">Yang, Chia-Ping Huang; Horwitz, Susan Band</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1733/1-1733/11</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Taxol, an antitumor drug with significant activity, is the first microtubule stabilizing agent described in the literature.  This short review of the mechanism of action of Taxol emphasizes the research done in the Horwitz' lab.  It discusses the contribution of photoaffinity labeled analogs of Taxol toward our understanding of the binding site of the drug on the microtubule.  The importance of hydrogen/deuterium exchange expts. to further our insights into the stabilization of microtubules by Taxol is addressed.  The development of drug resistance, a major problem that arises in the clinic, is discussed.  Studies describing differential drug binding to distinct β-tubulin isotypes are presented.  Looking forward, it is suggested that the β-tubulin isotype content of a tumor may influence its responses to Taxol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFUMBXgAHw7rVg90H21EOLACvtfcHk0lj-m4G59hRBJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVWgurvM&md5=9f591b369cba246d8860fb491bd85ef8</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.3390%2Fijms18081733&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18081733%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DC.%2BH.%26aulast%3DHorwitz%26aufirst%3DS.%2BB.%26atitle%3DTaxol%25C2%25AE%253A%2520The%2520first%2520microtubule%2520stabilizing%2520agent%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D1733%26doi%3D10.3390%2Fijms18081733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kavallaris, M.</span></span> <span> </span><span class="NLM_article-title">Microtubules and resistance to tubulin-binding agents</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">194</span>– <span class="NLM_lpage">204</span>, <span class="refDoi"> DOI: 10.1038/nrc2803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1038%2Fnrc2803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=20147901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvVKrtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=194-204&author=M.+Kavallaris&title=Microtubules+and+resistance+to+tubulin-binding+agents&doi=10.1038%2Fnrc2803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubules and resistance to tubulin-binding agents</span></div><div class="casAuthors">Kavallaris, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">194-204</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Microtubules are dynamic structures composed of α-β-tubulin heterodimers that are essential in cell division and are important targets for cancer drugs.  Mutations in β-tubulin that affect microtubule polymer mass and/or drug binding are assocd. with resistance to tubulin-binding agents such as paclitaxel.  The aberrant expression of specific β-tubulin isotypes, in particular βIII-tubulin, or of microtubule-regulating proteins is important clin. in tumor aggressiveness and resistance to chemotherapy.  In addn., changes in actin regulation can also mediate resistance to tubulin-binding agents.  Understanding the mol. mechanisms that mediate resistance to tubulin-binding agents will be vital to improve the efficacy of these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNkoVu03ikmrVg90H21EOLACvtfcHk0lj-m4G59hRBJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvVKrtbg%253D&md5=1ce71cc537091459d7ee6866c0950b33</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrc2803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2803%26sid%3Dliteratum%253Aachs%26aulast%3DKavallaris%26aufirst%3DM.%26atitle%3DMicrotubules%2520and%2520resistance%2520to%2520tubulin-binding%2520agents%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D194%26epage%3D204%26doi%3D10.1038%2Fnrc2803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verrills, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavallaris, M.</span></span> <span> </span><span class="NLM_article-title">Improving the targeting of tubulin-binding agents: lessons from drug resistance studies</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1719</span>– <span class="NLM_lpage">1733</span>, <span class="refDoi"> DOI: 10.2174/1381612053764706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.2174%2F1381612053764706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=15892670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktlajur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=1719-1733&author=N.+M.+Verrillsauthor=M.+Kavallaris&title=Improving+the+targeting+of+tubulin-binding+agents%3A+lessons+from+drug+resistance+studies&doi=10.2174%2F1381612053764706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Improving the targeting of tubulin-binding agents: Lessons from drug resistance studies</span></div><div class="casAuthors">Verrills, N. M.; Kavallaris, M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1719-1733</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Natural product drugs that target the tubulin/microtubule system remain an important component in the therapeutic arsenal to treat many types of malignancies.  Agents such as the taxanes and vinca alkaloids bind to β-tubulin and disrupt microtubule dynamics by inducing a potent mitotic block and subsequent cell death.  Understanding why certain cancers do not respond to treatment or develop resistance has been subject of numerous studies in recent years.  An increasing body of evidence suggests that alterations in the drug target, such as tubulin mutations, altered microtubule dynamics, altered tubulin isotype expression, and modifications in microtubule regulatory proteins, are key mechanisms of antimicrotubule drug resistance.  In addn., recent work indicates that other cytoskeletal proteins that can regulate microtubule dynamics through signaling or structural interactions may be important determinants of antimicrotubule resistance.  As our understanding of drug action and resistance mechanisms has increased, we can now begin to exploit these to design strategies that overcome, or counteract resistance, hence improving the efficacy of antimicrotubule agents for the treatment of cancer.  This review highlights the major areas of investigation as they relate to the tubulin/microtubule system and discusses opportunities that potentially exist for improved therapeutic benefit in the treatment of drug resistant disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrApSnhIVkcHrVg90H21EOLACvtfcHk0lj-m4G59hRBJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktlajur0%253D&md5=e9b7e356e6c31cca4355c13f88cd5e35</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2174%2F1381612053764706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612053764706%26sid%3Dliteratum%253Aachs%26aulast%3DVerrills%26aufirst%3DN.%2BM.%26aulast%3DKavallaris%26aufirst%3DM.%26atitle%3DImproving%2520the%2520targeting%2520of%2520tubulin-binding%2520agents%253A%2520lessons%2520from%2520drug%2520resistance%2520studies%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2005%26volume%3D11%26spage%3D1719%26epage%3D1733%26doi%3D10.2174%2F1381612053764706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Canta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiorazzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavaletti, G.</span></span> <span> </span><span class="NLM_article-title">Tubulin: a target for antineoplastic drugs into the cancer cells but also in the peripheral nervous system</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1315</span>– <span class="NLM_lpage">1324</span>, <span class="refDoi"> DOI: 10.2174/092986709787846488</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.2174%2F092986709787846488" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=19355888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltVeqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=1315-1324&author=A.+Cantaauthor=A.+Chiorazziauthor=G.+Cavaletti&title=Tubulin%3A+a+target+for+antineoplastic+drugs+into+the+cancer+cells+but+also+in+the+peripheral+nervous+system&doi=10.2174%2F092986709787846488"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Tubulin as a target for antineoplastic drugs into the cancer cells but also in the peripheral nervous system</span></div><div class="casAuthors">Canta, Annalisa; Chiorazzi, Alessia; Cavaletti, Guido</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1315-1324</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Since the introduction into clin. practice of vinca alkaloids, tubulin has become a key and well-established target of modern antineoplastic chemotherapy.  When taxanes became available their broad spectrum of activity was striking and opened up new horizons for cancer patients' treatment.  However, taxanes' susceptibility to drug resistance caused by the drug efflux pump protein, P-glycoprotein, is not infrequent and their use may be limited by poor soly., synthetic problems and toxicity.  The epothilones are a new class of chemotherapeutic agents with a mechanism of action similar to that of taxanes, but different enough to escape, for example, the multidrug resistance caused by P-glycoprotein.  Moreover, the epothilones (that are strong promoters of tubulin polymn.) have significant antitumor activity against human cancer cells that are taxane-resistant, express the multidrug resistance gene MDR-1, and have acquired tubulin mutations.  Finally, starting from the natural mols., several synthetic analogs have been developed.  Besides their antineoplastic efficacy, all the antitubulin drugs share a common toxicity on the peripheral nervous system and peripheral neurotoxicity is a major, potentially dose-limiting side effect also of the epothilones.  The current knowledge regarding the features of epothilones' peripheral neurotoxicity and their comparison with taxanes will be reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrud9z8vnFGFLVg90H21EOLACvtfcHk0lixBAXdO10L0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltVeqsbo%253D&md5=88fe8b8400cb3ec5be160439503c914f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2174%2F092986709787846488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986709787846488%26sid%3Dliteratum%253Aachs%26aulast%3DCanta%26aufirst%3DA.%26aulast%3DChiorazzi%26aufirst%3DA.%26aulast%3DCavaletti%26aufirst%3DG.%26atitle%3DTubulin%253A%2520a%2520target%2520for%2520antineoplastic%2520drugs%2520into%2520the%2520cancer%2520cells%2520but%2520also%2520in%2520the%2520peripheral%2520nervous%2520system%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2009%26volume%3D16%26spage%3D1315%26epage%3D1324%26doi%3D10.2174%2F092986709787846488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talevi, A.</span></span> <span> </span><span class="NLM_article-title">Multi-target pharmacology: possibilities and limitations of the “skeleton key approach” from a medicinal chemist perspective</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">205</span>, <span class="refDoi"> DOI: 10.3389/fphar.2015.00205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.3389%2Ffphar.2015.00205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=26441661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1amurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=205&author=A.+Talevi&title=Multi-target+pharmacology%3A+possibilities+and+limitations+of+the+%E2%80%9Cskeleton+key+approach%E2%80%9D+from+a+medicinal+chemist+perspective&doi=10.3389%2Ffphar.2015.00205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target pharmacology: possibilities and limitations of the "skeleton key approach" from a medicinal chemist perspective</span></div><div class="casAuthors">Talevi, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">205/1-205/7</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Multi-target drugs have raised considerable interest in the last decade owing to their advantages in the treatment of complex diseases and health conditions linked to drug resistance issues.  Prospective drug repositioning to treat comorbid conditions is an addnl., overlooked application of multi-target ligands.  While medicinal chemists usually rely on some version of the lock and key paradigm to design novel therapeutics, modern pharmacol. recognizes that the mid- and long-term effects of a given drug on a biol. system may depend not only on the specific ligand-target recognition events but also on the influence of the repeated administration of a drug on the cell gene signature.  The design of multi-target agents usually imposes challenging restrictions on the topol. or flexibility of the candidate drugs, which are briefly discussed in the present article.  Finally, computational strategies to approach the identification of novel multi-target agents are overviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSdZokyMjNSLVg90H21EOLACvtfcHk0lixBAXdO10L0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1amurnM&md5=169718a4644d962da33806772a9a33e3</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2015.00205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2015.00205%26sid%3Dliteratum%253Aachs%26aulast%3DTalevi%26aufirst%3DA.%26atitle%3DMulti-target%2520pharmacology%253A%2520possibilities%2520and%2520limitations%2520of%2520the%2520%25E2%2580%259Cskeleton%2520key%2520approach%25E2%2580%259D%2520from%2520a%2520medicinal%2520chemist%2520perspective%26jtitle%3DFront.%2520Pharmacol.%26date%3D2015%26volume%3D6%26spage%3D205%26doi%3D10.3389%2Ffphar.2015.00205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosini, M.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology: the rise of multitarget drugs over combination therapies</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">485</span>– <span class="NLM_lpage">487</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.25</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.4155%2Ffmc.14.25" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=24649950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2cXksFyitb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=485-487&author=M.+Rosini&title=Polypharmacology%3A+the+rise+of+multitarget+drugs+over+combination+therapies&doi=10.4155%2Ffmc.14.25"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: the rise of multitarget drugs over combination therapies</span></div><div class="casAuthors">Rosini, Michela</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">485-487</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvNBzYCAfAa7Vg90H21EOLACvtfcHk0ljwEtAd7pcknA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXksFyitb0%253D&md5=0c32e1a1ae5a13cd25483ba18833fd54</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.25&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.25%26sid%3Dliteratum%253Aachs%26aulast%3DRosini%26aufirst%3DM.%26atitle%3DPolypharmacology%253A%2520the%2520rise%2520of%2520multitarget%2520drugs%2520over%2520combination%2520therapies%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D485%26epage%3D487%26doi%3D10.4155%2Ffmc.14.25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology in a single drug: Multitarget drugs</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1639</span>– <span class="NLM_lpage">1645</span>, <span class="refDoi"> DOI: 10.2174/0929867311320130004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.2174%2F0929867311320130004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=23410164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotl2jtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1639-1645&author=M.+L.+Bolognesi&title=Polypharmacology+in+a+single+drug%3A+Multitarget+drugs&doi=10.2174%2F0929867311320130004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology in a single drug: multitarget drugs</span></div><div class="casAuthors">Bolognesi, M. L.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1639-1645</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Polypharmacol. offers a model for the way drug discovery must evolve to develop therapies most suited to treating currently incurable diseases.  It is driven by a worldwide demand for safer, more effective, and affordable medicines against the most complex diseases, and by the failures of modern drug discovery to provide these.  Polypharmacol. can involve combinations and/or multitarget drugs (MTD).  Although not mutually exclusive, my premise is that MTDs have inherent advantages over combinations.  This review article focuses on MTDs from a medicinal chem. perspective.  I will explore their use in current clin. practice, their likely application in the future, and the challenges to be overcome to achieve this goal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeSnmeFeRpMrVg90H21EOLACvtfcHk0ljwEtAd7pcknA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotl2jtLk%253D&md5=0e69395566711e018db8a61b1ae0f56e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2174%2F0929867311320130004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867311320130004%26sid%3Dliteratum%253Aachs%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DPolypharmacology%2520in%2520a%2520single%2520drug%253A%2520Multitarget%2520drugs%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D20%26spage%3D1639%26epage%3D1645%26doi%3D10.2174%2F0929867311320130004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehár, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keith, C. T.</span></span> <span> </span><span class="NLM_article-title">Multi-target therapeutics: when the whole is greater than the sum of the parts</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2006.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.drudis.2006.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=17198971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252Fgt1ygtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=34-42&author=G.+R.+Zimmermannauthor=J.+Leh%C3%A1rauthor=C.+T.+Keith&title=Multi-target+therapeutics%3A+when+the+whole+is+greater+than+the+sum+of+the+parts&doi=10.1016%2Fj.drudis.2006.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target therapeutics: when the whole is greater than the sum of the parts</span></div><div class="casAuthors">Zimmermann Grant R; Lehar Joseph; Keith Curtis T</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">34-42</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">Drugs designed to act against individual molecular targets cannot usually combat multigenic diseases such as cancer, or diseases that affect multiple tissues or cell types such as diabetes and immunoinflammatory disorders.  Combination drugs that impact multiple targets simultaneously are better at controlling complex disease systems, are less prone to drug resistance and are the standard of care in many important therapeutic areas.  The combination drugs currently employed are primarily of rational design, but the increased efficacy they provide justifies in vitro discovery efforts for identifying novel multi-target mechanisms.  In this review, we discuss the biological rationale for combination therapeutics, review some existing combination drugs and present a systematic approach to identify interactions between molecular pathways that could be leveraged for therapeutic benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTI14vYK2Q1LENHe_gFldTbfW6udTcc2eZb60O2zk16r7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252Fgt1ygtQ%253D%253D&md5=66715499ce21c2855dc6c477aa87f161</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2006.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2006.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DG.%2BR.%26aulast%3DLeh%25C3%25A1r%26aufirst%3DJ.%26aulast%3DKeith%26aufirst%3DC.%2BT.%26atitle%3DMulti-target%2520therapeutics%253A%2520when%2520the%2520whole%2520is%2520greater%2520than%2520the%2520sum%2520of%2520the%2520parts%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2007%26volume%3D12%26spage%3D34%26epage%3D42%26doi%3D10.1016%2Fj.drudis.2006.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anighoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajorath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rastelli, G.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology: challenges and opportunities in drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7874</span>– <span class="NLM_lpage">7887</span>, <span class="refDoi"> DOI: 10.1021/jm5006463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7874-7887&author=A.+Anighoroauthor=J.+Bajorathauthor=G.+Rastelli&title=Polypharmacology%3A+challenges+and+opportunities+in+drug+discovery&doi=10.1021%2Fjm5006463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: Challenges and Opportunities in Drug Discovery</span></div><div class="casAuthors">Anighoro, Andrew; Bajorath, Jurgen; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7874-7887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biol. target, shares the spotlight with an emerging and alternative polypharmacol. approach.  Polypharmacol. suggests that more effective drugs can be developed by specifically modulating multiple targets.  It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches.  In this respect, a drug that "hits" multiple sensitive nodes belonging to a network of interacting targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs.  In this review, we will compare advantages and disadvantages of multitarget vs. combination therapies, discuss potential drug promiscuity arising from off-target effects, comment on drug repurposing, and introduce approaches to the computational design of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOTyEu80AZrVg90H21EOLACvtfcHk0lg4uZq2gegDWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I&md5=5ab36c961a84462d90bc25130d90a281</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm5006463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006463%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DPolypharmacology%253A%2520challenges%2520and%2520opportunities%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7874%26epage%3D7887%26doi%3D10.1021%2Fjm5006463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arnst, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span> <span> </span><span class="NLM_article-title">Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1398</span>– <span class="NLM_lpage">1426</span>, <span class="refDoi"> DOI: 10.1002/med.21568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1002%2Fmed.21568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=30746734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A280%3ADC%252BB3cfhslejug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2019&pages=1398-1426&author=K.+E.+Arnstauthor=S.+Banerjeeauthor=H.+Chenauthor=S.+Dengauthor=D.+J.+Hwangauthor=W.+Liauthor=D.+D.+Miller&title=Current+advances+of+tubulin+inhibitors+as+dual+acting+small+molecules+for+cancer+therapy&doi=10.1002%2Fmed.21568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy</span></div><div class="casAuthors">Arnst Kinsie E; Banerjee Souvik; Chen Hao; Deng Shanshan; Hwang Dong-Jin; Li Wei; Miller Duane D</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal research reviews</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1398-1426</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Microtubule (MT)-targeting agents are highly successful drugs as chemotherapeutic agents, and this is attributed to their ability to target MT dynamics and interfere with critical cellular functions, including, mitosis, cell signaling, intracellular trafficking, and angiogenesis.  Because MT dynamics vary in the different stages of the cell cycle, these drugs tend to be the most effective against mitotic cells.  While this class of drug has proven to be effective against many cancer types, significant hurdles still exist and include overcoming aspects such as dose limited toxicities and the development of resistance.  Newer generations of developed drugs attack these problems and alternative approaches such as the development of dual tubulin and kinase inhibitors are being investigated.  This approach offers the potential to show increased efficacy and lower toxicities.  This review covers different categories of MT-targeting agents, recent advances in dual inhibitors, and current challenges for this drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTqfJ98Efo_uekdrW1FkXG-fW6udTcc2eZOkyoj-yAJ6rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cfhslejug%253D%253D&md5=dafb1dbc34589cd0e9a9ac0f384252f1</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fmed.21568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21568%26sid%3Dliteratum%253Aachs%26aulast%3DArnst%26aufirst%3DK.%2BE.%26aulast%3DBanerjee%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DDeng%26aufirst%3DS.%26aulast%3DHwang%26aufirst%3DD.%2BJ.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26atitle%3DCurrent%2520advances%2520of%2520tubulin%2520inhibitors%2520as%2520dual%2520acting%2520small%2520molecules%2520for%2520cancer%2520therapy%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2019%26volume%3D39%26spage%3D1398%26epage%3D1426%26doi%3D10.1002%2Fmed.21568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanabe, K.</span></span> <span> </span><span class="NLM_article-title">Microtubule depolymerization by kinase inhibitors: Unexpected findings of dual inhibitors</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2508</span>, <span class="refDoi"> DOI: 10.3390/ijms18122508</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.3390%2Fijms18122508" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVOgtrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=2508&author=K.+Tanabe&title=Microtubule+depolymerization+by+kinase+inhibitors%3A+Unexpected+findings+of+dual+inhibitors&doi=10.3390%2Fijms18122508"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule depolymerization by kinase inhibitors: unexpected findings of dual inhibitors</span></div><div class="casAuthors">Tanabe, Kenji</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2508/1-2508/10</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Microtubule-targeting agents are widely used as clin. drugs in the treatment of cancer.  However, some kinase inhibitors can also disrupt microtubule organization by directly binding to tubulin.  These unexpected effects may result in a plethora of harmful events and/or a misinterpretation of the exptl. results.  Thus, further studies are needed to understand these dual inhibitors.  In this review, I discuss the roles of dual inhibitors of kinase activity and microtubule function as well as describe the properties underlining their dual roles.  Since both kinase and microtubule inhibitors cause cell toxicity and cell cycle arrest, it is difficult to det. which inhibitor is responsible for each phenotype.  A discrimination of cell cycle arrest at G0/G1 or G2/M and/or image analyses of cellular phenotype may eventually lead to new insights on drug duality.  Because of the indispensable roles of microtubules in mitosis and vesicle transport, I propose a simple and easy method to identify microtubule depolymg. compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtx7y9QgYgvrVg90H21EOLACvtfcHk0lg4uZq2gegDWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVOgtrbI&md5=97e65694545ed24fae1e4b97093eb454</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.3390%2Fijms18122508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18122508%26sid%3Dliteratum%253Aachs%26aulast%3DTanabe%26aufirst%3DK.%26atitle%3DMicrotubule%2520depolymerization%2520by%2520kinase%2520inhibitors%253A%2520Unexpected%2520findings%2520of%2520dual%2520inhibitors%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D2508%26doi%3D10.3390%2Fijms18122508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Horio, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murata, T.</span></span> <span> </span><span class="NLM_article-title">The role of dynamic instability in microtubule organization</span>. <i>Front. Plant Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">511</span>, <span class="refDoi"> DOI: 10.3389/fpls.2014.00511</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.3389%2Ffpls.2014.00511" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=25339962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A280%3ADC%252BC2M3ivVynsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=511&author=T.+Horioauthor=T.+Murata&title=The+role+of+dynamic+instability+in+microtubule+organization&doi=10.3389%2Ffpls.2014.00511"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The role of dynamic instability in microtubule organization</span></div><div class="casAuthors">Horio Tetsuya; Murata Takashi</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in plant science</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">511</span>
        ISSN:<span class="NLM_cas:issn">1664-462X</span>.
    </div><div class="casAbstract">Microtubules are one of the three major cytoskeletal components in eukaryotic cells.  Heterodimers composed of GTP-bound α- and β-tubulin molecules polymerize to form microtubule protofilaments, which associate laterally to form a hollow microtubule.  Tubulin has GTPase activity and the GTP molecules associated with β-tubulin molecules are hydrolyzed shortly after being incorporated into the polymerizing microtubules.  GTP hydrolysis alters the conformation of the tubulin molecules and drives the dynamic behavior of microtubules.  Periods of rapid microtubule polymerization alternate with periods of shrinkage in a process known as dynamic instability.  In plants, dynamic instability plays a key role in determining the organization of microtubules into arrays, and these arrays vary throughout the cell cycle.  In this review, we describe the mechanisms that regulate microtubule dynamics and underlie dynamic instability, and discuss how dynamic instability may shape microtubule organization in plant cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTKIELlIMPJoxcr74wzj5o5fW6udTcc2eZlFUbWqpixbbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M3ivVynsA%253D%253D&md5=144a44253d931a66c1a2fe49283440b9</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.3389%2Ffpls.2014.00511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffpls.2014.00511%26sid%3Dliteratum%253Aachs%26aulast%3DHorio%26aufirst%3DT.%26aulast%3DMurata%26aufirst%3DT.%26atitle%3DThe%2520role%2520of%2520dynamic%2520instability%2520in%2520microtubule%2520organization%26jtitle%3DFront.%2520Plant%2520Sci.%26date%3D2014%26volume%3D5%26spage%3D511%26doi%3D10.3389%2Ffpls.2014.00511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stanton, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gernert, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nettles, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aneja, R.</span></span> <span> </span><span class="NLM_article-title">Drugs that target dynamic microtubules: a new molecular perspective</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">443</span>– <span class="NLM_lpage">481</span>, <span class="refDoi"> DOI: 10.1002/med.20242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1002%2Fmed.20242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=21381049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3MXksVKlsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=443-481&author=R.+A.+Stantonauthor=K.+M.+Gernertauthor=J.+H.+Nettlesauthor=R.+Aneja&title=Drugs+that+target+dynamic+microtubules%3A+a+new+molecular+perspective&doi=10.1002%2Fmed.20242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Drugs that target dynamic microtubules: A new molecular perspective</span></div><div class="casAuthors">Stanton, Richard A.; Gernert, Kim M.; Nettles, James H.; Aneja, Ritu</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">443-481</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Microtubules have long been considered an ideal target for anticancer drugs because of the essential role they play in mitosis, forming the dynamic spindle app.  As such, there is a wide variety of compds. currently in clin. use and in development that act as antimitotic agents by altering microtubule dynamics.  Although these diverse mols. are known to affect microtubule dynamics upon binding to one of the three established drug domains (taxane, vinca alkaloid, or colchicine site), the exact mechanism by which each drug works is still an area of intense speculation and research.  In this study, we review the effects of microtubule-binding chemotherapeutic agents from a new perspective, considering how their mode of binding induces conformational changes and alters biol. function relative to the mol. vectors of microtubule assembly or disassembly.  These "biol. vectors" can thus be used as a spatiotemporal context to describe mol. mechanisms by which microtubule-targeting drugs work. © 2011 Wiley Periodicals, Inc.  Med Res Rev, 31, No. 3, 443-481, 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB6_lcUQbXYrVg90H21EOLACvtfcHk0lj-1t5W7IhSuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXksVKlsLs%253D&md5=acce5b9cc89581a7dab0236072b68c72</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fmed.20242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20242%26sid%3Dliteratum%253Aachs%26aulast%3DStanton%26aufirst%3DR.%2BA.%26aulast%3DGernert%26aufirst%3DK.%2BM.%26aulast%3DNettles%26aufirst%3DJ.%2BH.%26aulast%3DAneja%26aufirst%3DR.%26atitle%3DDrugs%2520that%2520target%2520dynamic%2520microtubules%253A%2520a%2520new%2520molecular%2520perspective%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2011%26volume%3D31%26spage%3D443%26epage%3D481%26doi%3D10.1002%2Fmed.20242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brouhard, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, L. M.</span></span> <span> </span><span class="NLM_article-title">The contribution of αβ-tubulin curvature to microtubule dynamics</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>207</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">334</span>, <span class="refDoi"> DOI: 10.1083/jcb.201407095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1083%2Fjcb.201407095" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=25385183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFGhs7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=207&publication_year=2014&pages=323-334&author=G.+J.+Brouhardauthor=L.+M.+Rice&title=The+contribution+of+%CE%B1%CE%B2-tubulin+curvature+to+microtubule+dynamics&doi=10.1083%2Fjcb.201407095"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The contribution of αβ-tubulin curvature to microtubule dynamics</span></div><div class="casAuthors">Brouhard, Gary J.; Rice, Luke M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">207</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">323-334</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">A review.  Microtubules are dynamic polymers of αβ-tubulin that form diverse cellular structures, such as the mitotic spindle for cell division, the backbone of neurons, and axonemes.  To control the architecture of microtubule networks, microtubule-assocd. proteins (MAPs) and motor proteins regulate microtubule growth, shrinkage, and the transitions between these states.  Recent evidence shows that many MAPs exert their effects by selectively binding to distinct conformations of polymd. or unpolymd. αβ-tubulin.  The ability of αβ-tubulin to adopt distinct conformations contributes to the intrinsic polymn. dynamics of microtubules.  αβ-Tubulin conformation is a fundamental property that MAPs monitor and control to build proper microtubule networks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGyoU-iIkFELVg90H21EOLACvtfcHk0lj-1t5W7IhSuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFGhs7jE&md5=5ff241f0a021843f7678daec3f7476f1</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1083%2Fjcb.201407095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.201407095%26sid%3Dliteratum%253Aachs%26aulast%3DBrouhard%26aufirst%3DG.%2BJ.%26aulast%3DRice%26aufirst%3DL.%2BM.%26atitle%3DThe%2520contribution%2520of%2520%25CE%25B1%25CE%25B2-tubulin%2520curvature%2520to%2520microtubule%2520dynamics%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2014%26volume%3D207%26spage%3D323%26epage%3D334%26doi%3D10.1083%2Fjcb.201407095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alushin, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogales, E.</span></span> <span> </span><span class="NLM_article-title">Mechanistic origin of microtubule dynamic instability and its modulation by EB proteins</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">849</span>– <span class="NLM_lpage">859</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2015.07.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.cell.2015.07.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=26234155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Kgur3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2015&pages=849-859&author=R.+Zhangauthor=G.+M.+Alushinauthor=A.+Brownauthor=E.+Nogales&title=Mechanistic+origin+of+microtubule+dynamic+instability+and+its+modulation+by+EB+proteins&doi=10.1016%2Fj.cell.2015.07.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic Origin of Microtubule Dynamic Instability and Its Modulation by EB Proteins</span></div><div class="casAuthors">Zhang, Rui; Alushin, Gregory M.; Brown, Alan; Nogales, Eva</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">849-859</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Microtubule (MT) dynamic instability is driven by GTP hydrolysis and regulated by microtubule-assocd. proteins, including the plus-end tracking end-binding protein (EB) family.  We report six cryo-electron microscopy (cryo-EM) structures of MTs, at 3.5 Å or better resoln., bound to GMPCPP, GTPγS, or GDP, either decorated with kinesin motor domain after polymn. or copolymd. with EB3.  Subtle changes around the E-site nucleotide during hydrolysis trigger conformational changes in α-tubulin around an "anchor point," leading to global lattice rearrangements and strain generation.  Unlike the extended lattice of the GMPCPP-MT, the EB3-bound GTPγS-MT has a compacted lattice that differs in lattice twist from that of the also compacted GDP-MT.  These results and the observation that EB3 promotes rapid hydrolysis of GMPCPP suggest that EB proteins modulate structural transitions at growing MT ends by recognizing and promoting an intermediate state generated during GTP hydrolysis.  Our findings explain both EBs end-tracking behavior and their effect on microtubule dynamics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBy-PiTA751LVg90H21EOLACvtfcHk0lhYDVBtDMcIyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Kgur3L&md5=c2e4759869fb36e3fff2756ecde0fa14</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2015.07.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2015.07.012%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DAlushin%26aufirst%3DG.%2BM.%26aulast%3DBrown%26aufirst%3DA.%26aulast%3DNogales%26aufirst%3DE.%26atitle%3DMechanistic%2520origin%2520of%2520microtubule%2520dynamic%2520instability%2520and%2520its%2520modulation%2520by%2520EB%2520proteins%26jtitle%3DCell%26date%3D2015%26volume%3D162%26spage%3D849%26epage%3D859%26doi%3D10.1016%2Fj.cell.2015.07.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamyar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrhardt, D. W.</span></span> <span> </span><span class="NLM_article-title">Sustained microtubule treadmilling in Arabidopsis cortical arrays</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>300</i></span>,  <span class="NLM_fpage">1715</span>– <span class="NLM_lpage">1718</span>, <span class="refDoi"> DOI: 10.1126/science.1083529</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1126%2Fscience.1083529" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=12714675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD3sXksVKis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=300&publication_year=2003&pages=1715-1718&author=S.+L.+Shawauthor=R.+Kamyarauthor=D.+W.+Ehrhardt&title=Sustained+microtubule+treadmilling+in+Arabidopsis+cortical+arrays&doi=10.1126%2Fscience.1083529"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Sustained Microtubule Treadmilling in Arabidopsis Cortical Arrays</span></div><div class="casAuthors">Shaw, Sidney L.; Kamyar, Roheena; Ehrhardt, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">300</span>
        (<span class="NLM_cas:issue">5626</span>),
    <span class="NLM_cas:pages">1715-1718</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Plant cells create highly structured microtubule arrays at the cell cortex without a central organizing center to anchor the microtubule ends.  In vivo imaging of individual microtubules in Arabidopsis plants revealed that new microtubules are initiated at the cell cortex and exhibit dynamics at both ends.  Polymn.-biased dynamic instability at one end and slow depolymn. at the other end result in sustained microtubule migration across the cell cortex by a hybrid treadmilling mechanism.  This motility causes widespread microtubule repositioning and contributes to changes in array organization through microtubule reorientation and bundling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEQ1HoiUsu5bVg90H21EOLACvtfcHk0lhYDVBtDMcIyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXksVKis70%253D&md5=d598fdbcc0bce564265f5d2ad6bf69d7</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1126%2Fscience.1083529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1083529%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DS.%2BL.%26aulast%3DKamyar%26aufirst%3DR.%26aulast%3DEhrhardt%26aufirst%3DD.%2BW.%26atitle%3DSustained%2520microtubule%2520treadmilling%2520in%2520Arabidopsis%2520cortical%2520arrays%26jtitle%3DScience%26date%3D2003%26volume%3D300%26spage%3D1715%26epage%3D1718%26doi%3D10.1126%2Fscience.1083529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vicente-Blázquez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Álvarez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Mazo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medarde, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peláez, R.</span></span> <span> </span><span class="NLM_article-title">Antitubulin sulfonamides: the successful combination of an established drug class and a multifaceted target</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">775</span>– <span class="NLM_lpage">830</span>, <span class="refDoi"> DOI: 10.1002/med.21541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1002%2Fmed.21541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=30362234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntlGktrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2019&pages=775-830&author=A.+Vicente-Bl%C3%A1zquezauthor=M.+Gonz%C3%A1lezauthor=R.+%C3%81lvarezauthor=S.+Del+Mazoauthor=M.+Medardeauthor=R.+Pel%C3%A1ez&title=Antitubulin+sulfonamides%3A+the+successful+combination+of+an+established+drug+class+and+a+multifaceted+target&doi=10.1002%2Fmed.21541"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Antitubulin sulfonamides: The successful combination of an established drug class and a multifaceted target</span></div><div class="casAuthors">Vicente-Blazquez, Alba; Gonzalez, Myriam; Alvarez, Raquel; del Mazo, Sara; Medarde, Manuel; Pelaez, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">775-830</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Tubulin, the microtubules and their dynamic behavior are amongst the most successful antitumor, antifungal, antiparasitic, and herbicidal drug targets.  Sulfonamides are exemplary drugs with applications in the clinic, in veterinary and in the agrochem. industry.  This review summarizes the actual state and recent progress of both fields looking from the double point of view of the target and its drugs, with special focus onto the structural aspects.  The article starts with a brief description of tubulin structure and its dynamic assembly and disassembly into microtubules and other polymers.  Posttranslational modifications and the many cellular means of regulating and modulating tubulin's biol. are briefly presented in the tubulin code.  Next, the structurally characterized drug binding sites, their occupying drugs and the effects they induce are described, emphasizing on the structural requirements for high potency, selectivity, and low toxicity.  The second part starts with a summary of the favorable and highly tunable combination of phys.-chem. and biol. properties that render sulfonamides a prototypical example of privileged scaffolds with representatives in many therapeutic areas.  A complete description of tubulin-binding sulfonamides is provided, covering the different species and drug sites.  Some of the antimitotic sulfonamides have met with very successful applications and others less so, thus illustrating the advances, limitations, and future perspectives of the field.  All of them combine in a mechanism of action and a clin. outcome that conform efficient drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBjccN56DGCLVg90H21EOLACvtfcHk0lhYDVBtDMcIyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntlGktrs%253D&md5=43582a156e310ef92cca3ef94ff9362e</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fmed.21541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21541%26sid%3Dliteratum%253Aachs%26aulast%3DVicente-Bl%25C3%25A1zquez%26aufirst%3DA.%26aulast%3DGonz%25C3%25A1lez%26aufirst%3DM.%26aulast%3D%25C3%2581lvarez%26aufirst%3DR.%26aulast%3DDel%2BMazo%26aufirst%3DS.%26aulast%3DMedarde%26aufirst%3DM.%26aulast%3DPel%25C3%25A1ez%26aufirst%3DR.%26atitle%3DAntitubulin%2520sulfonamides%253A%2520the%2520successful%2520combination%2520of%2520an%2520established%2520drug%2520class%2520and%2520a%2520multifaceted%2520target%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2019%26volume%3D39%26spage%3D775%26epage%3D830%26doi%3D10.1002%2Fmed.21541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamath, K.</span></span> <span> </span><span class="NLM_article-title">How do microtubule-targeted drugs work? An overview</span>. <i>Curr. Cancer Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">730</span>– <span class="NLM_lpage">742</span>, <span class="refDoi"> DOI: 10.2174/156800907783220417</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.2174%2F156800907783220417" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=18220533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFOnsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=730-742&author=M.+A.+Jordanauthor=K.+Kamath&title=How+do+microtubule-targeted+drugs+work%3F+An+overview&doi=10.2174%2F156800907783220417"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">How do microtubule-targeted drugs work? An overview</span></div><div class="casAuthors">Jordan, Mary Ann; Kamath, Kathy</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">730-742</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The importance of microtubules in mitosis makes them a superb target for a group of highly successful, chem. diverse anticancer drugs.  Knowledge of the mechanistic differences among the many drugs of this class is vital to understanding their tissue and cell specificity, the development of resistance, the design of novel improved drugs, optimal scheduling of treatment, and potential synergistic combinations.  This overview covers microtubule assembly dynamics, the exquisite regulation of microtubule dynamics in cells by endogenous regulators, the important role of microtubule dynamics in mitosis, the diversity and no. of microtubule-targeted drugs undergoing clin. development, the antimitotic mechanisms of microtubule-targeted drugs with emphasis on suppression of microtubule dynamics by vinblastine and taxol, the role of drug uptake and retention in the efficacy of microtubule-targeted drugs, and the anti-angiogenic and vascular-disrupting mechanisms of microtubule targeted drugs.  In view of the success of this class of drugs, it has been argued that microtubules represent the single best cancer target identified to date, and it seems likely that drugs in this class will continue to remain an important chemotherapeutic class of drugs even as more selective chemotherapeutic approaches are developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrblMjKhFIo0rVg90H21EOLACvtfcHk0ljVX9Jv9Jyhbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFOnsbg%253D&md5=58b841471750af2499f766da0ea5e0d6</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.2174%2F156800907783220417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156800907783220417%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DM.%2BA.%26aulast%3DKamath%26aufirst%3DK.%26atitle%3DHow%2520do%2520microtubule-targeted%2520drugs%2520work%253F%2520An%2520overview%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2007%26volume%3D7%26spage%3D730%26epage%3D742%26doi%3D10.2174%2F156800907783220417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Field, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Díaz, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. H.</span></span> <span> </span><span class="NLM_article-title">The binding sites of microtubule-stabilizing agents</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">301</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2013.01.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.chembiol.2013.01.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=23521789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksFOht7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=301-315&author=J.+J.+Fieldauthor=J.+F.+D%C3%ADazauthor=J.+H.+Miller&title=The+binding+sites+of+microtubule-stabilizing+agents&doi=10.1016%2Fj.chembiol.2013.01.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The Binding Sites of Microtubule-Stabilizing Agents</span></div><div class="casAuthors">Field, Jessica J.; Diaz, Jose Fernando; Miller, John H.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">301-315</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Microtubules (MTs) are a highly successful target for anticancer therapy.  MT-stabilizing agents (MSAs) bind to MTs, promoting their polymn., blocking mitosis, and causing cell death.  There are currently four clin. important MSAs, with many others in preclin. and clin. development.  MTs have three binding sites for these compds.; however, the exact locations and drug-protein interactions of these sites are still controversial.  This review will describe the possible binding sites, the compds. that bind to them, and the effect of this binding on MT function.  The binding site of an MSA on tubulin is important for characterizing the compd. as an anticancer agent and provides insight not only into possible synergistic interactions with other compds. but also on the MSA "pharmacophore." This information can aid in the design of novel MSAs with improved properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHPdMr7yFqnbVg90H21EOLACvtfcHk0ljVX9Jv9Jyhbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksFOht7o%253D&md5=6180c154afeafb39f8463582c22eef44</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2013.01.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2013.01.014%26sid%3Dliteratum%253Aachs%26aulast%3DField%26aufirst%3DJ.%2BJ.%26aulast%3DD%25C3%25ADaz%26aufirst%3DJ.%2BF.%26aulast%3DMiller%26aufirst%3DJ.%2BH.%26atitle%3DThe%2520binding%2520sites%2520of%2520microtubule-stabilizing%2520agents%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D301%26epage%3D315%26doi%3D10.1016%2Fj.chembiol.2013.01.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ojima, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtenthal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Taxane anticancer agents: a patent perspective</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1517/13543776.2016.1111872</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1517%2F13543776.2016.1111872" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=26651178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2rsrjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=1-20&author=I.+Ojimaauthor=B.+Lichtenthalauthor=S.+Leeauthor=C.+Wangauthor=X.+Wang&title=Taxane+anticancer+agents%3A+a+patent+perspective&doi=10.1517%2F13543776.2016.1111872"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Taxane anticancer agents: a patent perspective</span></div><div class="casAuthors">Ojima, Iwao; Lichtenthal, Brendan; Lee, Siyeon; Wang, Changwei; Wang, Xin</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-20</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Paclitaxel and docetaxel were two epoch-making anticancer drugs and have been successfully used in chemotherapy for a variety of cancer types.  In the year 2010, a new taxane, cabazitaxel, was approved by FDA for use in combination with prednisone for the treatment of metastatic hormone-refractory prostate cancer.  Albumin-bound paclitaxel (nab-paclitaxel; abraxane) nanodroplet formulation was another notable invention (FDA approval 2005 for refractory, metastatic, or relapsed breast cancer).  Abraxane in combination with gemcitabine for the treatment of pancreatic cancer was approved by FDA in 2013.  Accordingly, there have been a huge no. of patent applications dealing with taxane anticancer agents in the last 5 years.  Thus, it is a good time to review the progress in this area and find the next wave for new developments.  This review covers the patent literature from the year 2010 to early 2015 on various aspects of taxane-based chemotherapies and drug developments.  Three FDA-approved taxane anticancer drugs will continue to expand their therapeutic applications, esp. through drug combinations and new formulations.  Inspired by the success of abraxane, new nano-formulations are emerging.  Highly potent new-generation taxanes will play a key role in the development of efficacious tumor-targeted drug delivery systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDS7GwTPBwRrVg90H21EOLACvtfcHk0ljVX9Jv9Jyhbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2rsrjO&md5=a14ecf2ee7e39daaef522fb0c0a1ba7e</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1517%2F13543776.2016.1111872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2016.1111872%26sid%3Dliteratum%253Aachs%26aulast%3DOjima%26aufirst%3DI.%26aulast%3DLichtenthal%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DTaxane%2520anticancer%2520agents%253A%2520a%2520patent%2520perspective%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2016%26volume%3D26%26spage%3D1%26epage%3D20%26doi%3D10.1517%2F13543776.2016.1111872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnett, J. P.,  Jr</span></span> <span> </span><span class="NLM_article-title">The vinca alkaloids: A new class of oncolytic agents</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1963</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1390</span>– <span class="NLM_lpage">1427</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=14070392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADyaF2cXht1agsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1963&pages=1390-1427&author=I.+S.+Johnsonauthor=J.+G.+Armstrongauthor=M.+Gormanauthor=J.+P.+Burnett&title=The+vinca+alkaloids%3A+A+new+class+of+oncolytic+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The Vinca alkaloids. A new class of oncolytic agents</span></div><div class="casAuthors">Johnson, Irving S.; Armstrong, James G.; Gorman, Marvin; Burnett, J. Paul, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1963</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1390-1427</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDNvwRwHsWf7Vg90H21EOLACvtfcHk0lhzCSx8BLOFSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2cXht1agsQ%253D%253D&md5=27ad156de3a422753052d30e72835deb</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DI.%2BS.%26aulast%3DArmstrong%26aufirst%3DJ.%2BG.%26aulast%3DGorman%26aufirst%3DM.%26aulast%3DBurnett%26aufirst%3DJ.%2BP.%26atitle%3DThe%2520vinca%2520alkaloids%253A%2520A%2520new%2520class%2520of%2520oncolytic%2520agents%26jtitle%3DCancer%2520Res.%26date%3D1963%26volume%3D23%26spage%3D1390%26epage%3D1427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Pérez, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priego, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bueno, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canela, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liekens, S.</span></span> <span> </span><span class="NLM_article-title">Blocking blood flow to solid tumors by destabilizing tubulin: an approach to targeting tumor growth</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8685</span>– <span class="NLM_lpage">8711</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVCrsr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8685-8711&author=M.+J.+P%C3%A9rez-P%C3%A9rezauthor=E.+M.+Priegoauthor=O.+Buenoauthor=M.+S.+Martinsauthor=M.+D.+Canelaauthor=S.+Liekens&title=Blocking+blood+flow+to+solid+tumors+by+destabilizing+tubulin%3A+an+approach+to+targeting+tumor+growth&doi=10.1021%2Facs.jmedchem.6b00463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Blocking Blood Flow to Solid Tumors by Destabilizing Tubulin: An Approach to Targeting Tumor Growth</span></div><div class="casAuthors">Perez-Perez, Maria-Jesus; Priego, Eva-Maria; Bueno, Oskia; Martins, Maria Solange; Canela, Maria-Dolores; Liekens, Sandra</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8685-8711</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The unique characteristics of the tumor vasculature offer the possibility to selectively target tumor growth and vascularization using tubulin-destabilizing agents.  Evidence accumulated with combretastatin A-4 (CA-4) and its prodrug CA-4P support the therapeutic value of compds. sharing this mechanism of action.  However, the chem. instability and poor soly. of CA-4 demand alternative compds. that are able to surmount these limitations.  This Perspective illustrates the different classes of compds. that behave similar to CA-4, analyzes their binding mode to αβ-tubulin according to recently available structural complexes, and includes described approaches to improve their delivery.  In addn., dissecting the mechanism of action of CA-4 and analogs allows a closer insight into the advantages and drawbacks assocd. with these tubulin-destabilizing agents that behave as vascular disrupting agents (VDAs).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoro5_yHCDZJ7Vg90H21EOLACvtfcHk0lhzCSx8BLOFSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVCrsr7K&md5=47929ab2eb71284781c8b5ff16fcb023</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00463%26sid%3Dliteratum%253Aachs%26aulast%3DP%25C3%25A9rez-P%25C3%25A9rez%26aufirst%3DM.%2BJ.%26aulast%3DPriego%26aufirst%3DE.%2BM.%26aulast%3DBueno%26aufirst%3DO.%26aulast%3DMartins%26aufirst%3DM.%2BS.%26aulast%3DCanela%26aufirst%3DM.%2BD.%26aulast%3DLiekens%26aufirst%3DS.%26atitle%3DBlocking%2520blood%2520flow%2520to%2520solid%2520tumors%2520by%2520destabilizing%2520tubulin%253A%2520an%2520approach%2520to%2520targeting%2520tumor%2520growth%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8685%26epage%3D8711%26doi%3D10.1021%2Facs.jmedchem.6b00463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greene, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meegan, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zisterer, D. M.</span></span> <span> </span><span class="NLM_article-title">Combretastatins: more than just vascular targeting agents?</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">212</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1124/jpet.115.226225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1124%2Fjpet.115.226225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=26354991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslantLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2015&pages=212-227&author=L.+M.+Greeneauthor=M.+J.+Meeganauthor=D.+M.+Zisterer&title=Combretastatins%3A+more+than+just+vascular+targeting+agents%3F&doi=10.1124%2Fjpet.115.226225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Combretastatins: more than just vascular targeting agents?</span></div><div class="casAuthors">Greene, Lisa M.; Meegan, Mary J.; Zisterer, Daniela M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">212-227</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Several prodrugs of the naturally occurring combretastatins have undergone extensive clin. evaluation as vascular targeting agents (VTAs).  Their increased selectivity toward endothelial cells together with their innate ability to rapidly induce vascular shutdown and inhibit tumor growth at doses up to 10-fold less than the max. tolerated dose led to the clin. evaluation of combretastatins as VTAs.  Tubulin is well established as the mol. target of the combretastatins and the vast majority of its synthetic derivs.  Furthermore, tubulin is a highly validated mol. target of many direct anticancer agents routinely used as front-line chemotherapeutics.  The unique vascular targeting properties of the combretastatins have somewhat overshadowed their development as direct anticancer agents and the delineation of the various cell death pathways and anticancer properties assocd. with such chemotherapeutics.  Moreover, the ongoing clin. trial of OXi4503 (combretastatin-A1 diphosphate) together with preliminary preclin. evaluation for the treatment of refractory acute myelogenous leukemia has successfully highlighted both the indirect and direct anticancer properties of combretastatins.  In this review, we discuss the development of the combretastatins from nature to the clinic.  The various mechanisms underlying combretastatin-induced cell cycle arrest, mitotic catastrophe, cell death, and survival are also reviewed in an attempt to further enhance the clin. prospects of this unique class of VTAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonKpiV5x3vPLVg90H21EOLACvtfcHk0lhzCSx8BLOFSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslantLY%253D&md5=7e965d3cd51715cec3f84fde9cd6e88e</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.226225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.226225%26sid%3Dliteratum%253Aachs%26aulast%3DGreene%26aufirst%3DL.%2BM.%26aulast%3DMeegan%26aufirst%3DM.%2BJ.%26aulast%3DZisterer%26aufirst%3DD.%2BM.%26atitle%3DCombretastatins%253A%2520more%2520than%2520just%2520vascular%2520targeting%2520agents%253F%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D355%26spage%3D212%26epage%3D227%26doi%3D10.1124%2Fjpet.115.226225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Leo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aziz, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvirbule, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bines, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arbushites, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrera, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dering, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Press, M. F.</span></span> <span> </span><span class="NLM_article-title">Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">5544</span>– <span class="NLM_lpage">5552</span>, <span class="refDoi"> DOI: 10.1200/JCO.2008.16.2578</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1200%2FJCO.2008.16.2578" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=18955454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmsVSktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=5544-5552&author=A.+Di%0ALeoauthor=H.+L.+Gomezauthor=Z.+Azizauthor=Z.+Zvirbuleauthor=J.+Binesauthor=M.+C.+Arbushitesauthor=S.+F.+Guerreraauthor=M.+Koehlerauthor=C.+Olivaauthor=S.+H.+Steinauthor=L.+S.+Williamsauthor=J.+Deringauthor=R.+S.+Finnauthor=M.+F.+Press&title=Phase+III%2C+double-blind%2C+randomized+study+comparing+lapatinib+plus+paclitaxel+with+placebo+plus+paclitaxel+as+first-line+treatment+for+metastatic+breast+cancer&doi=10.1200%2FJCO.2008.16.2578"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer</span></div><div class="casAuthors">Di Leo, Angelo; Gomez, Henry L.; Aziz, Zeba; Zvirbule, Zanete; Bines, Jose; Arbushites, Michael C.; Guerrera, Stephanie F.; Koehler, Maria; Oliva, Cristina; Stein, Steven H.; Williams, Lisa S.; Dering, Judy; Finn, Richard S.; Press, Michael F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">5544-5552</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Lapatinib, a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER-2/ErbB2), is effective against HER-2-pos. locally advanced or metastatic breast cancer (MBC).  This phase III trial evaluated the efficacy of lapatinib in HER-2-neg. and HER-2-uncharacterized MBC.  Women with MBC were randomly assigned to first-line therapy with paclitaxel 175 mg/m2 every 3 wk plus lapatinib 1500 mg/d or placebo.  A preplanned retrospective evaluation of HER-2 status was performed using fluorescence in situ hybridization and immunohistochem.  The primary end point was time to progression (TTP); secondary end points were objective response rate (ORR), clin. benefit rate (CBR), event-free survival (EFS), and overall survival (OS).  In the intent-to-treat population (n = 579), there were no significant differences in TTP, EFS, or OS between treatment arms, although differences in ORR and CBR were noted.  In 86 HER-2-pos. patients (15%), treatment with paclitaxel-lapatinib resulted in statistically significant improvements in TTP, EFS, ORR, and CBR compared with paclitaxel-placebo.  No differences between treatment groups were obsd. for any end point in HER-2-neg. patients.  The most common adverse events were alopecia, rash, and diarrhea.  The incidence of diarrhea and rash was significantly higher in the paclitaxel-lapatinib arm.  The rate of cardiac events was low, and no difference was obsd. between treatment arms.  Patients with HER-2-neg. or HER-2-untested MBC did not benefit from the addn. of lapatinib to paclitaxel.  However, first-line therapy with paclitaxel-lapatinib significantly improved clin. outcomes in HER-2-pos. patients.  Prospective evaluation of the efficacy and safety of this combination is ongoing in early and metastatic HER-2-pos. breast cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGKFocbCrkurVg90H21EOLACvtfcHk0ljjAMi80eOG2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmsVSktA%253D%253D&md5=988f08798b7880b0da1575c3f01a180f</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.16.2578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.16.2578%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BLeo%26aufirst%3DA.%26aulast%3DGomez%26aufirst%3DH.%2BL.%26aulast%3DAziz%26aufirst%3DZ.%26aulast%3DZvirbule%26aufirst%3DZ.%26aulast%3DBines%26aufirst%3DJ.%26aulast%3DArbushites%26aufirst%3DM.%2BC.%26aulast%3DGuerrera%26aufirst%3DS.%2BF.%26aulast%3DKoehler%26aufirst%3DM.%26aulast%3DOliva%26aufirst%3DC.%26aulast%3DStein%26aufirst%3DS.%2BH.%26aulast%3DWilliams%26aufirst%3DL.%2BS.%26aulast%3DDering%26aufirst%3DJ.%26aulast%3DFinn%26aufirst%3DR.%2BS.%26aulast%3DPress%26aufirst%3DM.%2BF.%26atitle%3DPhase%2520III%252C%2520double-blind%252C%2520randomized%2520study%2520comparing%2520lapatinib%2520plus%2520paclitaxel%2520with%2520placebo%2520plus%2520paclitaxel%2520as%2520first-line%2520treatment%2520for%2520metastatic%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D5544%26epage%3D5552%26doi%3D10.1200%2FJCO.2008.16.2578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cesca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morosi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berndt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nerini, I. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frapolli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dirsch, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Micotti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Incalci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davoli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zucchetti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giavazzi, R.</span></span> <span> </span><span class="NLM_article-title">Bevacizumab-induced inhibition of angiogenesis promotes a more homogeneous intratumoral distribution of paclitaxel, improving the antitumor response</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-0063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1158%2F1535-7163.MCT-15-0063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=26494857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC28Xmslelug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=125-135&author=M.+Cescaauthor=L.+Morosiauthor=A.+Berndtauthor=I.+F.+Neriniauthor=R.+Frapolliauthor=P.+Richterauthor=A.+Decioauthor=O.+Dirschauthor=E.+Micottiauthor=S.+Giordanoauthor=M.+D%E2%80%99Incalciauthor=E.+Davoliauthor=M.+Zucchettiauthor=R.+Giavazzi&title=Bevacizumab-induced+inhibition+of+angiogenesis+promotes+a+more+homogeneous+intratumoral+distribution+of+paclitaxel%2C+improving+the+antitumor+response&doi=10.1158%2F1535-7163.MCT-15-0063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response</span></div><div class="casAuthors">Cesca, Marta; Morosi, Lavinia; Berndt, Alexander; Nerini, Ilaria Fuso; Frapolli, Roberta; Richter, Petra; Decio, Alessandra; Dirsch, Olaf; Micotti, Edoardo; Giordano, Silvia; D'Incalci, Maurizio; Davoli, Enrico; Zucchetti, Massimo; Giavazzi, Raffaella</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">125-135</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The antitumor activity of angiogenesis inhibitors is reinforced in combination with chemotherapy.  It is debated whether this potentiation is related to a better drug delivery to the tumor due to the antiangiogenic effects on tumor vessel phenotype and functionality.  We addressed this question by combining bevacizumab with paclitaxel on A2780-1A9 ovarian carcinoma and HT-29 colon carcinoma transplanted ectopically in the subcutis of nude mice and on A2780-1A9 and IGROV1 ovarian carcinoma transplanted orthotopically in the bursa of the mouse ovary.  Paclitaxel concns. together with its distribution by MALDI mass spectrometry imaging (MALDI MSI) were measured to det. the drug in different areas of the tumor, which was immunostained to depict vessel morphol. and tumor proliferation.  Bevacizumab modified the vessel bed, assessed by CD31 staining and dynamic contrast enhanced MRI (DCE-MRI), and potentiated the antitumor activity of paclitaxel in all the models.  Although tumor paclitaxel concns. were lower after bevacizumab, the drug distributed more homogeneously, particularly in vascularized, non-necrotic areas, and was cleared more slowly than controls.  This happened specifically in tumor tissue, as there was no change in paclitaxel pharmacokinetics or drug distribution in normal tissues.  In addn., the drug concn. and distribution were not influenced by the site of tumor growth, as A2780-1A9 and IGROV1 growing in the ovary gave results similar to the tumor growing s.c.  We suggest that the changes in the tumor microenvironment architecture induced by bevacizumab, together with the better distribution of paclitaxel, may explain the significant antitumor potentiation by the combination.  Mol Cancer Ther; 15(1); 125-35.  ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV5sZCCsBwxbVg90H21EOLACvtfcHk0ljjAMi80eOG2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xmslelug%253D%253D&md5=da09e8ead5db6fe2ccb2b9a1c18074fa</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0063%26sid%3Dliteratum%253Aachs%26aulast%3DCesca%26aufirst%3DM.%26aulast%3DMorosi%26aufirst%3DL.%26aulast%3DBerndt%26aufirst%3DA.%26aulast%3DNerini%26aufirst%3DI.%2BF.%26aulast%3DFrapolli%26aufirst%3DR.%26aulast%3DRichter%26aufirst%3DP.%26aulast%3DDecio%26aufirst%3DA.%26aulast%3DDirsch%26aufirst%3DO.%26aulast%3DMicotti%26aufirst%3DE.%26aulast%3DGiordano%26aufirst%3DS.%26aulast%3DD%25E2%2580%2599Incalci%26aufirst%3DM.%26aulast%3DDavoli%26aufirst%3DE.%26aulast%3DZucchetti%26aufirst%3DM.%26aulast%3DGiavazzi%26aufirst%3DR.%26atitle%3DBevacizumab-induced%2520inhibition%2520of%2520angiogenesis%2520promotes%2520a%2520more%2520homogeneous%2520intratumoral%2520distribution%2520of%2520paclitaxel%252C%2520improving%2520the%2520antitumor%2520response%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D125%26epage%3D135%26doi%3D10.1158%2F1535-7163.MCT-15-0063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotili, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerbara, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valente, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeoni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragno, R.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylation in epigenetics: an attractive target for anticancer therapy</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1002/med.20024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1002%2Fmed.20024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=15717297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjslGit7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2005&pages=261-309&author=A.+Maiauthor=S.+Massaauthor=D.+Rotiliauthor=I.+Cerbaraauthor=S.+Valenteauthor=R.+Pezziauthor=S.+Simeoniauthor=R.+Ragno&title=Histone+deacetylation+in+epigenetics%3A+an+attractive+target+for+anticancer+therapy&doi=10.1002%2Fmed.20024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylation in epigenetics: An attractive target for anticancer therapy</span></div><div class="casAuthors">Mai, Antonello; Massa, Silvio; Rotili, Dante; Cerbara, Ilaria; Valente, Sergio; Pezzi, Riccardo; Simeoni, Silvia; Ragno, Rino</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">261-309</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The reversible histone acetylation and deacetylation are epigenetic phenomena that play crit. roles in the modulation of chromatin topol. and the regulation of gene expression.  Aberrant transcription due to altered expression or mutation of genes that encode histone acetyltransferase (HAT) or histone deacetylase (HDAC) enzymes or their binding partners, has been clearly linked to carcinogenesis.  The histone deacetylase inhibitors are a new promising class of anticancer agents (some of which in clin. trials), that inhibit the proliferation of tumor cells in culture and in vivo by inducing cell-cycle arrest, terminal differentiation, and/or apoptosis.  This report reviews the chem. and the biol. of HDACs and HDAC inhibitors, laying particular emphasis on agents actually in clin. trials for cancer therapy and on new potential anticancer lead compds. more selective and less toxic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDbzbbO5ZKrLVg90H21EOLACvtfcHk0ljjAMi80eOG2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjslGit7w%253D&md5=60112258470a6d520cbc0af24046e994</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1002%2Fmed.20024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20024%26sid%3Dliteratum%253Aachs%26aulast%3DMai%26aufirst%3DA.%26aulast%3DMassa%26aufirst%3DS.%26aulast%3DRotili%26aufirst%3DD.%26aulast%3DCerbara%26aufirst%3DI.%26aulast%3DValente%26aufirst%3DS.%26aulast%3DPezzi%26aufirst%3DR.%26aulast%3DSimeoni%26aufirst%3DS.%26aulast%3DRagno%26aufirst%3DR.%26atitle%3DHistone%2520deacetylation%2520in%2520epigenetics%253A%2520an%2520attractive%2520target%2520for%2520anticancer%2520therapy%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2005%26volume%3D25%26spage%3D261%26epage%3D309%26doi%3D10.1002%2Fmed.20024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chao, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, C. M.</span></span> <span> </span><span class="NLM_article-title">The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">82</span>, <span class="refDoi"> DOI: 10.1186/s13045-015-0176-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1186%2Fs13045-015-0176-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=26156322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FhsFKjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=82&author=M.+W.+Chaoauthor=M.+J.+Laiauthor=J.+P.+Liouauthor=Y.+L.+Changauthor=J.+C.+Wangauthor=S.+L.+Panauthor=C.+M.+Teng&title=The+synergic+effect+of+vincristine+and+vorinostat+in+leukemia+in+vitro+and+in+vivo&doi=10.1186%2Fs13045-015-0176-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo</span></div><div class="casAuthors">Chao Min-Wu; Chang Ya-Ling; Teng Che-Ming; Lai Mei-Jung; Liou Jing-Ping; Wang Jing-Chi; Pan Shiow-Lin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hematology & oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">82</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Combination therapy is a key strategy for minimizing drug resistance, a common problem in cancer therapy.  The microtubule-depolymerizing agent vincristine is widely used in the treatment of acute leukemia.  In order to decrease toxicity and chemoresistance of vincristine, this study will investigate the effects of combination vincristine and vorinostat (suberoylanilide hydroxamic acid (SAHA)), a pan-histone deacetylase inhibitor, on human acute T cell lymphoblastic leukemia cells.  METHODS:  Cell viability experiments were determined by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay, and cell cycle distributions as well as mitochondria membrane potential were analyzed by flow cytometry.  In vitro tubulin polymerization assay was used to test tubulin assembly, and immunofluorescence analysis was performed to detect microtubule distribution and morphology.  In vivo effect of the combination was evaluated by a MOLT-4 xenograft model.  Statistical analysis was assessed by Bonferroni's t test.  RESULTS:  Cell viability showed that the combination of vincristine and SAHA exhibited greater cytotoxicity with an IC50 value of 0.88 nM, compared to each drug alone, 3.3 and 840 nM.  This combination synergically induced G2/M arrest, followed by an increase in cell number at the sub-G1 phase and caspase activation.  Moreover, the results of vincristine combined with an HDAC6 inhibitor (tubastatin A), which acetylated α-tubulin, were consistent with the effects of vincristine/SAHA co-treatment, thus suggesting that SAHA may alter microtubule dynamics through HDAC6 inhibition.  CONCLUSION:  These findings indicate that the combination of vincristine and SAHA on T cell leukemic cells resulted in a change in microtubule dynamics contributing to M phase arrest followed by induction of the apoptotic pathway.  These data suggest that the combination effect of vincristine/SAHA could have an important preclinical basis for future clinical trial testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTZWw7KK08a6Zp6t8nS6Nc3fW6udTcc2eYuHmyZlbajtbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FhsFKjtA%253D%253D&md5=b22f13563067cc55509bc41110bb86ab</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1186%2Fs13045-015-0176-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-015-0176-7%26sid%3Dliteratum%253Aachs%26aulast%3DChao%26aufirst%3DM.%2BW.%26aulast%3DLai%26aufirst%3DM.%2BJ.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26aulast%3DChang%26aufirst%3DY.%2BL.%26aulast%3DWang%26aufirst%3DJ.%2BC.%26aulast%3DPan%26aufirst%3DS.%2BL.%26aulast%3DTeng%26aufirst%3DC.%2BM.%26atitle%3DThe%2520synergic%2520effect%2520of%2520vincristine%2520and%2520vorinostat%2520in%2520leukemia%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2015%26volume%3D8%26spage%3D82%26doi%3D10.1186%2Fs13045-015-0176-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chobanian, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenberg, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gass, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desimone, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Nagell, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, S. G.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 status</span>. <i>Anticancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">539</span>– <span class="NLM_lpage">545</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=15160991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkvVegtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=539-545&author=N.+H.+Chobanianauthor=V.+L.+Greenbergauthor=J.+M.+Gassauthor=C.+P.+Desimoneauthor=J.+R.+Van+Nagellauthor=S.+G.+Zimmer&title=Histone+deacetylase+inhibitors+enhance+paclitaxel-induced+cell+death+in+ovarian+cancer+cell+lines+independent+of+p53+status"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 status</span></div><div class="casAuthors">Chobanian, Nishan H.; Greenberg, Victoria L.; Gass, Jennifer M.; Desimone, Christopher P.; Van Nagell, John R.; Zimmer, Stephen G.</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2B</span>),
    <span class="NLM_cas:pages">539-545</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">Recurrence of drug-resistant disease contributes to the high mortality of ovarian cancer patients, which necessitates the identification of addnl. chemotherapeutic drugs.  Histone deacetylase inhibitors (HDAIs) induce apoptosis in a no. of malignant cell types and may represent a new class of drugs clin. relevant in the treatment of ovarian cancer.  Ovarian cancer cells were treated with various combinations of a HDAI and paclitaxel (PTX).  Cell death was measured using annexin V/propidium iodide exclusion.  The PTX/HDAI drug combination was as efficient in inducing cell death as continuous PTX treatment and superior to continuous HDAI treatment.  Reversing the sequence of drug exposure reduced the cytotoxic efficacy of the drug combination.  The p53 status of the cell lines did not alter the cytotoxic efficacy of the treatment protocols.  These results suggest that HDAIs possess possible clin. applications as an adjuvant therapy in the treatment of ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr930zCusS9XLVg90H21EOLACvtfcHk0lgg9IKQlWoayQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkvVegtb0%253D&md5=31429aa419349152ac124cc1c1e2e342</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChobanian%26aufirst%3DN.%2BH.%26aulast%3DGreenberg%26aufirst%3DV.%2BL.%26aulast%3DGass%26aufirst%3DJ.%2BM.%26aulast%3DDesimone%26aufirst%3DC.%2BP.%26aulast%3DVan%2BNagell%26aufirst%3DJ.%2BR.%26aulast%3DZimmer%26aufirst%3DS.%2BG.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520enhance%2520paclitaxel-induced%2520cell%2520death%2520in%2520ovarian%2520cancer%2520cell%2520lines%2520independent%2520of%2520p53%2520status%26jtitle%3DAnticancer%2520Res.%26date%3D2004%26volume%3D24%26spage%3D539%26epage%3D545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zuco, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Cesare, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cincinelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaffaroni, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zunino, F.</span></span> <span> </span><span class="NLM_article-title">Synergistic antitumor effects of novel HDAC inhibitors and paclitaxel in vitro and in vivo</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">e29085</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0029085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1371%2Fjournal.pone.0029085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=22194993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFOksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&author=V.+Zucoauthor=M.+De+Cesareauthor=R.+Cincinelliauthor=R.+Nanneiauthor=C.+Pisanoauthor=N.+Zaffaroniauthor=F.+Zunino&title=Synergistic+antitumor+effects+of+novel+HDAC+inhibitors+and+paclitaxel+in+vitro+and+in+vivo&doi=10.1371%2Fjournal.pone.0029085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic antitumor effects of novel HDAC inhibitors and paclitaxel in vitro and in vivo</span></div><div class="casAuthors">Zuco, Valentina; De Cesare, Michelandrea; Cincinelli, Raffaella; Nannei, Raffaella; Pisano, Claudio; Zaffaroni, Nadia; Zunino, Franco</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e29085</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Preclin. studies support the therapeutic potential of histone deacetylases inhibitors (HDACi) in combination with taxanes.  The efficacy of combination was mainly ascribed to a cooperative effect on microtubule stabilization following tubulin acetylation.  In the present study we investigated the effect of paclitaxel in combination with 2 novel HDACi, ST2782 or ST3595, able to induce p53 and tubulin hyperacetylation.  A synergistic effect of the paclitaxel/ST2782 (or ST3595) combination was found in wild-type p53 ovarian carcinoma cells, but not in a p53 mutant subline, in spite of a marked tubulin acetylation.  Such a synergistic interaction was confirmed in addnl. human solid tumor cell lines harboring wild-type p53 but not in those expressing mutant or null p53.  In addn., a synergistic cytotoxic effect was found when ST2782 was combined with the depolymerising agent vinorelbine.  In contrast to SAHA, which was substantially less effective in sensitizing cells to paclitaxel-induced apoptosis, ST2782 prevented up-regulation of p21WAF1/Cip1 by paclitaxel, which has a protective role in response to taxanes, and caused p53 down-regulation, acetylation and mitochondrial localization of acetylated p53.  The synergistic antitumor effects of the paclitaxel/ST3595 combination were confirmed in 2 tumor xenograft models.  Our results support the relevance of p53 modulation as a major determinant of the synergistic interaction obsd. between paclitaxel and novel HDACi and emphasize the therapeutic interest of this combination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFdXXd1e7KArVg90H21EOLACvtfcHk0lgg9IKQlWoayQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFOksQ%253D%253D&md5=136708d5f58c8e01531a3563b576898b</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0029085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0029085%26sid%3Dliteratum%253Aachs%26aulast%3DZuco%26aufirst%3DV.%26aulast%3DDe%2BCesare%26aufirst%3DM.%26aulast%3DCincinelli%26aufirst%3DR.%26aulast%3DNannei%26aufirst%3DR.%26aulast%3DPisano%26aufirst%3DC.%26aulast%3DZaffaroni%26aufirst%3DN.%26aulast%3DZunino%26aufirst%3DF.%26atitle%3DSynergistic%2520antitumor%2520effects%2520of%2520novel%2520HDAC%2520inhibitors%2520and%2520paclitaxel%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26doi%3D10.1371%2Fjournal.pone.0029085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katsumata, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isonishi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jobo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochiai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noda, K.</span></span> <span> </span><span class="NLM_article-title">Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">1331</span>– <span class="NLM_lpage">1338</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(09)61157-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2FS0140-6736%2809%2961157-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=19767092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Ogu7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2009&pages=1331-1338&author=N.+Katsumataauthor=M.+Yasudaauthor=F.+Takahashiauthor=S.+Isonishiauthor=T.+Joboauthor=D.+Aokiauthor=H.+Tsudaauthor=T.+Sugiyamaauthor=S.+Kodamaauthor=E.+Kimuraauthor=K.+Ochiaiauthor=K.+Noda&title=Dose-dense+paclitaxel+once+a+week+in+combination+with+carboplatin+every+3+weeks+for+advanced+ovarian+cancer%3A+a+phase+3%2C+open-label%2C+randomised+controlled+trial&doi=10.1016%2FS0140-6736%2809%2961157-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomized controlled trial</span></div><div class="casAuthors">Katsumata, Noriyuki; Yasuda, Makoto; Takahashi, Fumiaki; Isonishi, Seiji; Jobo, Toshiko; Aoki, Daisuke; Tsuda, Hiroshi; Sugiyama, Toru; Kodama, Shoji; Kimura, Eizo; Ochiai, Kazunori; Noda, Kiichiro</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">9698</span>),
    <span class="NLM_cas:pages">1331-1338</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Paclitaxel and carboplatin given every 3 wk is std. treatment for advanced ovarian carcinoma.  Attempts to improve patient survival by including other drugs have yielded disappointing results.  We compared a conventional regimen of paclitaxel and carboplatin with a dose-dense weekly regimen in women with advanced ovarian cancer.  Patients with stage II to IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer were eligible for enrollment in this phase 3, open-label, randomized controlled trial at 85 centers in Japan.  Patients were randomly assigned by computer-generated randomization sequence to receive six cycles of either paclitaxel (180 mg/m2; 3-h i.v. infusion) plus carboplatin (area under the curve [AUC] 6 mg/mL per min), given on day 1 of a 21-day cycle (conventional regimen; n = 320), or dose-dense paclitaxel (80 mg/m2; 1-h i.v. infusion) given on days 1, 8, and 15 plus carboplatin given on day 1 of a 21-day cycle (dose-dense regimen; n = 317).  The primary endpoint was progression-free survival.  Anal. was by intention to treat (ITT).  This trial is registered with ClinicalTrials.gov, no. NCT00226915.  Findings: 631 of the 637 enrolled patients were eligible for treatment and were included in the ITT population (dose-dense regimen, n = 312; conventional regimen, n = 319).  Median progression-free survival was longer in the dose-dense treatment group (28.0 mo, 95% CI 22.3-35.4) than in the conventional treatment group (17.2 mo, 15.7-21.1; hazard ratio [HR] 0.71; 95% CI 0.58-0.88; p = 0.0015).  Overall survival at 3 years was higher in the dose-dense regimen group (72.1%) than in the conventional treatment group (65.1%; HR 0.75, 0.57-0.98; p = 0.03).  165 Patients assigned to the dose-dense regimen and 117 assigned to the conventional regimen discontinued treatment early.  Reasons for participant dropout were balanced between the groups, apart from withdrawal because of toxicity, which was higher in the dose-dense regimen group than in the conventional regimen group (n = 113 vs n = 69).  The most common adverse event was neutropenia (dose-dense regimen, 286 [92%] of 312; conventional regimen, 276 [88%] of 314).  The frequency of grade 3 and 4 anemia was higher in the dose-dense treatment group (214 [69%]) than in the conventional treatment group (137 [44%]; p<0.0001).  The frequencies of other toxic effects were similar between groups.  Dose-dense weekly paclitaxel plus carboplatin improved survival compared with the conventional regimen and represents a new treatment option in women with advanced epithelial ovarian cancer.  Funding: Bristol-Myers Squibb.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNTrRgsgOozbVg90H21EOLACvtfcHk0lh4JwbMV8yAzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Ogu7fJ&md5=acee94531683ffc822f52cc62059754a</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2809%2961157-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252809%252961157-0%26sid%3Dliteratum%253Aachs%26aulast%3DKatsumata%26aufirst%3DN.%26aulast%3DYasuda%26aufirst%3DM.%26aulast%3DTakahashi%26aufirst%3DF.%26aulast%3DIsonishi%26aufirst%3DS.%26aulast%3DJobo%26aufirst%3DT.%26aulast%3DAoki%26aufirst%3DD.%26aulast%3DTsuda%26aufirst%3DH.%26aulast%3DSugiyama%26aufirst%3DT.%26aulast%3DKodama%26aufirst%3DS.%26aulast%3DKimura%26aufirst%3DE.%26aulast%3DOchiai%26aufirst%3DK.%26aulast%3DNoda%26aufirst%3DK.%26atitle%3DDose-dense%2520paclitaxel%2520once%2520a%2520week%2520in%2520combination%2520with%2520carboplatin%2520every%25203%2520weeks%2520for%2520advanced%2520ovarian%2520cancer%253A%2520a%2520phase%25203%252C%2520open-label%252C%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2009%26volume%3D374%26spage%3D1331%26epage%3D1338%26doi%3D10.1016%2FS0140-6736%2809%2961157-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paz-Ares, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luft, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicente, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tafreshi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gümüş, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazières, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Çay Şenler, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csőszi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fülöp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Cid, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugawara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novello, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halmos, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubiniecki, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piperdi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalski, D. M.</span></span> <span> </span><span class="NLM_article-title">Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>379</i></span>,  <span class="NLM_fpage">2040</span>– <span class="NLM_lpage">2051</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1810865</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1056%2FNEJMoa1810865" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=30280635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisV2rs7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2018&pages=2040-2051&author=L.+Paz-Aresauthor=A.+Luftauthor=D.+Vicenteauthor=A.+Tafreshiauthor=M.+G%C3%BCm%C3%BC%C5%9Fauthor=J.+Mazi%C3%A8resauthor=B.+Hermesauthor=F.+%C3%87ay+%C5%9Eenlerauthor=T.+Cs%C5%91sziauthor=A.+F%C3%BCl%C3%B6pauthor=J.+Rodr%C3%ADguez-Cidauthor=J.+Wilsonauthor=S.+Sugawaraauthor=T.+Katoauthor=K.+H.+Leeauthor=Y.+Chengauthor=S.+Novelloauthor=B.+Halmosauthor=X.+Liauthor=G.+M.+Lubinieckiauthor=B.+Piperdiauthor=D.+M.+Kowalski&title=Pembrolizumab+plus+chemotherapy+for+squamous+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa1810865"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer</span></div><div class="casAuthors">Paz-Ares, L.; Luft, A.; Vicente, D.; Tafreshi, A.; Gumus, M.; Mazieres, J.; Hermes, B.; Senler, F. Cay; Csoszi, T.; Fulop, A.; Rodriguez-Cid, J.; Wilson, J.; Sugawara, S.; Kato, T.; Lee, K. H.; Cheng, Y.; Novello, S.; Halmos, B.; Li, X.; Lubiniecki, G. M.; Piperdi, B.; Kowalski, D. M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2040-2051</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Std. first-line therapy for metastatic, squamous non-small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on ≥50% of tumor cells).  More recently, pembrolizumab plus chemotherapy was shown to significantly prolong overall survival among patients with nonsquamous NSCLC. methods In this double-blind, phase 3 trial, we randomly assigned, in a 1:1 ratio, 559 patients with untreated metastatic, squamous NSCLC to receive 200 mg of pembrolizumab or saline placebo for up to 35 cycles; all the patients also received carboplatin and either paclitaxel or nanoparticle albumin-bound [nab]-paclitaxel for the first 4 cycles.  Primary end points were overall survival and progression-free survival. results After a median follow-up of 7.8 mo, the median overall survival was 15.9 mo (95% confidence interval [CI], 13.2 to not reached) in the pembrolizumab-combination group and 11.3 mo (95% CI, 9.5 to 14.8) in the placebo-combination group (hazard ratio for death, 0.64; 95% CI, 0.49 to 0.85; P<0.001).  The overall survival benefit was consistent regardless of the level of PD-L1 expression.  The median progression-free survival was 6.4 mo (95% CI, 6.2 to 8.3) in the pembrolizumab-combination group and 4.8 mo (95% CI, 4.3 to 5.7) in the placebo-combination group (hazard ratio for disease progression or death, 0.56; 95% CI, 0.45 to 0.70; P<0.001).  Adverse events of grade 3 or higher occurred in 69.8% of the patients in the pembrolizumab-combination group and in 68.2% of the patients in the placebo-combination group.  Discontinuation of treatment because of adverse events was more frequent in the pembrolizumab-combination group than in the placebo-combination group (13.3% vs. 6.4%). conclusions In patients with previously untreated metastatic, squamous NSCLC, the addn. of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in significantly longer overall survival and progression-free survival than chemotherapy alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqfd87OOvD17Vg90H21EOLACvtfcHk0lh4JwbMV8yAzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisV2rs7vI&md5=c82761f20089ea398420429dbe7e4673</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1810865&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1810865%26sid%3Dliteratum%253Aachs%26aulast%3DPaz-Ares%26aufirst%3DL.%26aulast%3DLuft%26aufirst%3DA.%26aulast%3DVicente%26aufirst%3DD.%26aulast%3DTafreshi%26aufirst%3DA.%26aulast%3DG%25C3%25BCm%25C3%25BC%25C5%259F%26aufirst%3DM.%26aulast%3DMazi%25C3%25A8res%26aufirst%3DJ.%26aulast%3DHermes%26aufirst%3DB.%26aulast%3D%25C3%2587ay%2B%25C5%259Eenler%26aufirst%3DF.%26aulast%3DCs%25C5%2591szi%26aufirst%3DT.%26aulast%3DF%25C3%25BCl%25C3%25B6p%26aufirst%3DA.%26aulast%3DRodr%25C3%25ADguez-Cid%26aufirst%3DJ.%26aulast%3DWilson%26aufirst%3DJ.%26aulast%3DSugawara%26aufirst%3DS.%26aulast%3DKato%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DNovello%26aufirst%3DS.%26aulast%3DHalmos%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLubiniecki%26aufirst%3DG.%2BM.%26aulast%3DPiperdi%26aufirst%3DB.%26aulast%3DKowalski%26aufirst%3DD.%2BM.%26atitle%3DPembrolizumab%2520plus%2520chemotherapy%2520for%2520squamous%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D379%26spage%3D2040%26epage%3D2051%26doi%3D10.1056%2FNEJMoa1810865" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Socinski, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jotte, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappuzzo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroyakovskiy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Abreu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moro-Sibilot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlesi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finley, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowanetz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Chavez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reck, M.</span></span> <span> </span><span class="NLM_article-title">Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">2288</span>– <span class="NLM_lpage">2301</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1716948</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1056%2FNEJMoa1716948" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=29863955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFKkt77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=2288-2301&author=M.+A.+Socinskiauthor=R.+M.+Jotteauthor=F.+Cappuzzoauthor=F.+Orlandiauthor=D.+Stroyakovskiyauthor=N.+Nogamiauthor=D.+Rodr%C3%ADguez-Abreuauthor=D.+Moro-Sibilotauthor=C.+A.+Thomasauthor=F.+Barlesiauthor=G.+Finleyauthor=C.+Kelschauthor=A.+Leeauthor=S.+Colemanauthor=Y.+Dengauthor=Y.+Shenauthor=M.+Kowanetzauthor=A.+Lopez-Chavezauthor=A.+Sandlerauthor=M.+Reck&title=Atezolizumab+for+first-line+treatment+of+metastatic+nonsquamous+NSCLC&doi=10.1056%2FNEJMoa1716948"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC</span></div><div class="casAuthors">Socinski, M. A.; Jotte, R. M.; Cappuzzo, F.; Orlandi, F.; Stroyakovskiy, D.; Nogami, N.; Rodriguez-Abreu, D.; Moro-Sibilot, D.; Thomas, C. A.; Barlesi, F.; Finley, G.; Kelsch, C.; Lee, A.; Coleman, S.; Deng, Y.; Shen, Y.; Kowanetz, M.; Lopez-Chavez, A.; Sandler, A.; Reck, M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2288-2301</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The cancer-cell-killing property of atezolizumab may be enhanced by the blockade of vascular endothelial growth factor-mediated immunosuppression with bevacizumab.  This open-label, phase 3 study evaluated atezolizumab plus bevacizumab plus chemotherapy in patients with metastatic nonsquamous non-small-cell lung cancer (NSCLC) who had not previously received chemotherapy.  We randomly assigned patients to receive atezolizumab plus carboplatin plus paclitaxel (ACP), bevacizumab plus carboplatin plus paclitaxel (BCP), or atezolizumab plus BCP (ABCP) every 3 wk for four or six cycles, followed by maintenance therapy with atezolizumab, bevacizumab, or both.  The two primary end points were investigator-assessed progression-free survival both among patients in the intention-to-treat population who had a wild-type genotype (WT population; patients with EGFR or ALK genetic alterations were excluded) and among patients in the WT population who had high expression of an effector T-cell (Teff) gene signature in the tumor (Teff-high WT population) and overall survival in the WT population.  The ABCP group was compared with the BCP group before the ACP group was compared with the BCP group. results In the WT population, 356 patients were assigned to the ABCP group, and 336 to the BCP group.  The median progression-free survival was longer in the ABCP group than in the BCP group (8.3 mo vs. 6.8 mo; hazard ratio for disease progression or death, 0.62; 95% confidence interval [CI], 0.52 to 0.74; P<0.001); the corresponding values in the Teff-high WT population were 11.3 mo and 6.8 mo (hazard ratio, 0.51 [95% CI, 0.38 to 0.68]; P<0.001).  Progressioin-free survival was also longer in the ABCP group than in the BCP group in the entire intention-to-treat population (including those with EGFR or ALK genetic alterations) and among patients with low or neg. programmed death ligand 1 (PD-L1) expression, those with low Teff gene-signature expression, and those with liver metastases.  Median overall survival among the patients in the WT population was longer in the ABCP group than in the BCP group (19.2 mo vs. 14.7 mo; hazard ratio for death, 0.78; 95% CI, 0.64 to 0.96; P = 0.02).  The addn. of atezolizumab to bevacizumab plus chemotherapy significantly improved progression-free survival and overall survival among patients with metastatic nonsquamous NSCLC, regardless of PD-L1 expression and EGFR or ALK genetic alteration status.  The safety profile of ABCP was consistent with previously reported safety risks of the individual medicines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPXyYm4dRnKLVg90H21EOLACvtfcHk0lh4JwbMV8yAzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFKkt77K&md5=93f7f76c2e79bf42de2e7a8a403c9c93</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1716948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1716948%26sid%3Dliteratum%253Aachs%26aulast%3DSocinski%26aufirst%3DM.%2BA.%26aulast%3DJotte%26aufirst%3DR.%2BM.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DOrlandi%26aufirst%3DF.%26aulast%3DStroyakovskiy%26aufirst%3DD.%26aulast%3DNogami%26aufirst%3DN.%26aulast%3DRodr%25C3%25ADguez-Abreu%26aufirst%3DD.%26aulast%3DMoro-Sibilot%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DC.%2BA.%26aulast%3DBarlesi%26aufirst%3DF.%26aulast%3DFinley%26aufirst%3DG.%26aulast%3DKelsch%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DColeman%26aufirst%3DS.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DKowanetz%26aufirst%3DM.%26aulast%3DLopez-Chavez%26aufirst%3DA.%26aulast%3DSandler%26aufirst%3DA.%26aulast%3DReck%26aufirst%3DM.%26atitle%3DAtezolizumab%2520for%2520first-line%2520treatment%2520of%2520metastatic%2520nonsquamous%2520NSCLC%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26spage%3D2288%26epage%3D2301%26doi%3D10.1056%2FNEJMoa1716948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eisen, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodward, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitznagel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przybeck, T. R.</span></span> <span> </span><span class="NLM_article-title">The effect of prescribed daily dose frequency on patient medication compliance</span>. <i>Arch. Intern. Med.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">1881</span>– <span class="NLM_lpage">1884</span>, <span class="refDoi"> DOI: 10.1001/archinte.1990.00390200073014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1001%2Farchinte.1990.00390200073014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=2102668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A280%3ADyaK3czmsFGltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=1990&pages=1881-1884&author=S.+A.+Eisenauthor=D.+K.+Millerauthor=R.+S.+Woodwardauthor=E.+Spitznagelauthor=T.+R.+Przybeck&title=The+effect+of+prescribed+daily+dose+frequency+on+patient+medication+compliance&doi=10.1001%2Farchinte.1990.00390200073014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of prescribed daily dose frequency on patient medication compliance</span></div><div class="casAuthors">Eisen S A; Miller D K; Woodward R S; Spitznagel E; Przybeck T R</div><div class="citationInfo"><span class="NLM_cas:title">Archives of internal medicine</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1881-4</span>
        ISSN:<span class="NLM_cas:issn">0003-9926</span>.
    </div><div class="casAbstract">The objective of this study was to determine the relationship between prescribed daily dose frequency and patient medication compliance.  The medication compliance of 105 patients receiving antihypertensive medications was monitored by analyzing data obtained from special pill containers that electronically record the date and time of medication removal.  Inaccurate compliance estimates derived using the simple pill count method were thereby avoided.  Compliance was defined as the percent of days during which the prescribed number of doses were removed.  Compliance improved from 59.0% on a three-time daily regimen to 83.6% on a once-daily regimen.  Thus, compliance improves dramatically as prescribed dose frequency decreases.  Probably the single most important action that health care providers can take to improve compliance is to select medications that permit the lowest daily prescribed dose frequency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ77B5mAT4PZMRAV4D_Ins_fW6udTcc2eb96TNpFmWYBbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3czmsFGltg%253D%253D&md5=83afa34a4f1dafc6e0ab4bc87c33026c</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1001%2Farchinte.1990.00390200073014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchinte.1990.00390200073014%26sid%3Dliteratum%253Aachs%26aulast%3DEisen%26aufirst%3DS.%2BA.%26aulast%3DMiller%26aufirst%3DD.%2BK.%26aulast%3DWoodward%26aufirst%3DR.%2BS.%26aulast%3DSpitznagel%26aufirst%3DE.%26aulast%3DPrzybeck%26aufirst%3DT.%2BR.%26atitle%3DThe%2520effect%2520of%2520prescribed%2520daily%2520dose%2520frequency%2520on%2520patient%2520medication%2520compliance%26jtitle%3DArch.%2520Intern.%2520Med.%26date%3D1990%26volume%3D150%26spage%3D1881%26epage%3D1884%26doi%3D10.1001%2Farchinte.1990.00390200073014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poornima, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blunder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efferth, T.</span></span> <span> </span><span class="NLM_article-title">Network pharmacology of cancer: From understanding of complex interactomes to the design of multi-target specific therapeutics from nature</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">290</span>– <span class="NLM_lpage">302</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2016.06.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.phrs.2016.06.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=27329331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFShsr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2016&pages=290-302&author=P.+Poornimaauthor=J.+D.+Kumarauthor=Q.+Zhaoauthor=M.+Blunderauthor=T.+Efferth&title=Network+pharmacology+of+cancer%3A+From+understanding+of+complex+interactomes+to+the+design+of+multi-target+specific+therapeutics+from+nature&doi=10.1016%2Fj.phrs.2016.06.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Network pharmacology of cancer: From understanding of complex interactomes to the design of multi-target specific therapeutics from nature</span></div><div class="casAuthors">Poornima, Paramasivan; Kumar, Jothi Dinesh; Zhao, Qiaoli; Blunder, Martina; Efferth, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">290-302</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Despite massive investments in drug research and development, the significant decline in the no. of new drugs approved or translated to clin. use raises the question, whether single targeted drug discovery is the right approach.  To combat complex systemic diseases that harbor robust biol. networks such as cancer, single target intervention is proved to be ineffective.  In such cases, network pharmacol. approaches are highly useful, because they differ from conventional drug discovery by addressing the ability of drugs to target numerous proteins or networks involved in a disease.  Pleiotropic natural products are one of the promising strategies due to their multi-targeting and due to lower side effects.  In this review, we discuss the application of network pharmacol. for cancer drug discovery.  We provide an overview of the current state of knowledge on network pharmacol., focus on different tech. approaches and implications for cancer therapy (e.g. polypharmacol. and synthetic lethality), and illustrate the therapeutic potential with selected examples green tea polyphenolics, Eleutherococcus senticosus, Rhodiola rosea, and Schisandra chinensis.  Finally, we present future perspectives on their plausible applications for diagnosis and therapy of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwqqjqEH_wtrVg90H21EOLACvtfcHk0lgXIQFSQMc7Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFShsr%252FM&md5=be3757ac287f3b90ebbcb69016a9410c</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2016.06.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2016.06.018%26sid%3Dliteratum%253Aachs%26aulast%3DPoornima%26aufirst%3DP.%26aulast%3DKumar%26aufirst%3DJ.%2BD.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DBlunder%26aufirst%3DM.%26aulast%3DEfferth%26aufirst%3DT.%26atitle%3DNetwork%2520pharmacology%2520of%2520cancer%253A%2520From%2520understanding%2520of%2520complex%2520interactomes%2520to%2520the%2520design%2520of%2520multi-target%2520specific%2520therapeutics%2520from%2520nature%26jtitle%3DPharmacol.%2520Res.%26date%3D2016%26volume%3D111%26spage%3D290%26epage%3D302%26doi%3D10.1016%2Fj.phrs.2016.06.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jørgensen, J. T.</span></span> <span> </span><span class="NLM_article-title">The importance of predictive biomarkers in oncology drug development</span>. <i>Expert Rev. Mol. Diagn.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">807</span>– <span class="NLM_lpage">809</span>, <span class="refDoi"> DOI: 10.1080/14737159.2016.1199962</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1080%2F14737159.2016.1199962" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=27282189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FosVChug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=807-809&author=J.+T.+J%C3%B8rgensen&title=The+importance+of+predictive+biomarkers+in+oncology+drug+development&doi=10.1080%2F14737159.2016.1199962"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The importance of predictive biomarkers in oncology drug development</span></div><div class="casAuthors">Jorgensen Jan Trost</div><div class="citationInfo"><span class="NLM_cas:title">Expert review of molecular diagnostics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">807-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSpjsop5xOrXENoizSOkG_FfW6udTcc2eb96TNpFmWYBbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FosVChug%253D%253D&md5=a98aabac63825ef0d86e882456e73061</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1080%2F14737159.2016.1199962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14737159.2016.1199962%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25B8rgensen%26aufirst%3DJ.%2BT.%26atitle%3DThe%2520importance%2520of%2520predictive%2520biomarkers%2520in%2520oncology%2520drug%2520development%26jtitle%3DExpert%2520Rev.%2520Mol.%2520Diagn.%26date%3D2016%26volume%3D16%26spage%3D807%26epage%3D809%26doi%3D10.1080%2F14737159.2016.1199962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koutsoukas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simms, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirchmair, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bond, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitmore, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glen, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A.</span></span> <span> </span><span class="NLM_article-title">From in silico target prediction to multi-target drug design: current databases, methods and applications</span>. <i>J. Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">2554</span>– <span class="NLM_lpage">2574</span>, <span class="refDoi"> DOI: 10.1016/j.jprot.2011.05.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.jprot.2011.05.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=21621023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVOjtrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2011&pages=2554-2574&author=A.+Koutsoukasauthor=B.+Simmsauthor=J.+Kirchmairauthor=P.+J.+Bondauthor=A.+V.+Whitmoreauthor=S.+Zimmerauthor=M.+P.+Youngauthor=J.+L.+Jenkinsauthor=M.+Glickauthor=R.+C.+Glenauthor=A.+Bender&title=From+in+silico+target+prediction+to+multi-target+drug+design%3A+current+databases%2C+methods+and+applications&doi=10.1016%2Fj.jprot.2011.05.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">From in silico target prediction to multi-target drug design: Current databases, methods and applications</span></div><div class="casAuthors">Koutsoukas, Alexios; Simms, Benjamin; Kirchmair, Johannes; Bond, Peter J.; Whitmore, Alan V.; Zimmer, Steven; Young, Malcolm P.; Jenkins, Jeremy L.; Glick, Meir; Glen, Robert C.; Bender, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Proteomics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2554-2574</span>CODEN:
                <span class="NLM_cas:coden">JPORFQ</span>;
        ISSN:<span class="NLM_cas:issn">1874-3919</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Given the tremendous growth of bioactivity databases, the use of computational tools to predict protein targets of small mols. has been gaining importance in recent years.  Applications span a wide range, from the designed polypharmacol.' of compds. to mode-of-action anal.  In this review, we firstly survey databases that can be used for ligand-based target prediction and which have grown tremendously in size in the past.  We furthermore outline methods for target prediction that exist, both based on the knowledge of bioactivities from the ligand side and methods that can be applied in situations when a protein structure is known.  Applications of successful in silico target identification attempts are discussed in detail, which were based partly or in whole on computational target predictions in the first instance.  This includes the authors' own experience using target prediction tools, in this case considering phenotypic antibacterial screens and the anal. of high-throughput screening data.  Finally, we will conclude with the prospective application of databases to not only predict, retrospectively, the protein targets of a small mol., but also how to design ligands with desired polypharmacol. in a prospective manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQAhthzL8wiLVg90H21EOLACvtfcHk0lhG1PwPx7PYCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVOjtrfE&md5=3fd699639ef3faf347537ef400030dd9</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.jprot.2011.05.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jprot.2011.05.011%26sid%3Dliteratum%253Aachs%26aulast%3DKoutsoukas%26aufirst%3DA.%26aulast%3DSimms%26aufirst%3DB.%26aulast%3DKirchmair%26aufirst%3DJ.%26aulast%3DBond%26aufirst%3DP.%2BJ.%26aulast%3DWhitmore%26aufirst%3DA.%2BV.%26aulast%3DZimmer%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DM.%2BP.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26aulast%3DGlick%26aufirst%3DM.%26aulast%3DGlen%26aufirst%3DR.%2BC.%26aulast%3DBender%26aufirst%3DA.%26atitle%3DFrom%2520in%2520silico%2520target%2520prediction%2520to%2520multi-target%2520drug%2520design%253A%2520current%2520databases%252C%2520methods%2520and%2520applications%26jtitle%3DJ.%2520Proteomics%26date%3D2011%26volume%3D74%26spage%3D2554%26epage%3D2574%26doi%3D10.1016%2Fj.jprot.2011.05.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moffat, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, D.</span></span> <span> </span><span class="NLM_article-title">Phenotypic screening in cancer drug discovery - past, present and future</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">588</span>– <span class="NLM_lpage">602</span>, <span class="refDoi"> DOI: 10.1038/nrd4366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1038%2Fnrd4366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=25033736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFygsr7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=588-602&author=J.+G.+Moffatauthor=J.+Rudolphauthor=D.+Bailey&title=Phenotypic+screening+in+cancer+drug+discovery+-+past%2C+present+and+future&doi=10.1038%2Fnrd4366"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Phenotypic screening in cancer drug discovery - past, present and future</span></div><div class="casAuthors">Moffat, John G.; Rudolph, Joachim; Bailey, David</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">588-602</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  There has been a resurgence of interest in the use of phenotypic screens in drug discovery as an alternative to target-focused approaches.  Given that oncol. is currently the most active therapeutic area, and also one in which target-focused approaches have been particularly prominent in the past two decades, we investigated the contribution of phenotypic assays to oncol. drug discovery by analyzing the origins of all new small-mol. cancer drugs approved by the US Food and Drug Administration (FDA) over the past 15 years and those currently in clin. development.  Although the majority of these drugs originated from target-based discovery, we identified a significant no. whose discovery depended on phenotypic screening approaches.  We postulate that the contribution of phenotypic screening to cancer drug discovery has been hampered by a reliance on 'classical' nonspecific drug effects such as cytotoxicity and mitotic arrest, exacerbated by a paucity of mechanistically defined cellular models for therapeutically translatable cancer phenotypes.  However, tech. and biol. advances that enable such mechanistically informed phenotypic models have the potential to empower phenotypic drug discovery in oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTWtoTIgWqvbVg90H21EOLACvtfcHk0lhG1PwPx7PYCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFygsr7L&md5=0e8efed90e5bc4b47f959b83a6ab5b96</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnrd4366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4366%26sid%3Dliteratum%253Aachs%26aulast%3DMoffat%26aufirst%3DJ.%2BG.%26aulast%3DRudolph%26aufirst%3DJ.%26aulast%3DBailey%26aufirst%3DD.%26atitle%3DPhenotypic%2520screening%2520in%2520cancer%2520drug%2520discovery%2520-%2520past%252C%2520present%2520and%2520future%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D588%26epage%3D602%26doi%3D10.1038%2Fnrd4366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology by design: A medicinal chemist’s perspective on multitargeting compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">420</span>– <span class="NLM_lpage">444</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00760</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlKms7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=420-444&author=E.+Proschakauthor=H.+Starkauthor=D.+Merk&title=Polypharmacology+by+design%3A+A+medicinal+chemist%E2%80%99s+perspective+on+multitargeting+compounds&doi=10.1021%2Facs.jmedchem.8b00760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds</span></div><div class="casAuthors">Proschak, Ewgenij; Stark, Holger; Merk, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">420-444</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multitargeting compds. comprising activity on more than a single biol. target have gained remarkable relevance in drug discovery owing to the complexity of multifactorial diseases such as cancer, inflammation, or the metabolic syndrome.  Polypharmacol. drug profiles can produce additive or synergistic effects while reducing side effects and significantly contribute to the high therapeutic success of indispensable drugs such as aspirin.  While their identification has long been the result of serendipity, medicinal chem. now tends to design polypharmacol.  Modern in vitro pharmacol. methods and chem. probes allow a systematic search for rational target combinations and recent innovations in computational technologies, crystallog., or fragment-based design equip multitarget compd. development with valuable tools.  In this Perspective, we analyze the relevance of multiple ligands in drug discovery and the versatile toolbox to design polypharmacol.  We conclude that despite some characteristic challenges remaining unresolved, designed polypharmacol. holds enormous potential to secure future therapeutic innovation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOEwJSxWw3vbVg90H21EOLACvtfcHk0lhG1PwPx7PYCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlKms7fE&md5=6dc4b8e1c4777372396626140a302663</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00760%26sid%3Dliteratum%253Aachs%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DMerk%26aufirst%3DD.%26atitle%3DPolypharmacology%2520by%2520design%253A%2520A%2520medicinal%2520chemist%25E2%2580%2599s%2520perspective%2520on%2520multitargeting%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D420%26epage%3D444%26doi%3D10.1021%2Facs.jmedchem.8b00760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benek, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korabecny, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soukup, O.</span></span> <span> </span><span class="NLM_article-title">A perspective on multi-target drugs for Alzheimer’s Disease</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">434</span>– <span class="NLM_lpage">445</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2020.04.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.tips.2020.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=32448557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpsVKjsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2020&pages=434-445&author=O.+Benekauthor=J.+Korabecnyauthor=O.+Soukup&title=A+perspective+on+multi-target+drugs+for+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.tips.2020.04.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">A Perspective on Multi-target Drugs for Alzheimer's Disease</span></div><div class="casAuthors">Benek, Ondrej; Korabecny, Jan; Soukup, Ondrej</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">434-445</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease (AD) has a complex pathophysiol. that includes aggregation of pathol. proteins, impaired neurotransmission, increased oxidative stress, or microglia-mediated neuroinflammation.  Therapeutics targeting only one of these AD-related subpathologies have not yet been successful in the search for a disease-modifying treatment.  Therefore, multi-target drugs (MTDs) aiming simultaneously at several subpathologies are expected to be a better approach.  However, the concept of MTD is inherently connected with several limitations, which are often ignored during MTD design and development.  Here, we provide an overview of the MTD approach and discuss its potential pitfalls in the context of AD treatment.  We also put forward ideas to be used in the rational design of MTDs to obtain drugs that are effective against AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKMBfma_4sU7Vg90H21EOLACvtfcHk0li82HiIYpxHdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpsVKjsLY%253D&md5=535e634a85861105f799fe500ee11ad6</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2020.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2020.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DBenek%26aufirst%3DO.%26aulast%3DKorabecny%26aufirst%3DJ.%26aulast%3DSoukup%26aufirst%3DO.%26atitle%3DA%2520perspective%2520on%2520multi-target%2520drugs%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2020%26volume%3D41%26spage%3D434%26epage%3D445%26doi%3D10.1016%2Fj.tips.2020.04.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel dual-target inhibitor of ERK1 and ERK5 that induces regulated cell death to overcome compensatory mechanism in specific tumor types</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">3976</span>– <span class="NLM_lpage">3995</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01896</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01896" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjsFOku7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=3976-3995&author=G.+Wangauthor=Y.+Zhaoauthor=Y.+Liuauthor=D.+Sunauthor=Y.+Zhenauthor=J.+Liuauthor=L.+Fuauthor=L.+Zhangauthor=L.+Ouyang&title=Discovery+of+a+novel+dual-target+inhibitor+of+ERK1+and+ERK5+that+induces+regulated+cell+death+to+overcome+compensatory+mechanism+in+specific+tumor+types&doi=10.1021%2Facs.jmedchem.9b01896"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel Dual-Target Inhibitor of ERK1 and ERK5 That Induces Regulated Cell Death to Overcome Compensatory Mechanism in Specific Tumor Types</span></div><div class="casAuthors">Wang, Guan; Zhao, Yuqian; Liu, Yao; Sun, Dejuan; Zhen, Yongqi; Liu, Jie; Fu, Leilei; Zhang, Lan; Ouyang, Liang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3976-3995</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">ERK1 and ERK5 are proposed to have pivotal roles in several types of cancer.  Under some circumstance, ERK5 may provide a common bypass route, which rescues proliferation upon abrogation of ERK1 signaling.  Thus, we accurately classified the tumor types from The Cancer Genome Atlas (TCGA) based on the expression levels of ERK1 and ERK5.  We proposed a novel therapeutic strategy to overcome the above-mentioned compensatory mechanism in specific tumor types by co-targeting both ERK1 and ERK5.  On the basis of the idea of overcoming ERK5 compensation mechanism, 22ac (ADTL-EI1712) as the first selective dual-target inhibitor of ERK1 and ERK5 was discovered to have potent antitumor effects in vitro and in vivo.  Interestingly, this compd. was found to induce regulated cell death accompanied by autophagy in MKN-74 cells.  Taken together, our results warrant the potential of this dual-target inhibitor as a new candidate drug that conquers compensatory mechanism in certain tumor types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlxVBmkLH7mrVg90H21EOLACvtfcHk0li82HiIYpxHdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjsFOku7c%253D&md5=a39e2b19b4e97ba739e78f2453335714</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01896%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DG.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DZhen%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DOuyang%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520dual-target%2520inhibitor%2520of%2520ERK1%2520and%2520ERK5%2520that%2520induces%2520regulated%2520cell%2520death%2520to%2520overcome%2520compensatory%2520mechanism%2520in%2520specific%2520tumor%2520types%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D3976%26epage%3D3995%26doi%3D10.1021%2Facs.jmedchem.9b01896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span> <span> </span><span class="NLM_article-title">Strategies for modern biomarker and drug development in oncology</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">70</span>, <span class="refDoi"> DOI: 10.1186/s13045-014-0070-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1186%2Fs13045-014-0070-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=25277503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsVOrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=70&author=A.+D.+Smithauthor=D.+Rodaauthor=T.+A.+Yap&title=Strategies+for+modern+biomarker+and+drug+development+in+oncology&doi=10.1186%2Fs13045-014-0070-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for modern biomarker and drug development in oncology</span></div><div class="casAuthors">Smith, Alan D.; Roda, Desam; Yap, Timothy A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">70/1-70/16</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Technol. advancements in the mol. characterization of cancers have enabled researchers to identify an increasing no. of key mol. drivers of cancer progression.  These discoveries have led to multiple novel anticancer therapeutics, and clin. benefit in selected patient populations.  Despite this, the identification of clin. relevant predictive biomarkers of response continues to lag behind.  In this review, we discuss strategies for the mol. characterization of cancers and the importance of biomarkers for the development of novel antitumor therapeutics.  We also review crit. successes and failures in oncol., and detail the lessons learnt, which may aid in the acceleration of anticancer drug development and biomarker discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWNEkFi4M0pLVg90H21EOLACvtfcHk0li82HiIYpxHdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsVOrsQ%253D%253D&md5=735ba9bd2f866b407057dd5cb89e839f</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1186%2Fs13045-014-0070-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-014-0070-8%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DA.%2BD.%26aulast%3DRoda%26aufirst%3DD.%26aulast%3DYap%26aufirst%3DT.%2BA.%26atitle%3DStrategies%2520for%2520modern%2520biomarker%2520and%2520drug%2520development%2520in%2520oncology%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2014%26volume%3D7%26spage%3D70%26doi%3D10.1186%2Fs13045-014-0070-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span> <span> </span><span class="NLM_article-title">Dual-target kinase drug design: Current strategies and future directions in cancer therapy</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>188</i></span>,  <span class="NLM_fpage">112025</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.112025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejmech.2019.112025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=31931340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFCjtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=2020&pages=112025&author=D.+Sunauthor=Y.+Zhaoauthor=S.+Zhangauthor=L.+Zhangauthor=B.+Liuauthor=L.+Ouyang&title=Dual-target+kinase+drug+design%3A+Current+strategies+and+future+directions+in+cancer+therapy&doi=10.1016%2Fj.ejmech.2019.112025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-target kinase drug design: Current strategies and future directions in cancer therapy</span></div><div class="casAuthors">Sun, Dejuan; Zhao, Yuqian; Zhang, Shouyue; Zhang, Lan; Liu, Bo; Ouyang, Liang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">188</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112025</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Protein kinases are well-known to orchestrate the activation of signaling cascades in response to extracellular and intracellular stimuli to control cell proliferation and survival.  The perturbation of such kinases by some mutation or abnormal protein expressions has been closely linked to cancer.  Drug development aimed at several targetable kinases may alter their participated pathways that are able to trigger carcinogenesis.  A series of small-mol. drugs have been approved for the current cancer therapy.  However, their complicated inherent mechanisms may lead to the resistance to such small mols.  Consequently, development of new dual-target kinase drugs simultaneously aimed at two targetable kinases may improve their anti-tumor efficiency and solve resistant mechanism problems.  In this review, we focus on summarizing an overview of the current strategies of dual-target kinase drug design, including medicinal chem. strategies and computational approaches.  Taken together, we believe the above-mentioned strategies will provide a new insight into future directions of dual-target kinase drug design to improve potential cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL4dbUqruISrVg90H21EOLACvtfcHk0ljk9WGj7al6Vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFCjtLg%253D&md5=7b4830183b0b7045331f6d62ded69b1d</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.112025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.112025%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DOuyang%26aufirst%3DL.%26atitle%3DDual-target%2520kinase%2520drug%2520design%253A%2520Current%2520strategies%2520and%2520future%2520directions%2520in%2520cancer%2520therapy%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D188%26spage%3D112025%26doi%3D10.1016%2Fj.ejmech.2019.112025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology by dsign: A medicinal chemist’s perspective on multitargeting compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">420</span>– <span class="NLM_lpage">444</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00760</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlKms7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=420-444&author=E.+Proschakauthor=H.+Starkauthor=D.+Merk&title=Polypharmacology+by+dsign%3A+A+medicinal+chemist%E2%80%99s+perspective+on+multitargeting+compounds&doi=10.1021%2Facs.jmedchem.8b00760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds</span></div><div class="casAuthors">Proschak, Ewgenij; Stark, Holger; Merk, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">420-444</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multitargeting compds. comprising activity on more than a single biol. target have gained remarkable relevance in drug discovery owing to the complexity of multifactorial diseases such as cancer, inflammation, or the metabolic syndrome.  Polypharmacol. drug profiles can produce additive or synergistic effects while reducing side effects and significantly contribute to the high therapeutic success of indispensable drugs such as aspirin.  While their identification has long been the result of serendipity, medicinal chem. now tends to design polypharmacol.  Modern in vitro pharmacol. methods and chem. probes allow a systematic search for rational target combinations and recent innovations in computational technologies, crystallog., or fragment-based design equip multitarget compd. development with valuable tools.  In this Perspective, we analyze the relevance of multiple ligands in drug discovery and the versatile toolbox to design polypharmacol.  We conclude that despite some characteristic challenges remaining unresolved, designed polypharmacol. holds enormous potential to secure future therapeutic innovation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOEwJSxWw3vbVg90H21EOLACvtfcHk0ljk9WGj7al6Vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlKms7fE&md5=6dc4b8e1c4777372396626140a302663</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00760%26sid%3Dliteratum%253Aachs%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DMerk%26aufirst%3DD.%26atitle%3DPolypharmacology%2520by%2520dsign%253A%2520A%2520medicinal%2520chemist%25E2%2580%2599s%2520perspective%2520on%2520multitargeting%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D420%26epage%3D444%26doi%3D10.1021%2Facs.jmedchem.8b00760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minucci, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelicci, P. G.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1038/nrc1779</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1038%2Fnrc1779" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=16397526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1GgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=38-51&author=S.+Minucciauthor=P.+G.+Pelicci&title=Histone+deacetylase+inhibitors+and+the+promise+of+epigenetic+%28and+more%29+treatments+for+cancer&doi=10.1038%2Fnrc1779"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer</span></div><div class="casAuthors">Minucci, Saverio; Pelicci, Pier Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">38-51</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) are considered to be among the most promising targets in drug development for cancer therapy, and first-generation histone deacetylase inhibitors (HDACi) are currently being tested in phase I/II clin. trials.  A wide-ranging knowledge of the role of HDACs in tumorigenesis, and of the action of HDACi, has been achieved.  However, several basic aspects are not yet fully understood.  Investigating these aspects in the context of what we now understand about HDACi action both in vitro and in vivo will further improve the design of optimized clin. protocols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxXiACZV1sK7Vg90H21EOLACvtfcHk0ljk9WGj7al6Vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1GgsA%253D%253D&md5=384e1f8d676d61531e46843c060a9380</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fnrc1779&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1779%26sid%3Dliteratum%253Aachs%26aulast%3DMinucci%26aufirst%3DS.%26aulast%3DPelicci%26aufirst%3DP.%2BG.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520and%2520the%2520promise%2520of%2520epigenetic%2520%2528and%2520more%2529%2520treatments%2520for%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D38%26epage%3D51%26doi%3D10.1038%2Fnrc1779" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J. L.</span></span> <span> </span><span class="NLM_article-title">Microtubule-severing enzymes at the cutting edge</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">2561</span>– <span class="NLM_lpage">2569</span>, <span class="refDoi"> DOI: 10.1242/jcs.101139</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1242%2Fjcs.101139" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=22595526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1OrsrzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2012&pages=2561-2569&author=D.+J.+Sharpauthor=J.+L.+Ross&title=Microtubule-severing+enzymes+at+the+cutting+edge&doi=10.1242%2Fjcs.101139"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-severing enzymes at the cutting edge</span></div><div class="casAuthors">Sharp, David J.; Ross, Jennifer L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2561-2569</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review.  ATP-dependent severing of microtubules was first reported in Xenopus laevis egg exts. in 1991.  Two years later this observation led to the purifn. of the first known microtubule-severing enzyme, katanin.  Katanin homologs have now been identified throughout the animal kingdom and in plants.  Moreover, members of two closely related enzyme subfamilies, spastin and fidgetin, have been found to sever microtubules and might act alongside katanins in some contexts.  Over the past few years, it has become clear that microtubule-severing enzymes contribute to a wide range of cellular activities including mitosis and meiosis, morphogenesis, cilia biogenesis and disassembly, and cell migration.  Thus, this group of enzymes is revealing itself to be among the most important of the microtubule regulators.  This Commentary focuses on our growing understanding of how microtubule-severing enzymes contribute to the organization and dynamics of diverse microtubule arrays, as well as the structural and biophys. characteristics that afford them the unique capacity to catalyze the removal of tubulin from the interior microtubule lattice.  Our goal is to provide a broader perspective, focusing on a limited no. of particularly informative, representative and/or timely findings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg2sHb_W6V1LVg90H21EOLACvtfcHk0ljk9WGj7al6Vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1OrsrzO&md5=3effc3d0c73720e2a9d77fff656eb6b0</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1242%2Fjcs.101139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.101139%26sid%3Dliteratum%253Aachs%26aulast%3DSharp%26aufirst%3DD.%2BJ.%26aulast%3DRoss%26aufirst%3DJ.%2BL.%26atitle%3DMicrotubule-severing%2520enzymes%2520at%2520the%2520cutting%2520edge%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2012%26volume%3D125%26spage%3D2561%26epage%3D2569%26doi%3D10.1242%2Fjcs.101139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sherbet, G. V.</span></span> <span> </span><span class="NLM_article-title">Suppression of angiogenesis and tumour progression by combretastatin and derivatives</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>403</i></span>,  <span class="NLM_fpage">289</span>– <span class="NLM_lpage">295</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2017.06.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.canlet.2017.06.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=28688972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFCrtL3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=403&publication_year=2017&pages=289-295&author=G.+V.+Sherbet&title=Suppression+of+angiogenesis+and+tumour+progression+by+combretastatin+and+derivatives&doi=10.1016%2Fj.canlet.2017.06.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of angiogenesis and tumour progression by combretastatin and derivatives</span></div><div class="casAuthors">Sherbet, G. V.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">403</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">289-295</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The search for small mol. inhibitors has gained prominence with the recognition of their inherent advantage for cancer therapy.  Combretastatin is a naturally occurring small stilbenoid.  By virtue of the ability to bind to tubulin combretastatin and its derivs. promote depolymn. of microtubules as well as inhibit tubulin polymn.  This suppresses cell proliferation signalling and induces apoptosis.  Combretastatins activate mitotic checkpoints that lead to mitotic catastrophe and apoptosis.  They subvert the signalling systems which stimulate invasion, activate EMT (epithelial mesenchyme transition) and promote tumor progression.  Allied with the ability to suppress angiogenesis these compds. have been viewed as potential inhibitors of metastasis.  The notion of merging RTK (receptor tyrosine kinase) inhibition with suppression of invasion and possible inhibition of EMT has contributed to the credibility of combretastatins as anti-cancer agents.  Invaluable are their attributes of inhibiting tumor growth and induction of apoptosis and necrosis by reducing blood supply to the tumor.  Aside from these biol. effects, this commentary also discusses the issues of the targeting of combretastatins to the tumor vasculature and effective delivery of the drugs encapsulated in nanospheres.  Notwithstanding the perceived benefits, one can see a compelling need to understand the effects of combretastatin on the actin cytoskeletal dynamics and the disruption of microtubule polymn., and whether it is more efficient a tumor inhibitor than the conventional drugs that target microtubule dynamics.  Combinations of combretastatins with other vascular disrupting agents have been attempted.  It is essential to establish the perceived inhibition of EMT beyond reasonable doubt.  This might justify using the combretastatins with allosteric EMT and Akt inhibitors as addnl. choices for pre-clin./clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcF3mg-kruNbVg90H21EOLACvtfcHk0lhMT4H1zFumuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFCrtL3J&md5=1e831ec2ba63c62e10e6b43d328b4439</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2017.06.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2017.06.032%26sid%3Dliteratum%253Aachs%26aulast%3DSherbet%26aufirst%3DG.%2BV.%26atitle%3DSuppression%2520of%2520angiogenesis%2520and%2520tumour%2520progression%2520by%2520combretastatin%2520and%2520derivatives%26jtitle%3DCancer%2520Lett.%26date%3D2017%26volume%3D403%26spage%3D289%26epage%3D295%26doi%3D10.1016%2Fj.canlet.2017.06.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Dual-targeting hybrid peptide-conjugated doxorubicin for drug resistance reversal in breast cancer</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>512</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.1016/j.ijpharm.2016.08.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ijpharm.2016.08.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=27521706" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyktb%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=512&publication_year=2016&pages=1-13&author=Y.+Shengauthor=Y.+Youauthor=Y.+Chen&title=Dual-targeting+hybrid+peptide-conjugated+doxorubicin+for+drug+resistance+reversal+in+breast+cancer&doi=10.1016%2Fj.ijpharm.2016.08.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-targeting hybrid peptide-conjugated doxorubicin for drug resistance reversal in breast cancer</span></div><div class="casAuthors">Sheng, Yuan; You, Yiwen; Chen, Yun</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">512</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-13</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The extended use of doxorubicin (DOX) could be limited due to the emergence of drug resistance assocd. with its treatment.  In addn. to the overexpression of ATP-binding cassette (ABC) transporters such as P-glycoprotein (P-gp), other mechanisms including apoptosis evasion and tumor cell survival may also be important contributor to drug resistance.  Within this context, targeting extracellular signal-regulated kinases (ERK), one of the principle protein mols. in cell apoptosis has emerged as an attractive therapeutic concept.  In this study, a dual-targeting hybrid peptide HAIYPRHGGCGMPKKKPTPIQLNP (T10-ERK), which is composed of ERK peptide inhibitor MPKKKPTPIQLNP, a thiol spacer (i.e., GGCG) and transferrin receptor (TfR)-binding peptide HAIYPRH, was designed.  Then, this thiol-modified hybrid peptide was conjugated to DOXO-EMCH (6-maleimidocaproyl) hydrazone of DOX, forming a novel peptide-DOX conjugate T10-ERK-DOX.  The structure and properties of this conjugate were characterized using 1H NMR, mass spectrometry and HPLC.  Using MCF-7/ADR cells as an in vitro model system and nude mice bearing MCF-7/ADR xenografts as an in vivo model, the ability of T10-ERK-DOX to reverse drug resistance was accessed as compared with free DOX and T10-DOX.  As a result, T10-ERK-DOX demonstrated a much lower in vitro IC50 (20.8 ± 1.1 μM) and its in vivo extent of inhibition in mice was more evident (72.2 ± 4.6%).  Induction of various apoptosis pathways was also obsd.  Furthermore, the potency of ERK peptide inhibitor to reverse drug resistance was individually assessed, given the pronounced efficacy of T10-DOX indicated by our previous work.  The results provided evidence of its additive effect with T10-DOX, which leads to greater efficacy and less susceptibility to drug resistance.  Finally, the success of multi-targeting strategy in the present study implied that multi-target drugs with rational design could be more promising in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT7-zyXxfctLVg90H21EOLACvtfcHk0lhMT4H1zFumuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyktb%252FJ&md5=b93858a1608988876ba31751957f8c7d</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2016.08.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2016.08.016%26sid%3Dliteratum%253Aachs%26aulast%3DSheng%26aufirst%3DY.%26aulast%3DYou%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DDual-targeting%2520hybrid%2520peptide-conjugated%2520doxorubicin%2520for%2520drug%2520resistance%2520reversal%2520in%2520breast%2520cancer%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2016%26volume%3D512%26spage%3D1%26epage%3D13%26doi%3D10.1016%2Fj.ijpharm.2016.08.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aarsland, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molinuevo, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fladby, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbett, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sultana, J.</span></span> <span> </span><span class="NLM_article-title">Drug repositioning and repurposing for Alzheimer disease</span>. <i>Nat. Rev. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">661</span>– <span class="NLM_lpage">673</span>, <span class="refDoi"> DOI: 10.1038/s41582-020-0397-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1038%2Fs41582-020-0397-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=32939050" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A280%3ADC%252BB38bpslOqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2020&pages=661-673&author=C.+Ballardauthor=D.+Aarslandauthor=J.+Cummingsauthor=J.+O%E2%80%99Brienauthor=R.+Millsauthor=J.+L.+Molinuevoauthor=T.+Fladbyauthor=G.+Williamsauthor=P.+Dohertyauthor=A.+Corbettauthor=J.+Sultana&title=Drug+repositioning+and+repurposing+for+Alzheimer+disease&doi=10.1038%2Fs41582-020-0397-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Drug repositioning and repurposing for Alzheimer disease</span></div><div class="casAuthors">Ballard Clive; Corbett Anne; Aarsland Dag; Mills Roger; Williams Gareth; Doherty Pat; Aarsland Dag; Cummings Jeffrey; O'Brien John; Mills Roger; Molinuevo Jose Luis; Fladby Tormod; Sultana Janet</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Neurology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">661-673</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Drug repositioning and repurposing can enhance traditional drug development efforts and could accelerate the identification of new treatments for individuals with Alzheimer disease (AD) dementia and mild cognitive impairment.  Transcriptional profiling offers a new and highly efficient approach to the identification of novel candidates for repositioning and repurposing.  In the future, novel AD transcriptional signatures from cells isolated at early stages of disease, or from human neurons or microglia that carry mutations that increase the risk of AD, might be used as probes to identify additional candidate drugs.  Phase II trials assessing repurposed agents must consider the best target population for a specific candidate therapy as well as the mechanism of action of the treatment.  In this Review, we highlight promising compounds to prioritize for clinical trials in individuals with AD, and discuss the value of Delphi consensus methodology and evidence-based reviews to inform this prioritization process.  We also describe emerging work, focusing on the potential value of transcript signatures as a cost-effective approach to the identification of novel candidates for repositioning.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQsEBm4piE20QxyojvcjibhfW6udTcc2eYAnLg7Re1Wxrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38bpslOqtQ%253D%253D&md5=803127f9862f6a9eb12536b61f07787f</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fs41582-020-0397-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41582-020-0397-4%26sid%3Dliteratum%253Aachs%26aulast%3DBallard%26aufirst%3DC.%26aulast%3DAarsland%26aufirst%3DD.%26aulast%3DCummings%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DJ.%26aulast%3DMills%26aufirst%3DR.%26aulast%3DMolinuevo%26aufirst%3DJ.%2BL.%26aulast%3DFladby%26aufirst%3DT.%26aulast%3DWilliams%26aufirst%3DG.%26aulast%3DDoherty%26aufirst%3DP.%26aulast%3DCorbett%26aufirst%3DA.%26aulast%3DSultana%26aufirst%3DJ.%26atitle%3DDrug%2520repositioning%2520and%2520repurposing%2520for%2520Alzheimer%2520disease%26jtitle%3DNat.%2520Rev.%2520Neurol.%26date%3D2020%26volume%3D16%26spage%3D661%26epage%3D673%26doi%3D10.1038%2Fs41582-020-0397-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designed multiple ligands. An emerging drug discovery paradigm</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6523</span>– <span class="NLM_lpage">6543</span>, <span class="refDoi"> DOI: 10.1021/jm058225d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+multiple+ligands.+An+emerging+drug+discovery+paradigm&doi=10.1021%2Fjm058225d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0ljSO06TVioCVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520multiple%2520ligands.%2520An%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6523%26epage%3D6543%26doi%3D10.1021%2Fjm058225d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minarini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumiatti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recanatini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melchiorre, C.</span></span> <span> </span><span class="NLM_article-title">Multi-target-directed ligands to combat neurodegenerative diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">347</span>– <span class="NLM_lpage">372</span>, <span class="refDoi"> DOI: 10.1021/jm7009364</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm7009364" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsl2qsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=347-372&author=A.+Cavalliauthor=M.+L.+Bolognesiauthor=A.+Minariniauthor=M.+Rosiniauthor=V.+Tumiattiauthor=M.+Recanatiniauthor=C.+Melchiorre&title=Multi-target-directed+ligands+to+combat+neurodegenerative+diseases&doi=10.1021%2Fjm7009364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target-Directed Ligands to Combat Neurodegenerative Diseases</span></div><div class="casAuthors">Cavalli, Andrea; Bolognesi, Maria Laura; Minarini, Anna; Rosini, Michela; Tumiatti, Vincenzo; Recanatini, Maurizio; Melchiorre, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">347-372</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The authors review the investigations reported in the past decade that illustrate the ability of medicinal chemists to design multi-target-directed ligands (MTDLs) to confront neurodegenerative diseases.  The authors briefly illustrate the multifactorial nature of these diseases before discussing the possible development of MTDLs in light of the known mol. bases of the main neurodegenerative pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYY0I0UHEir7Vg90H21EOLACvtfcHk0ljSO06TVioCVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsl2qsbk%253D&md5=c682235151489316d043cf97f78e56f3</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fjm7009364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7009364%26sid%3Dliteratum%253Aachs%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DMinarini%26aufirst%3DA.%26aulast%3DRosini%26aufirst%3DM.%26aulast%3DTumiatti%26aufirst%3DV.%26aulast%3DRecanatini%26aufirst%3DM.%26aulast%3DMelchiorre%26aufirst%3DC.%26atitle%3DMulti-target-directed%2520ligands%2520to%2520combat%2520neurodegenerative%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D347%26epage%3D372%26doi%3D10.1021%2Fjm7009364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, L.</span></span> <span> </span><span class="NLM_article-title">Computational multitarget drug design</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">403</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.6b00491</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.6b00491" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFCntr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2017&pages=403-412&author=W.+Zhangauthor=J.+Peiauthor=L.+Lai&title=Computational+multitarget+drug+design&doi=10.1021%2Facs.jcim.6b00491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Computational Multitarget Drug Design</span></div><div class="casAuthors">Zhang, Weilin; Pei, Jianfeng; Lai, Luhua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">403-412</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Designing drugs that can simultaneously interact with multiple targets is a promising approach for treating complicated diseases.  Compared to using combinations of single target drugs, multitarget drugs have advantages of higher efficacy, improved safety profile, and simpler administration.  Many in silico methods have been developed to approach different aspects of this polypharmacol.-guided drug design, particularly for drug repurposing and multitarget drug design.  In this review, the authors summarize recent progress in computational multitarget drug design and discuss their advantages and limitations.  Perspectives for future drug development will also be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-J4p0tdEUR7Vg90H21EOLACvtfcHk0ljSO06TVioCVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFCntr8%253D&md5=e00ed6650471d786a04b828a8064f5e9</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.6b00491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.6b00491%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DPei%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DL.%26atitle%3DComputational%2520multitarget%2520drug%2520design%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2017%26volume%3D57%26spage%3D403%26epage%3D412%26doi%3D10.1021%2Facs.jcim.6b00491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sonawane, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohd Siddique, M. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadav, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaprakash, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhuri, B.</span></span> <span> </span><span class="NLM_article-title">Cink4T, a quinazolinone-based dual inhibitor of Cdk4 and tubulin polymerization, identified via ligand-based virtual screening, for efficient anticancer therapy</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.01.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejmech.2019.01.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=30665142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVyit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2019&pages=115-132&author=V.+Sonawaneauthor=M.+U.+Mohd+Siddiqueauthor=S.+S.+Jadavauthor=B.+N.+Sinhaauthor=V.+Jayaprakashauthor=B.+Chaudhuri&title=Cink4T%2C+a+quinazolinone-based+dual+inhibitor+of+Cdk4+and+tubulin+polymerization%2C+identified+via+ligand-based+virtual+screening%2C+for+efficient+anticancer+therapy&doi=10.1016%2Fj.ejmech.2019.01.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Cink4T, a quinazolinone-based dual inhibitor of Cdk4 and tubulin polymerization, identified via ligand-based virtual screening, for efficient anticancer therapy</span></div><div class="casAuthors">Sonawane, Vinay; Mohd. Siddique, Mohd. Usman; Jadav, Surender Singh; Sinha, Barij Nayan; Jayaprakash, Venkatesan; Chaudhuri, Bhabatosh</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">115-132</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Inhibition of cyclin dependent kinase 4 (Cdk4) prevents cancer cells from entering the early G0/G1 phase of the cell division cycle whereas inhibiting tubulin polymn. blocks cancer cells' ability to undergo mitosis (M) late in the cell cycle.  We had reported earlier that two non-planar and relatively non-toxic fascaplysin derivs., an indole and a tryptoline, inhibit Cdk4 with IC50 values of 6.2 and 10 μM, resp.  Serendipitously, we had also found that they inhibited tubulin polymn.  The mols. were efficacious in mouse tumor models.  We have now identified Cink4T in a 59-compd. quinazolinone library, designed on the basis of ligand-based virtual screening, as a compd. that inhibits Cdk4 and tubulin.  Its IC50 value for Cdk4 inhibition is 0.47 μM and >50 μM for inhibition of Cdk1, Cdk2, Cdk6, Cdk9.  Cink4T inhibits tubulin polymn. with an IC50 of 0.6 μM.  Mol. modeling studies on Cink4T with Cdk4 and tubulin crystal structures lend support to these observations.  Cancer cell cycle analyses confirm that Cink4T blocks cells at both G0/G1 and M phases as it should if it were to inhibit both Cdk4 and tubulin polymn.  Our results show, for the very first time, that virtual screening can be used to design novel inhibitors that can potently block two crucial phases of the cell division cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomphGxgW4-J7Vg90H21EOLACvtfcHk0ljSO06TVioCVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVyit7k%253D&md5=2898dfdc7c064e9bd96bea72466b5906</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.01.011%26sid%3Dliteratum%253Aachs%26aulast%3DSonawane%26aufirst%3DV.%26aulast%3DMohd%2BSiddique%26aufirst%3DM.%2BU.%26aulast%3DJadav%26aufirst%3DS.%2BS.%26aulast%3DSinha%26aufirst%3DB.%2BN.%26aulast%3DJayaprakash%26aufirst%3DV.%26aulast%3DChaudhuri%26aufirst%3DB.%26atitle%3DCink4T%252C%2520a%2520quinazolinone-based%2520dual%2520inhibitor%2520of%2520Cdk4%2520and%2520tubulin%2520polymerization%252C%2520identified%2520via%2520ligand-based%2520virtual%2520screening%252C%2520for%2520efficient%2520anticancer%2520therapy%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D165%26spage%3D115%26epage%3D132%26doi%3D10.1016%2Fj.ejmech.2019.01.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lo, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cormier, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nettles, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stearns, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, R. B.</span></span> <span> </span><span class="NLM_article-title">Pocket similarity identifies selective estrogen receptor modulators as microtubule modulators at the taxane site</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1033</span>, <span class="refDoi"> DOI: 10.1038/s41467-019-08965-w</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1038%2Fs41467-019-08965-w" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=30833575" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A280%3ADC%252BB3cbgtl2gtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1033&author=Y.-C.+Loauthor=O.+Cormierauthor=T.+Liuauthor=K.+W.+Nettlesauthor=J.+A.+Katzenellenbogenauthor=T.+Stearnsauthor=R.+B.+Altman&title=Pocket+similarity+identifies+selective+estrogen+receptor+modulators+as+microtubule+modulators+at+the+taxane+site&doi=10.1038%2Fs41467-019-08965-w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Pocket similarity identifies selective estrogen receptor modulators as microtubule modulators at the taxane site</span></div><div class="casAuthors">Lo Yu-Chen; Liu Tianyun; Altman Russ B; Cormier Olga; Stearns Tim; Liu Tianyun; Stearns Tim; Altman Russ B; Nettles Kendall W; Katzenellenbogen John A</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1033</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Taxanes are a family of natural products with a broad spectrum of anticancer activity.  This activity is mediated by interaction with the taxane site of beta-tubulin, leading to microtubule stabilization and cell death.  Although widely used in the treatment of breast cancer and other malignancies, existing taxane-based therapies including paclitaxel and the second-generation docetaxel are currently limited by severe adverse effects and dose-limiting toxicity.  To discover taxane site modulators, we employ a computational binding site similarity screen of > 14,000 drug-like pockets from PDB, revealing an unexpected similarity between the estrogen receptor and the beta-tubulin taxane binding pocket.  Evaluation of nine selective estrogen receptor modulators (SERMs) via cellular and biochemical assays confirms taxane site interaction, microtubule stabilization, and cell proliferation inhibition.  Our study demonstrates that SERMs can modulate microtubule assembly and raises the possibility of an estrogen receptor-independent mechanism for inhibiting cell proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRKDjpfXAfQCYIRAdBLKY41fW6udTcc2eYN9jlMq6fb97ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbgtl2gtQ%253D%253D&md5=fbdb1a879b6c654adf72f5a2635a4454</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fs41467-019-08965-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-019-08965-w%26sid%3Dliteratum%253Aachs%26aulast%3DLo%26aufirst%3DY.-C.%26aulast%3DCormier%26aufirst%3DO.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DNettles%26aufirst%3DK.%2BW.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26aulast%3DStearns%26aufirst%3DT.%26aulast%3DAltman%26aufirst%3DR.%2BB.%26atitle%3DPocket%2520similarity%2520identifies%2520selective%2520estrogen%2520receptor%2520modulators%2520as%2520microtubule%2520modulators%2520at%2520the%2520taxane%2520site%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26spage%3D1033%26doi%3D10.1038%2Fs41467-019-08965-w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gangjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavana, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihnat, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorpe, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Disch, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey-Downs, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, R.</span></span> <span> </span><span class="NLM_article-title">Discovery of antitubulin agents with antiangiogenic activity as single entities with multitarget chemotherapy potential</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">480</span>– <span class="NLM_lpage">484</span>, <span class="refDoi"> DOI: 10.1021/ml4004793</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml4004793" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjt1yntbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=480-484&author=A.+Gangjeeauthor=R.+K.+Pavanaauthor=M.+A.+Ihnatauthor=J.+E.+Thorpeauthor=B.+C.+Dischauthor=A.+Bastianauthor=L.+C.+Bailey-Downsauthor=E.+Hamelauthor=R.+Bai&title=Discovery+of+antitubulin+agents+with+antiangiogenic+activity+as+single+entities+with+multitarget+chemotherapy+potential&doi=10.1021%2Fml4004793"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Antitubulin Agents with Antiangiogenic Activity as Single Entities with Multitarget Chemotherapy Potential</span></div><div class="casAuthors">Gangjee, Aleem; Pavana, Roheeth Kumar; Ihnat, Michael A.; Thorpe, Jessica E.; Disch, Bryan C.; Bastian, Anja; Bailey-Downs, Lora C.; Hamel, Ernest; Bai, Rouli</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">480-484</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antiangiogenic agents (AA) are cytostatic, and their utility in cancer chemotherapy lies in their combination with cytotoxic chemotherapeutic agents.  Clin. combinations of vascular endothelial growth factor receptor-2 (VEGFR2) inhibitors with antitubulin agents have been particularly successful.  We have discovered a novel, potentially important analog, that combines potent VEGFR2 inhibitory activity (comparable to that of sunitinib) with potent antitubulin activity (comparable to that of combretastatin A-4 (CA)) in a single mol., with GI50 values of 10-7 M across the entire NCI 60 tumor cell panel.  It potently inhibited tubulin assembly and circumvented the most clin. relevant tumor resistance mechanisms (P-glycoprotein and β-III tubulin expression) to antimicrotubule agents.  The compd. is freely water-sol. as its HCl salt and afforded excellent antitumor activity in vivo, superior to docetaxel, sunitinib, or Temozolomide, without any toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7Gh9q5qJzs7Vg90H21EOLACvtfcHk0liWBG6c3OjZow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjt1yntbw%253D&md5=85cb234c235a0738619d7ab984b20fc9</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Fml4004793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml4004793%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DPavana%26aufirst%3DR.%2BK.%26aulast%3DIhnat%26aufirst%3DM.%2BA.%26aulast%3DThorpe%26aufirst%3DJ.%2BE.%26aulast%3DDisch%26aufirst%3DB.%2BC.%26aulast%3DBastian%26aufirst%3DA.%26aulast%3DBailey-Downs%26aufirst%3DL.%2BC.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DBai%26aufirst%3DR.%26atitle%3DDiscovery%2520of%2520antitubulin%2520agents%2520with%2520antiangiogenic%2520activity%2520as%2520single%2520entities%2520with%2520multitarget%2520chemotherapy%2520potential%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D480%26epage%3D484%26doi%3D10.1021%2Fml4004793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pavana, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhary, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihnat, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangjee, A.</span></span> <span> </span><span class="NLM_article-title">Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">545</span>– <span class="NLM_lpage">556</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.11.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.bmc.2016.11.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=27894589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCntr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=545-556&author=R.+K.+Pavanaauthor=S.+Choudharyauthor=A.+Bastianauthor=M.+A.+Ihnatauthor=R.+Baiauthor=E.+Hamelauthor=A.+Gangjee&title=Discovery+and+preclinical+evaluation+of+7-benzyl-N-%28substituted%29-pyrrolo%5B3%2C2-d%5Dpyrimidin-4-amines+as+single+agents+with+microtubule+targeting+effects+along+with+triple-acting+angiokinase+inhibition+as+antitumor+agents&doi=10.1016%2Fj.bmc.2016.11.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents</span></div><div class="casAuthors">Pavana, Roheeth Kumar; Choudhary, Shruti; Bastian, Anja; Ihnat, Michael A.; Bai, Ruoli; Hamel, Ernest; Gangjee, Aleem</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">545-556</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The utility of cytostatic antiangiogenic agents (AA) in cancer chemotherapy lies in their combination with cytotoxic chemotherapeutic agents.  Clin. combinations of AA with microtubule targeting agents (MTAs) have been particularly successful.  The discovery, synthesis and biol. evaluations of a series of 7-benzyl-N-substituted-pyrrolo[3,2-d]pyrimidin-4-amines are reported.  Novel compds. which inhibit proangiogenic receptor tyrosine kinases (RTKs) including vascular endothelial growth factor receptor-2 (VEGFR-2), platelet-derived growth factor receptor-β (PDGFR-β) and epidermal growth factor receptor (EGFR), along with microtubule targeting in single mols. are described.  These compds. also inhibited blood vessel formation in the chicken chorioallantoic membrane (CAM) assay, and some potently inhibited tubulin assembly (with activity comparable to that of combretastatin A-4 (CA)).  In addn., some of the analogs circumvent the most clin. relevant tumor resistance mechanisms (P-glycoprotein and β-III tubulin expression) to microtubule targeting agents (MTA).  These MTAs bind at the colchicine site on tubulin.  Two analogs displayed two to three digit nanomolar GIC50 values across the entire NCI 60 tumor cell panel and one of these, compd. 7, freely water sol. as its HCl salt, afforded excellent in vivo antitumor activity against an orthotopic triple neg. 4T1 breast cancer model and was superior to doxorubicin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwGOvmBOf0h7Vg90H21EOLACvtfcHk0liWBG6c3OjZow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCntr%252FM&md5=9fd3c0008bda8c9222761f9d344610e6</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.11.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.11.026%26sid%3Dliteratum%253Aachs%26aulast%3DPavana%26aufirst%3DR.%2BK.%26aulast%3DChoudhary%26aufirst%3DS.%26aulast%3DBastian%26aufirst%3DA.%26aulast%3DIhnat%26aufirst%3DM.%2BA.%26aulast%3DBai%26aufirst%3DR.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DGangjee%26aufirst%3DA.%26atitle%3DDiscovery%2520and%2520preclinical%2520evaluation%2520of%25207-benzyl-N-%2528substituted%2529-pyrrolo%255B3%252C2-d%255Dpyrimidin-4-amines%2520as%2520single%2520agents%2520with%2520microtubule%2520targeting%2520effects%2520along%2520with%2520triple-acting%2520angiokinase%2520inhibition%2520as%2520antitumor%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D545%26epage%3D556%26doi%3D10.1016%2Fj.bmc.2016.11.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghavan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihnat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorpe, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Disch, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey-Downs, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dybdal-Hargreaves, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohena, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooberry, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangjee, A.</span></span> <span> </span><span class="NLM_article-title">The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">3753</span>– <span class="NLM_lpage">3772</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.04.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.bmc.2014.04.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=24890652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslCns78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=3753-3772&author=X.+Zhangauthor=S.+Raghavanauthor=M.+Ihnatauthor=J.+E.+Thorpeauthor=B.+C.+Dischauthor=A.+Bastianauthor=L.+C.+Bailey-Downsauthor=N.+F.+Dybdal-Hargreavesauthor=C.+C.+Rohenaauthor=E.+Hamelauthor=S.+L.+Mooberryauthor=A.+Gangjee&title=The+design+and+discovery+of+water+soluble+4-substituted-2%2C6-dimethylfuro%5B2%2C3-d%5Dpyrimidines+as+multitargeted+receptor+tyrosine+kinase+inhibitors+and+microtubule+targeting+antitumor+agents&doi=10.1016%2Fj.bmc.2014.04.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents</span></div><div class="casAuthors">Zhang, Xin; Raghavan, Sudhir; Ihnat, Michael; Thorpe, Jessica E.; Disch, Bryan C.; Bastian, Anja; Bailey-Downs, Lora C.; Dybdal-Hargreaves, Nicholas F.; Rohena, Cristina C.; Hamel, Ernest; Mooberry, Susan L.; Gangjee, Aleem</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3753-3772</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The design, synthesis and biol. evaluations of fourteen 4-substituted 2,6-dimethylfuro[2,3-d]pyrimidines are reported.  Four compds. inhibit vascular endothelial growth factor receptor-2 (VEGFR-2), platelet-derived growth factor receptor β (PDGFR-β), and target tubulin leading to cytotoxicity.  Compd. I has nanomolar potency, comparable to sunitinib and semaxinib, against tumor cell lines overexpressing VEGFR-2 and PDGFR-β.  Further, I binds at the colchicine site on tubulin, depolymerizes cellular microtubules and inhibits purified tubulin assembly and overcomes both βIII-tubulin and P-glycoprotein-mediated drug resistance, and initiates mitotic arrest leading to apoptosis.  In vivo, its HCl salt, I·HCl, reduced tumor size and vascularity in xenograft and allograft murine models and was superior to docetaxel and sunitinib, without overt toxicity.  Thus I·HCl affords potential combination chemotherapy in a single agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpz0a4q7mfRm7Vg90H21EOLACvtfcHk0lhu-bFGjBplKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslCns78%253D&md5=b35cd4ed7f053ea14d7ef5ee33828b38</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.04.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.04.049%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DRaghavan%26aufirst%3DS.%26aulast%3DIhnat%26aufirst%3DM.%26aulast%3DThorpe%26aufirst%3DJ.%2BE.%26aulast%3DDisch%26aufirst%3DB.%2BC.%26aulast%3DBastian%26aufirst%3DA.%26aulast%3DBailey-Downs%26aufirst%3DL.%2BC.%26aulast%3DDybdal-Hargreaves%26aufirst%3DN.%2BF.%26aulast%3DRohena%26aufirst%3DC.%2BC.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26aulast%3DGangjee%26aufirst%3DA.%26atitle%3DThe%2520design%2520and%2520discovery%2520of%2520water%2520soluble%25204-substituted-2%252C6-dimethylfuro%255B2%252C3-d%255Dpyrimidines%2520as%2520multitargeted%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520and%2520microtubule%2520targeting%2520antitumor%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D3753%26epage%3D3772%26doi%3D10.1016%2Fj.bmc.2014.04.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghavan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihnat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zammiello, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooberry, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangjee, A.</span></span> <span> </span><span class="NLM_article-title">The design, synthesis and biological evaluation of conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase and microtubule inhibitors as potential antitumor agents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2408</span>– <span class="NLM_lpage">2423</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.03.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.bmc.2015.03.061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=25882519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXls1Gmu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=2408-2423&author=X.+Zhangauthor=S.+Raghavanauthor=M.+Ihnatauthor=E.+Hamelauthor=C.+Zammielloauthor=A.+Bastianauthor=S.+L.+Mooberryauthor=A.+Gangjee&title=The+design%2C+synthesis+and+biological+evaluation+of+conformationally+restricted+4-substituted-2%2C6-dimethylfuro%5B2%2C3-d%5Dpyrimidines+as+multi-targeted+receptor+tyrosine+kinase+and+microtubule+inhibitors+as+potential+antitumor+agents&doi=10.1016%2Fj.bmc.2015.03.061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">The design, synthesis and biological evaluation of conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase and microtubule inhibitors as potential antitumor agents</span></div><div class="casAuthors">Zhang, Xin; Raghavan, Sudhir; Ihnat, Michael; Hamel, Ernest; Zammiello, Cynthia; Bastian, Anja; Mooberry, Susan L.; Gangjee, Aleem</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2408-2423</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of eleven conformationally restricted, 4-substituted 2,6-dimethylfuro[2,3-d]pyrimidines was designed to explore the bioactive conformation required for dual inhibition of microtubule assembly and receptor tyrosine kinases (RTKs), and their biol. activities are reported.  All three rotatable single bonds in the lead compd. were sequentially restricted to address the role of each in SAR for microtubule and RTK inhibitory effects.  Several compds. showed microtubule depolymg. activity comparable to or better than the lead compd., some with nanomolar EC50 values.  One compd. had no effect on microtubules, others showed potent RTK inhibition with nanomolar IC50s.  These compds. confirm that the bioactive conformation for RTK inhibition is different from that for tubulin inhibition.  A tetrahydroquinoline analog showed the most potent dual tubulin inhibitors (i.e., tubulin polymn. inhibitors, microtubule-disrupting agents) and RTK inhibitory activities [i.e., low nanomolar inhibition of epidermal growth factor receptors (EGFR), vascular endothelial growth factor receptor 2 (VEGFR2) and platelet derived growth factor receptor β (PDGFR-β)].  The tetrahydroquinoline analog has highly potent activity against many NCI cancer cell lines, including several chemo-resistant cell lines, and could serve as a lead for further preclin. studies.  The synthesis of the target compds. was achieved by a reaction of 4-chloro-2,6-dimethylfuro[2,3-d]pyrimidine with amine derivs., such as benzenamine derivs., benzofuranamine derivs., tetrahydroquinoline derivs., indole derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3IUVQLu9YarVg90H21EOLACvtfcHk0lhu-bFGjBplKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXls1Gmu78%253D&md5=4a6d65424606155db3ab4ec5751ad213</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.03.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.03.061%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DRaghavan%26aufirst%3DS.%26aulast%3DIhnat%26aufirst%3DM.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DZammiello%26aufirst%3DC.%26aulast%3DBastian%26aufirst%3DA.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26aulast%3DGangjee%26aufirst%3DA.%26atitle%3DThe%2520design%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520conformationally%2520restricted%25204-substituted-2%252C6-dimethylfuro%255B2%252C3-d%255Dpyrimidines%2520as%2520multi-targeted%2520receptor%2520tyrosine%2520kinase%2520and%2520microtubule%2520inhibitors%2520as%2520potential%2520antitumor%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D2408%26epage%3D2423%26doi%3D10.1016%2Fj.bmc.2015.03.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romagnoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prencipe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliva, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiaffino Ortega, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chayah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimatrai Salvador, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Cara, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brancale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortolozzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariotto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattiuzzo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viola, G.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and biological evaluation of 6-substituted thieno[3,2- d]pyrimidine analogues as dual epidermal growth factor receptor kinase and microtubule inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1274</span>– <span class="NLM_lpage">1290</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01391</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01391" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvFKntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1274-1290&author=R.+Romagnoliauthor=F.+Prencipeauthor=P.+Olivaauthor=S.+Baraldiauthor=P.+G.+Baraldiauthor=S.+Schiaffino+Ortegaauthor=M.+Chayahauthor=M.+Kimatrai+Salvadorauthor=L.+C.+Lopez-Caraauthor=A.+Brancaleauthor=S.+Ferlaauthor=E.+Hamelauthor=R.+Roncaauthor=R.+Bortolozziauthor=E.+Mariottoauthor=E.+Mattiuzzoauthor=G.+Viola&title=Design%2C+Synthesis%2C+and+biological+evaluation+of+6-substituted+thieno%5B3%2C2-+d%5Dpyrimidine+analogues+as+dual+epidermal+growth+factor+receptor+kinase+and+microtubule+inhibitors&doi=10.1021%2Facs.jmedchem.8b01391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of 6-Substituted Thieno[3,2-d]pyrimidine Analogues as Dual Epidermal Growth Factor Receptor Kinase and Microtubule Inhibitors</span></div><div class="casAuthors">Romagnoli, Romeo; Prencipe, Filippo; Oliva, Paola; Baraldi, Stefania; Baraldi, Pier Giovanni; Schiaffino Ortega, Santiago; Chayah, Mariem; Kimatrai Salvador, Maria; Lopez-Cara, Luisa Carlota; Brancale, Andrea; Ferla, Salvatore; Hamel, Ernest; Ronca, Roberto; Bortolozzi, Roberta; Mariotto, Elena; Mattiuzzo, Elena; Viola, Giampietro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1274-1290</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The clin. evidence for the success of tyrosine kinase inhibitors in combination with microtubule-targeting agents prompted us to design and develop single agents that possess both epidermal growth factor receptor (EGFR) kinase and tubulin polymn. inhibitory properties.  A series of 6-aryl/heteroaryl-4-(3',4',5'-trimethoxyanilino)thieno[3,2-d]pyrimidine derivs. were discovered as novel dual tubulin polymn. and EGFR kinase inhibitors.  The 4-(3',4',5'-trimethoxyanilino)-6-(p-tolyl)thieno[3,2-d]pyrimidine deriv. I was the most potent compd. of the series as an antiproliferative agent, with half-maximal inhibitory concn. (IC50) values in the single- or double-digit nanomolar range.  Compd. I bound to tubulin in the colchicine site and inhibited tubulin assembly with an IC50 value of 0.71 μM, and I inhibited EGFR activity with an IC50 value of 30 nM.  Our data suggested that the excellent in vitro and in vivo profile of I may be derived from its dual inhibition of tubulin polymn. and EGFR kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYN985WxHFmrVg90H21EOLACvtfcHk0lh2bbODsAEnzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvFKntg%253D%253D&md5=5eeb122171d04ae5201ee42efbe0c773</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01391%26sid%3Dliteratum%253Aachs%26aulast%3DRomagnoli%26aufirst%3DR.%26aulast%3DPrencipe%26aufirst%3DF.%26aulast%3DOliva%26aufirst%3DP.%26aulast%3DBaraldi%26aufirst%3DS.%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DSchiaffino%2BOrtega%26aufirst%3DS.%26aulast%3DChayah%26aufirst%3DM.%26aulast%3DKimatrai%2BSalvador%26aufirst%3DM.%26aulast%3DLopez-Cara%26aufirst%3DL.%2BC.%26aulast%3DBrancale%26aufirst%3DA.%26aulast%3DFerla%26aufirst%3DS.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DRonca%26aufirst%3DR.%26aulast%3DBortolozzi%26aufirst%3DR.%26aulast%3DMariotto%26aufirst%3DE.%26aulast%3DMattiuzzo%26aufirst%3DE.%26aulast%3DViola%26aufirst%3DG.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520biological%2520evaluation%2520of%25206-substituted%2520thieno%255B3%252C2-%2520d%255Dpyrimidine%2520analogues%2520as%2520dual%2520epidermal%2520growth%2520factor%2520receptor%2520kinase%2520and%2520microtubule%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1274%26epage%3D1290%26doi%3D10.1021%2Facs.jmedchem.8b01391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, C. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Y.</span></span> <span> </span><span class="NLM_article-title">Naturally occurring homoisoflavonoids function as potent protein tyrosine kinase inhibitors by c-Src-based high-throughput screening</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">4419</span>– <span class="NLM_lpage">4429</span>, <span class="refDoi"> DOI: 10.1021/jm701501x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701501x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD1cXot1ertr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4419-4429&author=L.+G.+Linauthor=H.+Xieauthor=H.+L.+Liauthor=L.+J.+Tongauthor=C.+P.+Tangauthor=C.+Q.+Keauthor=Q.+F.+Liuauthor=L.+P.+Linauthor=M.+Y.+Gengauthor=H.+Jiangauthor=W.+M.+Zhaoauthor=J.+Dingauthor=Y.+Ye&title=Naturally+occurring+homoisoflavonoids+function+as+potent+protein+tyrosine+kinase+inhibitors+by+c-Src-based+high-throughput+screening&doi=10.1021%2Fjm701501x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Naturally Occurring Homoisoflavonoids Function as Potent Protein Tyrosine Kinase Inhibitors by c-Src-Based High-Throughput Screening</span></div><div class="casAuthors">Lin, Li-Gen; Xie, Hua; Li, Hong-Lin; Tong, Lin-Jiang; Tang, Chun-Ping; Ke, Chang-Qiang; Liu, Qun-Fang; Lin, Li-Ping; Geng, Mei-Yu; Jiang, Hualiang; Zhao, Wei-Min; Ding, Jian; Ye, Yang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4419-4429</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Protein tyrosine kinase (PTK) inhibitors represent emerging therapeutics for cancer chemoprevention.  In our study, hematoxylin (26) was identified as one of the most remarkable c-Src inhibitors in an orthogonal compd.-mixing library (32200 compds.) by using an ELISA-based automated high-throughput screening (HTS) strategy.  Interestingly, hematoxylin was found to be an ATP competitive broad-spectrum PTK inhibitor in vitro, with IC50 values ranging from nanomolar to micromolar level.  Further studies showed that such inhibition was assocd. with the PTK phosphorylation and subsequent downstream signaling pathways.  The structure-activity relationship assessment of the PTK inhibitory potency of hematoxylin analogs isolated from Haematoxylon campechianum was in good agreement with the result of concurrent mol. docking simulation: the catechol moiety in ring A and the hematoxylin-like three-dimensional structure were essential for c-Src-targeted activities.  Hematoxylin and its natural analogs were substantially validated to function as a new class of PTK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodTHKq1I_xl7Vg90H21EOLACvtfcHk0lh2bbODsAEnzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXot1ertr8%253D&md5=90e47e434d10a4e968ef0085648b8972</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjm701501x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701501x%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DL.%2BG.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DH.%2BL.%26aulast%3DTong%26aufirst%3DL.%2BJ.%26aulast%3DTang%26aufirst%3DC.%2BP.%26aulast%3DKe%26aufirst%3DC.%2BQ.%26aulast%3DLiu%26aufirst%3DQ.%2BF.%26aulast%3DLin%26aufirst%3DL.%2BP.%26aulast%3DGeng%26aufirst%3DM.%2BY.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DW.%2BM.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DY.%26atitle%3DNaturally%2520occurring%2520homoisoflavonoids%2520function%2520as%2520potent%2520protein%2520tyrosine%2520kinase%2520inhibitors%2520by%2520c-Src-based%2520high-throughput%2520screening%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4419%26epage%3D4429%26doi%3D10.1021%2Fjm701501x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leng, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span> <span> </span><span class="NLM_article-title">Identification of DW532 as a novel anti-tumor agent targeting both kinases and tubulin</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">916</span>– <span class="NLM_lpage">928</span>, <span class="refDoi"> DOI: 10.1038/aps.2014.33</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1038%2Faps.2014.33" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=24858311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtV2qtr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=916-928&author=T.+Pengauthor=J.+R.+Wuauthor=L.+J.+Tongauthor=M.+Y.+Liauthor=F.+Chenauthor=Y.+X.+Lengauthor=R.+Quauthor=K.+Hanauthor=Y.+Suauthor=Y.+Chenauthor=W.+H.+Duanauthor=H.+Xieauthor=J.+Ding&title=Identification+of+DW532+as+a+novel+anti-tumor+agent+targeting+both+kinases+and+tubulin&doi=10.1038%2Faps.2014.33"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of DW532 as a novel anti-tumor agent targeting both kinases and tubulin</span></div><div class="casAuthors">Peng, Ting; Wu, Jian-rui; Tong, Lin-jiang; Li, Meng-yuan; Chen, Fang; Leng, Yi-xin; Qu, Rong; Han, Kun; Su, Yi; Chen, Yi; Duan, Wen-hu; Xie, Hua; Ding, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">916-928</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Aim: 7,8-Dihydroxy-4-(3-hydroxy-4-methoxyphenyl)-2H-chromen-2-one (DW532) is one of simplified analogs of hematoxylin that has shown broad-spectrum inhibition on tyrosine kinases and in vitro anti-cancer activities.  The aim of this study was to identify DW532 as a agent targeting both kinases and tubulin, and to investigate its anti-cancer and anti-angiogenesis activities.  Methods: In vitro tyrosine kinases activity was examd. with ELISA, and tyrosine kinases activity in cells was evaluated with Western blot anal.  Tubulin turbidity assay, surface plasmon resonance and immunofluorescence technique were used to characterize the tubulin inhibitory activity.  Cell proliferation was examd. with SRB assay, and cell apoptosis and cell cycle distribution were analyzed with Annexin-V/PI staining and flow cytometry.  Tube formation, aortic ring and chick chorioallantoic membrane assays were used to evaluate the anti-angiogenesis efficacy.  Results: DW532 inhibited EGFR and VEGFR2 in vitro kinase activity (the IC50 values were 4.9 and 5.5 μmol/L, resp.), and suppressed their downstream signaling.  DW532 dose-dependently inhibited tubulin polymn. via direct binding to tubulin, thus disrupting the mitotic spindle assembly and leading to abnormal cell division.  In a panel of human cancer cells, DW532 (1 and 10 μmol/L) induced G2/M phase arrest and cell apoptosis, which subsequently resulted in cytotoxicity.  Knockdown of BubR1 or Mps1, the two core proteins of the spindle assembly checkpoint dramatically decreased DW532-induced cell cycle arrest in MDA-MB-468 cells.  Moreover, treatment with DW532 potently and dose-dependently suppressed angiogenesis in vitro and in vivo.  Conclusion: DW532 is a dual inhibitor against tubulin and tyrosine kinases, and deserves further development as a novel anti-cancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYnVQmKb9o6LVg90H21EOLACvtfcHk0lh2bbODsAEnzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtV2qtr3F&md5=dce90f38ed786a90a2226e092d09c1d5</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1038%2Faps.2014.33&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2014.33%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DJ.%2BR.%26aulast%3DTong%26aufirst%3DL.%2BJ.%26aulast%3DLi%26aufirst%3DM.%2BY.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DLeng%26aufirst%3DY.%2BX.%26aulast%3DQu%26aufirst%3DR.%26aulast%3DHan%26aufirst%3DK.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDuan%26aufirst%3DW.%2BH.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DDing%26aufirst%3DJ.%26atitle%3DIdentification%2520of%2520DW532%2520as%2520a%2520novel%2520anti-tumor%2520agent%2520targeting%2520both%2520kinases%2520and%2520tubulin%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2014%26volume%3D35%26spage%3D916%26epage%3D928%26doi%3D10.1038%2Faps.2014.33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chekler, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiselyov, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattaropong, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuma, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doody, J. F.</span></span> <span> </span><span class="NLM_article-title">Discovery of dual VEGFR-2 and tubulin inhibitors with in vivo efficacy</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">488</span>– <span class="NLM_lpage">492</span>, <span class="refDoi"> DOI: 10.1021/ml1001568</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml1001568" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVCnsb3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=488-492&author=E.+L.+Cheklerauthor=A.+S.+Kiselyovauthor=X.+Ouyangauthor=X.+Chenauthor=V.+Pattaropongauthor=Y.+Wangauthor=M.+C.+Tumaauthor=J.+F.+Doody&title=Discovery+of+dual+VEGFR-2+and+tubulin+inhibitors+with+in+vivo+efficacy&doi=10.1021%2Fml1001568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Dual VEGFR-2 and Tubulin Inhibitors with in Vivo Efficacy</span></div><div class="casAuthors">Chekler, Eugene L. Piatnitski; Kiselyov, Alexander S.; Ouyang, Xiaohu; Chen, Xiaoling; Pattaropong, Vatee; Wang, Ying; Tuma, M. Carolina; Doody, Jacqueline F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">488-492</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In an effort to develop potent, orally bioavailable compds. for the treatment of neoplastic diseases, we developed a class of dual VEGFR-2 kinase and tubulin inhibitors.  Targeting the VEGFR receptor kinase and tubulin structure allows for inhibition of both tumor cells and tumor vasculature.  Previously, a combination of two compds., a VEGF receptor tyrosine kinase inhibitor and tubulin agent, was demonstrated to produce an enhanced antitumor response in animal studies.  We have reaffirmed their results, with the added benefit that both activities are found in one compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlVdKkxgFvarVg90H21EOLACvtfcHk0lg33hzXGOQriw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVCnsb3F&md5=30d9f1b69d14b85b986abd79c04ada40</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Fml1001568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml1001568%26sid%3Dliteratum%253Aachs%26aulast%3DChekler%26aufirst%3DE.%2BL.%26aulast%3DKiselyov%26aufirst%3DA.%2BS.%26aulast%3DOuyang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DPattaropong%26aufirst%3DV.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DTuma%26aufirst%3DM.%2BC.%26aulast%3DDoody%26aufirst%3DJ.%2BF.%26atitle%3DDiscovery%2520of%2520dual%2520VEGFR-2%2520and%2520tubulin%2520inhibitors%2520with%2520in%2520vivo%2520efficacy%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D488%26epage%3D492%26doi%3D10.1021%2Fml1001568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aouad, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Mohammadi, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Blewi, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihmaid, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elbadawy, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Althagfan, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezki, N.</span></span> <span> </span><span class="NLM_article-title">Introducing of acyclonucleoside analogues tethered 1,2,4-triazole as anticancer agents with dual epidermal growth factor receptor kinase and microtubule inhibitors</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">103446</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2019.103446</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.bioorg.2019.103446" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=31791685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit12ktL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2020&pages=103446&author=M.+R.+Aouadauthor=H.+M.+Al-Mohammadiauthor=F.+F.+Al-Blewiauthor=S.+Ihmaidauthor=H.+M.+Elbadawyauthor=S.+S.+Althagfanauthor=N.+Rezki&title=Introducing+of+acyclonucleoside+analogues+tethered+1%2C2%2C4-triazole+as+anticancer+agents+with+dual+epidermal+growth+factor+receptor+kinase+and+microtubule+inhibitors&doi=10.1016%2Fj.bioorg.2019.103446"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Introducing of acyclonucleoside analogues tethered 1,2,4-triazole as anticancer agents with dual epidermal growth factor receptor kinase and microtubule inhibitors</span></div><div class="casAuthors">Aouad, Mohamed Reda; Al-Mohammadi, Hannan Musallam; Al-blewi, Fawzia Faleh; Ihmaid, Saleh; Elbadawy, Hossein Mostafa; Althagfan, Sultan Saad; Rezki, Nadjet</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103446</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This study reports an efficient and convenient regioselective synthesis of a novel series of S- and S,N-bis(acyclonucleoside) analogs carrying 5-(2-chlorophenyl)-2,4-dihydro-1,2,4-triazole-3-thione.  A facile and straightforward synthesis of thiazolotriazole and triazolothiazines has also been reported.  Structures of all newly synthesized compds. were well characterized by IR IR, 1H and 13C NMR (NMR) and mass (MS) spectra analyses.  Cytotoxic screening was performed according to (3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium (MTT) assay method using staurosporine as a ref. drug against three different types: human liver cancer cell line (Hep G2), Michigan cancer foundation-7 (MCF-7) and human colorectal carcinoma cell line (HCT116).  These data showed considerable anticancer activity for these newly synthesized compds.  Biol. data for most of the S-acyclonucleoside analogs and S,N-bis(acyclonucleoside) analogs showed excellent activity with micromolar (μM) half maximal inhibitory concn. (IC50) values against tumor cells.  EGFR assay and tubulin inhibition assay anal. were performed for the most active compds. to get more details about their mechanism of action.  In order to assess and explain their binding affinities, mol. docking simulation was studied against EGFR and tubulin binding sites.  The results obtained from mol. docking study and those obtained from cytotoxic screening were correlated.  Extensive structure activity relationship (SAR) analyses were also carried out.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqvl40K-Xd8bVg90H21EOLACvtfcHk0lg33hzXGOQriw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit12ktL%252FE&md5=8c800df4fcf0a885b8746feb190deb55</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2019.103446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2019.103446%26sid%3Dliteratum%253Aachs%26aulast%3DAouad%26aufirst%3DM.%2BR.%26aulast%3DAl-Mohammadi%26aufirst%3DH.%2BM.%26aulast%3DAl-Blewi%26aufirst%3DF.%2BF.%26aulast%3DIhmaid%26aufirst%3DS.%26aulast%3DElbadawy%26aufirst%3DH.%2BM.%26aulast%3DAlthagfan%26aufirst%3DS.%2BS.%26aulast%3DRezki%26aufirst%3DN.%26atitle%3DIntroducing%2520of%2520acyclonucleoside%2520analogues%2520tethered%25201%252C2%252C4-triazole%2520as%2520anticancer%2520agents%2520with%2520dual%2520epidermal%2520growth%2520factor%2520receptor%2520kinase%2520and%2520microtubule%2520inhibitors%26jtitle%3DBioorg.%2520Chem.%26date%3D2020%26volume%3D94%26spage%3D103446%26doi%3D10.1016%2Fj.bioorg.2019.103446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phimmachanh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J. Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, Y. E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latham, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croucher, D. R.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylases and histone deacetylase inhibitors in neuroblastoma</span>. <i>Front. Cell Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">578770</span>, <span class="refDoi"> DOI: 10.3389/fcell.2020.578770</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.3389%2Ffcell.2020.578770" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=33117806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A280%3ADC%252BB3s7nsFKmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2020&pages=578770&author=M.+Phimmachanhauthor=J.+Z.+R.+Hanauthor=Y.+E.+I.+O%E2%80%99Donnellauthor=S.+L.+Lathamauthor=D.+R.+Croucher&title=Histone+deacetylases+and+histone+deacetylase+inhibitors+in+neuroblastoma&doi=10.3389%2Ffcell.2020.578770"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma</span></div><div class="casAuthors">Phimmachanh Monica; Han Jeremy Z R; O'Donnell Yolande E I; Latham Sharissa L; Croucher David R; Latham Sharissa L; Croucher David R</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in cell and developmental biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">578770</span>
        ISSN:<span class="NLM_cas:issn">2296-634X</span>.
    </div><div class="casAbstract">Histone deacetylases (HDACs) are enzymes that play a key role in regulating gene expression by remodeling chromatin structure.  An imbalance of histone acetylation caused by deregulated HDAC expression and activity is known to promote tumor progression in a number of tumor types, including neuroblastoma, the most common solid tumor in children.  Consequently, the inhibition of HDACs has emerged as a potential strategy to reverse these aberrant epigenetic changes, and several classes of HDAC inhibitors (HDACi) have been shown to inhibit tumor proliferation, or induce differentiation, apoptosis and cell cycle arrest in neuroblastoma.  Further, the combined use of HDACi with other chemotherapy agents, or radiotherapy, has shown promising pre-clinical results and various HDACi have progressed to different stages in clinical trials.  Despite this, the effects of HDACi are multifaceted and more work needs to be done to unravel their specific mechanisms of actions.  In this review, we discuss the functional role of HDACs in neuroblastoma and the potential of HDACi to be optimized for development and use in the clinic for treatment of patients with neuroblastoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRA7zzW8lfA_VMGsG_HTXYFfW6udTcc2eYcvzdkBE0IIrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3s7nsFKmtg%253D%253D&md5=2f1cf1d5a60c597eee36eb72e4cfe480</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.3389%2Ffcell.2020.578770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffcell.2020.578770%26sid%3Dliteratum%253Aachs%26aulast%3DPhimmachanh%26aufirst%3DM.%26aulast%3DHan%26aufirst%3DJ.%2BZ.%2BR.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DY.%2BE.%2BI.%26aulast%3DLatham%26aufirst%3DS.%2BL.%26aulast%3DCroucher%26aufirst%3DD.%2BR.%26atitle%3DHistone%2520deacetylases%2520and%2520histone%2520deacetylase%2520inhibitors%2520in%2520neuroblastoma%26jtitle%3DFront.%2520Cell%2520Dev.%2520Biol.%26date%3D2020%26volume%3D8%26spage%3D578770%26doi%3D10.3389%2Ffcell.2020.578770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glozak, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sengupta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, E.</span></span> <span> </span><span class="NLM_article-title">Acetylation and deacetylation of non-histone proteins</span>. <i>Gene</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1016/j.gene.2005.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.gene.2005.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=16289629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Klu7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2005&pages=15-23&author=M.+A.+Glozakauthor=N.+Senguptaauthor=X.+Zhangauthor=E.+Seto&title=Acetylation+and+deacetylation+of+non-histone+proteins&doi=10.1016%2Fj.gene.2005.09.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Acetylation and deacetylation of non-histone proteins</span></div><div class="casAuthors">Glozak, Michele A.; Sengupta, Nilanjan; Zhang, Xiaohong; Seto, Edward</div><div class="citationInfo"><span class="NLM_cas:title">Gene</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15-23</span>CODEN:
                <span class="NLM_cas:coden">GENED6</span>;
        ISSN:<span class="NLM_cas:issn">0378-1119</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Since the first report of p53 as a non-histone target of a histone acetyltransferase (HAT), there has been a rapid proliferation in the description of new non-histone targets of HATs.  Of these, transcription factors comprise the largest class of new targets.  The substrates for HATs extend to cytoskeletal proteins, mol. chaperones and nuclear import factors.  Deacetylation of these non-histone proteins by histone deacetylases (HDACs) opens yet another exciting new field of discovery in the role of the dynamic acetylation and deacetylation on cellular function.  This review will focus on these non-histone targets of HATs and HDACs and the consequences of their modification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrghezJOUSImbVg90H21EOLACvtfcHk0ljOge7x8ndrJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Klu7%252FN&md5=c6befd12e4556a9154628d9fe9ebe53a</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.gene.2005.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gene.2005.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DGlozak%26aufirst%3DM.%2BA.%26aulast%3DSengupta%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSeto%26aufirst%3DE.%26atitle%3DAcetylation%2520and%2520deacetylation%2520of%2520non-histone%2520proteins%26jtitle%3DGene%26date%3D2005%26volume%3D363%26spage%3D15%26epage%3D23%26doi%3D10.1016%2Fj.gene.2005.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grant, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, P.</span></span> <span> </span><span class="NLM_article-title">Vorinostat</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1038/nrd2227</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1038%2Fnrd2227" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=17269160" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlGktbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=21-22&author=S.+Grantauthor=C.+Easleyauthor=P.+Kirkpatrick&title=Vorinostat&doi=10.1038%2Fnrd2227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Vorinostat</span></div><div class="casAuthors">Grant, Steven; Easley, Chris; Kirkpatrick, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-22</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYtFgooxRrcbVg90H21EOLACvtfcHk0ljOge7x8ndrJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlGktbfK&md5=4017dcf775971088e24fca37e8a369af</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1038%2Fnrd2227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2227%26sid%3Dliteratum%253Aachs%26aulast%3DGrant%26aufirst%3DS.%26aulast%3DEasley%26aufirst%3DC.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DVorinostat%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D21%26epage%3D22%26doi%3D10.1038%2Fnrd2227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poole, R. M.</span></span> <span> </span><span class="NLM_article-title">Belinostat: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">1543</span>– <span class="NLM_lpage">1554</span>, <span class="refDoi"> DOI: 10.1007/s40265-014-0275-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1007%2Fs40265-014-0275-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=25134672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtl2nsrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=1543-1554&author=R.+M.+Poole&title=Belinostat%3A+first+global+approval&doi=10.1007%2Fs40265-014-0275-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Belinostat: First Global Approval</span></div><div class="casAuthors">Poole, Raewyn M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1543-1554</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Belinostat [Beleodaq (US)], a small-mol. hydroxamate-type inhibitor of class I, II and IV histone deacetylase (HDAC) enzymes, has been developed by TopoTarget and Spectrum Pharmaceuticals for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL).  Belinostat has received its first global approval as monotherapy for this indication in the US, under the Food and Drug Administration's accelerated approval program.  This article summarizes the milestones in the development of belinostat leading to this first approval for the treatment of PTCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm9C6yBRy7Q7Vg90H21EOLACvtfcHk0lhVzNkMuPiAow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtl2nsrzL&md5=b8bc6efe62e7fd78d6a9d022a8d96559</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1007%2Fs40265-014-0275-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-014-0275-8%26sid%3Dliteratum%253Aachs%26aulast%3DPoole%26aufirst%3DR.%2BM.%26atitle%3DBelinostat%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2014%26volume%3D74%26spage%3D1543%26epage%3D1554%26doi%3D10.1007%2Fs40265-014-0275-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zagni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floresta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monciino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rescifina, A.</span></span> <span> </span><span class="NLM_article-title">The search for potent, small-molecule HDACIs in cancer treatment: A decade after vorinostat</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1373</span>– <span class="NLM_lpage">1428</span>, <span class="refDoi"> DOI: 10.1002/med.21437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1002%2Fmed.21437" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=28181261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A280%3ADC%252BC1c3ltFWktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=1373-1428&author=C.+Zagniauthor=G.+Florestaauthor=G.+Monciinoauthor=A.+Rescifina&title=The+search+for+potent%2C+small-molecule+HDACIs+in+cancer+treatment%3A+A+decade+after+vorinostat&doi=10.1002%2Fmed.21437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat</span></div><div class="casAuthors">Zagni Chiara; Floresta Giuseppe; Monciino Giulia; Rescifina Antonio; Floresta Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal research reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1373-1428</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Histone deacetylases (HDACs) play a crucial role in the remodeling of chromatin, and are involved in the epigenetic regulation of gene expression.  In the last decade, inhibition of HDACs came out as a target for specific epigenetic changes associated with cancer and other diseases.  Until now, more than 20 HDAC inhibitors (HDACIs) have entered clinical studies, and some of them (e.g., vorinostat, romidepsin) have been approved for the treatment of cutaneous T-cell lymphoma.  This review provides an overview of current knowledge, progress, and molecular mechanisms of HDACIs, covering a period from 2011 until 2015.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSPT4s_HXWveWmbXvSEQle5fW6udTcc2eYNRctm3mm1U7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3ltFWktQ%253D%253D&md5=79f4fe123e5ee6ba072e9147536fab67</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1002%2Fmed.21437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21437%26sid%3Dliteratum%253Aachs%26aulast%3DZagni%26aufirst%3DC.%26aulast%3DFloresta%26aufirst%3DG.%26aulast%3DMonciino%26aufirst%3DG.%26aulast%3DRescifina%26aufirst%3DA.%26atitle%3DThe%2520search%2520for%2520potent%252C%2520small-molecule%2520HDACIs%2520in%2520cancer%2520treatment%253A%2520A%2520decade%2520after%2520vorinostat%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2017%26volume%3D37%26spage%3D1373%26epage%3D1428%26doi%3D10.1002%2Fmed.21437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ezzeldin, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diasio, R. B.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors: current status and overview of recent clinical trials</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">1911</span>– <span class="NLM_lpage">1934</span>, <span class="refDoi"> DOI: 10.2165/11315680-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.2165%2F11315680-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=19747008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlOrsLbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=1911-1934&author=X.+Maauthor=H.+H.+Ezzeldinauthor=R.+B.+Diasio&title=Histone+deacetylase+inhibitors%3A+current+status+and+overview+of+recent+clinical+trials&doi=10.2165%2F11315680-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors: current status and overview of recent clinical trials</span></div><div class="casAuthors">Ma, Xujun; Ezzeldin, Hany H.; Diasio, Robert B.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1911-1934</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis Data Information BV</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (HDAC) inhibitors are a new group of anticancer agents that have a potential role in the regulation of gene expression, induction of cell death, apoptosis and cell cycle arrest of cancer cells by altering the acetylation status of chromatin and other non-histone proteins.  In clin. trials, HDAC inhibitors have demonstrated promising antitumor activity as monotherapy in cutaneous T-cell lymphoma and other haematol. malignancies.  In solid tumors, several HDAC inhibitors have been shown to be efficacious as single agents; however, results of most clin. trials were in favor of using HDAC inhibitors either prior to the initiation of chemotherapy or in combination with other treatments.  Currently, the mol. basis of response to HDAC inhibitors in patients is not fully understood.  In this review, we summarize the current status of HDAC inhibitors, as single agents or in combination with other agents in different phases of clin. trials.  In most of the clin. trials, HDAC inhibitors were tolerable and exerted biol. or antitumor activity.  HDAC inhibitors have been studied in phase I, II and III clin. trials with variable efficacy.  The combination of HDAC inhibitors with other anticancer agents including epigenetic or chemotherapeutic agents demonstrated favorable clin. outcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdv-nIzRilyLVg90H21EOLACvtfcHk0lhVzNkMuPiAow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlOrsLbI&md5=7bffcf6f0627d58907d0e98085f4bdf5</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.2165%2F11315680-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11315680-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DX.%26aulast%3DEzzeldin%26aufirst%3DH.%2BH.%26aulast%3DDiasio%26aufirst%3DR.%2BB.%26atitle%3DHistone%2520deacetylase%2520inhibitors%253A%2520current%2520status%2520and%2520overview%2520of%2520recent%2520clinical%2520trials%26jtitle%3DDrugs%26date%3D2009%26volume%3D69%26spage%3D1911%26epage%3D1934%26doi%3D10.2165%2F11315680-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>192</i></span>,  <span class="NLM_fpage">112158</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejmech.2020.112158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=32171161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvFams7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2020&pages=112158&author=W.+C.+Wuauthor=Y.+M.+Liuauthor=M.+H.+Linauthor=Y.+H.+Liaoauthor=M.+J.+Laiauthor=H.+Y.+Chuangauthor=T.+Y.+Hungauthor=C.+H.+Chenauthor=J.+P.+Liou&title=Design%2C+synthesis%2C+and+evaluation+of+N-phenyl-4-%282-phenylsulfonamido%29-benzamides+as+microtubule-targeting+agents+in+drug-resistant+cancer+cells%2C+displaying+HDAC+inhibitory+response&doi=10.1016%2Fj.ejmech.2020.112158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response</span></div><div class="casAuthors">Wu, Wei-Cheng; Liu, Yi-Min; Lin, Mei-Hsiang; Liao, Yu-Hsuan; Lai, Mei-Jung; Chuang, Hsun-Yueh; Hung, To-Yu; Chen, Chun-Han; Liou, Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112158</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A synthesis of a series of N-phenyl-4-(2-(phenylsulfonamido)phenethyl)benzamides I [R1 = H, 2-NH2, 2-OH, etc.; R2 = H, OMe, 4-F, etc.; X = C, NH, O] was described.  A new compd. I [R1 = 2-NH2; R2 = 4-OMe; X = NH] displayed promising anticancer activity with GI50 of 22 ± 2 and 12 ± 0.1 nM in vincristine-resistant nasopharyngeal (KB-Vin) cancer cells and etoposide-resistant nasopharyngeal (KB-7D) cancer cells and was better than vincristine, etoposide, ABT-751, and MS-275.  A mechanistic study revealed that I [R1 = 2-NH2; R2 = 4-OMe; X = NH] interfered with the cell cycle distribution and induces cell cycle arrest at the G2/M phase and severe mitotic spindle defects followed by apoptosis.  In addn., it produced much more significant cytotoxicity than vincristine and etoposide in the corresponding resistant cells, indicating that it may be a promising candidate to overcome drug resistance in cancer cells.  Compd. I [R1 = 2-NH2; R2 = 4-OMe; X = NH] also displayed inhibitory activity against HDAC 1 and HDAC 2 with IC50 values of 1.07μM, and 1.47μM, resp.  These findings may lead to a new type of structural motif for future development of drugs that could overcome acquired resistance to MTAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod01WmBTU_qbVg90H21EOLACvtfcHk0lgkC-2rVr9Ssw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvFams7o%253D&md5=c10c36ffccb5eb553abf7746ed4fd91c</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112158%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DW.%2BC.%26aulast%3DLiu%26aufirst%3DY.%2BM.%26aulast%3DLin%26aufirst%3DM.%2BH.%26aulast%3DLiao%26aufirst%3DY.%2BH.%26aulast%3DLai%26aufirst%3DM.%2BJ.%26aulast%3DChuang%26aufirst%3DH.%2BY.%26aulast%3DHung%26aufirst%3DT.%2BY.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520N-phenyl-4-%25282-phenylsulfonamido%2529-benzamides%2520as%2520microtubule-targeting%2520agents%2520in%2520drug-resistant%2520cancer%2520cells%252C%2520displaying%2520HDAC%2520inhibitory%2520response%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D192%26spage%3D112158%26doi%3D10.1016%2Fj.ejmech.2020.112158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span> <span> </span><span class="NLM_article-title">1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">612</span>– <span class="NLM_lpage">630</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.10.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejmech.2018.10.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=30476825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit12ktrbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2019&pages=612-630&author=M.+J.+Laiauthor=R.+Ojhaauthor=M.+H.+Linauthor=Y.+M.+Liuauthor=H.+Y.+Leeauthor=T.+E.+Linauthor=K.+C.+Hsuauthor=C.+Y.+Changauthor=M.+C.+Chenauthor=K.+Nepaliauthor=J.+Y.+Changauthor=J.+P.+Liou&title=1-Arylsulfonyl+indoline-benzamides+as+a+new+antitubulin+agents%2C+with+inhibition+of+histone+deacetylase&doi=10.1016%2Fj.ejmech.2018.10.066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase</span></div><div class="casAuthors">Lai, Mei-Jung; Ojha, Ritu; Lin, Mei-Hsiang; Liu, Yi-Min; Lee, Hsueh-Yun; Lin, Tony Eight; Hsu, Kai-Cheng; Chang, Chi-Yen; Chen, Mei-Chuan; Nepali, Kunal; Chang, Jang-Yang; Liou, Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">612-630</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">We report structure-activity relationships of 1-arylsulfonyl indoline based benzamides.  The benzamide (9) exhibits striking tubulin inhibition with an IC50 value of 1.1 μM, better than that of combretastain A-4 (3), and substantial antiproliferative activity against a variety of cancer cells, including MDR-pos. cell lines with an IC50 value of 49 nM (KB), 79 nM (A549), 63 nM (MKN45), 64 nM (KB-VIN10), 43 nM (KB-S15), and 46 nM (KB-7D).  Dual inhibitory potential of compd. 9 was found as it demonstrated significant inhibitory potential against HDAC1, 2 and 6 in comparison to MS-275 (6).  Some key interactions of 9 with the amino acid residues of the active site of tubulin and with amino acid residues of HDAC 1 isoform have been figured out by mol. modeling.  Compd. 9 also demonstrated significant in vivo efficacy in the human non-small cell lung cancer A549 xenograft model as well as B-cell lymphoma BJAB xenograft tumor model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro7mdjL0vVK7Vg90H21EOLACvtfcHk0lgkC-2rVr9Ssw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit12ktrbE&md5=7baa00d4d539dc3edb43bb63411eb744</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.10.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.10.066%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DM.%2BJ.%26aulast%3DOjha%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DM.%2BH.%26aulast%3DLiu%26aufirst%3DY.%2BM.%26aulast%3DLee%26aufirst%3DH.%2BY.%26aulast%3DLin%26aufirst%3DT.%2BE.%26aulast%3DHsu%26aufirst%3DK.%2BC.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DChen%26aufirst%3DM.%2BC.%26aulast%3DNepali%26aufirst%3DK.%26aulast%3DChang%26aufirst%3DJ.%2BY.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26atitle%3D1-Arylsulfonyl%2520indoline-benzamides%2520as%2520a%2520new%2520antitubulin%2520agents%252C%2520with%2520inhibition%2520of%2520histone%2520deacetylase%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D162%26spage%3D612%26epage%3D630%26doi%3D10.1016%2Fj.ejmech.2018.10.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">HuangFu, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span> <span> </span><span class="NLM_article-title">3-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">1268</span>– <span class="NLM_lpage">1278</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.11.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejmech.2016.11.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=27886544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFGru77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2017&pages=1268-1278&author=H.+Y.+Leeauthor=J.+F.+Leeauthor=S.+Kumarauthor=Y.+W.+Wuauthor=W.+C.+HuangFuauthor=M.+J.+Laiauthor=Y.+H.+Liauthor=H.+L.+Huangauthor=F.+C.+Kuoauthor=C.+J.+Hsiaoauthor=C.+C.+Chengauthor=C.+R.+Yangauthor=J.+P.+Liou&title=3-Aroylindoles+display+antitumor+activity+in+vitro+and+in+vivo%3A+Effects+of+N1-substituents+on+biological+activity&doi=10.1016%2Fj.ejmech.2016.11.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">3-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity</span></div><div class="casAuthors">Lee, Hsueh-Yun; Lee, Jiann-Fong; Kumar, Sunil; Wu, Yi-Wen; HuangFu, Wei-Chun; Lai, Mei-Jung; Li, Yu-Hsuan; Huang, Hsiang-Ling; Kuo, Fei-Chiao; Hsiao, Che-Jen; Cheng, Chun-Chun; Yang, Chia-Ron; Liou, Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1268-1278</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 3-aroylindole hydroxamic acids (10-17) were developed based on the concept of a structural combination of tubulin and histone deacetylase (HDAC) inhibitors.  This was accomplished by introducing hydroxamic acid-contg. moieties at the N1 position of the tubulin assembly inhibitor, compd. 9 (SCB01A, BPR0L075, phase II trial).  Most of synthetic compds. produced in this way displayed comparable HDAC inhibitory activity, and four (10, 12-14) of them also inhibit tubulin assembly.  Notably, compd. 12 possesses not only tubulin and HDAC inhibitory activity but also shows HDAC6 selectivity over other HDAC isoforms.  In addn., it exhibits remarkable inhibitory activity against the growth cancer cells in vitro and in vivo (PC3 and RPMI-8226 cells).  Notably, it suppresses the growth of multiple myeloma xenografts without leading to the death of teated animals like ref. compd.  In sum, this study provided potential compds. with safer profiles for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouAXwj00pZ2bVg90H21EOLACvtfcHk0lgkC-2rVr9Ssw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFGru77M&md5=b7e348261fef66bab674a6e699822515</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.11.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.11.033%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.%2BY.%26aulast%3DLee%26aufirst%3DJ.%2BF.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DY.%2BW.%26aulast%3DHuangFu%26aufirst%3DW.%2BC.%26aulast%3DLai%26aufirst%3DM.%2BJ.%26aulast%3DLi%26aufirst%3DY.%2BH.%26aulast%3DHuang%26aufirst%3DH.%2BL.%26aulast%3DKuo%26aufirst%3DF.%2BC.%26aulast%3DHsiao%26aufirst%3DC.%2BJ.%26aulast%3DCheng%26aufirst%3DC.%2BC.%26aulast%3DYang%26aufirst%3DC.%2BR.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26atitle%3D3-Aroylindoles%2520display%2520antitumor%2520activity%2520in%2520vitro%2520and%2520in%2520vivo%253A%2520Effects%2520of%2520N1-substituents%2520on%2520biological%2520activity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D125%26spage%3D1268%26epage%3D1278%26doi%3D10.1016%2Fj.ejmech.2016.11.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamaa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zig, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauvais, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollot, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bignon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levaique, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pamlard, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubois, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouaissi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souce, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasselouri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saller, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayat-Vignoles, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Mouhammad, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feuillard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benihoud, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamze, A.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of tubulin and histone deacetylase inhibitor based on iso-combretastatin A-4</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6574</span>– <span class="NLM_lpage">6591</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00050</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00050" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlWrtrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6574-6591&author=D.+Lamaaauthor=H.+P.+Linauthor=L.+Zigauthor=C.+Bauvaisauthor=G.+Bollotauthor=J.+Bignonauthor=H.+Levaiqueauthor=O.+Pamlardauthor=J.+Duboisauthor=M.+Ouaissiauthor=M.+Souceauthor=A.+Kasselouriauthor=F.+Sallerauthor=D.+Borgelauthor=C.+Jayat-Vignolesauthor=H.+Al-Mouhammadauthor=J.+Feuillardauthor=K.+Benihoudauthor=M.+Alamiauthor=A.+Hamze&title=Design+and+synthesis+of+tubulin+and+histone+deacetylase+inhibitor+based+on+iso-combretastatin+A-4&doi=10.1021%2Facs.jmedchem.8b00050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on iso-Combretastatin A-4</span></div><div class="casAuthors">Lamaa, Diana; Lin, Hsin-Ping; Zig, Lena; Bauvais, Cyril; Bollot, Guillaume; Bignon, Jerome; Levaique, Helene; Pamlard, Olivier; Dubois, Joelle; Ouaissi, Mehdi; Souce, Martin; Kasselouri, Athena; Saller, Francois; Borgel, Delphine; Jayat-Vignoles, Chantal; Al-Mouhammad, Hazar; Feuillard, Jean; Benihoud, Karim; Alami, Mouad; Hamze, Abdallah</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6574-6591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Designing multitarget drugs have raised considerable interest due to their advantages in the treatment of complex diseases such as cancer.  Their design constitutes a challenge in antitumor drug discovery.  The present study reports a dual inhibition of tubulin polymn. and HDAC activity.  On the basis of 1,1-diarylethylenes (isoCA-4) and belinostat, a series of hybrid mols. was successfully designed and synthesized.  In particular compds., 5f and 5h were proven to be potent inhibitors of both tubulin polymn. and HDAC8 leading to excellent antiproliferative activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGq5rq0opowLVg90H21EOLACvtfcHk0li3t2p9SAG2Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlWrtrzN&md5=9d7ffe7d11f3dc2e55adcd8d0c511606</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00050%26sid%3Dliteratum%253Aachs%26aulast%3DLamaa%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DH.%2BP.%26aulast%3DZig%26aufirst%3DL.%26aulast%3DBauvais%26aufirst%3DC.%26aulast%3DBollot%26aufirst%3DG.%26aulast%3DBignon%26aufirst%3DJ.%26aulast%3DLevaique%26aufirst%3DH.%26aulast%3DPamlard%26aufirst%3DO.%26aulast%3DDubois%26aufirst%3DJ.%26aulast%3DOuaissi%26aufirst%3DM.%26aulast%3DSouce%26aufirst%3DM.%26aulast%3DKasselouri%26aufirst%3DA.%26aulast%3DSaller%26aufirst%3DF.%26aulast%3DBorgel%26aufirst%3DD.%26aulast%3DJayat-Vignoles%26aufirst%3DC.%26aulast%3DAl-Mouhammad%26aufirst%3DH.%26aulast%3DFeuillard%26aufirst%3DJ.%26aulast%3DBenihoud%26aufirst%3DK.%26aulast%3DAlami%26aufirst%3DM.%26aulast%3DHamze%26aufirst%3DA.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520tubulin%2520and%2520histone%2520deacetylase%2520inhibitor%2520based%2520on%2520iso-combretastatin%2520A-4%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6574%26epage%3D6591%26doi%3D10.1021%2Facs.jmedchem.8b00050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">The discovery of colchicine-SAHA hybrids as a new class of antitumor agents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">3240</span>– <span class="NLM_lpage">3244</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.03.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.bmc.2013.03.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=23602523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtV2lt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=3240-3244&author=X.+Zhangauthor=J.+Zhangauthor=L.+Tongauthor=Y.+Luoauthor=M.+Suauthor=Y.+Zangauthor=J.+Liauthor=W.+Luauthor=Y.+Chen&title=The+discovery+of+colchicine-SAHA+hybrids+as+a+new+class+of+antitumor+agents&doi=10.1016%2Fj.bmc.2013.03.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of colchicine-SAHA hybrids as a new class of antitumor agents</span></div><div class="casAuthors">Zhang, Xuan; Zhang, Jie; Tong, Linjiang; Luo, Yu; Su, Mingbo; Zang, Yi; Li, Jia; Lu, Wei; Chen, Yi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3240-3244</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel class of colchicine-SAHA hybrids were designed and synthesized based on the synergistic antitumor effect tubulin inhibitors and histone deacetylases(HDAC) inhibitors.  To the best of our knowledge, this is the first design of mols. that are dual inhibitors of tubulin and HDAC.  Biol. evaluations of these compds. included the inhibitory activity of HDAC, in vitro cell cycle anal. in BEL-7402 cells as well as cytotoxicity in five cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi-0eT4cJg3rVg90H21EOLACvtfcHk0li3t2p9SAG2Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtV2lt7c%253D&md5=2a3020c5a48b617bd04f5c2cb214df99</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.03.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.03.049%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DZang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DThe%2520discovery%2520of%2520colchicine-SAHA%2520hybrids%2520as%2520a%2520new%2520class%2520of%2520antitumor%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D3240%26epage%3D3244%26doi%3D10.1016%2Fj.bmc.2013.03.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.03.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejmech.2015.03.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=25805446" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVWis7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2015&pages=127-135&author=X.+Zhangauthor=Y.+Kongauthor=J.+Zhangauthor=M.+Suauthor=Y.+Zhouauthor=Y.+Zangauthor=J.+Liauthor=Y.+Chenauthor=Y.+Fangauthor=X.+Zhangauthor=W.+Lu&title=Design%2C+synthesis+and+biological+evaluation+of+colchicine+derivatives+as+novel+tubulin+and+histone+deacetylase+dual+inhibitors&doi=10.1016%2Fj.ejmech.2015.03.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors</span></div><div class="casAuthors">Zhang, Xuan; Kong, Yannan; Zhang, Jie; Su, Mingbo; Zhou, Yubo; Zang, Yi; Li, Jia; Chen, Yi; Fang, Yanfen; Zhang, Xiongwen; Lu, Wei</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">127-135</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A new class of colchicine derivs. were designed and synthesized as tubulin-HDAC dual inhibitors.  Biol. evaluations of these hybrids included the inhibitory activity of HDAC, tubulin polymn. anal., in vitro cell cycle anal. in HCT-116 cells and cytotoxicity against different cancer cell lines.  Hybrid I behaved as potent HDAC-tubulin dual inhibitor and showed comparable cytotoxicity with colchicine.  Compd. II exhibited powerful tubulin inhibitory activity, moderate anti-HDAC activity and the most potent cytotoxicity (IC50 = 2-105 nM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6P07-g6WBfbVg90H21EOLACvtfcHk0li3t2p9SAG2Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVWis7o%253D&md5=e532028d8f03179da99f533eefa62568</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.03.035%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DKong%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DZang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DW.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520colchicine%2520derivatives%2520as%2520novel%2520tubulin%2520and%2520histone%2520deacetylase%2520dual%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D95%26spage%3D127%26epage%3D135%26doi%3D10.1016%2Fj.ejmech.2015.03.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">SKLB-23bb, a HDAC6-selective inhibitor, exhibits superior and broad-spectrum antitumor activity via additionally targeting microtubules</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">763</span>– <span class="NLM_lpage">775</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-17-0332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1158%2F1535-7163.MCT-17-0332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=29610282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXms1ejtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=763-775&author=F.+Wangauthor=L.+Zhengauthor=Y.+Yiauthor=Z.+Yangauthor=Q.+Qiuauthor=X.+Wangauthor=W.+Yanauthor=P.+Baiauthor=J.+Yangauthor=D.+Liauthor=H.+Peiauthor=T.+Niuauthor=H.+Yeauthor=C.+Nieauthor=Y.+Huauthor=S.+Yangauthor=Y.+Weiauthor=L.+Chen&title=SKLB-23bb%2C+a+HDAC6-selective+inhibitor%2C+exhibits+superior+and+broad-spectrum+antitumor+activity+via+additionally+targeting+microtubules&doi=10.1158%2F1535-7163.MCT-17-0332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">SKLB-23bb, A HDAC6-Selective Inhibitor, Exhibits Superior and Broad-Spectrum Antitumor Activity via Additionally Targeting Microtubules</span></div><div class="casAuthors">Wang, Fang; Zheng, Li; Yi, Yuyao; Yang, Zhuang; Qiu, Qiang; Wang, Xiaoyan; Yan, Wei; Bai, Peng; Yang, Jianhong; Li, Dan; Pei, Heying; Niu, Ting; Ye, Haoyu; Nie, Chunlai; Hu, Yiguo; Yang, Shengyong; Wei, Yuquan; Chen, Lijuan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">763-775</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Our previous study reported that SKLB-23bb, an orally bioavailable HDAC6-selective inhibitor, exhibited superior antitumor efficiency both in vitro and in vivo in comparison with ACY1215, a HDAC6-selective inhibitor recently in phase II clin. trial.  This study focused on the mechanism related to the activity of SKLB-23bb.  We discovered that despite having HDAC6-selective inhibition equal to ACY1215, SKLB-23bb showed cytotoxic effects against a panel of solid and hematol. tumor cell lines at the low submicromolar level.  Interestingly, in contrast to the reported HDAC6-selective inhibitors, SKLB-23bb was more efficient against solid tumor cells.  Utilizing HDAC6 stably knockout cell lines constructed by CRISPR-Cas9 gene editing, we illustrated that SKLB-23bb could remain cytotoxic independent of HDAC6 status.  Investigation of the mechanism confirmed that SKLB-23bb exerted its cytotoxic activity by addnl. targeting microtubules.  SKLB-23bb could bind to the colchicine site in β-tubulin and act as a microtubule polymn. inhibitor.  Consistent with its microtubule-disrupting ability, SKLB-23bb also blocked tumor cell cycle at G2-M phase and triggered cellular apoptosis.  In solid tumor xenografts, oral administration of SKLB-23bb efficiently inhibited tumor growth.  These results suggested that SKLB-23bb was an orally bioavailable HDAC6 and microtubule dual targeting agent.  The microtubule targeting profile enhanced the antitumor activity and expanded the antitumor spectrum of SKLB-23bb, thus breaking through the limitation of HDAC6 inhibitors.  Mol Cancer Ther; 17(4); 763-75. ©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq02sK3SMQsq7Vg90H21EOLACvtfcHk0lh64hGMnCIbRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXms1ejtLY%253D&md5=db43d2066c8a814dc07c0ca98438a55c</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-17-0332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-17-0332%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DF.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DYi%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DQiu%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DYan%26aufirst%3DW.%26aulast%3DBai%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DPei%26aufirst%3DH.%26aulast%3DNiu%26aufirst%3DT.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DNie%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DSKLB-23bb%252C%2520a%2520HDAC6-selective%2520inhibitor%252C%2520exhibits%2520superior%2520and%2520broad-spectrum%2520antitumor%2520activity%2520via%2520additionally%2520targeting%2520microtubules%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2018%26volume%3D17%26spage%3D763%26epage%3D775%26doi%3D10.1158%2F1535-7163.MCT-17-0332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luan, Y.</span></span> <span> </span><span class="NLM_article-title">Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">2638</span>– <span class="NLM_lpage">2645</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.07.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.bmcl.2019.07.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=31400938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFKjsbfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=2638-2645&author=B.+Wangauthor=X.+Chenauthor=J.+Gaoauthor=L.+Suauthor=L.+Zhangauthor=H.+Xuauthor=Y.+Luan&title=Anti-tumor+activity+evaluation+of+novel+tubulin+and+HDAC+dual-targeting+inhibitors&doi=10.1016%2Fj.bmcl.2019.07.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors</span></div><div class="casAuthors">Wang, Baolei; Chen, Xuehong; Gao, Jianjun; Su, Li; Zhang, Li; Xu, Hongwei; Luan, Yepeng</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2638-2645</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) have proven to be promising targets for the development of anti-cancer drugs.  In this study, we reported a series of novel chalcone based tubulin and HDAC dual-targeting inhibitors.  Three compds. inhibited the activities of HDAC and tubulin polymn. simultaneously and displayed anti-proliferative activities toward eleven human tumor cell lines.  Compd. 8a remarkably induced growth inhibition, apoptosis and G2/M phase arrest of A549 tumor cells.  Finally, the inhibitory activities of 8a against HDAC6 and tubulin were rationalized by mol. docking studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY7ecC0j2FibVg90H21EOLACvtfcHk0lh64hGMnCIbRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFKjsbfI&md5=ac1e230b5a2b579f503f87bf6821e887</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.07.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.07.045%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DLuan%26aufirst%3DY.%26atitle%3DAnti-tumor%2520activity%2520evaluation%2520of%2520novel%2520tubulin%2520and%2520HDAC%2520dual-targeting%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D2638%26epage%3D2645%26doi%3D10.1016%2Fj.bmcl.2019.07.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosch, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dittmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothemund, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schobert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biersack, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volkamer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Höpfner, M.</span></span> <span> </span><span class="NLM_article-title">Oxazole-bridged combretastatin A-4 derivatives with tethered hydroxamic acids: structure-activity relations of new inhibitors of HDAC and/or tubulin function</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">383</span>, <span class="refDoi"> DOI: 10.3390/ijms20020383</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.3390%2Fijms20020383" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFahs7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=383&author=F.+Schmittauthor=L.+C.+Goschauthor=A.+Dittmerauthor=M.+Rothemundauthor=T.+Muellerauthor=R.+Schobertauthor=B.+Biersackauthor=A.+Volkamerauthor=M.+H%C3%B6pfner&title=Oxazole-bridged+combretastatin+A-4+derivatives+with+tethered+hydroxamic+acids%3A+structure-activity+relations+of+new+inhibitors+of+HDAC+and%2For+tubulin+function&doi=10.3390%2Fijms20020383"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Oxazole-bridged combretastatin A-4 derivatives with tethered hydroxamic acids: structure-activity relations of new inhibitors of HDAC and/or tubulin function</span></div><div class="casAuthors">Schmitt, Florian; Gosch, Lisa Chiara; Dittmer, Alexandra; Rothemund, Matthias; Mueller, Thomas; Schobert, Rainer; Biersack, Bernhard; Volkamer, Andrea; Hoepfner, Michael</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">383/1-383/26</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">New inhibitors of tubulin polymn. and/or histone deacetylase (HDAC) activity were synthesized by attaching alkyl tethered hydroxamic acid appendages of varying length to oxazole-bridged combretastatin A-4 analogous caps.  While their antiproliferative and microtubule disrupting effect was most pronounced for derivs. with short spacers, HDAC inhibition was strongest for those with longer spacers.  These findings were further supported by computational methods such as structure-based docking expts. exploring the target interactions of the derivs. with varying linkers.  For instance, compds. featuring short four-atom spacers between cap and hydroxamic acid inhibited the growth of various cancer cell lines and human endothelial hybrid cells with IC50 values in the low nanomolar range.  In line with their ability to inhibit the microtubule assembly, four- and five-atom spacered hydroxamic acids caused an accumulation of 518A2 melanoma cells in G2/M phase, whereas a compd. featuring a six-atom spacer and performing best in HDAC inhibition, induced a G1 arrest in these cells.  All these beneficial anticancer activities together with their selectivity for cancer cells over non-malignant cells, point out the great potential of these novel pleiotropic HDAC and tubulin inhibitors as drug candidates for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnd6vxUZSv1bVg90H21EOLACvtfcHk0lh64hGMnCIbRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFahs7nE&md5=c1c66ac969fd55fe4bfe78527375d8d3</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.3390%2Fijms20020383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20020383%26sid%3Dliteratum%253Aachs%26aulast%3DSchmitt%26aufirst%3DF.%26aulast%3DGosch%26aufirst%3DL.%2BC.%26aulast%3DDittmer%26aufirst%3DA.%26aulast%3DRothemund%26aufirst%3DM.%26aulast%3DMueller%26aufirst%3DT.%26aulast%3DSchobert%26aufirst%3DR.%26aulast%3DBiersack%26aufirst%3DB.%26aulast%3DVolkamer%26aufirst%3DA.%26aulast%3DH%25C3%25B6pfner%26aufirst%3DM.%26atitle%3DOxazole-bridged%2520combretastatin%2520A-4%2520derivatives%2520with%2520tethered%2520hydroxamic%2520acids%253A%2520structure-activity%2520relations%2520of%2520new%2520inhibitors%2520of%2520HDAC%2520and%252For%2520tubulin%2520function%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D383%26doi%3D10.3390%2Fijms20020383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span> <span> </span><span class="NLM_article-title">CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>215</i></span>,  <span class="NLM_fpage">113169</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2021.113169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejmech.2021.113169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=33588178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3MXksFSnsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=215&publication_year=2021&pages=113169&author=A.+Singhauthor=T.+Y.+Changauthor=N.+Kaurauthor=K.+C.+Hsuauthor=Y.+Yenauthor=T.+E.+Linauthor=M.+J.+Laiauthor=S.+B.+Leeauthor=J.+P.+Liou&title=CAP+rigidification+of+MS-275+and+chidamide+leads+to+enhanced+antiproliferative+effects+mediated+through+HDAC1%2C+2+and+tubulin+polymerization+inhibition&doi=10.1016%2Fj.ejmech.2021.113169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition</span></div><div class="casAuthors">Singh, Arshdeep; Chang, Ting-Yu; Kaur, Navdeep; Hsu, Kai-Cheng; Yen, Yun; Lin, Tony Eight; Lai, Mei-Jung; Lee, Sung-Bau; Liou, Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">215</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113169</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The study focused on the prudent design and synthesis of anilide type class I HDAC inhibitors I [R1 = H, OMe, Cl; R2 = H,F,Cl,OMe; R3 = H, OMe; R4 = H2N] employing a functionalized pyrrolo[2,3-d]pyrimidine skeleton as the surface recognition part.  Utilization of the bicyclic arom. ring to fabricate the target compds. was envisioned to confer rigidity to the chem. architecture of MS-275 and chidamide.  In-vitro enzymic and cellular assays led to the identification of compd. I [R1 = R3 = H; R2 = OMe; R4 = H2N] as a potent inhibitor of HDAC1 and 2 isoform that exerted substantial cell growth inhibitory effects against human breast MDA-MB-231, cervical HeLa, breast MDA-MB-468, colorectal DLD1, and colorectal HCT116 cell lines with an IC50 values of 0.05-0.47μM, better than MS-275 and chidamide.  In addn., the anilide I [R1 = R3 = H; R2 = OMe; R4 = H2N] was also endowed with a superior antiproliferative profile than MS275 and chidamide towards the human cutaneous T cell lymphoma (HH and HuT78), leukemia (HL60 and KG-1), and HDACi sensitive/resistant gastric cell lines (YCC11 and YCC3/7).  Exhaustive exploration of the construct I [R1 = R3 = H; R2 = OMe; R4 = H2N] confirmed it to be a microtubule-targeting agent that could trigger the cell-cycle arrest in mitosis.  In pursuit of extg. the benefits of evidenced microtubule-destabilizing activity of the anilide I [R1 = R3 = H; R2 = OMe; R4 = H2N], it was further evaluated against non-small-cell lung cancer cell lines as well as the multiple-drug resistant uterine cancer cell line (MES-SA/Dx5) and overwhelmingly pos. results in context of inhibitory effects were attained.  Furthermore, mol. modeling studies were performed and some key interactions of the anilide I [R1 = R3 = H; R2 = OMe; R4 = H2N] with the amino acid residues of the active site of HDAC1 isoform and tubulin were figured out.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkmNaG2FVRj7Vg90H21EOLACvtfcHk0lggqIXRmbACOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXksFSnsbc%253D&md5=6e419995af06c3e6ecc70db9a791b58d</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2021.113169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2021.113169%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DChang%26aufirst%3DT.%2BY.%26aulast%3DKaur%26aufirst%3DN.%26aulast%3DHsu%26aufirst%3DK.%2BC.%26aulast%3DYen%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DT.%2BE.%26aulast%3DLai%26aufirst%3DM.%2BJ.%26aulast%3DLee%26aufirst%3DS.%2BB.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26atitle%3DCAP%2520rigidification%2520of%2520MS-275%2520and%2520chidamide%2520leads%2520to%2520enhanced%2520antiproliferative%2520effects%2520mediated%2520through%2520HDAC1%252C%25202%2520and%2520tubulin%2520polymerization%2520inhibition%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D215%26spage%3D113169%26doi%3D10.1016%2Fj.ejmech.2021.113169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peyrot, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briand, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Momburg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sari, J. C.</span></span> <span> </span><span class="NLM_article-title">In vitro mechanism study of microtubule assembly inhibition by cis-dichlorodiammine-platinum(II)</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">375</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(86)90207-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2F0006-2952%2886%2990207-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=3947376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADyaL28XhtVajurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1986&pages=371-375&author=V.+Peyrotauthor=C.+Briandauthor=R.+Momburgauthor=J.+C.+Sari&title=In+vitro+mechanism+study+of+microtubule+assembly+inhibition+by+cis-dichlorodiammine-platinum%28II%29&doi=10.1016%2F0006-2952%2886%2990207-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro mechanism study of microtubule assembly inhibition by cis-dichlorodiammine-platinum(II)</span></div><div class="casAuthors">Peyrot, V.; Briand, C.; Momburg, R.; Sari, J. C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">371-84</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">The inhibitions of microtubule protein (MTP) and tubulin 6S polymn. by cis-dichlorodiammineplatinum(II) (CDDP)  [15663-27-1] were investigated by turbidity measurements and electron microscopy.  With 2.5 × 10-4M CDDP after a 40-min contact at 27°, the inhibition was 60% for MTP (1.2 mg/mL) and nearly 90% for tubulin 6S (1.2 mg/mL).  The microtubules were not present after a 1-h contact at 27° with 2.5 × 10-4M CDDP.  Free SH group detns. with 5,5'-dithiobis(2-nitrobenzoate) showed that 20.10 SH groups were found per tubulin dimer.  In the presence of excess CDDP, this no. was reduced to 17.74 after a 1- h contact at 27°.  By using CDDP-tubulin dialysis assays, the CDDP-tubulin complex formation was found to be an irreversible reaction through a covalent binding at the SH group sites.  By a DEAE filter paper method, CDDP slightly decreased Vinca alkaloid and colchicine bindings to tubulin, likely by inducing a conformational change of the protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsA3W9TXTh5LVg90H21EOLACvtfcHk0lggqIXRmbACOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XhtVajurY%253D&md5=5d203719b64097e6feae0790822344e0</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2886%2990207-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252886%252990207-8%26sid%3Dliteratum%253Aachs%26aulast%3DPeyrot%26aufirst%3DV.%26aulast%3DBriand%26aufirst%3DC.%26aulast%3DMomburg%26aufirst%3DR.%26aulast%3DSari%26aufirst%3DJ.%2BC.%26atitle%3DIn%2520vitro%2520mechanism%2520study%2520of%2520microtubule%2520assembly%2520inhibition%2520by%2520cis-dichlorodiammine-platinum%2528II%2529%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1986%26volume%3D35%26spage%3D371%26epage%3D375%26doi%3D10.1016%2F0006-2952%2886%2990207-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Combretastatin A-4 analogue: A dual-targeting and tubulin inhibitor containing antitumor Pt(IV) moiety with a unique mode of action</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2132</span>– <span class="NLM_lpage">2148</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.6b00353</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.6b00353" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1yrsbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=2132-2148&author=X.+Huangauthor=R.+Huangauthor=S.+Gouauthor=Z.+Wangauthor=Z.+Liaoauthor=H.+Wang&title=Combretastatin+A-4+analogue%3A+A+dual-targeting+and+tubulin+inhibitor+containing+antitumor+Pt%28IV%29+moiety+with+a+unique+mode+of+action&doi=10.1021%2Facs.bioconjchem.6b00353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Combretastatin A-4 Analogue: A Dual-Targeting and Tubulin Inhibitor Containing Antitumor Pt(IV) Moiety with a Unique Mode of Action</span></div><div class="casAuthors">Huang, Xiaochao; Huang, Rizhen; Gou, Shaohua; Wang, Zhimei; Liao, Zhixin; Wang, Hengshan</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2132-2148</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Abstr.: Three new Pt(IV) complexes comprising a combretastatin A-4 analog were designed and synthesized.  The resulting antitumor Pt(IV) complexes could significantly improve the antiproliferative activity and overcome the drug resistance of cisplatin in vitro.  Interestingly, these novel compds. can not only carry the DNA binding Pt(II) warhead into the cancer cells but also have a small mol. fragment that can inhibit tubulin polymn.  Among them, complex 13, which was attached to an inhibitor of tubulin at one axial position of Pt(IV) octahedral coordination sphere, could effectively enter cancer cells, arrest the cell cycle in HepG-2 cancer cells at G2/M phases, and induce activation of caspases triggering apoptotic signaling via the mitochondrial-dependent apoptosis pathways.  Moreover, complex 13 has the ability of effectively inhibiting the tumor growth in the HepG-2 xenograft model without causing significant loss of animal body wt. in comparison with cisplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_P-MRBiNaU7Vg90H21EOLACvtfcHk0lggqIXRmbACOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1yrsbfO&md5=a86ac2b4f6898e01dc0910d4112ddf03</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.6b00353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.6b00353%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DR.%26aulast%3DGou%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLiao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DCombretastatin%2520A-4%2520analogue%253A%2520A%2520dual-targeting%2520and%2520tubulin%2520inhibitor%2520containing%2520antitumor%2520Pt%2528IV%2529%2520moiety%2520with%2520a%2520unique%2520mode%2520of%2520action%26jtitle%3DBioconjugate%2520Chem.%26date%3D2016%26volume%3D27%26spage%3D2132%26epage%3D2148%26doi%3D10.1021%2Facs.bioconjchem.6b00353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Pt(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>156</i></span>,  <span class="NLM_fpage">666</span>– <span class="NLM_lpage">679</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.07.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejmech.2018.07.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=30031977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlOjs7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2018&pages=666-679&author=L.+Liauthor=X.+Huangauthor=R.+Huangauthor=S.+Gouauthor=Z.+Wangauthor=H.+Wang&title=Pt%28IV%29+prodrugs+containing+microtubule+inhibitors+displayed+potent+antitumor+activity+and+ability+to+overcome+cisplatin+resistance&doi=10.1016%2Fj.ejmech.2018.07.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Pt(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance</span></div><div class="casAuthors">Li, Lingxue; Huang, Xiaochao; Huang, Rizhen; Gou, Shaohua; Wang, Zhimei; Wang, Hengshan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">666-679</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">It is well-known that cisplatin exhibited a broad spectrum of anticancer activities against many solid tumors, but its severe toxicity and drug resistance have largely limited wider clin. applications.  Various strategies have been tried to discover new Pt (II) drugs with at least equal activity as well as low toxicity compared to cisplatin, but the inherent problem remains unsolved.  Here the authors report that Pt (IV) complexes comprising a CA-4 analog, as dual-targeting Pt (IV) prodrug, were synthesized and evaluated for anti-proliferative activity using MTT assay.  Among them, complex 19 displayed most potent activity against the tested cancer cell lines, and simultaneously exhibited better cell selectivity between cancer cells and normal cells than that of cisplatin.  Mechanism studies revealed that complex 19 effectively induced cell cycle arrest at the G2/M phase and dramatically disrupted the microtubule organization.  Moreover, complex 19 significantly induced cell apoptosis and decreased MMP.  Importantly, complex 19 significantly inhibited tumor growth in SK-OV-3 xenograft model in vivo without apparent toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiwKqAE7zEeLVg90H21EOLACvtfcHk0lhm3NjuBPBaHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlOjs7zO&md5=54d9c42a743b4b43548876874a932561</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.07.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.07.016%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DR.%26aulast%3DGou%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DPt%2528IV%2529%2520prodrugs%2520containing%2520microtubule%2520inhibitors%2520displayed%2520potent%2520antitumor%2520activity%2520and%2520ability%2520to%2520overcome%2520cisplatin%2520resistance%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D156%26spage%3D666%26epage%3D679%26doi%3D10.1016%2Fj.ejmech.2018.07.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Dual-targeting antitumor conjugates derived from platinum(IV) prodrugs and microtubule inhibitor CA-4 significantly exhibited potent ability to overcome cisplatin resistance</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">103236</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2019.103236</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.bioorg.2019.103236" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=31494328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslCgs7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2019&pages=103236&author=X.+Huangauthor=M.+Wangauthor=C.+Wangauthor=W.+Huauthor=Q.+Youauthor=Y.+Yangauthor=C.+Yuauthor=Z.+Liaoauthor=S.+Gouauthor=H.+Wang&title=Dual-targeting+antitumor+conjugates+derived+from+platinum%28IV%29+prodrugs+and+microtubule+inhibitor+CA-4+significantly+exhibited+potent+ability+to+overcome+cisplatin+resistance&doi=10.1016%2Fj.bioorg.2019.103236"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-targeting antitumor conjugates derived from platinum(IV) prodrugs and microtubule inhibitor CA-4 significantly exhibited potent ability to overcome cisplatin resistance</span></div><div class="casAuthors">Huang, Xiaochao; Wang, Meng; Wang, Chungu; Hu, Weiwei; You, Qinghong; Yang, Yong; Yu, Chunhao; Liao, Zhixin; Gou, Shaohua; Wang, Hengshan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103236</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Here the authors report that three Pt(IV) prodrugs contg. a tubulin inhibitor CA-4, as dual-targeting Pt(IV) prodrug, were synthesized and evaluated for antitumor activity using MTT assay.  Among them, complex 9 exhibited the most potent antitumor activity against the tested cancer lines including cisplatin resistance cancer cells, and simultaneously displayed lower toxicity compared to cisplatin, resp.  Also, complex 9, in which was conjugated to an inhibitor of tubulin at one axial position of Pt(IV) complex, could effectively enter the cancer cells, and significantly induce cell apoptosis and arrest the cell cycle in A549 cells at G2/M stage, and dramatically disrupt the microtubule organization.  Mechanism studies suggested that complex 9 significantly induced reactive O species (ROS) generation and decreased mitochondrial trans-membrane potential (MMP) in A549 cells, and effectively induced activation of caspases triggering apoptotic signaling through mitochondrial dependent apoptosis pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUECytRFUAr7Vg90H21EOLACvtfcHk0lhm3NjuBPBaHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslCgs7bI&md5=857d08372ab2cbb1998e81609d60abc2</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2019.103236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2019.103236%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DYou%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DLiao%26aufirst%3DZ.%26aulast%3DGou%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DDual-targeting%2520antitumor%2520conjugates%2520derived%2520from%2520platinum%2528IV%2529%2520prodrugs%2520and%2520microtubule%2520inhibitor%2520CA-4%2520significantly%2520exhibited%2520potent%2520ability%2520to%2520overcome%2520cisplatin%2520resistance%26jtitle%3DBioorg.%2520Chem.%26date%3D2019%26volume%3D92%26spage%3D103236%26doi%3D10.1016%2Fj.bioorg.2019.103236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Dual-targeting antitumor hybrids derived from Pt(IV) species and millepachine analogues</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.02.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejmech.2018.02.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=29448138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCmtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2018&pages=1-25&author=X.+Huangauthor=S.+Huaauthor=R.+Huangauthor=Z.+Liuauthor=S.+Gouauthor=Z.+Wangauthor=Z.+Liaoauthor=H.+Wang&title=Dual-targeting+antitumor+hybrids+derived+from+Pt%28IV%29+species+and+millepachine+analogues&doi=10.1016%2Fj.ejmech.2018.02.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-targeting antitumor hybrids derived from Pt(IV) species and millepachine analogues</span></div><div class="casAuthors">Huang, Xiaochao; Hua, Shixian; Huang, Rizhen; Liu, Zhikun; Gou, Shaohua; Wang, Zhimei; Liao, Zhixin; Wang, Hengshan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-25</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Many strategies have been developed to circumvent the shortcomings of Pt(II)-based chemotherapy, but the inherent problems still have not been effectively resolved.  Here the authors report a new series of dual-targeting Pt(IV) prodrugs, conjugates of millepachine analogs with the related Pt(IV) complexes derived from cisplatin or oxaliplatin, resp., which can inhibit tubulin polymn. and induce DNA damage.  Among them, compd. 19 possessed excellent antitumor activities against the tested human cancer cell lines, and arrested the cell cycle at the G2/M phases and ultimately induced cell apoptosis.  Interestingly, its low cytotoxicity toward two human normal cells and sensitivity toward two cisplatin-resistant cells revealed the possibility for cancer therapy.  More importantly, 19 displayed excellent antitumor efficacy in the SK-OV-3 xenograft model better than cisplatin and the corresponding millepachine analog.  The authors' research provided an efficient strategy for multi-targeting antitumor drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn0CG0sCrShrVg90H21EOLACvtfcHk0lhm3NjuBPBaHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCmtLs%253D&md5=1f33af82177105468fd71e61ec9fabf4</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.02.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.02.012%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DHua%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DGou%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLiao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DDual-targeting%2520antitumor%2520hybrids%2520derived%2520from%2520Pt%2528IV%2529%2520species%2520and%2520millepachine%2520analogues%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D148%26spage%3D1%26epage%3D25%26doi%3D10.1016%2Fj.ejmech.2018.02.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Pt(IV) complexes conjugating with chalcone analogue as inhibitors of microtubule polymerization exhibited selective inhibition in human cancer cells</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">435</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.01.075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejmech.2018.01.075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=29407969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Wrs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2018&pages=435-450&author=X.+Huangauthor=R.+Huangauthor=Z.+Wangauthor=L.+Liauthor=S.+Gouauthor=Z.+Liaoauthor=H.+Wang&title=Pt%28IV%29+complexes+conjugating+with+chalcone+analogue+as+inhibitors+of+microtubule+polymerization+exhibited+selective+inhibition+in+human+cancer+cells&doi=10.1016%2Fj.ejmech.2018.01.075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Pt(IV) complexes conjugating with chalcone analogue as inhibitors of microtubule polymerization exhibited selective inhibition in human cancer cells</span></div><div class="casAuthors">Huang, Xiaochao; Huang, Rizhen; Wang, Zhimei; Li, Lingxue; Gou, Shaohua; Liao, Zhixin; Wang, Hengshan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">435-450</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Six novel of Pt(IV) complexes comprising chalcone analogs were synthesized and evaluated for anti-proliferative activity using MTT assay.  In vitro evaluation revealed that all Pt(IV) complexes showed better and more potent activity against three human cancer cells including CDDP resistant cells than that of their corresponding mother Pt(II) species.  Among them, two representative complexes, 14 (I) and 17 (II), exhibited better cell selectivity between cancer cells and normal cells than CDDP.  Mol. docking study indicated that complexes 14 and 17 could bind to the colchicine site of tubulin.  Moreover, complexes 14 and 17 also remarkably displayed inhibition of cell migration against HUVEC cells in vitro.  Mol. mechanism studies suggested that 14 and 17 induced prodn. of reactive oxygen species (ROS), cell cycle arrest at the G2/M phase, and mitochondria-mediated apoptosis by regulating the expression of Bcl-2 family members.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqppgv9QQ1HdrVg90H21EOLACvtfcHk0lgjkT4Oum_Fpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Wrs74%253D&md5=acb303482c16a94ff0f0926544e8c61d</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.01.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.01.075%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DGou%26aufirst%3DS.%26aulast%3DLiao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DPt%2528IV%2529%2520complexes%2520conjugating%2520with%2520chalcone%2520analogue%2520as%2520inhibitors%2520of%2520microtubule%2520polymerization%2520exhibited%2520selective%2520inhibition%2520in%2520human%2520cancer%2520cells%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D146%26spage%3D435%26epage%3D450%26doi%3D10.1016%2Fj.ejmech.2018.01.075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. C.</span></span> <span> </span><span class="NLM_article-title">Cellular roles of DNA topoisomerases: a molecular perspective</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">430</span>– <span class="NLM_lpage">440</span>, <span class="refDoi"> DOI: 10.1038/nrm831</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1038%2Fnrm831" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=12042765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD38XltlartLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=430-440&author=J.+C.+Wang&title=Cellular+roles+of+DNA+topoisomerases%3A+a+molecular+perspective&doi=10.1038%2Fnrm831"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular roles of DNA topoisomerases: a molecular perspective</span></div><div class="casAuthors">Wang, James C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">430-440</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  DNA topoisomerases are the magicians of the DNA world , by allowing DNA strands or double helixes to pass through each other, they can solve all of the topol. problems of DNA in replication, transcription and other cellular transactions.  Extensive biochem. and structural studies over the past three decades have provided mol. models of how the various subfamilies of DNA topoisomerase manipulate DNA.  In this review, the cellular roles of these enzymes are examd. from a mol. point of view.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1ptPGi1NWFLVg90H21EOLACvtfcHk0lgjkT4Oum_Fpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltlartLw%253D&md5=5b9641a6d78a019ebad9307c854a7f7e</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1038%2Fnrm831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm831%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%2BC.%26atitle%3DCellular%2520roles%2520of%2520DNA%2520topoisomerases%253A%2520a%2520molecular%2520perspective%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2002%26volume%3D3%26spage%3D430%26epage%3D440%26doi%3D10.1038%2Fnrm831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rudolf, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervinka, M.</span></span> <span> </span><span class="NLM_article-title">Topoisomerases and tubulin inhibitors: a promising combination for cancer treatment</span>. <i>Curr. Med. Chem.: Anti-Cancer Agents</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">421</span>– <span class="NLM_lpage">429</span>, <span class="refDoi"> DOI: 10.2174/1568011033482242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.2174%2F1568011033482242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=14529450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotFOns7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=421-429&author=E.+Rudolfauthor=M.+Cervinka&title=Topoisomerases+and+tubulin+inhibitors%3A+a+promising+combination+for+cancer+treatment&doi=10.2174%2F1568011033482242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Topoisomerases and tubulin inhibitors: A promising combination for cancer treatment</span></div><div class="casAuthors">Rudolf, E.; Cervinka, M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry: Anti-Cancer Agents</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">421-429</span>CODEN:
                <span class="NLM_cas:coden">CMCACI</span>;
        ISSN:<span class="NLM_cas:issn">1568-0118</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Modern approaches to treatment of cancer seek to activate the internal suicide program in the malignant cells, and thereby effectively eliminate them without engaging most of other bodily systems.  Many currently used cytostatics are known to induce apoptosis and efforts are being paid to develop new ones with better and more effective proapoptotic potential.  Nevertheless, despite recent developments in this field, there are still numerous malignancies showing a varying degree of resistance to cell death due to the corrupted signaling pathways and genetic alterations, often in conjunction with expansive proliferation rate.  It has been shown that topoisomerase inhibiting agents such as etoposide, camptothecin and others represent a powerful and dynamic group of cytostatic chems. used in exptl. and clin. conditions.  So, it is a group of microtubule targeting poisons comprising classical colchicines on the one hand and new taxanes on the other hand.  Since several members of both groups have been evidenced as apoptosis inducers operating via distinct mechanism, their combination should theor. enhance the final therapeutic outcome.  This minireview focuses on the possibilities of such a combinational approach with respect to possible benefits and hazards of this strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJiCqrOtqGHLVg90H21EOLACvtfcHk0lgjkT4Oum_Fpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotFOns7s%253D&md5=2ecc33565f5b54921de17a2fac21e916</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.2174%2F1568011033482242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568011033482242%26sid%3Dliteratum%253Aachs%26aulast%3DRudolf%26aufirst%3DE.%26aulast%3DCervinka%26aufirst%3DM.%26atitle%3DTopoisomerases%2520and%2520tubulin%2520inhibitors%253A%2520a%2520promising%2520combination%2520for%2520cancer%2520treatment%26jtitle%3DCurr.%2520Med.%2520Chem.%253A%2520Anti-Cancer%2520Agents%26date%3D2003%26volume%3D3%26spage%3D421%26epage%3D429%26doi%3D10.2174%2F1568011033482242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathi, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathi, M. K.</span></span> <span> </span><span class="NLM_article-title">Mechanisms regulating resistance to inhibitors of topoisomerase II</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">89</span>, <span class="refDoi"> DOI: 10.3389/fphar.2013.00089</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.3389%2Ffphar.2013.00089" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=23914174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A280%3ADC%252BC3sfmslWqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=89&author=R.+N.+Ganapathiauthor=M.+K.+Ganapathi&title=Mechanisms+regulating+resistance+to+inhibitors+of+topoisomerase+II&doi=10.3389%2Ffphar.2013.00089"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms regulating resistance to inhibitors of topoisomerase II</span></div><div class="casAuthors">Ganapathi Ram N; Ganapathi Mahrukh K</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">89</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">Inhibitors of topoisomerase II (topo II) are clinically effective in the management of hematological malignancies and solid tumors.  The efficacy of anti-tumor drugs targeting topo II is often limited by resistance and studies with in vitro cell culture models have provided several insights on potential mechanisms.  Multidrug transporters that are involved in the efflux and consequently reduced cytotoxicity of diverse anti-tumor agents suggest that they play an important role in resistance to clinically active drugs.  However, in clinical trials, modulating the multidrug-resistant phenotype with agents that inhibit the efflux pump has not had an impact.  Since reduced drug accumulation per se is insufficient to explain tumor cell resistance to topo II inhibitors several studies have focused on characterizing mechanisms that impact on DNA damage mediated by drugs that target the enzyme.  Mammalian topo IIα and topo IIβ isozymes exhibit similar catalytic, but different biologic, activities.  Whereas topo IIα is associated with cell division, topo IIβ is involved in differentiation.  In addition to site specific mutations that can affect drug-induced topo II-mediated DNA damage, post-translation modification of topo II primarily by phosphorylation can potentially affect enzyme-mediated DNA damage and the downstream cytotoxic response of drugs targeting topo II.  Signaling pathways that can affect phosphorylation and changes in intracellular calcium levels/calcium dependent signaling that can regulate site-specific phosphorylation of topoisomerase have an impact on downstream cytotoxic effects of topo II inhibitors.  Overall, tumor cell resistance to inhibitors of topo II is a complex process that is orchestrated not only by cellular pharmacokinetics but more importantly by enzymatic alterations that govern the intrinsic drug sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR-P0PWb68VA8ScOqQTSkOffW6udTcc2eZIW0J2ThCH57ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sfmslWqtQ%253D%253D&md5=7828c568fa64b072dd47e8dee2ce767c</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2013.00089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2013.00089%26sid%3Dliteratum%253Aachs%26aulast%3DGanapathi%26aufirst%3DR.%2BN.%26aulast%3DGanapathi%26aufirst%3DM.%2BK.%26atitle%3DMechanisms%2520regulating%2520resistance%2520to%2520inhibitors%2520of%2520topoisomerase%2520II%26jtitle%3DFront.%2520Pharmacol.%26date%3D2013%26volume%3D4%26spage%3D89%26doi%3D10.3389%2Ffphar.2013.00089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perez, E. A.</span></span> <span> </span><span class="NLM_article-title">Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2086</span>– <span class="NLM_lpage">2095</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1158%2F1535-7163.MCT-09-0366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=19671735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpvFCnurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=2086-2095&author=E.+A.+Perez&title=Microtubule+inhibitors%3A+Differentiating+tubulin-inhibiting+agents+based+on+mechanisms+of+action%2C+clinical+activity%2C+and+resistance&doi=10.1158%2F1535-7163.MCT-09-0366"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance</span></div><div class="casAuthors">Perez, Edith A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2086-2095</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Microtubules are important cellular targets for anticancer therapy because of their key role in mitosis.  Microtubule inhibitors (MTI) such as taxanes, vinca alkaloids, and epothilones stabilize or destabilize microtubules, thereby suppressing microtubule dynamics required for proper mitotic function, effectively blocking cell cycle progression and resulting in apoptosis.  In spite of their antitumor activity, innate or acquired drug resistance to MTIs such as the taxanes is common, limiting their overall clin. efficacy.  Further insight into the mechanisms of action of microtubule-targeting drugs has lead to the discovery of novel agents that may provide higher efficacy with limited toxicity and help overcome resistance to conventional MTIs.  This review will focus on the different mechanisms of action of MTIs, potential factors related to resistance and tolerability, and will discuss the recent approval as well as the development of new antineoplastic agents. [Mol Cancer Ther 2009;8(8):2086-95].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1HM8JP4QG8LVg90H21EOLACvtfcHk0lgIpUokrriL7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpvFCnurw%253D&md5=1d8dec9ed6c0f061032cec57c96c833e</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0366%26sid%3Dliteratum%253Aachs%26aulast%3DPerez%26aufirst%3DE.%2BA.%26atitle%3DMicrotubule%2520inhibitors%253A%2520Differentiating%2520tubulin-inhibiting%2520agents%2520based%2520on%2520mechanisms%2520of%2520action%252C%2520clinical%2520activity%252C%2520and%2520resistance%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D2086%26epage%3D2095%26doi%3D10.1158%2F1535-7163.MCT-09-0366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diéras, V.</span></span> <span> </span><span class="NLM_article-title">Review of docetaxel/doxorubicin combination in metastatic breast cancer</span>. <i>Oncology (Williston Park)</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">33</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=9364539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A280%3ADyaK1c%252FjtFWhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1997&pages=31-33&author=V.+Di%C3%A9ras&title=Review+of+docetaxel%2Fdoxorubicin+combination+in+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Review of docetaxel/doxorubicin combination in metastatic breast cancer</span></div><div class="casAuthors">Dieras V</div><div class="citationInfo"><span class="NLM_cas:title">Oncology (Williston Park, N.Y.)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8 Suppl 8</span>),
    <span class="NLM_cas:pages">31-3</span>
        ISSN:<span class="NLM_cas:issn">0890-9091</span>.
    </div><div class="casAbstract">Docetaxel (Taxotere) and doxorubicin (Adriamycin) have each demonstrated significant activity in metastatic breast cancer.  Thus, the combination of docetaxel and doxorubicin has been evaluated in phase I trials to establish the dose-limiting toxicity, maximum tolerated dose, recommended dose for future phase II and III studies, and toxicity profile of the two agents used in combination.  Results from phase I trials in patients with metastatic breast cancer indicate that the docetaxel/doxorubicin combination is well tolerated.  The recommended dose for the combination regimen is either 50 mg/m2 of doxorubicin followed by 75 mg/m2 of docetaxel or 60 mg/m2 of both drugs, without granulocyte colony-stimulating factor (G-CSF) support.  Febrile neutropenia complicated by grade 3 infection was the dose-limiting effect at the maximum tolerated dose.  The response rate at this dose level was 90%.  Based on the preliminary results of phase I studies, further phase II and III studies of a docetaxel/doxorubicin combination regimen are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRugEZYQeiChWGmni0r9GoKfW6udTcc2eZTJVb1OnrHVLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c%252FjtFWhsA%253D%253D&md5=d352b42637b90485d1e996c70fc833e6</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDi%25C3%25A9ras%26aufirst%3DV.%26atitle%3DReview%2520of%2520docetaxel%252Fdoxorubicin%2520combination%2520in%2520metastatic%2520breast%2520cancer%26jtitle%3DOncology%2520%2528Williston%2520Park%2529%26date%3D1997%26volume%3D11%26spage%3D31%26epage%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hao, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, L.</span></span> <span> </span><span class="NLM_article-title">Novel conjugates of podophyllotoxin and coumarin: synthesis, cytotoxicities, cell cycle arrest, binding CT DNA and inhibition of Topo IIβ</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">2129</span>– <span class="NLM_lpage">2135</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.06.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.bmcl.2019.06.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=31278032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlejs77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=2129-2135&author=S.+Y.+Haoauthor=S.+L.+Fengauthor=X.+R.+Wangauthor=Z.+Wangauthor=S.+W.+Chenauthor=L.+Hui&title=Novel+conjugates+of+podophyllotoxin+and+coumarin%3A+synthesis%2C+cytotoxicities%2C+cell+cycle+arrest%2C+binding+CT+DNA+and+inhibition+of+Topo+II%CE%B2&doi=10.1016%2Fj.bmcl.2019.06.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Novel conjugates of podophyllotoxin and coumarin: Synthesis, cytotoxicities, cell cycle arrest, binding CT DNA and inhibition of Topo IIβ</span></div><div class="casAuthors">Hao, Shu-Yi; Feng, Shi-Liang; Wang, Xing-Rong; Wang, Zhichao; Chen, Shi-Wu; Hui, Ling</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2129-2135</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of conjugates of podophyllotoxin and coumarin, I (X = O, NH, R1 = H, Me, Br, OMe, R2 = H, Br, OMe), were prepd. using the click reaction, and their cytotoxicities against A549, HepG2, HeLa, and LoVo cells were evaluated.  Among them, compd. I (X = NH, R1 = OMe, R2 = H) (II) exhibited the strongest cytotoxicities against these cancer cells with IC50 values of 4.9-17.5 μM.  Furthermore, II disrupted microtubules and induced cell cycle arrest at G1 phase by regulating P21 and Cyclin D1 in LoVo cells.  In addn., II bound CT DNA and selectively inhibited Topo IIβ over Topo IIα.  Mol. docking model showed that II appeared to form stable hydrogen bonds with several DNA bases and residue Gln778.  Taken together, these conjugates have the potential to be developed as anti-tumor drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-st5yLtlaqrVg90H21EOLACvtfcHk0lgIpUokrriL7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlejs77N&md5=5e9deabb0c6d9ad91c5ec1e9eedde56c</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.06.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.06.063%26sid%3Dliteratum%253Aachs%26aulast%3DHao%26aufirst%3DS.%2BY.%26aulast%3DFeng%26aufirst%3DS.%2BL.%26aulast%3DWang%26aufirst%3DX.%2BR.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DS.%2BW.%26aulast%3DHui%26aufirst%3DL.%26atitle%3DNovel%2520conjugates%2520of%2520podophyllotoxin%2520and%2520coumarin%253A%2520synthesis%252C%2520cytotoxicities%252C%2520cell%2520cycle%2520arrest%252C%2520binding%2520CT%2520DNA%2520and%2520inhibition%2520of%2520Topo%2520II%25CE%25B2%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D2129%26epage%3D2135%26doi%3D10.1016%2Fj.bmcl.2019.06.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hernández, A.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Díez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Andrés, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jambrina, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Díez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuentes, M.</span></span> <span> </span><span class="NLM_article-title">A novel cytotoxic conjugate derived from the natural product podophyllotoxin as a direct-target protein dual inhibitor</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">4258</span>, <span class="refDoi"> DOI: 10.3390/molecules25184258</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.3390%2Fmolecules25184258" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2020&pages=4258&author=A.-P.+Hern%C3%A1ndezauthor=P.+D%C3%ADezauthor=P.+A.+Garc%C3%ADaauthor=M.+P%C3%A9rez-Andr%C3%A9sauthor=P.+Ortegaauthor=P.+G.+Jambrinaauthor=D.+D%C3%ADezauthor=M.+Castroauthor=M.+Fuentes&title=A+novel+cytotoxic+conjugate+derived+from+the+natural+product+podophyllotoxin+as+a+direct-target+protein+dual+inhibitor&doi=10.3390%2Fmolecules25184258"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.3390%2Fmolecules25184258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules25184258%26sid%3Dliteratum%253Aachs%26aulast%3DHern%25C3%25A1ndez%26aufirst%3DA.-P.%26aulast%3DD%25C3%25ADez%26aufirst%3DP.%26aulast%3DGarc%25C3%25ADa%26aufirst%3DP.%2BA.%26aulast%3DP%25C3%25A9rez-Andr%25C3%25A9s%26aufirst%3DM.%26aulast%3DOrtega%26aufirst%3DP.%26aulast%3DJambrina%26aufirst%3DP.%2BG.%26aulast%3DD%25C3%25ADez%26aufirst%3DD.%26aulast%3DCastro%26aufirst%3DM.%26aulast%3DFuentes%26aufirst%3DM.%26atitle%3DA%2520novel%2520cytotoxic%2520conjugate%2520derived%2520from%2520the%2520natural%2520product%2520podophyllotoxin%2520as%2520a%2520direct-target%2520protein%2520dual%2520inhibitor%26jtitle%3DMolecules%26date%3D2020%26volume%3D25%26spage%3D4258%26doi%3D10.3390%2Fmolecules25184258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yi, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huan, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Q. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z. H.</span></span> <span> </span><span class="NLM_article-title">Dual targeting of microtubule and topoisomerase II by α-carboline derivative YCH337 for tumor proliferation and growth inhibition</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">8960</span>– <span class="NLM_lpage">8973</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.3264</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.18632%2Foncotarget.3264" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=25840421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjgs1Oltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=8960-8973&author=J.+M.+Yiauthor=X.+F.+Zhangauthor=X.+J.+Huanauthor=S.+S.+Songauthor=W.+Wangauthor=Q.+T.+Tianauthor=Y.+M.+Sunauthor=Y.+Chenauthor=J.+Dingauthor=Y.+Q.+Wangauthor=C.+H.+Yangauthor=Z.+H.+Miao&title=Dual+targeting+of+microtubule+and+topoisomerase+II+by+%CE%B1-carboline+derivative+YCH337+for+tumor+proliferation+and+growth+inhibition&doi=10.18632%2Foncotarget.3264"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Dual targeting of microtubule and topoisomerase II by α-carboline derivative YCH337 for tumor proliferation and growth inhibition</span></div><div class="casAuthors">Yi Jun-Mei; Huan Xia-Juan; Song Shan-Shan; Wang Wei; Tian Qian-Ting; Sun Yi-Ming; Chen Yi; Ding Jian; Wang Ying-Qing; Miao Ze-Hong; Zhang Xiao-Fei; Yang Chun-Hao</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">8960-73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Both microtubule and topoisomerase II (Top2) are important anticancer targets and their respective inhibitors are widely used in combination for cancer therapy.  However, some combinations could be mutually antagonistic and drug resistance further limits their therapeutic efficacy.  Here we report YCH337, a novel α-carboline derivative that targets both microtubule and Top2, eliciting tumor proliferation and growth inhibition and overcoming drug resistance.  YCH337 inhibited microtubule polymerization by binding to the colchicine site and subsequently led to mitotic arrest.  It also suppressed Top2 and caused DNA double-strand breaks.  It disrupted microtubule more potently than Top2.  YCH337 induced reversible mitotic arrest at low concentrations but persistent DNA damage.  YCH337 caused intrinsic and extrinsic apoptosis and decreased MCL-1, cIAP1 and XIAP proteins.  In this aspect, YCH337 behaved differently from the combination of vincristine and etoposide.  YCH337 inhibited proliferation of tumor cells with an averaged IC50 of 0.3 μM.  It significantly suppressed the growth of HT-29 xenografts in nude mice too.  Importantly, YCH337 nearly equally killed different-mechanism-mediated resistant tumor cells and corresponding parent cells.  Together with the novelty of its chemical structure, YCH337 could serve as a promising lead for drug development and a prototype for a dual microtubule/Top2 targeting strategy for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSG7_gaQunNwoJKJbLTgsvCfW6udTcc2eaYWM8DmD4Ttbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjgs1Oltw%253D%253D&md5=bd05960113eda9a65fa6626a8277ca20</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.3264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.3264%26sid%3Dliteratum%253Aachs%26aulast%3DYi%26aufirst%3DJ.%2BM.%26aulast%3DZhang%26aufirst%3DX.%2BF.%26aulast%3DHuan%26aufirst%3DX.%2BJ.%26aulast%3DSong%26aufirst%3DS.%2BS.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DTian%26aufirst%3DQ.%2BT.%26aulast%3DSun%26aufirst%3DY.%2BM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%2BQ.%26aulast%3DYang%26aufirst%3DC.%2BH.%26aulast%3DMiao%26aufirst%3DZ.%2BH.%26atitle%3DDual%2520targeting%2520of%2520microtubule%2520and%2520topoisomerase%2520II%2520by%2520%25CE%25B1-carboline%2520derivative%2520YCH337%2520for%2520tumor%2520proliferation%2520and%2520growth%2520inhibition%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D8960%26epage%3D8973%26doi%3D10.18632%2Foncotarget.3264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Podolski-Renić, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banković, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinić, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ríos-Luci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovačević-Grujičić, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martín, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padrón, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pešić, M.</span></span> <span> </span><span class="NLM_article-title">DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">168</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2017.05.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejps.2017.05.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=28502672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotVCmtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2017&pages=159-168&author=A.+Podolski-Reni%C4%87author=J.+Bankovi%C4%87author=J.+Dini%C4%87author=C.+R%C3%ADos-Luciauthor=M.+X.+Fernandesauthor=N.+Ortegaauthor=N.+Kova%C4%8Devi%C4%87-Gruji%C4%8Di%C4%87author=V.+S.+Mart%C3%ADnauthor=J.+M.+Padr%C3%B3nauthor=M.+Pe%C5%A1i%C4%87&title=DTA0100%2C+dual+topoisomerase+II+and+microtubule+inhibitor%2C+evades+paclitaxel+resistance+in+P-glycoprotein+overexpressing+cancer+cells&doi=10.1016%2Fj.ejps.2017.05.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells</span></div><div class="casAuthors">Podolski-Renic, Ana; Bankovic, Jasna; Dinic, Jelena; Rios-Luci, Carla; Fernandes, Miguel X.; Ortega, Nuria; Kovacevic-Grujicic, Natasa; Martin, Victor S.; Padron, Jose M.; Pesic, Milica</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">159-168</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The efficacy of microtubule targeting agents in cancer treatment has been compromised by the development of drug resistance that may involve both, P-glycoprotein overexpression and the changes in β-tubulin isoforms' expression.  The anti-Topoisomerase II activity of Me 4-((E)-2-(methoxycarbonyl)vinyloxy)oct-2-ynoate (DTA0100) was recently reported.  Herein, we further evaluated this propargylic enol ether deriv. and found that it exerts inhibitory effect on tubulin polymn. by binding to colchicine binding site.  DTA0100 mitotic arrest properties were investigated in two multi-drug resistant cancer cell lines with P-glycoprotein overexpression (colorectal carcinoma and glioblastoma).  The sensitivity of multi-drug resistant cancer cell lines to DTA0100 was not significantly changed in contrast to microtubule targeting agents such as paclitaxel, vinblastine and colchicine.  DTA0100 clearly induced microtubule depolymn., leading to disturbance of cell cycle kinetics and subsequent apoptosis.  The fine-tuning in β-tubulin isoforms expression obsd. in multi-drug resistant cancer cells may influence the efficacy of DTA0100.  Importantly, DTA0100 blocked the P-glycoprotein function in both multi-drug resistant cancer cell lines without inducing the increase in P-glycoprotein expression.  Therefore, DTA0100 acting as dual inhibitor of Topoisomerase II and microtubule formation could be considered as multi-potent anticancer agent.  Besides, it is able to overcome the problem of drug resistance that emerges in the therapeutic approaches with either Topoisomerase II or microtubule targeting agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3Yr0A5xxeibVg90H21EOLACvtfcHk0lg23-8zF2P6eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotVCmtr4%253D&md5=415d67d933dd9d2933cb3b4f5dd37b45</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2017.05.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2017.05.011%26sid%3Dliteratum%253Aachs%26aulast%3DPodolski-Reni%25C4%2587%26aufirst%3DA.%26aulast%3DBankovi%25C4%2587%26aufirst%3DJ.%26aulast%3DDini%25C4%2587%26aufirst%3DJ.%26aulast%3DR%25C3%25ADos-Luci%26aufirst%3DC.%26aulast%3DFernandes%26aufirst%3DM.%2BX.%26aulast%3DOrtega%26aufirst%3DN.%26aulast%3DKova%25C4%258Devi%25C4%2587-Gruji%25C4%258Di%25C4%2587%26aufirst%3DN.%26aulast%3DMart%25C3%25ADn%26aufirst%3DV.%2BS.%26aulast%3DPadr%25C3%25B3n%26aufirst%3DJ.%2BM.%26aulast%3DPe%25C5%25A1i%25C4%2587%26aufirst%3DM.%26atitle%3DDTA0100%252C%2520dual%2520topoisomerase%2520II%2520and%2520microtubule%2520inhibitor%252C%2520evades%2520paclitaxel%2520resistance%2520in%2520P-glycoprotein%2520overexpressing%2520cancer%2520cells%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2017%26volume%3D105%26spage%3D159%26epage%3D168%26doi%3D10.1016%2Fj.ejps.2017.05.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verma, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fatima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudi, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabassum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luqman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mondhe, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negi, A. S.</span></span> <span> </span><span class="NLM_article-title">Antiproliferative activity of diarylnaphthylpyrrolidine derivative via dual target inhibition</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>188</i></span>,  <span class="NLM_fpage">111986</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111986</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejmech.2019.111986" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=31884407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFOltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=2020&pages=111986&author=A.+K.+Vermaauthor=K.+Fatimaauthor=R.+K.+Dudiauthor=M.+Tabassumauthor=H.+Iqbalauthor=Y.+Kumarauthor=S.+Luqmanauthor=D.+M.+Mondheauthor=D.+Chandaauthor=F.+Khanauthor=K.+Shankerauthor=A.+S.+Negi&title=Antiproliferative+activity+of+diarylnaphthylpyrrolidine+derivative+via+dual+target+inhibition&doi=10.1016%2Fj.ejmech.2019.111986"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Antiproliferative activity of diarylnaphthylpyrrolidine derivative via dual target inhibition</span></div><div class="casAuthors">Verma, Amit Kumar; Fatima, Kaneez; Dudi, Rajesh Kumar; Tabassum, Misbah; Iqbal, Hina; Kumar, Yogesh; Luqman, Suaib; Mondhe, D. M.; Chanda, Debabrata; Khan, Feroz; Shanker, Karuna; Negi, Arvind S.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">188</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111986</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Breast cancer is the second leading cause of deaths in women globally.  Present communication deals with design and synthesis of a few diarylnaphthyls as possible anti-breast cancer agents.  Among the thirteen thirty three representatives with significant antiproliferative activity compds. 23 and 50 were quite efficacious against human breast cancer cells.  Compd. 50 induced apoptosis in both MCF-7 and MDA-MB-231 cells and exerted S phase and G2/M phase arrest resp. via distinct mechanistic pathways.  It showed moderate microtubule destabilization.  Further, it exhibited DNA topoisomerase-II inhibition effect in MCF-7 cells.  It was well tolerable and found safe up to 300 mg/kg dose in Swiss albino mice.  The dual action antiproliferative effect of compd. 50 is quite interesting and warrants for future development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAodPaPs01bLVg90H21EOLACvtfcHk0lg23-8zF2P6eQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFOltw%253D%253D&md5=5476a0e2326bf6dad0850d898406fb35</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111986&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111986%26sid%3Dliteratum%253Aachs%26aulast%3DVerma%26aufirst%3DA.%2BK.%26aulast%3DFatima%26aufirst%3DK.%26aulast%3DDudi%26aufirst%3DR.%2BK.%26aulast%3DTabassum%26aufirst%3DM.%26aulast%3DIqbal%26aufirst%3DH.%26aulast%3DKumar%26aufirst%3DY.%26aulast%3DLuqman%26aufirst%3DS.%26aulast%3DMondhe%26aufirst%3DD.%2BM.%26aulast%3DChanda%26aufirst%3DD.%26aulast%3DKhan%26aufirst%3DF.%26aulast%3DShanker%26aufirst%3DK.%26aulast%3DNegi%26aufirst%3DA.%2BS.%26atitle%3DAntiproliferative%2520activity%2520of%2520diarylnaphthylpyrrolidine%2520derivative%2520via%2520dual%2520target%2520inhibition%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D188%26spage%3D111986%26doi%3D10.1016%2Fj.ejmech.2019.111986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Scaffold diversity inspired by the natural product evodiamine: Discovery of highly potent and multitargeting antitumor agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6678</span>– <span class="NLM_lpage">6696</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00910</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00910" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Gms7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6678-6696&author=S.+Wangauthor=K.+Fangauthor=G.+Dongauthor=S.+Chenauthor=N.+Liuauthor=Z.+Miaoauthor=J.+Yaoauthor=J.+Liauthor=W.+Zhangauthor=C.+Sheng&title=Scaffold+diversity+inspired+by+the+natural+product+evodiamine%3A+Discovery+of+highly+potent+and+multitargeting+antitumor+agents&doi=10.1021%2Facs.jmedchem.5b00910"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Scaffold diversity inspired by the natural product evodiamine: discovery of highly potent and multitargeting antitumor agents</span></div><div class="casAuthors">Wang, Shengzheng; Fang, Kun; Dong, Guoqiang; Chen, Shuqiang; Liu, Na; Miao, Zhenyuan; Yao, Jianzhong; Li, Jian; Zhang, Wannian; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6678-6696</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A crit. question in natural product-based drug discovery is how to translate the product into drug-like mols. with optimal pharmacol. properties.  The generation of natural product-inspired scaffold diversity is an effective but challenging strategy to investigate the broader chem. space and identify promising drug leads.  Extending the efforts to the natural product evodiamine, a diverse library contg. 11 evodiamine-inspired novel scaffolds and their derivs. were designed and synthesized.  Most of them showed good to excellent antitumor activity against various human cancer cell lines.  In particular, 3-chloro-10-hydroxyl thio-evodiamine I showed excellent in vitro and in vivo antitumor efficacy with good tolerability and low toxicity.  Antitumor mechanism and target profiling studies indicate that compd. I is the first-in-class triple topoisomerase I/topoisomerase II/tubulin inhibitor.  Overall, this study provided an effective strategy for natural product-based drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFmWoZPbDbVrVg90H21EOLACvtfcHk0lhsJG64Td119g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Gms7%252FO&md5=eac1cb75b532b53aada4cbc25c0de4bf</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00910%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DFang%26aufirst%3DK.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DYao%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DScaffold%2520diversity%2520inspired%2520by%2520the%2520natural%2520product%2520evodiamine%253A%2520Discovery%2520of%2520highly%2520potent%2520and%2520multitargeting%2520antitumor%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6678%26epage%3D6696%26doi%3D10.1021%2Facs.jmedchem.5b00910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Scaffold hopping of natural product evodiamine: Discovery of a novel antitumor scaffold with excellent potency against colon cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">696</span>– <span class="NLM_lpage">713</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01626</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01626" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3cXosFOi" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=696-713&author=L.+Wangauthor=K.+Fangauthor=J.+Chengauthor=Y.+Liauthor=Y.+Huangauthor=S.+Chenauthor=G.+Dongauthor=S.+Wuauthor=C.+Sheng&title=Scaffold+hopping+of+natural+product+evodiamine%3A+Discovery+of+a+novel+antitumor+scaffold+with+excellent+potency+against+colon+cancer&doi=10.1021%2Facs.jmedchem.9b01626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Scaffold Hopping of Natural Product Evodiamine: Discovery of a Novel Antitumor Scaffold with Excellent Potency against Colon Cancer</span></div><div class="casAuthors">Wang, Lei; Fang, Kun; Cheng, Junfei; Li, Yu; Huang, Yahui; Chen, Shuqiang; Dong, Guoqiang; Wu, Shanchao; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">696-713</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inspired by the natural product evodiamine, a novel antitumor indolopyrazinoquinazolinone scaffold was designed by scaffold hopping.  Structure-activity relationship studies led to the discovery of compd. 15j, which shows low nanomolar inhibitory activity against the HCT116 cell line.  Further antitumor mechanism studies indicated that compd. 15j acted by the dual inhibition of topoisomerase 1 and tubulin and induced apoptosis with G2 cell-cycle arrest.  The quaternary ammonium salt of compd. 15j (compd. 15js) exhibited excellent in vivo antitumor activity (TGI = 66.6%) in the HCT116 xenograft model with low toxicity.  Indolopyrazinoquinazolinone derivs. represent promising multitargeting antitumor leads for the development of novel antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdvRim1Ho107Vg90H21EOLACvtfcHk0lhsJG64Td119g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXosFOi&md5=7d9556dcd1d5aaf92c7eccfcc09b862c</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01626%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DFang%26aufirst%3DK.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DScaffold%2520hopping%2520of%2520natural%2520product%2520evodiamine%253A%2520Discovery%2520of%2520a%2520novel%2520antitumor%2520scaffold%2520with%2520excellent%2520potency%2520against%2520colon%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D696%26epage%3D713%26doi%3D10.1021%2Facs.jmedchem.9b01626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ceramella, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caruso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Occhiuzzi, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacopetta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbarossa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzuti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallemagne, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rault, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kashef, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saturnino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grande, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinicropi, M. S.</span></span> <span> </span><span class="NLM_article-title">Benzothienoquinazolinones as new multi-target scaffolds: Dual inhibition of human Topoisomerase I and tubulin polymerization</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">111583</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejmech.2019.111583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=31400710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFGjt7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2019&pages=111583&author=J.+Ceramellaauthor=A.+Carusoauthor=M.+A.+Occhiuzziauthor=D.+Iacopettaauthor=A.+Barbarossaauthor=B.+Rizzutiauthor=P.+Dallemagneauthor=S.+Raultauthor=H.+El-Kashefauthor=C.+Saturninoauthor=F.+Grandeauthor=M.+S.+Sinicropi&title=Benzothienoquinazolinones+as+new+multi-target+scaffolds%3A+Dual+inhibition+of+human+Topoisomerase+I+and+tubulin+polymerization&doi=10.1016%2Fj.ejmech.2019.111583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Benzothienoquinazolinones as new multi-target scaffolds: Dual inhibition of human Topoisomerase I and tubulin polymerization</span></div><div class="casAuthors">Ceramella, Jessica; Caruso, Anna; Occhiuzzi, Maria Antonietta; Iacopetta, Domenico; Barbarossa, Alexia; Rizzuti, Bruno; Dallemagne, Patrick; Rault, Sylvain; El-Kashef, Hussein; Saturnino, Carmela; Grande, Fedora; Sinicropi, Maria Stefania</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111583pp.</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">3-(Alkyl(dialkyl)amino)benzothieno[2,3-f]quinazolin-1(2H)-ones I [R = H, Pr, n-pentyl; R1 = Pr, Bu, n-pentyl, cyclopentyl; RR1 = morpholin-1-yl] were designed using Ellipticine structure as a model, replacing the carbazole core and the pyridine ring with a dibenzothiophene and a pyrimidine moiety, resp.  New benzothienoquinazolinones I were synthesized by a simple one-pot reaction employing 3-aminodibenzothiophene as starting material.  The benzothienoquinazolinones obtained I were evaluated for their anticancer activity against two breast cancer cell lines, MDA-MB-231 and MCF-7.  The results revealed that compds. I [R = H, R1 = n-propyl; R = R1 = n-propyl] presented a good antitumor activity toward the triple neg. MDA-MB-231, without cytotoxicity against non-tumoral cells.  Furthermore, the compds. I [R = H, R1 = n-propyl; R = R1 = n-propyl] can be considered important mol. multi-target tools for their dual inhibition of different cellular proteins, i.e. tubulin and human topoisomerase I, involved in relevant cellular processes, as predicted by in-silico studies and demonstrated by in-vitro assays (for compd. I [R = H, R1 = n-propyl]).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRYyLuCUV5MLVg90H21EOLACvtfcHk0lhsJG64Td119g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFGjt7zE&md5=d83067a2da6624e77f2d8174556eed70</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111583%26sid%3Dliteratum%253Aachs%26aulast%3DCeramella%26aufirst%3DJ.%26aulast%3DCaruso%26aufirst%3DA.%26aulast%3DOcchiuzzi%26aufirst%3DM.%2BA.%26aulast%3DIacopetta%26aufirst%3DD.%26aulast%3DBarbarossa%26aufirst%3DA.%26aulast%3DRizzuti%26aufirst%3DB.%26aulast%3DDallemagne%26aufirst%3DP.%26aulast%3DRault%26aufirst%3DS.%26aulast%3DEl-Kashef%26aufirst%3DH.%26aulast%3DSaturnino%26aufirst%3DC.%26aulast%3DGrande%26aufirst%3DF.%26aulast%3DSinicropi%26aufirst%3DM.%2BS.%26atitle%3DBenzothienoquinazolinones%2520as%2520new%2520multi-target%2520scaffolds%253A%2520Dual%2520inhibition%2520of%2520human%2520Topoisomerase%2520I%2520and%2520tubulin%2520polymerization%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D181%26spage%3D111583%26doi%3D10.1016%2Fj.ejmech.2019.111583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noha, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdelhameid, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismail, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammed, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salwa, E.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and screening of benzimidazole containing compounds with methoxylated aryl radicals as cytotoxic molecules on (HCT-116) colon cancer cells</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>209</i></span>,  <span class="NLM_fpage">112870</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112870</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejmech.2020.112870" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=33158579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3cXit1GqsbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=209&publication_year=2021&pages=112870&author=R.+M.+Nohaauthor=M.+K.+Abdelhameidauthor=M.+M.+Ismailauthor=M.+R.+Mohammedauthor=E.+Salwa&title=Design%2C+synthesis+and+screening+of+benzimidazole+containing+compounds+with+methoxylated+aryl+radicals+as+cytotoxic+molecules+on+%28HCT-116%29+colon+cancer+cells&doi=10.1016%2Fj.ejmech.2020.112870"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and screening of benzimidazole containing compounds with methoxylated aryl radicals as cytotoxic molecules on (HCT-116) colon cancer cells</span></div><div class="casAuthors">Noha, Ryad M.; Abdelhameid, Mohammed. K.; Ismail, M. Mohsen; Mohammed, Manal. R.; Salwa, Elmeligie</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">209</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112870</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A novel series of benzimidazole derivs. I [R = NH2, NO2; R1 = H, OMe; R2 = OH, OMe, Cl, etc.; R3 = H, OMe] and II [R4 = NO2, NHC(O)CH3] with methoxylated aryl groups was designed and synthesized as mols. with potential cytotoxic activity.  In vitro cytotoxic activity over HCT-116 cells showed that N-(benzimidazothiazolone)acetamides II [R1 = H, R2 = OH, R3 = OMe, R4 = NHC(O)Me; R1 = R2 = R3 = OMe, R4 = NHC(O)Me; R1 = H, R2 = Me, R3 = H, R4 = NHC(O)Me] were found to be the most cytotoxic compds. compared camptothecin (CPT).  The tested compds. had a dual topoisomerase I-β (Topo I-β) and tubulin inhibiting activities when compared to CPT and Podophyllotoxin (Podo) where, compds. II [R1 = H, R2 = OH, R3 = OMe, R4 = NO2; R1 = H, R2 = OH, R3 = OMe, R4 = NO2; R1 = H, R2 = OH, R3 = OMe, R4 = NHC(O)Me; R1 = R2 = R3 = OMe, R4 = NHC(O)Me] exhibited a potent inhibitory activity on Topo I-β enzyme in nano-molar concn., on the other hand, compds. I [R = NO2, R1 = R2 = R3 = OMe; R = NH2, R1 = R2 = R3 = OMe] exhibited the best inhibitory activity β-tubulin polymn.  Results of the cell cycle anal. as well as the results of annexin-V on HCT-116 cells showed that benzimidazothiazoles I [R = NO2, R1 = R2 = R3 = OMe; R = NH2, R1 = R2 = R3 = OMe] had a pro-apoptotic activity higher than CPT by 1.33- and 1.30-folds, resp.  Moreover, the concn. of p53, Bax/Bcl-2 ratio and caspase 3/7 increased in compds. I [R = NO2, R1 = R2 = R3 = OMe; R = NH2, R1 = R2 = R3 = OMe] and II [R1 = R2 = R3 = OMe, R4 = NHC(O)Me; R1 = R2 = R3 = OMe, R4 = NO2].  Finally, compd. II [R1 = R2 = R3 = OMe, R4 = NHC(O)Me] regulated the radiosensitizing activity of the HCT-116 cells by modulating the chromosomal instability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiKHAgzedL8bVg90H21EOLACvtfcHk0ljltnlhIYblqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXit1GqsbvL&md5=9c8eecc14ebbe75abdb1a1c17601e744</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112870%26sid%3Dliteratum%253Aachs%26aulast%3DNoha%26aufirst%3DR.%2BM.%26aulast%3DAbdelhameid%26aufirst%3DM.%2BK.%26aulast%3DIsmail%26aufirst%3DM.%2BM.%26aulast%3DMohammed%26aufirst%3DM.%2BR.%26aulast%3DSalwa%26aufirst%3DE.%26atitle%3DDesign%252C%2520synthesis%2520and%2520screening%2520of%2520benzimidazole%2520containing%2520compounds%2520with%2520methoxylated%2520aryl%2520radicals%2520as%2520cytotoxic%2520molecules%2520on%2520%2528HCT-116%2529%2520colon%2520cancer%2520cells%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D209%26spage%3D112870%26doi%3D10.1016%2Fj.ejmech.2020.112870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span> <span> </span><span class="NLM_article-title">Role of IDO and TDO in cancers and related diseases and the therapeutic implications</span>. <i>J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2771</span>– <span class="NLM_lpage">2782</span>, <span class="refDoi"> DOI: 10.7150/jca.31727</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.7150%2Fjca.31727" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=31258785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjsFeisLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=2771-2782&author=Z.+Yeauthor=L.+Yueauthor=J.+Shiauthor=M.+Shaoauthor=T.+Wu&title=Role+of+IDO+and+TDO+in+cancers+and+related+diseases+and+the+therapeutic+implications&doi=10.7150%2Fjca.31727"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Role of IDO and TDO in cancers and related diseases and the therapeutic implications</span></div><div class="casAuthors">Ye, Zixiang; Yue, Linxiu; Shi, Jiachen; Shao, Mingmei; Wu, Tao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cancer (Wyoming, Australia)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2771-2782</span>CODEN:
                <span class="NLM_cas:coden">JCWAAL</span>;
        ISSN:<span class="NLM_cas:issn">1837-9664</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher Pty Ltd.</span>)
        </div><div class="casAbstract">Kynurenine (Kyn) pathway is a significant metabolic pathway of tryptophan (Trp).  The metabolites of the Kyn pathway are closely correlated with numerous diseases.  Two main enzymes, indoleamine-2,3-dioxygenase (IDO) and tryptophan-2,3-dioxygenase (TDO or TDO2), regulate the first and rate-limiting step of the Kyn pathway.  These enzymes are directly or indirectly involved in various diseases, including inflammatory diseases, cancer, diabetes, and mental disorders.  Presently, an increasing no. of potential mechanisms have been revealed.  In the present review, we depict the structure of IDO and TDO and explicate their functions in various diseases to facilitate a better understanding of them and to indicate new therapeutic plans to target them.  Moreover, we summarize the inhibitors of IDO/TDO that are currently under development and their efficacy in the treatment of cancer and other diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGZfh-B1VYnrVg90H21EOLACvtfcHk0ljltnlhIYblqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjsFeisLY%253D&md5=36feb2b7de3d8252e8f13da7bdeb9801</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.7150%2Fjca.31727&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fjca.31727%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DZ.%26aulast%3DYue%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DT.%26atitle%3DRole%2520of%2520IDO%2520and%2520TDO%2520in%2520cancers%2520and%2520related%2520diseases%2520and%2520the%2520therapeutic%2520implications%26jtitle%3DJ.%2520Cancer%26date%3D2019%26volume%3D10%26spage%3D2771%26epage%3D2782%26doi%3D10.7150%2Fjca.31727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuHadaway, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donover, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutanto-Ward, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span> <span> </span><span class="NLM_article-title">Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">312</span>– <span class="NLM_lpage">319</span>, <span class="refDoi"> DOI: 10.1038/nm1196</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1038%2Fnm1196" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=15711557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A280%3ADC%252BD2M7hs1Wiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=312-319&author=A.+J.+Mullerauthor=J.+B.+DuHadawayauthor=P.+S.+Donoverauthor=E.+Sutanto-Wardauthor=G.+C.+Prendergast&title=Inhibition+of+indoleamine+2%2C3-dioxygenase%2C+an+immunoregulatory+target+of+the+cancer+suppression+gene+Bin1%2C+potentiates+cancer+chemotherapy&doi=10.1038%2Fnm1196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy</span></div><div class="casAuthors">Muller Alexander J; DuHadaway James B; Donover P Scott; Sutanto-Ward Erika; Prendergast George C</div><div class="citationInfo"><span class="NLM_cas:title">Nature medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">312-9</span>
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    </div><div class="casAbstract">Immune escape is a crucial feature of cancer progression about which little is known.  Elevation of the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO) in tumor cells can facilitate immune escape.  Not known is how IDO becomes elevated or whether IDO inhibitors will be useful for cancer treatment.  Here we show that IDO is under genetic control of Bin1, which is attenuated in many human malignancies.  Mouse knockout studies indicate that Bin1 loss elevates the STAT1- and NF-kappaB-dependent expression of IDO, driving escape of oncogenically transformed cells from T cell-dependent antitumor immunity.  In MMTV-Neu mice, an established breast cancer model, we show that small-molecule inhibitors of IDO cooperate with cytotoxic agents to elicit regression of established tumors refractory to single-agent therapy.  Our findings suggest that Bin1 loss promotes immune escape in cancer by deregulating IDO and that IDO inhibitors may improve responses to cancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSmoMRy8m8ZDAyMywPm6HgQfW6udTcc2eZNZ0va22YWk7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M7hs1Wiuw%253D%253D&md5=2871eb26a11432381462091144b227f1</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1038%2Fnm1196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1196%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26aulast%3DDuHadaway%26aufirst%3DJ.%2BB.%26aulast%3DDonover%26aufirst%3DP.%2BS.%26aulast%3DSutanto-Ward%26aufirst%3DE.%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26atitle%3DInhibition%2520of%2520indoleamine%25202%252C3-dioxygenase%252C%2520an%2520immunoregulatory%2520target%2520of%2520the%2520cancer%2520suppression%2520gene%2520Bin1%252C%2520potentiates%2520cancer%2520chemotherapy%26jtitle%3DNat.%2520Med.%26date%3D2005%26volume%3D11%26spage%3D312%26epage%3D319%26doi%3D10.1038%2Fnm1196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pilotte, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrieu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroobant, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolusic, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frédérick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Plaen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uyttenhove, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wouters, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masereel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den Eynde, B. J.</span></span> <span> </span><span class="NLM_article-title">Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">2497</span>– <span class="NLM_lpage">2502</span>, <span class="refDoi"> DOI: 10.1073/pnas.1113873109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1073%2Fpnas.1113873109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=22308364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC38XivVKnt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=2497-2502&author=L.+Pilotteauthor=P.+Larrieuauthor=V.+Stroobantauthor=D.+Colauauthor=E.+Dolusicauthor=R.+Fr%C3%A9d%C3%A9rickauthor=E.+De+Plaenauthor=C.+Uyttenhoveauthor=J.+Woutersauthor=B.+Masereelauthor=B.+J.+Van+den+Eynde&title=Reversal+of+tumoral+immune+resistance+by+inhibition+of+tryptophan+2%2C3-dioxygenase&doi=10.1073%2Fpnas.1113873109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase</span></div><div class="casAuthors">Pilotte, Luc; Larrieu, Pierre; Stroobant, Vincent; Colau, Didier; Dolusic, Eduard; Frederick, Raphael; De Plaen, Etienne; Uyttenhove, Catherine; Wouters, Johan; Masereel, Bernard; Vand den Eynde, Benoit</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2497-2502, S2497/1-S2497/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Tryptophan catabolism mediated by indoleamine 2,3-dioxygenase (IDO1) is an important mechanism of peripheral immune tolerance contributing to tumoral immune resistance, and IDO1 inhibition is an active area of drug development.  Tryptophan 2,3-dioxygenase (TDO) is an unrelated hepatic enzyme that also degrades tryptophan along the kynurenine pathway.  Here, we show that enzymically active TDO is expressed in a significant proportion of human tumors.  In a preclin. model, TDO expression by tumors prevented their rejection by immunized mice.  We developed a TDO inhibitor, which, upon systemic treatment, restored the ability of mice to reject TDO-expressing tumors.  Our results describe a mechanism of tumoral immune resistance based on TDO expression and establish proof-of-concept for the use of TDO inhibitors in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUOPsopvoi1LVg90H21EOLACvtfcHk0lgvmbmeb2sjdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivVKnt7o%253D&md5=e29b0d7a9180526a2b79173c75765e6c</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1113873109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1113873109%26sid%3Dliteratum%253Aachs%26aulast%3DPilotte%26aufirst%3DL.%26aulast%3DLarrieu%26aufirst%3DP.%26aulast%3DStroobant%26aufirst%3DV.%26aulast%3DColau%26aufirst%3DD.%26aulast%3DDolusic%26aufirst%3DE.%26aulast%3DFr%25C3%25A9d%25C3%25A9rick%26aufirst%3DR.%26aulast%3DDe%2BPlaen%26aufirst%3DE.%26aulast%3DUyttenhove%26aufirst%3DC.%26aulast%3DWouters%26aufirst%3DJ.%26aulast%3DMasereel%26aufirst%3DB.%26aulast%3DVan%2Bden%2BEynde%26aufirst%3DB.%2BJ.%26atitle%3DReversal%2520of%2520tumoral%2520immune%2520resistance%2520by%2520inhibition%2520of%2520tryptophan%25202%252C3-dioxygenase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3D2497%26epage%3D2502%26doi%3D10.1073%2Fpnas.1113873109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Awuah, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemann, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">A Pt(IV) pro-drug preferentially targets indoleamine-2,3-dioxygenase, providing enhanced ovarian cancer immuno-chemotherapy</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">14854</span>– <span class="NLM_lpage">14857</span>, <span class="refDoi"> DOI: 10.1021/jacs.5b10182</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.5b10182" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVahtrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=14854-14857&author=S.+G.+Awuahauthor=Y.+R.+Zhengauthor=P.+M.+Brunoauthor=M.+T.+Hemannauthor=S.+J.+Lippard&title=A+Pt%28IV%29+pro-drug+preferentially+targets+indoleamine-2%2C3-dioxygenase%2C+providing+enhanced+ovarian+cancer+immuno-chemotherapy&doi=10.1021%2Fjacs.5b10182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy</span></div><div class="casAuthors">Awuah, Samuel G.; Zheng, Yao-Rong; Bruno, Peter M.; Hemann, Michael T.; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">14854-14857</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Expression of indoleamine-2,3-dioxygenase (IDO), an immunosuppressive enzyme in human tumors, leads to immune evasion and tumor tolerance.  IDO is therefore a tumor immunotherapeutic target, and several IDO inhibitors are currently undergoing clin. trials.  IDO inhibitors can enhance the efficacy of common cancer chemotherapeutics.  Here the authors investigate Pt(IV)-(D)-1-methyltryptophan conjugates cis,cis,trans-[Pt(NH3)2Cl2(O2C-D-1-MT)2] (1) and cis,cis,trans-[Pt(NH3)2Cl2(O2CC2H4OCNHC2H4O2C-D-1MT)(O2CNHC16H33)] (2) for combined immunomodulation and DNA crosslink-triggered apoptosis for cancer "immuno-chemotherapy".  Compd. (2) effectively kills hormone-dependent, cisplatin-resistant human ovarian cancer cells, inhibiting IDO by transcriptional deregulation of the autocrine-signaling loop IDO-AHR-IL6, which blocks kynurenine prodn. and promotes T-cell proliferation.  Addnl., (1) and (2) display low toxicity in mice and are stable in blood.  To the authors' knowledge, this construct is the first Pt drug candidate with immune checkpoint blockade properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjz_KgWt-JOLVg90H21EOLACvtfcHk0lgvmbmeb2sjdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVahtrbI&md5=04851d0bb481296b00294bc985190c28</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1021%2Fjacs.5b10182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.5b10182%26sid%3Dliteratum%253Aachs%26aulast%3DAwuah%26aufirst%3DS.%2BG.%26aulast%3DZheng%26aufirst%3DY.%2BR.%26aulast%3DBruno%26aufirst%3DP.%2BM.%26aulast%3DHemann%26aufirst%3DM.%2BT.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DA%2520Pt%2528IV%2529%2520pro-drug%2520preferentially%2520targets%2520indoleamine-2%252C3-dioxygenase%252C%2520providing%2520enhanced%2520ovarian%2520cancer%2520immuno-chemotherapy%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2015%26volume%3D137%26spage%3D14854%26epage%3D14857%26doi%3D10.1021%2Fjacs.5b10182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hua, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span> <span> </span><span class="NLM_article-title">Multifunctional platinum(IV) complexes as immunostimulatory agents to promote cancer immunochemotherapy by inhibiting tryptophan-2,3-dioxygenase</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>169</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">41</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.02.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejmech.2019.02.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=30852385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1MXks12itrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2019&pages=29-41&author=S.+Huaauthor=F.+Chenauthor=G.+Xuauthor=S.+Gou&title=Multifunctional+platinum%28IV%29+complexes+as+immunostimulatory+agents+to+promote+cancer+immunochemotherapy+by+inhibiting+tryptophan-2%2C3-dioxygenase&doi=10.1016%2Fj.ejmech.2019.02.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Multifunctional platinum(IV) complexes as immunostimulatory agents to promote cancer immunochemotherapy by inhibiting tryptophan-2,3-dioxygenase</span></div><div class="casAuthors">Hua, Shixian; Chen, Feihong; Xu, Gang; Gou, Shaohua</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">29-41</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Increasing evidences suggested that cisplatin can be involved in a tumor-specific immune response as an immunomodulator to improve antitumor immunity, but the designation and development are limited.  Here, we report a series of novel Pt(IV) complexes derived from the conjugation of platinum(II) anticancer agents with an immune checkpoint TDO inhibitor.  These complexes not only showed significant cytotoxic effects on the tested cancer cell lines, but also could enhance antitumor immune response.  Particularly, complex T2, the mono-conjugate of oxoplatin and (E)-4-oxo-4-(3-(2-(pyridin-3-yl)vinyl)-1H-indol-1-yl)butanoic acid, displayed 35-fold more potency than cisplatin against TDO-overexpressed HepG-2 cancer cells.  Further study indicated that T2 could inhibit TDO via releasing a deriv. of a TDO inhibitor and block kynurenine prodn., resulting in T-cell activation and proliferation in vitro.  In vivo tests proved that T2 as a potent immunomodulator could highly promote the antitumor activity of cisplatin and effectively suppress the expression of TDO.  This immunochemotherapeutic strategy can be promisingly applied to treat with TDO-overexpressed cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraJ66nUl2NzbVg90H21EOLACvtfcHk0lgvmbmeb2sjdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXks12itrc%253D&md5=c2abc299a2d18a2bffed504df3e24a4f</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.02.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.02.063%26sid%3Dliteratum%253Aachs%26aulast%3DHua%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DGou%26aufirst%3DS.%26atitle%3DMultifunctional%2520platinum%2528IV%2529%2520complexes%2520as%2520immunostimulatory%2520agents%2520to%2520promote%2520cancer%2520immunochemotherapy%2520by%2520inhibiting%2520tryptophan-2%252C3-dioxygenase%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D169%26spage%3D29%26epage%3D41%26doi%3D10.1016%2Fj.ejmech.2019.02.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hua, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span> <span> </span><span class="NLM_article-title">Microtubule inhibitors containing immunostimulatory agents promote cancer immunochemotherapy by inhibiting tubulin polymerization and tryptophan-2,3-dioxygenase</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>187</i></span>,  <span class="NLM_fpage">111949</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111949</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejmech.2019.111949" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=31830637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlGhu7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=2020&pages=111949&author=S.+Huaauthor=F.+Chenauthor=S.+Gou&title=Microtubule+inhibitors+containing+immunostimulatory+agents+promote+cancer+immunochemotherapy+by+inhibiting+tubulin+polymerization+and+tryptophan-2%2C3-dioxygenase&doi=10.1016%2Fj.ejmech.2019.111949"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule inhibitors containing immunostimulatory agents promote cancer immunochemotherapy by inhibiting tubulin polymerization and tryptophan-2,3-dioxygenase</span></div><div class="casAuthors">Hua, Shixian; Chen, Feihong; Gou, Shaohua</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111949</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A combination therapeutic regimen via introducing tryptophan 2,3-dioxygenase inhibitors into microtubule inhibitors was performed and evaluated for their antitumor activity.  Thereinto, HT2, composed of combretastatin A-4 (CA-4) and tryptophan-2,3-dioxygenase (TDO) inhibitor by a linker, displayed the most potent activity with 10-fold higher than its parent CA-4 against HepG2, A549 and HCT-116 cancer cell lines.  Mechanism studies suggested that HT2 inhibited tubulin polymn. and cell migration, caused G2 phase arrest, induced apoptosis by mitochondrial mediated apoptotic pathway, concurrent depolarized the mitochondria membrane potentials and caused reactive oxygen species (ROS) prodn. in HepG2 cells.  Moreover, HT2 could enhance T-cell immune responses in vitro by releasing a TDO inhibitor to suppress TDO expression and blockade kynurenine prodn.  As expected, HT2 could remarkably promote the antitumor activity of CA-4 in either immunocompetent H22 or immunodeficient A549 tumor xenograft models without observable toxic effects.  More importantly, HT2 increased the level of splenic and tumor-infiltrated T cells and in turn effectively boosted the inhibition effect in H22 xenografted tumor growth.  Collectively, this immunochemotherapeutic strategy can be applied to promote chemotherapeutic effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaKG5W_QhNz7Vg90H21EOLACvtfcHk0ljnH0QhlpUZHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlGhu7zJ&md5=a8d8e6f33d2ad2f5dd02c4403ba2ed94</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111949%26sid%3Dliteratum%253Aachs%26aulast%3DHua%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DGou%26aufirst%3DS.%26atitle%3DMicrotubule%2520inhibitors%2520containing%2520immunostimulatory%2520agents%2520promote%2520cancer%2520immunochemotherapy%2520by%2520inhibiting%2520tubulin%2520polymerization%2520and%2520tryptophan-2%252C3-dioxygenase%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D187%26spage%3D111949%26doi%3D10.1016%2Fj.ejmech.2019.111949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hua, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span> <span> </span><span class="NLM_article-title">Dual-functional conjugates improving cancer immunochemotherapy by inhibiting tubulin polymerization and indoleamine-2,3-dioxygenase</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>189</i></span>,  <span class="NLM_fpage">112041</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejmech.2020.112041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=31954880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFGjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2020&pages=112041&author=S.+Huaauthor=F.+Chenauthor=X.+Wangauthor=S.+Gou&title=Dual-functional+conjugates+improving+cancer+immunochemotherapy+by+inhibiting+tubulin+polymerization+and+indoleamine-2%2C3-dioxygenase&doi=10.1016%2Fj.ejmech.2020.112041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-functional conjugates improving cancer immunochemotherapy by inhibiting tubulin polymerization and indoleamine-2,3-dioxygenase</span></div><div class="casAuthors">Hua, Shixian; Chen, Feihong; Wang, Xinyi; Gou, Shaohua</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">189</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112041</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of novel conjugates comprising tublin and IDO inhibitors were designed, synthesized and evaluated for their antiproliferative activity.  Among them, HI5, composed of combretastatin A-4 (CA-4) and (D)-1-methyltryptophan (D-MT) by a linker, exhibited the most potent antitumor activity, in particular with higher IC50 value (0.07 μM) than CA-4 (0.21 μM) against HeLa cancer cell line.  Mechanism studies indicated that HI5 can inhibit tubulin polymn. and cell migration, cause G2/M phase arrest, concurrent induce apoptosis via the mitochondrial dependent apoptosis pathway and cause reactive oxidative stress generation in HeLa cells.  Furthermore, HI5 can inhibit IDO expression and decrease kynurenine prodn., leading to stimulating T cells activation and proliferation to enhance antitumor immunity in vitro.  Interestingly, HI5 can effectively limit the tumor growth in the HeLa xenograft mice models without causing significant loss of body wt.  Consequently, such a conjugation can be a potent and safe immunochemotherapeutic method for improving cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK6mjQcEaBRbVg90H21EOLACvtfcHk0ljnH0QhlpUZHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFGjt7Y%253D&md5=f6e05a7ba52c4112d0d767f0f1f7f1f3</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112041%26sid%3Dliteratum%253Aachs%26aulast%3DHua%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGou%26aufirst%3DS.%26atitle%3DDual-functional%2520conjugates%2520improving%2520cancer%2520immunochemotherapy%2520by%2520inhibiting%2520tubulin%2520polymerization%2520and%2520indoleamine-2%252C3-dioxygenase%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D189%26spage%3D112041%26doi%3D10.1016%2Fj.ejmech.2020.112041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dasgupta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luthra, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awasthi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nag, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakrabarti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakrabarti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sen, S.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of a novel library of antimitotic C(2)-aroyl/arylimino tryptamine derivatives that are also potent inhibitors of indoleamine-2, 3-dioxygenase (IDO)</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">249</span>– <span class="NLM_lpage">265</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2018.08.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejps.2018.08.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=30170210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1GqtL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2018&pages=249-265&author=J.+Chauhanauthor=M.+Dasguptaauthor=T.+Luthraauthor=A.+Awasthiauthor=S.+Tripathyauthor=A.+Banerjeeauthor=S.+Paulauthor=D.+Nagauthor=S.+Chakrabartiauthor=G.+Chakrabartiauthor=S.+Sen&title=Design%2C+synthesis+and+biological+evaluation+of+a+novel+library+of+antimitotic+C%282%29-aroyl%2Farylimino+tryptamine+derivatives+that+are+also+potent+inhibitors+of+indoleamine-2%2C+3-dioxygenase+%28IDO%29&doi=10.1016%2Fj.ejps.2018.08.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of a novel library of antimitotic C2-aroyl/arylimino tryptamine derivatives that are also potent inhibitors of indoleamine-2, 3-dioxygenase (IDO)</span></div><div class="casAuthors">Chauhan, Jyoti; Dasgupta, Moumita; Luthra, Tania; Awasthi, Akanksha; Tripathy, Sayantan; Banerjee, Anindyajit; Paul, Santanu; Nag, Debasish; Chakrabarti, Saikat; Chakrabarti, Gopal; Sen, Subhabrata</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">249-265</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel library of C2-substituted tryptamines (based on diverse C2-aroyl/arylimino indoles and indole-diketopiperazine hybrids) possessing antimitotic properties were designed, synthesized and screened for their inhibitory activity against tubulin polymn., and against proliferation of A549 lung cancer, HeLa cervical cancer, MCF7 breast cancer and HePG2 liver cancer cell lines.  The design of mols. were inspired from known antimitotic compds. and natural products.  The mol. docking of the designed compds. indicated that they bind to the colchicin binding site of tubulin.  They were synthesized by a unique iodine catalyzed oxidative ring opening reaction of 1-aryltetrahydro-β-carbolines.  Among the compds. synthesized quite a few compds. induced cytotoxicity on the cancer cells by disrupting the tubulin polymn.  They were found to be non-toxic for healthy cells.  Immuno Fluorescence study for the most active mols. (between ~ 6μM concn.) against A549 and HeLa cells demonstrated complete disruption and shrinkage of the microtubule structures.  These compds. also inhibited indoleamine-2, 3-dioxygenase with low micromolar IC50.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3TM5khkpf-rVg90H21EOLACvtfcHk0ljnH0QhlpUZHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1GqtL3N&md5=01a650de48f157b4bc97873f4d6314fa</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2018.08.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2018.08.033%26sid%3Dliteratum%253Aachs%26aulast%3DChauhan%26aufirst%3DJ.%26aulast%3DDasgupta%26aufirst%3DM.%26aulast%3DLuthra%26aufirst%3DT.%26aulast%3DAwasthi%26aufirst%3DA.%26aulast%3DTripathy%26aufirst%3DS.%26aulast%3DBanerjee%26aufirst%3DA.%26aulast%3DPaul%26aufirst%3DS.%26aulast%3DNag%26aufirst%3DD.%26aulast%3DChakrabarti%26aufirst%3DS.%26aulast%3DChakrabarti%26aufirst%3DG.%26aulast%3DSen%26aufirst%3DS.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520a%2520novel%2520library%2520of%2520antimitotic%2520C%25282%2529-aroyl%252Farylimino%2520tryptamine%2520derivatives%2520that%2520are%2520also%2520potent%2520inhibitors%2520of%2520indoleamine-2%252C%25203-dioxygenase%2520%2528IDO%2529%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2018%26volume%3D124%26spage%3D249%26epage%3D265%26doi%3D10.1016%2Fj.ejps.2018.08.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meegan, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lloyd, D. G.</span></span> <span> </span><span class="NLM_article-title">Advances in the science of estrogen receptor modulation</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.2174/0929867033368501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.2174%2F0929867033368501" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=12570707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlt1Ghtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2003&pages=181-210&author=M.+J.+Meeganauthor=D.+G.+Lloyd&title=Advances+in+the+science+of+estrogen+receptor+modulation&doi=10.2174%2F0929867033368501"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the science of estrogen receptor modulation</span></div><div class="casAuthors">Meegan, M. J.; Lloyd, D. G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">181-210</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers</span>)
        </div><div class="casAbstract">A review.  This work details recent advances in the science of estrogen receptor (ER) modulation, with emphasis on the discovery of novel ligands for the ER ligand binding domain (LBD).  A detailed examn. of structural studies of the ERs is presented with anal. of the impact of such works on contemporary ligand design and the mol. pharmacol. of the ER.  The various classes of ER modulators are discussed on the basis of structural similarities including selective estrogen receptor modulators (SERMs) and pure nonsteroidal antiestrogens.  Addnl. the authors review the emergence of a novel selective class of modulator - which is termed the selective estrogen receptor subtype modulators (SERSMs) and, in a departure from LBD strategies the authors examine the discovery of novel peptide inhibitors of the ER which inhibit transcriptional activation of agonist liganded receptor through interaction with coactivator recruitment proteins, and offer unique insight to the mechanism of action of all classes of ER modulators.  Through examn. of patent and classical literature the authors present a thorough and informative cross-section of the contemporary state of the art in this exciting field of pharmaceutical research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjk0iqK7f-9rVg90H21EOLACvtfcHk0ljnH0QhlpUZHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlt1Ghtw%253D%253D&md5=c84e9564c709148ca17206fa6ce6ada9</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.2174%2F0929867033368501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867033368501%26sid%3Dliteratum%253Aachs%26aulast%3DMeegan%26aufirst%3DM.%2BJ.%26aulast%3DLloyd%26aufirst%3DD.%2BG.%26atitle%3DAdvances%2520in%2520the%2520science%2520of%2520estrogen%2520receptor%2520modulation%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2003%26volume%3D10%26spage%3D181%26epage%3D210%26doi%3D10.2174%2F0929867033368501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ershler, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brawley, O. W.</span></span> <span> </span><span class="NLM_article-title">Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1023/A:1020299707510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1023%2FA%3A1020299707510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=12408373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD38XntVKjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2002&pages=27-36&author=W.+F.+Andersonauthor=N.+Chatterjeeauthor=W.+B.+Ershlerauthor=O.+W.+Brawley&title=Estrogen+receptor+breast+cancer+phenotypes+in+the+Surveillance%2C+Epidemiology%2C+and+End+Results+database&doi=10.1023%2FA%3A1020299707510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results Database</span></div><div class="casAuthors">Anderson, William F.; Chatterjee, Nilanjan; Ershler, William B.; Brawley, Otis W.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-36</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">Researchers question whether estrogen receptor α-neg. (ERN) and -pos. (ERP) represent different stages of one disease or different breast cancer types.  To further examine ERα phenotypes, the authors stratified incident tumor characteristics in the Surveillance, Epidemiol., and End Results (SEER) Database (n = 82,488) by ERN and ERP.  Study variables included black-white race, age-at-diagnosis, and std. incident tumor characteristics.  These characteristics were arbitrarily dichotomized into good vs. poor prognostic factor groups, for example, good (tumor size ≤ 2.0 cm, neg. axillary lymph nodes, and good histol. grade) vs. poor (tumor size > 2.0 cm, pos. nodes, and poor grade).  Age frequency d. plots were generated from the corresponding age-at-diagnosis frequency histograms.  Av. annual age-specific incidence rates (or risks) were adjusted to the 1970 United States std. female population.  Age frequency d. plots demonstrated bimodal premenopausal and postmenopausal breast cancer populations.  ERN was correlated with premenopausal disease, black race, and poor prognostic factor groups, whereas ERP was assocd. with postmenopausal disease, white race, and favorable tumor characteristics.  ERN rates increased premenopausally and then flattened to a nearly const. level after 50 yr of age.  ERP risk rose for most of a woman's lifetime with the greatest risk occurring between 75 and 79 yr.  ERα exhibited bimodal age frequency distribution with a dichotomous pattern for age-specific rates, racial, and prognostic factor profiles.  Menopause had a greater effect on ERN than ERP.  Possible implications for breast carcinogenesis and cancer prevention are discussed in the text.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrREH2KVZKrbVg90H21EOLACvtfcHk0lhOJqbZgz2kgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntVKjtbo%253D&md5=a40a50fe92135da539717096d1722e01</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1023%2FA%3A1020299707510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1020299707510%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DW.%2BF.%26aulast%3DChatterjee%26aufirst%3DN.%26aulast%3DErshler%26aufirst%3DW.%2BB.%26aulast%3DBrawley%26aufirst%3DO.%2BW.%26atitle%3DEstrogen%2520receptor%2520breast%2520cancer%2520phenotypes%2520in%2520the%2520Surveillance%252C%2520Epidemiology%252C%2520and%2520End%2520Results%2520database%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2002%26volume%3D76%26spage%3D27%26epage%3D36%26doi%3D10.1023%2FA%3A1020299707510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berd, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mastrangelo, M. J.</span></span> <span> </span><span class="NLM_article-title">Paclitaxel and tamoxifen: An active regimen for patients with metastatic melanoma</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">87</span>, <span class="refDoi"> DOI: 10.1002/(SICI)1097-0142(20000101)88:1<79::AID-CNCR12>3.0.CO;2-L</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1002%2F%28SICI%291097-0142%2820000101%2988%3A1%3C79%3A%3AAID-CNCR12%3E3.0.CO%3B2-L" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10618609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmtV2gsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2000&pages=79-87&author=F.+E.+Nathanauthor=D.+Berdauthor=T.+Satoauthor=M.+J.+Mastrangelo&title=Paclitaxel+and+tamoxifen%3A+An+active+regimen+for+patients+with+metastatic+melanoma&doi=10.1002%2F%28SICI%291097-0142%2820000101%2988%3A1%3C79%3A%3AAID-CNCR12%3E3.0.CO%3B2-L"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Paclitaxel and tamoxifen: An active regimen for patients with metastatic melanoma</span></div><div class="casAuthors">Nathan, Faith E.; Berd, David; Sato, Takami; Mastrangelo, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (New York)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">79-87</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">In early trials of paclitaxel administered as a 24-h infusion, an overall response rate of 16% was reported for patients with metastatic melanoma.  Paclitaxel is a natural product-based agent and is thus subject to the problem of multidrug resistance (MDR).  Tamoxifen is an agent that can abrogate MDR and potentially enhance the effect of paclitaxel.  A Phase II trial of the combination was undertaken with previously treated patients.  Patients with metastatic cutaneous or mucosal melanoma who were previously treated with the Dartmouth chemotherapy regimen (dacarbazine, carmustine, cisplatin, and tamoxifen) were evaluated.  Paclitaxel was administered at a dose of 225 mg/m2 i.v. over 3 h every 3 wk.  All patients also took tamoxifen 40 mg orally daily.  Treatment continued until disease progression.  Twenty-one patients completed at least two cycles of paclitaxel and were evaluable for response.  Five responses were obsd., 1 complete response, and 4 partial responses, for an overall response rate of 24%.  The combination was well tolerated.  The most common nonhematol. side effects were myalgia and paresthesia.  Hematol. toxicity was mild.  No patients developed neutropenic fever.  This is the first report of a Phase II trial evaluating paclitaxel as a 3-h infusion in melanoma patients.  The 3-h infusion is well tolerated and results in little myelosuppression and minimal neurotoxicity.  The contribution of tamoxifen is difficult to evaluate because plasma levels were not measured.  It is possible that a higher response rate might be obsd. with larger doses of tamoxifen.  Further investigation of paclitaxel in the treatment of patients with metastatic melanoma is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjfS5pgcF2zLVg90H21EOLACvtfcHk0lhOJqbZgz2kgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmtV2gsw%253D%253D&md5=d7bb071cfb264c8ea70801dd7009867a</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291097-0142%2820000101%2988%3A1%3C79%3A%3AAID-CNCR12%3E3.0.CO%3B2-L&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291097-0142%252820000101%252988%253A1%253C79%253A%253AAID-CNCR12%253E3.0.CO%253B2-L%26sid%3Dliteratum%253Aachs%26aulast%3DNathan%26aufirst%3DF.%2BE.%26aulast%3DBerd%26aufirst%3DD.%26aulast%3DSato%26aufirst%3DT.%26aulast%3DMastrangelo%26aufirst%3DM.%2BJ.%26atitle%3DPaclitaxel%2520and%2520tamoxifen%253A%2520An%2520active%2520regimen%2520for%2520patients%2520with%2520metastatic%2520melanoma%26jtitle%3DCancer%26date%3D2000%26volume%3D88%26spage%3D79%26epage%3D87%26doi%3D10.1002%2F%28SICI%291097-0142%2820000101%2988%3A1%3C79%3A%3AAID-CNCR12%3E3.0.CO%3B2-L" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Boyle, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knox, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathwani, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caboni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zisterer, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meegan, M. J.</span></span> <span> </span><span class="NLM_article-title">β-Lactam estrogen receptor antagonists and a dual-targeting estrogen receptor/tubulin ligand</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">9370</span>– <span class="NLM_lpage">9382</span>, <span class="refDoi"> DOI: 10.1021/jm500670d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500670d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGls7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=9370-9382&author=N.+M.+O%E2%80%99Boyleauthor=J.+K.+Pollockauthor=M.+Carrauthor=A.+J.+Knoxauthor=S.+M.+Nathwaniauthor=S.+Wangauthor=L.+Caboniauthor=D.+M.+Zistererauthor=M.+J.+Meegan&title=%CE%B2-Lactam+estrogen+receptor+antagonists+and+a+dual-targeting+estrogen+receptor%2Ftubulin+ligand&doi=10.1021%2Fjm500670d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">β-Lactam Estrogen Receptor Antagonists and a Dual-Targeting Estrogen Receptor/Tubulin Ligand</span></div><div class="casAuthors">O'Boyle, Niamh M.; Pollock, Jade K.; Carr, Miriam; Knox, Andrew J. S.; Nathwani, Seema M.; Wang, Shu; Caboni, Laura; Zisterer, Daniela M.; Meegan, Mary J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9370-9382</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Twelve novel β-lactams were synthesized and their antiproliferative effects and binding affinity for the predominant isoforms of the estrogen receptor (ER), ERα and ERβ, were detd.  β-Lactams I and II had the strongest binding affinities for ERα (IC50 values: 40 and 8 nM, resp.) and ERβ (IC50 values: 19 and 15 nM).  β-Lactam II was the most potent in antiproliferative assays using MCF-7 breast cancer cells; and further biochem. anal. showed that it caused accumulation of cells in G2/M phase (mitotic blockade) and depolymn. of tubulin in MCF-7 cells.  Compd. II also induced apoptosis and down-regulation of the expression of pro-survival proteins Bcl-2 and Mcl-1.  Computational modeling predicted binding preferences for the dual ER/tubulin ligand II.  This series is an important addn. to the known pool of ER antagonists and β-lactam II is the first reported compd. that has dual-targeting properties for both the ER and tubulin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtrx6ltjEnGrVg90H21EOLACvtfcHk0lhOJqbZgz2kgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGls7nJ&md5=f28caec3db6b9a8fad76d1abe5007f78</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1021%2Fjm500670d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500670d%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DN.%2BM.%26aulast%3DPollock%26aufirst%3DJ.%2BK.%26aulast%3DCarr%26aufirst%3DM.%26aulast%3DKnox%26aufirst%3DA.%2BJ.%26aulast%3DNathwani%26aufirst%3DS.%2BM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DCaboni%26aufirst%3DL.%26aulast%3DZisterer%26aufirst%3DD.%2BM.%26aulast%3DMeegan%26aufirst%3DM.%2BJ.%26atitle%3D%25CE%25B2-Lactam%2520estrogen%2520receptor%2520antagonists%2520and%2520a%2520dual-targeting%2520estrogen%2520receptor%252Ftubulin%2520ligand%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D9370%26epage%3D9382%26doi%3D10.1021%2Fjm500670d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span> <span> </span><span class="NLM_article-title">The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism</span>. <i>Nat. Rev. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">606</span>– <span class="NLM_lpage">619</span>, <span class="refDoi"> DOI: 10.1038/nrg1879</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1038%2Fnrg1879" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=16847462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFCnu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=606-619&author=J.+A.+Engelmanauthor=J.+Luoauthor=L.+C.+Cantley&title=The+evolution+of+phosphatidylinositol+3-kinases+as+regulators+of+growth+and+metabolism&doi=10.1038%2Fnrg1879"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism</span></div><div class="casAuthors">Engelman, Jeffrey A.; Luo, Ji; Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Genetics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">606-619</span>CODEN:
                <span class="NLM_cas:coden">NRGAAM</span>;
        ISSN:<span class="NLM_cas:issn">1471-0056</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Phosphatidylinositol 3-kinases (PI3Ks) evolved from a single enzyme that regulates vesicle trafficking in unicellular eukaryotes into a family of enzymes that regulate cellular metab. and growth in multicellular organisms.  In this review, we examine how the PI3K pathway has evolved to control these fundamental processes, and how this pathway is in turn regulated by intricate feedback and crosstalk mechanisms.  In light of the recent advances in our understanding of the function of PI3Ks in the pathogenesis of diabetes and cancer, we discuss the exciting therapeutic opportunities for targeting this pathway to treat these diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphucxYJIwcQLVg90H21EOLACvtfcHk0lhun7ucW8sKwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFCnu7Y%253D&md5=cd9eb85158710db6b33336af4e0a8cfe</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1038%2Fnrg1879&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrg1879%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DThe%2520evolution%2520of%2520phosphatidylinositol%25203-kinases%2520as%2520regulators%2520of%2520growth%2520and%2520metabolism%26jtitle%3DNat.%2520Rev.%2520Genet.%26date%3D2006%26volume%3D7%26spage%3D606%26epage%3D619%26doi%3D10.1038%2Fnrg1879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pons-Tostivint, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thibault, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillermet-Guibert, J.</span></span> <span> </span><span class="NLM_article-title">Targeting PI3K signaling in combination cancer therapy</span>. <i>Trends Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">454</span>– <span class="NLM_lpage">469</span>, <span class="refDoi"> DOI: 10.1016/j.trecan.2017.04.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.trecan.2017.04.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=28718419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1MXksVOksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=454-469&author=E.+Pons-Tostivintauthor=B.+Thibaultauthor=J.+Guillermet-Guibert&title=Targeting+PI3K+signaling+in+combination+cancer+therapy&doi=10.1016%2Fj.trecan.2017.04.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting PI3K Signaling in Combination Cancer Therapy</span></div><div class="casAuthors">Pons-Tostivint, Elvire; Thibault, Benoit; Guillermet-Guibert, Julie</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">454-469</span>CODEN:
                <span class="NLM_cas:coden">TCRAB5</span>;
        ISSN:<span class="NLM_cas:issn">2405-8033</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Targeting upstream phosphatidylinositol-3-kinases (PI3Ks) in the PI3K/Akt/mTOR pathway appears to be a promising therapy in solid cancers; however, first early clin. trials with PI3K inhibitors in monotherapy have been disappointing.  A massive array of preclin. and clin. trials are currently evaluating combinations of PI3K inhibitors in targeted therapies.  These combinations include co-treatments with drugs directed against other intra-/extracellular signaling mols., nuclear hormone receptors, DNA damage repair enzymes, and immune modulators.  We review the literature and pinpoint mechanisms of action in different genomic and organ contexts.  Combinatorial approaches are potentially superior to monotherapies and should become alternative clin. strategies to treat cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotS0vLAVeC87Vg90H21EOLACvtfcHk0lhun7ucW8sKwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXksVOksQ%253D%253D&md5=3b905f4d00de4428b52078434ad11f12</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.trecan.2017.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.trecan.2017.04.002%26sid%3Dliteratum%253Aachs%26aulast%3DPons-Tostivint%26aufirst%3DE.%26aulast%3DThibault%26aufirst%3DB.%26aulast%3DGuillermet-Guibert%26aufirst%3DJ.%26atitle%3DTargeting%2520PI3K%2520signaling%2520in%2520combination%2520cancer%2520therapy%26jtitle%3DTrends%2520Cancer%26date%3D2017%26volume%3D3%26spage%3D454%26epage%3D469%26doi%3D10.1016%2Fj.trecan.2017.04.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosokawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanimura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohno, M.</span></span> <span> </span><span class="NLM_article-title">Blockade of the phosphatidylinositol-3-kinase-Akt signaling pathway enhances the induction of apoptosis by microtubule-destabilizing agents in tumor cells in which the pathway is constitutively activated</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1133</span>– <span class="NLM_lpage">1142</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-06-0639</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1158%2F1535-7163.MCT-06-0639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=17363506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2ntL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=1133-1142&author=Y.+Fujiwaraauthor=Y.+Hosokawaauthor=K.+Watanabeauthor=S.+Tanimuraauthor=K.+Ozakiauthor=M.+Kohno&title=Blockade+of+the+phosphatidylinositol-3-kinase-Akt+signaling+pathway+enhances+the+induction+of+apoptosis+by+microtubule-destabilizing+agents+in+tumor+cells+in+which+the+pathway+is+constitutively+activated&doi=10.1158%2F1535-7163.MCT-06-0639"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of the phosphatidylinositol-3-kinase-Akt signaling pathway enhances the induction of apoptosis by microtubule-destabilizing agents in tumor cells in which the pathway is constitutively activated</span></div><div class="casAuthors">Fujiwara, Yusuke; Hosokawa, Yoshihisa; Watanabe, Kazushi; Tanimura, Susumu; Ozaki, Kei-Ichi; Kohno, Michiaki</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1133-1142</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Constitutive activation of the phosphatidylinositol-3-kinase (PI3K)-Akt signaling pathway is assocd. with the neoplastic phenotype in many human tumor cell types.  Given the antiapoptotic role of this pathway, we examd. whether its specific blockade might sensitize human tumor cells to the induction of apoptosis by various anticancer drugs.  Although specific blockade of the PI3K-Akt pathway alone with inhibitors such as LY294002 did not induce cell death, it resulted in marked and selective enhancement of the induction of apoptosis by microtubule-destabilizing agents such as vincristine.  This effect was apparent only in tumor cells in which the PI3K-Akt pathway is constitutively activated.  Blockade of the PI3K-Akt pathway induced the activation of glycogen synthase kinase-3β, which phosphorylates microtubule-assocd. proteins such as tau and thereby reduces their ability to bind and stabilize microtubules.  The consequent destabilization of microtubules induced by the inhibition of PI3K-Akt signaling appeared to increase their sensitivity to low concns. of microtubule-destabilizing agents that alone do not lead to the disruption of cytoplasmic microtubules in tumor cells.  Such a synergistic effect on microtubule integrity was not apparent for stable microtubules in the neurites of neuronal cells.  These results suggest that the administration of a combination of a PI3K-Akt pathway inhibitor and a microtubule-destabilizing agent is a potential chemotherapeutic strategy for the treatment of tumor cells in which this signaling pathway is constitutively activated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcCv9iTqdlvbVg90H21EOLACvtfcHk0lhun7ucW8sKwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2ntL0%253D&md5=ed8077b440c71649160eb7b63c7e6656</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0639%26sid%3Dliteratum%253Aachs%26aulast%3DFujiwara%26aufirst%3DY.%26aulast%3DHosokawa%26aufirst%3DY.%26aulast%3DWatanabe%26aufirst%3DK.%26aulast%3DTanimura%26aufirst%3DS.%26aulast%3DOzaki%26aufirst%3DK.%26aulast%3DKohno%26aufirst%3DM.%26atitle%3DBlockade%2520of%2520the%2520phosphatidylinositol-3-kinase-Akt%2520signaling%2520pathway%2520enhances%2520the%2520induction%2520of%2520apoptosis%2520by%2520microtubule-destabilizing%2520agents%2520in%2520tumor%2520cells%2520in%2520which%2520the%2520pathway%2520is%2520constitutively%2520activated%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D1133%26epage%3D1142%26doi%3D10.1158%2F1535-7163.MCT-06-0639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sekino, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawaguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teishima, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiota, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasui, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsubara, A.</span></span> <span> </span><span class="NLM_article-title">TUBB3 reverses resistance to docetaxel and cabazitaxel in prostate cancer</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">3936</span>, <span class="refDoi"> DOI: 10.3390/ijms20163936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.3390%2Fijms20163936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVCmtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=3936&author=Y.+Sekinoauthor=X.+Hanauthor=T.+Kawaguchiauthor=T.+Babasakiauthor=K.+Gotoauthor=S.+Inoueauthor=T.+Hayashiauthor=J.+Teishimaauthor=M.+Shiotaauthor=W.+Yasuiauthor=A.+Matsubara&title=TUBB3+reverses+resistance+to+docetaxel+and+cabazitaxel+in+prostate+cancer&doi=10.3390%2Fijms20163936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">TUBB3 reverses resistance to docetaxel and cabazitaxel in prostate cancer</span></div><div class="casAuthors">Sekino, Yohei; Han, Xiangrui; Kawaguchi, Takafumi; Babasaki, Takashi; Goto, Keisuke; Inoue, Shogo; Hayashi, Tetsutaro; Teishima, Jun; Shiota, Masaki; Yasui, Wataru; Matsubara, Akio</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3936</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Recent studies have reported that TUBB3 overexpression is involved in docetaxel (DTX) resistance in prostate cancer (PCa).  The aim of this study was to clarify the role of TUBB3 in DTX and cabazitaxel (CBZ) resistance, and cross-resistance between DTX and CBZ in PCa.  We analyzed the effect of TUBB3 knockdown on DTX and CBZ resistance and examd. the interaction between TUBB3 and PTEN.  We also investigated the role of phosphoinositide 3-kinases (PI3K) inhibitor (LY294002) in DTX and CBZ resistance.  TUBB3 expression was upregulated in DTX-resistant and CBZ-resistant cells.  TUBB3 knockdown re-sensitized DTX-resistant cells to DTX and CBZ-resistant cells to CBZ.  Addnl., TUBB3 knockdown re-sensitized DTX-resistant cell lines to CBZ, indicating that TUBB3 mediates cross-resistance between DTX and CBZ.  Knockdown of TUBB3 enhanced PTEN expression, and PTEN knockout enhanced TUBB3 expression.  LY294002 suppressed TUBB3 expression in DTX-resistant and CBZ-resistant cell lines.  LY294002 re-sensitized DTX-resistant cell lines to DTX and CBZ-resistant cell lines to CBZ.  These results suggest that TUBB3 is involved in DTX resistance and CBZ resistance.  A combination of LY294002/DTX and that of LY294002/CBZ could be potential strategies for PCa treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1sLyEntEtXbVg90H21EOLACvtfcHk0lhz67AhR-L7GA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVCmtr0%253D&md5=bcb7c3966eddd83b32cb0107623873a3</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.3390%2Fijms20163936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20163936%26sid%3Dliteratum%253Aachs%26aulast%3DSekino%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DKawaguchi%26aufirst%3DT.%26aulast%3DBabasaki%26aufirst%3DT.%26aulast%3DGoto%26aufirst%3DK.%26aulast%3DInoue%26aufirst%3DS.%26aulast%3DHayashi%26aufirst%3DT.%26aulast%3DTeishima%26aufirst%3DJ.%26aulast%3DShiota%26aufirst%3DM.%26aulast%3DYasui%26aufirst%3DW.%26aulast%3DMatsubara%26aufirst%3DA.%26atitle%3DTUBB3%2520reverses%2520resistance%2520to%2520docetaxel%2520and%2520cabazitaxel%2520in%2520prostate%2520cancer%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D3936%26doi%3D10.3390%2Fijms20163936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maira, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sterker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guthy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brachmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chène, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Pover, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martiny-Baron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlegel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Echeverría, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voliva, C. F.</span></span> <span> </span><span class="NLM_article-title">Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">317</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0474</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1158%2F1535-7163.MCT-11-0474" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=22188813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFWltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=317-328&author=S.+M.+Mairaauthor=S.+Pecchiauthor=A.+Huangauthor=M.+Burgerauthor=M.+Knappauthor=D.+Sterkerauthor=C.+Schnellauthor=D.+Guthyauthor=T.+Nagelauthor=M.+Wiesmannauthor=S.+Brachmannauthor=C.+Fritschauthor=M.+Dorschauthor=P.+Ch%C3%A8neauthor=K.+Shoemakerauthor=A.+De+Poverauthor=D.+Menezesauthor=G.+Martiny-Baronauthor=D.+Fabbroauthor=C.+J.+Wilsonauthor=R.+Schlegelauthor=F.+Hofmannauthor=C.+Garc%C3%ADa-Echeverr%C3%ADaauthor=W.+R.+Sellersauthor=C.+F.+Voliva&title=Identification+and+characterization+of+NVP-BKM120%2C+an+orally+available+pan-class+I+PI3-kinase+inhibitor&doi=10.1158%2F1535-7163.MCT-11-0474"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor</span></div><div class="casAuthors">Maira, Sauveur-Michel; Pecchi, Sabina; Huang, Alan; Burger, Matthew; Knapp, Mark; Sterker, Dario; Schnell, Christian; Guthy, Daniel; Nagel, Tobi; Wiesmann, Marion; Brachmann, Saskia; Fritsch, Christine; Dorsch, Marion; Chene, Patrick; Shoemaker, Kevin; De Pover, Alain; Menezes, Daniel; Martiny-Baron, Georg; Fabbro, Doriano; Wilson, Christopher J.; Schlegel, Robert; Hofmann, Francesco; Garcia-Echeverria, Carlos; Sellers, William R.; Voliva, Charles F.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">317-328</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Following the discovery of NVP-BEZ235, our first dual pan-PI3K/mTOR clin. compd., we sought to identify addnl. phosphoinositide 3-kinase (PI3K) inhibitors from different chem. classes with a different selectivity profile.  The key to achieve these objectives was to couple a structure-based design approach with intensive pharmacol. evaluation of selected compds. during the medicinal chem. optimization process.  Here, we report on the biol. characterization of the 2-morpholino pyrimidine deriv. pan-PI3K inhibitor NVP-BKM120.  This compd. inhibits all four class I PI3K isoforms in biochem. assays with at least 50-fold selectivity against other protein kinases.  The compd. is also active against the most common somatic PI3Kα mutations but does not significantly inhibit the related class III (Vps34) and class IV (mTOR, DNA-PK) PI3K kinases.  Consistent with its mechanism of action, NVP-BKM120 decreases the cellular levels of p-Akt in mechanistic models and relevant tumor cell lines, as well as downstream effectors in a concn.-dependent and pathway-specific manner.  Tested in a panel of 353 cell lines, NVP-BKM120 exhibited preferential inhibition of tumor cells bearing PIK3CA mutations, in contrast to either KRAS or PTEN mutant models.  NVP-BKM120 shows dose-dependent in vivo pharmacodynamic activity as measured by significant inhibition of p-Akt and tumor growth inhibition in mechanistic xenograft models.  NVP-BKM120 behaves synergistically when combined with either targeted agents such as MEK or HER2 inhibitors or with cytotoxic agents such as docetaxel or temozolomide.  The pharmacol., biol., and preclin. safety profile of NVP-BKM120 supports its clin. development and the compd. is undergoing phase II clin. trials in patients with cancer.  Mol Cancer Ther; 11(2); 317-28.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps2mNHzJneaLVg90H21EOLACvtfcHk0lhz67AhR-L7GA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFWltb8%253D&md5=4c3b225d45591e9cd49800baa06e8152</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0474&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0474%26sid%3Dliteratum%253Aachs%26aulast%3DMaira%26aufirst%3DS.%2BM.%26aulast%3DPecchi%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DA.%26aulast%3DBurger%26aufirst%3DM.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DSterker%26aufirst%3DD.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DGuthy%26aufirst%3DD.%26aulast%3DNagel%26aufirst%3DT.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DBrachmann%26aufirst%3DS.%26aulast%3DFritsch%26aufirst%3DC.%26aulast%3DDorsch%26aufirst%3DM.%26aulast%3DCh%25C3%25A8ne%26aufirst%3DP.%26aulast%3DShoemaker%26aufirst%3DK.%26aulast%3DDe%2BPover%26aufirst%3DA.%26aulast%3DMenezes%26aufirst%3DD.%26aulast%3DMartiny-Baron%26aufirst%3DG.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DC.%2BJ.%26aulast%3DSchlegel%26aufirst%3DR.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DGarc%25C3%25ADa-Echeverr%25C3%25ADa%26aufirst%3DC.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DVoliva%26aufirst%3DC.%2BF.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520NVP-BKM120%252C%2520an%2520orally%2520available%2520pan-class%2520I%2520PI3-kinase%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D317%26epage%3D328%26doi%3D10.1158%2F1535-7163.MCT-11-0474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bohnacker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prota, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inglis, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sele, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargsten, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhmanova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Díaz, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvelebil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">14683</span>, <span class="refDoi"> DOI: 10.1038/ncomms14683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1038%2Fncomms14683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=28276440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A280%3ADC%252BC1czksV2ruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=14683&author=T.+Bohnackerauthor=A.+E.+Protaauthor=F.+Beaufilsauthor=J.+E.+Burkeauthor=A.+Meloneauthor=A.+J.+Inglisauthor=D.+Rageotauthor=A.+M.+Seleauthor=V.+Cmiljanovicauthor=N.+Cmiljanovicauthor=K.+Bargstenauthor=A.+Aherauthor=A.+Akhmanovaauthor=J.+F.+D%C3%ADazauthor=D.+Fabbroauthor=M.+Zvelebilauthor=R.+L.+Williamsauthor=M.+O.+Steinmetzauthor=M.+P.+Wymann&title=Deconvolution+of+Buparlisib%E2%80%99s+mechanism+of+action+defines+specific+PI3K+and+tubulin+inhibitors+for+therapeutic+intervention&doi=10.1038%2Fncomms14683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention</span></div><div class="casAuthors">Bohnacker Thomas; Beaufils Florent; Melone Anna; Rageot Denise; Sele Alexander M; Cmiljanovic Vladimir; Cmiljanovic Natasa; Wymann Matthias P; Prota Andrea E; Bargsten Katja; Steinmetz Michel O; Burke John E; Inglis Alison J; Williams Roger L; Aher Amol; Akhmanova Anna; Diaz J Fernando; Fabbro Doriano; Zvelebil Marketa</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14683</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BKM120 (Buparlisib) is one of the most advanced phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer, but it interferes as an off-target effect with microtubule polymerization.  Here, we developed two chemical derivatives that differ from BKM120 by only one atom.  We show that these minute changes separate the dual activity of BKM120 into discrete PI3K and tubulin inhibitors.  Analysis of the compounds cellular growth arrest phenotypes and microtubule dynamics suggest that the antiproliferative activity of BKM120 is mainly due to microtubule-dependent cytotoxicity rather than through inhibition of PI3K.  Crystal structures of BKM120 and derivatives in complex with tubulin and PI3K provide insights into the selective mode of action of this class of drugs.  Our results raise concerns over BKM120's generally accepted mode of action, and provide a unique mechanistic basis for next-generation PI3K inhibitors with improved safety profiles and flexibility for use in combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRzPPj8gFbG6HWEEzDrymxmfW6udTcc2eaxPbXu5kKv3Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czksV2ruw%253D%253D&md5=97d27a7d83bf6ab6094a587565f82bf6</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1038%2Fncomms14683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms14683%26sid%3Dliteratum%253Aachs%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DBurke%26aufirst%3DJ.%2BE.%26aulast%3DMelone%26aufirst%3DA.%26aulast%3DInglis%26aufirst%3DA.%2BJ.%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DSele%26aufirst%3DA.%2BM.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DCmiljanovic%26aufirst%3DN.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DAher%26aufirst%3DA.%26aulast%3DAkhmanova%26aufirst%3DA.%26aulast%3DD%25C3%25ADaz%26aufirst%3DJ.%2BF.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DZvelebil%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DDeconvolution%2520of%2520Buparlisib%25E2%2580%2599s%2520mechanism%2520of%2520action%2520defines%2520specific%2520PI3K%2520and%2520tubulin%2520inhibitors%2520for%2520therapeutic%2520intervention%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D14683%26doi%3D10.1038%2Fncomms14683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agoni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basu, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfieri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gambino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guha, C.</span></span> <span> </span><span class="NLM_article-title">Rigosertib is a more effective radiosensitizer than cisplatin in concurrent chemoradiation treatment of cervical carcinoma, in vitro and in vivo</span>. <i>Int. J. Radiat. Oncol., Biol., Phys.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">1180</span>– <span class="NLM_lpage">1187</span>, <span class="refDoi"> DOI: 10.1016/j.ijrobp.2013.12.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ijrobp.2013.12.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=24529717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFejur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2014&pages=1180-1187&author=L.+Agoniauthor=I.+Basuauthor=S.+Guptaauthor=A.+Alfieriauthor=A.+Gambinoauthor=G.+L.+Goldbergauthor=E.+P.+Reddyauthor=C.+Guha&title=Rigosertib+is+a+more+effective+radiosensitizer+than+cisplatin+in+concurrent+chemoradiation+treatment+of+cervical+carcinoma%2C+in+vitro+and+in+vivo&doi=10.1016%2Fj.ijrobp.2013.12.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Rigosertib Is a More Effective Radiosensitizer Than Cisplatin in Concurrent Chemoradiation Treatment of Cervical Carcinoma, In Vitro and In Vivo</span></div><div class="casAuthors">Agoni, Lorenzo; Basu, Indranil; Gupta, Seema; Alfieri, Alan; Gambino, Angela; Goldberg, Gary L.; Reddy, E. Premkumar; Guha, Chandan</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Radiation Oncology, Biology, Physics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1180-1187</span>CODEN:
                <span class="NLM_cas:coden">IOBPD3</span>;
        ISSN:<span class="NLM_cas:issn">0360-3016</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">To compare rigosertib vs. cisplatin as an effective radiosensitizing agent for cervical malignancies.  Rigosertib and cisplatin were tested in cervical cancer cell lines, HeLa and C33A.  A 24-h incubation with rigosertib and cisplatin, before irradn. (2-8 Gy), was used for clonogenic survival assays.  Cell cycle anal. (propidium iodide staining) and DNA damage (γ-H2AX expression) were evaluated by fluorescence-activated cell sorter cytometry.  Rigosertib was also tested in vivo in tumor growth expts. on cervical cancer xenografts.Rigosertib was demonstrated to induce a G2/M block in cancer cells.  Survival curve comparison revealed a dose modification factor, as index of radiosensitization effect, of 1.1-1.3 for cisplatin and 1.4-2.2 for rigosertib.  With 6-Gy irradn., an increase in DNA damage of 15%-25% was achieved in both HeLa and C33A cells with cisplatin pretreatment, and a 71-108% increase with rigosertib pretreatment.  In vivo tumor growth studies demonstrated higher performance of rigosertib when compared with cisplatin, with 53% longer tumor growth delay.Rigosertib was more effective than cisplatin when combined with radiation and caused minimal toxicity.  These data support the need for clin. trials with rigosertib in combination therapy for patients with cervical carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp4WxezwzrXrVg90H21EOLACvtfcHk0lh3cVZe-oPDNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFejur4%253D&md5=e44b7983b086c8d87800c9761b2579bc</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2Fj.ijrobp.2013.12.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijrobp.2013.12.051%26sid%3Dliteratum%253Aachs%26aulast%3DAgoni%26aufirst%3DL.%26aulast%3DBasu%26aufirst%3DI.%26aulast%3DGupta%26aufirst%3DS.%26aulast%3DAlfieri%26aufirst%3DA.%26aulast%3DGambino%26aufirst%3DA.%26aulast%3DGoldberg%26aufirst%3DG.%2BL.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26aulast%3DGuha%26aufirst%3DC.%26atitle%3DRigosertib%2520is%2520a%2520more%2520effective%2520radiosensitizer%2520than%2520cisplatin%2520in%2520concurrent%2520chemoradiation%2520treatment%2520of%2520cervical%2520carcinoma%252C%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DInt.%2520J.%2520Radiat.%2520Oncol.%252C%2520Biol.%252C%2520Phys.%26date%3D2014%26volume%3D88%26spage%3D1180%26epage%3D1187%26doi%3D10.1016%2Fj.ijrobp.2013.12.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatapuram, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallireddigari, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallela, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosenza, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robell, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akula, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, E. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2′,4′,6′-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910. Na): synthesis, structure-activity relationship, and biological activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6254</span>– <span class="NLM_lpage">6276</span>, <span class="refDoi"> DOI: 10.1021/jm200570p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200570p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVegt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6254-6276&author=M.+V.+Reddyauthor=P.+Venkatapuramauthor=M.+R.+Mallireddigariauthor=V.+R.+Pallelaauthor=S.+C.+Cosenzaauthor=K.+A.+Robellauthor=B.+Akulaauthor=B.+S.+Hoffmanauthor=E.+P.+Reddy&title=Discovery+of+a+clinical+stage+multi-kinase+inhibitor+sodium+%28E%29-2-%7B2-methoxy-5-%5B%282%E2%80%B2%2C4%E2%80%B2%2C6%E2%80%B2-trimethoxystyrylsulfonyl%29methyl%5Dphenylamino%7Dacetate+%28ON+01910.+Na%29%3A+synthesis%2C+structure-activity+relationship%2C+and+biological+activity&doi=10.1021%2Fjm200570p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Clinical Stage Multi-Kinase Inhibitor Sodium (E)-2-{2-Methoxy-5-[(2',4',6'-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): Synthesis, Structure-Activity Relationship, and Biological Activity</span></div><div class="casAuthors">Reddy, M. V. Ramana; Venkatapuram, Padmavathi; Mallireddigari, Muralidhar R.; Pallela, Venkat R.; Cosenza, Stephen C.; Robell, Kimberly A.; Akula, Balaiah; Hoffman, Benjamin S.; Reddy, E. Premkumar</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6254-6276</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin D proteins are elevated in many cancer cells, and targeted deletion of cyclin D1 gene in the mammary tissues protects mice from breast cancer.  Accordingly, there is an increasing awareness of this novel nonenzymic target for cancer therapeutics.  We have developed novel, nonalkylating styrylbenzylsulfones that induce cell death in wide variety of cancer cells without affecting the proliferation and survival of normal cells.  The development of styrylbenzylsulfone derivs. followed logically from a tumor cell cytotoxicity screen performed in our lab. that did not have an a priori target profile.  Modifications of some of the precursor mols. led to lead optimization with regard to tumor cell cytotoxicity.  In this report we describe the synthesis and structure-activity relationships of novel, nonalkylating (E)-styrylbenzylsulfones and the development of the novel anticancer agent sodium (E)-2-{2-methoxy-5-[(2',4',6'-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (I) (ON 01910.Na), which is in phase III trials for myelodysplastic syndromes (MDS) assocd. with aberrant expression of cyclin D proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXyWp-VIWe7rVg90H21EOLACvtfcHk0lh3cVZe-oPDNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVegt7vP&md5=216de055e27dc53794018fc1416bc62f</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1021%2Fjm200570p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200570p%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DM.%2BV.%26aulast%3DVenkatapuram%26aufirst%3DP.%26aulast%3DMallireddigari%26aufirst%3DM.%2BR.%26aulast%3DPallela%26aufirst%3DV.%2BR.%26aulast%3DCosenza%26aufirst%3DS.%2BC.%26aulast%3DRobell%26aufirst%3DK.%2BA.%26aulast%3DAkula%26aufirst%3DB.%26aulast%3DHoffman%26aufirst%3DB.%2BS.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DDiscovery%2520of%2520a%2520clinical%2520stage%2520multi-kinase%2520inhibitor%2520sodium%2520%2528E%2529-2-%257B2-methoxy-5-%255B%25282%25E2%2580%25B2%252C4%25E2%2580%25B2%252C6%25E2%2580%25B2-trimethoxystyrylsulfonyl%2529methyl%255Dphenylamino%257Dacetate%2520%2528ON%252001910.%2520Na%2529%253A%2520synthesis%252C%2520structure-activity%2520relationship%252C%2520and%2520biological%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6254%26epage%3D6276%26doi%3D10.1021%2Fjm200570p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Athuluri-Divakar, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasquez-Del Carpio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosenza, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basu, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogt, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulholland, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guha, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, E. P.</span></span> <span> </span><span class="NLM_article-title">A small molecule RAS-mimetic disrupts RAS association with effector proteins to block signaling</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">643</span>– <span class="NLM_lpage">655</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2016.03.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.cell.2016.03.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=27104980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC28XmslShtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2016&pages=643-655&author=S.+K.+Athuluri-Divakarauthor=R.+Vasquez-Del+Carpioauthor=K.+Duttaauthor=S.+J.+Bakerauthor=S.+C.+Cosenzaauthor=I.+Basuauthor=Y.+K.+Guptaauthor=M.+V.+Reddyauthor=L.+Uenoauthor=J.+R.+Hartauthor=P.+K.+Vogtauthor=D.+Mulhollandauthor=C.+Guhaauthor=A.+K.+Aggarwalauthor=E.+P.+Reddy&title=A+small+molecule+RAS-mimetic+disrupts+RAS+association+with+effector+proteins+to+block+signaling&doi=10.1016%2Fj.cell.2016.03.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling</span></div><div class="casAuthors">Athuluri-Divakar, Sai Krishna; Vasquez-Del Carpio, Rodrigo; Dutta, Kaushik; Baker, Stacey J.; Cosenza, Stephen C.; Basu, Indranil; Gupta, Yogesh K.; Reddy, M. V. Ramana; Ueno, Lynn; Hart, Jonathan R.; Vogt, Peter K.; Mulholland, David; Guha, Chandan; Aggarwal, Aneel K.; Reddy, E. Premkumar</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">643-655</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Oncogenic activation of RAS genes via point mutations occurs in 20%-30% of human cancers.  The development of effective RAS inhibitors has been challenging, necessitating new approaches to inhibit this oncogenic protein.  Functional studies have shown that the switch region of RAS interacts with a large no. of effector proteins contg. a common RAS-binding domain (RBD).  Because RBD-mediated interactions are essential for RAS signaling, blocking RBD assocn. with small mols. constitutes an attractive therapeutic approach.  Here, the authors present evidence that rigosertib, a styryl-benzyl sulfone, acts as a RAS-mimetic and interacts with the RBDs of RAF kinases, resulting in their inability to bind to RAS, disruption of RAF activation, and inhibition of the RAS-RAF-MEK pathway.  The authors also find that ribosertib binds to the RBDs of Ral-GDS and PI3Ks.  These results suggest that targeting of RBDs across multiple signaling pathways by rigosertib may represent an effective strategy for inactivation of RAS signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoa5skbfbqCQrVg90H21EOLACvtfcHk0ljgoGj9uTMftA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmslShtbs%253D&md5=c79482e4a9cc6819034dd9117348b8bc</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2016.03.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2016.03.045%26sid%3Dliteratum%253Aachs%26aulast%3DAthuluri-Divakar%26aufirst%3DS.%2BK.%26aulast%3DVasquez-Del%2BCarpio%26aufirst%3DR.%26aulast%3DDutta%26aufirst%3DK.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DCosenza%26aufirst%3DS.%2BC.%26aulast%3DBasu%26aufirst%3DI.%26aulast%3DGupta%26aufirst%3DY.%2BK.%26aulast%3DReddy%26aufirst%3DM.%2BV.%26aulast%3DUeno%26aufirst%3DL.%26aulast%3DHart%26aufirst%3DJ.%2BR.%26aulast%3DVogt%26aufirst%3DP.%2BK.%26aulast%3DMulholland%26aufirst%3DD.%26aulast%3DGuha%26aufirst%3DC.%26aulast%3DAggarwal%26aufirst%3DA.%2BK.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DA%2520small%2520molecule%2520RAS-mimetic%2520disrupts%2520RAS%2520association%2520with%2520effector%2520proteins%2520to%2520block%2520signaling%26jtitle%3DCell%26date%3D2016%26volume%3D165%26spage%3D643%26epage%3D655%26doi%3D10.1016%2Fj.cell.2016.03.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jost, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horlbeck, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krenning, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menchon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stern, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prota, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kampmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhmanova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanenbaum, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissman, J. S.</span></span> <span> </span><span class="NLM_article-title">Combined CRISPRi/a-based chemical genetic screens reveal that rigosertib is a microtubule-destabilizing agent</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">210</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2017.09.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.molcel.2017.09.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=28985505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Wqs77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2017&pages=210-223&author=M.+Jostauthor=Y.+Chenauthor=L.+A.+Gilbertauthor=M.+A.+Horlbeckauthor=L.+Krenningauthor=G.+Menchonauthor=A.+Raiauthor=M.+Y.+Choauthor=J.+J.+Sternauthor=A.+E.+Protaauthor=M.+Kampmannauthor=A.+Akhmanovaauthor=M.+O.+Steinmetzauthor=M.+E.+Tanenbaumauthor=J.+S.+Weissman&title=Combined+CRISPRi%2Fa-based+chemical+genetic+screens+reveal+that+rigosertib+is+a+microtubule-destabilizing+agent&doi=10.1016%2Fj.molcel.2017.09.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent</span></div><div class="casAuthors">Jost, Marco; Chen, Yuwen; Gilbert, Luke A.; Horlbeck, Max A.; Krenning, Lenno; Menchon, Gregory; Rai, Ankit; Cho, Min Y.; Stern, Jacob J.; Prota, Andrea E.; Kampmann, Martin; Akhmanova, Anna; Steinmetz, Michel O.; Tanenbaum, Marvin E.; Weissman, Jonathan S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">210-223.e6</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Chem. libraries paired with phenotypic screens can now readily identify compds. with therapeutic potential.  A central limitation to exploiting these compds., however, has been in identifying their relevant cellular targets.  Here, we present a two-tiered CRISPR-mediated chem.-genetic strategy for target identification: combined genome-wide knockdown and overexpression screening as well as focused, comparative chem.-genetic profiling.  Application of these strategies to rigosertib, a drug in phase 3 clin. trials for high-risk myelodysplastic syndrome whose mol. target had remained controversial, pointed singularly to microtubules as rigosertib's target.  We showed that rigosertib indeed directly binds to and destabilizes microtubules using cell biol., in vitro, and structural approaches.  Finally, expression of tubulin with a structure-guided mutation in the rigosertib-binding pocket conferred resistance to rigosertib, establishing that rigosertib kills cancer cells by destabilizing microtubules.  These results demonstrate the power of our chem.-genetic screening strategies for pinpointing the physiol. relevant targets of chem. agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBsbZCZePrwLVg90H21EOLACvtfcHk0ljgoGj9uTMftA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Wqs77L&md5=115f89a6cc9eef8c3709c06b74109c51</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2017.09.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2017.09.012%26sid%3Dliteratum%253Aachs%26aulast%3DJost%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DGilbert%26aufirst%3DL.%2BA.%26aulast%3DHorlbeck%26aufirst%3DM.%2BA.%26aulast%3DKrenning%26aufirst%3DL.%26aulast%3DMenchon%26aufirst%3DG.%26aulast%3DRai%26aufirst%3DA.%26aulast%3DCho%26aufirst%3DM.%2BY.%26aulast%3DStern%26aufirst%3DJ.%2BJ.%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DKampmann%26aufirst%3DM.%26aulast%3DAkhmanova%26aufirst%3DA.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26aulast%3DTanenbaum%26aufirst%3DM.%2BE.%26aulast%3DWeissman%26aufirst%3DJ.%2BS.%26atitle%3DCombined%2520CRISPRi%252Fa-based%2520chemical%2520genetic%2520screens%2520reveal%2520that%2520rigosertib%2520is%2520a%2520microtubule-destabilizing%2520agent%26jtitle%3DMol.%2520Cell%26date%3D2017%26volume%3D68%26spage%3D210%26epage%3D223%26doi%3D10.1016%2Fj.molcel.2017.09.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, G. S.</span></span> <span> </span><span class="NLM_article-title">The hunting of the Src</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">475</span>, <span class="refDoi"> DOI: 10.1038/35073094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1038%2F35073094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=11389470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD3MXks1agsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=467-475&author=G.+S.+Martin&title=The+hunting+of+the+Src&doi=10.1038%2F35073094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">The hunting of the Src</span></div><div class="casAuthors">Martin, G. Steven</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">467-475</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review, with 120 refs.  The non-receptor tyrosine kinase Src is important for many aspects of cell physiol.  The viral src gene was the 1st retroviral oncogene to be identified, and its cellular counterpart was the 1st protooncogene to be discovered in the vertebrate genome.  Src has been important, not only as an object of study in itself, but also as an entry point into the mol. genetics of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqId3YlI11q77Vg90H21EOLACvtfcHk0ljgoGj9uTMftA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXks1agsLw%253D&md5=36cad805c8b312f84b692efc42b16094</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1038%2F35073094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35073094%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DG.%2BS.%26atitle%3DThe%2520hunting%2520of%2520the%2520Src%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2001%26volume%3D2%26spage%3D467%26epage%3D475%26doi%3D10.1038%2F35073094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frame, M. C.</span></span> <span> </span><span class="NLM_article-title">Src in cancer: deregulation and consequences for cell behaviour</span>. <i>Biochim. Biophys. Acta, Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1602</i></span>,  <span class="NLM_fpage">114</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.1016/S0304-419X(02)00040-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2FS0304-419X%2802%2900040-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=12020799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvVeitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1602&publication_year=2002&pages=114-130&author=M.+C.+Frame&title=Src+in+cancer%3A+deregulation+and+consequences+for+cell+behaviour&doi=10.1016%2FS0304-419X%2802%2900040-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Src in cancer: deregulation and consequences for cell behavior</span></div><div class="casAuthors">Frame, Margaret C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Reviews on Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1602</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">114-130</span>CODEN:
                <span class="NLM_cas:coden">BBACEU</span>;
        ISSN:<span class="NLM_cas:issn">0304-419X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Considerable evidence now implicates elevated expression and/or activity of Src in cancer development.  In cells, endogenous Src is switched from an inactive to an active state by a variety of mechanisms that simultaneously relieve constraints on the kinase and protein-interacting Src homol. (SH) domains.  As a result, Src is translocated to the cell periphery, often to sites of cell adhesion, where myristylation mediates attachment to the inner surface of the plasma membrane.  From these peripheral sites, Src's catalytic activity initiates intracellular signal transduction pathways that influence cell growth and adhesion strength, the latter contributing to control of cell migration.  De-regulation in cancer cells may therefore enhance tumor growth and/or stimulate migratory or invasive potential in cells that would normally be relatively non-motile.  Evidence now exists to suggest that Src may also influence the life or death decisions that cells make during many biol. processes.  Thus, Src modulation in cancer cells can alter cell responses that are often perturbed in cancer.  Consequently, there is optimism that drugs which inhibit Src's kinase activity, or the activity of its downstream effectors, might have profound effects on cancer cell behavior and be useful therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4PUbbCfYCTrVg90H21EOLACvtfcHk0ljgoGj9uTMftA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvVeitLs%253D&md5=ac3f4d59c7979798349ea7f0db807d67</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1016%2FS0304-419X%2802%2900040-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0304-419X%252802%252900040-9%26sid%3Dliteratum%253Aachs%26aulast%3DFrame%26aufirst%3DM.%2BC.%26atitle%3DSrc%2520in%2520cancer%253A%2520deregulation%2520and%2520consequences%2520for%2520cell%2520behaviour%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Rev.%2520Cancer%26date%3D2002%26volume%3D1602%26spage%3D114%26epage%3D130%26doi%3D10.1016%2FS0304-419X%2802%2900040-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smolinski, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clements, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelman, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegab, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutler, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, J. W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fetterly, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnett, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J. Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D. G.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel dual mechanism of action Src signaling and tubulin polymerization inhibitors (KX2–391 and KX2–361)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4704</span>– <span class="NLM_lpage">4719</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00164</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00164" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVCmt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4704-4719&author=M.+P.+Smolinskiauthor=Y.+Buauthor=J.+Clementsauthor=I.+H.+Gelmanauthor=T.+Hegabauthor=D.+L.+Cutlerauthor=J.+W.+S.+Fangauthor=G.+Fetterlyauthor=R.+Kwanauthor=A.+Barnettauthor=J.+Y.+N.+Lauauthor=D.+G.+Hangauer&title=Discovery+of+novel+dual+mechanism+of+action+Src+signaling+and+tubulin+polymerization+inhibitors+%28KX2%E2%80%93391+and+KX2%E2%80%93361%29&doi=10.1021%2Facs.jmedchem.8b00164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361)</span></div><div class="casAuthors">Smolinski, Michael P.; Bu, Yahao; Clements, James; Gelman, Irwin H.; Hegab, Taher; Cutler, David L.; Fang, Jane W. S.; Fetterly, Gerald; Kwan, Rudolf; Barnett, Allen; Lau, Johnson Y. N.; Hangauer, David G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4704-4719</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of potent, peptide site directed, tyrosine kinase inhibitors has remained an elusive goal.  Herein we describe the discovery of two such clin. candidates that inhibit the tyrosine kinase Src.  Compd. 1 is a phase 3 clin. trial candidate that is likely to provide a first in class topical treatment for actinic keratosis (AK) with good efficacy and dramatically less toxicity compared to existing std. therapy.  Compd. 2 is a phase 1 clin. trial candidate that is likely to provide a first in class treatment of malignant glioblastoma and induces 30% long-term complete tumor remission in animal models.  The discovery strategy for these compds. iteratively utilized mol. modeling, along with the synthesis and testing of increasingly elaborated proof of concept compds., until the final clin. candidates were arrived at.  This was followed with mechanism of action (MOA) studies that revealed tubulin polymn. inhibition as the second MOA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY6WD_5NG6-7Vg90H21EOLACvtfcHk0lhauRGL-XSuGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVCmt7k%253D&md5=b35b9fb022675d3d4c37e3ac8225ab67</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00164%26sid%3Dliteratum%253Aachs%26aulast%3DSmolinski%26aufirst%3DM.%2BP.%26aulast%3DBu%26aufirst%3DY.%26aulast%3DClements%26aufirst%3DJ.%26aulast%3DGelman%26aufirst%3DI.%2BH.%26aulast%3DHegab%26aufirst%3DT.%26aulast%3DCutler%26aufirst%3DD.%2BL.%26aulast%3DFang%26aufirst%3DJ.%2BW.%2BS.%26aulast%3DFetterly%26aufirst%3DG.%26aulast%3DKwan%26aufirst%3DR.%26aulast%3DBarnett%26aufirst%3DA.%26aulast%3DLau%26aufirst%3DJ.%2BY.%2BN.%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26atitle%3DDiscovery%2520of%2520novel%2520dual%2520mechanism%2520of%2520action%2520Src%2520signaling%2520and%2520tubulin%2520polymerization%2520inhibitors%2520%2528KX2%25E2%2580%2593391%2520and%2520KX2%25E2%2580%2593361%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4704%26epage%3D4719%26doi%3D10.1021%2Facs.jmedchem.8b00164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padmanabha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moquin, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doweyko, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Fex, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuster, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behnia, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schieven, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wityak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span> <span> </span><span class="NLM_article-title">2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">6819</span>– <span class="NLM_lpage">6832</span>, <span class="refDoi"> DOI: 10.1021/jm060727j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060727j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFSlsLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6819-6832&author=J.+Dasauthor=P.+Chenauthor=D.+Norrisauthor=R.+Padmanabhaauthor=J.+Linauthor=R.+V.+Moquinauthor=Z.+Shenauthor=L.+S.+Cookauthor=A.+M.+Doweykoauthor=S.+Pittauthor=S.+Pangauthor=D.+R.+Shenauthor=Q.+Fangauthor=H.+F.+de+Fexauthor=K.+W.+McIntyreauthor=D.+J.+Shusterauthor=K.+M.+Gilloolyauthor=K.+Behniaauthor=G.+L.+Schievenauthor=J.+Wityakauthor=J.+C.+Barrish&title=2-aminothiazole+as+a+novel+kinase+inhibitor+template.+Structure-activity+relationship+studies+toward+the+discovery+of+N-%282-chloro-6-methylphenyl%29-2-%5B%5B6-%5B4-%282-hydroxyethyl%29-1-+piperazinyl%29%5D-2-methyl-4-pyrimidinyl%5Damino%29%5D-1%2C3-thiazole-5-carboxamide+%28dasatinib%2C+BMS-354825%29+as+a+potent+pan-Src+kinase+inhibitor&doi=10.1021%2Fjm060727j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">2-Aminothiazole as a Novel Kinase Inhibitor Template. Structure-Activity Relationship Studies toward the Discovery of N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a Potent pan-Src Kinase Inhibitor</span></div><div class="casAuthors">Das, Jagabandhu; Chen, Ping; Norris, Derek; Padmanabha, Ramesh; Lin, James; Moquin, Robert V.; Shen, Zhongqi; Cook, Lynda S.; Doweyko, Arthur M.; Pitt, Sidney; Pang, Suhong; Shen, Ding Ren; Fang, Qiong; de Fex, Henry F.; McIntyre, Kim W.; Shuster, David J.; Gillooly, Kathleen M.; Behnia, Kamelia; Schieven, Gary L.; Wityak, John; Barrish, Joel C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6819-6832</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">2-Aminothiazole was discovered as a novel Src family kinase inhibitor template through screening of our internal compd. collection.  Optimization through successive structure-activity relationship iterations identified analogs I [R = 4-(2-hydroxyethyl)piperazino, Q] (Dasatinib, BMS-354825) and I [R = Me]as pan-Src inhibitors with nanomolar to subnanomolar potencies in biochem. and cellular assays.  Mol. modeling was used to construct a putative binding model for Lck inhibition by this class of compds.  The framework of key hydrogen-bond interactions proposed by this model was in agreement with the subsequent, published crystal structure of I [R = Q] bound to structurally similar Abl kinase.  The oral efficacy of this class of inhibitors was demonstrated with I [R = Me] in inhibiting the proinflammatory cytokine IL-2 ex vivo in mice (ED50 ∼ 5 mg/kg) and in reducing TNF levels in an acute murine model of inflammation (90% inhibition in LPS-induced TNFα prodn. when dosed orally at 60 mg/kg, 2 h prior to LPS administration).  The oral efficacy of I [R = Me] was further demonstrated in a chronic model of adjuvant arthritis in rats with established disease when administered orally at 0.3 and 3 mg/kg twice daily.  I [R = Q] is currently in clin. trials for the treatment of chronic myelogenous leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrbDd3Qks9cLVg90H21EOLACvtfcHk0lhauRGL-XSuGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFSlsLrI&md5=9eed66048de7ab90b8a8015385d6f581</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1021%2Fjm060727j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060727j%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DPadmanabha%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DMoquin%26aufirst%3DR.%2BV.%26aulast%3DShen%26aufirst%3DZ.%26aulast%3DCook%26aufirst%3DL.%2BS.%26aulast%3DDoweyko%26aufirst%3DA.%2BM.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DPang%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DFang%26aufirst%3DQ.%26aulast%3Dde%2BFex%26aufirst%3DH.%2BF.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DShuster%26aufirst%3DD.%2BJ.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DBehnia%26aufirst%3DK.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DWityak%26aufirst%3DJ.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26atitle%3D2-aminothiazole%2520as%2520a%2520novel%2520kinase%2520inhibitor%2520template.%2520Structure-activity%2520relationship%2520studies%2520toward%2520the%2520discovery%2520of%2520N-%25282-chloro-6-methylphenyl%2529-2-%255B%255B6-%255B4-%25282-hydroxyethyl%2529-1-%2520piperazinyl%2529%255D-2-methyl-4-pyrimidinyl%255Damino%2529%255D-1%252C3-thiazole-5-carboxamide%2520%2528dasatinib%252C%2520BMS-354825%2529%2520as%2520a%2520potent%2520pan-Src%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6819%26epage%3D6832%26doi%3D10.1021%2Fjm060727j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, I.</span></span> <span> </span><span class="NLM_article-title">Photoaffinity labeling in target- and binding-site identification</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">183</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.4155%2Ffmc.14.152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=25686004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivVegu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=159-183&author=E.+Smithauthor=I.+Collins&title=Photoaffinity+labeling+in+target-+and+binding-site+identification&doi=10.4155%2Ffmc.14.152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Photoaffinity labeling in target- and binding-site identification</span></div><div class="casAuthors">Smith, Ewan; Collins, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">159-183</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Photoaffinity labeling (PAL) using a chem. probe to covalently bind its target in response to activation by light has become a frequently used tool in drug discovery for identifying new drug targets and mol. interactions, and for probing the location and structure of binding sites.  Methods to identify the specific target proteins of hit mols. from phenotypic screens are highly valuable in early drug discovery.  In this review, we summarize the principles of PAL including probe design and exptl. techniques for in vitro and live cell investigations.  We emphasize the need to optimize and validate probes and highlight examples of the successful application of PAL across multiple disease areas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpIXjEh35goLVg90H21EOLACvtfcHk0li-grlEVMFRoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivVegu7c%253D&md5=ca00880405324587a542f19f8bd10d6c</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.152%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DE.%26aulast%3DCollins%26aufirst%3DI.%26atitle%3DPhotoaffinity%2520labeling%2520in%2520target-%2520and%2520binding-site%2520identification%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2015%26volume%3D7%26spage%3D159%26epage%3D183%26doi%3D10.4155%2Ffmc.14.152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Reversible binding of the anticancer drug KXO1 (tirbanibulin) to the colchicine-binding site of β-tubulin explains KXO1’s low clinical toxicity</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>294</i></span>,  <span class="NLM_fpage">18099</span>– <span class="NLM_lpage">18108</span>, <span class="refDoi"> DOI: 10.1074/jbc.RA119.010732</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1074%2Fjbc.RA119.010732" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=31628188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A280%3ADC%252BB3MnpsVaksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=2019&pages=18099-18108&author=L.+Niuauthor=J.+Yangauthor=W.+Yanauthor=Y.+Yuauthor=Y.+Zhengauthor=H.+Yeauthor=Q.+Chenauthor=L.+Chen&title=Reversible+binding+of+the+anticancer+drug+KXO1+%28tirbanibulin%29+to+the+colchicine-binding+site+of+%CE%B2-tubulin+explains+KXO1%E2%80%99s+low+clinical+toxicity&doi=10.1074%2Fjbc.RA119.010732"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Reversible binding of the anticancer drug KXO1 (tirbanibulin) to the colchicine-binding site of β-tubulin explains KXO1's low clinical toxicity</span></div><div class="casAuthors">Niu Lu; Yang Jianhong; Yan Wei; Yu Yamei; Zheng Yunhua; Ye Haoyu; Chen Qiang; Chen Lijuan</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of biological chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">18099-18108</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">KXO1 (tirbanibulin or KX2-391) is as a non-ATP-competitive inhibitor of SRC proto-oncogene nonreceptor tyrosine kinase (SRC) and is being clinically investigated for the management of various cancers and actinic keratosis.  Recently, KXO1 has also been shown to strongly inhibit tubulin.  Interestingly, unlike conventional tubulin-targeting drugs, KXO1 has exhibited low toxicity in preclinical and clinical studies, but the reason for this remains elusive, as are the KXO1-binding site and other details of the interaction of KXO1 with tubulin.  Here, cell-based experiments revealed that KXO1 induces tubulin depolymerization and G2/M phase cell cycle arrest at low nanomolar concentrations, similar to colchicine, used as a positive control.  Results from biochemical experiments, including an N,N-ethylenebis(iodoacetamide) competition assay, disclosed that KXO1 binds to the colchicine-binding site on β-tubulin, further confirmed by the crystal structure of the tubulin-KXO1 complex at 2.5-ÅA resolution.  A high-quality electron density map of the crystallographic data enabled us to unambiguously determine the position and orientation of KXO1 in the colchicine-binding site, revealing the detailed interactions between KXO1 and tubulin.  We also found that KXO1 binds reversibly to purified tubulin, induces a totally reversible cellular effect (G2/M cell cycle arrest), and possesses no cellular toxicity 5 days after drug washout, explaining KXO1's low toxicity.  In summary, we show that KXO1 binds to the colchicine-binding site of tubulin and resolved the crystal structure of the tubulin-KXO1 complex.  Importantly, KXO1's reversible binding to tubulin explains its clinically low toxicity, an insight that could guide further clinical applications of KXO1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQhfWQ2BlTvKJZoeNcnHOQ9fW6udTcc2eaI6TvAjjVAZLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnpsVaksA%253D%253D&md5=b3eac35ef261149a46a2531ff014ced1</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1074%2Fjbc.RA119.010732&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.RA119.010732%26sid%3Dliteratum%253Aachs%26aulast%3DNiu%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DW.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DReversible%2520binding%2520of%2520the%2520anticancer%2520drug%2520KXO1%2520%2528tirbanibulin%2529%2520to%2520the%2520colchicine-binding%2520site%2520of%2520%25CE%25B2-tubulin%2520explains%2520KXO1%25E2%2580%2599s%2520low%2520clinical%2520toxicity%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2019%26volume%3D294%26spage%3D18099%26epage%3D18108%26doi%3D10.1074%2Fjbc.RA119.010732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anbalagan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsden, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowan, B. G.</span></span> <span> </span><span class="NLM_article-title">Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1936</span>– <span class="NLM_lpage">1947</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-0146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1158%2F1535-7163.MCT-12-0146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=22784709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlWhsrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1936-1947&author=M.+Anbalaganauthor=A.+Aliauthor=R.+K.+Jonesauthor=C.+G.+Marsdenauthor=M.+Shengauthor=L.+Carrierauthor=Y.+Buauthor=D.+Hangauerauthor=B.+G.+Rowan&title=Peptidomimetic+Src%2Fpretubulin+inhibitor+KX-01+alone+and+in+combination+with+paclitaxel+suppresses+growth%2C+metastasis+in+human+ER%2FPR%2FHER2-negative+tumor+xenografts&doi=10.1158%2F1535-7163.MCT-12-0146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Peptidomimetic Src/Pretubulin Inhibitor KX-01 Alone and in Combination with Paclitaxel Suppresses Growth, Metastasis in Human ER/PR/HER2-Negative Tumor Xenografts</span></div><div class="casAuthors">Anbalagan, Muralidharan; Ali, Alaa; Jones, Ryan K.; Marsden, Carolyn G.; Sheng, Mei; Carrier, Latonya; Bu, Yahao; Hangauer, David; Rowan, Brian G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1936-1947</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Src kinase is elevated in breast tumors that are ER/PR neg. and do not overexpress HER2, but clin. trials with Src inhibitors have shown little activity.  The present study evaluated preclin. efficacy of a novel peptidomimetic compd., KX-01 (KX2-391), that exhibits dual action as an Src and pretubulin inhibitor.  KX-01 was evaluated as a single-agent and in combination with paclitaxel in MDA-MB-231, MDA-MB-157, and MDA-MB-468 human ER/PR/HER2-neg. breast cancer cells.  Treatments were evaluated by growth/apoptosis, isobologram anal., migration/invasion assays, tumor xenograft vol., metastasis, and measurement of Src, focal adhesion kinase (FAK), microtubules, Ki67, and microvessel d.  KX-01 inhibited cell growth in vitro and in combination with paclitaxel resulted in synergistic growth inhibition.  KX-01 resulted in a dose-dependent inhibition of MDA-MB-231 and MDA-MB-157 tumor xenografts (1 and 5 mg/kg, twice daily).  KX-01 inhibited activity of Src and downstream mediator FAK in tumors that was coincident with reduced proliferation and angiogenesis and increased apoptosis.  KX01 also resulted in microtubule disruption in tumors.  Combination of KX-01 with paclitaxel resulted in significant regression of MDA-MB-231 tumors and reduced metastasis to mouse lung and liver.  KX-01 is a potently active Src/pretubulin inhibitor that inhibits breast tumor growth and metastasis.  As ER/PR/HER2-neg. patients are candidates for paclitaxel therapy, combination with KX-01 may potentiate antitumor efficacy in management of this aggressive breast cancer subtype.  Mol Cancer Ther; 11(9); 1936-47. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTPQgufjmNZ7Vg90H21EOLACvtfcHk0li-grlEVMFRoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlWhsrrI&md5=dd688323209801ec45284d3dc86ead48</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0146%26sid%3Dliteratum%253Aachs%26aulast%3DAnbalagan%26aufirst%3DM.%26aulast%3DAli%26aufirst%3DA.%26aulast%3DJones%26aufirst%3DR.%2BK.%26aulast%3DMarsden%26aufirst%3DC.%2BG.%26aulast%3DSheng%26aufirst%3DM.%26aulast%3DCarrier%26aufirst%3DL.%26aulast%3DBu%26aufirst%3DY.%26aulast%3DHangauer%26aufirst%3DD.%26aulast%3DRowan%26aufirst%3DB.%2BG.%26atitle%3DPeptidomimetic%2520Src%252Fpretubulin%2520inhibitor%2520KX-01%2520alone%2520and%2520in%2520combination%2520with%2520paclitaxel%2520suppresses%2520growth%252C%2520metastasis%2520in%2520human%2520ER%252FPR%252FHER2-negative%2520tumor%2520xenografts%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D1936%26epage%3D1947%26doi%3D10.1158%2F1535-7163.MCT-12-0146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, S. A.</span></span> <span> </span><span class="NLM_article-title">Antitumor effect of KX-01 through inhibiting Src family kinases and mitosis</span>. <i>Cancer Res. Treat</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">643</span>– <span class="NLM_lpage">655</span>, <span class="refDoi"> DOI: 10.4143/crt.2016.168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.4143%2Fcrt.2016.168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=27737538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmvF2rt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2017&pages=643-655&author=S.+Kimauthor=A.+Minauthor=K.+H.+Leeauthor=Y.+Yangauthor=T.+Y.+Kimauthor=J.+M.+Limauthor=S.+J.+Parkauthor=H.+J.+Namauthor=J.+E.+Kimauthor=S.+H.+Songauthor=S.+W.+Hanauthor=D.+Y.+Ohauthor=J.+H.+Kimauthor=T.+Y.+Kimauthor=D.+Hangauerauthor=J.+Y.+Lauauthor=K.+Imauthor=D.+S.+Leeauthor=Y.+J.+Bangauthor=S.+A.+Im&title=Antitumor+effect+of+KX-01+through+inhibiting+Src+family+kinases+and+mitosis&doi=10.4143%2Fcrt.2016.168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor effect of KX-01 through inhibiting Src family kinases and mitosis</span></div><div class="casAuthors">Kim, Seongyeong; Min, Ahrum; Lee, Kyung-Hun; Yang, Yaewon; Kim, Tae-Yong; Lim, Jee Min; Park, So Jung; Nam, Hyun-Jin; Kim, Jung Eun; Song, Sang-Hyun; Han, Sae-Won; Oh, Do-Youn; Kim, Jee Hyun; Kim, Tae-You; Hangauer, David; Lau, Johnson Yiu-Nam; Im, Kyongok; Lee, Dong Soon; Bang, Yung-Jue; Im, Seock-Ah</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">643-655</span>CODEN:
                <span class="NLM_cas:coden">CRTAC2</span>;
        ISSN:<span class="NLM_cas:issn">2005-9256</span>.
    
            (<span class="NLM_cas:orgname">Korean Cancer Association</span>)
        </div><div class="casAbstract">Purpose KX-01 is a novel dual inhibitor of Src and tubulin.  Unlike previous Src inhibitors that failed to show clin. benefit during treatment of breast cancer, KX-01 can potentially overcome the therapeutic limitations of current Src inhibitors through inhibition of both Src and tubulin.  The present study further evaluates the activity and mechanism of KX-01 in vitro and in vivo.  Materials and Methods The antitumor effect of KX-01 in triple neg. breast cancer (TNBC) cell lines was detd. by MTT assay.  Wound healing and immunofluorescence assays were performed to evaluate the action mechanisms of KX-01.  Changes in the cell cycle and mol. changes induced by KX-01 were also evaluated.  A MDA-MB-231 mouse xenograft model was used to demonstrate the in vivo effects.  Results KX-01 effectively inhibited the growth of breast cancer cell lines.  The expression of phospho-Src and proliferative-signaling mols. were down-regulated in KX-01-sensitive TNBC cell lines.  In addn., migration inhibition was obsd. by wound healing assay.  KX-01-induced G2/M cell cycle arrest and increased the aneuploid cell population in KX-01-sensitive cell lines.  Multi-nucleated cells were significantly increased after KX-01 treatment.  Furthermore, KX-01 effectively delayed tumor growth in a MDA-MB-231 mouse xenograft model.  Conclusion KX-01 effectively inhibited cell growth and migration of TNBC cells.  Moreover, this study demonstrated that KX-01 showed antitumor effects through the inhibition of Src signaling and the induction of mitotic catastrophe.  The antitumor effects of KX-01 were also demonstrated in vivo using a mouse xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmHqWoyrQksbVg90H21EOLACvtfcHk0lhS44VFY2K6JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmvF2rt7k%253D&md5=936b6a9d11d1b626394fb0605cdbdf4a</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.4143%2Fcrt.2016.168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4143%252Fcrt.2016.168%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%26aulast%3DMin%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DT.%2BY.%26aulast%3DLim%26aufirst%3DJ.%2BM.%26aulast%3DPark%26aufirst%3DS.%2BJ.%26aulast%3DNam%26aufirst%3DH.%2BJ.%26aulast%3DKim%26aufirst%3DJ.%2BE.%26aulast%3DSong%26aufirst%3DS.%2BH.%26aulast%3DHan%26aufirst%3DS.%2BW.%26aulast%3DOh%26aufirst%3DD.%2BY.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DT.%2BY.%26aulast%3DHangauer%26aufirst%3DD.%26aulast%3DLau%26aufirst%3DJ.%2BY.%26aulast%3DIm%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DD.%2BS.%26aulast%3DBang%26aufirst%3DY.%2BJ.%26aulast%3DIm%26aufirst%3DS.%2BA.%26atitle%3DAntitumor%2520effect%2520of%2520KX-01%2520through%2520inhibiting%2520Src%2520family%2520kinases%2520and%2520mitosis%26jtitle%3DCancer%2520Res.%2520Treat%26date%3D2017%26volume%3D49%26spage%3D643%26epage%3D655%26doi%3D10.4143%2Fcrt.2016.168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradeep, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecot, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottsford-Miller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zand, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennings, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallick, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baggerly, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frumovitz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sood, A. K.</span></span> <span> </span><span class="NLM_article-title">Targeting SRC and tubulin in mucinous ovarian carcinoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">6532</span>– <span class="NLM_lpage">6543</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-1305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1158%2F1078-0432.CCR-13-1305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=24100628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVOitbzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=6532-6543&author=T.+Liuauthor=W.+Huauthor=H.+J.+Daltonauthor=H.+J.+Choiauthor=J.+Huangauthor=Y.+Kangauthor=S.+Pradeepauthor=T.+Miyakeauthor=J.+H.+Songauthor=Y.+Wenauthor=C.+Luauthor=C.+V.+Pecotauthor=J.+Bottsford-Millerauthor=B.+Zandauthor=N.+B.+Jenningsauthor=C.+Ivanauthor=G.+E.+Gallickauthor=K.+A.+Baggerlyauthor=D.+G.+Hangauerauthor=R.+L.+Colemanauthor=M.+Frumovitzauthor=A.+K.+Sood&title=Targeting+SRC+and+tubulin+in+mucinous+ovarian+carcinoma&doi=10.1158%2F1078-0432.CCR-13-1305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Src and Tubulin in Mucinous Ovarian Carcinoma</span></div><div class="casAuthors">Liu, Tao; Hu, Wei; Dalton, Heather J.; Choi, Hyun Jin; Huang, Jie; Kang, Yu; Pradeep, Sunila; Miyake, Takahito; Song, Jian H.; Wen, Yunfei; Lu, Chunhua; Pecot, Chad V.; Bottsford-Miller, Justin; Zand, Behrouz; Jennings, Nicholas B.; Ivan, Cristina; Gallick, Gary E.; Baggerly, Keith A.; Hangauer, David G.; Coleman, Robert L.; Frumovitz, Michael; Sood, Anil K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6532-6543</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: To investigate the antitumor effects of targeting Src and tubulin in mucinous ovarian carcinoma.  Exptl. Design: The in vitro and in vivo effects and mol. mechanisms of KX-01, which inhibits Src pathway and tubulin polymn., were examd. in mucinous ovarian cancer models.  Results: In vitro studies using RMUG-S and RMUG-L cell lines showed that KX-01 inhibited cell proliferation, induced apoptosis, arrested the cell cycle at the G2-M phase, and enhanced the cytotoxicity of oxaliplatin in the KX-01-sensitive cell line, RMUG-S.  In vivo studies showed that KX-01 significantly decreased tumor burden in RMUG-S and RMUG-L mouse models relative to untreated controls, and the effects were greater when KX-01 was combined with oxaliplatin.  KX-01 alone and in combination with oxaliplatin significantly inhibited tumor growth by reducing cell proliferation and inducing apoptosis in vivo.  PTEN knock-in expts. in RMUG-L cells showed improved response to KX-01.  Reverse phase protein array anal. showed that in addn. to blocking downstream mols. of Src family kinases, KX-01 also activated acute stress-inducing mols.  Conclusion: Our results showed that targeting both the Src pathway and tubulin with KX-01 significantly inhibited tumor growth in preclin. mucinous ovarian cancer models, suggesting that this may be a promising therapeutic approach for patients with mucinous ovarian carcinoma.  Clin Cancer Res; 19(23); 6532-43. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGph-wBwf5SGhLVg90H21EOLACvtfcHk0lhS44VFY2K6JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVOitbzM&md5=cea052b1774b6850f996f05a5d02d10b</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-1305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-1305%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DDalton%26aufirst%3DH.%2BJ.%26aulast%3DChoi%26aufirst%3DH.%2BJ.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DY.%26aulast%3DPradeep%26aufirst%3DS.%26aulast%3DMiyake%26aufirst%3DT.%26aulast%3DSong%26aufirst%3DJ.%2BH.%26aulast%3DWen%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DPecot%26aufirst%3DC.%2BV.%26aulast%3DBottsford-Miller%26aufirst%3DJ.%26aulast%3DZand%26aufirst%3DB.%26aulast%3DJennings%26aufirst%3DN.%2BB.%26aulast%3DIvan%26aufirst%3DC.%26aulast%3DGallick%26aufirst%3DG.%2BE.%26aulast%3DBaggerly%26aufirst%3DK.%2BA.%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26aulast%3DColeman%26aufirst%3DR.%2BL.%26aulast%3DFrumovitz%26aufirst%3DM.%26aulast%3DSood%26aufirst%3DA.%2BK.%26atitle%3DTargeting%2520SRC%2520and%2520tubulin%2520in%2520mucinous%2520ovarian%2520carcinoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D6532%26epage%3D6543%26doi%3D10.1158%2F1078-0432.CCR-13-1305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anbalagan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glodowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowan, B. G.</span></span> <span> </span><span class="NLM_article-title">KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">391</span>– <span class="NLM_lpage">409</span>, <span class="refDoi"> DOI: 10.1007/s10549-011-1513-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1007%2Fs10549-011-1513-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=21509526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC38XktFOjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2012&pages=391-409&author=M.+Anbalaganauthor=L.+Carrierauthor=S.+Glodowskiauthor=D.+Hangauerauthor=B.+Shanauthor=B.+G.+Rowan&title=KX-01%2C+a+novel+Src+kinase+inhibitor+directed+toward+the+peptide+substrate+site%2C+synergizes+with+tamoxifen+in+estrogen+receptor+%CE%B1+positive+breast+cancer&doi=10.1007%2Fs10549-011-1513-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer</span></div><div class="casAuthors">Anbalagan, Muralidharan; Carrier, Latonya; Glodowski, Seth; Hangauer, David; Shan, Bin; Rowan, Brian G.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">391-409</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">KX-01 is the first clin. Src inhibitor of the novel peptidomimetic class that targets the peptide substrate site of Src providing more specificity toward Src kinase.  The present study was designed to evaluate the effects of KX-01 as a single agent and in combination with tamoxifen (TAM) on cell growth and apoptosis of ERα pos. breast cancer in vitro and in vivo.  Flow cytometry demonstrated that KX-01 induced cell cycle arrest in G2/M phase.  Immunofluorescent staining for mitotic phase markers and TUNEL staining indicated that cells had arrested in the mitotic phase and mitotic arrested cells were undergoing apoptosis.  KX-01 induced nuclear accumulation of cyclin B1, and activation of CDK1, MPM2, and Cdc25C that is required for progression past the G2/M checkpoint.  Apoptosis resulted from activation of caspases 6, 7, 8, and 9.  Combinational index anal. revealed that combinations of KX-01 with TAM resulted in synergistic growth inhibition of breast cancer cell lines.  KX-01 combined with TAM resulted in decreased ERα phosphorylation at Src-regulated phosphorylation sites serines 118 and 167 that were assocd. with reduced ERα transcriptional activity.  Orally administered KX-01 resulted in a dose dependent growth inhibition of MCF-7 tumor xenografts, and in combination with TAM exhibited synergistic growth inhibition.  Immunohistochem. anal. revealed that combinational treatment reduced angiogenesis, and ERα signaling in tumors compared to either drug alone that may underlie the synergistic tumor growth inhibition.  Combinations of KX-01 with endocrine therapy present a promising new strategy for clin. management of ERα pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDjBSgfh5qJbVg90H21EOLACvtfcHk0lhS44VFY2K6JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktFOjt7Y%253D&md5=e55cc94c076cfd5f38a715c4b55b15dd</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1007%2Fs10549-011-1513-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-011-1513-3%26sid%3Dliteratum%253Aachs%26aulast%3DAnbalagan%26aufirst%3DM.%26aulast%3DCarrier%26aufirst%3DL.%26aulast%3DGlodowski%26aufirst%3DS.%26aulast%3DHangauer%26aufirst%3DD.%26aulast%3DShan%26aufirst%3DB.%26aulast%3DRowan%26aufirst%3DB.%2BG.%26atitle%3DKX-01%252C%2520a%2520novel%2520Src%2520kinase%2520inhibitor%2520directed%2520toward%2520the%2520peptide%2520substrate%2520site%252C%2520synergizes%2520with%2520tamoxifen%2520in%2520estrogen%2520receptor%2520%25CE%25B1%2520positive%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2012%26volume%3D132%26spage%3D391%26epage%3D409%26doi%3D10.1007%2Fs10549-011-1513-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ciesielski, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munich, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teegarden, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smolinski, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clements, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J. Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenstermaker, R. A.</span></span> <span> </span><span class="NLM_article-title">KX2–361: a novel orally bioavailable small molecule dual Src/tubulin inhibitor that provides long term survival in a murine model of glioblastoma</span>. <i>J. Neuro-Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">519</span>– <span class="NLM_lpage">527</span>, <span class="refDoi"> DOI: 10.1007/s11060-018-2992-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1007%2Fs11060-018-2992-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=30238350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslOjsrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2018&pages=519-527&author=M.+J.+Ciesielskiauthor=Y.+Buauthor=S.+A.+Munichauthor=P.+Teegardenauthor=M.+P.+Smolinskiauthor=J.+L.+Clementsauthor=J.+Y.+N.+Lauauthor=D.+G.+Hangauerauthor=R.+A.+Fenstermaker&title=KX2%E2%80%93361%3A+a+novel+orally+bioavailable+small+molecule+dual+Src%2Ftubulin+inhibitor+that+provides+long+term+survival+in+a+murine+model+of+glioblastoma&doi=10.1007%2Fs11060-018-2992-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">KX2-361: a novel orally bioavailable small molecule dual Src/tubulin inhibitor that provides long term survival in a murine model of glioblastoma</span></div><div class="casAuthors">Ciesielski, Michael J.; Bu, Yahao; Munich, Stephan A.; Teegarden, Paola; Smolinski, Michael P.; Clements, James L.; Lau, Johnson Y. N.; Hangauer, David G.; Fenstermaker, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuro-Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">519-527</span>CODEN:
                <span class="NLM_cas:coden">JNODD2</span>;
        ISSN:<span class="NLM_cas:issn">0167-594X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: A major challenge to developing new therapies for patients with malignant brain tumors is that relatively few small mol. anticancer drugs penetrate the blood-brain barrier (BBB) well enough to provide therapeutically effective concns. in brain tissue before drug exposure in non-CNS tissues results in unacceptable toxicity.  Methods: KX2-361, a member of a novel family of compds. with Src-kinase and tubulin polymn. inhibitory activity, demonstrates good oral bioavailability and readily crosses the BBB in mice.  The objective of this study was to investigate the activity of KX2-361 against human and murine glioma cells and assess its therapeutic effect in a syngeneic orthotopic model of glioblastoma.  Results: In addn. to reducing the level of Src autophosphorylation in the GL261 murine glioblastoma cell line, KX2-361 binds directly to tubulin and disrupts microtubule architecture in glioma cells maintained in culture.  Conclusions: The drug is active in vivo against orthotopic GL261 gliomas in syngeneic C57BL/6 mice.  Long term survival is not obsd. in mice lacking an adaptive immune system, indicating that KX2-361 works in concert with the host immune system to control tumor growth and promote long-term survival in the GL261 glioma model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIImeMoLHmy7Vg90H21EOLACvtfcHk0li0MzOY18YlwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslOjsrjM&md5=df3e383df04e08671bd7fc4df6e5d824</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1007%2Fs11060-018-2992-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11060-018-2992-4%26sid%3Dliteratum%253Aachs%26aulast%3DCiesielski%26aufirst%3DM.%2BJ.%26aulast%3DBu%26aufirst%3DY.%26aulast%3DMunich%26aufirst%3DS.%2BA.%26aulast%3DTeegarden%26aufirst%3DP.%26aulast%3DSmolinski%26aufirst%3DM.%2BP.%26aulast%3DClements%26aufirst%3DJ.%2BL.%26aulast%3DLau%26aufirst%3DJ.%2BY.%2BN.%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26aulast%3DFenstermaker%26aufirst%3DR.%2BA.%26atitle%3DKX2%25E2%2580%2593361%253A%2520a%2520novel%2520orally%2520bioavailable%2520small%2520molecule%2520dual%2520Src%252Ftubulin%2520inhibitor%2520that%2520provides%2520long%2520term%2520survival%2520in%2520a%2520murine%2520model%2520of%2520glioblastoma%26jtitle%3DJ.%2520Neuro-Oncol.%26date%3D2018%26volume%3D140%26spage%3D519%26epage%3D527%26doi%3D10.1007%2Fs11060-018-2992-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tainsky, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huebner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croce, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vande
Woude, G. F.</span></span> <span> </span><span class="NLM_article-title">Molecular cloning of a new transforming gene from a chemically transformed human cell line</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>311</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1038/311029a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1038%2F311029a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=6590967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADyaL2cXmt1ersbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=1984&pages=29-33&author=C.+S.+Cooperauthor=M.+Parkauthor=D.+G.+Blairauthor=M.+A.+Tainskyauthor=K.+Huebnerauthor=C.+M.+Croceauthor=G.+F.+Vande%0AWoude&title=Molecular+cloning+of+a+new+transforming+gene+from+a+chemically+transformed+human+cell+line&doi=10.1038%2F311029a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular cloning of a new transforming gene from a chemically transformed human cell line</span></div><div class="casAuthors">Cooper, Colin S.; Park, Morag; Blair, Donald G.; Tainsky, Michael A.; Huebner, Kay; Croce, Carlo M.; Vande Woude, George F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">311</span>
        (<span class="NLM_cas:issue">5981</span>),
    <span class="NLM_cas:pages">29-33</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">Mol. cloning of the transforming gene from a chem. transformed human osteosarcoma-derived cell line enables the gene to be mapped to chromosome 7 (7p11.4-7qter) and by this criterion and by direct hybridization to be unrelated to known oncogenes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP9IGyWhLtabVg90H21EOLACvtfcHk0li0MzOY18YlwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXmt1ersbk%253D&md5=7cf32881870e75ecabce2c8206b31c20</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1038%2F311029a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F311029a0%26sid%3Dliteratum%253Aachs%26aulast%3DCooper%26aufirst%3DC.%2BS.%26aulast%3DPark%26aufirst%3DM.%26aulast%3DBlair%26aufirst%3DD.%2BG.%26aulast%3DTainsky%26aufirst%3DM.%2BA.%26aulast%3DHuebner%26aufirst%3DK.%26aulast%3DCroce%26aufirst%3DC.%2BM.%26aulast%3DVande%2BWoude%26aufirst%3DG.%2BF.%26atitle%3DMolecular%2520cloning%2520of%2520a%2520new%2520transforming%2520gene%2520from%2520a%2520chemically%2520transformed%2520human%2520cell%2520line%26jtitle%3DNature%26date%3D1984%26volume%3D311%26spage%3D29%26epage%3D33%26doi%3D10.1038%2F311029a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Danilkovitch-Miagkova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zbar, B.</span></span> <span> </span><span class="NLM_article-title">Dysregulation of Met receptor tyrosine kinase activity in invasive tumors</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">863</span>– <span class="NLM_lpage">867</span>, <span class="refDoi"> DOI: 10.1172/JCI0215418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1172%2FJCI0215418" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=11927612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD38Xis1Kju74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2002&pages=863-867&author=A.+Danilkovitch-Miagkovaauthor=B.+Zbar&title=Dysregulation+of+Met+receptor+tyrosine+kinase+activity+in+invasive+tumors&doi=10.1172%2FJCI0215418"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Dysregulation of met receptor tyrosine kinase activity in invasive tumors</span></div><div class="casAuthors">Danilkovitch-Miagkova, Alla; Zbar, Berton</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">863-867</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  The oncogenic Met has the ability to mediate chem. induced transformation of a human osteogenic sarcoma cell line.  Met expression has been found in papillary carcinomas of the thyroid gland, in carcinomas of colon, pancreas, and ovary, in osteogenic sarcomas, and in other types of cancer.  Several exptl. and clin. data showed the role of HGF and Met in tumor invasive growth, a stage of tumor progression resulting in metastases.  Dysregulation of Met activity in cells is thought to be a key event underlying tumor metastasis, and Met overexpression and hyperactivation correlated with metastatic ability of the tumor cells.  The mechanisms resulting in dysregulation in tumor cells and the consequences of Met dysregulation by various mechanisms are discussed.  The dysregulated cell motility and the resulting tumor metastasis that follow from inappropriate Met activation involve collaborations with many other receptors and multiple signaling pathways.  Met can function as part of other receptor complexes and can respond to stimuli that do not impinge on it directly.  On the other hand, dysregulated Met may promote activation of these other receptors.  Both kinds of interactions have profound consequences for the invasive growth of tumors and, indeed, of healthy cells and tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2BsZnOEEDt7Vg90H21EOLACvtfcHk0li0MzOY18YlwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xis1Kju74%253D&md5=58373f3f2bf58ce5be1702d7580ba20e</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1172%2FJCI0215418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI0215418%26sid%3Dliteratum%253Aachs%26aulast%3DDanilkovitch-Miagkova%26aufirst%3DA.%26aulast%3DZbar%26aufirst%3DB.%26atitle%3DDysregulation%2520of%2520Met%2520receptor%2520tyrosine%2520kinase%2520activity%2520in%2520invasive%2520tumors%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2002%26volume%3D109%26spage%3D863%26epage%3D867%26doi%3D10.1172%2FJCI0215418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">France, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashwell, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moussa, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leggett, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. J.</span></span> <span> </span><span class="NLM_article-title">ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1544</span>– <span class="NLM_lpage">1553</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-1173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1158%2F1535-7163.MCT-09-1173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=20484018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntFGgsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=1544-1553&author=N.+Munshiauthor=S.+Jeayauthor=Y.+Liauthor=C.+R.+Chenauthor=D.+S.+Franceauthor=M.+A.+Ashwellauthor=J.+Hillauthor=M.+M.+Moussaauthor=D.+S.+Leggettauthor=C.+J.+Li&title=ARQ+197%2C+a+novel+and+selective+inhibitor+of+the+human+c-Met+receptor+tyrosine+kinase+with+antitumor+activity&doi=10.1158%2F1535-7163.MCT-09-1173"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity</span></div><div class="casAuthors">Munshi, Neru; Jeay, Sebastien; Li, Youzhi; Chen, Chang-Rung; France, Dennis S.; Ashwell, Mark A.; Hill, Jason; Moussa, Magdi M.; Leggett, David S.; Li, Chiang J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1544-1553</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The met proto-oncogene is functionally linked with tumorigenesis and metastatic progression.  Validation of the receptor tyrosine kinase c-Met as a selective anticancer target has awaited the emergence of selective c-Met inhibitors.  Herein, we report ARQ 197 as the first non-ATP-competitive small mol. that selectively targets the c-Met receptor tyrosine kinase.  Exposure to ARQ 197 resulted in the inhibition of proliferation of c-Met-expressing cancer cell lines as well as the induction of caspase-dependent apoptosis in cell lines with constitutive c-Met activity.  These cellular responses to ARQ 197 were phenocopied by RNAi-mediated c-Met depletion and further demonstrated by the growth inhibition of human tumors following oral administration of ARQ 197 in multiple mouse xenograft efficacy studies.  Cumulatively, these data suggest that ARQ 197, currently in phase II clin. trials, is a promising agent for targeting cancers in which c-Met-driven signaling is important for their survival and proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxYa8M1T1wfLVg90H21EOLACvtfcHk0lgow2_hhx4R5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntFGgsL0%253D&md5=2fd9c4ad5be6e1a119f2aa9699bb9519</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-1173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-1173%26sid%3Dliteratum%253Aachs%26aulast%3DMunshi%26aufirst%3DN.%26aulast%3DJeay%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DC.%2BR.%26aulast%3DFrance%26aufirst%3DD.%2BS.%26aulast%3DAshwell%26aufirst%3DM.%2BA.%26aulast%3DHill%26aufirst%3DJ.%26aulast%3DMoussa%26aufirst%3DM.%2BM.%26aulast%3DLeggett%26aufirst%3DD.%2BS.%26aulast%3DLi%26aufirst%3DC.%2BJ.%26atitle%3DARQ%2520197%252C%2520a%2520novel%2520and%2520selective%2520inhibitor%2520of%2520the%2520human%2520c-Met%2520receptor%2520tyrosine%2520kinase%2520with%2520antitumor%2520activity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D1544%26epage%3D1553%26doi%3D10.1158%2F1535-7163.MCT-09-1173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adjei, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garmey, E.</span></span> <span> </span><span class="NLM_article-title">Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">788</span>– <span class="NLM_lpage">799</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.2010-0380</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1634%2Ftheoncologist.2010-0380" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=21632449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlSkt7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=788-799&author=A.+A.+Adjeiauthor=B.+Schwartzauthor=E.+Garmey&title=Early+clinical+development+of+ARQ+197%2C+a+selective%2C+non-ATP-competitive+inhibitor+targeting+MET+tyrosine+kinase+for+the+treatment+of+advanced+cancers&doi=10.1634%2Ftheoncologist.2010-0380"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers</span></div><div class="casAuthors">Adjei, Alex A.; Schwartz, Brian; Garmey, Edward</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">788-799</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">A review.  Expression of the receptor tyrosine kinase c-MET (MET, mesenchymal-epithelial transition factor) in many cancers, and its participation in multiple signal transduction pathways involved in malignant tumor growth, suggest a wide therapeutic potential for MET inhibition in human cancer.  Here we describe the discovery and early clin. development of ARQ 197, a novel, selective, non-ATP-competitive inhibitor of MET.  Phase I studies demonstrate that ARQ 197 has a predictable pharmacokinetics and favorable safety profile, making it a potentially ideal partner for combination with cytotoxic chemotherapies and targeted anticancer agents.  Results from phase I and phase II trials demonstrate preliminary evidence of anticancer activity.  New data from a global phase II randomized trial comparing a combination of ARQ 197 plus erlotinib with erlotinib/placebo, in endothelial growth factor receptor inhibitor-naive patients with locally advanced/metastatic non-small cell lung cancer, demonstrate improvement in progression-free and overall survival with combined therapy.  Results were esp. pronounced for patients with non-squamous lung cancer histologies, and in particular molecularly defined subgroups including KRAS mutations.  These and other data from ARQ 197 clin. trials in hepatocellular, germ-cell, pancreatic (in combination with gemcitabine), and colorectal (in combination with cetuximab and irinotecan) cancers further highlight the potential role of ARQ 197 in existing and emerging anticancer therapeutic regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqjgY3d_H9lrVg90H21EOLACvtfcHk0lgow2_hhx4R5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlSkt7nK&md5=d2c0a70dcb044937bbb938e5d9f8b5d4</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2010-0380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2010-0380%26sid%3Dliteratum%253Aachs%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DGarmey%26aufirst%3DE.%26atitle%3DEarly%2520clinical%2520development%2520of%2520ARQ%2520197%252C%2520a%2520selective%252C%2520non-ATP-competitive%2520inhibitor%2520targeting%2520MET%2520tyrosine%2520kinase%2520for%2520the%2520treatment%2520of%2520advanced%2520cancers%26jtitle%3DOncologist%26date%3D2011%26volume%3D16%26spage%3D788%26epage%3D799%26doi%3D10.1634%2Ftheoncologist.2010-0380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laux, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savage, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garmey, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Just, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, L. S.</span></span> <span> </span><span class="NLM_article-title">Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">5903</span>– <span class="NLM_lpage">5911</span>, <span class="refDoi"> DOI: 10.1002/cncr.27575</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1002%2Fcncr.27575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=22605616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs12itLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2012&pages=5903-5911&author=J.+W.+Goldmanauthor=I.+Lauxauthor=F.+Chaiauthor=R.+E.+Savageauthor=D.+Ferrariauthor=E.+G.+Garmeyauthor=R.+G.+Justauthor=L.+S.+Rosen&title=Phase+1+dose-escalation+trial+evaluating+the+combination+of+the+selective+MET+%28mesenchymal-epithelial+transition+factor%29+inhibitor+tivantinib+%28ARQ+197%29+plus+erlotinib&doi=10.1002%2Fcncr.27575"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib</span></div><div class="casAuthors">Goldman, Jonathan W.; Laux, Isett; Chai, Feng; Savage, Ronald E.; Ferrari, Dora; Garmey, Edward G.; Just, Richard G.; Rosen, Lee S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5903-5911</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">BACKGROUND: : Amplification of the mesenchymal-epithelial transition factor (MET) gene can promote tumor resistance to epidermal growth factor receptor (EGFR) inhibition.  Dual EGFR-MET inhibition may overcome this resistance.  Tivantinib (ARQ 197) is a selective, oral, non-ATP-competitive, small-mol. inhibitor of the MET receptor tyrosine kinase.  This phase 1 trial assessed the safety, pharmacokinetics, and preliminary antitumor activity of tivantinib combined with the EGFR inhibitor erlotinib.  METHODS: : Patients with advanced solid malignancies were administered oral tivantinib at escalating doses of 120, 240, 360, and 480 mg twice daily (BID) plus 150 mg erlotinib once daily (QD).  Single or multiple intrapatient dose escalation was planned in the absence of dose-limiting toxicity in the first cycle of therapy (21 days).  RESULTS: : Thirty-two patients received combination treatment.  Tivantinib serum concns. were not dose-proportional.  The most common (≥20%) adverse events (AEs) regardless of causality included rash (n = 17), fatigue (n = 12), nausea (n = 10), abdominal pain (n = 10), diarrhea (n = 9), bradycardia (n = 9), and anemia (n = 7).  AEs considered related to study treatment occurred in 28 patients (87.5%), and 5 patients (15.6%) had treatment-related serious AEs, including neutropenia, leukopenia, syncope, sinus bradycardia, and sick sinus syndrome.  Fifteen of 32 patients (46.8%) had a partial response (n = 1) or stable disease (n = 14) as assessed by Response Evaluation Criteria in Solid Tumors.  Six of 8 patients with nonsmall cell lung cancer achieved stable disease.  The recommended phase 2 dose is tivantinib 360 mg BID plus erlotinib 150 mg QD.  CONCLUSIONS: : Tivantinib plus erlotinib was well tolerated with encouraging clin. activity, esp. in patients with nonsmall cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGos__Hafq2fDLVg90H21EOLACvtfcHk0lgow2_hhx4R5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs12itLnL&md5=22a89a1273b9c4919236a0bc689f28a3</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1002%2Fcncr.27575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.27575%26sid%3Dliteratum%253Aachs%26aulast%3DGoldman%26aufirst%3DJ.%2BW.%26aulast%3DLaux%26aufirst%3DI.%26aulast%3DChai%26aufirst%3DF.%26aulast%3DSavage%26aufirst%3DR.%2BE.%26aulast%3DFerrari%26aufirst%3DD.%26aulast%3DGarmey%26aufirst%3DE.%2BG.%26aulast%3DJust%26aufirst%3DR.%2BG.%26aulast%3DRosen%26aufirst%3DL.%2BS.%26atitle%3DPhase%25201%2520dose-escalation%2520trial%2520evaluating%2520the%2520combination%2520of%2520the%2520selective%2520MET%2520%2528mesenchymal-epithelial%2520transition%2520factor%2529%2520inhibitor%2520tivantinib%2520%2528ARQ%2520197%2529%2520plus%2520erlotinib%26jtitle%3DCancer%26date%3D2012%26volume%3D118%26spage%3D5903%26epage%3D5911%26doi%3D10.1002%2Fcncr.27575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoyama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh-Hara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, N.</span></span> <span> </span><span class="NLM_article-title">Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">3087</span>– <span class="NLM_lpage">3096</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-12-3256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1158%2F0008-5472.CAN-12-3256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=23598276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsFejsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=3087-3096&author=R.+Katayamaauthor=A.+Aoyamaauthor=T.+Yamoriauthor=J.+Qiauthor=T.+Oh-Haraauthor=Y.+Songauthor=J.+A.+Engelmanauthor=N.+Fujita&title=Cytotoxic+activity+of+tivantinib+%28ARQ+197%29+is+not+due+solely+to+c-MET+inhibition&doi=10.1158%2F0008-5472.CAN-12-3256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition</span></div><div class="casAuthors">Katayama, Ryohei; Aoyama, Aki; Yamori, Takao; Qi, Jie; Oh-hara, Tomoko; Song, Youngchul; Engelman, Jeffrey A.; Fujita, Naoya</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3087-3096</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase c-MET is the high-affinity receptor for the hepatocyte growth factor (HGF).  The HGF/c-MET axis is often dysregulated in tumors. c-MET activation can be caused by MET gene amplification, activating mutations, and auto- or paracrine mechanisms.  Thus, c-MET inhibitors are under development as anticancer drugs.  Tivantinib (ARQ 197) was reported as a small-mol. c-MET inhibitor and early clin. studies suggest antitumor activity.  To assess whether the antitumor activity of tivantinib was due to inhibition of c-MET, we compared the activity of tivantinib with other c-MET inhibitors in both c-MET-addicted and nonaddicted cancer cells.  As expected, other c-MET inhibitors, crizotinib and PHA-665752, suppressed the growth of c-MET-addicted cancers, but not the growth of cancers that are not addicted to c-MET.  In contrast, tivantinib inhibited cell viability with similar potency in both c-MET-addicted and nonaddicted cells.  These results suggest that tivantinib exhibits its antitumor activity in a manner independent of c-MET status.  Tivantinib treatment induced a G2-M cell-cycle arrest in EBC1 cells similarly to vincristine treatment, whereas PHA-665752 or crizotinib treatment markedly induced G0-G1 cell-cycle arrest.  To identify the addnl. mol. target of tivantinib, we conducted COMPARE anal., an in silico screening of a database of drug sensitivities across 39 cancer cell lines (JFCR39), and identified microtubule as a target of tivantinib.  Tivantinib-treated cells showed typical microtubule disruption similar to vincristine and inhibited microtubule assembly in vitro.  These results suggest that tivantinib inhibits microtubule polymn. in addn. to inhibiting c-MET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTD-_8Jg3bHbVg90H21EOLACvtfcHk0lhBsmAHbcxjPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsFejsb4%253D&md5=dea0d14f1c5e1739064899f2f7e85257</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-12-3256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-12-3256%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DAoyama%26aufirst%3DA.%26aulast%3DYamori%26aufirst%3DT.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DOh-Hara%26aufirst%3DT.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DFujita%26aufirst%3DN.%26atitle%3DCytotoxic%2520activity%2520of%2520tivantinib%2520%2528ARQ%2520197%2529%2520is%2520not%2520due%2520solely%2520to%2520c-MET%2520inhibition%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D3087%26epage%3D3096%26doi%3D10.1158%2F0008-5472.CAN-12-3256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gigant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery</span>. <i>FEBS J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">102</span>– <span class="NLM_lpage">111</span>, <span class="refDoi"> DOI: 10.1111/febs.13555</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1111%2Ffebs.13555" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=26462166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKktrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2016&pages=102-111&author=Y.+Wangauthor=H.+Zhangauthor=B.+Gigantauthor=Y.+Yuauthor=Y.+Wuauthor=X.+Chenauthor=Q.+Laiauthor=Z.+Yangauthor=Q.+Chenauthor=J.+Yang&title=Structures+of+a+diverse+set+of+colchicine+binding+site+inhibitors+in+complex+with+tubulin+provide+a+rationale+for+drug+discovery&doi=10.1111%2Ffebs.13555"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery</span></div><div class="casAuthors">Wang, Yuxi; Zhang, Hang; Gigant, Benoit; Yu, Yamei; Wu, Yangping; Chen, Xiangzheng; Lai, Qinhuai; Yang, Zhaoya; Chen, Qiang; Yang, Jinliang</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">102-111</span>CODEN:
                <span class="NLM_cas:coden">FJEOAC</span>;
        ISSN:<span class="NLM_cas:issn">1742-464X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Microtubules are dynamic assemblies of αβ-tubulin heterodimers and have been recognized as highly attractive targets for cancer chemotherapy.  A broad range of agents bind to tubulin and interfere with microtubule assembly.  Despite having a long history of characterization, colchicine binding site inhibitors (CBSIs) have not yet reached the com. phase as anti-cancer drugs to date.  We detd. the structures of tubulin complexed with a set of structurally diverse CBSIs (lexibulin, nocodazole, plinabulin and tivantinib), among which nocodazole and tivantinib are both binary-function inhibitors targeting cancer-related kinases and microtubules simultaneously.  High resoln. structures revealed the detailed interactions between these ligands and tubulin.  Our results showed that the binding modes of the CBSIs were different from previous docking models, highlighting the importance of crystal structure information in structure-based drug design.  A real structure-based pharmacophore was proposed to rationalize key common interactions of the CBSIs at the colchicine domain.  Our studies provide a solid structural basis for developing new anti-cancer agents for the colchicine binding site.  Database : The at. coordinates and structure factors for tubulin complexed with lexibulin, nocodazole, plinabulin and tivantinib have been deposited in the Protein Data Bank under accession codes , , and , resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSIAVSS_EsIbVg90H21EOLACvtfcHk0lhBsmAHbcxjPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKktrzP&md5=d5a17d9a3ac54d8eda44d0543ffa5fbd</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1111%2Ffebs.13555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Ffebs.13555%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DGigant%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLai%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DStructures%2520of%2520a%2520diverse%2520set%2520of%2520colchicine%2520binding%2520site%2520inhibitors%2520in%2520complex%2520with%2520tubulin%2520provide%2520a%2520rationale%2520for%2520drug%2520discovery%26jtitle%3DFEBS%2520J.%26date%3D2016%26volume%3D283%26spage%3D102%26epage%3D111%26doi%3D10.1111%2Ffebs.13555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eathiraj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volckova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirschi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">France, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashwell, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, T. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>286</i></span>,  <span class="NLM_fpage">20666</span>– <span class="NLM_lpage">20676</span>, <span class="refDoi"> DOI: 10.1074/jbc.M110.213801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1074%2Fjbc.M110.213801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=21454604" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFCgtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=20666-20676&author=S.+Eathirajauthor=R.+Palmaauthor=E.+Volckovaauthor=M.+Hirschiauthor=D.+S.+Franceauthor=M.+A.+Ashwellauthor=T.+C.+Chan&title=Discovery+of+a+novel+mode+of+protein+kinase+inhibition+characterized+by+the+mechanism+of+inhibition+of+human+mesenchymal-epithelial+transition+factor+%28c-Met%29+protein+autophosphorylation+by+ARQ+197&doi=10.1074%2Fjbc.M110.213801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel Mode of Protein Kinase Inhibition Characterized by the Mechanism of Inhibition of Human Mesenchymal-epithelial Transition Factor (c-Met) Protein Autophosphorylation by ARQ 197</span></div><div class="casAuthors">Eathiraj, Sudharshan; Palma, Rocio; Volckova, Erika; Hirschi, Marscha; France, Dennis S.; Ashwell, Mark A.; Chan, Thomas C. K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">20666-20676</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A no. of human malignancies exhibit sustained stimulation, mutation, or gene amplification of the receptor tyrosine kinase human mesenchymal-epithelial transition factor c-Met.  ARQ 197 is a clin. advanced, selective, orally bioavailable, and well tolerated c-Met inhibitor, currently in Phase 3 clin. testing in non-small cell lung cancer patients.  Herein, the authors describe the mol. and structural basis by which ARQ 197 selectively targets c-Met.  Through the authors' anal. the authors reveal a previously undisclosed, novel inhibitory mechanism that utilizes distinct regulatory elements of the c-Met kinase.  The structure of ARQ 197 in complex with the c-Met kinase domain shows that the inhibitor binds a conformation that is distinct from published kinase structures.  ARQ 197 inhibits c-Met autophosphorylation and is highly selective for the inactive or unphosphorylated form of c-Met.  Through the authors' anal. of the interplay between the regulatory and catalytic residues of c-Met, and by comparison between the autoinhibited canonical conformation of c-Met bound by ARQ 197 to previously described kinase domains of type III receptor tyrosine kinases, the authors believe this to be the basis of a powerful new in silico approach for the design of similar inhibitors for other protein kinases of therapeutic interest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY0thp4qAFF7Vg90H21EOLACvtfcHk0lhalBA2UKRtHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFCgtbo%253D&md5=e7cf95b0bd6893514fd9a1c726ad71b9</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M110.213801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M110.213801%26sid%3Dliteratum%253Aachs%26aulast%3DEathiraj%26aufirst%3DS.%26aulast%3DPalma%26aufirst%3DR.%26aulast%3DVolckova%26aufirst%3DE.%26aulast%3DHirschi%26aufirst%3DM.%26aulast%3DFrance%26aufirst%3DD.%2BS.%26aulast%3DAshwell%26aufirst%3DM.%2BA.%26aulast%3DChan%26aufirst%3DT.%2BC.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520mode%2520of%2520protein%2520kinase%2520inhibition%2520characterized%2520by%2520the%2520mechanism%2520of%2520inhibition%2520of%2520human%2520mesenchymal-epithelial%2520transition%2520factor%2520%2528c-Met%2529%2520protein%2520autophosphorylation%2520by%2520ARQ%2520197%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26spage%3D20666%26epage%3D20676%26doi%3D10.1074%2Fjbc.M110.213801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ye, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choueiri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logothetis, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu-Lee, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. H.</span></span> <span> </span><span class="NLM_article-title">Aberrant expression of katanin p60 in prostate cancer bone metastasis</span>. <i>Prostate</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">291</span>– <span class="NLM_lpage">300</span>, <span class="refDoi"> DOI: 10.1002/pros.21431</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1002%2Fpros.21431" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=21681775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjsl2itA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=291-300&author=X.+Yeauthor=Y.+C.+Leeauthor=M.+Choueiriauthor=K.+Chuauthor=C.+F.+Huangauthor=W.+W.+Tsaiauthor=R.+Kobayashiauthor=C.+J.+Logothetisauthor=L.+Y.+Yu-Leeauthor=S.+H.+Lin&title=Aberrant+expression+of+katanin+p60+in+prostate+cancer+bone+metastasis&doi=10.1002%2Fpros.21431"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Aberrant expression of katanin p60 in prostate cancer bone metastasis</span></div><div class="casAuthors">Ye, Xiangcang; Lee, Yu-Chen; Choueiri, Michel; Chu, Khoi; Huang, Chih-Fen; Tsai, Wen-Wei; Kobayashi, Ryuji; Logothetis, Christopher J.; Yu-Lee, Li-Yuan; Lin, Sue-Hwa</div><div class="citationInfo"><span class="NLM_cas:title">Prostate (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">291-300</span>CODEN:
                <span class="NLM_cas:coden">PRSTDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-4137</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Katanin p60 is a microtubule-severing protein and is involved in microtubule cytoskeleton organization in both mitotic and non-mitotic processes.  Its role in cancer metastasis is unknown.  Differential protein profiles of bone marrow aspirates were analyzed by chromatog., electrophoresis, and mass spectrometry.  Expression of katanin p60 in primary and metastatic prostate cancer was examd. by immunohistochem.  Cellular function of katanin p60 was further examd. in prostate cell lines.  In a proteomic profiling of bone marrow aspirates from men with prostate cancer, we found that katanin p60 was one of the proteins differentially expressed in bone metastasis samples.  Immunohistochem. staining showed that katanin p60 was expressed in the basal cells in normal human prostate glands.  In prostatic adenocarcinomas, in which the basal cells were absent, katanin p60 was expressed in the prostate cancer cells.  In the specimens from bone metastasis, katanin p60 was detectable in the metastatic cancer cells.  Strikingly, some of the metastatic cancer cells also co-expressed basal cell biomarkers including the tumor suppressor p53-homologous protein p63 and the high mol. wt. cytokeratins, suggesting that the metastatic prostate cancer cells may have a basal cell-like phenotype.  Moreover, overexpression of katanin p60 inhibited prostate cancer cell proliferation but enhanced cell migration activity.  Katanin p60 was aberrantly expressed during prostate cancer progression.  Its expression in the metastatic cells in bone was assocd. with the re-emergence of a basal cell-like phenotype.  The elevated katanin p60 expression may contribute to cancer cell metastasis via a stimulatory effect on cell motility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9sgS_WA-2CbVg90H21EOLACvtfcHk0lhalBA2UKRtHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjsl2itA%253D%253D&md5=f1d4077463247cff8591da9126e1adc7</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1002%2Fpros.21431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpros.21431%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DX.%26aulast%3DLee%26aufirst%3DY.%2BC.%26aulast%3DChoueiri%26aufirst%3DM.%26aulast%3DChu%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DC.%2BF.%26aulast%3DTsai%26aufirst%3DW.%2BW.%26aulast%3DKobayashi%26aufirst%3DR.%26aulast%3DLogothetis%26aufirst%3DC.%2BJ.%26aulast%3DYu-Lee%26aufirst%3DL.%2BY.%26aulast%3DLin%26aufirst%3DS.%2BH.%26atitle%3DAberrant%2520expression%2520of%2520katanin%2520p60%2520in%2520prostate%2520cancer%2520bone%2520metastasis%26jtitle%3DProstate%26date%3D2012%26volume%3D72%26spage%3D291%26epage%3D300%26doi%3D10.1002%2Fpros.21431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sudo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maru, Y.</span></span> <span> </span><span class="NLM_article-title">LAPSER1 is a putative cytokinetic tumor suppressor that shows the same centrosome and midbody subcellular localization pattern as p80 katanin</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2086</span>– <span class="NLM_lpage">2100</span>, <span class="refDoi"> DOI: 10.1096/fj.06-7254com</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1096%2Ffj.06-7254com" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=17351128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnvVagsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=2086-2100&author=H.+Sudoauthor=Y.+Maru&title=LAPSER1+is+a+putative+cytokinetic+tumor+suppressor+that+shows+the+same+centrosome+and+midbody+subcellular+localization+pattern+as+p80+katanin&doi=10.1096%2Ffj.06-7254com"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">LAPSER1 is a putative cytokinetic tumor suppressor that shows the same centrosome and midbody subcellular localization pattern as p80 katanin</span></div><div class="casAuthors">Sudo, Haruka; Maru, Yoshiro</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2086-2100, 10.1096/fj.06-7254com</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Prostate cancer is one of the most common cancers in men, with more than 500,000 new worldwide cases reported annually, resulting in 200,000 deaths of mainly older men in developed countries.  Existing treatments have not proved very effective in managing prostate cancer, and continuing efforts therefore are ongoing to explore novel targets and strategies for future therapies.  LAPSER1 has been identified as a candidate tumor suppressor gene in prostate cancer, but its true functions remain unknown.  We report here that LAPSER1 colocalizes to the centrosomes and mid-bodies in mitotic cells with γ-tubulin, MKLP1, and p80 katanin, and is involved in cytokinesis.  Moreover, RNAi-mediated disruption of LAPSER1, which is accompanied by the mislocalization of p80 katanin, results in malformation of the central spindle.  Significantly, the enhanced expression of LAPSER1 induces binucleation and renders the cells resistant to oncogenic transformation.  In cells transformed by the v-Fps oncogene, overexpressed LAPSER1 induces abortive cytokinesis, followed by mitotic catastrophe in a p80 katanin-dependent manner.  Cells that are rescued from this apoptotic pathway with Z-VAD-fmk display karyokinesis.  These results suggest that LAPSER1 participates in cytokinesis by interacting with p80 katanin, the disruption of which may potentially cause genetic instability and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6HEJ2ibPbU7Vg90H21EOLACvtfcHk0lhalBA2UKRtHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnvVagsL8%253D&md5=d615348025024af922cb3d487f08e641</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1096%2Ffj.06-7254com&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.06-7254com%26sid%3Dliteratum%253Aachs%26aulast%3DSudo%26aufirst%3DH.%26aulast%3DMaru%26aufirst%3DY.%26atitle%3DLAPSER1%2520is%2520a%2520putative%2520cytokinetic%2520tumor%2520suppressor%2520that%2520shows%2520the%2520same%2520centrosome%2520and%2520midbody%2520subcellular%2520localization%2520pattern%2520as%2520p80%2520katanin%26jtitle%3DFASEB%2520J.%26date%3D2007%26volume%3D21%26spage%3D2086%26epage%3D2100%26doi%3D10.1096%2Ffj.06-7254com" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. C.</span></span> <span> </span><span class="NLM_article-title">Purine-type compounds induce microtubule fragmentation and lung cancer cell death through interaction with katanin</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8521</span>– <span class="NLM_lpage">8534</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00797</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00797" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOgtrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8521-8534&author=T.+C.+Kuoauthor=L.+W.+Liauthor=S.+H.+Panauthor=J.+M.+Fangauthor=J.+H.+Liuauthor=T.+J.+Chengauthor=C.+J.+Wangauthor=P.+F.+Hungauthor=H.+Y.+Chenauthor=T.+M.+Hongauthor=Y.+L.+Hsuauthor=C.+H.+Wongauthor=P.+C.+Yang&title=Purine-type+compounds+induce+microtubule+fragmentation+and+lung+cancer+cell+death+through+interaction+with+katanin&doi=10.1021%2Facs.jmedchem.6b00797"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Purine-Type Compounds Induce Microtubule Fragmentation and Lung Cancer Cell Death through Interaction with Katanin</span></div><div class="casAuthors">Kuo, Ting-Chun; Li, Ling-Wei; Pan, Szu-Hua; Fang, Jim-Min; Liu, Jyung-Hurng; Cheng, Ting-Jen; Wang, Chia-Jen; Hung, Pei-Fang; Chen, Hsuan-Yu; Hong, Tse-Ming; Hsu, Yuan-Ling; Wong, Chi-Huey; Yang, Pan-Chyr</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8521-8534</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Microtubule targeting agents (MTAs) constitute a class of drugs for cancer treatment.  Despite many MTAs have been proven to significantly improve the treatment outcomes of various malignancies, resistance has usually occurred.  By selection from a 2-million entry chem. library based on the efficacy and safety, the authors identified purine-type compds. that were active against lung small cell lung cancer (NSCLC).  The purine compd. I (GRC0321) was an MTA with good effects against NSCLC.  Lung cancer cells H1975 treated with I could induce microtubule fragmentation, leading to G2/M cell cycle arrest and intrinsic apoptosis.  Compd. I directly targeted katanin and regulated the severing activity of katanin, which cut the cellular microtubules into short pieces and activated c-Jun N-terminal kinases (JNK).  The microtubule fragmenting effect of I is a unique mechanism in MTAs.  It might overcome the resistance problems that most of the MTAs have faced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHYxyvm45m4bVg90H21EOLACvtfcHk0liT12loV6bIUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOgtrnI&md5=069f8498e6fd14cac3f86324b77e09cb</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00797%26sid%3Dliteratum%253Aachs%26aulast%3DKuo%26aufirst%3DT.%2BC.%26aulast%3DLi%26aufirst%3DL.%2BW.%26aulast%3DPan%26aufirst%3DS.%2BH.%26aulast%3DFang%26aufirst%3DJ.%2BM.%26aulast%3DLiu%26aufirst%3DJ.%2BH.%26aulast%3DCheng%26aufirst%3DT.%2BJ.%26aulast%3DWang%26aufirst%3DC.%2BJ.%26aulast%3DHung%26aufirst%3DP.%2BF.%26aulast%3DChen%26aufirst%3DH.%2BY.%26aulast%3DHong%26aufirst%3DT.%2BM.%26aulast%3DHsu%26aufirst%3DY.%2BL.%26aulast%3DWong%26aufirst%3DC.%2BH.%26aulast%3DYang%26aufirst%3DP.%2BC.%26atitle%3DPurine-type%2520compounds%2520induce%2520microtubule%2520fragmentation%2520and%2520lung%2520cancer%2520cell%2520death%2520through%2520interaction%2520with%2520katanin%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8521%26epage%3D8534%26doi%3D10.1021%2Facs.jmedchem.6b00797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, antitumor activities and biological studies of novel diaryl substituted fused heterocycles as dual ligands targeting tubulin and katanin</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>178</i></span>,  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">194</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.05.072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejmech.2019.05.072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=31185410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFKqs7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2019&pages=177-194&author=F.+Gaoauthor=Y.+Liangauthor=P.+Zhouauthor=J.+Chengauthor=K.+Dingauthor=Y.+Wang&title=Design%2C+synthesis%2C+antitumor+activities+and+biological+studies+of+novel+diaryl+substituted+fused+heterocycles+as+dual+ligands+targeting+tubulin+and+katanin&doi=10.1016%2Fj.ejmech.2019.05.072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, antitumor activities and biological studies of novel diaryl substituted fused heterocycles as dual ligands targeting tubulin and katanin</span></div><div class="casAuthors">Gao, Feng; Liang, Yuru; Zhou, Pengfei; Cheng, Jiayi; Ding, Kuiling; Wang, Yang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">177-194</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Microtubule is one of the important targets for cancer treatment.  A novel class of diaryl substituted imidazo[4,5-c]pyridin-2-ones and imidazo[4,5-c]pyridines were designed based on combination principles by merging the structures of β-lactams and purine-type compds. known as tubulin polymn. inhibitor and katanin activity up-regulator, resp.  Their antitumor activities were evaluated in vitro and the mechanism was elucidated, leading to the identification of 1,6-diaryl-1H-imidazo[4,5-c]pyridin-2(3H)-one I as the first bifunctional agent that can target both tubulin and katanin simultaneously.  The in vivo assays verified that compd. I significantly inhibited xenograft tumor growth with good pharmacokinetic characteristics, demonstrating a promising potential for further development into anti-tumor drug candidates with a unique mechanism of dual-targeting microtubule.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmwI1A_To45rVg90H21EOLACvtfcHk0liT12loV6bIUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFKqs7fI&md5=4b71536c807d513c707371370dd966a0</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.05.072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.05.072%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DF.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DP.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%252C%2520antitumor%2520activities%2520and%2520biological%2520studies%2520of%2520novel%2520diaryl%2520substituted%2520fused%2520heterocycles%2520as%2520dual%2520ligands%2520targeting%2520tubulin%2520and%2520katanin%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D178%26spage%3D177%26epage%3D194%26doi%3D10.1016%2Fj.ejmech.2019.05.072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of quinazolin-4(3 H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">156</span>– <span class="NLM_lpage">180</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2020.06.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.apsb.2020.06.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=33532187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3MXhtVOms7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2021&pages=156-180&author=X.+Changauthor=D.+Sunauthor=D.+Shiauthor=G.+Wangauthor=Y.+Chenauthor=K.+Zhangauthor=H.+Tanauthor=J.+Liuauthor=B.+Liuauthor=L.+Ouyang&title=Design%2C+synthesis%2C+and+biological+evaluation+of+quinazolin-4%283+H%29-one+derivatives+co-targeting+poly%28ADP-ribose%29+polymerase-1+and+bromodomain+containing+protein+4+for+breast+cancer+therapy&doi=10.1016%2Fj.apsb.2020.06.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy</span></div><div class="casAuthors">Chang, Xiaosa; Sun, Dejuan; Shi, Danfeng; Wang, Guan; Chen, Yanmei; Zhang, Kai; Tan, Huidan; Liu, Jie; Liu, Bo; Ouyang, Liang</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmaceutica Sinica B</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">156-180</span>CODEN:
                <span class="NLM_cas:coden">APSBCW</span>;
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This study was aimed to design the first dual-target small-mol. inhibitor co-targeting poly (ADP-ribose) polymerase-1 (PARP1) and bromodomain contg. protein 4 (BRD4), which had important cross relation in the global network of breast cancer, reflecting the synthetic lethal effect.  A series of new BRD4 and PARP1 dual-target inhibitors were discovered and synthesized by fragment-based combinatorial screening and activity assays that together led to the chem. optimization.  Among these compds., 19d was selected and exhibited micromole enzymic potencies against BRD4 and PARP1, resp.  Compd. 19d was further shown to efficiently modulate the expression of BRD4 and PARP1.  Subsequently, compd. 19d was found to induce breast cancer cell apoptosis and stimulate cell cycle arrest at G1 phase.  Following pharmacokinetic studies, compd. 19d showed its antitumor activity in breast cancer susceptibility gene 1/2 (BRCA1/2) wild-type MDA-MB-468 and MCF-7 xenograft models without apparent toxicity and loss of body wt.  These results together demonstrated that a highly potent dual-targeted inhibitor was successfully synthesized and indicated that co-targeting of BRD4 and PARP1 based on the concept of synthetic lethality would be a promising therapeutic strategy for breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDduOqn_KYnLVg90H21EOLACvtfcHk0liT12loV6bIUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXhtVOms7bF&md5=1b99b491690caa69d35863bf0b99a615</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2020.06.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2020.06.003%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DShi%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DTan%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DOuyang%26aufirst%3DL.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520quinazolin-4%25283%2520H%2529-one%2520derivatives%2520co-targeting%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520and%2520bromodomain%2520containing%2520protein%25204%2520for%2520breast%2520cancer%2520therapy%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2021%26volume%3D11%26spage%3D156%26epage%3D180%26doi%3D10.1016%2Fj.apsb.2020.06.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fong, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boss, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tutt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mergui-Roelvink, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortimer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaisland, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmichael, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bono, J. S.</span></span> <span> </span><span class="NLM_article-title">Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>361</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa0900212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1056%2FNEJMoa0900212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=19553641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVKrtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=123-134&author=P.+C.+Fongauthor=D.+S.+Bossauthor=T.+A.+Yapauthor=A.+Tuttauthor=P.+Wuauthor=M.+Mergui-Roelvinkauthor=P.+Mortimerauthor=H.+Swaislandauthor=A.+Lauauthor=M.+J.+O%E2%80%99Connorauthor=A.+Ashworthauthor=J.+Carmichaelauthor=S.+B.+Kayeauthor=J.+H.+Schellensauthor=J.+S.+de+Bono&title=Inhibition+of+poly%28ADP-ribose%29+polymerase+in+tumors+from+BRCA+mutation+carriers&doi=10.1056%2FNEJMoa0900212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers</span></div><div class="casAuthors">Fong, Peter C.; Boss, David S.; Yap, Timothy A.; Tutt, Andrew; Wu, Peijun; Mergui-Roelvink, Marja; Mortimer, Peter; Swaisland, Helen; Lau, Alan; O'Connor, Mark J.; Ashworth, Alan; Carmichael, James; Kaye, Stan B.; Schellens, Jan H. M.; de Bono, Johann S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-134</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The inhibition of poly(ADP-ribose) polymerase (PARP) is a potential synthetic lethal therapeutic strategy for the treatment of cancers with specific DNA-repair defects, including those arising in carriers of a BRCA1 or BRCA2 mutation.  We conducted a clin. evaluation in humans of olaparib (AZD2281), a novel, potent, orally active PARP inhibitor.  This was a phase 1 trial that included the anal. of pharmacokinetic and pharmacodynamic characteristics of olaparib.  Selection was aimed at having a study population enriched in carriers of a BRCA1 or BRCA2 mutation.  We enrolled and treated 60 patients; 22 were carriers of a BRCA1 or BRCA2 mutation and 1 had a strong family history of BRCA-assocd. cancer but declined to undergo mutational testing.  The olaparib dose and schedule were increased from 10 mg daily for 2 of every 3 wk to 600 mg twice daily continuously.  Reversible dose-limiting toxicity was seen in one of eight patients receiving 400 mg twice daily (grade 3 mood alteration and fatigue) and two of five patients receiving 600 mg twice daily (grade 4 thrombocytopenia and grade 3 somnolence).  This led us to enroll another cohort, consisting only of carriers of a BRCA1 or BRCA2 mutation, to receive olaparib at a dose of 200 mg twice daily.  Other adverse effects included mild gastrointestinal symptoms.  There was no obvious increase in adverse effects seen in the mutation carriers.  Pharmacokinetic data indicated rapid absorption and elimination; pharmacodynamic studies confirmed PARP inhibition in surrogate samples (of peripheral-blood mononuclear cells and plucked eyebrow-hair follicles) and tumor tissue.  Objective antitumor activity was reported only in mutation carriers, all of whom had ovarian, breast, or prostate cancer and had received multiple treatment regimens.  Olaparib has few of the adverse effects of conventional chemotherapy, inhibits PARP, and has antitumor activity in cancer assocd. with the BRCA1 or BRCA2 mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCT49Hz0HbW7Vg90H21EOLACvtfcHk0ljBJXMw7gP3SA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVKrtrw%253D&md5=aec7dcffe3d3cf614362a4f38bbb369a</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0900212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0900212%26sid%3Dliteratum%253Aachs%26aulast%3DFong%26aufirst%3DP.%2BC.%26aulast%3DBoss%26aufirst%3DD.%2BS.%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DTutt%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DMergui-Roelvink%26aufirst%3DM.%26aulast%3DMortimer%26aufirst%3DP.%26aulast%3DSwaisland%26aufirst%3DH.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DAshworth%26aufirst%3DA.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DKaye%26aufirst%3DS.%2BB.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26atitle%3DInhibition%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%2520in%2520tumors%2520from%2520BRCA%2520mutation%2520carriers%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D123%26epage%3D134%26doi%3D10.1056%2FNEJMoa0900212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brodie, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khuri, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vertino, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandes, J. C.</span></span> <span> </span><span class="NLM_article-title">Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">30773</span>– <span class="NLM_lpage">30786</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.5040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.18632%2Foncotarget.5040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=26356822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A280%3ADC%252BC283htVantA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=30773-30786&author=S.+A.+Brodieauthor=G.+Liauthor=D.+Harveyauthor=F.+R.+Khuriauthor=P.+M.+Vertinoauthor=J.+C.+Brandes&title=Small+molecule+inhibition+of+the+CHFR-PARP1+interaction+as+novel+approach+to+overcome+intrinsic+taxane+resistance+in+cancer&doi=10.18632%2Foncotarget.5040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer</span></div><div class="casAuthors">Brodie Seth A; Li Ge; Harvey Donald; Khuri Fadlo R; Brandes Johann C; Brodie Seth A; Li Ge; Harvey Donald; Khuri Fadlo R; Vertino Paula M; Brandes Johann C; Vertino Paula M; Brandes Johann C</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">30773-86</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The mitotic checkpoint protein CHFR has emerged as a major mediator of taxane resistance in cancer.  Here we show that CHFR's PAR-binding zinc finger domain (PBZ) mediates a protein interaction with poly-ADP ribosylated PARP1 leading to stabilization of CHFR.  Disruption of the CHFR-PARP1 interaction through either PARP1 shRNA-mediated knockdown or overexpression of a PBZ domain peptide induces loss of CHFR protein expression.  In an attempt to exploit this observation therapeutically, and to develop compounds with synthetic lethality in combination with taxanes, we performed a high-throughput computational screen of 5,256,508 chemical structures against the published crystal structure of the CHFR PBZ domain to identify candidate small molecule CHFR protein-protein interaction inhibitors.  The 10 compounds with the best docking scores (< -9.7) were used for further in vitro testing.  One lead compound in particular, termed 'A3', completely disrupted the protein-protein interaction between CHFR and PARP1, resulting in the inhibition of mitotic checkpoint function, and led to therapeutic synergy with docetaxel in cell viability and colony formation assays.  In mouse xenografts, i.p. administration of 'A3' led to a significant reduction in nuclear CHFR protein expression with a maximal effect 4 hours after administration, confirming relevant pharmacodynamics following the peak of 'A3' plasma concentration in vivo.  Furthermore, combination of A3 and taxane led to significant reduction of implanted tumor size without increase in hematological, hepatic or renal toxicity.  These findings provide a proof-of-principle that small molecule inhibition of CHFR PBZ domain interaction is a novel potential therapeutic approach to increase the efficacy of taxane-based chemotherapy in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSEPbu_Txv-kO2mnZh2OgS0fW6udTcc2eavwVy3bC4GUbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283htVantA%253D%253D&md5=6d0355b7f95c6e2fa33443d7853717e0</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.5040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.5040%26sid%3Dliteratum%253Aachs%26aulast%3DBrodie%26aufirst%3DS.%2BA.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DHarvey%26aufirst%3DD.%26aulast%3DKhuri%26aufirst%3DF.%2BR.%26aulast%3DVertino%26aufirst%3DP.%2BM.%26aulast%3DBrandes%26aufirst%3DJ.%2BC.%26atitle%3DSmall%2520molecule%2520inhibition%2520of%2520the%2520CHFR-PARP1%2520interaction%2520as%2520novel%2520approach%2520to%2520overcome%2520intrinsic%2520taxane%2520resistance%2520in%2520cancer%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D30773%26epage%3D30786%26doi%3D10.18632%2Foncotarget.5040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dent, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindeman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemons, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wildiers, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmichael, J.</span></span> <span> </span><span class="NLM_article-title">Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">R88</span>, <span class="refDoi"> DOI: 10.1186/bcr3484</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1186%2Fbcr3484" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=24063698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFOhsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=R88&author=R.+A.+Dentauthor=G.+J.+Lindemanauthor=M.+Clemonsauthor=H.+Wildiersauthor=A.+Chanauthor=N.+J.+McCarthyauthor=C.+F.+Singerauthor=E.+S.+Loweauthor=C.+L.+Watkinsauthor=J.+Carmichael&title=Phase+I+trial+of+the+oral+PARP+inhibitor+olaparib+in+combination+with+paclitaxel+for+first-+or+second-line+treatment+of+patients+with+metastatic+triple-negative+breast+cancer&doi=10.1186%2Fbcr3484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer</span></div><div class="casAuthors">Dent, Rebecca A.; Lindeman, Geoffrey J.; Clemons, Mark; Wildiers, Hans; Chan, Arlene; McCarthy, Nicole J.; Singer, Christian F.; Lowe, Elizabeth S.; Watkins, Claire L.; Carmichael, James</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">R88/1-R88/8, 8 pp.</span>CODEN:
                <span class="NLM_cas:coden">BRCRFS</span>;
        ISSN:<span class="NLM_cas:issn">1465-542X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Introduction: This Phase I study evaluated the safety, tolerability and efficacy of olaparib, a potent oral poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with paclitaxel in patients with metastatic triple-neg. breast cancer (mTNBC).  Methods: Eligible patients who had received ≤1 prior cytotoxic regimen for mTNBC were treated with olaparib 200 mg bid continuously plus weekly paclitaxel 90 mg/m2 for three weeks per four-week cycle.  Dose modifications in a large proportion of patients due to neutropenia resulted in enrollment of a second cohort of patients who, if they experienced grade ≥2 neutropenia in cycle 1, received granulocyte-colony stimulating factor, which was continued prophylactically in subsequent cycles.  All patients had measurable disease; tumor responses were evaluated according to RECIST (version 1.0).  Results: Nineteen patients (cohort 1, n = 9; cohort 2, n = 10) received treatment; 15 had received prior taxane chemotherapy.  The most frequent adverse events were diarrhea (n = 12, 63%), nausea (n = 11, 58%) and neutropenia (n = 11, 58%).  Seven neutropenia events were reported in cohort 1 (four grade ≥3) and four in cohort 2 (two grade ≥3, including one event of febrile neutropenia).  The median (range) dose intensity of paclitaxel was 57% (26 to 100%) in cohort 1 and 73% (29 to 100%) in cohort 2.  Seven patients (37%) had a confirmed partial response; one patient remains on olaparib monotherapy without progression.  Conclusions: The combination of olaparib and weekly paclitaxel was complicated by a significant clin. interaction, with higher-than-expected rates of neutropenia despite secondary prophylaxis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFe81cPlJPr7Vg90H21EOLACvtfcHk0ljBJXMw7gP3SA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFOhsb8%253D&md5=1da261cd68c4d2cd5b8eb222dc61db9c</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1186%2Fbcr3484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fbcr3484%26sid%3Dliteratum%253Aachs%26aulast%3DDent%26aufirst%3DR.%2BA.%26aulast%3DLindeman%26aufirst%3DG.%2BJ.%26aulast%3DClemons%26aufirst%3DM.%26aulast%3DWildiers%26aufirst%3DH.%26aulast%3DChan%26aufirst%3DA.%26aulast%3DMcCarthy%26aufirst%3DN.%2BJ.%26aulast%3DSinger%26aufirst%3DC.%2BF.%26aulast%3DLowe%26aufirst%3DE.%2BS.%26aulast%3DWatkins%26aufirst%3DC.%2BL.%26aulast%3DCarmichael%26aufirst%3DJ.%26atitle%3DPhase%2520I%2520trial%2520of%2520the%2520oral%2520PARP%2520inhibitor%2520olaparib%2520in%2520combination%2520with%2520paclitaxel%2520for%2520first-%2520or%2520second-line%2520treatment%2520of%2520patients%2520with%2520metastatic%2520triple-negative%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2013%26volume%3D15%26spage%3DR88%26doi%3D10.1186%2Fbcr3484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poruchynsky, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komlodi-Pasztor, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trostel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkerson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regairaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar Maity, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burotto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sackett, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guha, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fojo, A. T.</span></span> <span> </span><span class="NLM_article-title">Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">1571</span>– <span class="NLM_lpage">1576</span>, <span class="refDoi"> DOI: 10.1073/pnas.1416418112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1073%2Fpnas.1416418112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=25605897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOhu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=1571-1576&author=M.+S.+Poruchynskyauthor=E.+Komlodi-Pasztorauthor=S.+Trostelauthor=J.+Wilkersonauthor=M.+Regairazauthor=Y.+Pommierauthor=X.+Zhangauthor=T.+Kumar+Maityauthor=R.+Robeyauthor=M.+Burottoauthor=D.+Sackettauthor=U.+Guhaauthor=A.+T.+Fojo&title=Microtubule-targeting+agents+augment+the+toxicity+of+DNA-damaging+agents+by+disrupting+intracellular+trafficking+of+DNA+repair+proteins&doi=10.1073%2Fpnas.1416418112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins</span></div><div class="casAuthors">Poruchynsky, Marianne S.; Komlodi-Pasztor, Edina; Trostel, Shana; Wilkerson, Julia; Regairaz, Marie; Pommier, Yves; Zhang, Xu; Maity, Tapan Kumar; Robey, Robert; Burotto, Mauricio; Sackett, Dan; Guha, Udayan; Fojo, Antonio Tito</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1571-1576</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The paradigm that microtubule-targeting agents (MTAs) cause cell death via mitotic arrest applies to rapidly dividing cells but cannot explain MTA activity in slowly growing human cancers.  Many preferred cancer regimens combine a MTA with a DNA-damaging agent (DDA).  We hypothesized that MTAs synergize with DDAs by interfering with trafficking of DNA repair proteins on interphase microtubules.  We investigated nine proteins involved in DNA repair: ATM, ATR, DNA-PK, Rad50, Mre11, p95/NBS1, p53, 53BP1, and p63.  The proteins were sequestered in the cytoplasm by vincristine and paclitaxel but not by an aurora kinase inhibitor, colocalized with tubulin by confocal microscopy and coimmunopptd. with the microtubule motor dynein.  Furthermore, adding MTAs to radiation, doxorubicin, or etoposide led to more sustained γ-H2AX levels.  We conclude DNA damage-repair proteins traffic on microtubules and addn. of MTAs sequesters them in the cytoplasm, explaining why MTA/DDA combinations are common anticancer regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4RzUulWoZyLVg90H21EOLACvtfcHk0liXdRB_nPZykA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOhu74%253D&md5=f7f94679f54bf5859c18437a40076aae</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1416418112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1416418112%26sid%3Dliteratum%253Aachs%26aulast%3DPoruchynsky%26aufirst%3DM.%2BS.%26aulast%3DKomlodi-Pasztor%26aufirst%3DE.%26aulast%3DTrostel%26aufirst%3DS.%26aulast%3DWilkerson%26aufirst%3DJ.%26aulast%3DRegairaz%26aufirst%3DM.%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DKumar%2BMaity%26aufirst%3DT.%26aulast%3DRobey%26aufirst%3DR.%26aulast%3DBurotto%26aufirst%3DM.%26aulast%3DSackett%26aufirst%3DD.%26aulast%3DGuha%26aufirst%3DU.%26aulast%3DFojo%26aufirst%3DA.%2BT.%26atitle%3DMicrotubule-targeting%2520agents%2520augment%2520the%2520toxicity%2520of%2520DNA-damaging%2520agents%2520by%2520disrupting%2520intracellular%2520trafficking%2520of%2520DNA%2520repair%2520proteins%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D1571%26epage%3D1576%26doi%3D10.1073%2Fpnas.1416418112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemjabbar-Alaoui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peto, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jablons, D. M.</span></span> <span> </span><span class="NLM_article-title">AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers</span>. <i>Am. J. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2649</span>– <span class="NLM_lpage">2676</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=32905466" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFant77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=2649-2676&author=H.+Lemjabbar-Alaouiauthor=C.+J.+Petoauthor=Y.+W.+Yangauthor=D.+M.+Jablons&title=AMXI-5001%2C+a+novel+dual+parp1%2F2+and+microtubule+polymerization+inhibitor+for+the+treatment+of+human+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers</span></div><div class="casAuthors">Lemjabbar-Alaoui, Hassan; Peto, Csaba J.; Yang, Yi-Wei; Jablons, David M.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Cancer Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2649-2676</span>CODEN:
                <span class="NLM_cas:coden">AJCRFT</span>;
        ISSN:<span class="NLM_cas:issn">2156-6976</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">Poly (ADP-ribose) polymerase (PARP) has recently emerged as a central mediator in cancer resistance against numerous anticancer agents to include chemotherapeutic agents such as microtubule targeting agents and DNA damaging agents.  Here, we describe AMXI-5001, a novel, highly potent dual PARP1/2 and microtubule polymn. inhibitor with favorable metabolic stability, oral bioavailability, and pharmacokinetic properties.  The potency and selectivity of AMXI-5001 were detd. by biochem. assays.  Anticancer activity either as a singleagent or in combination with other antitumor agents was evaluated in vitro.  In vivo antitumor activity as a singleagent was assessed in a triple-neg. breast cancer (TNBC) model.  AMXI-5001 demonstrates comparable IC50 inhibition against PARP and microtubule polymn. as clin. PARP inhibitors (Olaparib, Rucaparib, Niraparib, and Talazoparib) and the potent polymn. inhibitor (Vinblastine), resp.  In vitro, AMXI-5001 exhibited selective antitumor cytotoxicity across a wide variety of human cancer cells with much lower IC50s than existing clin. PARP1/2 inhibitors.  AMXI-5001 is highly active in both BRCA mutated and wild type cancers.  AMXI-5001 is orally bioavailable.  AMXI-5001 elicited a remarkable In vivo preclin. anti-tumor activity in a BRCA mutated TNBC model.  Oral administration of AMXI-5001 induced complete regression of established tumors, including exceedingly large tumors.  AMXI-5001 resulted in superior anti-tumor effects compared to either single agent (PARP or microtubule) inhibitor or combination with both agents.  AMXI-5001 will enter clin. trial testing soon and represents a promising, novel first in class dual PARP1/2 and microtubule polymn. inhibitor that delivers continuous and synchronous one-two punch cancer therapy with one mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ3bQO97CJV7Vg90H21EOLACvtfcHk0liXdRB_nPZykA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFant77P&md5=eece5fd2fe270f97cb9c0d7f0ec907db</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLemjabbar-Alaoui%26aufirst%3DH.%26aulast%3DPeto%26aufirst%3DC.%2BJ.%26aulast%3DYang%26aufirst%3DY.%2BW.%26aulast%3DJablons%26aufirst%3DD.%2BM.%26atitle%3DAMXI-5001%252C%2520a%2520novel%2520dual%2520parp1%252F2%2520and%2520microtubule%2520polymerization%2520inhibitor%2520for%2520the%2520treatment%2520of%2520human%2520cancers%26jtitle%3DAm.%2520J.%2520Cancer%2520Res.%26date%3D2020%26volume%3D10%26spage%3D2649%26epage%3D2676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hengst, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegde, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geffert, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kester, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loughran, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulson, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claxton, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, J. K.</span></span> <span> </span><span class="NLM_article-title">SKI-178: A multitargeted inhibitor of sphingosine kinase and microtubule dynamics demonstrating therapeutic efficacy in acute myeloid leukemia models</span>. <i>Cancer Transl Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">121</span>, <span class="refDoi"> DOI: 10.4103/ctm.ctm_7_17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.4103%2Fctm.ctm_7_17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=28890935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFOhtL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=109-121&author=J.+A.+Hengstauthor=T.+E.+Dickauthor=A.+Sharmaauthor=K.+Doiauthor=S.+Hegdeauthor=S.+F.+Tanauthor=L.+M.+Geffertauthor=T.+E.+Foxauthor=A.+K.+Sharmaauthor=D.+Desaiauthor=S.+Aminauthor=M.+Kesterauthor=T.+P.+Loughranauthor=R.+F.+Paulsonauthor=D.+F.+Claxtonauthor=H.+G.+Wangauthor=J.+K.+Yun&title=SKI-178%3A+A+multitargeted+inhibitor+of+sphingosine+kinase+and+microtubule+dynamics+demonstrating+therapeutic+efficacy+in+acute+myeloid+leukemia+models&doi=10.4103%2Fctm.ctm_7_17"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">SKI-178: a multitargeted inhibitor of sphingosine kinase and microtubule dynamics demonstrating therapeutic efficacy in acute myeloid leukemia models</span></div><div class="casAuthors">Hengst, Jeremy A.; Dick, Taryn E.; Sharma, Arati; Doi, Kenichiro; Hegde, Shailaja; Tan, Su-Fern; Geffert, Laura M.; Fox, Todd E.; Sharma, Arun K.; Desai, Dhimant; Amin, Shantu; Kester, Mark; Loughran, Thomas P.; Paulson, Robert F.; Claxton, David F.; Wang, Hong-Gang; Yun, Jong K.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Translational Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">109-121, S1</span>CODEN:
                <span class="NLM_cas:coden">CTMABE</span>;
        ISSN:<span class="NLM_cas:issn">2395-3012</span>.
    
            (<span class="NLM_cas:orgname">Medknow Publications</span>)
        </div><div class="casAbstract">Aim: To further characterize the selectivity, mechanism of action, and therapeutic efficacy of the novel small mol. inhibitor, SKI-178.  Methods: We used the state-of-the-art cellular thermal shift assay technique to detect "direct target engagement" of proteins in intact cells.  In vitro and in vivo assays, pharmacol. assays, and multiple mouse models of acute myeloid leukemia (AML) were also used.  Results: Herein, we demonstrate that SKI-178 directly target engages both sphingosine kinase 1 and 2 (SphK1 and 2).  We also present evidence that, in addn. to its actions as a sphingosine kinase inhibitor, SKI-178 functions as a microtubule network disrupting agent both in vitro and in intact cells.  Interestingly, we sep. demonstrate that simultaneous SphK inhibition and microtubule disruption synergistically induce apoptosis in AML cell lines.  Furthermore, we demonstrate that SKI-178 is well tolerated in normal healthy mice.  Most importantly, we demonstrate that SKI-178 has therapeutic efficacy in several mouse models of AML.  Conclusion: SKI-178 is a multitargeted agent that functions both as an inhibitor of the SphKs as well as a disruptor of the microtubule network.  SKI-178-induced apoptosis arises from a synergistic interaction of these two activities.  SKI-178 is safe and effective in mouse models of AML, supporting its further development as a multitargeted anticancer therapeutic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4CVSGc0jL9LVg90H21EOLACvtfcHk0liXdRB_nPZykA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFOhtL7I&md5=ef8a162ad34dbdc947433d302cced3d7</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.4103%2Fctm.ctm_7_17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252Fctm.ctm_7_17%26sid%3Dliteratum%253Aachs%26aulast%3DHengst%26aufirst%3DJ.%2BA.%26aulast%3DDick%26aufirst%3DT.%2BE.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DDoi%26aufirst%3DK.%26aulast%3DHegde%26aufirst%3DS.%26aulast%3DTan%26aufirst%3DS.%2BF.%26aulast%3DGeffert%26aufirst%3DL.%2BM.%26aulast%3DFox%26aufirst%3DT.%2BE.%26aulast%3DSharma%26aufirst%3DA.%2BK.%26aulast%3DDesai%26aufirst%3DD.%26aulast%3DAmin%26aufirst%3DS.%26aulast%3DKester%26aufirst%3DM.%26aulast%3DLoughran%26aufirst%3DT.%2BP.%26aulast%3DPaulson%26aufirst%3DR.%2BF.%26aulast%3DClaxton%26aufirst%3DD.%2BF.%26aulast%3DWang%26aufirst%3DH.%2BG.%26aulast%3DYun%26aufirst%3DJ.%2BK.%26atitle%3DSKI-178%253A%2520A%2520multitargeted%2520inhibitor%2520of%2520sphingosine%2520kinase%2520and%2520microtubule%2520dynamics%2520demonstrating%2520therapeutic%2520efficacy%2520in%2520acute%2520myeloid%2520leukemia%2520models%26jtitle%3DCancer%2520Transl%2520Med.%26date%3D2017%26volume%3D3%26spage%3D109%26epage%3D121%26doi%3D10.4103%2Fctm.ctm_7_17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hengst, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegde, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulson, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, J. K.</span></span> <span> </span><span class="NLM_article-title">Development of SKI-349, a dual-targeted inhibitor of sphingosine kinase and microtubule polymerization</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">127453</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127453</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.bmcl.2020.127453" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=32736077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFGls7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127453&author=J.+A.+Hengstauthor=S.+Hegdeauthor=R.+F.+Paulsonauthor=J.+K.+Yun&title=Development+of+SKI-349%2C+a+dual-targeted+inhibitor+of+sphingosine+kinase+and+microtubule+polymerization&doi=10.1016%2Fj.bmcl.2020.127453"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Development of SKI-349, a dual-targeted inhibitor of sphingosine kinase and microtubule polymerization</span></div><div class="casAuthors">Hengst, Jeremy A.; Hegde, Shailaja; Paulson, Robert F.; Yun, Jong K.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">127453</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Our sphingosine kinase inhibitor (SKI) optimization studies originated with the optimization of the SKI-I chemotype by replacement of the substituted benzyl rings with substituted Ph rings giving rise to the discovery of SKI-178.  We have recently reported that SKI-178 is a dual-targeted inhibitor of both sphingosine kinase isoforms (SphK1/2) and a microtubule disrupting agent (MDA).  In mechanism-of-action studies, we have shown that these two sep. actions synergize to induce cancer cell death in acute myeloid leukemia (AML) cell and animal models.  Owning to the effectiveness of SKI-178, we sought to further refine the chemotype while maintaining "on-target" SKI and MDA activities.  Herein, we modified the "linker region" between the substituted Ph rings of SKI-178 through a structure guided approach.  These studies have yielded the discovery of an SKI-178 congener, SKI-349, with log-fold enhancements in both SphK inhibition and cytotoxic potency.  Importantly, SKI-349 also demonstrates log-fold improvements in therapeutic efficacy in a retro-viral transduction model of MLL-AF9 AML as compared to previous studies with SKI-178.  Together, our results strengthen the hypothesis that simultaneous targeting of the sphingosine kinases (SphK1/2) and the induction of mitotic spindle assembly checkpoint arrest, via microtubule disruption, might be an effective therapeutic strategy for hematol. malignancies including AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7z_h5g2BX0bVg90H21EOLACvtfcHk0lhV0w9CrX56kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFGls7bM&md5=e9393ea1c84933ace638edb892ca1fd6</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127453%26sid%3Dliteratum%253Aachs%26aulast%3DHengst%26aufirst%3DJ.%2BA.%26aulast%3DHegde%26aufirst%3DS.%26aulast%3DPaulson%26aufirst%3DR.%2BF.%26aulast%3DYun%26aufirst%3DJ.%2BK.%26atitle%3DDevelopment%2520of%2520SKI-349%252C%2520a%2520dual-targeted%2520inhibitor%2520of%2520sphingosine%2520kinase%2520and%2520microtubule%2520polymerization%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26spage%3D127453%26doi%3D10.1016%2Fj.bmcl.2020.127453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khandelwal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merfeld, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munthali, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matts, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, B. S. J.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibition of the Hsp90α Isoform</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">10547</span>– <span class="NLM_lpage">10551</span>, <span class="refDoi"> DOI: 10.1002/anie.202015422</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1002%2Fanie.202015422" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3MXnt1Oms7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2021&pages=10547-10551&author=S.+J.+Mishraauthor=A.+Khandelwalauthor=M.+Banerjeeauthor=M.+Balchauthor=S.+Pengauthor=R.+E.+Davisauthor=T.+Merfeldauthor=V.+Munthaliauthor=J.+Dengauthor=R.+L.+Mattsauthor=B.+S.+J.+Blagg&title=Selective+Inhibition+of+the+Hsp90%CE%B1+Isoform&doi=10.1002%2Fanie.202015422"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of the Hsp90α Isoform</span></div><div class="casAuthors">Mishra, Sanket J.; Khandelwal, Anuj; Banerjee, Monimoy; Balch, Maurie; Peng, Shuxia; Davis, Rachel E.; Merfeld, Taylor; Munthali, Vitumbiko; Deng, Junpeng; Matts, Robert L.; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">10547-10551</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The 90 kDa heat shock protein (Hsp90) is a mol. chaperone that processes nascent polypeptides into their biol. active conformations.  Many of these proteins contribute to the progression of cancer, and consequently, inhibition of the Hsp90 protein folding machinery represents an innovative approach toward cancer chemotherapy.  However, clin. trials with Hsp90 N-terminal inhibitors have encountered deleterious side effects and toxicities, which appear to result from the pan-inhibition of all four Hsp90 isoforms.  Therefore, the development of isoform-selective Hsp90 inhibitors is sought to delineate the pathol. role played by each isoform.  Herein, we describe a structure-based approach that was used to design the first Hsp90α-selective inhibitors, which exhibit >50-fold selectivity vs. other Hsp90 isoforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf_-tPiVfjqLVg90H21EOLACvtfcHk0lhV0w9CrX56kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXnt1Oms7w%253D&md5=a13fa7b40d3c2cd467bcc67e47358b85</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1002%2Fanie.202015422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.202015422%26sid%3Dliteratum%253Aachs%26aulast%3DMishra%26aufirst%3DS.%2BJ.%26aulast%3DKhandelwal%26aufirst%3DA.%26aulast%3DBanerjee%26aufirst%3DM.%26aulast%3DBalch%26aufirst%3DM.%26aulast%3DPeng%26aufirst%3DS.%26aulast%3DDavis%26aufirst%3DR.%2BE.%26aulast%3DMerfeld%26aufirst%3DT.%26aulast%3DMunthali%26aufirst%3DV.%26aulast%3DDeng%26aufirst%3DJ.%26aulast%3DMatts%26aufirst%3DR.%2BL.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DSelective%2520Inhibition%2520of%2520the%2520Hsp90%25CE%25B1%2520Isoform%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2021%26volume%3D60%26spage%3D10547%26epage%3D10551%26doi%3D10.1002%2Fanie.202015422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Echeverría, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernthaler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupuis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picard, D.</span></span> <span> </span><span class="NLM_article-title">An interaction network predicted from public data as a discovery tool: application to the Hsp90 molecular chaperone machine</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">e26044</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0026044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1371%2Fjournal.pone.0026044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=22022502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtl2lsrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=e26044&author=P.+C.+Echeverr%C3%ADaauthor=A.+Bernthalerauthor=P.+Dupuisauthor=B.+Mayerauthor=D.+Picard&title=An+interaction+network+predicted+from+public+data+as+a+discovery+tool%3A+application+to+the+Hsp90+molecular+chaperone+machine&doi=10.1371%2Fjournal.pone.0026044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">An interaction network predicted from public data as a discovery tool: application to the Hsp90 molecular chaperone machine</span></div><div class="casAuthors">Echeverria, Pablo C.; Bernthaler, Andreas; Dupuis, Pierre; Mayer, Bernd; Picard, Didier</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e26044</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Understanding the functions of proteins requires information about their protein-protein interactions (PPI).  The collective effort of the scientific community generates far more data on any given protein than individual exptl. approaches.  The latter are often too limited to reveal an interactome comprehensively.  We developed a workflow for parallel mining of all major PPI databases, contg. data from several model organisms, and to integrate data from the literature for a protein of interest.  We applied this novel approach to build the PPI network of the human Hsp90 mol. chaperone machine (Hsp90Int) for which previous efforts have yielded limited and poorly overlapping sets of interactors.  We demonstrate the power of the Hsp90Int database as a discovery tool by validating the prediction that the Hsp90 co-chaperone Aha1 is involved in nucleocytoplasmic transport.  Thus, we both describe how to build a custom database and introduce a powerful new resource for the scientific community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR31go7KI5lLVg90H21EOLACvtfcHk0lhV0w9CrX56kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtl2lsrrL&md5=e1908fb96cd467c7e315e1ca93c00391</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0026044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0026044%26sid%3Dliteratum%253Aachs%26aulast%3DEcheverr%25C3%25ADa%26aufirst%3DP.%2BC.%26aulast%3DBernthaler%26aufirst%3DA.%26aulast%3DDupuis%26aufirst%3DP.%26aulast%3DMayer%26aufirst%3DB.%26aulast%3DPicard%26aufirst%3DD.%26atitle%3DAn%2520interaction%2520network%2520predicted%2520from%2520public%2520data%2520as%2520a%2520discovery%2520tool%253A%2520application%2520to%2520the%2520Hsp90%2520molecular%2520chaperone%2520machine%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26spage%3De26044%26doi%3D10.1371%2Fjournal.pone.0026044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knox, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawlak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golfis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flood, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fayne, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meegan, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lloyd, D. G.</span></span> <span> </span><span class="NLM_article-title">Integration of ligand and structure-based virtual screening for the identification of the first dual targeting agent for heat shock protein 90 (Hsp90) and tubulin</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">2177</span>– <span class="NLM_lpage">2180</span>, <span class="refDoi"> DOI: 10.1021/jm801569z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801569z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktFGrt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2177-2180&author=A.+J.+Knoxauthor=T.+Priceauthor=M.+Pawlakauthor=G.+Golfisauthor=C.+T.+Floodauthor=D.+Fayneauthor=D.+C.+Williamsauthor=M.+J.+Meeganauthor=D.+G.+Lloyd&title=Integration+of+ligand+and+structure-based+virtual+screening+for+the+identification+of+the+first+dual+targeting+agent+for+heat+shock+protein+90+%28Hsp90%29+and+tubulin&doi=10.1021%2Fjm801569z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Integration of Ligand and Structure-Based Virtual Screening for the Identification of the First Dual Targeting Agent for Heat Shock Protein 90 (Hsp90) and Tubulin</span></div><div class="casAuthors">Knox, Andrew J. S.; Price, Trevor; Pawlak, Michal; Golfis, Georgia; Flood, Christopher T.; Fayne, Darren; Williams, D. Clive; Meegan, Mary J.; Lloyd, David G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2177-2180</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We describe the discovery of a novel indazole-based scaffold that represents the "first-in-class" dual Hsp90/tubulin binding compd.  Individual known ligands for both targets shared similar 3',4',5'-trimethoxyphenyl cores, and from this it was hypothesized that application of an integrated ligand and structure-based virtual screening (VS) workflow could yield a single scaffold with dual binding affinity.  Following validation of the VS protocol, we successfully identified a novel dual inhibitor, sourced from a com. screening collection of 160 000 compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRptEHjoTCsLVg90H21EOLACvtfcHk0liuz2gveSBvtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktFGrt70%253D&md5=c8268f36a0da627404be37696c5afe4b</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1021%2Fjm801569z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801569z%26sid%3Dliteratum%253Aachs%26aulast%3DKnox%26aufirst%3DA.%2BJ.%26aulast%3DPrice%26aufirst%3DT.%26aulast%3DPawlak%26aufirst%3DM.%26aulast%3DGolfis%26aufirst%3DG.%26aulast%3DFlood%26aufirst%3DC.%2BT.%26aulast%3DFayne%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DD.%2BC.%26aulast%3DMeegan%26aufirst%3DM.%2BJ.%26aulast%3DLloyd%26aufirst%3DD.%2BG.%26atitle%3DIntegration%2520of%2520ligand%2520and%2520structure-based%2520virtual%2520screening%2520for%2520the%2520identification%2520of%2520the%2520first%2520dual%2520targeting%2520agent%2520for%2520heat%2520shock%2520protein%252090%2520%2528Hsp90%2529%2520and%2520tubulin%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2177%26epage%3D2180%26doi%3D10.1021%2Fjm801569z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, B.</span></span> <span> </span><span class="NLM_article-title">Anti-tumor selectivity of a novel tubulin and HSP90 dual-targeting inhibitor in non-small cell lung cancer models</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">351</span>– <span class="NLM_lpage">360</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2013.05.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.bcp.2013.05.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=23743233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVWgtb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2013&pages=351-360&author=Q.+Zhangauthor=S.+Zhaiauthor=L.+Liauthor=X.+Liauthor=H.+Zhouauthor=A.+Liuauthor=G.+Suauthor=Q.+Muauthor=Y.+Duauthor=B.+Yan&title=Anti-tumor+selectivity+of+a+novel+tubulin+and+HSP90+dual-targeting+inhibitor+in+non-small+cell+lung+cancer+models&doi=10.1016%2Fj.bcp.2013.05.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-tumor selectivity of a novel Tubulin and HSP90 dual-targeting inhibitor in non-small cell lung cancer models</span></div><div class="casAuthors">Zhang, Qiu; Zhai, Shumei; Li, Liwen; Li, Xiue; Zhou, Hongyu; Liu, Aifeng; Su, Gaoxing; Mu, Qingxin; Du, Yuhong; Yan, Bing</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">351-360</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Dose-limiting toxicity is a main road blocker for successful cancer chemotherapy.  By phenotype screening, a novel chem. agent 2-(2-Chlorophenylimino)-5-(4-dimethylamino-benzylidene) thiazolidin-4-one (CDBT) was found to strongly inhibit the proliferation of non-small cell lung cancer (NSCLC) cells H460 and H322 while displaying no obvious toxicity to normal fast-dividing fibroblast cells NHFB and WI-38 at a concn. 100-fold higher than its EC50 to NSCLC cells.  CDBT targets microtubule and heat shock protein 90 (HSP90) simultaneously with moderate affinities compared to microtubule targeting Colchicine and HSP90 inhibitor 17-dimethylaminoethylamino-17-demethoxygaldanamcyin (17-DMAG).  CDBT blocks microtubule formation, decreases cancer-essential proteins CRAF-1, ERBB2 and phosphorylated AKT, and causes G2/M arrest and apoptosis.  The moderate inhibitory effects of CDBT on targets require a higher cellular concn. of targets, a situation only exist in cancer cells.  This accounts for its good cancer selectivity.  Furthermore, CDBT effectively inhibits tumor growth by 62.4% relative to the vehicle control after i.p. administration at 30 mg/kg for 11 days while showing no toxicity to normal tissues in NSCLC H460 xenograft mouse model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr435e-wAVfCrVg90H21EOLACvtfcHk0liuz2gveSBvtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVWgtb3N&md5=13bdd37754a95a1352ba70b611d74d88</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2013.05.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2013.05.019%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DZhai%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DA.%26aulast%3DSu%26aufirst%3DG.%26aulast%3DMu%26aufirst%3DQ.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DB.%26atitle%3DAnti-tumor%2520selectivity%2520of%2520a%2520novel%2520tubulin%2520and%2520HSP90%2520dual-targeting%2520inhibitor%2520in%2520non-small%2520cell%2520lung%2520cancer%2520models%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2013%26volume%3D86%26spage%3D351%26epage%3D360%26doi%3D10.1016%2Fj.bcp.2013.05.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, B.</span></span> <span> </span><span class="NLM_article-title">P-glycoprotein-evading anti-tumor activity of a novel tubulin and HSP90 dual inhibitor in a non-small-cell lung cancer model</span>. <i>J. Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">66</span>– <span class="NLM_lpage">76</span>, <span class="refDoi"> DOI: 10.1254/jphs.14050FP</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1254%2Fjphs.14050FP" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=25185500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1OgsLzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2014&pages=66-76&author=Q.+Zhangauthor=S.+Zhaiauthor=L.+Liauthor=X.+Liauthor=C.+Jiangauthor=C.+Zhangauthor=B.+Yan&title=P-glycoprotein-evading+anti-tumor+activity+of+a+novel+tubulin+and+HSP90+dual+inhibitor+in+a+non-small-cell+lung+cancer+model&doi=10.1254%2Fjphs.14050FP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">P-glycoprotein-evading anti-tumor activity of a novel tubulin and HSP90 dual inhibitor in a non-small-cell lung cancer model</span></div><div class="casAuthors">Zhang, Qiu; Zhai, Shumei; Li, Liwen; Li, Xiue; Jiang, Cuijuan; Zhang, Chengke; Yan, Bing</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological Sciences (Tokyo, Japan)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">66-76</span>CODEN:
                <span class="NLM_cas:coden">JPSTGJ</span>;
        ISSN:<span class="NLM_cas:issn">1347-8613</span>.
    
            (<span class="NLM_cas:orgname">Japanese Pharmacological Society</span>)
        </div><div class="casAbstract">P-glycoprotein (P-gp)-induced drug resistance is a major road block for successful cancer chemotherapy.  Through phenotypic screening, the compd. 2-(2-chlorophenylimino)-5-(4-dimethylaminobenzylidene) thiazolidin-4-one (CDBT) was discovered to have potent anti-tumor activity in P-gp over-expressing drug-resistant non-small-cell lung cancer (NSCLC) H460TaxR cells.  Here, we report mechanistic investigations of the P-gp-evading anti-tumor activity of CDBT.  CDBT is evidently not a P-gp substrate and escapes the P-gp efflux pump.  As a novel microtubule and heat shock protein 90 (HSP90) dual targeting inhibitor, CDBT causes the destabilization of microtubules and degrdn. of HSP90 client proteins CRAF-1 and ERBB2, resulting in cell cycle arrest at the G2/M phase and apoptosis.  Furthermore, CDBT effectively inhibits tumor growth by 60.4% relative to the vehicle control after i.p. administration at 30 mg/kg for 11 days and shows no toxicity in normal tissues in the NSCLC H460TaxR xenograft mouse model.  Our data suggest a novel drug discovery strategy to combat P-gp over-expressing drug-resistant NSCLC cancer cells with a single therapeutic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozWR0jNMTVmbVg90H21EOLACvtfcHk0li8-ZBnsdauPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1OgsLzP&md5=03be83b93e7235ba627900687da66a14</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1254%2Fjphs.14050FP&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1254%252Fjphs.14050FP%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DZhai%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DYan%26aufirst%3DB.%26atitle%3DP-glycoprotein-evading%2520anti-tumor%2520activity%2520of%2520a%2520novel%2520tubulin%2520and%2520HSP90%2520dual%2520inhibitor%2520in%2520a%2520non-small-cell%2520lung%2520cancer%2520model%26jtitle%3DJ.%2520Pharmacol.%2520Sci.%26date%3D2014%26volume%3D126%26spage%3D66%26epage%3D76%26doi%3D10.1254%2Fjphs.14050FP" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nepali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. Y.</span></span> <span> </span><span class="NLM_article-title">2-Aroylquinoline-5,8-diones as potent anticancer agents displaying tubulin and heat shock protein 90 (HSP90) inhibition</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">716</span>– <span class="NLM_lpage">723</span>, <span class="refDoi"> DOI: 10.1039/C5OB02100F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1039%2FC5OB02100F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=26694589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyqs7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=716-723&author=K.+Nepaliauthor=S.+Kumarauthor=H.+L.+Huangauthor=F.+C.+Kuoauthor=C.+H.+Leeauthor=C.+C.+Kuoauthor=T.+K.+Yehauthor=Y.+H.+Liauthor=J.+Y.+Changauthor=J.+P.+Liouauthor=H.+Y.+Lee&title=2-Aroylquinoline-5%2C8-diones+as+potent+anticancer+agents+displaying+tubulin+and+heat+shock+protein+90+%28HSP90%29+inhibition&doi=10.1039%2FC5OB02100F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">2-Aroylquinoline-5,8-diones as potent anticancer agents displaying tubulin and heat shock protein 90 (HSP90) inhibition</span></div><div class="casAuthors">Nepali, Kunal; Kumar, Sunil; Huang, Hsiang-Ling; Kuo, Fei-Chiao; Lee, Cheng-Hsin; Kuo, Ching-Chuan; Yeh, Teng-Kuang; Li, Yu-Hsuan; Chang, Jang-Yang; Liou, Jing-Ping; Lee, Hsueh-Yun</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">716-723</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Amine-substituted aroylquinolinediones I [R = MeO, Me2N, EtNH, H2C:CHCH2NH, Me2CH2CH2NH, 2-(4-morpholinyl)ethyl, PhNH, 1-pyrrolidinyl, 4-morpholinyl, 4-Me-1-piperazinyl, H; R1 = H, 4-morpholinyl, Me2N, 1-pyrrolidinyl] were prepd. and tested for inhibition of human cancer cell lines; selected compds. were tested for inhibition of tubulin polymn. and for binding to the colchicine tubulin binding site and for the inhibition of HSP90 activity (and consequent induction of HSP70 and degrdn. of Akt).  I were prepd. in seven steps from 1,2,4-trimethoxybenzene, crotonaldehyde, 3,4,5-trimethoxyphenylmagnesium bromide, and amines.  The use of 6-methoxy-substituted quinolinedione intermediates allowed regioselective prepn. of the corresponding 6-aminated products and assisted in detn. of product regiochem.  Among the compds. prepd., I (R = Me2N; R1 = H) and I (R = H; R1 = 1-pyrrolidinyl) exhibited antiproliferative activity against human cancer cell lines, with mean IC50 values of 0.14 μM and 0.27 μM, resp.  I (R = H; R1 = 1-pyrrolidinyl) inhibited tubulin polymn. with an IC50 value of 5.9 μM.  I (R = H; R1 = 1-pyrrolidinyl) caused induction of HSP70 and degrdn. of Akt consistent with inhibition of HSP90.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr76oB0EPM7kLVg90H21EOLACvtfcHk0lj6Eql7zKQZww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyqs7fO&md5=f57c77b0ea7d4d8a78225f8fcbebd81f</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1039%2FC5OB02100F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5OB02100F%26sid%3Dliteratum%253Aachs%26aulast%3DNepali%26aufirst%3DK.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DH.%2BL.%26aulast%3DKuo%26aufirst%3DF.%2BC.%26aulast%3DLee%26aufirst%3DC.%2BH.%26aulast%3DKuo%26aufirst%3DC.%2BC.%26aulast%3DYeh%26aufirst%3DT.%2BK.%26aulast%3DLi%26aufirst%3DY.%2BH.%26aulast%3DChang%26aufirst%3DJ.%2BY.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26aulast%3DLee%26aufirst%3DH.%2BY.%26atitle%3D2-Aroylquinoline-5%252C8-diones%2520as%2520potent%2520anticancer%2520agents%2520displaying%2520tubulin%2520and%2520heat%2520shock%2520protein%252090%2520%2528HSP90%2529%2520inhibition%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2016%26volume%3D14%26spage%3D716%26epage%3D723%26doi%3D10.1039%2FC5OB02100F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span> <span> </span><span class="NLM_article-title">Discovery of a dual tubulin polymerization and cell division cycle 20 homologue inhibitor via structural modification on apcin</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">4685</span>– <span class="NLM_lpage">4700</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b02097</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b02097" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntFCnur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=4685-4700&author=P.+Huangauthor=X.+Leauthor=F.+Huangauthor=J.+Yangauthor=H.+Yangauthor=J.+Maauthor=G.+Huauthor=Q.+Liauthor=Z.+Chen&title=Discovery+of+a+dual+tubulin+polymerization+and+cell+division+cycle+20+homologue+inhibitor+via+structural+modification+on+apcin&doi=10.1021%2Facs.jmedchem.9b02097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Dual Tubulin Polymerization and Cell Division Cycle 20 Homologue Inhibitor via Structural Modification on Apcin</span></div><div class="casAuthors">Huang, Pan; Le, Xiangyang; Huang, Fei; Yang, Jie; Yang, Haofeng; Ma, Junlong; Hu, Gaoyun; Li, Qianbin; Chen, Zhuo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4685-4700</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Apcin is one of the few compds. that have been previously reported as a Cdc20 specific inhibitor, although Cdc20 is a very promising drug target.  We reported here the design, synthesis, and biol. evaluations of 2,2,2-trichloro-1-aryl carbamate derivs. as Cdc20 inhibitors.  Among these derivs., compd. 9f(I) was much more efficient than the pos. compd. apcin in inhibiting cancer cell growth, but it had approx. the same binding affinity with apcin in SPR assays.  It is possible that another mechanism of action might exist.  Further evidence demonstrated that compd. 9f also inhibited tubulin polymn., disorganized the microtubule network, and blocked the cell cycle at the M phase with changes in the expression of cyclins.  Thus, it induced apoptosis through the activation of caspase-3 and PARP.  In addn., compd. 9f inhibited cell migration and invasion in a concn.-dependent manner.  These results provide guidance for developing the current series as potential new anticancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTMpILvY9XMbVg90H21EOLACvtfcHk0lj6Eql7zKQZww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntFCnur0%253D&md5=4757f94005b5221e7f837981d4a27194</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b02097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b02097%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DP.%26aulast%3DLe%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DZ.%26atitle%3DDiscovery%2520of%2520a%2520dual%2520tubulin%2520polymerization%2520and%2520cell%2520division%2520cycle%252020%2520homologue%2520inhibitor%2520via%2520structural%2520modification%2520on%2520apcin%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D4685%26epage%3D4700%26doi%3D10.1021%2Facs.jmedchem.9b02097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghinet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuru, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floquet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubois, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farce, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigo, B.</span></span> <span> </span><span class="NLM_article-title">Enhanced antitumor potential induced by chloroacetate-loaded benzophenones acting as fused tubulin-pyruvate dehydrogenase kinase 1 (PDHK1) ligands</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">103643</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2020.103643</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.bioorg.2020.103643" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=32035298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisV2ntbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2020&pages=103643&author=A.+Ghinetauthor=X.+Thuruauthor=E.+Floquetauthor=J.+Duboisauthor=A.+Farceauthor=B.+Rigo&title=Enhanced+antitumor+potential+induced+by+chloroacetate-loaded+benzophenones+acting+as+fused+tubulin-pyruvate+dehydrogenase+kinase+1+%28PDHK1%29+ligands&doi=10.1016%2Fj.bioorg.2020.103643"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced antitumor potential induced by chloroacetate-loaded benzophenones acting as fused tubulin-pyruvate dehydrogenase kinase 1 (PDHK1) ligands</span></div><div class="casAuthors">Ghinet, Alina; Thuru, Xavier; Floquet, Emilie; Dubois, Joelle; Farce, Amaury; Rigo, Benoit</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103643</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The majority of cancers detected every year are treated with anti-cancer compds.  Unfortunately, many tumors become resistant to antineoplastic drugs.  One option is to use cocktails of compds. acting on different targets to try to overcome the resistant cells.  This type of approach can produce good results, but is often accompanied by a sharp increase of assocd. side effects.  The strategy presented herein focuses on the use of a single compd. acting on two different biol. targets enhancing potency and lowering the toxicity of the chemotherapy.  In this light, the approach presented in the current study involves the dual inhibition of human pyruvate dehydrogenase kinase-1 (PDHK1) and tubulin polymn. using mono-, di- and tri-chloroacetate-loaded benzophenones and benzothiophenones.  Synthesized mols. were evaluated in vitro on tubulin polymn. and on pyruvate dehydrogenase kinase 1.  The cell cycle distribution after treatment of DA1-3b leukemic cells with active compds. was tested.  Twenty-two benzo(thio)phenones have been selected by the National Cancer Institute (USA) for evaluation of their anti-proliferative potential against NCI-60 cancer cell lines including multidrug-resistant tumor cell lines.  Seventeen mols. proved to be very effective in combating the growth of tumor cells exhibiting inhibitory activities up to nanomolar range.  The mol. docking of best antitumor mols. in the study was realized with GOLD in the tubulin and PDHK1 binding sites, and allowed to understand the positioning of active mols.  Chloroacetate-loaded benzo(thio)phenones are dual targeted tubulin- and pyruvate dehydrogenase kinase 1 (PDHK1)-binding antitumor agents and exhibited superior antitumor activity compared to non-chlorinated congeners particularly on leukemia, colon, melanoma and breast cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqM4jINFrNYU7Vg90H21EOLACvtfcHk0liCiNnHid-hmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisV2ntbc%253D&md5=1045b4b0a47ec2dced17dec680bc50dc</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2020.103643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2020.103643%26sid%3Dliteratum%253Aachs%26aulast%3DGhinet%26aufirst%3DA.%26aulast%3DThuru%26aufirst%3DX.%26aulast%3DFloquet%26aufirst%3DE.%26aulast%3DDubois%26aufirst%3DJ.%26aulast%3DFarce%26aufirst%3DA.%26aulast%3DRigo%26aufirst%3DB.%26atitle%3DEnhanced%2520antitumor%2520potential%2520induced%2520by%2520chloroacetate-loaded%2520benzophenones%2520acting%2520as%2520fused%2520tubulin-pyruvate%2520dehydrogenase%2520kinase%25201%2520%2528PDHK1%2529%2520ligands%26jtitle%3DBioorg.%2520Chem.%26date%3D2020%26volume%3D96%26spage%3D103643%26doi%3D10.1016%2Fj.bioorg.2020.103643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malik, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krohn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saleem, R. S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faisal, A.</span></span> <span> </span><span class="NLM_article-title">Natural and semisynthetic chalcones as dual FLT3 and microtubule polymerization inhibitors</span>. <i>J. Nat. Prod.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">3111</span>– <span class="NLM_lpage">3121</span>, <span class="refDoi"> DOI: 10.1021/acs.jnatprod.0c00699</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jnatprod.0c00699" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFShtbrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2020&pages=3111-3121&author=H.+S.+Malikauthor=A.+Bilalauthor=R.+Ullahauthor=M.+Iqbalauthor=S.+Khanauthor=I.+Ahmedauthor=K.+Krohnauthor=R.+S.+Z.+Saleemauthor=H.+Hussainauthor=A.+Faisal&title=Natural+and+semisynthetic+chalcones+as+dual+FLT3+and+microtubule+polymerization+inhibitors&doi=10.1021%2Facs.jnatprod.0c00699"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Natural and Semisynthetic Chalcones as Dual FLT3 and Microtubule Polymerization Inhibitors</span></div><div class="casAuthors">Malik, Haleema Sadia; Bilal, Aishah; Ullah, Rahim; Iqbal, Maheen; Khan, Sardraz; Ahmed, Ishtiaq; Krohn, Karsten; Saleem, Rahman Shah Zaib; Hussain, Hidayat; Faisal, Amir</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Natural Products</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3111-3121</span>CODEN:
                <span class="NLM_cas:coden">JNPRDF</span>;
        ISSN:<span class="NLM_cas:issn">0163-3864</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society-American Society of Pharmacognosy</span>)
        </div><div class="casAbstract">Activating mutations in FLT3 receptor tyrosine kinase are found in a third of acute myeloid leukemia (AML) patients and are assocd. with disease relapse and a poor prognosis.  The majority of these mutations are internal tandem duplications (ITDs) in the juxtamembrane domain of FLT3, which have been validated as a therapeutic target.  The clin. success of selective inhibitors targeting oncogenic FLT3, however, has been limited due to the acquisition of drug resistance.  Herein the identification of a dual FLT3/microtubule polymn. inhibitor, chalcone 4 (2'-allyloxy-4,4'-dimethoxychalcone), is reported through screening of 15 related chalcones for differential antiproliferative activity in leukemia cell lines dependent on FLT3-ITD (MV-4-11) or BCR-ABL (K562) oncogenes and by subsequent screening for mitotic inducers in the HCT116 cell line.  Three natural chalcones (1-3) were found to be differentially more potent toward the MV-4-11 (FLT3-ITD) cell line compared to the K562 (BCR-ABL) cell line.  Notably, the new semisynthetic chalcone 4, which is a 2'-O-allyl analog of the natural chalcone 3, was found to be more potent toward the FLT3-ITD+ cell line and inhibited FLT3 signaling in FLT3-dependent cells.  An in vitro kinase assay confirmed that chalcone 4 directly inhibited FLT3.  Moreover, chalcone 4 induced mitotic arrest in these cells and inhibited tubulin polymn. in both cellular and biochem. assays.  Treatment of MV-4-11 cells with this inhibitor for 24 and 48 h resulted in apoptotic cell death.  Finally, chalcone 4 was able to overcome TKD mutation-mediated acquired resistance to FLT3 inhibitors in a MOLM-13 cell line expressing FLT3-ITD with the D835Y mutation.  Chalcone 4 is, therefore, a promising lead for the discovery of dual-target FLT3 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTRPjcQDcXK7Vg90H21EOLACvtfcHk0liCiNnHid-hmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFShtbrO&md5=f6849db4f55a74fe7e54bced928c7a3a</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1021%2Facs.jnatprod.0c00699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jnatprod.0c00699%26sid%3Dliteratum%253Aachs%26aulast%3DMalik%26aufirst%3DH.%2BS.%26aulast%3DBilal%26aufirst%3DA.%26aulast%3DUllah%26aufirst%3DR.%26aulast%3DIqbal%26aufirst%3DM.%26aulast%3DKhan%26aufirst%3DS.%26aulast%3DAhmed%26aufirst%3DI.%26aulast%3DKrohn%26aufirst%3DK.%26aulast%3DSaleem%26aufirst%3DR.%2BS.%2BZ.%26aulast%3DHussain%26aufirst%3DH.%26aulast%3DFaisal%26aufirst%3DA.%26atitle%3DNatural%2520and%2520semisynthetic%2520chalcones%2520as%2520dual%2520FLT3%2520and%2520microtubule%2520polymerization%2520inhibitors%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D2020%26volume%3D83%26spage%3D3111%26epage%3D3121%26doi%3D10.1021%2Facs.jnatprod.0c00699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moise, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bîcu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farce, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubois, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghinet, A.</span></span> <span> </span><span class="NLM_article-title">Indolizine-phenothiazine hybrids as the first dual inhibitors of tubulin polymerization and farnesyltransferase with synergistic antitumor activity</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">104184</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2020.104184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.bioorg.2020.104184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=32891861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVSnu7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2020&pages=104184&author=I.+M.+Moiseauthor=E.+B%C3%AEcuauthor=A.+Farceauthor=J.+Duboisauthor=A.+Ghinet&title=Indolizine-phenothiazine+hybrids+as+the+first+dual+inhibitors+of+tubulin+polymerization+and+farnesyltransferase+with+synergistic+antitumor+activity&doi=10.1016%2Fj.bioorg.2020.104184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Indolizine-phenothiazine hybrids as the first dual inhibitors of tubulin polymerization and farnesyltransferase with synergistic antitumor activity</span></div><div class="casAuthors">Moise, Iuliana-Monica; Bicu, Elena; Farce, Amaury; Dubois, Joelle; Ghinet, Alina</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104184</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of indolizine-phenothiazine hybrids amides I [R = 8-Me, 7-OMe, 6-Br] and ketones such as II [R = H, 5-Me, 7-Me, etc.; R1 = H, Me] was obtained in a 4-step procedure.  The combination of the two heterocycles provided potent tubulin polymn. inhibitors with similar efficiency as the ref. phenstatin and (-)-desoxypodophyllotoxin.  Ketones II were also able to inhibit human farnesyltransferase (FTase) in vitro.  Interestingly, three mols. II [R = 5-Me, 7-Me, 7-OMe, R1 = H] were very effective against both considered biol. targets.  Nine indolizine-phenothiazine hybrids I [R = 8-Me, 7-OMe], II [R = H, 5-Me, 5-Me, 7-Me, 6,8-di-Me, 7-OMe, R1 = H] and bis-(5-methylindolizin-1-yl)carbonyl(10H-phenothiazin-3,7-diyl) were evaluated for their cell growth inhibition potential on the NCI-60 cancer cell lines panel.  Ketones II [R = H, 5-Me, 5-Me, 7-Me, 6,8-di-Me, 7-OMe, R1 = H] were the most active and arrested the cell growth of almost all tested cancer cells, also displayed cytotoxicity potential with GI50 values in the low nanomolar range.  The most sensitive cell lines upon treatment with indolizine-phenothiazine hybrids I and II were NCI-H522 (lung cancer), COLO-205 and HT29 (colon cancer), SF-539 (human glioblastoma), OVCAR-3 (ovarian cancer), A498 (renal cancer) and esp. MDA-MB-435 (melanoma).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXqREImYNM-rVg90H21EOLACvtfcHk0liCiNnHid-hmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVSnu7nK&md5=0ba0dadcda1f2b30bf0c8a3d684bf15f</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2020.104184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2020.104184%26sid%3Dliteratum%253Aachs%26aulast%3DMoise%26aufirst%3DI.%2BM.%26aulast%3DB%25C3%25AEcu%26aufirst%3DE.%26aulast%3DFarce%26aufirst%3DA.%26aulast%3DDubois%26aufirst%3DJ.%26aulast%3DGhinet%26aufirst%3DA.%26atitle%3DIndolizine-phenothiazine%2520hybrids%2520as%2520the%2520first%2520dual%2520inhibitors%2520of%2520tubulin%2520polymerization%2520and%2520farnesyltransferase%2520with%2520synergistic%2520antitumor%2520activity%26jtitle%3DBioorg.%2520Chem.%26date%3D2020%26volume%3D103%26spage%3D104184%26doi%3D10.1016%2Fj.bioorg.2020.104184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gurgis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Åkerfeldt, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemin, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johns, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chircop, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, L.</span></span> <span> </span><span class="NLM_article-title">Cytotoxic activity of the MK2 inhibitor CMPD1 in glioblastoma cells is independent of MK2</span>. <i>Cell Death Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">15028</span>, <span class="refDoi"> DOI: 10.1038/cddiscovery.2015.28</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1038%2Fcddiscovery.2015.28" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=27551460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1aisrnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=15028&author=F.+Gurgisauthor=M.+C.+%C3%85kerfeldtauthor=B.+Hengauthor=C.+Wongauthor=S.+Adamsauthor=G.+J.+Guilleminauthor=T.+G.+Johnsauthor=M.+Chircopauthor=L.+Munoz&title=Cytotoxic+activity+of+the+MK2+inhibitor+CMPD1+in+glioblastoma+cells+is+independent+of+MK2&doi=10.1038%2Fcddiscovery.2015.28"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Cytotoxic activity of the MK2 inhibitor CMPD1 in glioblastoma cells is independent of MK2</span></div><div class="casAuthors">Gurgis, F. M. S.; Akerfeldt, M. C.; Heng, B.; Wong, C.; Adams, S.; Guillemin, G. J.; Johns, T. G.; Chircop, M.; Munoz, L.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15028</span>CODEN:
                <span class="NLM_cas:coden">CDDEB5</span>;
        ISSN:<span class="NLM_cas:issn">2058-7716</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">MAPK-activated protein kinase 2 (MK2) is a checkpoint kinase involved in the DNA damage response.  MK2 inhibition enhances the efficacy of chemotherapeutic agents; however, whether MK2 inhibition alone, without concurrent chemotherapy, would attenuate survival of cancer cells has not been investigated.  CMPD1 is a widely used non-ATP competitive inhibitor that prevents MK2 phosphorylation.  We employed CMPD1 together with MK2 knock-down and ATP-competitive MK2 inhibitor III (MK2i) in a panel of glioblastoma cells to assess whether MK2 inhibition could induce cancer cell death.  While CMPD1 was effective at selective killing of cancer cells, MK2i and MK2 knock-down had no effect on viability of glioblastoma cells.  CMPD1 treatment induced a significant G2/M arrest but MK2i-treated cells were only minimally arrested at G1 phase.  Intriguingly, at doses that were cytotoxic to glioblastoma cells, CMPD1 did not inhibit phosphorylation of MK2 and of its downstream substrate Hsp27.  These results suggest that CMPD1 exhibits cytotoxic activity independently of MK2 inhibition.  Indeed, we identified tubulin as a primary target of the CMPD1 cytotoxic activity.  This study demonstrates how functional and mechanistic studies with appropriate selection of test compds., combining genetic knock-down and pharmacol. inhibition, coordinating timing and dose levels enabled us to uncover the primary target of an MK2 inhibitor commonly used in the research community.  Tubulin is emerging as one of the most common non-kinase targets for kinase inhibitors and we propose that potential tubulin-targeting activity should be assessed in preclin. pharmacol. studies of all novel kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSxasb1evR3bVg90H21EOLACvtfcHk0liCiNnHid-hmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1aisrnP&md5=9648be4c4664b6b7360e6c05a1714217</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1038%2Fcddiscovery.2015.28&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcddiscovery.2015.28%26sid%3Dliteratum%253Aachs%26aulast%3DGurgis%26aufirst%3DF.%26aulast%3D%25C3%2585kerfeldt%26aufirst%3DM.%2BC.%26aulast%3DHeng%26aufirst%3DB.%26aulast%3DWong%26aufirst%3DC.%26aulast%3DAdams%26aufirst%3DS.%26aulast%3DGuillemin%26aufirst%3DG.%2BJ.%26aulast%3DJohns%26aufirst%3DT.%2BG.%26aulast%3DChircop%26aufirst%3DM.%26aulast%3DMunoz%26aufirst%3DL.%26atitle%3DCytotoxic%2520activity%2520of%2520the%2520MK2%2520inhibitor%2520CMPD1%2520in%2520glioblastoma%2520cells%2520is%2520independent%2520of%2520MK2%26jtitle%3DCell%2520Death%2520Discovery%26date%3D2015%26volume%3D1%26spage%3D15028%26doi%3D10.1038%2Fcddiscovery.2015.28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tripodi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliarin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fumagalli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fusi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frattini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coccetti, P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of 1,4-diaryl-2-azetidinones as specific anticancer agents: activation of adenosine monophosphate activated protein kinase and induction of apoptosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">2112</span>– <span class="NLM_lpage">2124</span>, <span class="refDoi"> DOI: 10.1021/jm201344a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201344a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFCjsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2112-2124&author=F.+Tripodiauthor=R.+Pagliarinauthor=G.+Fumagalliauthor=A.+Bigiauthor=P.+Fusiauthor=F.+Orsiniauthor=M.+Frattiniauthor=P.+Coccetti&title=Synthesis+and+biological+evaluation+of+1%2C4-diaryl-2-azetidinones+as+specific+anticancer+agents%3A+activation+of+adenosine+monophosphate+activated+protein+kinase+and+induction+of+apoptosis&doi=10.1021%2Fjm201344a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of 1,4-diaryl-2-azetidinones as specific anticancer agents: Activation of adenosine monophosphate activated protein kinase and induction of apoptosis</span></div><div class="casAuthors">Tripodi, Farida; Pagliarin, Roberto; Fumagalli, Gabriele; Bigi, Alessandra; Fusi, Paola; Orsini, Fulvia; Frattini, Milo; Coccetti, Paola</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2112-2124</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 1,4-diaryl-2-azetidinones, e.g., I, were synthesized and evaluated for antiproliferative activity, cell cycle effects, and apoptosis induction.  Strong cytotoxicity was obsd. with the best compds. (±)-trans-20, (±)-trans-21, and enantiomers (+)-trans-20 and (+)-trans-21, which exhibited IC50 values of 3-13 nM against duodenal adenocarcinoma cells.  They induced inhibition of tubulin polymn. and subsequent G2/M arrest.  This effect was accompanied by activation of AMP-activated protein kinase, activation of caspase-3, and induction of apoptosis.  Addnl., the most potent compds. displayed antiproliferative activity against different colon cancer cell lines, opening the route to a new class of potential therapeutic agents against colon cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrunWqTtiFUv7Vg90H21EOLACvtfcHk0liOSetGW8EYmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFCjsb8%253D&md5=728ba8ed7433a73953bc3afe6f944aeb</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1021%2Fjm201344a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201344a%26sid%3Dliteratum%253Aachs%26aulast%3DTripodi%26aufirst%3DF.%26aulast%3DPagliarin%26aufirst%3DR.%26aulast%3DFumagalli%26aufirst%3DG.%26aulast%3DBigi%26aufirst%3DA.%26aulast%3DFusi%26aufirst%3DP.%26aulast%3DOrsini%26aufirst%3DF.%26aulast%3DFrattini%26aufirst%3DM.%26aulast%3DCoccetti%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%25201%252C4-diaryl-2-azetidinones%2520as%2520specific%2520anticancer%2520agents%253A%2520activation%2520of%2520adenosine%2520monophosphate%2520activated%2520protein%2520kinase%2520and%2520induction%2520of%2520apoptosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2112%26epage%3D2124%26doi%3D10.1021%2Fjm201344a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lötsch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geisslinger, G.</span></span> <span> </span><span class="NLM_article-title">Low-dose drug combinations along molecular pathways could maximize therapeutic effectiveness while minimizing collateral adverse effects</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1001</span>– <span class="NLM_lpage">1006</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2011.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.drudis.2011.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=22016087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A280%3ADC%252BC38%252FjtVygtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=1001-1006&author=J.+L%C3%B6tschauthor=G.+Geisslinger&title=Low-dose+drug+combinations+along+molecular+pathways+could+maximize+therapeutic+effectiveness+while+minimizing+collateral+adverse+effects&doi=10.1016%2Fj.drudis.2011.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Low-dose drug combinations along molecular pathways could maximize therapeutic effectiveness while minimizing collateral adverse effects</span></div><div class="casAuthors">Lotsch Jorn; Geisslinger Gerd</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">23-24</span>),
    <span class="NLM_cas:pages">1001-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Increasing knowledge of molecular signaling processes has enabled the identification of drug targets that synergistically address multifactorial symptoms along several contributing pathways.  The idea behind 'polypills' is that minor doses of pharmacodynamically interacting drugs would selectively achieve intended clinical effects.  Analogously, monofactorial symptoms could be addressed vertically along their main pathway.  Clinical selectivity follows from successive incomplete inhibitions of the pathological pathway at several steps.  Here, we discuss and exemplify of how successive inhibitions in the prostaglandin E2 (PGE(2)) signaling pathway could achieve anti-inflammatory and analgesic effects while preserving physiological PGE(2) signaling in organs of major toxicity.  Intentionally using intelligent low-dose drug combinations might provide an innovative therapeutic concept that directs combined small-drug effects towards a large, selective clinical effect with minor collateral damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQRu7M3C_0-j-dfST00W0BcfW6udTcc2eYcuq0Rxwh0dLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252FjtVygtg%253D%253D&md5=f88337f88016a3736e13e493dc064089</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B6tsch%26aufirst%3DJ.%26aulast%3DGeisslinger%26aufirst%3DG.%26atitle%3DLow-dose%2520drug%2520combinations%2520along%2520molecular%2520pathways%2520could%2520maximize%2520therapeutic%2520effectiveness%2520while%2520minimizing%2520collateral%2520adverse%2520effects%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26spage%3D1001%26epage%3D1006%26doi%3D10.1016%2Fj.drudis.2011.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doak, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobritzsch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kihlberg, J.</span></span> <span> </span><span class="NLM_article-title">How beyond rule of 5 drugs and clinical candidates bind to their targets</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2312</span>– <span class="NLM_lpage">2327</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01286</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Cgu77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2312-2327&author=B.+C.+Doakauthor=J.+Zhengauthor=D.+Dobritzschauthor=J.+Kihlberg&title=How+beyond+rule+of+5+drugs+and+clinical+candidates+bind+to+their+targets&doi=10.1021%2Facs.jmedchem.5b01286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets</span></div><div class="casAuthors">Doak, Bradley C.; Zheng, Jie; Dobritzsch, Doreen; Kihlberg, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2312-2327</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To improve discovery of drugs for difficult targets, the opportunities of chem. space beyond the rule of 5 (bRo5) were examd. by retrospective anal. of a comprehensive set of structures for complexes between drugs and clin. candidates and their targets.  The anal. illustrates the potential of compds. far beyond rule of 5 space to modulate novel and difficult target classes that have large, flat, and groove-shaped binding sites.  However, ligand efficiencies are significantly reduced for flat- and groove-shape binding sites, suggesting that adjustments of how to use such metrics are required.  Ligands bRo5 appear to benefit from an appropriate balance between rigidity and flexibility to bind with sufficient affinity to their targets, with macrocycles and nonmacrocycles being found to have similar flexibility.  However, macrocycles were more disk- and spherelike, which may contribute to their superior binding to flat sites, while rigidification of nonmacrocycles lead to rodlike ligands that bind well to groove-shaped binding sites.  These insights should contribute to altering perceptions of what targets are considered "druggable" and provide support for drug design in beyond rule of 5 space.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZD-h9VodiPLVg90H21EOLACvtfcHk0liOSetGW8EYmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Cgu77F&md5=a417b605d1a3ffbc7ee84706401f01f4</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01286%26sid%3Dliteratum%253Aachs%26aulast%3DDoak%26aufirst%3DB.%2BC.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DDobritzsch%26aufirst%3DD.%26aulast%3DKihlberg%26aufirst%3DJ.%26atitle%3DHow%2520beyond%2520rule%2520of%25205%2520drugs%2520and%2520clinical%2520candidates%2520bind%2520to%2520their%2520targets%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2312%26epage%3D2327%26doi%3D10.1021%2Facs.jmedchem.5b01286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">The physicochemical challenges of designing multiple ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">4961</span>– <span class="NLM_lpage">4970</span>, <span class="refDoi"> DOI: 10.1021/jm0603015</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0603015" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFejtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4961-4970&author=R.+Morphyauthor=Z.+Rankovic&title=The+physicochemical+challenges+of+designing+multiple+ligands&doi=10.1021%2Fjm0603015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">The Physicochemical Challenges of Designing Multiple Ligands</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4961-4970</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Compds. designed to bind more than one target can provide a therapeutic benefit relative to highly target-selective ligands.  The physicochem. properties of designed multiple ligands were found to be less druglike than those for preclin. compds. in general.  These properties are controlled by the superfamily to which the targets belong and the lead discovery strategy that was followed.  The properties for peptide G-protein-coupled receptor (GPCR) ligands were the least favorable for oral delivery, whereas transporter, monoamine GPCR, and oxidase ligands were the most druglike.  The lead discovery strategy, framework combination or screening, exerts a profound influence on the property values.  Combining the frameworks from two selective ligands often results in large, complex dual ligands, but druglike ligands can be achieved if the degree of framework overlap is maximized and the size of the selective ligands minimized.  For some target combinations, a screening approach may provide a route to smaller, less complex leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonGHbXyxgv4LVg90H21EOLACvtfcHk0lgcXGp83MOLIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFejtL4%253D&md5=c7a227848516d0aa58ed037a582943fe</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1021%2Fjm0603015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0603015%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DThe%2520physicochemical%2520challenges%2520of%2520designing%2520multiple%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4961%26epage%3D4970%26doi%3D10.1021%2Fjm0603015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engkvist, O.</span>; <span class="NLM_string-name">Chen, H.</span>; <span class="NLM_string-name">Bauer, U.</span></span> <i>Merged multiple ligands</i>; <span class="NLM_publisher-name">Wiley-VCH Verlag</span>, <span class="NLM_year">2017</span>; pp  <span class="NLM_fpage">247</span>– <span class="NLM_lpage">274</span>, <span class="refDoi"> DOI: 10.1002/9783527674381.ch9</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1002%2F9783527674381.ch9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=247-274&author=O.+Engkvist&author=H.+Chen&author=U.+Bauer&title=Merged+multiple+ligands"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1002%2F9783527674381.ch9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783527674381.ch9%26sid%3Dliteratum%253Aachs%26aulast%3DEngkvist%26aufirst%3DO.%26btitle%3DMerged%2520multiple%2520ligands%26pub%3DWiley-VCH%2520Verlag%26date%3D2017%26spage%3D247%26epage%3D274%26doi%3D10.1002%2F9783527674381.ch9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, A. M.</span></span> <span> </span><span class="NLM_article-title">Artificial intelligence in drug design-the storm before the calm?</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1150</span>– <span class="NLM_lpage">1152</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00500</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00500" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVKktL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1150-1152&author=A.+M.+Jordan&title=Artificial+intelligence+in+drug+design-the+storm+before+the+calm%3F&doi=10.1021%2Facsmedchemlett.8b00500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Artificial Intelligence in Drug Design-The Storm Before the Calm?</span></div><div class="casAuthors">Jordan, Allan M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1150-1152</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Artificial intelligence in drug design in experiencing a wave of excitement not seen since the emergence of computational chem. in the late 1980s and early 1990s.  Apparently failing to learn the lessons of recent history, we are promised imminent and pervasive solns. to the ills of drug design and significant increases in productivity as we seek to deliver innovative new therapeutics.  However, do significant issues remain to be answered before AI enters the day-to-day toolbox of the practicing medicinal chemist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBn1rYzHOJi7Vg90H21EOLACvtfcHk0lgcXGp83MOLIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVKktL7I&md5=b0a7a61b5046a024891b034f413fe894</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00500%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DA.%2BM.%26atitle%3DArtificial%2520intelligence%2520in%2520drug%2520design-the%2520storm%2520before%2520the%2520calm%253F%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D1150%26epage%3D1152%26doi%3D10.1021%2Facsmedchemlett.8b00500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hessler, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baringhaus, K. H.</span></span> <span> </span><span class="NLM_article-title">Artificial intelligence in drug design</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2520</span>, <span class="refDoi"> DOI: 10.3390/molecules23102520</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.3390%2Fmolecules23102520" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1ygurfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=2520&author=G.+Hesslerauthor=K.+H.+Baringhaus&title=Artificial+intelligence+in+drug+design&doi=10.3390%2Fmolecules23102520"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Artificial intelligence in drug design</span></div><div class="casAuthors">Hessler, Gerhard; Baringhaus, Karl-Heinz</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2520/1-2520/13</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Artificial Intelligence (AI) plays a pivotal role in drug discovery.  In particular artificial neural networks such as deep neural networks or recurrent networks drive this area.  Numerous applications in property or activity predictions like physicochem. and ADMET properties have recently appeared and underpin the strength of this technol. in quant. structure-property relationships (QSPR) or quant. structure-activity relationships (QSAR).  Artificial intelligence in de novo design drives the generation of meaningful new biol. active mols. towards desired properties.  Several examples establish the strength of artificial intelligence in this field.  Combination with synthesis planning and ease of synthesis is feasible and more and more automated drug discovery by computers is expected in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO50YM96eg57Vg90H21EOLACvtfcHk0lgcXGp83MOLIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1ygurfE&md5=7f01179fe4fdd97570aedcd1ad817c7f</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.3390%2Fmolecules23102520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules23102520%26sid%3Dliteratum%253Aachs%26aulast%3DHessler%26aufirst%3DG.%26aulast%3DBaringhaus%26aufirst%3DK.%2BH.%26atitle%3DArtificial%2520intelligence%2520in%2520drug%2520design%26jtitle%3DMolecules%26date%3D2018%26volume%3D23%26spage%3D2520%26doi%3D10.3390%2Fmolecules23102520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Du, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. H.</span></span> <span> </span><span class="NLM_article-title">New techniques and strategies in drug discovery</span>. <i>Chin. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1695</span>– <span class="NLM_lpage">1708</span>, <span class="refDoi"> DOI: 10.1016/j.cclet.2020.03.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.cclet.2020.03.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsVaqs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2020&pages=1695-1708&author=J.+T.+Duauthor=J.+Guoauthor=D.+W.+Kangauthor=Z.+H.+Liauthor=G.+Wangauthor=J.+B.+Wuauthor=Z.+Zhangauthor=H.+Fangauthor=X.+B.+Houauthor=Z.+J.+Huangauthor=G.+B.+Liauthor=X.+Y.+Luauthor=X.+Y.+Liuauthor=L.+Ouyangauthor=L.+Raoauthor=P.+Zhanauthor=X.+J.+Zhangauthor=Y.+H.+Zhang&title=New+techniques+and+strategies+in+drug+discovery&doi=10.1016%2Fj.cclet.2020.03.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">New techniques and strategies in drug discovery</span></div><div class="casAuthors">Du, Jintong; Guo, Jing; Kang, Dongwei; Li, Zhihong; Wang, Guan; Wu, Jianbing; Zhang, Zhen; Fang, Hao; Hou, Xuben; Huang, Zhangjian; Li, Guobo; Lu, Xiaoyun; Liu, Xinyong; Ouyang, Liang; Rao, Li; Zhan, Peng; Zhang, Xiaojin; Zhang, Yihua</div><div class="citationInfo"><span class="NLM_cas:title">Chinese Chemical Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1695-1708</span>CODEN:
                <span class="NLM_cas:coden">CCLEE7</span>;
        ISSN:<span class="NLM_cas:issn">1001-8417</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review. Perspective.  Great success has been witnessed in last decades, some new techniques and strategies have been widely used in drug discovery.  In this roadmap, several representative techniques and strategies are highlighted to show recent advances in this filed.  (A) A DOX protocol has been developed for accurate protein-ligand binding structure prediction, in which first principle method was used to rank the binding poses.  Validation against crystal structures have found that DOX prediction achieved an impressive success rate of 99%, indicating significant improvement over mol. docking method.  (B) Virtual target profiling is a compd.-centric strategy enabling a parallel implementation of interrogating compds. against various targets in a single screen, which has been used in hit/lead identification, drug repositioning, and mechanism-of-action studies.  Current and emerging methods for virtual target profiling are briefly summarized herein.  (C) Research on targeted autophagy to treat diseases has received encouraging progress.  However, due to the complexity of autophagy and disease, exptl. and in silico methods should be performed synergistically for the entire process.  This part focuses on in silico methods in autophagy research to promote their use in medicinal research.  (D) Histone deacetylases (HDACs) play important roles in various biol. functions through the deacetylation of lysine residues.  Recent studies demonstrated that HDACs, which possess low deacetylase activities, exhibited more efficient defatty-acylase activities.  Here, we review the defatty-acylase activity of HDACs and describe examples for the design of isoform selective HDAC inhibitor.  (E) The FDA approval of three kinase allosteric inhibitors and some others entering clin. study has spurred considerable interests in this targeted drug discovery area.  (F) Recent advances are reviewed in structure-based design of novel antiviral agents to combat drug resistance.  (G) Since nitric oxide (NO) exerts anticancer activity depending on its concn., optimal levels of NO in cancer cells is desirable.  In this minireview, we briefly describe recent advances in the research of NO-based anticancer agents by our group and present some opinions on the future development of these agents.  (H) The field of photoactivation strategies have been extensively developed for controlling chem. and biol. processes with light.  This review will summarize and provide insight into recent research advances in the understanding of photoactivatable mols. including photoactivatable caged prodrugs and photoswitchable mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp60y_k9ZgfoLVg90H21EOLACvtfcHk0lh9uVQKZKe-Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsVaqs7s%253D&md5=1b37a0ea77ee3e77dfd974ebf16f3e24</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1016%2Fj.cclet.2020.03.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cclet.2020.03.028%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DJ.%2BT.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DD.%2BW.%26aulast%3DLi%26aufirst%3DZ.%2BH.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DWu%26aufirst%3DJ.%2BB.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DFang%26aufirst%3DH.%26aulast%3DHou%26aufirst%3DX.%2BB.%26aulast%3DHuang%26aufirst%3DZ.%2BJ.%26aulast%3DLi%26aufirst%3DG.%2BB.%26aulast%3DLu%26aufirst%3DX.%2BY.%26aulast%3DLiu%26aufirst%3DX.%2BY.%26aulast%3DOuyang%26aufirst%3DL.%26aulast%3DRao%26aufirst%3DL.%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DX.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%2BH.%26atitle%3DNew%2520techniques%2520and%2520strategies%2520in%2520drug%2520discovery%26jtitle%3DChin.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D31%26spage%3D1695%26epage%3D1708%26doi%3D10.1016%2Fj.cclet.2020.03.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abola, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span> <span> </span><span class="NLM_article-title">Serial crystallography for structure-based drug discovery</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">830</span>– <span class="NLM_lpage">839</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2020.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.tips.2020.08.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=32950259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVeqtL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2020&pages=830-839&author=L.+Zhuauthor=X.+Chenauthor=E.+E.+Abolaauthor=L.+Jingauthor=W.+Liu&title=Serial+crystallography+for+structure-based+drug+discovery&doi=10.1016%2Fj.tips.2020.08.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Serial Crystallography for Structure-Based Drug Discovery</span></div><div class="casAuthors">Zhu, Lan; Chen, Xiaoyu; Abola, Enrique E.; Jing, Liang; Liu, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">830-839</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Rational drug discovery has greatly accelerated the development of safer and more efficacious therapeutics, assisted significantly by insights from exptl. detd. 3D structures of ligands in complex with their targets.  Serial crystallog. (SX) with X-ray free-electron lasers has enabled structural detd. using micrometer- or nanometer-size crystals.  This technol. applied in the past decade to solve structures of notoriously difficult-to-study drug targets at room temps., has now been adapted for use in synchrotron radiation facilities.  Ultrashort time scales allow time-resolved characterization of dynamic structural changes and pave the road to study the mol. mechanisms by 'mol. movie'.  This article summarizes the latest progress in SX technol. and deliberates its demanding applications in future structure-based drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohfNLnXuV617Vg90H21EOLACvtfcHk0lh9uVQKZKe-Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVeqtL%252FE&md5=8b180cb643b51b35fb929aa834bb547b</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2020.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2020.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DAbola%26aufirst%3DE.%2BE.%26aulast%3DJing%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26atitle%3DSerial%2520crystallography%2520for%2520structure-based%2520drug%2520discovery%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2020%26volume%3D41%26spage%3D830%26epage%3D839%26doi%3D10.1016%2Fj.tips.2020.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/medium/jm1c00100_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/medium/jm1c00100_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure and dynamic instability of the microtubule. The dynamic instability of the microtubule is driven by the hydrolysis of GTP on β-tubulin subunits, which enable the microtubule to switch between catastrophe and rescue (α-tubulin, wheat color; β-tubulin, blue).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/medium/jm1c00100_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Six binding sites of microtubule-target agents on tubulin (α-tubulin, wheat; β-tubulin, blue).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/medium/jm1c00100_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Design and SAR analysis of dual tubulin–RTK inhibitors <b>3</b>, <b>4</b>, <b>7</b>, and <b>8</b>. (A) Design and SAR summaries of dual tubulin–RTK inhibitors based on compounds <b>1</b> and <b>2</b>; (B) design and SAR summaries of dual tubulin–RTK inhibitors based on compounds <b>5</b> and <b>6</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/medium/jm1c00100_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Design and SAR analysis of dual tubulin–RTK inhibitors <b>11</b>, <b>14</b>, <b>16</b>, and <b>17</b>. (A) Design and SAR summary of dual tubulin–RTK inhibitor <b>11</b>; (B) chemical structure of DW532 (<b>14</b>); (C) chemical structure and modification process of dual tubulin–VEGFR inhibitor <b>16</b>; (D) chemical structure of dual tubulin–EGFR inhibitor <b>17</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/medium/jm1c00100_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Design and SAR analysis of dual tubulin–HDAC inhibitors with sulfonamide moiety as the capping group and benzamide moiety as ZBG.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/medium/jm1c00100_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Design and SAR analysis of dual tubulin–HDAC inhibitors <b>22</b> and <b>24</b>. (A) Design and SAR analysis of dual tubulin–HDAC inhibitor <b>22</b> with BPR0L075 as the capping group; (B) design and SAR analysis of dual tubulin–HDAC inhibitor <b>24</b> with <i>iso</i>CA-4 as the capping group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/medium/jm1c00100_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Design and SAR analysis of dual tubulin–HDAC inhibitors <b>25</b>–<b>30</b>. (A) Design and SAR analysis of dual tubulin–HDAC inhibitors with colchicine as the capping group; (B) chemical structures of dual tubulin–HDAC inhibitors with quinazoline skeleton and chalcone derivatives as the capping group; (C) chemical structures of dual tubulin–HDAC inhibitors <b>29</b> and <b>30</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/medium/jm1c00100_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Design and SAR analysis of dual tubulin–DNA inhibitors. (A) Design and chemical structures of Pt(IV) pro-drugs with combretastatin A-4; (B) design and chemical structures of Pt(IV) pro-drugs with chalcone derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/medium/jm1c00100_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Design and chemical structures of dual topoisomerase II–tubulin inhibitors with podophyllotoxin moiety via pharmacophore-linked approach.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/medium/jm1c00100_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Design and SAR analysis of dual tubulin–topos inhibitors. (A) Chemical structures of dual tubulin–topo II inhibitors <b>40</b>, <b>41</b>, and <b>42</b>; (B) discovery and structures of dual tubulin–topos inhibitors <b>43</b> and <b>44</b>; (C) chemical structures of dual tubulin–topo I inhibitors <b>45</b> and <b>46</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/medium/jm1c00100_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Design and SAR analysis of dual tubulin–TDO/–IDO inhibitors. (A) Design and SARs of dual tubulin–TDO/–IDO inhibitors based on CA-4; (B) chemical structures of dual tubulin–IDO inhibitors <b>51a</b> and <b>51b</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/medium/jm1c00100_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Dual tubulin–ER inhibitors. (A) In silico binding pocket similarity screening, revealing that the selective estrogen receptor modulator RAL can bind to taxane pockets of tubulin, and tubulin polymerization assay and cell-based analysis performed to determine the effects of RAL on microtubule; (B) design and SAR analysis of dual tubulin–ER inhibitor <b>54</b> (α-tubulin, wheat; β-tubulin, blue).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/medium/jm1c00100_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Dual tubulin–PI3K inhibitor BKM120 (<b>55</b>). (A) Chemical structures of BKM120 and its derivatives; (B) binding mode of BKM120 in complex with tubulin (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5M7E">5M7E</a>); (C) binding mode of BKM120 in complex with PI3K (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3SD5">3SD5</a>). The hydrogen bonds are highlighted in yellow dashes; the water molecules are highlighted in red spheres.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/medium/jm1c00100_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Chemical structure and mechanism of action of Rigosertib. The chemical–genetic strategy was applied to identify the mechanism of action of Rigosertib. The cellular analysis indicated that Rigosertib caused spindle defects and microtubule destabilization. The cocrystal structure of Rigosertib in complex with tubulin demonstrated that Rigosertib can bind to the colchicine site. (α-tubulin, wheat; β-tubulin, blue)</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/medium/jm1c00100_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Design and SAR analysis of dual tubulin–Src/–c-Met inhibitors. (A) Chemical structures of dual tubulin–Src inhibitors KX2-391 and KX2-361 and the binding mode of KX2-391 in complex with tubulin (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6KNZ">6KNZ</a>); (B) binding modes of dual tubulin–c-Met inhibitor Tivantinib in complex with tubulin (left; PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CB4">5CB4</a>) and c-Met (right; PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3RHK">3RHK</a>), respectively. The hydrogen bonds are highlighted in yellow dashes, and water molecules are highlighted in red spheres.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/medium/jm1c00100_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Design and SAR analysis of dual tubulin–katanin/–PARP1/–SphK inhibitors. (A) Design and SARs analysis of dual tubulin–katanin modulator <b>64</b>; (B) binding mode of AMXI-5001 (<b>65</b>) in complex with PARP1 (hydrogen bonds, highlighted in green dashes; stacking interactions, highlighted in blue dashes); (C) chemical structures of dual tubulin–SphK inhibitors SKI-178 (<b>66</b>) and SKI-349 (<b>67</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/medium/jm1c00100_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Design and SAR analysis of dual-target tubulin inhibitors <b>68</b>–<b>76</b>. (A) Chemical structures of dual tubulin–Hsp90 inhibitors <b>68</b>–<b>70</b> and dual tubulin–Cdc20 inhibitor <b>71</b>; (B) design and chemical structure of dual tubulin–PDHK1 inhibitor (<b>72</b>); (C) chemical structures of dual inhibitors of tubulin and FLT3 (<b>73</b>), FTase (<b>74</b>), MK2 (<b>75</b>), and AMPK (<b>76</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00100/20210616/images/large/jm1c00100_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00100&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i36">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67070" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67070" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 174 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, L.</span></span> <span> </span><span class="NLM_article-title">Microtubules as a target for anticancer drugs</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">265</span>, <span class="refDoi"> DOI: 10.1038/nrc1317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1038%2Fnrc1317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=15057285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=253-265&author=M.+A.+Jordanauthor=L.+Wilson&title=Microtubules+as+a+target+for+anticancer+drugs&doi=10.1038%2Fnrc1317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubules as a target for anticancer drugs</span></div><div class="casAuthors">Jordan, Mary Ann; Wilson, Leslie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">253-265</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Highly dynamic mitotic-spindle microtubules are among the most successful targets for anticancer therapy.  Microtubule-targeted drugs, including paclitaxel and Vinca alkaloids, were previously considered to work primarily by increasing or decreasing the cellular microtubule mass.  Although these effects might have a role in their chemotherapeutic actions, we now know that at lower concns., microtubule-targeted drugs can suppress microtubule dynamics without changing microtubule mass; this action leads to mitotic block and apoptosis.  In addn. to the expanding array of chem. diverse antimitotic agents, some microtubule-targeted drugs can act as vascular-targeting agents, rapidly depolymg. microtubules of newly formed vasculature to shut down the blood supply to tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRJbrFnzwqjbVg90H21EOLACvtfcHk0ljfHXbtn5XUcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D&md5=bbbf212e03ffe6763098fc41f21a8158</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc1317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1317%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DM.%2BA.%26aulast%3DWilson%26aufirst%3DL.%26atitle%3DMicrotubules%2520as%2520a%2520target%2520for%2520anticancer%2520drugs%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D253%26epage%3D265%26doi%3D10.1038%2Fnrc1317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prota, A. E.</span></span> <span> </span><span class="NLM_article-title">Microtubule-targeting agents: strategies to hijack the cytoskeleton</span>. <i>Trends Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">776</span>– <span class="NLM_lpage">792</span>, <span class="refDoi"> DOI: 10.1016/j.tcb.2018.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.tcb.2018.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=29871823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpslaksL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=776-792&author=M.+O.+Steinmetzauthor=A.+E.+Prota&title=Microtubule-targeting+agents%3A+strategies+to+hijack+the+cytoskeleton&doi=10.1016%2Fj.tcb.2018.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-Targeting Agents: Strategies To Hijack the Cytoskeleton</span></div><div class="casAuthors">Steinmetz, Michel O.; Prota, Andrea E.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">776-792</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Microtubule-targeting agents (MTAs) such as paclitaxel and the vinca alkaloids are among the most important medical weapons available to combat cancer.  MTAs interfere with intracellular transport, inhibit eukaryotic cell proliferation, and promote cell death by suppressing microtubule dynamics.  Recent advances in the structural anal. of MTAs have enabled the extensive characterization of their interactions with microtubules and their building block tubulin.  We review here our current knowledge on the mol. mechanisms used by MTAs to hijack the microtubule cytoskeleton, and discuss dual inhibitors that target both kinases and microtubules.  We further formulate some outstanding questions related to MTA structural biol. and present possible routes for future investigations of this fascinating class of antimitotic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0akrt04GstbVg90H21EOLACvtfcHk0ljfHXbtn5XUcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpslaksL0%253D&md5=b6ec960a802f658b3f21e030e687c60e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.tcb.2018.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcb.2018.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26aulast%3DProta%26aufirst%3DA.%2BE.%26atitle%3DMicrotubule-targeting%2520agents%253A%2520strategies%2520to%2520hijack%2520the%2520cytoskeleton%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2018%26volume%3D28%26spage%3D776%26epage%3D792%26doi%3D10.1016%2Fj.tcb.2018.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dumontet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, M. A.</span></span> <span> </span><span class="NLM_article-title">Microtubule-binding agents: a dynamic field of cancer therapeutics</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">790</span>– <span class="NLM_lpage">803</span>, <span class="refDoi"> DOI: 10.1038/nrd3253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1038%2Fnrd3253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=20885410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1akur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=790-803&author=C.+Dumontetauthor=M.+A.+Jordan&title=Microtubule-binding+agents%3A+a+dynamic+field+of+cancer+therapeutics&doi=10.1038%2Fnrd3253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-binding agents: a dynamic field of cancer therapeutics</span></div><div class="casAuthors">Dumontet, Charles; Jordan, Mary Ann</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">790-803</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Microtubules are dynamic filamentous cytoskeletal proteins composed of tubulin and are an important therapeutic target in tumor cells.  Agents that bind to microtubules have been part of the pharmacopoeia of anticancer therapy for decades and until the advent of targeted therapy, microtubules were the only alternative to DNA as a therapeutic target in cancer.  The screening of a range of botanical species and marine organisms has yielded promising new antitubulin agents with novel properties.  In the current search for novel microtubule-binding agents, enhanced tumor specificity, reduced neurotoxicity and insensitivity to chemoresistance mechanisms are the three main objectives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ43DyXjdN7rVg90H21EOLACvtfcHk0ljwmdnhhdIsWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1akur%252FI&md5=9fc6fd966859785605936ecbe6dca44e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd3253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3253%26sid%3Dliteratum%253Aachs%26aulast%3DDumontet%26aufirst%3DC.%26aulast%3DJordan%26aufirst%3DM.%2BA.%26atitle%3DMicrotubule-binding%2520agents%253A%2520a%2520dynamic%2520field%2520of%2520cancer%2520therapeutics%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D790%26epage%3D803%26doi%3D10.1038%2Fnrd3253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horwitz, S. B.</span></span> <span> </span><span class="NLM_article-title">Taxol<sup>®</sup>: The first microtubule stabilizing agent</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1733</span>, <span class="refDoi"> DOI: 10.3390/ijms18081733</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.3390%2Fijms18081733" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVWgurvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1733&author=C.+H.+Yangauthor=S.+B.+Horwitz&title=Taxol%C2%AE%3A+The+first+microtubule+stabilizing+agent&doi=10.3390%2Fijms18081733"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Taxol: the first microtubule stabilizing agent</span></div><div class="casAuthors">Yang, Chia-Ping Huang; Horwitz, Susan Band</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1733/1-1733/11</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Taxol, an antitumor drug with significant activity, is the first microtubule stabilizing agent described in the literature.  This short review of the mechanism of action of Taxol emphasizes the research done in the Horwitz' lab.  It discusses the contribution of photoaffinity labeled analogs of Taxol toward our understanding of the binding site of the drug on the microtubule.  The importance of hydrogen/deuterium exchange expts. to further our insights into the stabilization of microtubules by Taxol is addressed.  The development of drug resistance, a major problem that arises in the clinic, is discussed.  Studies describing differential drug binding to distinct β-tubulin isotypes are presented.  Looking forward, it is suggested that the β-tubulin isotype content of a tumor may influence its responses to Taxol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFUMBXgAHw7rVg90H21EOLACvtfcHk0ljwmdnhhdIsWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVWgurvM&md5=9f591b369cba246d8860fb491bd85ef8</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.3390%2Fijms18081733&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18081733%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DC.%2BH.%26aulast%3DHorwitz%26aufirst%3DS.%2BB.%26atitle%3DTaxol%25C2%25AE%253A%2520The%2520first%2520microtubule%2520stabilizing%2520agent%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D1733%26doi%3D10.3390%2Fijms18081733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kavallaris, M.</span></span> <span> </span><span class="NLM_article-title">Microtubules and resistance to tubulin-binding agents</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">194</span>– <span class="NLM_lpage">204</span>, <span class="refDoi"> DOI: 10.1038/nrc2803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1038%2Fnrc2803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=20147901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvVKrtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=194-204&author=M.+Kavallaris&title=Microtubules+and+resistance+to+tubulin-binding+agents&doi=10.1038%2Fnrc2803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubules and resistance to tubulin-binding agents</span></div><div class="casAuthors">Kavallaris, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">194-204</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Microtubules are dynamic structures composed of α-β-tubulin heterodimers that are essential in cell division and are important targets for cancer drugs.  Mutations in β-tubulin that affect microtubule polymer mass and/or drug binding are assocd. with resistance to tubulin-binding agents such as paclitaxel.  The aberrant expression of specific β-tubulin isotypes, in particular βIII-tubulin, or of microtubule-regulating proteins is important clin. in tumor aggressiveness and resistance to chemotherapy.  In addn., changes in actin regulation can also mediate resistance to tubulin-binding agents.  Understanding the mol. mechanisms that mediate resistance to tubulin-binding agents will be vital to improve the efficacy of these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNkoVu03ikmrVg90H21EOLACvtfcHk0ljwmdnhhdIsWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvVKrtbg%253D&md5=1ce71cc537091459d7ee6866c0950b33</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrc2803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2803%26sid%3Dliteratum%253Aachs%26aulast%3DKavallaris%26aufirst%3DM.%26atitle%3DMicrotubules%2520and%2520resistance%2520to%2520tubulin-binding%2520agents%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D194%26epage%3D204%26doi%3D10.1038%2Fnrc2803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verrills, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavallaris, M.</span></span> <span> </span><span class="NLM_article-title">Improving the targeting of tubulin-binding agents: lessons from drug resistance studies</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1719</span>– <span class="NLM_lpage">1733</span>, <span class="refDoi"> DOI: 10.2174/1381612053764706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.2174%2F1381612053764706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=15892670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktlajur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=1719-1733&author=N.+M.+Verrillsauthor=M.+Kavallaris&title=Improving+the+targeting+of+tubulin-binding+agents%3A+lessons+from+drug+resistance+studies&doi=10.2174%2F1381612053764706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Improving the targeting of tubulin-binding agents: Lessons from drug resistance studies</span></div><div class="casAuthors">Verrills, N. M.; Kavallaris, M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1719-1733</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Natural product drugs that target the tubulin/microtubule system remain an important component in the therapeutic arsenal to treat many types of malignancies.  Agents such as the taxanes and vinca alkaloids bind to β-tubulin and disrupt microtubule dynamics by inducing a potent mitotic block and subsequent cell death.  Understanding why certain cancers do not respond to treatment or develop resistance has been subject of numerous studies in recent years.  An increasing body of evidence suggests that alterations in the drug target, such as tubulin mutations, altered microtubule dynamics, altered tubulin isotype expression, and modifications in microtubule regulatory proteins, are key mechanisms of antimicrotubule drug resistance.  In addn., recent work indicates that other cytoskeletal proteins that can regulate microtubule dynamics through signaling or structural interactions may be important determinants of antimicrotubule resistance.  As our understanding of drug action and resistance mechanisms has increased, we can now begin to exploit these to design strategies that overcome, or counteract resistance, hence improving the efficacy of antimicrotubule agents for the treatment of cancer.  This review highlights the major areas of investigation as they relate to the tubulin/microtubule system and discusses opportunities that potentially exist for improved therapeutic benefit in the treatment of drug resistant disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrApSnhIVkcHrVg90H21EOLACvtfcHk0ljwmdnhhdIsWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktlajur0%253D&md5=e9b7e356e6c31cca4355c13f88cd5e35</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2174%2F1381612053764706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612053764706%26sid%3Dliteratum%253Aachs%26aulast%3DVerrills%26aufirst%3DN.%2BM.%26aulast%3DKavallaris%26aufirst%3DM.%26atitle%3DImproving%2520the%2520targeting%2520of%2520tubulin-binding%2520agents%253A%2520lessons%2520from%2520drug%2520resistance%2520studies%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2005%26volume%3D11%26spage%3D1719%26epage%3D1733%26doi%3D10.2174%2F1381612053764706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Canta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiorazzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavaletti, G.</span></span> <span> </span><span class="NLM_article-title">Tubulin: a target for antineoplastic drugs into the cancer cells but also in the peripheral nervous system</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1315</span>– <span class="NLM_lpage">1324</span>, <span class="refDoi"> DOI: 10.2174/092986709787846488</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.2174%2F092986709787846488" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=19355888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltVeqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=1315-1324&author=A.+Cantaauthor=A.+Chiorazziauthor=G.+Cavaletti&title=Tubulin%3A+a+target+for+antineoplastic+drugs+into+the+cancer+cells+but+also+in+the+peripheral+nervous+system&doi=10.2174%2F092986709787846488"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Tubulin as a target for antineoplastic drugs into the cancer cells but also in the peripheral nervous system</span></div><div class="casAuthors">Canta, Annalisa; Chiorazzi, Alessia; Cavaletti, Guido</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1315-1324</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Since the introduction into clin. practice of vinca alkaloids, tubulin has become a key and well-established target of modern antineoplastic chemotherapy.  When taxanes became available their broad spectrum of activity was striking and opened up new horizons for cancer patients' treatment.  However, taxanes' susceptibility to drug resistance caused by the drug efflux pump protein, P-glycoprotein, is not infrequent and their use may be limited by poor soly., synthetic problems and toxicity.  The epothilones are a new class of chemotherapeutic agents with a mechanism of action similar to that of taxanes, but different enough to escape, for example, the multidrug resistance caused by P-glycoprotein.  Moreover, the epothilones (that are strong promoters of tubulin polymn.) have significant antitumor activity against human cancer cells that are taxane-resistant, express the multidrug resistance gene MDR-1, and have acquired tubulin mutations.  Finally, starting from the natural mols., several synthetic analogs have been developed.  Besides their antineoplastic efficacy, all the antitubulin drugs share a common toxicity on the peripheral nervous system and peripheral neurotoxicity is a major, potentially dose-limiting side effect also of the epothilones.  The current knowledge regarding the features of epothilones' peripheral neurotoxicity and their comparison with taxanes will be reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrud9z8vnFGFLVg90H21EOLACvtfcHk0liIdq5nS9Laow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltVeqsbo%253D&md5=88fe8b8400cb3ec5be160439503c914f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2174%2F092986709787846488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986709787846488%26sid%3Dliteratum%253Aachs%26aulast%3DCanta%26aufirst%3DA.%26aulast%3DChiorazzi%26aufirst%3DA.%26aulast%3DCavaletti%26aufirst%3DG.%26atitle%3DTubulin%253A%2520a%2520target%2520for%2520antineoplastic%2520drugs%2520into%2520the%2520cancer%2520cells%2520but%2520also%2520in%2520the%2520peripheral%2520nervous%2520system%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2009%26volume%3D16%26spage%3D1315%26epage%3D1324%26doi%3D10.2174%2F092986709787846488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talevi, A.</span></span> <span> </span><span class="NLM_article-title">Multi-target pharmacology: possibilities and limitations of the “skeleton key approach” from a medicinal chemist perspective</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">205</span>, <span class="refDoi"> DOI: 10.3389/fphar.2015.00205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.3389%2Ffphar.2015.00205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=26441661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1amurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=205&author=A.+Talevi&title=Multi-target+pharmacology%3A+possibilities+and+limitations+of+the+%E2%80%9Cskeleton+key+approach%E2%80%9D+from+a+medicinal+chemist+perspective&doi=10.3389%2Ffphar.2015.00205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target pharmacology: possibilities and limitations of the "skeleton key approach" from a medicinal chemist perspective</span></div><div class="casAuthors">Talevi, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">205/1-205/7</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Multi-target drugs have raised considerable interest in the last decade owing to their advantages in the treatment of complex diseases and health conditions linked to drug resistance issues.  Prospective drug repositioning to treat comorbid conditions is an addnl., overlooked application of multi-target ligands.  While medicinal chemists usually rely on some version of the lock and key paradigm to design novel therapeutics, modern pharmacol. recognizes that the mid- and long-term effects of a given drug on a biol. system may depend not only on the specific ligand-target recognition events but also on the influence of the repeated administration of a drug on the cell gene signature.  The design of multi-target agents usually imposes challenging restrictions on the topol. or flexibility of the candidate drugs, which are briefly discussed in the present article.  Finally, computational strategies to approach the identification of novel multi-target agents are overviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSdZokyMjNSLVg90H21EOLACvtfcHk0liIdq5nS9Laow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1amurnM&md5=169718a4644d962da33806772a9a33e3</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2015.00205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2015.00205%26sid%3Dliteratum%253Aachs%26aulast%3DTalevi%26aufirst%3DA.%26atitle%3DMulti-target%2520pharmacology%253A%2520possibilities%2520and%2520limitations%2520of%2520the%2520%25E2%2580%259Cskeleton%2520key%2520approach%25E2%2580%259D%2520from%2520a%2520medicinal%2520chemist%2520perspective%26jtitle%3DFront.%2520Pharmacol.%26date%3D2015%26volume%3D6%26spage%3D205%26doi%3D10.3389%2Ffphar.2015.00205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosini, M.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology: the rise of multitarget drugs over combination therapies</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">485</span>– <span class="NLM_lpage">487</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.25</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.4155%2Ffmc.14.25" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=24649950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2cXksFyitb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=485-487&author=M.+Rosini&title=Polypharmacology%3A+the+rise+of+multitarget+drugs+over+combination+therapies&doi=10.4155%2Ffmc.14.25"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: the rise of multitarget drugs over combination therapies</span></div><div class="casAuthors">Rosini, Michela</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">485-487</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvNBzYCAfAa7Vg90H21EOLACvtfcHk0liIdq5nS9Laow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXksFyitb0%253D&md5=0c32e1a1ae5a13cd25483ba18833fd54</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.25&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.25%26sid%3Dliteratum%253Aachs%26aulast%3DRosini%26aufirst%3DM.%26atitle%3DPolypharmacology%253A%2520the%2520rise%2520of%2520multitarget%2520drugs%2520over%2520combination%2520therapies%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D485%26epage%3D487%26doi%3D10.4155%2Ffmc.14.25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology in a single drug: Multitarget drugs</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1639</span>– <span class="NLM_lpage">1645</span>, <span class="refDoi"> DOI: 10.2174/0929867311320130004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.2174%2F0929867311320130004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=23410164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotl2jtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1639-1645&author=M.+L.+Bolognesi&title=Polypharmacology+in+a+single+drug%3A+Multitarget+drugs&doi=10.2174%2F0929867311320130004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology in a single drug: multitarget drugs</span></div><div class="casAuthors">Bolognesi, M. L.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1639-1645</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Polypharmacol. offers a model for the way drug discovery must evolve to develop therapies most suited to treating currently incurable diseases.  It is driven by a worldwide demand for safer, more effective, and affordable medicines against the most complex diseases, and by the failures of modern drug discovery to provide these.  Polypharmacol. can involve combinations and/or multitarget drugs (MTD).  Although not mutually exclusive, my premise is that MTDs have inherent advantages over combinations.  This review article focuses on MTDs from a medicinal chem. perspective.  I will explore their use in current clin. practice, their likely application in the future, and the challenges to be overcome to achieve this goal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeSnmeFeRpMrVg90H21EOLACvtfcHk0liIdq5nS9Laow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotl2jtLk%253D&md5=0e69395566711e018db8a61b1ae0f56e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2174%2F0929867311320130004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867311320130004%26sid%3Dliteratum%253Aachs%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DPolypharmacology%2520in%2520a%2520single%2520drug%253A%2520Multitarget%2520drugs%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D20%26spage%3D1639%26epage%3D1645%26doi%3D10.2174%2F0929867311320130004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehár, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keith, C. T.</span></span> <span> </span><span class="NLM_article-title">Multi-target therapeutics: when the whole is greater than the sum of the parts</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2006.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.drudis.2006.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=17198971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252Fgt1ygtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=34-42&author=G.+R.+Zimmermannauthor=J.+Leh%C3%A1rauthor=C.+T.+Keith&title=Multi-target+therapeutics%3A+when+the+whole+is+greater+than+the+sum+of+the+parts&doi=10.1016%2Fj.drudis.2006.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target therapeutics: when the whole is greater than the sum of the parts</span></div><div class="casAuthors">Zimmermann Grant R; Lehar Joseph; Keith Curtis T</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">34-42</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">Drugs designed to act against individual molecular targets cannot usually combat multigenic diseases such as cancer, or diseases that affect multiple tissues or cell types such as diabetes and immunoinflammatory disorders.  Combination drugs that impact multiple targets simultaneously are better at controlling complex disease systems, are less prone to drug resistance and are the standard of care in many important therapeutic areas.  The combination drugs currently employed are primarily of rational design, but the increased efficacy they provide justifies in vitro discovery efforts for identifying novel multi-target mechanisms.  In this review, we discuss the biological rationale for combination therapeutics, review some existing combination drugs and present a systematic approach to identify interactions between molecular pathways that could be leveraged for therapeutic benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTI14vYK2Q1LENHe_gFldTbfW6udTcc2ebEvX-a1ANYb7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252Fgt1ygtQ%253D%253D&md5=66715499ce21c2855dc6c477aa87f161</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2006.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2006.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DG.%2BR.%26aulast%3DLeh%25C3%25A1r%26aufirst%3DJ.%26aulast%3DKeith%26aufirst%3DC.%2BT.%26atitle%3DMulti-target%2520therapeutics%253A%2520when%2520the%2520whole%2520is%2520greater%2520than%2520the%2520sum%2520of%2520the%2520parts%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2007%26volume%3D12%26spage%3D34%26epage%3D42%26doi%3D10.1016%2Fj.drudis.2006.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anighoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajorath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rastelli, G.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology: challenges and opportunities in drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7874</span>– <span class="NLM_lpage">7887</span>, <span class="refDoi"> DOI: 10.1021/jm5006463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7874-7887&author=A.+Anighoroauthor=J.+Bajorathauthor=G.+Rastelli&title=Polypharmacology%3A+challenges+and+opportunities+in+drug+discovery&doi=10.1021%2Fjm5006463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: Challenges and Opportunities in Drug Discovery</span></div><div class="casAuthors">Anighoro, Andrew; Bajorath, Jurgen; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7874-7887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biol. target, shares the spotlight with an emerging and alternative polypharmacol. approach.  Polypharmacol. suggests that more effective drugs can be developed by specifically modulating multiple targets.  It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches.  In this respect, a drug that "hits" multiple sensitive nodes belonging to a network of interacting targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs.  In this review, we will compare advantages and disadvantages of multitarget vs. combination therapies, discuss potential drug promiscuity arising from off-target effects, comment on drug repurposing, and introduce approaches to the computational design of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOTyEu80AZrVg90H21EOLACvtfcHk0lj5Or74F8Llmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I&md5=5ab36c961a84462d90bc25130d90a281</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm5006463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006463%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DPolypharmacology%253A%2520challenges%2520and%2520opportunities%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7874%26epage%3D7887%26doi%3D10.1021%2Fjm5006463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arnst, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span> <span> </span><span class="NLM_article-title">Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1398</span>– <span class="NLM_lpage">1426</span>, <span class="refDoi"> DOI: 10.1002/med.21568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1002%2Fmed.21568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=30746734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A280%3ADC%252BB3cfhslejug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2019&pages=1398-1426&author=K.+E.+Arnstauthor=S.+Banerjeeauthor=H.+Chenauthor=S.+Dengauthor=D.+J.+Hwangauthor=W.+Liauthor=D.+D.+Miller&title=Current+advances+of+tubulin+inhibitors+as+dual+acting+small+molecules+for+cancer+therapy&doi=10.1002%2Fmed.21568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy</span></div><div class="casAuthors">Arnst Kinsie E; Banerjee Souvik; Chen Hao; Deng Shanshan; Hwang Dong-Jin; Li Wei; Miller Duane D</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal research reviews</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1398-1426</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Microtubule (MT)-targeting agents are highly successful drugs as chemotherapeutic agents, and this is attributed to their ability to target MT dynamics and interfere with critical cellular functions, including, mitosis, cell signaling, intracellular trafficking, and angiogenesis.  Because MT dynamics vary in the different stages of the cell cycle, these drugs tend to be the most effective against mitotic cells.  While this class of drug has proven to be effective against many cancer types, significant hurdles still exist and include overcoming aspects such as dose limited toxicities and the development of resistance.  Newer generations of developed drugs attack these problems and alternative approaches such as the development of dual tubulin and kinase inhibitors are being investigated.  This approach offers the potential to show increased efficacy and lower toxicities.  This review covers different categories of MT-targeting agents, recent advances in dual inhibitors, and current challenges for this drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTqfJ98Efo_uekdrW1FkXG-fW6udTcc2ebEvX-a1ANYb7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cfhslejug%253D%253D&md5=dafb1dbc34589cd0e9a9ac0f384252f1</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fmed.21568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21568%26sid%3Dliteratum%253Aachs%26aulast%3DArnst%26aufirst%3DK.%2BE.%26aulast%3DBanerjee%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DDeng%26aufirst%3DS.%26aulast%3DHwang%26aufirst%3DD.%2BJ.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26atitle%3DCurrent%2520advances%2520of%2520tubulin%2520inhibitors%2520as%2520dual%2520acting%2520small%2520molecules%2520for%2520cancer%2520therapy%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2019%26volume%3D39%26spage%3D1398%26epage%3D1426%26doi%3D10.1002%2Fmed.21568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanabe, K.</span></span> <span> </span><span class="NLM_article-title">Microtubule depolymerization by kinase inhibitors: Unexpected findings of dual inhibitors</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2508</span>, <span class="refDoi"> DOI: 10.3390/ijms18122508</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.3390%2Fijms18122508" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVOgtrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=2508&author=K.+Tanabe&title=Microtubule+depolymerization+by+kinase+inhibitors%3A+Unexpected+findings+of+dual+inhibitors&doi=10.3390%2Fijms18122508"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule depolymerization by kinase inhibitors: unexpected findings of dual inhibitors</span></div><div class="casAuthors">Tanabe, Kenji</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2508/1-2508/10</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Microtubule-targeting agents are widely used as clin. drugs in the treatment of cancer.  However, some kinase inhibitors can also disrupt microtubule organization by directly binding to tubulin.  These unexpected effects may result in a plethora of harmful events and/or a misinterpretation of the exptl. results.  Thus, further studies are needed to understand these dual inhibitors.  In this review, I discuss the roles of dual inhibitors of kinase activity and microtubule function as well as describe the properties underlining their dual roles.  Since both kinase and microtubule inhibitors cause cell toxicity and cell cycle arrest, it is difficult to det. which inhibitor is responsible for each phenotype.  A discrimination of cell cycle arrest at G0/G1 or G2/M and/or image analyses of cellular phenotype may eventually lead to new insights on drug duality.  Because of the indispensable roles of microtubules in mitosis and vesicle transport, I propose a simple and easy method to identify microtubule depolymg. compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtx7y9QgYgvrVg90H21EOLACvtfcHk0ljRUHtICMGvUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVOgtrbI&md5=97e65694545ed24fae1e4b97093eb454</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.3390%2Fijms18122508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18122508%26sid%3Dliteratum%253Aachs%26aulast%3DTanabe%26aufirst%3DK.%26atitle%3DMicrotubule%2520depolymerization%2520by%2520kinase%2520inhibitors%253A%2520Unexpected%2520findings%2520of%2520dual%2520inhibitors%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D2508%26doi%3D10.3390%2Fijms18122508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Horio, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murata, T.</span></span> <span> </span><span class="NLM_article-title">The role of dynamic instability in microtubule organization</span>. <i>Front. Plant Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">511</span>, <span class="refDoi"> DOI: 10.3389/fpls.2014.00511</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.3389%2Ffpls.2014.00511" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=25339962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A280%3ADC%252BC2M3ivVynsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=511&author=T.+Horioauthor=T.+Murata&title=The+role+of+dynamic+instability+in+microtubule+organization&doi=10.3389%2Ffpls.2014.00511"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The role of dynamic instability in microtubule organization</span></div><div class="casAuthors">Horio Tetsuya; Murata Takashi</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in plant science</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">511</span>
        ISSN:<span class="NLM_cas:issn">1664-462X</span>.
    </div><div class="casAbstract">Microtubules are one of the three major cytoskeletal components in eukaryotic cells.  Heterodimers composed of GTP-bound α- and β-tubulin molecules polymerize to form microtubule protofilaments, which associate laterally to form a hollow microtubule.  Tubulin has GTPase activity and the GTP molecules associated with β-tubulin molecules are hydrolyzed shortly after being incorporated into the polymerizing microtubules.  GTP hydrolysis alters the conformation of the tubulin molecules and drives the dynamic behavior of microtubules.  Periods of rapid microtubule polymerization alternate with periods of shrinkage in a process known as dynamic instability.  In plants, dynamic instability plays a key role in determining the organization of microtubules into arrays, and these arrays vary throughout the cell cycle.  In this review, we describe the mechanisms that regulate microtubule dynamics and underlie dynamic instability, and discuss how dynamic instability may shape microtubule organization in plant cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTKIELlIMPJoxcr74wzj5o5fW6udTcc2eaMZvahDFes6Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M3ivVynsA%253D%253D&md5=144a44253d931a66c1a2fe49283440b9</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.3389%2Ffpls.2014.00511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffpls.2014.00511%26sid%3Dliteratum%253Aachs%26aulast%3DHorio%26aufirst%3DT.%26aulast%3DMurata%26aufirst%3DT.%26atitle%3DThe%2520role%2520of%2520dynamic%2520instability%2520in%2520microtubule%2520organization%26jtitle%3DFront.%2520Plant%2520Sci.%26date%3D2014%26volume%3D5%26spage%3D511%26doi%3D10.3389%2Ffpls.2014.00511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stanton, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gernert, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nettles, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aneja, R.</span></span> <span> </span><span class="NLM_article-title">Drugs that target dynamic microtubules: a new molecular perspective</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">443</span>– <span class="NLM_lpage">481</span>, <span class="refDoi"> DOI: 10.1002/med.20242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1002%2Fmed.20242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=21381049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3MXksVKlsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=443-481&author=R.+A.+Stantonauthor=K.+M.+Gernertauthor=J.+H.+Nettlesauthor=R.+Aneja&title=Drugs+that+target+dynamic+microtubules%3A+a+new+molecular+perspective&doi=10.1002%2Fmed.20242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Drugs that target dynamic microtubules: A new molecular perspective</span></div><div class="casAuthors">Stanton, Richard A.; Gernert, Kim M.; Nettles, James H.; Aneja, Ritu</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">443-481</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Microtubules have long been considered an ideal target for anticancer drugs because of the essential role they play in mitosis, forming the dynamic spindle app.  As such, there is a wide variety of compds. currently in clin. use and in development that act as antimitotic agents by altering microtubule dynamics.  Although these diverse mols. are known to affect microtubule dynamics upon binding to one of the three established drug domains (taxane, vinca alkaloid, or colchicine site), the exact mechanism by which each drug works is still an area of intense speculation and research.  In this study, we review the effects of microtubule-binding chemotherapeutic agents from a new perspective, considering how their mode of binding induces conformational changes and alters biol. function relative to the mol. vectors of microtubule assembly or disassembly.  These "biol. vectors" can thus be used as a spatiotemporal context to describe mol. mechanisms by which microtubule-targeting drugs work. © 2011 Wiley Periodicals, Inc.  Med Res Rev, 31, No. 3, 443-481, 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB6_lcUQbXYrVg90H21EOLACvtfcHk0ljRUHtICMGvUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXksVKlsLs%253D&md5=acce5b9cc89581a7dab0236072b68c72</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fmed.20242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20242%26sid%3Dliteratum%253Aachs%26aulast%3DStanton%26aufirst%3DR.%2BA.%26aulast%3DGernert%26aufirst%3DK.%2BM.%26aulast%3DNettles%26aufirst%3DJ.%2BH.%26aulast%3DAneja%26aufirst%3DR.%26atitle%3DDrugs%2520that%2520target%2520dynamic%2520microtubules%253A%2520a%2520new%2520molecular%2520perspective%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2011%26volume%3D31%26spage%3D443%26epage%3D481%26doi%3D10.1002%2Fmed.20242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brouhard, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, L. M.</span></span> <span> </span><span class="NLM_article-title">The contribution of αβ-tubulin curvature to microtubule dynamics</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>207</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">334</span>, <span class="refDoi"> DOI: 10.1083/jcb.201407095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1083%2Fjcb.201407095" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=25385183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFGhs7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=207&publication_year=2014&pages=323-334&author=G.+J.+Brouhardauthor=L.+M.+Rice&title=The+contribution+of+%CE%B1%CE%B2-tubulin+curvature+to+microtubule+dynamics&doi=10.1083%2Fjcb.201407095"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The contribution of αβ-tubulin curvature to microtubule dynamics</span></div><div class="casAuthors">Brouhard, Gary J.; Rice, Luke M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">207</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">323-334</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">A review.  Microtubules are dynamic polymers of αβ-tubulin that form diverse cellular structures, such as the mitotic spindle for cell division, the backbone of neurons, and axonemes.  To control the architecture of microtubule networks, microtubule-assocd. proteins (MAPs) and motor proteins regulate microtubule growth, shrinkage, and the transitions between these states.  Recent evidence shows that many MAPs exert their effects by selectively binding to distinct conformations of polymd. or unpolymd. αβ-tubulin.  The ability of αβ-tubulin to adopt distinct conformations contributes to the intrinsic polymn. dynamics of microtubules.  αβ-Tubulin conformation is a fundamental property that MAPs monitor and control to build proper microtubule networks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGyoU-iIkFELVg90H21EOLACvtfcHk0ljRUHtICMGvUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFGhs7jE&md5=5ff241f0a021843f7678daec3f7476f1</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1083%2Fjcb.201407095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.201407095%26sid%3Dliteratum%253Aachs%26aulast%3DBrouhard%26aufirst%3DG.%2BJ.%26aulast%3DRice%26aufirst%3DL.%2BM.%26atitle%3DThe%2520contribution%2520of%2520%25CE%25B1%25CE%25B2-tubulin%2520curvature%2520to%2520microtubule%2520dynamics%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2014%26volume%3D207%26spage%3D323%26epage%3D334%26doi%3D10.1083%2Fjcb.201407095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alushin, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogales, E.</span></span> <span> </span><span class="NLM_article-title">Mechanistic origin of microtubule dynamic instability and its modulation by EB proteins</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">849</span>– <span class="NLM_lpage">859</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2015.07.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.cell.2015.07.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=26234155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Kgur3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2015&pages=849-859&author=R.+Zhangauthor=G.+M.+Alushinauthor=A.+Brownauthor=E.+Nogales&title=Mechanistic+origin+of+microtubule+dynamic+instability+and+its+modulation+by+EB+proteins&doi=10.1016%2Fj.cell.2015.07.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic Origin of Microtubule Dynamic Instability and Its Modulation by EB Proteins</span></div><div class="casAuthors">Zhang, Rui; Alushin, Gregory M.; Brown, Alan; Nogales, Eva</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">849-859</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Microtubule (MT) dynamic instability is driven by GTP hydrolysis and regulated by microtubule-assocd. proteins, including the plus-end tracking end-binding protein (EB) family.  We report six cryo-electron microscopy (cryo-EM) structures of MTs, at 3.5 Å or better resoln., bound to GMPCPP, GTPγS, or GDP, either decorated with kinesin motor domain after polymn. or copolymd. with EB3.  Subtle changes around the E-site nucleotide during hydrolysis trigger conformational changes in α-tubulin around an "anchor point," leading to global lattice rearrangements and strain generation.  Unlike the extended lattice of the GMPCPP-MT, the EB3-bound GTPγS-MT has a compacted lattice that differs in lattice twist from that of the also compacted GDP-MT.  These results and the observation that EB3 promotes rapid hydrolysis of GMPCPP suggest that EB proteins modulate structural transitions at growing MT ends by recognizing and promoting an intermediate state generated during GTP hydrolysis.  Our findings explain both EBs end-tracking behavior and their effect on microtubule dynamics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBy-PiTA751LVg90H21EOLACvtfcHk0ljUzWIzh7AXXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Kgur3L&md5=c2e4759869fb36e3fff2756ecde0fa14</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2015.07.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2015.07.012%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DAlushin%26aufirst%3DG.%2BM.%26aulast%3DBrown%26aufirst%3DA.%26aulast%3DNogales%26aufirst%3DE.%26atitle%3DMechanistic%2520origin%2520of%2520microtubule%2520dynamic%2520instability%2520and%2520its%2520modulation%2520by%2520EB%2520proteins%26jtitle%3DCell%26date%3D2015%26volume%3D162%26spage%3D849%26epage%3D859%26doi%3D10.1016%2Fj.cell.2015.07.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamyar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrhardt, D. W.</span></span> <span> </span><span class="NLM_article-title">Sustained microtubule treadmilling in Arabidopsis cortical arrays</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>300</i></span>,  <span class="NLM_fpage">1715</span>– <span class="NLM_lpage">1718</span>, <span class="refDoi"> DOI: 10.1126/science.1083529</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1126%2Fscience.1083529" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=12714675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD3sXksVKis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=300&publication_year=2003&pages=1715-1718&author=S.+L.+Shawauthor=R.+Kamyarauthor=D.+W.+Ehrhardt&title=Sustained+microtubule+treadmilling+in+Arabidopsis+cortical+arrays&doi=10.1126%2Fscience.1083529"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Sustained Microtubule Treadmilling in Arabidopsis Cortical Arrays</span></div><div class="casAuthors">Shaw, Sidney L.; Kamyar, Roheena; Ehrhardt, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">300</span>
        (<span class="NLM_cas:issue">5626</span>),
    <span class="NLM_cas:pages">1715-1718</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Plant cells create highly structured microtubule arrays at the cell cortex without a central organizing center to anchor the microtubule ends.  In vivo imaging of individual microtubules in Arabidopsis plants revealed that new microtubules are initiated at the cell cortex and exhibit dynamics at both ends.  Polymn.-biased dynamic instability at one end and slow depolymn. at the other end result in sustained microtubule migration across the cell cortex by a hybrid treadmilling mechanism.  This motility causes widespread microtubule repositioning and contributes to changes in array organization through microtubule reorientation and bundling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEQ1HoiUsu5bVg90H21EOLACvtfcHk0ljUzWIzh7AXXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXksVKis70%253D&md5=d598fdbcc0bce564265f5d2ad6bf69d7</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1126%2Fscience.1083529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1083529%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DS.%2BL.%26aulast%3DKamyar%26aufirst%3DR.%26aulast%3DEhrhardt%26aufirst%3DD.%2BW.%26atitle%3DSustained%2520microtubule%2520treadmilling%2520in%2520Arabidopsis%2520cortical%2520arrays%26jtitle%3DScience%26date%3D2003%26volume%3D300%26spage%3D1715%26epage%3D1718%26doi%3D10.1126%2Fscience.1083529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vicente-Blázquez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Álvarez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Mazo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medarde, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peláez, R.</span></span> <span> </span><span class="NLM_article-title">Antitubulin sulfonamides: the successful combination of an established drug class and a multifaceted target</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">775</span>– <span class="NLM_lpage">830</span>, <span class="refDoi"> DOI: 10.1002/med.21541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1002%2Fmed.21541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=30362234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntlGktrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2019&pages=775-830&author=A.+Vicente-Bl%C3%A1zquezauthor=M.+Gonz%C3%A1lezauthor=R.+%C3%81lvarezauthor=S.+Del+Mazoauthor=M.+Medardeauthor=R.+Pel%C3%A1ez&title=Antitubulin+sulfonamides%3A+the+successful+combination+of+an+established+drug+class+and+a+multifaceted+target&doi=10.1002%2Fmed.21541"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Antitubulin sulfonamides: The successful combination of an established drug class and a multifaceted target</span></div><div class="casAuthors">Vicente-Blazquez, Alba; Gonzalez, Myriam; Alvarez, Raquel; del Mazo, Sara; Medarde, Manuel; Pelaez, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">775-830</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Tubulin, the microtubules and their dynamic behavior are amongst the most successful antitumor, antifungal, antiparasitic, and herbicidal drug targets.  Sulfonamides are exemplary drugs with applications in the clinic, in veterinary and in the agrochem. industry.  This review summarizes the actual state and recent progress of both fields looking from the double point of view of the target and its drugs, with special focus onto the structural aspects.  The article starts with a brief description of tubulin structure and its dynamic assembly and disassembly into microtubules and other polymers.  Posttranslational modifications and the many cellular means of regulating and modulating tubulin's biol. are briefly presented in the tubulin code.  Next, the structurally characterized drug binding sites, their occupying drugs and the effects they induce are described, emphasizing on the structural requirements for high potency, selectivity, and low toxicity.  The second part starts with a summary of the favorable and highly tunable combination of phys.-chem. and biol. properties that render sulfonamides a prototypical example of privileged scaffolds with representatives in many therapeutic areas.  A complete description of tubulin-binding sulfonamides is provided, covering the different species and drug sites.  Some of the antimitotic sulfonamides have met with very successful applications and others less so, thus illustrating the advances, limitations, and future perspectives of the field.  All of them combine in a mechanism of action and a clin. outcome that conform efficient drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBjccN56DGCLVg90H21EOLACvtfcHk0ljUzWIzh7AXXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntlGktrs%253D&md5=43582a156e310ef92cca3ef94ff9362e</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fmed.21541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21541%26sid%3Dliteratum%253Aachs%26aulast%3DVicente-Bl%25C3%25A1zquez%26aufirst%3DA.%26aulast%3DGonz%25C3%25A1lez%26aufirst%3DM.%26aulast%3D%25C3%2581lvarez%26aufirst%3DR.%26aulast%3DDel%2BMazo%26aufirst%3DS.%26aulast%3DMedarde%26aufirst%3DM.%26aulast%3DPel%25C3%25A1ez%26aufirst%3DR.%26atitle%3DAntitubulin%2520sulfonamides%253A%2520the%2520successful%2520combination%2520of%2520an%2520established%2520drug%2520class%2520and%2520a%2520multifaceted%2520target%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2019%26volume%3D39%26spage%3D775%26epage%3D830%26doi%3D10.1002%2Fmed.21541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamath, K.</span></span> <span> </span><span class="NLM_article-title">How do microtubule-targeted drugs work? An overview</span>. <i>Curr. Cancer Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">730</span>– <span class="NLM_lpage">742</span>, <span class="refDoi"> DOI: 10.2174/156800907783220417</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.2174%2F156800907783220417" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=18220533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFOnsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=730-742&author=M.+A.+Jordanauthor=K.+Kamath&title=How+do+microtubule-targeted+drugs+work%3F+An+overview&doi=10.2174%2F156800907783220417"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">How do microtubule-targeted drugs work? An overview</span></div><div class="casAuthors">Jordan, Mary Ann; Kamath, Kathy</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">730-742</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The importance of microtubules in mitosis makes them a superb target for a group of highly successful, chem. diverse anticancer drugs.  Knowledge of the mechanistic differences among the many drugs of this class is vital to understanding their tissue and cell specificity, the development of resistance, the design of novel improved drugs, optimal scheduling of treatment, and potential synergistic combinations.  This overview covers microtubule assembly dynamics, the exquisite regulation of microtubule dynamics in cells by endogenous regulators, the important role of microtubule dynamics in mitosis, the diversity and no. of microtubule-targeted drugs undergoing clin. development, the antimitotic mechanisms of microtubule-targeted drugs with emphasis on suppression of microtubule dynamics by vinblastine and taxol, the role of drug uptake and retention in the efficacy of microtubule-targeted drugs, and the anti-angiogenic and vascular-disrupting mechanisms of microtubule targeted drugs.  In view of the success of this class of drugs, it has been argued that microtubules represent the single best cancer target identified to date, and it seems likely that drugs in this class will continue to remain an important chemotherapeutic class of drugs even as more selective chemotherapeutic approaches are developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrblMjKhFIo0rVg90H21EOLACvtfcHk0ljUzWIzh7AXXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFOnsbg%253D&md5=58b841471750af2499f766da0ea5e0d6</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.2174%2F156800907783220417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156800907783220417%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DM.%2BA.%26aulast%3DKamath%26aufirst%3DK.%26atitle%3DHow%2520do%2520microtubule-targeted%2520drugs%2520work%253F%2520An%2520overview%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2007%26volume%3D7%26spage%3D730%26epage%3D742%26doi%3D10.2174%2F156800907783220417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Field, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Díaz, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, J. H.</span></span> <span> </span><span class="NLM_article-title">The binding sites of microtubule-stabilizing agents</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">301</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2013.01.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.chembiol.2013.01.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=23521789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksFOht7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=301-315&author=J.+J.+Fieldauthor=J.+F.+D%C3%ADazauthor=J.+H.+Miller&title=The+binding+sites+of+microtubule-stabilizing+agents&doi=10.1016%2Fj.chembiol.2013.01.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The Binding Sites of Microtubule-Stabilizing Agents</span></div><div class="casAuthors">Field, Jessica J.; Diaz, Jose Fernando; Miller, John H.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">301-315</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Microtubules (MTs) are a highly successful target for anticancer therapy.  MT-stabilizing agents (MSAs) bind to MTs, promoting their polymn., blocking mitosis, and causing cell death.  There are currently four clin. important MSAs, with many others in preclin. and clin. development.  MTs have three binding sites for these compds.; however, the exact locations and drug-protein interactions of these sites are still controversial.  This review will describe the possible binding sites, the compds. that bind to them, and the effect of this binding on MT function.  The binding site of an MSA on tubulin is important for characterizing the compd. as an anticancer agent and provides insight not only into possible synergistic interactions with other compds. but also on the MSA "pharmacophore." This information can aid in the design of novel MSAs with improved properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHPdMr7yFqnbVg90H21EOLACvtfcHk0lhFJqyzdoXhwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksFOht7o%253D&md5=6180c154afeafb39f8463582c22eef44</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2013.01.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2013.01.014%26sid%3Dliteratum%253Aachs%26aulast%3DField%26aufirst%3DJ.%2BJ.%26aulast%3DD%25C3%25ADaz%26aufirst%3DJ.%2BF.%26aulast%3DMiller%26aufirst%3DJ.%2BH.%26atitle%3DThe%2520binding%2520sites%2520of%2520microtubule-stabilizing%2520agents%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D301%26epage%3D315%26doi%3D10.1016%2Fj.chembiol.2013.01.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ojima, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtenthal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Taxane anticancer agents: a patent perspective</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1517/13543776.2016.1111872</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1517%2F13543776.2016.1111872" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=26651178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2rsrjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=1-20&author=I.+Ojimaauthor=B.+Lichtenthalauthor=S.+Leeauthor=C.+Wangauthor=X.+Wang&title=Taxane+anticancer+agents%3A+a+patent+perspective&doi=10.1517%2F13543776.2016.1111872"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Taxane anticancer agents: a patent perspective</span></div><div class="casAuthors">Ojima, Iwao; Lichtenthal, Brendan; Lee, Siyeon; Wang, Changwei; Wang, Xin</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-20</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Paclitaxel and docetaxel were two epoch-making anticancer drugs and have been successfully used in chemotherapy for a variety of cancer types.  In the year 2010, a new taxane, cabazitaxel, was approved by FDA for use in combination with prednisone for the treatment of metastatic hormone-refractory prostate cancer.  Albumin-bound paclitaxel (nab-paclitaxel; abraxane) nanodroplet formulation was another notable invention (FDA approval 2005 for refractory, metastatic, or relapsed breast cancer).  Abraxane in combination with gemcitabine for the treatment of pancreatic cancer was approved by FDA in 2013.  Accordingly, there have been a huge no. of patent applications dealing with taxane anticancer agents in the last 5 years.  Thus, it is a good time to review the progress in this area and find the next wave for new developments.  This review covers the patent literature from the year 2010 to early 2015 on various aspects of taxane-based chemotherapies and drug developments.  Three FDA-approved taxane anticancer drugs will continue to expand their therapeutic applications, esp. through drug combinations and new formulations.  Inspired by the success of abraxane, new nano-formulations are emerging.  Highly potent new-generation taxanes will play a key role in the development of efficacious tumor-targeted drug delivery systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDS7GwTPBwRrVg90H21EOLACvtfcHk0lhFJqyzdoXhwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2rsrjO&md5=a14ecf2ee7e39daaef522fb0c0a1ba7e</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1517%2F13543776.2016.1111872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2016.1111872%26sid%3Dliteratum%253Aachs%26aulast%3DOjima%26aufirst%3DI.%26aulast%3DLichtenthal%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DTaxane%2520anticancer%2520agents%253A%2520a%2520patent%2520perspective%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2016%26volume%3D26%26spage%3D1%26epage%3D20%26doi%3D10.1517%2F13543776.2016.1111872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnett, J. P.,  Jr</span></span> <span> </span><span class="NLM_article-title">The vinca alkaloids: A new class of oncolytic agents</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1963</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1390</span>– <span class="NLM_lpage">1427</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=14070392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADyaF2cXht1agsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1963&pages=1390-1427&author=I.+S.+Johnsonauthor=J.+G.+Armstrongauthor=M.+Gormanauthor=J.+P.+Burnett&title=The+vinca+alkaloids%3A+A+new+class+of+oncolytic+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The Vinca alkaloids. A new class of oncolytic agents</span></div><div class="casAuthors">Johnson, Irving S.; Armstrong, James G.; Gorman, Marvin; Burnett, J. Paul, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1963</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1390-1427</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDNvwRwHsWf7Vg90H21EOLACvtfcHk0lhFJqyzdoXhwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2cXht1agsQ%253D%253D&md5=27ad156de3a422753052d30e72835deb</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DI.%2BS.%26aulast%3DArmstrong%26aufirst%3DJ.%2BG.%26aulast%3DGorman%26aufirst%3DM.%26aulast%3DBurnett%26aufirst%3DJ.%2BP.%26atitle%3DThe%2520vinca%2520alkaloids%253A%2520A%2520new%2520class%2520of%2520oncolytic%2520agents%26jtitle%3DCancer%2520Res.%26date%3D1963%26volume%3D23%26spage%3D1390%26epage%3D1427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Pérez, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priego, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bueno, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canela, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liekens, S.</span></span> <span> </span><span class="NLM_article-title">Blocking blood flow to solid tumors by destabilizing tubulin: an approach to targeting tumor growth</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8685</span>– <span class="NLM_lpage">8711</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVCrsr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8685-8711&author=M.+J.+P%C3%A9rez-P%C3%A9rezauthor=E.+M.+Priegoauthor=O.+Buenoauthor=M.+S.+Martinsauthor=M.+D.+Canelaauthor=S.+Liekens&title=Blocking+blood+flow+to+solid+tumors+by+destabilizing+tubulin%3A+an+approach+to+targeting+tumor+growth&doi=10.1021%2Facs.jmedchem.6b00463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Blocking Blood Flow to Solid Tumors by Destabilizing Tubulin: An Approach to Targeting Tumor Growth</span></div><div class="casAuthors">Perez-Perez, Maria-Jesus; Priego, Eva-Maria; Bueno, Oskia; Martins, Maria Solange; Canela, Maria-Dolores; Liekens, Sandra</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8685-8711</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The unique characteristics of the tumor vasculature offer the possibility to selectively target tumor growth and vascularization using tubulin-destabilizing agents.  Evidence accumulated with combretastatin A-4 (CA-4) and its prodrug CA-4P support the therapeutic value of compds. sharing this mechanism of action.  However, the chem. instability and poor soly. of CA-4 demand alternative compds. that are able to surmount these limitations.  This Perspective illustrates the different classes of compds. that behave similar to CA-4, analyzes their binding mode to αβ-tubulin according to recently available structural complexes, and includes described approaches to improve their delivery.  In addn., dissecting the mechanism of action of CA-4 and analogs allows a closer insight into the advantages and drawbacks assocd. with these tubulin-destabilizing agents that behave as vascular disrupting agents (VDAs).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoro5_yHCDZJ7Vg90H21EOLACvtfcHk0lh5zPnifLWenA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVCrsr7K&md5=47929ab2eb71284781c8b5ff16fcb023</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00463%26sid%3Dliteratum%253Aachs%26aulast%3DP%25C3%25A9rez-P%25C3%25A9rez%26aufirst%3DM.%2BJ.%26aulast%3DPriego%26aufirst%3DE.%2BM.%26aulast%3DBueno%26aufirst%3DO.%26aulast%3DMartins%26aufirst%3DM.%2BS.%26aulast%3DCanela%26aufirst%3DM.%2BD.%26aulast%3DLiekens%26aufirst%3DS.%26atitle%3DBlocking%2520blood%2520flow%2520to%2520solid%2520tumors%2520by%2520destabilizing%2520tubulin%253A%2520an%2520approach%2520to%2520targeting%2520tumor%2520growth%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8685%26epage%3D8711%26doi%3D10.1021%2Facs.jmedchem.6b00463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greene, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meegan, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zisterer, D. M.</span></span> <span> </span><span class="NLM_article-title">Combretastatins: more than just vascular targeting agents?</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">212</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1124/jpet.115.226225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1124%2Fjpet.115.226225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=26354991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslantLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2015&pages=212-227&author=L.+M.+Greeneauthor=M.+J.+Meeganauthor=D.+M.+Zisterer&title=Combretastatins%3A+more+than+just+vascular+targeting+agents%3F&doi=10.1124%2Fjpet.115.226225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Combretastatins: more than just vascular targeting agents?</span></div><div class="casAuthors">Greene, Lisa M.; Meegan, Mary J.; Zisterer, Daniela M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">212-227</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Several prodrugs of the naturally occurring combretastatins have undergone extensive clin. evaluation as vascular targeting agents (VTAs).  Their increased selectivity toward endothelial cells together with their innate ability to rapidly induce vascular shutdown and inhibit tumor growth at doses up to 10-fold less than the max. tolerated dose led to the clin. evaluation of combretastatins as VTAs.  Tubulin is well established as the mol. target of the combretastatins and the vast majority of its synthetic derivs.  Furthermore, tubulin is a highly validated mol. target of many direct anticancer agents routinely used as front-line chemotherapeutics.  The unique vascular targeting properties of the combretastatins have somewhat overshadowed their development as direct anticancer agents and the delineation of the various cell death pathways and anticancer properties assocd. with such chemotherapeutics.  Moreover, the ongoing clin. trial of OXi4503 (combretastatin-A1 diphosphate) together with preliminary preclin. evaluation for the treatment of refractory acute myelogenous leukemia has successfully highlighted both the indirect and direct anticancer properties of combretastatins.  In this review, we discuss the development of the combretastatins from nature to the clinic.  The various mechanisms underlying combretastatin-induced cell cycle arrest, mitotic catastrophe, cell death, and survival are also reviewed in an attempt to further enhance the clin. prospects of this unique class of VTAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonKpiV5x3vPLVg90H21EOLACvtfcHk0lh5zPnifLWenA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslantLY%253D&md5=7e965d3cd51715cec3f84fde9cd6e88e</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.226225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.226225%26sid%3Dliteratum%253Aachs%26aulast%3DGreene%26aufirst%3DL.%2BM.%26aulast%3DMeegan%26aufirst%3DM.%2BJ.%26aulast%3DZisterer%26aufirst%3DD.%2BM.%26atitle%3DCombretastatins%253A%2520more%2520than%2520just%2520vascular%2520targeting%2520agents%253F%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D355%26spage%3D212%26epage%3D227%26doi%3D10.1124%2Fjpet.115.226225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Leo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aziz, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvirbule, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bines, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arbushites, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrera, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dering, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Press, M. F.</span></span> <span> </span><span class="NLM_article-title">Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">5544</span>– <span class="NLM_lpage">5552</span>, <span class="refDoi"> DOI: 10.1200/JCO.2008.16.2578</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1200%2FJCO.2008.16.2578" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=18955454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmsVSktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=5544-5552&author=A.+Di%0ALeoauthor=H.+L.+Gomezauthor=Z.+Azizauthor=Z.+Zvirbuleauthor=J.+Binesauthor=M.+C.+Arbushitesauthor=S.+F.+Guerreraauthor=M.+Koehlerauthor=C.+Olivaauthor=S.+H.+Steinauthor=L.+S.+Williamsauthor=J.+Deringauthor=R.+S.+Finnauthor=M.+F.+Press&title=Phase+III%2C+double-blind%2C+randomized+study+comparing+lapatinib+plus+paclitaxel+with+placebo+plus+paclitaxel+as+first-line+treatment+for+metastatic+breast+cancer&doi=10.1200%2FJCO.2008.16.2578"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer</span></div><div class="casAuthors">Di Leo, Angelo; Gomez, Henry L.; Aziz, Zeba; Zvirbule, Zanete; Bines, Jose; Arbushites, Michael C.; Guerrera, Stephanie F.; Koehler, Maria; Oliva, Cristina; Stein, Steven H.; Williams, Lisa S.; Dering, Judy; Finn, Richard S.; Press, Michael F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">5544-5552</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Lapatinib, a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER-2/ErbB2), is effective against HER-2-pos. locally advanced or metastatic breast cancer (MBC).  This phase III trial evaluated the efficacy of lapatinib in HER-2-neg. and HER-2-uncharacterized MBC.  Women with MBC were randomly assigned to first-line therapy with paclitaxel 175 mg/m2 every 3 wk plus lapatinib 1500 mg/d or placebo.  A preplanned retrospective evaluation of HER-2 status was performed using fluorescence in situ hybridization and immunohistochem.  The primary end point was time to progression (TTP); secondary end points were objective response rate (ORR), clin. benefit rate (CBR), event-free survival (EFS), and overall survival (OS).  In the intent-to-treat population (n = 579), there were no significant differences in TTP, EFS, or OS between treatment arms, although differences in ORR and CBR were noted.  In 86 HER-2-pos. patients (15%), treatment with paclitaxel-lapatinib resulted in statistically significant improvements in TTP, EFS, ORR, and CBR compared with paclitaxel-placebo.  No differences between treatment groups were obsd. for any end point in HER-2-neg. patients.  The most common adverse events were alopecia, rash, and diarrhea.  The incidence of diarrhea and rash was significantly higher in the paclitaxel-lapatinib arm.  The rate of cardiac events was low, and no difference was obsd. between treatment arms.  Patients with HER-2-neg. or HER-2-untested MBC did not benefit from the addn. of lapatinib to paclitaxel.  However, first-line therapy with paclitaxel-lapatinib significantly improved clin. outcomes in HER-2-pos. patients.  Prospective evaluation of the efficacy and safety of this combination is ongoing in early and metastatic HER-2-pos. breast cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGKFocbCrkurVg90H21EOLACvtfcHk0lh5zPnifLWenA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmsVSktA%253D%253D&md5=988f08798b7880b0da1575c3f01a180f</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.16.2578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.16.2578%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BLeo%26aufirst%3DA.%26aulast%3DGomez%26aufirst%3DH.%2BL.%26aulast%3DAziz%26aufirst%3DZ.%26aulast%3DZvirbule%26aufirst%3DZ.%26aulast%3DBines%26aufirst%3DJ.%26aulast%3DArbushites%26aufirst%3DM.%2BC.%26aulast%3DGuerrera%26aufirst%3DS.%2BF.%26aulast%3DKoehler%26aufirst%3DM.%26aulast%3DOliva%26aufirst%3DC.%26aulast%3DStein%26aufirst%3DS.%2BH.%26aulast%3DWilliams%26aufirst%3DL.%2BS.%26aulast%3DDering%26aufirst%3DJ.%26aulast%3DFinn%26aufirst%3DR.%2BS.%26aulast%3DPress%26aufirst%3DM.%2BF.%26atitle%3DPhase%2520III%252C%2520double-blind%252C%2520randomized%2520study%2520comparing%2520lapatinib%2520plus%2520paclitaxel%2520with%2520placebo%2520plus%2520paclitaxel%2520as%2520first-line%2520treatment%2520for%2520metastatic%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D5544%26epage%3D5552%26doi%3D10.1200%2FJCO.2008.16.2578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cesca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morosi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berndt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nerini, I. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frapolli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dirsch, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Micotti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Incalci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davoli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zucchetti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giavazzi, R.</span></span> <span> </span><span class="NLM_article-title">Bevacizumab-induced inhibition of angiogenesis promotes a more homogeneous intratumoral distribution of paclitaxel, improving the antitumor response</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-0063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1158%2F1535-7163.MCT-15-0063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=26494857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC28Xmslelug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=125-135&author=M.+Cescaauthor=L.+Morosiauthor=A.+Berndtauthor=I.+F.+Neriniauthor=R.+Frapolliauthor=P.+Richterauthor=A.+Decioauthor=O.+Dirschauthor=E.+Micottiauthor=S.+Giordanoauthor=M.+D%E2%80%99Incalciauthor=E.+Davoliauthor=M.+Zucchettiauthor=R.+Giavazzi&title=Bevacizumab-induced+inhibition+of+angiogenesis+promotes+a+more+homogeneous+intratumoral+distribution+of+paclitaxel%2C+improving+the+antitumor+response&doi=10.1158%2F1535-7163.MCT-15-0063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response</span></div><div class="casAuthors">Cesca, Marta; Morosi, Lavinia; Berndt, Alexander; Nerini, Ilaria Fuso; Frapolli, Roberta; Richter, Petra; Decio, Alessandra; Dirsch, Olaf; Micotti, Edoardo; Giordano, Silvia; D'Incalci, Maurizio; Davoli, Enrico; Zucchetti, Massimo; Giavazzi, Raffaella</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">125-135</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The antitumor activity of angiogenesis inhibitors is reinforced in combination with chemotherapy.  It is debated whether this potentiation is related to a better drug delivery to the tumor due to the antiangiogenic effects on tumor vessel phenotype and functionality.  We addressed this question by combining bevacizumab with paclitaxel on A2780-1A9 ovarian carcinoma and HT-29 colon carcinoma transplanted ectopically in the subcutis of nude mice and on A2780-1A9 and IGROV1 ovarian carcinoma transplanted orthotopically in the bursa of the mouse ovary.  Paclitaxel concns. together with its distribution by MALDI mass spectrometry imaging (MALDI MSI) were measured to det. the drug in different areas of the tumor, which was immunostained to depict vessel morphol. and tumor proliferation.  Bevacizumab modified the vessel bed, assessed by CD31 staining and dynamic contrast enhanced MRI (DCE-MRI), and potentiated the antitumor activity of paclitaxel in all the models.  Although tumor paclitaxel concns. were lower after bevacizumab, the drug distributed more homogeneously, particularly in vascularized, non-necrotic areas, and was cleared more slowly than controls.  This happened specifically in tumor tissue, as there was no change in paclitaxel pharmacokinetics or drug distribution in normal tissues.  In addn., the drug concn. and distribution were not influenced by the site of tumor growth, as A2780-1A9 and IGROV1 growing in the ovary gave results similar to the tumor growing s.c.  We suggest that the changes in the tumor microenvironment architecture induced by bevacizumab, together with the better distribution of paclitaxel, may explain the significant antitumor potentiation by the combination.  Mol Cancer Ther; 15(1); 125-35.  ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV5sZCCsBwxbVg90H21EOLACvtfcHk0lidj94OZkwh3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xmslelug%253D%253D&md5=da09e8ead5db6fe2ccb2b9a1c18074fa</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0063%26sid%3Dliteratum%253Aachs%26aulast%3DCesca%26aufirst%3DM.%26aulast%3DMorosi%26aufirst%3DL.%26aulast%3DBerndt%26aufirst%3DA.%26aulast%3DNerini%26aufirst%3DI.%2BF.%26aulast%3DFrapolli%26aufirst%3DR.%26aulast%3DRichter%26aufirst%3DP.%26aulast%3DDecio%26aufirst%3DA.%26aulast%3DDirsch%26aufirst%3DO.%26aulast%3DMicotti%26aufirst%3DE.%26aulast%3DGiordano%26aufirst%3DS.%26aulast%3DD%25E2%2580%2599Incalci%26aufirst%3DM.%26aulast%3DDavoli%26aufirst%3DE.%26aulast%3DZucchetti%26aufirst%3DM.%26aulast%3DGiavazzi%26aufirst%3DR.%26atitle%3DBevacizumab-induced%2520inhibition%2520of%2520angiogenesis%2520promotes%2520a%2520more%2520homogeneous%2520intratumoral%2520distribution%2520of%2520paclitaxel%252C%2520improving%2520the%2520antitumor%2520response%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D125%26epage%3D135%26doi%3D10.1158%2F1535-7163.MCT-15-0063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotili, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerbara, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valente, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeoni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragno, R.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylation in epigenetics: an attractive target for anticancer therapy</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1002/med.20024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1002%2Fmed.20024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=15717297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjslGit7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2005&pages=261-309&author=A.+Maiauthor=S.+Massaauthor=D.+Rotiliauthor=I.+Cerbaraauthor=S.+Valenteauthor=R.+Pezziauthor=S.+Simeoniauthor=R.+Ragno&title=Histone+deacetylation+in+epigenetics%3A+an+attractive+target+for+anticancer+therapy&doi=10.1002%2Fmed.20024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylation in epigenetics: An attractive target for anticancer therapy</span></div><div class="casAuthors">Mai, Antonello; Massa, Silvio; Rotili, Dante; Cerbara, Ilaria; Valente, Sergio; Pezzi, Riccardo; Simeoni, Silvia; Ragno, Rino</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">261-309</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The reversible histone acetylation and deacetylation are epigenetic phenomena that play crit. roles in the modulation of chromatin topol. and the regulation of gene expression.  Aberrant transcription due to altered expression or mutation of genes that encode histone acetyltransferase (HAT) or histone deacetylase (HDAC) enzymes or their binding partners, has been clearly linked to carcinogenesis.  The histone deacetylase inhibitors are a new promising class of anticancer agents (some of which in clin. trials), that inhibit the proliferation of tumor cells in culture and in vivo by inducing cell-cycle arrest, terminal differentiation, and/or apoptosis.  This report reviews the chem. and the biol. of HDACs and HDAC inhibitors, laying particular emphasis on agents actually in clin. trials for cancer therapy and on new potential anticancer lead compds. more selective and less toxic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDbzbbO5ZKrLVg90H21EOLACvtfcHk0lidj94OZkwh3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjslGit7w%253D&md5=60112258470a6d520cbc0af24046e994</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1002%2Fmed.20024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20024%26sid%3Dliteratum%253Aachs%26aulast%3DMai%26aufirst%3DA.%26aulast%3DMassa%26aufirst%3DS.%26aulast%3DRotili%26aufirst%3DD.%26aulast%3DCerbara%26aufirst%3DI.%26aulast%3DValente%26aufirst%3DS.%26aulast%3DPezzi%26aufirst%3DR.%26aulast%3DSimeoni%26aufirst%3DS.%26aulast%3DRagno%26aufirst%3DR.%26atitle%3DHistone%2520deacetylation%2520in%2520epigenetics%253A%2520an%2520attractive%2520target%2520for%2520anticancer%2520therapy%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2005%26volume%3D25%26spage%3D261%26epage%3D309%26doi%3D10.1002%2Fmed.20024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chao, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, C. M.</span></span> <span> </span><span class="NLM_article-title">The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">82</span>, <span class="refDoi"> DOI: 10.1186/s13045-015-0176-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1186%2Fs13045-015-0176-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=26156322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FhsFKjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=82&author=M.+W.+Chaoauthor=M.+J.+Laiauthor=J.+P.+Liouauthor=Y.+L.+Changauthor=J.+C.+Wangauthor=S.+L.+Panauthor=C.+M.+Teng&title=The+synergic+effect+of+vincristine+and+vorinostat+in+leukemia+in+vitro+and+in+vivo&doi=10.1186%2Fs13045-015-0176-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo</span></div><div class="casAuthors">Chao Min-Wu; Chang Ya-Ling; Teng Che-Ming; Lai Mei-Jung; Liou Jing-Ping; Wang Jing-Chi; Pan Shiow-Lin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hematology & oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">82</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Combination therapy is a key strategy for minimizing drug resistance, a common problem in cancer therapy.  The microtubule-depolymerizing agent vincristine is widely used in the treatment of acute leukemia.  In order to decrease toxicity and chemoresistance of vincristine, this study will investigate the effects of combination vincristine and vorinostat (suberoylanilide hydroxamic acid (SAHA)), a pan-histone deacetylase inhibitor, on human acute T cell lymphoblastic leukemia cells.  METHODS:  Cell viability experiments were determined by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay, and cell cycle distributions as well as mitochondria membrane potential were analyzed by flow cytometry.  In vitro tubulin polymerization assay was used to test tubulin assembly, and immunofluorescence analysis was performed to detect microtubule distribution and morphology.  In vivo effect of the combination was evaluated by a MOLT-4 xenograft model.  Statistical analysis was assessed by Bonferroni's t test.  RESULTS:  Cell viability showed that the combination of vincristine and SAHA exhibited greater cytotoxicity with an IC50 value of 0.88 nM, compared to each drug alone, 3.3 and 840 nM.  This combination synergically induced G2/M arrest, followed by an increase in cell number at the sub-G1 phase and caspase activation.  Moreover, the results of vincristine combined with an HDAC6 inhibitor (tubastatin A), which acetylated α-tubulin, were consistent with the effects of vincristine/SAHA co-treatment, thus suggesting that SAHA may alter microtubule dynamics through HDAC6 inhibition.  CONCLUSION:  These findings indicate that the combination of vincristine and SAHA on T cell leukemic cells resulted in a change in microtubule dynamics contributing to M phase arrest followed by induction of the apoptotic pathway.  These data suggest that the combination effect of vincristine/SAHA could have an important preclinical basis for future clinical trial testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTZWw7KK08a6Zp6t8nS6Nc3fW6udTcc2eaJN3M_ANuaarntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FhsFKjtA%253D%253D&md5=b22f13563067cc55509bc41110bb86ab</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1186%2Fs13045-015-0176-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-015-0176-7%26sid%3Dliteratum%253Aachs%26aulast%3DChao%26aufirst%3DM.%2BW.%26aulast%3DLai%26aufirst%3DM.%2BJ.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26aulast%3DChang%26aufirst%3DY.%2BL.%26aulast%3DWang%26aufirst%3DJ.%2BC.%26aulast%3DPan%26aufirst%3DS.%2BL.%26aulast%3DTeng%26aufirst%3DC.%2BM.%26atitle%3DThe%2520synergic%2520effect%2520of%2520vincristine%2520and%2520vorinostat%2520in%2520leukemia%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2015%26volume%3D8%26spage%3D82%26doi%3D10.1186%2Fs13045-015-0176-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chobanian, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenberg, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gass, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desimone, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Nagell, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, S. G.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 status</span>. <i>Anticancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">539</span>– <span class="NLM_lpage">545</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=15160991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkvVegtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=539-545&author=N.+H.+Chobanianauthor=V.+L.+Greenbergauthor=J.+M.+Gassauthor=C.+P.+Desimoneauthor=J.+R.+Van+Nagellauthor=S.+G.+Zimmer&title=Histone+deacetylase+inhibitors+enhance+paclitaxel-induced+cell+death+in+ovarian+cancer+cell+lines+independent+of+p53+status"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 status</span></div><div class="casAuthors">Chobanian, Nishan H.; Greenberg, Victoria L.; Gass, Jennifer M.; Desimone, Christopher P.; Van Nagell, John R.; Zimmer, Stephen G.</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2B</span>),
    <span class="NLM_cas:pages">539-545</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">Recurrence of drug-resistant disease contributes to the high mortality of ovarian cancer patients, which necessitates the identification of addnl. chemotherapeutic drugs.  Histone deacetylase inhibitors (HDAIs) induce apoptosis in a no. of malignant cell types and may represent a new class of drugs clin. relevant in the treatment of ovarian cancer.  Ovarian cancer cells were treated with various combinations of a HDAI and paclitaxel (PTX).  Cell death was measured using annexin V/propidium iodide exclusion.  The PTX/HDAI drug combination was as efficient in inducing cell death as continuous PTX treatment and superior to continuous HDAI treatment.  Reversing the sequence of drug exposure reduced the cytotoxic efficacy of the drug combination.  The p53 status of the cell lines did not alter the cytotoxic efficacy of the treatment protocols.  These results suggest that HDAIs possess possible clin. applications as an adjuvant therapy in the treatment of ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr930zCusS9XLVg90H21EOLACvtfcHk0ljEaDQlqGdzTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkvVegtb0%253D&md5=31429aa419349152ac124cc1c1e2e342</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChobanian%26aufirst%3DN.%2BH.%26aulast%3DGreenberg%26aufirst%3DV.%2BL.%26aulast%3DGass%26aufirst%3DJ.%2BM.%26aulast%3DDesimone%26aufirst%3DC.%2BP.%26aulast%3DVan%2BNagell%26aufirst%3DJ.%2BR.%26aulast%3DZimmer%26aufirst%3DS.%2BG.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520enhance%2520paclitaxel-induced%2520cell%2520death%2520in%2520ovarian%2520cancer%2520cell%2520lines%2520independent%2520of%2520p53%2520status%26jtitle%3DAnticancer%2520Res.%26date%3D2004%26volume%3D24%26spage%3D539%26epage%3D545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zuco, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Cesare, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cincinelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaffaroni, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zunino, F.</span></span> <span> </span><span class="NLM_article-title">Synergistic antitumor effects of novel HDAC inhibitors and paclitaxel in vitro and in vivo</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">e29085</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0029085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1371%2Fjournal.pone.0029085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=22194993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFOksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&author=V.+Zucoauthor=M.+De+Cesareauthor=R.+Cincinelliauthor=R.+Nanneiauthor=C.+Pisanoauthor=N.+Zaffaroniauthor=F.+Zunino&title=Synergistic+antitumor+effects+of+novel+HDAC+inhibitors+and+paclitaxel+in+vitro+and+in+vivo&doi=10.1371%2Fjournal.pone.0029085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic antitumor effects of novel HDAC inhibitors and paclitaxel in vitro and in vivo</span></div><div class="casAuthors">Zuco, Valentina; De Cesare, Michelandrea; Cincinelli, Raffaella; Nannei, Raffaella; Pisano, Claudio; Zaffaroni, Nadia; Zunino, Franco</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e29085</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Preclin. studies support the therapeutic potential of histone deacetylases inhibitors (HDACi) in combination with taxanes.  The efficacy of combination was mainly ascribed to a cooperative effect on microtubule stabilization following tubulin acetylation.  In the present study we investigated the effect of paclitaxel in combination with 2 novel HDACi, ST2782 or ST3595, able to induce p53 and tubulin hyperacetylation.  A synergistic effect of the paclitaxel/ST2782 (or ST3595) combination was found in wild-type p53 ovarian carcinoma cells, but not in a p53 mutant subline, in spite of a marked tubulin acetylation.  Such a synergistic interaction was confirmed in addnl. human solid tumor cell lines harboring wild-type p53 but not in those expressing mutant or null p53.  In addn., a synergistic cytotoxic effect was found when ST2782 was combined with the depolymerising agent vinorelbine.  In contrast to SAHA, which was substantially less effective in sensitizing cells to paclitaxel-induced apoptosis, ST2782 prevented up-regulation of p21WAF1/Cip1 by paclitaxel, which has a protective role in response to taxanes, and caused p53 down-regulation, acetylation and mitochondrial localization of acetylated p53.  The synergistic antitumor effects of the paclitaxel/ST3595 combination were confirmed in 2 tumor xenograft models.  Our results support the relevance of p53 modulation as a major determinant of the synergistic interaction obsd. between paclitaxel and novel HDACi and emphasize the therapeutic interest of this combination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFdXXd1e7KArVg90H21EOLACvtfcHk0ljEaDQlqGdzTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFOksQ%253D%253D&md5=136708d5f58c8e01531a3563b576898b</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0029085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0029085%26sid%3Dliteratum%253Aachs%26aulast%3DZuco%26aufirst%3DV.%26aulast%3DDe%2BCesare%26aufirst%3DM.%26aulast%3DCincinelli%26aufirst%3DR.%26aulast%3DNannei%26aufirst%3DR.%26aulast%3DPisano%26aufirst%3DC.%26aulast%3DZaffaroni%26aufirst%3DN.%26aulast%3DZunino%26aufirst%3DF.%26atitle%3DSynergistic%2520antitumor%2520effects%2520of%2520novel%2520HDAC%2520inhibitors%2520and%2520paclitaxel%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26doi%3D10.1371%2Fjournal.pone.0029085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katsumata, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isonishi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jobo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochiai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noda, K.</span></span> <span> </span><span class="NLM_article-title">Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">1331</span>– <span class="NLM_lpage">1338</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(09)61157-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2FS0140-6736%2809%2961157-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=19767092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Ogu7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2009&pages=1331-1338&author=N.+Katsumataauthor=M.+Yasudaauthor=F.+Takahashiauthor=S.+Isonishiauthor=T.+Joboauthor=D.+Aokiauthor=H.+Tsudaauthor=T.+Sugiyamaauthor=S.+Kodamaauthor=E.+Kimuraauthor=K.+Ochiaiauthor=K.+Noda&title=Dose-dense+paclitaxel+once+a+week+in+combination+with+carboplatin+every+3+weeks+for+advanced+ovarian+cancer%3A+a+phase+3%2C+open-label%2C+randomised+controlled+trial&doi=10.1016%2FS0140-6736%2809%2961157-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomized controlled trial</span></div><div class="casAuthors">Katsumata, Noriyuki; Yasuda, Makoto; Takahashi, Fumiaki; Isonishi, Seiji; Jobo, Toshiko; Aoki, Daisuke; Tsuda, Hiroshi; Sugiyama, Toru; Kodama, Shoji; Kimura, Eizo; Ochiai, Kazunori; Noda, Kiichiro</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">9698</span>),
    <span class="NLM_cas:pages">1331-1338</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Paclitaxel and carboplatin given every 3 wk is std. treatment for advanced ovarian carcinoma.  Attempts to improve patient survival by including other drugs have yielded disappointing results.  We compared a conventional regimen of paclitaxel and carboplatin with a dose-dense weekly regimen in women with advanced ovarian cancer.  Patients with stage II to IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer were eligible for enrollment in this phase 3, open-label, randomized controlled trial at 85 centers in Japan.  Patients were randomly assigned by computer-generated randomization sequence to receive six cycles of either paclitaxel (180 mg/m2; 3-h i.v. infusion) plus carboplatin (area under the curve [AUC] 6 mg/mL per min), given on day 1 of a 21-day cycle (conventional regimen; n = 320), or dose-dense paclitaxel (80 mg/m2; 1-h i.v. infusion) given on days 1, 8, and 15 plus carboplatin given on day 1 of a 21-day cycle (dose-dense regimen; n = 317).  The primary endpoint was progression-free survival.  Anal. was by intention to treat (ITT).  This trial is registered with ClinicalTrials.gov, no. NCT00226915.  Findings: 631 of the 637 enrolled patients were eligible for treatment and were included in the ITT population (dose-dense regimen, n = 312; conventional regimen, n = 319).  Median progression-free survival was longer in the dose-dense treatment group (28.0 mo, 95% CI 22.3-35.4) than in the conventional treatment group (17.2 mo, 15.7-21.1; hazard ratio [HR] 0.71; 95% CI 0.58-0.88; p = 0.0015).  Overall survival at 3 years was higher in the dose-dense regimen group (72.1%) than in the conventional treatment group (65.1%; HR 0.75, 0.57-0.98; p = 0.03).  165 Patients assigned to the dose-dense regimen and 117 assigned to the conventional regimen discontinued treatment early.  Reasons for participant dropout were balanced between the groups, apart from withdrawal because of toxicity, which was higher in the dose-dense regimen group than in the conventional regimen group (n = 113 vs n = 69).  The most common adverse event was neutropenia (dose-dense regimen, 286 [92%] of 312; conventional regimen, 276 [88%] of 314).  The frequency of grade 3 and 4 anemia was higher in the dose-dense treatment group (214 [69%]) than in the conventional treatment group (137 [44%]; p<0.0001).  The frequencies of other toxic effects were similar between groups.  Dose-dense weekly paclitaxel plus carboplatin improved survival compared with the conventional regimen and represents a new treatment option in women with advanced epithelial ovarian cancer.  Funding: Bristol-Myers Squibb.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNTrRgsgOozbVg90H21EOLACvtfcHk0ljEaDQlqGdzTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Ogu7fJ&md5=acee94531683ffc822f52cc62059754a</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2809%2961157-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252809%252961157-0%26sid%3Dliteratum%253Aachs%26aulast%3DKatsumata%26aufirst%3DN.%26aulast%3DYasuda%26aufirst%3DM.%26aulast%3DTakahashi%26aufirst%3DF.%26aulast%3DIsonishi%26aufirst%3DS.%26aulast%3DJobo%26aufirst%3DT.%26aulast%3DAoki%26aufirst%3DD.%26aulast%3DTsuda%26aufirst%3DH.%26aulast%3DSugiyama%26aufirst%3DT.%26aulast%3DKodama%26aufirst%3DS.%26aulast%3DKimura%26aufirst%3DE.%26aulast%3DOchiai%26aufirst%3DK.%26aulast%3DNoda%26aufirst%3DK.%26atitle%3DDose-dense%2520paclitaxel%2520once%2520a%2520week%2520in%2520combination%2520with%2520carboplatin%2520every%25203%2520weeks%2520for%2520advanced%2520ovarian%2520cancer%253A%2520a%2520phase%25203%252C%2520open-label%252C%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2009%26volume%3D374%26spage%3D1331%26epage%3D1338%26doi%3D10.1016%2FS0140-6736%2809%2961157-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paz-Ares, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luft, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicente, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tafreshi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gümüş, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazières, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Çay Şenler, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csőszi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fülöp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Cid, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugawara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novello, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halmos, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubiniecki, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piperdi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalski, D. M.</span></span> <span> </span><span class="NLM_article-title">Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>379</i></span>,  <span class="NLM_fpage">2040</span>– <span class="NLM_lpage">2051</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1810865</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1056%2FNEJMoa1810865" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=30280635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisV2rs7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2018&pages=2040-2051&author=L.+Paz-Aresauthor=A.+Luftauthor=D.+Vicenteauthor=A.+Tafreshiauthor=M.+G%C3%BCm%C3%BC%C5%9Fauthor=J.+Mazi%C3%A8resauthor=B.+Hermesauthor=F.+%C3%87ay+%C5%9Eenlerauthor=T.+Cs%C5%91sziauthor=A.+F%C3%BCl%C3%B6pauthor=J.+Rodr%C3%ADguez-Cidauthor=J.+Wilsonauthor=S.+Sugawaraauthor=T.+Katoauthor=K.+H.+Leeauthor=Y.+Chengauthor=S.+Novelloauthor=B.+Halmosauthor=X.+Liauthor=G.+M.+Lubinieckiauthor=B.+Piperdiauthor=D.+M.+Kowalski&title=Pembrolizumab+plus+chemotherapy+for+squamous+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa1810865"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer</span></div><div class="casAuthors">Paz-Ares, L.; Luft, A.; Vicente, D.; Tafreshi, A.; Gumus, M.; Mazieres, J.; Hermes, B.; Senler, F. Cay; Csoszi, T.; Fulop, A.; Rodriguez-Cid, J.; Wilson, J.; Sugawara, S.; Kato, T.; Lee, K. H.; Cheng, Y.; Novello, S.; Halmos, B.; Li, X.; Lubiniecki, G. M.; Piperdi, B.; Kowalski, D. M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2040-2051</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Std. first-line therapy for metastatic, squamous non-small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on ≥50% of tumor cells).  More recently, pembrolizumab plus chemotherapy was shown to significantly prolong overall survival among patients with nonsquamous NSCLC. methods In this double-blind, phase 3 trial, we randomly assigned, in a 1:1 ratio, 559 patients with untreated metastatic, squamous NSCLC to receive 200 mg of pembrolizumab or saline placebo for up to 35 cycles; all the patients also received carboplatin and either paclitaxel or nanoparticle albumin-bound [nab]-paclitaxel for the first 4 cycles.  Primary end points were overall survival and progression-free survival. results After a median follow-up of 7.8 mo, the median overall survival was 15.9 mo (95% confidence interval [CI], 13.2 to not reached) in the pembrolizumab-combination group and 11.3 mo (95% CI, 9.5 to 14.8) in the placebo-combination group (hazard ratio for death, 0.64; 95% CI, 0.49 to 0.85; P<0.001).  The overall survival benefit was consistent regardless of the level of PD-L1 expression.  The median progression-free survival was 6.4 mo (95% CI, 6.2 to 8.3) in the pembrolizumab-combination group and 4.8 mo (95% CI, 4.3 to 5.7) in the placebo-combination group (hazard ratio for disease progression or death, 0.56; 95% CI, 0.45 to 0.70; P<0.001).  Adverse events of grade 3 or higher occurred in 69.8% of the patients in the pembrolizumab-combination group and in 68.2% of the patients in the placebo-combination group.  Discontinuation of treatment because of adverse events was more frequent in the pembrolizumab-combination group than in the placebo-combination group (13.3% vs. 6.4%). conclusions In patients with previously untreated metastatic, squamous NSCLC, the addn. of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in significantly longer overall survival and progression-free survival than chemotherapy alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqfd87OOvD17Vg90H21EOLACvtfcHk0lijLmmnHOoBJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisV2rs7vI&md5=c82761f20089ea398420429dbe7e4673</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1810865&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1810865%26sid%3Dliteratum%253Aachs%26aulast%3DPaz-Ares%26aufirst%3DL.%26aulast%3DLuft%26aufirst%3DA.%26aulast%3DVicente%26aufirst%3DD.%26aulast%3DTafreshi%26aufirst%3DA.%26aulast%3DG%25C3%25BCm%25C3%25BC%25C5%259F%26aufirst%3DM.%26aulast%3DMazi%25C3%25A8res%26aufirst%3DJ.%26aulast%3DHermes%26aufirst%3DB.%26aulast%3D%25C3%2587ay%2B%25C5%259Eenler%26aufirst%3DF.%26aulast%3DCs%25C5%2591szi%26aufirst%3DT.%26aulast%3DF%25C3%25BCl%25C3%25B6p%26aufirst%3DA.%26aulast%3DRodr%25C3%25ADguez-Cid%26aufirst%3DJ.%26aulast%3DWilson%26aufirst%3DJ.%26aulast%3DSugawara%26aufirst%3DS.%26aulast%3DKato%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DNovello%26aufirst%3DS.%26aulast%3DHalmos%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLubiniecki%26aufirst%3DG.%2BM.%26aulast%3DPiperdi%26aufirst%3DB.%26aulast%3DKowalski%26aufirst%3DD.%2BM.%26atitle%3DPembrolizumab%2520plus%2520chemotherapy%2520for%2520squamous%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D379%26spage%3D2040%26epage%3D2051%26doi%3D10.1056%2FNEJMoa1810865" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Socinski, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jotte, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappuzzo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroyakovskiy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Abreu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moro-Sibilot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlesi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finley, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowanetz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Chavez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reck, M.</span></span> <span> </span><span class="NLM_article-title">Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">2288</span>– <span class="NLM_lpage">2301</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1716948</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1056%2FNEJMoa1716948" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=29863955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFKkt77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=2288-2301&author=M.+A.+Socinskiauthor=R.+M.+Jotteauthor=F.+Cappuzzoauthor=F.+Orlandiauthor=D.+Stroyakovskiyauthor=N.+Nogamiauthor=D.+Rodr%C3%ADguez-Abreuauthor=D.+Moro-Sibilotauthor=C.+A.+Thomasauthor=F.+Barlesiauthor=G.+Finleyauthor=C.+Kelschauthor=A.+Leeauthor=S.+Colemanauthor=Y.+Dengauthor=Y.+Shenauthor=M.+Kowanetzauthor=A.+Lopez-Chavezauthor=A.+Sandlerauthor=M.+Reck&title=Atezolizumab+for+first-line+treatment+of+metastatic+nonsquamous+NSCLC&doi=10.1056%2FNEJMoa1716948"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC</span></div><div class="casAuthors">Socinski, M. A.; Jotte, R. M.; Cappuzzo, F.; Orlandi, F.; Stroyakovskiy, D.; Nogami, N.; Rodriguez-Abreu, D.; Moro-Sibilot, D.; Thomas, C. A.; Barlesi, F.; Finley, G.; Kelsch, C.; Lee, A.; Coleman, S.; Deng, Y.; Shen, Y.; Kowanetz, M.; Lopez-Chavez, A.; Sandler, A.; Reck, M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2288-2301</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The cancer-cell-killing property of atezolizumab may be enhanced by the blockade of vascular endothelial growth factor-mediated immunosuppression with bevacizumab.  This open-label, phase 3 study evaluated atezolizumab plus bevacizumab plus chemotherapy in patients with metastatic nonsquamous non-small-cell lung cancer (NSCLC) who had not previously received chemotherapy.  We randomly assigned patients to receive atezolizumab plus carboplatin plus paclitaxel (ACP), bevacizumab plus carboplatin plus paclitaxel (BCP), or atezolizumab plus BCP (ABCP) every 3 wk for four or six cycles, followed by maintenance therapy with atezolizumab, bevacizumab, or both.  The two primary end points were investigator-assessed progression-free survival both among patients in the intention-to-treat population who had a wild-type genotype (WT population; patients with EGFR or ALK genetic alterations were excluded) and among patients in the WT population who had high expression of an effector T-cell (Teff) gene signature in the tumor (Teff-high WT population) and overall survival in the WT population.  The ABCP group was compared with the BCP group before the ACP group was compared with the BCP group. results In the WT population, 356 patients were assigned to the ABCP group, and 336 to the BCP group.  The median progression-free survival was longer in the ABCP group than in the BCP group (8.3 mo vs. 6.8 mo; hazard ratio for disease progression or death, 0.62; 95% confidence interval [CI], 0.52 to 0.74; P<0.001); the corresponding values in the Teff-high WT population were 11.3 mo and 6.8 mo (hazard ratio, 0.51 [95% CI, 0.38 to 0.68]; P<0.001).  Progressioin-free survival was also longer in the ABCP group than in the BCP group in the entire intention-to-treat population (including those with EGFR or ALK genetic alterations) and among patients with low or neg. programmed death ligand 1 (PD-L1) expression, those with low Teff gene-signature expression, and those with liver metastases.  Median overall survival among the patients in the WT population was longer in the ABCP group than in the BCP group (19.2 mo vs. 14.7 mo; hazard ratio for death, 0.78; 95% CI, 0.64 to 0.96; P = 0.02).  The addn. of atezolizumab to bevacizumab plus chemotherapy significantly improved progression-free survival and overall survival among patients with metastatic nonsquamous NSCLC, regardless of PD-L1 expression and EGFR or ALK genetic alteration status.  The safety profile of ABCP was consistent with previously reported safety risks of the individual medicines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPXyYm4dRnKLVg90H21EOLACvtfcHk0lijLmmnHOoBJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFKkt77K&md5=93f7f76c2e79bf42de2e7a8a403c9c93</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1716948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1716948%26sid%3Dliteratum%253Aachs%26aulast%3DSocinski%26aufirst%3DM.%2BA.%26aulast%3DJotte%26aufirst%3DR.%2BM.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DOrlandi%26aufirst%3DF.%26aulast%3DStroyakovskiy%26aufirst%3DD.%26aulast%3DNogami%26aufirst%3DN.%26aulast%3DRodr%25C3%25ADguez-Abreu%26aufirst%3DD.%26aulast%3DMoro-Sibilot%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DC.%2BA.%26aulast%3DBarlesi%26aufirst%3DF.%26aulast%3DFinley%26aufirst%3DG.%26aulast%3DKelsch%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DA.%26aulast%3DColeman%26aufirst%3DS.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DKowanetz%26aufirst%3DM.%26aulast%3DLopez-Chavez%26aufirst%3DA.%26aulast%3DSandler%26aufirst%3DA.%26aulast%3DReck%26aufirst%3DM.%26atitle%3DAtezolizumab%2520for%2520first-line%2520treatment%2520of%2520metastatic%2520nonsquamous%2520NSCLC%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26spage%3D2288%26epage%3D2301%26doi%3D10.1056%2FNEJMoa1716948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eisen, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodward, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitznagel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przybeck, T. R.</span></span> <span> </span><span class="NLM_article-title">The effect of prescribed daily dose frequency on patient medication compliance</span>. <i>Arch. Intern. Med.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">1881</span>– <span class="NLM_lpage">1884</span>, <span class="refDoi"> DOI: 10.1001/archinte.1990.00390200073014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1001%2Farchinte.1990.00390200073014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=2102668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A280%3ADyaK3czmsFGltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=1990&pages=1881-1884&author=S.+A.+Eisenauthor=D.+K.+Millerauthor=R.+S.+Woodwardauthor=E.+Spitznagelauthor=T.+R.+Przybeck&title=The+effect+of+prescribed+daily+dose+frequency+on+patient+medication+compliance&doi=10.1001%2Farchinte.1990.00390200073014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of prescribed daily dose frequency on patient medication compliance</span></div><div class="casAuthors">Eisen S A; Miller D K; Woodward R S; Spitznagel E; Przybeck T R</div><div class="citationInfo"><span class="NLM_cas:title">Archives of internal medicine</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1881-4</span>
        ISSN:<span class="NLM_cas:issn">0003-9926</span>.
    </div><div class="casAbstract">The objective of this study was to determine the relationship between prescribed daily dose frequency and patient medication compliance.  The medication compliance of 105 patients receiving antihypertensive medications was monitored by analyzing data obtained from special pill containers that electronically record the date and time of medication removal.  Inaccurate compliance estimates derived using the simple pill count method were thereby avoided.  Compliance was defined as the percent of days during which the prescribed number of doses were removed.  Compliance improved from 59.0% on a three-time daily regimen to 83.6% on a once-daily regimen.  Thus, compliance improves dramatically as prescribed dose frequency decreases.  Probably the single most important action that health care providers can take to improve compliance is to select medications that permit the lowest daily prescribed dose frequency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ77B5mAT4PZMRAV4D_Ins_fW6udTcc2eYhTEZlKC3D_bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3czmsFGltg%253D%253D&md5=83afa34a4f1dafc6e0ab4bc87c33026c</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1001%2Farchinte.1990.00390200073014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchinte.1990.00390200073014%26sid%3Dliteratum%253Aachs%26aulast%3DEisen%26aufirst%3DS.%2BA.%26aulast%3DMiller%26aufirst%3DD.%2BK.%26aulast%3DWoodward%26aufirst%3DR.%2BS.%26aulast%3DSpitznagel%26aufirst%3DE.%26aulast%3DPrzybeck%26aufirst%3DT.%2BR.%26atitle%3DThe%2520effect%2520of%2520prescribed%2520daily%2520dose%2520frequency%2520on%2520patient%2520medication%2520compliance%26jtitle%3DArch.%2520Intern.%2520Med.%26date%3D1990%26volume%3D150%26spage%3D1881%26epage%3D1884%26doi%3D10.1001%2Farchinte.1990.00390200073014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poornima, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blunder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efferth, T.</span></span> <span> </span><span class="NLM_article-title">Network pharmacology of cancer: From understanding of complex interactomes to the design of multi-target specific therapeutics from nature</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">290</span>– <span class="NLM_lpage">302</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2016.06.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.phrs.2016.06.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=27329331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFShsr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2016&pages=290-302&author=P.+Poornimaauthor=J.+D.+Kumarauthor=Q.+Zhaoauthor=M.+Blunderauthor=T.+Efferth&title=Network+pharmacology+of+cancer%3A+From+understanding+of+complex+interactomes+to+the+design+of+multi-target+specific+therapeutics+from+nature&doi=10.1016%2Fj.phrs.2016.06.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Network pharmacology of cancer: From understanding of complex interactomes to the design of multi-target specific therapeutics from nature</span></div><div class="casAuthors">Poornima, Paramasivan; Kumar, Jothi Dinesh; Zhao, Qiaoli; Blunder, Martina; Efferth, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">290-302</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Despite massive investments in drug research and development, the significant decline in the no. of new drugs approved or translated to clin. use raises the question, whether single targeted drug discovery is the right approach.  To combat complex systemic diseases that harbor robust biol. networks such as cancer, single target intervention is proved to be ineffective.  In such cases, network pharmacol. approaches are highly useful, because they differ from conventional drug discovery by addressing the ability of drugs to target numerous proteins or networks involved in a disease.  Pleiotropic natural products are one of the promising strategies due to their multi-targeting and due to lower side effects.  In this review, we discuss the application of network pharmacol. for cancer drug discovery.  We provide an overview of the current state of knowledge on network pharmacol., focus on different tech. approaches and implications for cancer therapy (e.g. polypharmacol. and synthetic lethality), and illustrate the therapeutic potential with selected examples green tea polyphenolics, Eleutherococcus senticosus, Rhodiola rosea, and Schisandra chinensis.  Finally, we present future perspectives on their plausible applications for diagnosis and therapy of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwqqjqEH_wtrVg90H21EOLACvtfcHk0lgea3JrHiIBlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFShsr%252FM&md5=be3757ac287f3b90ebbcb69016a9410c</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2016.06.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2016.06.018%26sid%3Dliteratum%253Aachs%26aulast%3DPoornima%26aufirst%3DP.%26aulast%3DKumar%26aufirst%3DJ.%2BD.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DBlunder%26aufirst%3DM.%26aulast%3DEfferth%26aufirst%3DT.%26atitle%3DNetwork%2520pharmacology%2520of%2520cancer%253A%2520From%2520understanding%2520of%2520complex%2520interactomes%2520to%2520the%2520design%2520of%2520multi-target%2520specific%2520therapeutics%2520from%2520nature%26jtitle%3DPharmacol.%2520Res.%26date%3D2016%26volume%3D111%26spage%3D290%26epage%3D302%26doi%3D10.1016%2Fj.phrs.2016.06.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jørgensen, J. T.</span></span> <span> </span><span class="NLM_article-title">The importance of predictive biomarkers in oncology drug development</span>. <i>Expert Rev. Mol. Diagn.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">807</span>– <span class="NLM_lpage">809</span>, <span class="refDoi"> DOI: 10.1080/14737159.2016.1199962</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1080%2F14737159.2016.1199962" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=27282189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FosVChug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=807-809&author=J.+T.+J%C3%B8rgensen&title=The+importance+of+predictive+biomarkers+in+oncology+drug+development&doi=10.1080%2F14737159.2016.1199962"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The importance of predictive biomarkers in oncology drug development</span></div><div class="casAuthors">Jorgensen Jan Trost</div><div class="citationInfo"><span class="NLM_cas:title">Expert review of molecular diagnostics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">807-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSpjsop5xOrXENoizSOkG_FfW6udTcc2eYhTEZlKC3D_bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FosVChug%253D%253D&md5=a98aabac63825ef0d86e882456e73061</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1080%2F14737159.2016.1199962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14737159.2016.1199962%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25B8rgensen%26aufirst%3DJ.%2BT.%26atitle%3DThe%2520importance%2520of%2520predictive%2520biomarkers%2520in%2520oncology%2520drug%2520development%26jtitle%3DExpert%2520Rev.%2520Mol.%2520Diagn.%26date%3D2016%26volume%3D16%26spage%3D807%26epage%3D809%26doi%3D10.1080%2F14737159.2016.1199962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koutsoukas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simms, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirchmair, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bond, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitmore, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glen, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A.</span></span> <span> </span><span class="NLM_article-title">From in silico target prediction to multi-target drug design: current databases, methods and applications</span>. <i>J. Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">2554</span>– <span class="NLM_lpage">2574</span>, <span class="refDoi"> DOI: 10.1016/j.jprot.2011.05.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.jprot.2011.05.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=21621023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVOjtrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2011&pages=2554-2574&author=A.+Koutsoukasauthor=B.+Simmsauthor=J.+Kirchmairauthor=P.+J.+Bondauthor=A.+V.+Whitmoreauthor=S.+Zimmerauthor=M.+P.+Youngauthor=J.+L.+Jenkinsauthor=M.+Glickauthor=R.+C.+Glenauthor=A.+Bender&title=From+in+silico+target+prediction+to+multi-target+drug+design%3A+current+databases%2C+methods+and+applications&doi=10.1016%2Fj.jprot.2011.05.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">From in silico target prediction to multi-target drug design: Current databases, methods and applications</span></div><div class="casAuthors">Koutsoukas, Alexios; Simms, Benjamin; Kirchmair, Johannes; Bond, Peter J.; Whitmore, Alan V.; Zimmer, Steven; Young, Malcolm P.; Jenkins, Jeremy L.; Glick, Meir; Glen, Robert C.; Bender, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Proteomics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2554-2574</span>CODEN:
                <span class="NLM_cas:coden">JPORFQ</span>;
        ISSN:<span class="NLM_cas:issn">1874-3919</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Given the tremendous growth of bioactivity databases, the use of computational tools to predict protein targets of small mols. has been gaining importance in recent years.  Applications span a wide range, from the designed polypharmacol.' of compds. to mode-of-action anal.  In this review, we firstly survey databases that can be used for ligand-based target prediction and which have grown tremendously in size in the past.  We furthermore outline methods for target prediction that exist, both based on the knowledge of bioactivities from the ligand side and methods that can be applied in situations when a protein structure is known.  Applications of successful in silico target identification attempts are discussed in detail, which were based partly or in whole on computational target predictions in the first instance.  This includes the authors' own experience using target prediction tools, in this case considering phenotypic antibacterial screens and the anal. of high-throughput screening data.  Finally, we will conclude with the prospective application of databases to not only predict, retrospectively, the protein targets of a small mol., but also how to design ligands with desired polypharmacol. in a prospective manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQAhthzL8wiLVg90H21EOLACvtfcHk0linN5KXHnR_lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVOjtrfE&md5=3fd699639ef3faf347537ef400030dd9</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.jprot.2011.05.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jprot.2011.05.011%26sid%3Dliteratum%253Aachs%26aulast%3DKoutsoukas%26aufirst%3DA.%26aulast%3DSimms%26aufirst%3DB.%26aulast%3DKirchmair%26aufirst%3DJ.%26aulast%3DBond%26aufirst%3DP.%2BJ.%26aulast%3DWhitmore%26aufirst%3DA.%2BV.%26aulast%3DZimmer%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DM.%2BP.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26aulast%3DGlick%26aufirst%3DM.%26aulast%3DGlen%26aufirst%3DR.%2BC.%26aulast%3DBender%26aufirst%3DA.%26atitle%3DFrom%2520in%2520silico%2520target%2520prediction%2520to%2520multi-target%2520drug%2520design%253A%2520current%2520databases%252C%2520methods%2520and%2520applications%26jtitle%3DJ.%2520Proteomics%26date%3D2011%26volume%3D74%26spage%3D2554%26epage%3D2574%26doi%3D10.1016%2Fj.jprot.2011.05.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moffat, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, D.</span></span> <span> </span><span class="NLM_article-title">Phenotypic screening in cancer drug discovery - past, present and future</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">588</span>– <span class="NLM_lpage">602</span>, <span class="refDoi"> DOI: 10.1038/nrd4366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1038%2Fnrd4366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=25033736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFygsr7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=588-602&author=J.+G.+Moffatauthor=J.+Rudolphauthor=D.+Bailey&title=Phenotypic+screening+in+cancer+drug+discovery+-+past%2C+present+and+future&doi=10.1038%2Fnrd4366"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Phenotypic screening in cancer drug discovery - past, present and future</span></div><div class="casAuthors">Moffat, John G.; Rudolph, Joachim; Bailey, David</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">588-602</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  There has been a resurgence of interest in the use of phenotypic screens in drug discovery as an alternative to target-focused approaches.  Given that oncol. is currently the most active therapeutic area, and also one in which target-focused approaches have been particularly prominent in the past two decades, we investigated the contribution of phenotypic assays to oncol. drug discovery by analyzing the origins of all new small-mol. cancer drugs approved by the US Food and Drug Administration (FDA) over the past 15 years and those currently in clin. development.  Although the majority of these drugs originated from target-based discovery, we identified a significant no. whose discovery depended on phenotypic screening approaches.  We postulate that the contribution of phenotypic screening to cancer drug discovery has been hampered by a reliance on 'classical' nonspecific drug effects such as cytotoxicity and mitotic arrest, exacerbated by a paucity of mechanistically defined cellular models for therapeutically translatable cancer phenotypes.  However, tech. and biol. advances that enable such mechanistically informed phenotypic models have the potential to empower phenotypic drug discovery in oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTWtoTIgWqvbVg90H21EOLACvtfcHk0linN5KXHnR_lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFygsr7L&md5=0e8efed90e5bc4b47f959b83a6ab5b96</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnrd4366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4366%26sid%3Dliteratum%253Aachs%26aulast%3DMoffat%26aufirst%3DJ.%2BG.%26aulast%3DRudolph%26aufirst%3DJ.%26aulast%3DBailey%26aufirst%3DD.%26atitle%3DPhenotypic%2520screening%2520in%2520cancer%2520drug%2520discovery%2520-%2520past%252C%2520present%2520and%2520future%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D588%26epage%3D602%26doi%3D10.1038%2Fnrd4366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology by design: A medicinal chemist’s perspective on multitargeting compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">420</span>– <span class="NLM_lpage">444</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00760</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlKms7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=420-444&author=E.+Proschakauthor=H.+Starkauthor=D.+Merk&title=Polypharmacology+by+design%3A+A+medicinal+chemist%E2%80%99s+perspective+on+multitargeting+compounds&doi=10.1021%2Facs.jmedchem.8b00760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds</span></div><div class="casAuthors">Proschak, Ewgenij; Stark, Holger; Merk, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">420-444</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multitargeting compds. comprising activity on more than a single biol. target have gained remarkable relevance in drug discovery owing to the complexity of multifactorial diseases such as cancer, inflammation, or the metabolic syndrome.  Polypharmacol. drug profiles can produce additive or synergistic effects while reducing side effects and significantly contribute to the high therapeutic success of indispensable drugs such as aspirin.  While their identification has long been the result of serendipity, medicinal chem. now tends to design polypharmacol.  Modern in vitro pharmacol. methods and chem. probes allow a systematic search for rational target combinations and recent innovations in computational technologies, crystallog., or fragment-based design equip multitarget compd. development with valuable tools.  In this Perspective, we analyze the relevance of multiple ligands in drug discovery and the versatile toolbox to design polypharmacol.  We conclude that despite some characteristic challenges remaining unresolved, designed polypharmacol. holds enormous potential to secure future therapeutic innovation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOEwJSxWw3vbVg90H21EOLACvtfcHk0linN5KXHnR_lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlKms7fE&md5=6dc4b8e1c4777372396626140a302663</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00760%26sid%3Dliteratum%253Aachs%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DMerk%26aufirst%3DD.%26atitle%3DPolypharmacology%2520by%2520design%253A%2520A%2520medicinal%2520chemist%25E2%2580%2599s%2520perspective%2520on%2520multitargeting%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D420%26epage%3D444%26doi%3D10.1021%2Facs.jmedchem.8b00760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benek, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korabecny, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soukup, O.</span></span> <span> </span><span class="NLM_article-title">A perspective on multi-target drugs for Alzheimer’s Disease</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">434</span>– <span class="NLM_lpage">445</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2020.04.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.tips.2020.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=32448557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpsVKjsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2020&pages=434-445&author=O.+Benekauthor=J.+Korabecnyauthor=O.+Soukup&title=A+perspective+on+multi-target+drugs+for+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.tips.2020.04.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">A Perspective on Multi-target Drugs for Alzheimer's Disease</span></div><div class="casAuthors">Benek, Ondrej; Korabecny, Jan; Soukup, Ondrej</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">434-445</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease (AD) has a complex pathophysiol. that includes aggregation of pathol. proteins, impaired neurotransmission, increased oxidative stress, or microglia-mediated neuroinflammation.  Therapeutics targeting only one of these AD-related subpathologies have not yet been successful in the search for a disease-modifying treatment.  Therefore, multi-target drugs (MTDs) aiming simultaneously at several subpathologies are expected to be a better approach.  However, the concept of MTD is inherently connected with several limitations, which are often ignored during MTD design and development.  Here, we provide an overview of the MTD approach and discuss its potential pitfalls in the context of AD treatment.  We also put forward ideas to be used in the rational design of MTDs to obtain drugs that are effective against AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKMBfma_4sU7Vg90H21EOLACvtfcHk0linN5KXHnR_lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpsVKjsLY%253D&md5=535e634a85861105f799fe500ee11ad6</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2020.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2020.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DBenek%26aufirst%3DO.%26aulast%3DKorabecny%26aufirst%3DJ.%26aulast%3DSoukup%26aufirst%3DO.%26atitle%3DA%2520perspective%2520on%2520multi-target%2520drugs%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2020%26volume%3D41%26spage%3D434%26epage%3D445%26doi%3D10.1016%2Fj.tips.2020.04.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel dual-target inhibitor of ERK1 and ERK5 that induces regulated cell death to overcome compensatory mechanism in specific tumor types</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">3976</span>– <span class="NLM_lpage">3995</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01896</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01896" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjsFOku7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=3976-3995&author=G.+Wangauthor=Y.+Zhaoauthor=Y.+Liuauthor=D.+Sunauthor=Y.+Zhenauthor=J.+Liuauthor=L.+Fuauthor=L.+Zhangauthor=L.+Ouyang&title=Discovery+of+a+novel+dual-target+inhibitor+of+ERK1+and+ERK5+that+induces+regulated+cell+death+to+overcome+compensatory+mechanism+in+specific+tumor+types&doi=10.1021%2Facs.jmedchem.9b01896"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel Dual-Target Inhibitor of ERK1 and ERK5 That Induces Regulated Cell Death to Overcome Compensatory Mechanism in Specific Tumor Types</span></div><div class="casAuthors">Wang, Guan; Zhao, Yuqian; Liu, Yao; Sun, Dejuan; Zhen, Yongqi; Liu, Jie; Fu, Leilei; Zhang, Lan; Ouyang, Liang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3976-3995</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">ERK1 and ERK5 are proposed to have pivotal roles in several types of cancer.  Under some circumstance, ERK5 may provide a common bypass route, which rescues proliferation upon abrogation of ERK1 signaling.  Thus, we accurately classified the tumor types from The Cancer Genome Atlas (TCGA) based on the expression levels of ERK1 and ERK5.  We proposed a novel therapeutic strategy to overcome the above-mentioned compensatory mechanism in specific tumor types by co-targeting both ERK1 and ERK5.  On the basis of the idea of overcoming ERK5 compensation mechanism, 22ac (ADTL-EI1712) as the first selective dual-target inhibitor of ERK1 and ERK5 was discovered to have potent antitumor effects in vitro and in vivo.  Interestingly, this compd. was found to induce regulated cell death accompanied by autophagy in MKN-74 cells.  Taken together, our results warrant the potential of this dual-target inhibitor as a new candidate drug that conquers compensatory mechanism in certain tumor types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlxVBmkLH7mrVg90H21EOLACvtfcHk0likPW0gd9XF-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjsFOku7c%253D&md5=a39e2b19b4e97ba739e78f2453335714</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01896%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DG.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DZhen%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DOuyang%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520dual-target%2520inhibitor%2520of%2520ERK1%2520and%2520ERK5%2520that%2520induces%2520regulated%2520cell%2520death%2520to%2520overcome%2520compensatory%2520mechanism%2520in%2520specific%2520tumor%2520types%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D3976%26epage%3D3995%26doi%3D10.1021%2Facs.jmedchem.9b01896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span> <span> </span><span class="NLM_article-title">Strategies for modern biomarker and drug development in oncology</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">70</span>, <span class="refDoi"> DOI: 10.1186/s13045-014-0070-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1186%2Fs13045-014-0070-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=25277503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsVOrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=70&author=A.+D.+Smithauthor=D.+Rodaauthor=T.+A.+Yap&title=Strategies+for+modern+biomarker+and+drug+development+in+oncology&doi=10.1186%2Fs13045-014-0070-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for modern biomarker and drug development in oncology</span></div><div class="casAuthors">Smith, Alan D.; Roda, Desam; Yap, Timothy A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">70/1-70/16</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Technol. advancements in the mol. characterization of cancers have enabled researchers to identify an increasing no. of key mol. drivers of cancer progression.  These discoveries have led to multiple novel anticancer therapeutics, and clin. benefit in selected patient populations.  Despite this, the identification of clin. relevant predictive biomarkers of response continues to lag behind.  In this review, we discuss strategies for the mol. characterization of cancers and the importance of biomarkers for the development of novel antitumor therapeutics.  We also review crit. successes and failures in oncol., and detail the lessons learnt, which may aid in the acceleration of anticancer drug development and biomarker discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWNEkFi4M0pLVg90H21EOLACvtfcHk0likPW0gd9XF-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsVOrsQ%253D%253D&md5=735ba9bd2f866b407057dd5cb89e839f</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1186%2Fs13045-014-0070-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-014-0070-8%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DA.%2BD.%26aulast%3DRoda%26aufirst%3DD.%26aulast%3DYap%26aufirst%3DT.%2BA.%26atitle%3DStrategies%2520for%2520modern%2520biomarker%2520and%2520drug%2520development%2520in%2520oncology%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2014%26volume%3D7%26spage%3D70%26doi%3D10.1186%2Fs13045-014-0070-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span> <span> </span><span class="NLM_article-title">Dual-target kinase drug design: Current strategies and future directions in cancer therapy</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>188</i></span>,  <span class="NLM_fpage">112025</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.112025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejmech.2019.112025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=31931340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFCjtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=2020&pages=112025&author=D.+Sunauthor=Y.+Zhaoauthor=S.+Zhangauthor=L.+Zhangauthor=B.+Liuauthor=L.+Ouyang&title=Dual-target+kinase+drug+design%3A+Current+strategies+and+future+directions+in+cancer+therapy&doi=10.1016%2Fj.ejmech.2019.112025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-target kinase drug design: Current strategies and future directions in cancer therapy</span></div><div class="casAuthors">Sun, Dejuan; Zhao, Yuqian; Zhang, Shouyue; Zhang, Lan; Liu, Bo; Ouyang, Liang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">188</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112025</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Protein kinases are well-known to orchestrate the activation of signaling cascades in response to extracellular and intracellular stimuli to control cell proliferation and survival.  The perturbation of such kinases by some mutation or abnormal protein expressions has been closely linked to cancer.  Drug development aimed at several targetable kinases may alter their participated pathways that are able to trigger carcinogenesis.  A series of small-mol. drugs have been approved for the current cancer therapy.  However, their complicated inherent mechanisms may lead to the resistance to such small mols.  Consequently, development of new dual-target kinase drugs simultaneously aimed at two targetable kinases may improve their anti-tumor efficiency and solve resistant mechanism problems.  In this review, we focus on summarizing an overview of the current strategies of dual-target kinase drug design, including medicinal chem. strategies and computational approaches.  Taken together, we believe the above-mentioned strategies will provide a new insight into future directions of dual-target kinase drug design to improve potential cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL4dbUqruISrVg90H21EOLACvtfcHk0likPW0gd9XF-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFCjtLg%253D&md5=7b4830183b0b7045331f6d62ded69b1d</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.112025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.112025%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DOuyang%26aufirst%3DL.%26atitle%3DDual-target%2520kinase%2520drug%2520design%253A%2520Current%2520strategies%2520and%2520future%2520directions%2520in%2520cancer%2520therapy%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D188%26spage%3D112025%26doi%3D10.1016%2Fj.ejmech.2019.112025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology by dsign: A medicinal chemist’s perspective on multitargeting compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">420</span>– <span class="NLM_lpage">444</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00760</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlKms7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=420-444&author=E.+Proschakauthor=H.+Starkauthor=D.+Merk&title=Polypharmacology+by+dsign%3A+A+medicinal+chemist%E2%80%99s+perspective+on+multitargeting+compounds&doi=10.1021%2Facs.jmedchem.8b00760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds</span></div><div class="casAuthors">Proschak, Ewgenij; Stark, Holger; Merk, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">420-444</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multitargeting compds. comprising activity on more than a single biol. target have gained remarkable relevance in drug discovery owing to the complexity of multifactorial diseases such as cancer, inflammation, or the metabolic syndrome.  Polypharmacol. drug profiles can produce additive or synergistic effects while reducing side effects and significantly contribute to the high therapeutic success of indispensable drugs such as aspirin.  While their identification has long been the result of serendipity, medicinal chem. now tends to design polypharmacol.  Modern in vitro pharmacol. methods and chem. probes allow a systematic search for rational target combinations and recent innovations in computational technologies, crystallog., or fragment-based design equip multitarget compd. development with valuable tools.  In this Perspective, we analyze the relevance of multiple ligands in drug discovery and the versatile toolbox to design polypharmacol.  We conclude that despite some characteristic challenges remaining unresolved, designed polypharmacol. holds enormous potential to secure future therapeutic innovation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOEwJSxWw3vbVg90H21EOLACvtfcHk0lht1oMivxFeRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlKms7fE&md5=6dc4b8e1c4777372396626140a302663</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00760%26sid%3Dliteratum%253Aachs%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DMerk%26aufirst%3DD.%26atitle%3DPolypharmacology%2520by%2520dsign%253A%2520A%2520medicinal%2520chemist%25E2%2580%2599s%2520perspective%2520on%2520multitargeting%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D420%26epage%3D444%26doi%3D10.1021%2Facs.jmedchem.8b00760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minucci, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelicci, P. G.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1038/nrc1779</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1038%2Fnrc1779" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=16397526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1GgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=38-51&author=S.+Minucciauthor=P.+G.+Pelicci&title=Histone+deacetylase+inhibitors+and+the+promise+of+epigenetic+%28and+more%29+treatments+for+cancer&doi=10.1038%2Fnrc1779"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer</span></div><div class="casAuthors">Minucci, Saverio; Pelicci, Pier Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">38-51</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) are considered to be among the most promising targets in drug development for cancer therapy, and first-generation histone deacetylase inhibitors (HDACi) are currently being tested in phase I/II clin. trials.  A wide-ranging knowledge of the role of HDACs in tumorigenesis, and of the action of HDACi, has been achieved.  However, several basic aspects are not yet fully understood.  Investigating these aspects in the context of what we now understand about HDACi action both in vitro and in vivo will further improve the design of optimized clin. protocols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxXiACZV1sK7Vg90H21EOLACvtfcHk0lht1oMivxFeRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1GgsA%253D%253D&md5=384e1f8d676d61531e46843c060a9380</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fnrc1779&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1779%26sid%3Dliteratum%253Aachs%26aulast%3DMinucci%26aufirst%3DS.%26aulast%3DPelicci%26aufirst%3DP.%2BG.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520and%2520the%2520promise%2520of%2520epigenetic%2520%2528and%2520more%2529%2520treatments%2520for%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D38%26epage%3D51%26doi%3D10.1038%2Fnrc1779" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J. L.</span></span> <span> </span><span class="NLM_article-title">Microtubule-severing enzymes at the cutting edge</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">2561</span>– <span class="NLM_lpage">2569</span>, <span class="refDoi"> DOI: 10.1242/jcs.101139</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1242%2Fjcs.101139" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=22595526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1OrsrzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2012&pages=2561-2569&author=D.+J.+Sharpauthor=J.+L.+Ross&title=Microtubule-severing+enzymes+at+the+cutting+edge&doi=10.1242%2Fjcs.101139"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-severing enzymes at the cutting edge</span></div><div class="casAuthors">Sharp, David J.; Ross, Jennifer L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2561-2569</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review.  ATP-dependent severing of microtubules was first reported in Xenopus laevis egg exts. in 1991.  Two years later this observation led to the purifn. of the first known microtubule-severing enzyme, katanin.  Katanin homologs have now been identified throughout the animal kingdom and in plants.  Moreover, members of two closely related enzyme subfamilies, spastin and fidgetin, have been found to sever microtubules and might act alongside katanins in some contexts.  Over the past few years, it has become clear that microtubule-severing enzymes contribute to a wide range of cellular activities including mitosis and meiosis, morphogenesis, cilia biogenesis and disassembly, and cell migration.  Thus, this group of enzymes is revealing itself to be among the most important of the microtubule regulators.  This Commentary focuses on our growing understanding of how microtubule-severing enzymes contribute to the organization and dynamics of diverse microtubule arrays, as well as the structural and biophys. characteristics that afford them the unique capacity to catalyze the removal of tubulin from the interior microtubule lattice.  Our goal is to provide a broader perspective, focusing on a limited no. of particularly informative, representative and/or timely findings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg2sHb_W6V1LVg90H21EOLACvtfcHk0lht1oMivxFeRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1OrsrzO&md5=3effc3d0c73720e2a9d77fff656eb6b0</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1242%2Fjcs.101139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.101139%26sid%3Dliteratum%253Aachs%26aulast%3DSharp%26aufirst%3DD.%2BJ.%26aulast%3DRoss%26aufirst%3DJ.%2BL.%26atitle%3DMicrotubule-severing%2520enzymes%2520at%2520the%2520cutting%2520edge%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2012%26volume%3D125%26spage%3D2561%26epage%3D2569%26doi%3D10.1242%2Fjcs.101139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sherbet, G. V.</span></span> <span> </span><span class="NLM_article-title">Suppression of angiogenesis and tumour progression by combretastatin and derivatives</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>403</i></span>,  <span class="NLM_fpage">289</span>– <span class="NLM_lpage">295</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2017.06.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.canlet.2017.06.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=28688972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFCrtL3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=403&publication_year=2017&pages=289-295&author=G.+V.+Sherbet&title=Suppression+of+angiogenesis+and+tumour+progression+by+combretastatin+and+derivatives&doi=10.1016%2Fj.canlet.2017.06.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of angiogenesis and tumour progression by combretastatin and derivatives</span></div><div class="casAuthors">Sherbet, G. V.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">403</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">289-295</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The search for small mol. inhibitors has gained prominence with the recognition of their inherent advantage for cancer therapy.  Combretastatin is a naturally occurring small stilbenoid.  By virtue of the ability to bind to tubulin combretastatin and its derivs. promote depolymn. of microtubules as well as inhibit tubulin polymn.  This suppresses cell proliferation signalling and induces apoptosis.  Combretastatins activate mitotic checkpoints that lead to mitotic catastrophe and apoptosis.  They subvert the signalling systems which stimulate invasion, activate EMT (epithelial mesenchyme transition) and promote tumor progression.  Allied with the ability to suppress angiogenesis these compds. have been viewed as potential inhibitors of metastasis.  The notion of merging RTK (receptor tyrosine kinase) inhibition with suppression of invasion and possible inhibition of EMT has contributed to the credibility of combretastatins as anti-cancer agents.  Invaluable are their attributes of inhibiting tumor growth and induction of apoptosis and necrosis by reducing blood supply to the tumor.  Aside from these biol. effects, this commentary also discusses the issues of the targeting of combretastatins to the tumor vasculature and effective delivery of the drugs encapsulated in nanospheres.  Notwithstanding the perceived benefits, one can see a compelling need to understand the effects of combretastatin on the actin cytoskeletal dynamics and the disruption of microtubule polymn., and whether it is more efficient a tumor inhibitor than the conventional drugs that target microtubule dynamics.  Combinations of combretastatins with other vascular disrupting agents have been attempted.  It is essential to establish the perceived inhibition of EMT beyond reasonable doubt.  This might justify using the combretastatins with allosteric EMT and Akt inhibitors as addnl. choices for pre-clin./clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcF3mg-kruNbVg90H21EOLACvtfcHk0ljDsDSCFUv-BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFCrtL3J&md5=1e831ec2ba63c62e10e6b43d328b4439</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2017.06.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2017.06.032%26sid%3Dliteratum%253Aachs%26aulast%3DSherbet%26aufirst%3DG.%2BV.%26atitle%3DSuppression%2520of%2520angiogenesis%2520and%2520tumour%2520progression%2520by%2520combretastatin%2520and%2520derivatives%26jtitle%3DCancer%2520Lett.%26date%3D2017%26volume%3D403%26spage%3D289%26epage%3D295%26doi%3D10.1016%2Fj.canlet.2017.06.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Dual-targeting hybrid peptide-conjugated doxorubicin for drug resistance reversal in breast cancer</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>512</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.1016/j.ijpharm.2016.08.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ijpharm.2016.08.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=27521706" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyktb%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=512&publication_year=2016&pages=1-13&author=Y.+Shengauthor=Y.+Youauthor=Y.+Chen&title=Dual-targeting+hybrid+peptide-conjugated+doxorubicin+for+drug+resistance+reversal+in+breast+cancer&doi=10.1016%2Fj.ijpharm.2016.08.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-targeting hybrid peptide-conjugated doxorubicin for drug resistance reversal in breast cancer</span></div><div class="casAuthors">Sheng, Yuan; You, Yiwen; Chen, Yun</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">512</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-13</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The extended use of doxorubicin (DOX) could be limited due to the emergence of drug resistance assocd. with its treatment.  In addn. to the overexpression of ATP-binding cassette (ABC) transporters such as P-glycoprotein (P-gp), other mechanisms including apoptosis evasion and tumor cell survival may also be important contributor to drug resistance.  Within this context, targeting extracellular signal-regulated kinases (ERK), one of the principle protein mols. in cell apoptosis has emerged as an attractive therapeutic concept.  In this study, a dual-targeting hybrid peptide HAIYPRHGGCGMPKKKPTPIQLNP (T10-ERK), which is composed of ERK peptide inhibitor MPKKKPTPIQLNP, a thiol spacer (i.e., GGCG) and transferrin receptor (TfR)-binding peptide HAIYPRH, was designed.  Then, this thiol-modified hybrid peptide was conjugated to DOXO-EMCH (6-maleimidocaproyl) hydrazone of DOX, forming a novel peptide-DOX conjugate T10-ERK-DOX.  The structure and properties of this conjugate were characterized using 1H NMR, mass spectrometry and HPLC.  Using MCF-7/ADR cells as an in vitro model system and nude mice bearing MCF-7/ADR xenografts as an in vivo model, the ability of T10-ERK-DOX to reverse drug resistance was accessed as compared with free DOX and T10-DOX.  As a result, T10-ERK-DOX demonstrated a much lower in vitro IC50 (20.8 ± 1.1 μM) and its in vivo extent of inhibition in mice was more evident (72.2 ± 4.6%).  Induction of various apoptosis pathways was also obsd.  Furthermore, the potency of ERK peptide inhibitor to reverse drug resistance was individually assessed, given the pronounced efficacy of T10-DOX indicated by our previous work.  The results provided evidence of its additive effect with T10-DOX, which leads to greater efficacy and less susceptibility to drug resistance.  Finally, the success of multi-targeting strategy in the present study implied that multi-target drugs with rational design could be more promising in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT7-zyXxfctLVg90H21EOLACvtfcHk0ljDsDSCFUv-BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyktb%252FJ&md5=b93858a1608988876ba31751957f8c7d</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2016.08.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2016.08.016%26sid%3Dliteratum%253Aachs%26aulast%3DSheng%26aufirst%3DY.%26aulast%3DYou%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DDual-targeting%2520hybrid%2520peptide-conjugated%2520doxorubicin%2520for%2520drug%2520resistance%2520reversal%2520in%2520breast%2520cancer%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2016%26volume%3D512%26spage%3D1%26epage%3D13%26doi%3D10.1016%2Fj.ijpharm.2016.08.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aarsland, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molinuevo, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fladby, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbett, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sultana, J.</span></span> <span> </span><span class="NLM_article-title">Drug repositioning and repurposing for Alzheimer disease</span>. <i>Nat. Rev. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">661</span>– <span class="NLM_lpage">673</span>, <span class="refDoi"> DOI: 10.1038/s41582-020-0397-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1038%2Fs41582-020-0397-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=32939050" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A280%3ADC%252BB38bpslOqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2020&pages=661-673&author=C.+Ballardauthor=D.+Aarslandauthor=J.+Cummingsauthor=J.+O%E2%80%99Brienauthor=R.+Millsauthor=J.+L.+Molinuevoauthor=T.+Fladbyauthor=G.+Williamsauthor=P.+Dohertyauthor=A.+Corbettauthor=J.+Sultana&title=Drug+repositioning+and+repurposing+for+Alzheimer+disease&doi=10.1038%2Fs41582-020-0397-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Drug repositioning and repurposing for Alzheimer disease</span></div><div class="casAuthors">Ballard Clive; Corbett Anne; Aarsland Dag; Mills Roger; Williams Gareth; Doherty Pat; Aarsland Dag; Cummings Jeffrey; O'Brien John; Mills Roger; Molinuevo Jose Luis; Fladby Tormod; Sultana Janet</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Neurology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">661-673</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Drug repositioning and repurposing can enhance traditional drug development efforts and could accelerate the identification of new treatments for individuals with Alzheimer disease (AD) dementia and mild cognitive impairment.  Transcriptional profiling offers a new and highly efficient approach to the identification of novel candidates for repositioning and repurposing.  In the future, novel AD transcriptional signatures from cells isolated at early stages of disease, or from human neurons or microglia that carry mutations that increase the risk of AD, might be used as probes to identify additional candidate drugs.  Phase II trials assessing repurposed agents must consider the best target population for a specific candidate therapy as well as the mechanism of action of the treatment.  In this Review, we highlight promising compounds to prioritize for clinical trials in individuals with AD, and discuss the value of Delphi consensus methodology and evidence-based reviews to inform this prioritization process.  We also describe emerging work, focusing on the potential value of transcript signatures as a cost-effective approach to the identification of novel candidates for repositioning.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQsEBm4piE20QxyojvcjibhfW6udTcc2ebAQL9QMiLwV7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38bpslOqtQ%253D%253D&md5=803127f9862f6a9eb12536b61f07787f</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fs41582-020-0397-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41582-020-0397-4%26sid%3Dliteratum%253Aachs%26aulast%3DBallard%26aufirst%3DC.%26aulast%3DAarsland%26aufirst%3DD.%26aulast%3DCummings%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DJ.%26aulast%3DMills%26aufirst%3DR.%26aulast%3DMolinuevo%26aufirst%3DJ.%2BL.%26aulast%3DFladby%26aufirst%3DT.%26aulast%3DWilliams%26aufirst%3DG.%26aulast%3DDoherty%26aufirst%3DP.%26aulast%3DCorbett%26aufirst%3DA.%26aulast%3DSultana%26aufirst%3DJ.%26atitle%3DDrug%2520repositioning%2520and%2520repurposing%2520for%2520Alzheimer%2520disease%26jtitle%3DNat.%2520Rev.%2520Neurol.%26date%3D2020%26volume%3D16%26spage%3D661%26epage%3D673%26doi%3D10.1038%2Fs41582-020-0397-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designed multiple ligands. An emerging drug discovery paradigm</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6523</span>– <span class="NLM_lpage">6543</span>, <span class="refDoi"> DOI: 10.1021/jm058225d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+multiple+ligands.+An+emerging+drug+discovery+paradigm&doi=10.1021%2Fjm058225d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0ljDsDSCFUv-BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520multiple%2520ligands.%2520An%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6523%26epage%3D6543%26doi%3D10.1021%2Fjm058225d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minarini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumiatti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Recanatini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melchiorre, C.</span></span> <span> </span><span class="NLM_article-title">Multi-target-directed ligands to combat neurodegenerative diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">347</span>– <span class="NLM_lpage">372</span>, <span class="refDoi"> DOI: 10.1021/jm7009364</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm7009364" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsl2qsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=347-372&author=A.+Cavalliauthor=M.+L.+Bolognesiauthor=A.+Minariniauthor=M.+Rosiniauthor=V.+Tumiattiauthor=M.+Recanatiniauthor=C.+Melchiorre&title=Multi-target-directed+ligands+to+combat+neurodegenerative+diseases&doi=10.1021%2Fjm7009364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target-Directed Ligands to Combat Neurodegenerative Diseases</span></div><div class="casAuthors">Cavalli, Andrea; Bolognesi, Maria Laura; Minarini, Anna; Rosini, Michela; Tumiatti, Vincenzo; Recanatini, Maurizio; Melchiorre, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">347-372</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The authors review the investigations reported in the past decade that illustrate the ability of medicinal chemists to design multi-target-directed ligands (MTDLs) to confront neurodegenerative diseases.  The authors briefly illustrate the multifactorial nature of these diseases before discussing the possible development of MTDLs in light of the known mol. bases of the main neurodegenerative pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYY0I0UHEir7Vg90H21EOLACvtfcHk0lidlkr0D_U7qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsl2qsbk%253D&md5=c682235151489316d043cf97f78e56f3</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fjm7009364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7009364%26sid%3Dliteratum%253Aachs%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DMinarini%26aufirst%3DA.%26aulast%3DRosini%26aufirst%3DM.%26aulast%3DTumiatti%26aufirst%3DV.%26aulast%3DRecanatini%26aufirst%3DM.%26aulast%3DMelchiorre%26aufirst%3DC.%26atitle%3DMulti-target-directed%2520ligands%2520to%2520combat%2520neurodegenerative%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D347%26epage%3D372%26doi%3D10.1021%2Fjm7009364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, L.</span></span> <span> </span><span class="NLM_article-title">Computational multitarget drug design</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">403</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.6b00491</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.6b00491" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFCntr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2017&pages=403-412&author=W.+Zhangauthor=J.+Peiauthor=L.+Lai&title=Computational+multitarget+drug+design&doi=10.1021%2Facs.jcim.6b00491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Computational Multitarget Drug Design</span></div><div class="casAuthors">Zhang, Weilin; Pei, Jianfeng; Lai, Luhua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">403-412</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Designing drugs that can simultaneously interact with multiple targets is a promising approach for treating complicated diseases.  Compared to using combinations of single target drugs, multitarget drugs have advantages of higher efficacy, improved safety profile, and simpler administration.  Many in silico methods have been developed to approach different aspects of this polypharmacol.-guided drug design, particularly for drug repurposing and multitarget drug design.  In this review, the authors summarize recent progress in computational multitarget drug design and discuss their advantages and limitations.  Perspectives for future drug development will also be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-J4p0tdEUR7Vg90H21EOLACvtfcHk0lidlkr0D_U7qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFCntr8%253D&md5=e00ed6650471d786a04b828a8064f5e9</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.6b00491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.6b00491%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DPei%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DL.%26atitle%3DComputational%2520multitarget%2520drug%2520design%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2017%26volume%3D57%26spage%3D403%26epage%3D412%26doi%3D10.1021%2Facs.jcim.6b00491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sonawane, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohd Siddique, M. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadav, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaprakash, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhuri, B.</span></span> <span> </span><span class="NLM_article-title">Cink4T, a quinazolinone-based dual inhibitor of Cdk4 and tubulin polymerization, identified via ligand-based virtual screening, for efficient anticancer therapy</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.01.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejmech.2019.01.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=30665142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVyit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2019&pages=115-132&author=V.+Sonawaneauthor=M.+U.+Mohd+Siddiqueauthor=S.+S.+Jadavauthor=B.+N.+Sinhaauthor=V.+Jayaprakashauthor=B.+Chaudhuri&title=Cink4T%2C+a+quinazolinone-based+dual+inhibitor+of+Cdk4+and+tubulin+polymerization%2C+identified+via+ligand-based+virtual+screening%2C+for+efficient+anticancer+therapy&doi=10.1016%2Fj.ejmech.2019.01.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Cink4T, a quinazolinone-based dual inhibitor of Cdk4 and tubulin polymerization, identified via ligand-based virtual screening, for efficient anticancer therapy</span></div><div class="casAuthors">Sonawane, Vinay; Mohd. Siddique, Mohd. Usman; Jadav, Surender Singh; Sinha, Barij Nayan; Jayaprakash, Venkatesan; Chaudhuri, Bhabatosh</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">115-132</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Inhibition of cyclin dependent kinase 4 (Cdk4) prevents cancer cells from entering the early G0/G1 phase of the cell division cycle whereas inhibiting tubulin polymn. blocks cancer cells' ability to undergo mitosis (M) late in the cell cycle.  We had reported earlier that two non-planar and relatively non-toxic fascaplysin derivs., an indole and a tryptoline, inhibit Cdk4 with IC50 values of 6.2 and 10 μM, resp.  Serendipitously, we had also found that they inhibited tubulin polymn.  The mols. were efficacious in mouse tumor models.  We have now identified Cink4T in a 59-compd. quinazolinone library, designed on the basis of ligand-based virtual screening, as a compd. that inhibits Cdk4 and tubulin.  Its IC50 value for Cdk4 inhibition is 0.47 μM and >50 μM for inhibition of Cdk1, Cdk2, Cdk6, Cdk9.  Cink4T inhibits tubulin polymn. with an IC50 of 0.6 μM.  Mol. modeling studies on Cink4T with Cdk4 and tubulin crystal structures lend support to these observations.  Cancer cell cycle analyses confirm that Cink4T blocks cells at both G0/G1 and M phases as it should if it were to inhibit both Cdk4 and tubulin polymn.  Our results show, for the very first time, that virtual screening can be used to design novel inhibitors that can potently block two crucial phases of the cell division cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomphGxgW4-J7Vg90H21EOLACvtfcHk0lidlkr0D_U7qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVyit7k%253D&md5=2898dfdc7c064e9bd96bea72466b5906</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.01.011%26sid%3Dliteratum%253Aachs%26aulast%3DSonawane%26aufirst%3DV.%26aulast%3DMohd%2BSiddique%26aufirst%3DM.%2BU.%26aulast%3DJadav%26aufirst%3DS.%2BS.%26aulast%3DSinha%26aufirst%3DB.%2BN.%26aulast%3DJayaprakash%26aufirst%3DV.%26aulast%3DChaudhuri%26aufirst%3DB.%26atitle%3DCink4T%252C%2520a%2520quinazolinone-based%2520dual%2520inhibitor%2520of%2520Cdk4%2520and%2520tubulin%2520polymerization%252C%2520identified%2520via%2520ligand-based%2520virtual%2520screening%252C%2520for%2520efficient%2520anticancer%2520therapy%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D165%26spage%3D115%26epage%3D132%26doi%3D10.1016%2Fj.ejmech.2019.01.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lo, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cormier, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nettles, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stearns, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, R. B.</span></span> <span> </span><span class="NLM_article-title">Pocket similarity identifies selective estrogen receptor modulators as microtubule modulators at the taxane site</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1033</span>, <span class="refDoi"> DOI: 10.1038/s41467-019-08965-w</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1038%2Fs41467-019-08965-w" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=30833575" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A280%3ADC%252BB3cbgtl2gtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1033&author=Y.-C.+Loauthor=O.+Cormierauthor=T.+Liuauthor=K.+W.+Nettlesauthor=J.+A.+Katzenellenbogenauthor=T.+Stearnsauthor=R.+B.+Altman&title=Pocket+similarity+identifies+selective+estrogen+receptor+modulators+as+microtubule+modulators+at+the+taxane+site&doi=10.1038%2Fs41467-019-08965-w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Pocket similarity identifies selective estrogen receptor modulators as microtubule modulators at the taxane site</span></div><div class="casAuthors">Lo Yu-Chen; Liu Tianyun; Altman Russ B; Cormier Olga; Stearns Tim; Liu Tianyun; Stearns Tim; Altman Russ B; Nettles Kendall W; Katzenellenbogen John A</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1033</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Taxanes are a family of natural products with a broad spectrum of anticancer activity.  This activity is mediated by interaction with the taxane site of beta-tubulin, leading to microtubule stabilization and cell death.  Although widely used in the treatment of breast cancer and other malignancies, existing taxane-based therapies including paclitaxel and the second-generation docetaxel are currently limited by severe adverse effects and dose-limiting toxicity.  To discover taxane site modulators, we employ a computational binding site similarity screen of > 14,000 drug-like pockets from PDB, revealing an unexpected similarity between the estrogen receptor and the beta-tubulin taxane binding pocket.  Evaluation of nine selective estrogen receptor modulators (SERMs) via cellular and biochemical assays confirms taxane site interaction, microtubule stabilization, and cell proliferation inhibition.  Our study demonstrates that SERMs can modulate microtubule assembly and raises the possibility of an estrogen receptor-independent mechanism for inhibiting cell proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRKDjpfXAfQCYIRAdBLKY41fW6udTcc2eZpQkQ3N-YDV7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbgtl2gtQ%253D%253D&md5=fbdb1a879b6c654adf72f5a2635a4454</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fs41467-019-08965-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-019-08965-w%26sid%3Dliteratum%253Aachs%26aulast%3DLo%26aufirst%3DY.-C.%26aulast%3DCormier%26aufirst%3DO.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DNettles%26aufirst%3DK.%2BW.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26aulast%3DStearns%26aufirst%3DT.%26aulast%3DAltman%26aufirst%3DR.%2BB.%26atitle%3DPocket%2520similarity%2520identifies%2520selective%2520estrogen%2520receptor%2520modulators%2520as%2520microtubule%2520modulators%2520at%2520the%2520taxane%2520site%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26spage%3D1033%26doi%3D10.1038%2Fs41467-019-08965-w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gangjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavana, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihnat, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorpe, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Disch, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey-Downs, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, R.</span></span> <span> </span><span class="NLM_article-title">Discovery of antitubulin agents with antiangiogenic activity as single entities with multitarget chemotherapy potential</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">480</span>– <span class="NLM_lpage">484</span>, <span class="refDoi"> DOI: 10.1021/ml4004793</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml4004793" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjt1yntbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=480-484&author=A.+Gangjeeauthor=R.+K.+Pavanaauthor=M.+A.+Ihnatauthor=J.+E.+Thorpeauthor=B.+C.+Dischauthor=A.+Bastianauthor=L.+C.+Bailey-Downsauthor=E.+Hamelauthor=R.+Bai&title=Discovery+of+antitubulin+agents+with+antiangiogenic+activity+as+single+entities+with+multitarget+chemotherapy+potential&doi=10.1021%2Fml4004793"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Antitubulin Agents with Antiangiogenic Activity as Single Entities with Multitarget Chemotherapy Potential</span></div><div class="casAuthors">Gangjee, Aleem; Pavana, Roheeth Kumar; Ihnat, Michael A.; Thorpe, Jessica E.; Disch, Bryan C.; Bastian, Anja; Bailey-Downs, Lora C.; Hamel, Ernest; Bai, Rouli</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">480-484</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antiangiogenic agents (AA) are cytostatic, and their utility in cancer chemotherapy lies in their combination with cytotoxic chemotherapeutic agents.  Clin. combinations of vascular endothelial growth factor receptor-2 (VEGFR2) inhibitors with antitubulin agents have been particularly successful.  We have discovered a novel, potentially important analog, that combines potent VEGFR2 inhibitory activity (comparable to that of sunitinib) with potent antitubulin activity (comparable to that of combretastatin A-4 (CA)) in a single mol., with GI50 values of 10-7 M across the entire NCI 60 tumor cell panel.  It potently inhibited tubulin assembly and circumvented the most clin. relevant tumor resistance mechanisms (P-glycoprotein and β-III tubulin expression) to antimicrotubule agents.  The compd. is freely water-sol. as its HCl salt and afforded excellent antitumor activity in vivo, superior to docetaxel, sunitinib, or Temozolomide, without any toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7Gh9q5qJzs7Vg90H21EOLACvtfcHk0lhmPH8TOy7K-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjt1yntbw%253D&md5=85cb234c235a0738619d7ab984b20fc9</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Fml4004793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml4004793%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DPavana%26aufirst%3DR.%2BK.%26aulast%3DIhnat%26aufirst%3DM.%2BA.%26aulast%3DThorpe%26aufirst%3DJ.%2BE.%26aulast%3DDisch%26aufirst%3DB.%2BC.%26aulast%3DBastian%26aufirst%3DA.%26aulast%3DBailey-Downs%26aufirst%3DL.%2BC.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DBai%26aufirst%3DR.%26atitle%3DDiscovery%2520of%2520antitubulin%2520agents%2520with%2520antiangiogenic%2520activity%2520as%2520single%2520entities%2520with%2520multitarget%2520chemotherapy%2520potential%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D480%26epage%3D484%26doi%3D10.1021%2Fml4004793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pavana, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhary, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihnat, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangjee, A.</span></span> <span> </span><span class="NLM_article-title">Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">545</span>– <span class="NLM_lpage">556</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.11.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.bmc.2016.11.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=27894589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCntr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=545-556&author=R.+K.+Pavanaauthor=S.+Choudharyauthor=A.+Bastianauthor=M.+A.+Ihnatauthor=R.+Baiauthor=E.+Hamelauthor=A.+Gangjee&title=Discovery+and+preclinical+evaluation+of+7-benzyl-N-%28substituted%29-pyrrolo%5B3%2C2-d%5Dpyrimidin-4-amines+as+single+agents+with+microtubule+targeting+effects+along+with+triple-acting+angiokinase+inhibition+as+antitumor+agents&doi=10.1016%2Fj.bmc.2016.11.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents</span></div><div class="casAuthors">Pavana, Roheeth Kumar; Choudhary, Shruti; Bastian, Anja; Ihnat, Michael A.; Bai, Ruoli; Hamel, Ernest; Gangjee, Aleem</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">545-556</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The utility of cytostatic antiangiogenic agents (AA) in cancer chemotherapy lies in their combination with cytotoxic chemotherapeutic agents.  Clin. combinations of AA with microtubule targeting agents (MTAs) have been particularly successful.  The discovery, synthesis and biol. evaluations of a series of 7-benzyl-N-substituted-pyrrolo[3,2-d]pyrimidin-4-amines are reported.  Novel compds. which inhibit proangiogenic receptor tyrosine kinases (RTKs) including vascular endothelial growth factor receptor-2 (VEGFR-2), platelet-derived growth factor receptor-β (PDGFR-β) and epidermal growth factor receptor (EGFR), along with microtubule targeting in single mols. are described.  These compds. also inhibited blood vessel formation in the chicken chorioallantoic membrane (CAM) assay, and some potently inhibited tubulin assembly (with activity comparable to that of combretastatin A-4 (CA)).  In addn., some of the analogs circumvent the most clin. relevant tumor resistance mechanisms (P-glycoprotein and β-III tubulin expression) to microtubule targeting agents (MTA).  These MTAs bind at the colchicine site on tubulin.  Two analogs displayed two to three digit nanomolar GIC50 values across the entire NCI 60 tumor cell panel and one of these, compd. 7, freely water sol. as its HCl salt, afforded excellent in vivo antitumor activity against an orthotopic triple neg. 4T1 breast cancer model and was superior to doxorubicin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwGOvmBOf0h7Vg90H21EOLACvtfcHk0lhmPH8TOy7K-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCntr%252FM&md5=9fd3c0008bda8c9222761f9d344610e6</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.11.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.11.026%26sid%3Dliteratum%253Aachs%26aulast%3DPavana%26aufirst%3DR.%2BK.%26aulast%3DChoudhary%26aufirst%3DS.%26aulast%3DBastian%26aufirst%3DA.%26aulast%3DIhnat%26aufirst%3DM.%2BA.%26aulast%3DBai%26aufirst%3DR.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DGangjee%26aufirst%3DA.%26atitle%3DDiscovery%2520and%2520preclinical%2520evaluation%2520of%25207-benzyl-N-%2528substituted%2529-pyrrolo%255B3%252C2-d%255Dpyrimidin-4-amines%2520as%2520single%2520agents%2520with%2520microtubule%2520targeting%2520effects%2520along%2520with%2520triple-acting%2520angiokinase%2520inhibition%2520as%2520antitumor%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D545%26epage%3D556%26doi%3D10.1016%2Fj.bmc.2016.11.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghavan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihnat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorpe, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Disch, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey-Downs, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dybdal-Hargreaves, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohena, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooberry, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangjee, A.</span></span> <span> </span><span class="NLM_article-title">The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">3753</span>– <span class="NLM_lpage">3772</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.04.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.bmc.2014.04.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=24890652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslCns78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=3753-3772&author=X.+Zhangauthor=S.+Raghavanauthor=M.+Ihnatauthor=J.+E.+Thorpeauthor=B.+C.+Dischauthor=A.+Bastianauthor=L.+C.+Bailey-Downsauthor=N.+F.+Dybdal-Hargreavesauthor=C.+C.+Rohenaauthor=E.+Hamelauthor=S.+L.+Mooberryauthor=A.+Gangjee&title=The+design+and+discovery+of+water+soluble+4-substituted-2%2C6-dimethylfuro%5B2%2C3-d%5Dpyrimidines+as+multitargeted+receptor+tyrosine+kinase+inhibitors+and+microtubule+targeting+antitumor+agents&doi=10.1016%2Fj.bmc.2014.04.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents</span></div><div class="casAuthors">Zhang, Xin; Raghavan, Sudhir; Ihnat, Michael; Thorpe, Jessica E.; Disch, Bryan C.; Bastian, Anja; Bailey-Downs, Lora C.; Dybdal-Hargreaves, Nicholas F.; Rohena, Cristina C.; Hamel, Ernest; Mooberry, Susan L.; Gangjee, Aleem</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3753-3772</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The design, synthesis and biol. evaluations of fourteen 4-substituted 2,6-dimethylfuro[2,3-d]pyrimidines are reported.  Four compds. inhibit vascular endothelial growth factor receptor-2 (VEGFR-2), platelet-derived growth factor receptor β (PDGFR-β), and target tubulin leading to cytotoxicity.  Compd. I has nanomolar potency, comparable to sunitinib and semaxinib, against tumor cell lines overexpressing VEGFR-2 and PDGFR-β.  Further, I binds at the colchicine site on tubulin, depolymerizes cellular microtubules and inhibits purified tubulin assembly and overcomes both βIII-tubulin and P-glycoprotein-mediated drug resistance, and initiates mitotic arrest leading to apoptosis.  In vivo, its HCl salt, I·HCl, reduced tumor size and vascularity in xenograft and allograft murine models and was superior to docetaxel and sunitinib, without overt toxicity.  Thus I·HCl affords potential combination chemotherapy in a single agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpz0a4q7mfRm7Vg90H21EOLACvtfcHk0lhi92QnEs3cAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslCns78%253D&md5=b35cd4ed7f053ea14d7ef5ee33828b38</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.04.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.04.049%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DRaghavan%26aufirst%3DS.%26aulast%3DIhnat%26aufirst%3DM.%26aulast%3DThorpe%26aufirst%3DJ.%2BE.%26aulast%3DDisch%26aufirst%3DB.%2BC.%26aulast%3DBastian%26aufirst%3DA.%26aulast%3DBailey-Downs%26aufirst%3DL.%2BC.%26aulast%3DDybdal-Hargreaves%26aufirst%3DN.%2BF.%26aulast%3DRohena%26aufirst%3DC.%2BC.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26aulast%3DGangjee%26aufirst%3DA.%26atitle%3DThe%2520design%2520and%2520discovery%2520of%2520water%2520soluble%25204-substituted-2%252C6-dimethylfuro%255B2%252C3-d%255Dpyrimidines%2520as%2520multitargeted%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520and%2520microtubule%2520targeting%2520antitumor%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D3753%26epage%3D3772%26doi%3D10.1016%2Fj.bmc.2014.04.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghavan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihnat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zammiello, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooberry, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangjee, A.</span></span> <span> </span><span class="NLM_article-title">The design, synthesis and biological evaluation of conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase and microtubule inhibitors as potential antitumor agents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2408</span>– <span class="NLM_lpage">2423</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.03.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.bmc.2015.03.061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=25882519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXls1Gmu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=2408-2423&author=X.+Zhangauthor=S.+Raghavanauthor=M.+Ihnatauthor=E.+Hamelauthor=C.+Zammielloauthor=A.+Bastianauthor=S.+L.+Mooberryauthor=A.+Gangjee&title=The+design%2C+synthesis+and+biological+evaluation+of+conformationally+restricted+4-substituted-2%2C6-dimethylfuro%5B2%2C3-d%5Dpyrimidines+as+multi-targeted+receptor+tyrosine+kinase+and+microtubule+inhibitors+as+potential+antitumor+agents&doi=10.1016%2Fj.bmc.2015.03.061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">The design, synthesis and biological evaluation of conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase and microtubule inhibitors as potential antitumor agents</span></div><div class="casAuthors">Zhang, Xin; Raghavan, Sudhir; Ihnat, Michael; Hamel, Ernest; Zammiello, Cynthia; Bastian, Anja; Mooberry, Susan L.; Gangjee, Aleem</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2408-2423</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of eleven conformationally restricted, 4-substituted 2,6-dimethylfuro[2,3-d]pyrimidines was designed to explore the bioactive conformation required for dual inhibition of microtubule assembly and receptor tyrosine kinases (RTKs), and their biol. activities are reported.  All three rotatable single bonds in the lead compd. were sequentially restricted to address the role of each in SAR for microtubule and RTK inhibitory effects.  Several compds. showed microtubule depolymg. activity comparable to or better than the lead compd., some with nanomolar EC50 values.  One compd. had no effect on microtubules, others showed potent RTK inhibition with nanomolar IC50s.  These compds. confirm that the bioactive conformation for RTK inhibition is different from that for tubulin inhibition.  A tetrahydroquinoline analog showed the most potent dual tubulin inhibitors (i.e., tubulin polymn. inhibitors, microtubule-disrupting agents) and RTK inhibitory activities [i.e., low nanomolar inhibition of epidermal growth factor receptors (EGFR), vascular endothelial growth factor receptor 2 (VEGFR2) and platelet derived growth factor receptor β (PDGFR-β)].  The tetrahydroquinoline analog has highly potent activity against many NCI cancer cell lines, including several chemo-resistant cell lines, and could serve as a lead for further preclin. studies.  The synthesis of the target compds. was achieved by a reaction of 4-chloro-2,6-dimethylfuro[2,3-d]pyrimidine with amine derivs., such as benzenamine derivs., benzofuranamine derivs., tetrahydroquinoline derivs., indole derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3IUVQLu9YarVg90H21EOLACvtfcHk0lhi92QnEs3cAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXls1Gmu78%253D&md5=4a6d65424606155db3ab4ec5751ad213</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.03.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.03.061%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DRaghavan%26aufirst%3DS.%26aulast%3DIhnat%26aufirst%3DM.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DZammiello%26aufirst%3DC.%26aulast%3DBastian%26aufirst%3DA.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26aulast%3DGangjee%26aufirst%3DA.%26atitle%3DThe%2520design%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520conformationally%2520restricted%25204-substituted-2%252C6-dimethylfuro%255B2%252C3-d%255Dpyrimidines%2520as%2520multi-targeted%2520receptor%2520tyrosine%2520kinase%2520and%2520microtubule%2520inhibitors%2520as%2520potential%2520antitumor%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D2408%26epage%3D2423%26doi%3D10.1016%2Fj.bmc.2015.03.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romagnoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prencipe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliva, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiaffino Ortega, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chayah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimatrai Salvador, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Cara, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brancale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortolozzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariotto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattiuzzo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viola, G.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and biological evaluation of 6-substituted thieno[3,2- d]pyrimidine analogues as dual epidermal growth factor receptor kinase and microtubule inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1274</span>– <span class="NLM_lpage">1290</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01391</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01391" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvFKntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1274-1290&author=R.+Romagnoliauthor=F.+Prencipeauthor=P.+Olivaauthor=S.+Baraldiauthor=P.+G.+Baraldiauthor=S.+Schiaffino+Ortegaauthor=M.+Chayahauthor=M.+Kimatrai+Salvadorauthor=L.+C.+Lopez-Caraauthor=A.+Brancaleauthor=S.+Ferlaauthor=E.+Hamelauthor=R.+Roncaauthor=R.+Bortolozziauthor=E.+Mariottoauthor=E.+Mattiuzzoauthor=G.+Viola&title=Design%2C+Synthesis%2C+and+biological+evaluation+of+6-substituted+thieno%5B3%2C2-+d%5Dpyrimidine+analogues+as+dual+epidermal+growth+factor+receptor+kinase+and+microtubule+inhibitors&doi=10.1021%2Facs.jmedchem.8b01391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of 6-Substituted Thieno[3,2-d]pyrimidine Analogues as Dual Epidermal Growth Factor Receptor Kinase and Microtubule Inhibitors</span></div><div class="casAuthors">Romagnoli, Romeo; Prencipe, Filippo; Oliva, Paola; Baraldi, Stefania; Baraldi, Pier Giovanni; Schiaffino Ortega, Santiago; Chayah, Mariem; Kimatrai Salvador, Maria; Lopez-Cara, Luisa Carlota; Brancale, Andrea; Ferla, Salvatore; Hamel, Ernest; Ronca, Roberto; Bortolozzi, Roberta; Mariotto, Elena; Mattiuzzo, Elena; Viola, Giampietro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1274-1290</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The clin. evidence for the success of tyrosine kinase inhibitors in combination with microtubule-targeting agents prompted us to design and develop single agents that possess both epidermal growth factor receptor (EGFR) kinase and tubulin polymn. inhibitory properties.  A series of 6-aryl/heteroaryl-4-(3',4',5'-trimethoxyanilino)thieno[3,2-d]pyrimidine derivs. were discovered as novel dual tubulin polymn. and EGFR kinase inhibitors.  The 4-(3',4',5'-trimethoxyanilino)-6-(p-tolyl)thieno[3,2-d]pyrimidine deriv. I was the most potent compd. of the series as an antiproliferative agent, with half-maximal inhibitory concn. (IC50) values in the single- or double-digit nanomolar range.  Compd. I bound to tubulin in the colchicine site and inhibited tubulin assembly with an IC50 value of 0.71 μM, and I inhibited EGFR activity with an IC50 value of 30 nM.  Our data suggested that the excellent in vitro and in vivo profile of I may be derived from its dual inhibition of tubulin polymn. and EGFR kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYN985WxHFmrVg90H21EOLACvtfcHk0lhi92QnEs3cAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvFKntg%253D%253D&md5=5eeb122171d04ae5201ee42efbe0c773</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01391%26sid%3Dliteratum%253Aachs%26aulast%3DRomagnoli%26aufirst%3DR.%26aulast%3DPrencipe%26aufirst%3DF.%26aulast%3DOliva%26aufirst%3DP.%26aulast%3DBaraldi%26aufirst%3DS.%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DSchiaffino%2BOrtega%26aufirst%3DS.%26aulast%3DChayah%26aufirst%3DM.%26aulast%3DKimatrai%2BSalvador%26aufirst%3DM.%26aulast%3DLopez-Cara%26aufirst%3DL.%2BC.%26aulast%3DBrancale%26aufirst%3DA.%26aulast%3DFerla%26aufirst%3DS.%26aulast%3DHamel%26aufirst%3DE.%26aulast%3DRonca%26aufirst%3DR.%26aulast%3DBortolozzi%26aufirst%3DR.%26aulast%3DMariotto%26aufirst%3DE.%26aulast%3DMattiuzzo%26aufirst%3DE.%26aulast%3DViola%26aufirst%3DG.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520biological%2520evaluation%2520of%25206-substituted%2520thieno%255B3%252C2-%2520d%255Dpyrimidine%2520analogues%2520as%2520dual%2520epidermal%2520growth%2520factor%2520receptor%2520kinase%2520and%2520microtubule%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1274%26epage%3D1290%26doi%3D10.1021%2Facs.jmedchem.8b01391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, C. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Y.</span></span> <span> </span><span class="NLM_article-title">Naturally occurring homoisoflavonoids function as potent protein tyrosine kinase inhibitors by c-Src-based high-throughput screening</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">4419</span>– <span class="NLM_lpage">4429</span>, <span class="refDoi"> DOI: 10.1021/jm701501x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701501x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD1cXot1ertr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4419-4429&author=L.+G.+Linauthor=H.+Xieauthor=H.+L.+Liauthor=L.+J.+Tongauthor=C.+P.+Tangauthor=C.+Q.+Keauthor=Q.+F.+Liuauthor=L.+P.+Linauthor=M.+Y.+Gengauthor=H.+Jiangauthor=W.+M.+Zhaoauthor=J.+Dingauthor=Y.+Ye&title=Naturally+occurring+homoisoflavonoids+function+as+potent+protein+tyrosine+kinase+inhibitors+by+c-Src-based+high-throughput+screening&doi=10.1021%2Fjm701501x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Naturally Occurring Homoisoflavonoids Function as Potent Protein Tyrosine Kinase Inhibitors by c-Src-Based High-Throughput Screening</span></div><div class="casAuthors">Lin, Li-Gen; Xie, Hua; Li, Hong-Lin; Tong, Lin-Jiang; Tang, Chun-Ping; Ke, Chang-Qiang; Liu, Qun-Fang; Lin, Li-Ping; Geng, Mei-Yu; Jiang, Hualiang; Zhao, Wei-Min; Ding, Jian; Ye, Yang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4419-4429</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Protein tyrosine kinase (PTK) inhibitors represent emerging therapeutics for cancer chemoprevention.  In our study, hematoxylin (26) was identified as one of the most remarkable c-Src inhibitors in an orthogonal compd.-mixing library (32200 compds.) by using an ELISA-based automated high-throughput screening (HTS) strategy.  Interestingly, hematoxylin was found to be an ATP competitive broad-spectrum PTK inhibitor in vitro, with IC50 values ranging from nanomolar to micromolar level.  Further studies showed that such inhibition was assocd. with the PTK phosphorylation and subsequent downstream signaling pathways.  The structure-activity relationship assessment of the PTK inhibitory potency of hematoxylin analogs isolated from Haematoxylon campechianum was in good agreement with the result of concurrent mol. docking simulation: the catechol moiety in ring A and the hematoxylin-like three-dimensional structure were essential for c-Src-targeted activities.  Hematoxylin and its natural analogs were substantially validated to function as a new class of PTK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodTHKq1I_xl7Vg90H21EOLACvtfcHk0ljlfYjik03gfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXot1ertr8%253D&md5=90e47e434d10a4e968ef0085648b8972</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjm701501x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701501x%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DL.%2BG.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DH.%2BL.%26aulast%3DTong%26aufirst%3DL.%2BJ.%26aulast%3DTang%26aufirst%3DC.%2BP.%26aulast%3DKe%26aufirst%3DC.%2BQ.%26aulast%3DLiu%26aufirst%3DQ.%2BF.%26aulast%3DLin%26aufirst%3DL.%2BP.%26aulast%3DGeng%26aufirst%3DM.%2BY.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DW.%2BM.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DY.%26atitle%3DNaturally%2520occurring%2520homoisoflavonoids%2520function%2520as%2520potent%2520protein%2520tyrosine%2520kinase%2520inhibitors%2520by%2520c-Src-based%2520high-throughput%2520screening%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4419%26epage%3D4429%26doi%3D10.1021%2Fjm701501x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leng, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span> <span> </span><span class="NLM_article-title">Identification of DW532 as a novel anti-tumor agent targeting both kinases and tubulin</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">916</span>– <span class="NLM_lpage">928</span>, <span class="refDoi"> DOI: 10.1038/aps.2014.33</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1038%2Faps.2014.33" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=24858311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtV2qtr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=916-928&author=T.+Pengauthor=J.+R.+Wuauthor=L.+J.+Tongauthor=M.+Y.+Liauthor=F.+Chenauthor=Y.+X.+Lengauthor=R.+Quauthor=K.+Hanauthor=Y.+Suauthor=Y.+Chenauthor=W.+H.+Duanauthor=H.+Xieauthor=J.+Ding&title=Identification+of+DW532+as+a+novel+anti-tumor+agent+targeting+both+kinases+and+tubulin&doi=10.1038%2Faps.2014.33"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of DW532 as a novel anti-tumor agent targeting both kinases and tubulin</span></div><div class="casAuthors">Peng, Ting; Wu, Jian-rui; Tong, Lin-jiang; Li, Meng-yuan; Chen, Fang; Leng, Yi-xin; Qu, Rong; Han, Kun; Su, Yi; Chen, Yi; Duan, Wen-hu; Xie, Hua; Ding, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">916-928</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Aim: 7,8-Dihydroxy-4-(3-hydroxy-4-methoxyphenyl)-2H-chromen-2-one (DW532) is one of simplified analogs of hematoxylin that has shown broad-spectrum inhibition on tyrosine kinases and in vitro anti-cancer activities.  The aim of this study was to identify DW532 as a agent targeting both kinases and tubulin, and to investigate its anti-cancer and anti-angiogenesis activities.  Methods: In vitro tyrosine kinases activity was examd. with ELISA, and tyrosine kinases activity in cells was evaluated with Western blot anal.  Tubulin turbidity assay, surface plasmon resonance and immunofluorescence technique were used to characterize the tubulin inhibitory activity.  Cell proliferation was examd. with SRB assay, and cell apoptosis and cell cycle distribution were analyzed with Annexin-V/PI staining and flow cytometry.  Tube formation, aortic ring and chick chorioallantoic membrane assays were used to evaluate the anti-angiogenesis efficacy.  Results: DW532 inhibited EGFR and VEGFR2 in vitro kinase activity (the IC50 values were 4.9 and 5.5 μmol/L, resp.), and suppressed their downstream signaling.  DW532 dose-dependently inhibited tubulin polymn. via direct binding to tubulin, thus disrupting the mitotic spindle assembly and leading to abnormal cell division.  In a panel of human cancer cells, DW532 (1 and 10 μmol/L) induced G2/M phase arrest and cell apoptosis, which subsequently resulted in cytotoxicity.  Knockdown of BubR1 or Mps1, the two core proteins of the spindle assembly checkpoint dramatically decreased DW532-induced cell cycle arrest in MDA-MB-468 cells.  Moreover, treatment with DW532 potently and dose-dependently suppressed angiogenesis in vitro and in vivo.  Conclusion: DW532 is a dual inhibitor against tubulin and tyrosine kinases, and deserves further development as a novel anti-cancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYnVQmKb9o6LVg90H21EOLACvtfcHk0ljlfYjik03gfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtV2qtr3F&md5=dce90f38ed786a90a2226e092d09c1d5</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1038%2Faps.2014.33&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2014.33%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DJ.%2BR.%26aulast%3DTong%26aufirst%3DL.%2BJ.%26aulast%3DLi%26aufirst%3DM.%2BY.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DLeng%26aufirst%3DY.%2BX.%26aulast%3DQu%26aufirst%3DR.%26aulast%3DHan%26aufirst%3DK.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDuan%26aufirst%3DW.%2BH.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DDing%26aufirst%3DJ.%26atitle%3DIdentification%2520of%2520DW532%2520as%2520a%2520novel%2520anti-tumor%2520agent%2520targeting%2520both%2520kinases%2520and%2520tubulin%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2014%26volume%3D35%26spage%3D916%26epage%3D928%26doi%3D10.1038%2Faps.2014.33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chekler, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiselyov, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattaropong, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuma, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doody, J. F.</span></span> <span> </span><span class="NLM_article-title">Discovery of dual VEGFR-2 and tubulin inhibitors with in vivo efficacy</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">488</span>– <span class="NLM_lpage">492</span>, <span class="refDoi"> DOI: 10.1021/ml1001568</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml1001568" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVCnsb3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=488-492&author=E.+L.+Cheklerauthor=A.+S.+Kiselyovauthor=X.+Ouyangauthor=X.+Chenauthor=V.+Pattaropongauthor=Y.+Wangauthor=M.+C.+Tumaauthor=J.+F.+Doody&title=Discovery+of+dual+VEGFR-2+and+tubulin+inhibitors+with+in+vivo+efficacy&doi=10.1021%2Fml1001568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Dual VEGFR-2 and Tubulin Inhibitors with in Vivo Efficacy</span></div><div class="casAuthors">Chekler, Eugene L. Piatnitski; Kiselyov, Alexander S.; Ouyang, Xiaohu; Chen, Xiaoling; Pattaropong, Vatee; Wang, Ying; Tuma, M. Carolina; Doody, Jacqueline F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">488-492</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In an effort to develop potent, orally bioavailable compds. for the treatment of neoplastic diseases, we developed a class of dual VEGFR-2 kinase and tubulin inhibitors.  Targeting the VEGFR receptor kinase and tubulin structure allows for inhibition of both tumor cells and tumor vasculature.  Previously, a combination of two compds., a VEGF receptor tyrosine kinase inhibitor and tubulin agent, was demonstrated to produce an enhanced antitumor response in animal studies.  We have reaffirmed their results, with the added benefit that both activities are found in one compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlVdKkxgFvarVg90H21EOLACvtfcHk0ljlfYjik03gfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVCnsb3F&md5=30d9f1b69d14b85b986abd79c04ada40</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Fml1001568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml1001568%26sid%3Dliteratum%253Aachs%26aulast%3DChekler%26aufirst%3DE.%2BL.%26aulast%3DKiselyov%26aufirst%3DA.%2BS.%26aulast%3DOuyang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DPattaropong%26aufirst%3DV.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DTuma%26aufirst%3DM.%2BC.%26aulast%3DDoody%26aufirst%3DJ.%2BF.%26atitle%3DDiscovery%2520of%2520dual%2520VEGFR-2%2520and%2520tubulin%2520inhibitors%2520with%2520in%2520vivo%2520efficacy%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D488%26epage%3D492%26doi%3D10.1021%2Fml1001568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aouad, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Mohammadi, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Blewi, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihmaid, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elbadawy, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Althagfan, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezki, N.</span></span> <span> </span><span class="NLM_article-title">Introducing of acyclonucleoside analogues tethered 1,2,4-triazole as anticancer agents with dual epidermal growth factor receptor kinase and microtubule inhibitors</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">103446</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2019.103446</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.bioorg.2019.103446" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=31791685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit12ktL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2020&pages=103446&author=M.+R.+Aouadauthor=H.+M.+Al-Mohammadiauthor=F.+F.+Al-Blewiauthor=S.+Ihmaidauthor=H.+M.+Elbadawyauthor=S.+S.+Althagfanauthor=N.+Rezki&title=Introducing+of+acyclonucleoside+analogues+tethered+1%2C2%2C4-triazole+as+anticancer+agents+with+dual+epidermal+growth+factor+receptor+kinase+and+microtubule+inhibitors&doi=10.1016%2Fj.bioorg.2019.103446"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Introducing of acyclonucleoside analogues tethered 1,2,4-triazole as anticancer agents with dual epidermal growth factor receptor kinase and microtubule inhibitors</span></div><div class="casAuthors">Aouad, Mohamed Reda; Al-Mohammadi, Hannan Musallam; Al-blewi, Fawzia Faleh; Ihmaid, Saleh; Elbadawy, Hossein Mostafa; Althagfan, Sultan Saad; Rezki, Nadjet</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103446</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This study reports an efficient and convenient regioselective synthesis of a novel series of S- and S,N-bis(acyclonucleoside) analogs carrying 5-(2-chlorophenyl)-2,4-dihydro-1,2,4-triazole-3-thione.  A facile and straightforward synthesis of thiazolotriazole and triazolothiazines has also been reported.  Structures of all newly synthesized compds. were well characterized by IR IR, 1H and 13C NMR (NMR) and mass (MS) spectra analyses.  Cytotoxic screening was performed according to (3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium (MTT) assay method using staurosporine as a ref. drug against three different types: human liver cancer cell line (Hep G2), Michigan cancer foundation-7 (MCF-7) and human colorectal carcinoma cell line (HCT116).  These data showed considerable anticancer activity for these newly synthesized compds.  Biol. data for most of the S-acyclonucleoside analogs and S,N-bis(acyclonucleoside) analogs showed excellent activity with micromolar (μM) half maximal inhibitory concn. (IC50) values against tumor cells.  EGFR assay and tubulin inhibition assay anal. were performed for the most active compds. to get more details about their mechanism of action.  In order to assess and explain their binding affinities, mol. docking simulation was studied against EGFR and tubulin binding sites.  The results obtained from mol. docking study and those obtained from cytotoxic screening were correlated.  Extensive structure activity relationship (SAR) analyses were also carried out.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqvl40K-Xd8bVg90H21EOLACvtfcHk0lg1rnk1O-DAxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit12ktL%252FE&md5=8c800df4fcf0a885b8746feb190deb55</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2019.103446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2019.103446%26sid%3Dliteratum%253Aachs%26aulast%3DAouad%26aufirst%3DM.%2BR.%26aulast%3DAl-Mohammadi%26aufirst%3DH.%2BM.%26aulast%3DAl-Blewi%26aufirst%3DF.%2BF.%26aulast%3DIhmaid%26aufirst%3DS.%26aulast%3DElbadawy%26aufirst%3DH.%2BM.%26aulast%3DAlthagfan%26aufirst%3DS.%2BS.%26aulast%3DRezki%26aufirst%3DN.%26atitle%3DIntroducing%2520of%2520acyclonucleoside%2520analogues%2520tethered%25201%252C2%252C4-triazole%2520as%2520anticancer%2520agents%2520with%2520dual%2520epidermal%2520growth%2520factor%2520receptor%2520kinase%2520and%2520microtubule%2520inhibitors%26jtitle%3DBioorg.%2520Chem.%26date%3D2020%26volume%3D94%26spage%3D103446%26doi%3D10.1016%2Fj.bioorg.2019.103446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phimmachanh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J. Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, Y. E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latham, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croucher, D. R.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylases and histone deacetylase inhibitors in neuroblastoma</span>. <i>Front. Cell Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">578770</span>, <span class="refDoi"> DOI: 10.3389/fcell.2020.578770</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.3389%2Ffcell.2020.578770" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=33117806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A280%3ADC%252BB3s7nsFKmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2020&pages=578770&author=M.+Phimmachanhauthor=J.+Z.+R.+Hanauthor=Y.+E.+I.+O%E2%80%99Donnellauthor=S.+L.+Lathamauthor=D.+R.+Croucher&title=Histone+deacetylases+and+histone+deacetylase+inhibitors+in+neuroblastoma&doi=10.3389%2Ffcell.2020.578770"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma</span></div><div class="casAuthors">Phimmachanh Monica; Han Jeremy Z R; O'Donnell Yolande E I; Latham Sharissa L; Croucher David R; Latham Sharissa L; Croucher David R</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in cell and developmental biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">578770</span>
        ISSN:<span class="NLM_cas:issn">2296-634X</span>.
    </div><div class="casAbstract">Histone deacetylases (HDACs) are enzymes that play a key role in regulating gene expression by remodeling chromatin structure.  An imbalance of histone acetylation caused by deregulated HDAC expression and activity is known to promote tumor progression in a number of tumor types, including neuroblastoma, the most common solid tumor in children.  Consequently, the inhibition of HDACs has emerged as a potential strategy to reverse these aberrant epigenetic changes, and several classes of HDAC inhibitors (HDACi) have been shown to inhibit tumor proliferation, or induce differentiation, apoptosis and cell cycle arrest in neuroblastoma.  Further, the combined use of HDACi with other chemotherapy agents, or radiotherapy, has shown promising pre-clinical results and various HDACi have progressed to different stages in clinical trials.  Despite this, the effects of HDACi are multifaceted and more work needs to be done to unravel their specific mechanisms of actions.  In this review, we discuss the functional role of HDACs in neuroblastoma and the potential of HDACi to be optimized for development and use in the clinic for treatment of patients with neuroblastoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRA7zzW8lfA_VMGsG_HTXYFfW6udTcc2eYhaJIBFvdPMLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3s7nsFKmtg%253D%253D&md5=2f1cf1d5a60c597eee36eb72e4cfe480</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.3389%2Ffcell.2020.578770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffcell.2020.578770%26sid%3Dliteratum%253Aachs%26aulast%3DPhimmachanh%26aufirst%3DM.%26aulast%3DHan%26aufirst%3DJ.%2BZ.%2BR.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DY.%2BE.%2BI.%26aulast%3DLatham%26aufirst%3DS.%2BL.%26aulast%3DCroucher%26aufirst%3DD.%2BR.%26atitle%3DHistone%2520deacetylases%2520and%2520histone%2520deacetylase%2520inhibitors%2520in%2520neuroblastoma%26jtitle%3DFront.%2520Cell%2520Dev.%2520Biol.%26date%3D2020%26volume%3D8%26spage%3D578770%26doi%3D10.3389%2Ffcell.2020.578770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glozak, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sengupta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, E.</span></span> <span> </span><span class="NLM_article-title">Acetylation and deacetylation of non-histone proteins</span>. <i>Gene</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1016/j.gene.2005.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.gene.2005.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=16289629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Klu7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2005&pages=15-23&author=M.+A.+Glozakauthor=N.+Senguptaauthor=X.+Zhangauthor=E.+Seto&title=Acetylation+and+deacetylation+of+non-histone+proteins&doi=10.1016%2Fj.gene.2005.09.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Acetylation and deacetylation of non-histone proteins</span></div><div class="casAuthors">Glozak, Michele A.; Sengupta, Nilanjan; Zhang, Xiaohong; Seto, Edward</div><div class="citationInfo"><span class="NLM_cas:title">Gene</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15-23</span>CODEN:
                <span class="NLM_cas:coden">GENED6</span>;
        ISSN:<span class="NLM_cas:issn">0378-1119</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Since the first report of p53 as a non-histone target of a histone acetyltransferase (HAT), there has been a rapid proliferation in the description of new non-histone targets of HATs.  Of these, transcription factors comprise the largest class of new targets.  The substrates for HATs extend to cytoskeletal proteins, mol. chaperones and nuclear import factors.  Deacetylation of these non-histone proteins by histone deacetylases (HDACs) opens yet another exciting new field of discovery in the role of the dynamic acetylation and deacetylation on cellular function.  This review will focus on these non-histone targets of HATs and HDACs and the consequences of their modification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrghezJOUSImbVg90H21EOLACvtfcHk0lgSAmwhcMMLDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Klu7%252FN&md5=c6befd12e4556a9154628d9fe9ebe53a</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.gene.2005.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gene.2005.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DGlozak%26aufirst%3DM.%2BA.%26aulast%3DSengupta%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSeto%26aufirst%3DE.%26atitle%3DAcetylation%2520and%2520deacetylation%2520of%2520non-histone%2520proteins%26jtitle%3DGene%26date%3D2005%26volume%3D363%26spage%3D15%26epage%3D23%26doi%3D10.1016%2Fj.gene.2005.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grant, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, P.</span></span> <span> </span><span class="NLM_article-title">Vorinostat</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1038/nrd2227</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1038%2Fnrd2227" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=17269160" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlGktbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=21-22&author=S.+Grantauthor=C.+Easleyauthor=P.+Kirkpatrick&title=Vorinostat&doi=10.1038%2Fnrd2227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Vorinostat</span></div><div class="casAuthors">Grant, Steven; Easley, Chris; Kirkpatrick, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-22</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYtFgooxRrcbVg90H21EOLACvtfcHk0lgSAmwhcMMLDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlGktbfK&md5=4017dcf775971088e24fca37e8a369af</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1038%2Fnrd2227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2227%26sid%3Dliteratum%253Aachs%26aulast%3DGrant%26aufirst%3DS.%26aulast%3DEasley%26aufirst%3DC.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DVorinostat%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D21%26epage%3D22%26doi%3D10.1038%2Fnrd2227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poole, R. M.</span></span> <span> </span><span class="NLM_article-title">Belinostat: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">1543</span>– <span class="NLM_lpage">1554</span>, <span class="refDoi"> DOI: 10.1007/s40265-014-0275-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1007%2Fs40265-014-0275-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=25134672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtl2nsrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=1543-1554&author=R.+M.+Poole&title=Belinostat%3A+first+global+approval&doi=10.1007%2Fs40265-014-0275-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Belinostat: First Global Approval</span></div><div class="casAuthors">Poole, Raewyn M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1543-1554</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Belinostat [Beleodaq (US)], a small-mol. hydroxamate-type inhibitor of class I, II and IV histone deacetylase (HDAC) enzymes, has been developed by TopoTarget and Spectrum Pharmaceuticals for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL).  Belinostat has received its first global approval as monotherapy for this indication in the US, under the Food and Drug Administration's accelerated approval program.  This article summarizes the milestones in the development of belinostat leading to this first approval for the treatment of PTCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm9C6yBRy7Q7Vg90H21EOLACvtfcHk0lgSAmwhcMMLDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtl2nsrzL&md5=b8bc6efe62e7fd78d6a9d022a8d96559</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1007%2Fs40265-014-0275-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-014-0275-8%26sid%3Dliteratum%253Aachs%26aulast%3DPoole%26aufirst%3DR.%2BM.%26atitle%3DBelinostat%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2014%26volume%3D74%26spage%3D1543%26epage%3D1554%26doi%3D10.1007%2Fs40265-014-0275-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zagni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floresta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monciino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rescifina, A.</span></span> <span> </span><span class="NLM_article-title">The search for potent, small-molecule HDACIs in cancer treatment: A decade after vorinostat</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1373</span>– <span class="NLM_lpage">1428</span>, <span class="refDoi"> DOI: 10.1002/med.21437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1002%2Fmed.21437" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=28181261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A280%3ADC%252BC1c3ltFWktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=1373-1428&author=C.+Zagniauthor=G.+Florestaauthor=G.+Monciinoauthor=A.+Rescifina&title=The+search+for+potent%2C+small-molecule+HDACIs+in+cancer+treatment%3A+A+decade+after+vorinostat&doi=10.1002%2Fmed.21437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat</span></div><div class="casAuthors">Zagni Chiara; Floresta Giuseppe; Monciino Giulia; Rescifina Antonio; Floresta Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal research reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1373-1428</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Histone deacetylases (HDACs) play a crucial role in the remodeling of chromatin, and are involved in the epigenetic regulation of gene expression.  In the last decade, inhibition of HDACs came out as a target for specific epigenetic changes associated with cancer and other diseases.  Until now, more than 20 HDAC inhibitors (HDACIs) have entered clinical studies, and some of them (e.g., vorinostat, romidepsin) have been approved for the treatment of cutaneous T-cell lymphoma.  This review provides an overview of current knowledge, progress, and molecular mechanisms of HDACIs, covering a period from 2011 until 2015.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSPT4s_HXWveWmbXvSEQle5fW6udTcc2eY9CFLKnMCyUrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3ltFWktQ%253D%253D&md5=79f4fe123e5ee6ba072e9147536fab67</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1002%2Fmed.21437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21437%26sid%3Dliteratum%253Aachs%26aulast%3DZagni%26aufirst%3DC.%26aulast%3DFloresta%26aufirst%3DG.%26aulast%3DMonciino%26aufirst%3DG.%26aulast%3DRescifina%26aufirst%3DA.%26atitle%3DThe%2520search%2520for%2520potent%252C%2520small-molecule%2520HDACIs%2520in%2520cancer%2520treatment%253A%2520A%2520decade%2520after%2520vorinostat%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2017%26volume%3D37%26spage%3D1373%26epage%3D1428%26doi%3D10.1002%2Fmed.21437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ezzeldin, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diasio, R. B.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase inhibitors: current status and overview of recent clinical trials</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">1911</span>– <span class="NLM_lpage">1934</span>, <span class="refDoi"> DOI: 10.2165/11315680-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.2165%2F11315680-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=19747008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlOrsLbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=1911-1934&author=X.+Maauthor=H.+H.+Ezzeldinauthor=R.+B.+Diasio&title=Histone+deacetylase+inhibitors%3A+current+status+and+overview+of+recent+clinical+trials&doi=10.2165%2F11315680-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors: current status and overview of recent clinical trials</span></div><div class="casAuthors">Ma, Xujun; Ezzeldin, Hany H.; Diasio, Robert B.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1911-1934</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis Data Information BV</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (HDAC) inhibitors are a new group of anticancer agents that have a potential role in the regulation of gene expression, induction of cell death, apoptosis and cell cycle arrest of cancer cells by altering the acetylation status of chromatin and other non-histone proteins.  In clin. trials, HDAC inhibitors have demonstrated promising antitumor activity as monotherapy in cutaneous T-cell lymphoma and other haematol. malignancies.  In solid tumors, several HDAC inhibitors have been shown to be efficacious as single agents; however, results of most clin. trials were in favor of using HDAC inhibitors either prior to the initiation of chemotherapy or in combination with other treatments.  Currently, the mol. basis of response to HDAC inhibitors in patients is not fully understood.  In this review, we summarize the current status of HDAC inhibitors, as single agents or in combination with other agents in different phases of clin. trials.  In most of the clin. trials, HDAC inhibitors were tolerable and exerted biol. or antitumor activity.  HDAC inhibitors have been studied in phase I, II and III clin. trials with variable efficacy.  The combination of HDAC inhibitors with other anticancer agents including epigenetic or chemotherapeutic agents demonstrated favorable clin. outcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdv-nIzRilyLVg90H21EOLACvtfcHk0li61FYGB2or9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlOrsLbI&md5=7bffcf6f0627d58907d0e98085f4bdf5</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.2165%2F11315680-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11315680-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DX.%26aulast%3DEzzeldin%26aufirst%3DH.%2BH.%26aulast%3DDiasio%26aufirst%3DR.%2BB.%26atitle%3DHistone%2520deacetylase%2520inhibitors%253A%2520current%2520status%2520and%2520overview%2520of%2520recent%2520clinical%2520trials%26jtitle%3DDrugs%26date%3D2009%26volume%3D69%26spage%3D1911%26epage%3D1934%26doi%3D10.2165%2F11315680-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>192</i></span>,  <span class="NLM_fpage">112158</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejmech.2020.112158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=32171161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvFams7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2020&pages=112158&author=W.+C.+Wuauthor=Y.+M.+Liuauthor=M.+H.+Linauthor=Y.+H.+Liaoauthor=M.+J.+Laiauthor=H.+Y.+Chuangauthor=T.+Y.+Hungauthor=C.+H.+Chenauthor=J.+P.+Liou&title=Design%2C+synthesis%2C+and+evaluation+of+N-phenyl-4-%282-phenylsulfonamido%29-benzamides+as+microtubule-targeting+agents+in+drug-resistant+cancer+cells%2C+displaying+HDAC+inhibitory+response&doi=10.1016%2Fj.ejmech.2020.112158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response</span></div><div class="casAuthors">Wu, Wei-Cheng; Liu, Yi-Min; Lin, Mei-Hsiang; Liao, Yu-Hsuan; Lai, Mei-Jung; Chuang, Hsun-Yueh; Hung, To-Yu; Chen, Chun-Han; Liou, Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112158</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A synthesis of a series of N-phenyl-4-(2-(phenylsulfonamido)phenethyl)benzamides I [R1 = H, 2-NH2, 2-OH, etc.; R2 = H, OMe, 4-F, etc.; X = C, NH, O] was described.  A new compd. I [R1 = 2-NH2; R2 = 4-OMe; X = NH] displayed promising anticancer activity with GI50 of 22 ± 2 and 12 ± 0.1 nM in vincristine-resistant nasopharyngeal (KB-Vin) cancer cells and etoposide-resistant nasopharyngeal (KB-7D) cancer cells and was better than vincristine, etoposide, ABT-751, and MS-275.  A mechanistic study revealed that I [R1 = 2-NH2; R2 = 4-OMe; X = NH] interfered with the cell cycle distribution and induces cell cycle arrest at the G2/M phase and severe mitotic spindle defects followed by apoptosis.  In addn., it produced much more significant cytotoxicity than vincristine and etoposide in the corresponding resistant cells, indicating that it may be a promising candidate to overcome drug resistance in cancer cells.  Compd. I [R1 = 2-NH2; R2 = 4-OMe; X = NH] also displayed inhibitory activity against HDAC 1 and HDAC 2 with IC50 values of 1.07μM, and 1.47μM, resp.  These findings may lead to a new type of structural motif for future development of drugs that could overcome acquired resistance to MTAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod01WmBTU_qbVg90H21EOLACvtfcHk0li61FYGB2or9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvFams7o%253D&md5=c10c36ffccb5eb553abf7746ed4fd91c</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112158%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DW.%2BC.%26aulast%3DLiu%26aufirst%3DY.%2BM.%26aulast%3DLin%26aufirst%3DM.%2BH.%26aulast%3DLiao%26aufirst%3DY.%2BH.%26aulast%3DLai%26aufirst%3DM.%2BJ.%26aulast%3DChuang%26aufirst%3DH.%2BY.%26aulast%3DHung%26aufirst%3DT.%2BY.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520N-phenyl-4-%25282-phenylsulfonamido%2529-benzamides%2520as%2520microtubule-targeting%2520agents%2520in%2520drug-resistant%2520cancer%2520cells%252C%2520displaying%2520HDAC%2520inhibitory%2520response%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D192%26spage%3D112158%26doi%3D10.1016%2Fj.ejmech.2020.112158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span> <span> </span><span class="NLM_article-title">1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">612</span>– <span class="NLM_lpage">630</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.10.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejmech.2018.10.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=30476825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit12ktrbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2019&pages=612-630&author=M.+J.+Laiauthor=R.+Ojhaauthor=M.+H.+Linauthor=Y.+M.+Liuauthor=H.+Y.+Leeauthor=T.+E.+Linauthor=K.+C.+Hsuauthor=C.+Y.+Changauthor=M.+C.+Chenauthor=K.+Nepaliauthor=J.+Y.+Changauthor=J.+P.+Liou&title=1-Arylsulfonyl+indoline-benzamides+as+a+new+antitubulin+agents%2C+with+inhibition+of+histone+deacetylase&doi=10.1016%2Fj.ejmech.2018.10.066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase</span></div><div class="casAuthors">Lai, Mei-Jung; Ojha, Ritu; Lin, Mei-Hsiang; Liu, Yi-Min; Lee, Hsueh-Yun; Lin, Tony Eight; Hsu, Kai-Cheng; Chang, Chi-Yen; Chen, Mei-Chuan; Nepali, Kunal; Chang, Jang-Yang; Liou, Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">612-630</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">We report structure-activity relationships of 1-arylsulfonyl indoline based benzamides.  The benzamide (9) exhibits striking tubulin inhibition with an IC50 value of 1.1 μM, better than that of combretastain A-4 (3), and substantial antiproliferative activity against a variety of cancer cells, including MDR-pos. cell lines with an IC50 value of 49 nM (KB), 79 nM (A549), 63 nM (MKN45), 64 nM (KB-VIN10), 43 nM (KB-S15), and 46 nM (KB-7D).  Dual inhibitory potential of compd. 9 was found as it demonstrated significant inhibitory potential against HDAC1, 2 and 6 in comparison to MS-275 (6).  Some key interactions of 9 with the amino acid residues of the active site of tubulin and with amino acid residues of HDAC 1 isoform have been figured out by mol. modeling.  Compd. 9 also demonstrated significant in vivo efficacy in the human non-small cell lung cancer A549 xenograft model as well as B-cell lymphoma BJAB xenograft tumor model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro7mdjL0vVK7Vg90H21EOLACvtfcHk0li61FYGB2or9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit12ktrbE&md5=7baa00d4d539dc3edb43bb63411eb744</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.10.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.10.066%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DM.%2BJ.%26aulast%3DOjha%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DM.%2BH.%26aulast%3DLiu%26aufirst%3DY.%2BM.%26aulast%3DLee%26aufirst%3DH.%2BY.%26aulast%3DLin%26aufirst%3DT.%2BE.%26aulast%3DHsu%26aufirst%3DK.%2BC.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DChen%26aufirst%3DM.%2BC.%26aulast%3DNepali%26aufirst%3DK.%26aulast%3DChang%26aufirst%3DJ.%2BY.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26atitle%3D1-Arylsulfonyl%2520indoline-benzamides%2520as%2520a%2520new%2520antitubulin%2520agents%252C%2520with%2520inhibition%2520of%2520histone%2520deacetylase%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D162%26spage%3D612%26epage%3D630%26doi%3D10.1016%2Fj.ejmech.2018.10.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">HuangFu, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span> <span> </span><span class="NLM_article-title">3-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">1268</span>– <span class="NLM_lpage">1278</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.11.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejmech.2016.11.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=27886544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFGru77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2017&pages=1268-1278&author=H.+Y.+Leeauthor=J.+F.+Leeauthor=S.+Kumarauthor=Y.+W.+Wuauthor=W.+C.+HuangFuauthor=M.+J.+Laiauthor=Y.+H.+Liauthor=H.+L.+Huangauthor=F.+C.+Kuoauthor=C.+J.+Hsiaoauthor=C.+C.+Chengauthor=C.+R.+Yangauthor=J.+P.+Liou&title=3-Aroylindoles+display+antitumor+activity+in+vitro+and+in+vivo%3A+Effects+of+N1-substituents+on+biological+activity&doi=10.1016%2Fj.ejmech.2016.11.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">3-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity</span></div><div class="casAuthors">Lee, Hsueh-Yun; Lee, Jiann-Fong; Kumar, Sunil; Wu, Yi-Wen; HuangFu, Wei-Chun; Lai, Mei-Jung; Li, Yu-Hsuan; Huang, Hsiang-Ling; Kuo, Fei-Chiao; Hsiao, Che-Jen; Cheng, Chun-Chun; Yang, Chia-Ron; Liou, Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1268-1278</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 3-aroylindole hydroxamic acids (10-17) were developed based on the concept of a structural combination of tubulin and histone deacetylase (HDAC) inhibitors.  This was accomplished by introducing hydroxamic acid-contg. moieties at the N1 position of the tubulin assembly inhibitor, compd. 9 (SCB01A, BPR0L075, phase II trial).  Most of synthetic compds. produced in this way displayed comparable HDAC inhibitory activity, and four (10, 12-14) of them also inhibit tubulin assembly.  Notably, compd. 12 possesses not only tubulin and HDAC inhibitory activity but also shows HDAC6 selectivity over other HDAC isoforms.  In addn., it exhibits remarkable inhibitory activity against the growth cancer cells in vitro and in vivo (PC3 and RPMI-8226 cells).  Notably, it suppresses the growth of multiple myeloma xenografts without leading to the death of teated animals like ref. compd.  In sum, this study provided potential compds. with safer profiles for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouAXwj00pZ2bVg90H21EOLACvtfcHk0ljMTDViBA6NYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFGru77M&md5=b7e348261fef66bab674a6e699822515</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.11.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.11.033%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.%2BY.%26aulast%3DLee%26aufirst%3DJ.%2BF.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DY.%2BW.%26aulast%3DHuangFu%26aufirst%3DW.%2BC.%26aulast%3DLai%26aufirst%3DM.%2BJ.%26aulast%3DLi%26aufirst%3DY.%2BH.%26aulast%3DHuang%26aufirst%3DH.%2BL.%26aulast%3DKuo%26aufirst%3DF.%2BC.%26aulast%3DHsiao%26aufirst%3DC.%2BJ.%26aulast%3DCheng%26aufirst%3DC.%2BC.%26aulast%3DYang%26aufirst%3DC.%2BR.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26atitle%3D3-Aroylindoles%2520display%2520antitumor%2520activity%2520in%2520vitro%2520and%2520in%2520vivo%253A%2520Effects%2520of%2520N1-substituents%2520on%2520biological%2520activity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D125%26spage%3D1268%26epage%3D1278%26doi%3D10.1016%2Fj.ejmech.2016.11.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamaa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zig, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauvais, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollot, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bignon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levaique, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pamlard, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubois, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouaissi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souce, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasselouri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saller, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayat-Vignoles, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Mouhammad, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feuillard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benihoud, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamze, A.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of tubulin and histone deacetylase inhibitor based on iso-combretastatin A-4</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6574</span>– <span class="NLM_lpage">6591</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00050</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00050" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlWrtrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6574-6591&author=D.+Lamaaauthor=H.+P.+Linauthor=L.+Zigauthor=C.+Bauvaisauthor=G.+Bollotauthor=J.+Bignonauthor=H.+Levaiqueauthor=O.+Pamlardauthor=J.+Duboisauthor=M.+Ouaissiauthor=M.+Souceauthor=A.+Kasselouriauthor=F.+Sallerauthor=D.+Borgelauthor=C.+Jayat-Vignolesauthor=H.+Al-Mouhammadauthor=J.+Feuillardauthor=K.+Benihoudauthor=M.+Alamiauthor=A.+Hamze&title=Design+and+synthesis+of+tubulin+and+histone+deacetylase+inhibitor+based+on+iso-combretastatin+A-4&doi=10.1021%2Facs.jmedchem.8b00050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on iso-Combretastatin A-4</span></div><div class="casAuthors">Lamaa, Diana; Lin, Hsin-Ping; Zig, Lena; Bauvais, Cyril; Bollot, Guillaume; Bignon, Jerome; Levaique, Helene; Pamlard, Olivier; Dubois, Joelle; Ouaissi, Mehdi; Souce, Martin; Kasselouri, Athena; Saller, Francois; Borgel, Delphine; Jayat-Vignoles, Chantal; Al-Mouhammad, Hazar; Feuillard, Jean; Benihoud, Karim; Alami, Mouad; Hamze, Abdallah</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6574-6591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Designing multitarget drugs have raised considerable interest due to their advantages in the treatment of complex diseases such as cancer.  Their design constitutes a challenge in antitumor drug discovery.  The present study reports a dual inhibition of tubulin polymn. and HDAC activity.  On the basis of 1,1-diarylethylenes (isoCA-4) and belinostat, a series of hybrid mols. was successfully designed and synthesized.  In particular compds., 5f and 5h were proven to be potent inhibitors of both tubulin polymn. and HDAC8 leading to excellent antiproliferative activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGq5rq0opowLVg90H21EOLACvtfcHk0ljMTDViBA6NYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlWrtrzN&md5=9d7ffe7d11f3dc2e55adcd8d0c511606</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00050%26sid%3Dliteratum%253Aachs%26aulast%3DLamaa%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DH.%2BP.%26aulast%3DZig%26aufirst%3DL.%26aulast%3DBauvais%26aufirst%3DC.%26aulast%3DBollot%26aufirst%3DG.%26aulast%3DBignon%26aufirst%3DJ.%26aulast%3DLevaique%26aufirst%3DH.%26aulast%3DPamlard%26aufirst%3DO.%26aulast%3DDubois%26aufirst%3DJ.%26aulast%3DOuaissi%26aufirst%3DM.%26aulast%3DSouce%26aufirst%3DM.%26aulast%3DKasselouri%26aufirst%3DA.%26aulast%3DSaller%26aufirst%3DF.%26aulast%3DBorgel%26aufirst%3DD.%26aulast%3DJayat-Vignoles%26aufirst%3DC.%26aulast%3DAl-Mouhammad%26aufirst%3DH.%26aulast%3DFeuillard%26aufirst%3DJ.%26aulast%3DBenihoud%26aufirst%3DK.%26aulast%3DAlami%26aufirst%3DM.%26aulast%3DHamze%26aufirst%3DA.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520tubulin%2520and%2520histone%2520deacetylase%2520inhibitor%2520based%2520on%2520iso-combretastatin%2520A-4%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6574%26epage%3D6591%26doi%3D10.1021%2Facs.jmedchem.8b00050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">The discovery of colchicine-SAHA hybrids as a new class of antitumor agents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">3240</span>– <span class="NLM_lpage">3244</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.03.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.bmc.2013.03.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=23602523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtV2lt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=3240-3244&author=X.+Zhangauthor=J.+Zhangauthor=L.+Tongauthor=Y.+Luoauthor=M.+Suauthor=Y.+Zangauthor=J.+Liauthor=W.+Luauthor=Y.+Chen&title=The+discovery+of+colchicine-SAHA+hybrids+as+a+new+class+of+antitumor+agents&doi=10.1016%2Fj.bmc.2013.03.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of colchicine-SAHA hybrids as a new class of antitumor agents</span></div><div class="casAuthors">Zhang, Xuan; Zhang, Jie; Tong, Linjiang; Luo, Yu; Su, Mingbo; Zang, Yi; Li, Jia; Lu, Wei; Chen, Yi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3240-3244</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel class of colchicine-SAHA hybrids were designed and synthesized based on the synergistic antitumor effect tubulin inhibitors and histone deacetylases(HDAC) inhibitors.  To the best of our knowledge, this is the first design of mols. that are dual inhibitors of tubulin and HDAC.  Biol. evaluations of these compds. included the inhibitory activity of HDAC, in vitro cell cycle anal. in BEL-7402 cells as well as cytotoxicity in five cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi-0eT4cJg3rVg90H21EOLACvtfcHk0lgQ1tjbxjTf0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtV2lt7c%253D&md5=2a3020c5a48b617bd04f5c2cb214df99</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.03.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.03.049%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DZang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DThe%2520discovery%2520of%2520colchicine-SAHA%2520hybrids%2520as%2520a%2520new%2520class%2520of%2520antitumor%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D3240%26epage%3D3244%26doi%3D10.1016%2Fj.bmc.2013.03.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.03.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejmech.2015.03.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=25805446" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVWis7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2015&pages=127-135&author=X.+Zhangauthor=Y.+Kongauthor=J.+Zhangauthor=M.+Suauthor=Y.+Zhouauthor=Y.+Zangauthor=J.+Liauthor=Y.+Chenauthor=Y.+Fangauthor=X.+Zhangauthor=W.+Lu&title=Design%2C+synthesis+and+biological+evaluation+of+colchicine+derivatives+as+novel+tubulin+and+histone+deacetylase+dual+inhibitors&doi=10.1016%2Fj.ejmech.2015.03.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors</span></div><div class="casAuthors">Zhang, Xuan; Kong, Yannan; Zhang, Jie; Su, Mingbo; Zhou, Yubo; Zang, Yi; Li, Jia; Chen, Yi; Fang, Yanfen; Zhang, Xiongwen; Lu, Wei</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">127-135</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A new class of colchicine derivs. were designed and synthesized as tubulin-HDAC dual inhibitors.  Biol. evaluations of these hybrids included the inhibitory activity of HDAC, tubulin polymn. anal., in vitro cell cycle anal. in HCT-116 cells and cytotoxicity against different cancer cell lines.  Hybrid I behaved as potent HDAC-tubulin dual inhibitor and showed comparable cytotoxicity with colchicine.  Compd. II exhibited powerful tubulin inhibitory activity, moderate anti-HDAC activity and the most potent cytotoxicity (IC50 = 2-105 nM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6P07-g6WBfbVg90H21EOLACvtfcHk0lgQ1tjbxjTf0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVWis7o%253D&md5=e532028d8f03179da99f533eefa62568</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.03.035%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DKong%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DZang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DW.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520colchicine%2520derivatives%2520as%2520novel%2520tubulin%2520and%2520histone%2520deacetylase%2520dual%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D95%26spage%3D127%26epage%3D135%26doi%3D10.1016%2Fj.ejmech.2015.03.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">SKLB-23bb, a HDAC6-selective inhibitor, exhibits superior and broad-spectrum antitumor activity via additionally targeting microtubules</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">763</span>– <span class="NLM_lpage">775</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-17-0332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1158%2F1535-7163.MCT-17-0332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=29610282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXms1ejtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=763-775&author=F.+Wangauthor=L.+Zhengauthor=Y.+Yiauthor=Z.+Yangauthor=Q.+Qiuauthor=X.+Wangauthor=W.+Yanauthor=P.+Baiauthor=J.+Yangauthor=D.+Liauthor=H.+Peiauthor=T.+Niuauthor=H.+Yeauthor=C.+Nieauthor=Y.+Huauthor=S.+Yangauthor=Y.+Weiauthor=L.+Chen&title=SKLB-23bb%2C+a+HDAC6-selective+inhibitor%2C+exhibits+superior+and+broad-spectrum+antitumor+activity+via+additionally+targeting+microtubules&doi=10.1158%2F1535-7163.MCT-17-0332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">SKLB-23bb, A HDAC6-Selective Inhibitor, Exhibits Superior and Broad-Spectrum Antitumor Activity via Additionally Targeting Microtubules</span></div><div class="casAuthors">Wang, Fang; Zheng, Li; Yi, Yuyao; Yang, Zhuang; Qiu, Qiang; Wang, Xiaoyan; Yan, Wei; Bai, Peng; Yang, Jianhong; Li, Dan; Pei, Heying; Niu, Ting; Ye, Haoyu; Nie, Chunlai; Hu, Yiguo; Yang, Shengyong; Wei, Yuquan; Chen, Lijuan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">763-775</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Our previous study reported that SKLB-23bb, an orally bioavailable HDAC6-selective inhibitor, exhibited superior antitumor efficiency both in vitro and in vivo in comparison with ACY1215, a HDAC6-selective inhibitor recently in phase II clin. trial.  This study focused on the mechanism related to the activity of SKLB-23bb.  We discovered that despite having HDAC6-selective inhibition equal to ACY1215, SKLB-23bb showed cytotoxic effects against a panel of solid and hematol. tumor cell lines at the low submicromolar level.  Interestingly, in contrast to the reported HDAC6-selective inhibitors, SKLB-23bb was more efficient against solid tumor cells.  Utilizing HDAC6 stably knockout cell lines constructed by CRISPR-Cas9 gene editing, we illustrated that SKLB-23bb could remain cytotoxic independent of HDAC6 status.  Investigation of the mechanism confirmed that SKLB-23bb exerted its cytotoxic activity by addnl. targeting microtubules.  SKLB-23bb could bind to the colchicine site in β-tubulin and act as a microtubule polymn. inhibitor.  Consistent with its microtubule-disrupting ability, SKLB-23bb also blocked tumor cell cycle at G2-M phase and triggered cellular apoptosis.  In solid tumor xenografts, oral administration of SKLB-23bb efficiently inhibited tumor growth.  These results suggested that SKLB-23bb was an orally bioavailable HDAC6 and microtubule dual targeting agent.  The microtubule targeting profile enhanced the antitumor activity and expanded the antitumor spectrum of SKLB-23bb, thus breaking through the limitation of HDAC6 inhibitors.  Mol Cancer Ther; 17(4); 763-75. ©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq02sK3SMQsq7Vg90H21EOLACvtfcHk0lgaThn_hog3pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXms1ejtLY%253D&md5=db43d2066c8a814dc07c0ca98438a55c</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-17-0332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-17-0332%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DF.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DYi%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DQiu%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DYan%26aufirst%3DW.%26aulast%3DBai%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DPei%26aufirst%3DH.%26aulast%3DNiu%26aufirst%3DT.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DNie%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DSKLB-23bb%252C%2520a%2520HDAC6-selective%2520inhibitor%252C%2520exhibits%2520superior%2520and%2520broad-spectrum%2520antitumor%2520activity%2520via%2520additionally%2520targeting%2520microtubules%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2018%26volume%3D17%26spage%3D763%26epage%3D775%26doi%3D10.1158%2F1535-7163.MCT-17-0332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luan, Y.</span></span> <span> </span><span class="NLM_article-title">Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">2638</span>– <span class="NLM_lpage">2645</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.07.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.bmcl.2019.07.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=31400938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFKjsbfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=2638-2645&author=B.+Wangauthor=X.+Chenauthor=J.+Gaoauthor=L.+Suauthor=L.+Zhangauthor=H.+Xuauthor=Y.+Luan&title=Anti-tumor+activity+evaluation+of+novel+tubulin+and+HDAC+dual-targeting+inhibitors&doi=10.1016%2Fj.bmcl.2019.07.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors</span></div><div class="casAuthors">Wang, Baolei; Chen, Xuehong; Gao, Jianjun; Su, Li; Zhang, Li; Xu, Hongwei; Luan, Yepeng</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2638-2645</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) have proven to be promising targets for the development of anti-cancer drugs.  In this study, we reported a series of novel chalcone based tubulin and HDAC dual-targeting inhibitors.  Three compds. inhibited the activities of HDAC and tubulin polymn. simultaneously and displayed anti-proliferative activities toward eleven human tumor cell lines.  Compd. 8a remarkably induced growth inhibition, apoptosis and G2/M phase arrest of A549 tumor cells.  Finally, the inhibitory activities of 8a against HDAC6 and tubulin were rationalized by mol. docking studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY7ecC0j2FibVg90H21EOLACvtfcHk0lgaThn_hog3pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFKjsbfI&md5=ac1e230b5a2b579f503f87bf6821e887</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.07.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.07.045%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DLuan%26aufirst%3DY.%26atitle%3DAnti-tumor%2520activity%2520evaluation%2520of%2520novel%2520tubulin%2520and%2520HDAC%2520dual-targeting%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D2638%26epage%3D2645%26doi%3D10.1016%2Fj.bmcl.2019.07.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosch, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dittmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothemund, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schobert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biersack, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volkamer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Höpfner, M.</span></span> <span> </span><span class="NLM_article-title">Oxazole-bridged combretastatin A-4 derivatives with tethered hydroxamic acids: structure-activity relations of new inhibitors of HDAC and/or tubulin function</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">383</span>, <span class="refDoi"> DOI: 10.3390/ijms20020383</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.3390%2Fijms20020383" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFahs7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=383&author=F.+Schmittauthor=L.+C.+Goschauthor=A.+Dittmerauthor=M.+Rothemundauthor=T.+Muellerauthor=R.+Schobertauthor=B.+Biersackauthor=A.+Volkamerauthor=M.+H%C3%B6pfner&title=Oxazole-bridged+combretastatin+A-4+derivatives+with+tethered+hydroxamic+acids%3A+structure-activity+relations+of+new+inhibitors+of+HDAC+and%2For+tubulin+function&doi=10.3390%2Fijms20020383"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Oxazole-bridged combretastatin A-4 derivatives with tethered hydroxamic acids: structure-activity relations of new inhibitors of HDAC and/or tubulin function</span></div><div class="casAuthors">Schmitt, Florian; Gosch, Lisa Chiara; Dittmer, Alexandra; Rothemund, Matthias; Mueller, Thomas; Schobert, Rainer; Biersack, Bernhard; Volkamer, Andrea; Hoepfner, Michael</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">383/1-383/26</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">New inhibitors of tubulin polymn. and/or histone deacetylase (HDAC) activity were synthesized by attaching alkyl tethered hydroxamic acid appendages of varying length to oxazole-bridged combretastatin A-4 analogous caps.  While their antiproliferative and microtubule disrupting effect was most pronounced for derivs. with short spacers, HDAC inhibition was strongest for those with longer spacers.  These findings were further supported by computational methods such as structure-based docking expts. exploring the target interactions of the derivs. with varying linkers.  For instance, compds. featuring short four-atom spacers between cap and hydroxamic acid inhibited the growth of various cancer cell lines and human endothelial hybrid cells with IC50 values in the low nanomolar range.  In line with their ability to inhibit the microtubule assembly, four- and five-atom spacered hydroxamic acids caused an accumulation of 518A2 melanoma cells in G2/M phase, whereas a compd. featuring a six-atom spacer and performing best in HDAC inhibition, induced a G1 arrest in these cells.  All these beneficial anticancer activities together with their selectivity for cancer cells over non-malignant cells, point out the great potential of these novel pleiotropic HDAC and tubulin inhibitors as drug candidates for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnd6vxUZSv1bVg90H21EOLACvtfcHk0ljTkAJqPULAdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFahs7nE&md5=c1c66ac969fd55fe4bfe78527375d8d3</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.3390%2Fijms20020383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20020383%26sid%3Dliteratum%253Aachs%26aulast%3DSchmitt%26aufirst%3DF.%26aulast%3DGosch%26aufirst%3DL.%2BC.%26aulast%3DDittmer%26aufirst%3DA.%26aulast%3DRothemund%26aufirst%3DM.%26aulast%3DMueller%26aufirst%3DT.%26aulast%3DSchobert%26aufirst%3DR.%26aulast%3DBiersack%26aufirst%3DB.%26aulast%3DVolkamer%26aufirst%3DA.%26aulast%3DH%25C3%25B6pfner%26aufirst%3DM.%26atitle%3DOxazole-bridged%2520combretastatin%2520A-4%2520derivatives%2520with%2520tethered%2520hydroxamic%2520acids%253A%2520structure-activity%2520relations%2520of%2520new%2520inhibitors%2520of%2520HDAC%2520and%252For%2520tubulin%2520function%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D383%26doi%3D10.3390%2Fijms20020383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span> <span> </span><span class="NLM_article-title">CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>215</i></span>,  <span class="NLM_fpage">113169</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2021.113169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejmech.2021.113169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=33588178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3MXksFSnsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=215&publication_year=2021&pages=113169&author=A.+Singhauthor=T.+Y.+Changauthor=N.+Kaurauthor=K.+C.+Hsuauthor=Y.+Yenauthor=T.+E.+Linauthor=M.+J.+Laiauthor=S.+B.+Leeauthor=J.+P.+Liou&title=CAP+rigidification+of+MS-275+and+chidamide+leads+to+enhanced+antiproliferative+effects+mediated+through+HDAC1%2C+2+and+tubulin+polymerization+inhibition&doi=10.1016%2Fj.ejmech.2021.113169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition</span></div><div class="casAuthors">Singh, Arshdeep; Chang, Ting-Yu; Kaur, Navdeep; Hsu, Kai-Cheng; Yen, Yun; Lin, Tony Eight; Lai, Mei-Jung; Lee, Sung-Bau; Liou, Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">215</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113169</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The study focused on the prudent design and synthesis of anilide type class I HDAC inhibitors I [R1 = H, OMe, Cl; R2 = H,F,Cl,OMe; R3 = H, OMe; R4 = H2N] employing a functionalized pyrrolo[2,3-d]pyrimidine skeleton as the surface recognition part.  Utilization of the bicyclic arom. ring to fabricate the target compds. was envisioned to confer rigidity to the chem. architecture of MS-275 and chidamide.  In-vitro enzymic and cellular assays led to the identification of compd. I [R1 = R3 = H; R2 = OMe; R4 = H2N] as a potent inhibitor of HDAC1 and 2 isoform that exerted substantial cell growth inhibitory effects against human breast MDA-MB-231, cervical HeLa, breast MDA-MB-468, colorectal DLD1, and colorectal HCT116 cell lines with an IC50 values of 0.05-0.47μM, better than MS-275 and chidamide.  In addn., the anilide I [R1 = R3 = H; R2 = OMe; R4 = H2N] was also endowed with a superior antiproliferative profile than MS275 and chidamide towards the human cutaneous T cell lymphoma (HH and HuT78), leukemia (HL60 and KG-1), and HDACi sensitive/resistant gastric cell lines (YCC11 and YCC3/7).  Exhaustive exploration of the construct I [R1 = R3 = H; R2 = OMe; R4 = H2N] confirmed it to be a microtubule-targeting agent that could trigger the cell-cycle arrest in mitosis.  In pursuit of extg. the benefits of evidenced microtubule-destabilizing activity of the anilide I [R1 = R3 = H; R2 = OMe; R4 = H2N], it was further evaluated against non-small-cell lung cancer cell lines as well as the multiple-drug resistant uterine cancer cell line (MES-SA/Dx5) and overwhelmingly pos. results in context of inhibitory effects were attained.  Furthermore, mol. modeling studies were performed and some key interactions of the anilide I [R1 = R3 = H; R2 = OMe; R4 = H2N] with the amino acid residues of the active site of HDAC1 isoform and tubulin were figured out.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkmNaG2FVRj7Vg90H21EOLACvtfcHk0ljTkAJqPULAdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXksFSnsbc%253D&md5=6e419995af06c3e6ecc70db9a791b58d</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2021.113169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2021.113169%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DChang%26aufirst%3DT.%2BY.%26aulast%3DKaur%26aufirst%3DN.%26aulast%3DHsu%26aufirst%3DK.%2BC.%26aulast%3DYen%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DT.%2BE.%26aulast%3DLai%26aufirst%3DM.%2BJ.%26aulast%3DLee%26aufirst%3DS.%2BB.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26atitle%3DCAP%2520rigidification%2520of%2520MS-275%2520and%2520chidamide%2520leads%2520to%2520enhanced%2520antiproliferative%2520effects%2520mediated%2520through%2520HDAC1%252C%25202%2520and%2520tubulin%2520polymerization%2520inhibition%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D215%26spage%3D113169%26doi%3D10.1016%2Fj.ejmech.2021.113169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peyrot, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briand, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Momburg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sari, J. C.</span></span> <span> </span><span class="NLM_article-title">In vitro mechanism study of microtubule assembly inhibition by cis-dichlorodiammine-platinum(II)</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">375</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(86)90207-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2F0006-2952%2886%2990207-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=3947376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADyaL28XhtVajurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1986&pages=371-375&author=V.+Peyrotauthor=C.+Briandauthor=R.+Momburgauthor=J.+C.+Sari&title=In+vitro+mechanism+study+of+microtubule+assembly+inhibition+by+cis-dichlorodiammine-platinum%28II%29&doi=10.1016%2F0006-2952%2886%2990207-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro mechanism study of microtubule assembly inhibition by cis-dichlorodiammine-platinum(II)</span></div><div class="casAuthors">Peyrot, V.; Briand, C.; Momburg, R.; Sari, J. C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">371-84</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">The inhibitions of microtubule protein (MTP) and tubulin 6S polymn. by cis-dichlorodiammineplatinum(II) (CDDP)  [15663-27-1] were investigated by turbidity measurements and electron microscopy.  With 2.5 × 10-4M CDDP after a 40-min contact at 27°, the inhibition was 60% for MTP (1.2 mg/mL) and nearly 90% for tubulin 6S (1.2 mg/mL).  The microtubules were not present after a 1-h contact at 27° with 2.5 × 10-4M CDDP.  Free SH group detns. with 5,5'-dithiobis(2-nitrobenzoate) showed that 20.10 SH groups were found per tubulin dimer.  In the presence of excess CDDP, this no. was reduced to 17.74 after a 1- h contact at 27°.  By using CDDP-tubulin dialysis assays, the CDDP-tubulin complex formation was found to be an irreversible reaction through a covalent binding at the SH group sites.  By a DEAE filter paper method, CDDP slightly decreased Vinca alkaloid and colchicine bindings to tubulin, likely by inducing a conformational change of the protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsA3W9TXTh5LVg90H21EOLACvtfcHk0liIdLmL5vDjHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XhtVajurY%253D&md5=5d203719b64097e6feae0790822344e0</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2886%2990207-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252886%252990207-8%26sid%3Dliteratum%253Aachs%26aulast%3DPeyrot%26aufirst%3DV.%26aulast%3DBriand%26aufirst%3DC.%26aulast%3DMomburg%26aufirst%3DR.%26aulast%3DSari%26aufirst%3DJ.%2BC.%26atitle%3DIn%2520vitro%2520mechanism%2520study%2520of%2520microtubule%2520assembly%2520inhibition%2520by%2520cis-dichlorodiammine-platinum%2528II%2529%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1986%26volume%3D35%26spage%3D371%26epage%3D375%26doi%3D10.1016%2F0006-2952%2886%2990207-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Combretastatin A-4 analogue: A dual-targeting and tubulin inhibitor containing antitumor Pt(IV) moiety with a unique mode of action</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2132</span>– <span class="NLM_lpage">2148</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.6b00353</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.6b00353" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1yrsbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=2132-2148&author=X.+Huangauthor=R.+Huangauthor=S.+Gouauthor=Z.+Wangauthor=Z.+Liaoauthor=H.+Wang&title=Combretastatin+A-4+analogue%3A+A+dual-targeting+and+tubulin+inhibitor+containing+antitumor+Pt%28IV%29+moiety+with+a+unique+mode+of+action&doi=10.1021%2Facs.bioconjchem.6b00353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Combretastatin A-4 Analogue: A Dual-Targeting and Tubulin Inhibitor Containing Antitumor Pt(IV) Moiety with a Unique Mode of Action</span></div><div class="casAuthors">Huang, Xiaochao; Huang, Rizhen; Gou, Shaohua; Wang, Zhimei; Liao, Zhixin; Wang, Hengshan</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2132-2148</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Abstr.: Three new Pt(IV) complexes comprising a combretastatin A-4 analog were designed and synthesized.  The resulting antitumor Pt(IV) complexes could significantly improve the antiproliferative activity and overcome the drug resistance of cisplatin in vitro.  Interestingly, these novel compds. can not only carry the DNA binding Pt(II) warhead into the cancer cells but also have a small mol. fragment that can inhibit tubulin polymn.  Among them, complex 13, which was attached to an inhibitor of tubulin at one axial position of Pt(IV) octahedral coordination sphere, could effectively enter cancer cells, arrest the cell cycle in HepG-2 cancer cells at G2/M phases, and induce activation of caspases triggering apoptotic signaling via the mitochondrial-dependent apoptosis pathways.  Moreover, complex 13 has the ability of effectively inhibiting the tumor growth in the HepG-2 xenograft model without causing significant loss of animal body wt. in comparison with cisplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_P-MRBiNaU7Vg90H21EOLACvtfcHk0liIdLmL5vDjHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1yrsbfO&md5=a86ac2b4f6898e01dc0910d4112ddf03</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.6b00353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.6b00353%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DR.%26aulast%3DGou%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLiao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DCombretastatin%2520A-4%2520analogue%253A%2520A%2520dual-targeting%2520and%2520tubulin%2520inhibitor%2520containing%2520antitumor%2520Pt%2528IV%2529%2520moiety%2520with%2520a%2520unique%2520mode%2520of%2520action%26jtitle%3DBioconjugate%2520Chem.%26date%3D2016%26volume%3D27%26spage%3D2132%26epage%3D2148%26doi%3D10.1021%2Facs.bioconjchem.6b00353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Pt(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>156</i></span>,  <span class="NLM_fpage">666</span>– <span class="NLM_lpage">679</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.07.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejmech.2018.07.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=30031977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlOjs7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2018&pages=666-679&author=L.+Liauthor=X.+Huangauthor=R.+Huangauthor=S.+Gouauthor=Z.+Wangauthor=H.+Wang&title=Pt%28IV%29+prodrugs+containing+microtubule+inhibitors+displayed+potent+antitumor+activity+and+ability+to+overcome+cisplatin+resistance&doi=10.1016%2Fj.ejmech.2018.07.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Pt(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance</span></div><div class="casAuthors">Li, Lingxue; Huang, Xiaochao; Huang, Rizhen; Gou, Shaohua; Wang, Zhimei; Wang, Hengshan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">666-679</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">It is well-known that cisplatin exhibited a broad spectrum of anticancer activities against many solid tumors, but its severe toxicity and drug resistance have largely limited wider clin. applications.  Various strategies have been tried to discover new Pt (II) drugs with at least equal activity as well as low toxicity compared to cisplatin, but the inherent problem remains unsolved.  Here the authors report that Pt (IV) complexes comprising a CA-4 analog, as dual-targeting Pt (IV) prodrug, were synthesized and evaluated for anti-proliferative activity using MTT assay.  Among them, complex 19 displayed most potent activity against the tested cancer cell lines, and simultaneously exhibited better cell selectivity between cancer cells and normal cells than that of cisplatin.  Mechanism studies revealed that complex 19 effectively induced cell cycle arrest at the G2/M phase and dramatically disrupted the microtubule organization.  Moreover, complex 19 significantly induced cell apoptosis and decreased MMP.  Importantly, complex 19 significantly inhibited tumor growth in SK-OV-3 xenograft model in vivo without apparent toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiwKqAE7zEeLVg90H21EOLACvtfcHk0liIdLmL5vDjHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlOjs7zO&md5=54d9c42a743b4b43548876874a932561</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.07.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.07.016%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DR.%26aulast%3DGou%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DPt%2528IV%2529%2520prodrugs%2520containing%2520microtubule%2520inhibitors%2520displayed%2520potent%2520antitumor%2520activity%2520and%2520ability%2520to%2520overcome%2520cisplatin%2520resistance%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D156%26spage%3D666%26epage%3D679%26doi%3D10.1016%2Fj.ejmech.2018.07.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Dual-targeting antitumor conjugates derived from platinum(IV) prodrugs and microtubule inhibitor CA-4 significantly exhibited potent ability to overcome cisplatin resistance</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">103236</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2019.103236</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.bioorg.2019.103236" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=31494328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslCgs7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2019&pages=103236&author=X.+Huangauthor=M.+Wangauthor=C.+Wangauthor=W.+Huauthor=Q.+Youauthor=Y.+Yangauthor=C.+Yuauthor=Z.+Liaoauthor=S.+Gouauthor=H.+Wang&title=Dual-targeting+antitumor+conjugates+derived+from+platinum%28IV%29+prodrugs+and+microtubule+inhibitor+CA-4+significantly+exhibited+potent+ability+to+overcome+cisplatin+resistance&doi=10.1016%2Fj.bioorg.2019.103236"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-targeting antitumor conjugates derived from platinum(IV) prodrugs and microtubule inhibitor CA-4 significantly exhibited potent ability to overcome cisplatin resistance</span></div><div class="casAuthors">Huang, Xiaochao; Wang, Meng; Wang, Chungu; Hu, Weiwei; You, Qinghong; Yang, Yong; Yu, Chunhao; Liao, Zhixin; Gou, Shaohua; Wang, Hengshan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103236</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Here the authors report that three Pt(IV) prodrugs contg. a tubulin inhibitor CA-4, as dual-targeting Pt(IV) prodrug, were synthesized and evaluated for antitumor activity using MTT assay.  Among them, complex 9 exhibited the most potent antitumor activity against the tested cancer lines including cisplatin resistance cancer cells, and simultaneously displayed lower toxicity compared to cisplatin, resp.  Also, complex 9, in which was conjugated to an inhibitor of tubulin at one axial position of Pt(IV) complex, could effectively enter the cancer cells, and significantly induce cell apoptosis and arrest the cell cycle in A549 cells at G2/M stage, and dramatically disrupt the microtubule organization.  Mechanism studies suggested that complex 9 significantly induced reactive O species (ROS) generation and decreased mitochondrial trans-membrane potential (MMP) in A549 cells, and effectively induced activation of caspases triggering apoptotic signaling through mitochondrial dependent apoptosis pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUECytRFUAr7Vg90H21EOLACvtfcHk0lhQ3tUcIZChfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslCgs7bI&md5=857d08372ab2cbb1998e81609d60abc2</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2019.103236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2019.103236%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DYou%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DLiao%26aufirst%3DZ.%26aulast%3DGou%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DDual-targeting%2520antitumor%2520conjugates%2520derived%2520from%2520platinum%2528IV%2529%2520prodrugs%2520and%2520microtubule%2520inhibitor%2520CA-4%2520significantly%2520exhibited%2520potent%2520ability%2520to%2520overcome%2520cisplatin%2520resistance%26jtitle%3DBioorg.%2520Chem.%26date%3D2019%26volume%3D92%26spage%3D103236%26doi%3D10.1016%2Fj.bioorg.2019.103236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Dual-targeting antitumor hybrids derived from Pt(IV) species and millepachine analogues</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.02.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejmech.2018.02.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=29448138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCmtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2018&pages=1-25&author=X.+Huangauthor=S.+Huaauthor=R.+Huangauthor=Z.+Liuauthor=S.+Gouauthor=Z.+Wangauthor=Z.+Liaoauthor=H.+Wang&title=Dual-targeting+antitumor+hybrids+derived+from+Pt%28IV%29+species+and+millepachine+analogues&doi=10.1016%2Fj.ejmech.2018.02.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-targeting antitumor hybrids derived from Pt(IV) species and millepachine analogues</span></div><div class="casAuthors">Huang, Xiaochao; Hua, Shixian; Huang, Rizhen; Liu, Zhikun; Gou, Shaohua; Wang, Zhimei; Liao, Zhixin; Wang, Hengshan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-25</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Many strategies have been developed to circumvent the shortcomings of Pt(II)-based chemotherapy, but the inherent problems still have not been effectively resolved.  Here the authors report a new series of dual-targeting Pt(IV) prodrugs, conjugates of millepachine analogs with the related Pt(IV) complexes derived from cisplatin or oxaliplatin, resp., which can inhibit tubulin polymn. and induce DNA damage.  Among them, compd. 19 possessed excellent antitumor activities against the tested human cancer cell lines, and arrested the cell cycle at the G2/M phases and ultimately induced cell apoptosis.  Interestingly, its low cytotoxicity toward two human normal cells and sensitivity toward two cisplatin-resistant cells revealed the possibility for cancer therapy.  More importantly, 19 displayed excellent antitumor efficacy in the SK-OV-3 xenograft model better than cisplatin and the corresponding millepachine analog.  The authors' research provided an efficient strategy for multi-targeting antitumor drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn0CG0sCrShrVg90H21EOLACvtfcHk0lhQ3tUcIZChfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCmtLs%253D&md5=1f33af82177105468fd71e61ec9fabf4</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.02.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.02.012%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DHua%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DGou%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLiao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DDual-targeting%2520antitumor%2520hybrids%2520derived%2520from%2520Pt%2528IV%2529%2520species%2520and%2520millepachine%2520analogues%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D148%26spage%3D1%26epage%3D25%26doi%3D10.1016%2Fj.ejmech.2018.02.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Pt(IV) complexes conjugating with chalcone analogue as inhibitors of microtubule polymerization exhibited selective inhibition in human cancer cells</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">435</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.01.075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejmech.2018.01.075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=29407969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Wrs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2018&pages=435-450&author=X.+Huangauthor=R.+Huangauthor=Z.+Wangauthor=L.+Liauthor=S.+Gouauthor=Z.+Liaoauthor=H.+Wang&title=Pt%28IV%29+complexes+conjugating+with+chalcone+analogue+as+inhibitors+of+microtubule+polymerization+exhibited+selective+inhibition+in+human+cancer+cells&doi=10.1016%2Fj.ejmech.2018.01.075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Pt(IV) complexes conjugating with chalcone analogue as inhibitors of microtubule polymerization exhibited selective inhibition in human cancer cells</span></div><div class="casAuthors">Huang, Xiaochao; Huang, Rizhen; Wang, Zhimei; Li, Lingxue; Gou, Shaohua; Liao, Zhixin; Wang, Hengshan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">435-450</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Six novel of Pt(IV) complexes comprising chalcone analogs were synthesized and evaluated for anti-proliferative activity using MTT assay.  In vitro evaluation revealed that all Pt(IV) complexes showed better and more potent activity against three human cancer cells including CDDP resistant cells than that of their corresponding mother Pt(II) species.  Among them, two representative complexes, 14 (I) and 17 (II), exhibited better cell selectivity between cancer cells and normal cells than CDDP.  Mol. docking study indicated that complexes 14 and 17 could bind to the colchicine site of tubulin.  Moreover, complexes 14 and 17 also remarkably displayed inhibition of cell migration against HUVEC cells in vitro.  Mol. mechanism studies suggested that 14 and 17 induced prodn. of reactive oxygen species (ROS), cell cycle arrest at the G2/M phase, and mitochondria-mediated apoptosis by regulating the expression of Bcl-2 family members.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqppgv9QQ1HdrVg90H21EOLACvtfcHk0lhXn3cXJr64yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Wrs74%253D&md5=acb303482c16a94ff0f0926544e8c61d</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.01.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.01.075%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DGou%26aufirst%3DS.%26aulast%3DLiao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DPt%2528IV%2529%2520complexes%2520conjugating%2520with%2520chalcone%2520analogue%2520as%2520inhibitors%2520of%2520microtubule%2520polymerization%2520exhibited%2520selective%2520inhibition%2520in%2520human%2520cancer%2520cells%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D146%26spage%3D435%26epage%3D450%26doi%3D10.1016%2Fj.ejmech.2018.01.075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. C.</span></span> <span> </span><span class="NLM_article-title">Cellular roles of DNA topoisomerases: a molecular perspective</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">430</span>– <span class="NLM_lpage">440</span>, <span class="refDoi"> DOI: 10.1038/nrm831</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1038%2Fnrm831" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=12042765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD38XltlartLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=430-440&author=J.+C.+Wang&title=Cellular+roles+of+DNA+topoisomerases%3A+a+molecular+perspective&doi=10.1038%2Fnrm831"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular roles of DNA topoisomerases: a molecular perspective</span></div><div class="casAuthors">Wang, James C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">430-440</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  DNA topoisomerases are the magicians of the DNA world , by allowing DNA strands or double helixes to pass through each other, they can solve all of the topol. problems of DNA in replication, transcription and other cellular transactions.  Extensive biochem. and structural studies over the past three decades have provided mol. models of how the various subfamilies of DNA topoisomerase manipulate DNA.  In this review, the cellular roles of these enzymes are examd. from a mol. point of view.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1ptPGi1NWFLVg90H21EOLACvtfcHk0lhXn3cXJr64yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltlartLw%253D&md5=5b9641a6d78a019ebad9307c854a7f7e</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1038%2Fnrm831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm831%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%2BC.%26atitle%3DCellular%2520roles%2520of%2520DNA%2520topoisomerases%253A%2520a%2520molecular%2520perspective%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2002%26volume%3D3%26spage%3D430%26epage%3D440%26doi%3D10.1038%2Fnrm831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rudolf, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervinka, M.</span></span> <span> </span><span class="NLM_article-title">Topoisomerases and tubulin inhibitors: a promising combination for cancer treatment</span>. <i>Curr. Med. Chem.: Anti-Cancer Agents</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">421</span>– <span class="NLM_lpage">429</span>, <span class="refDoi"> DOI: 10.2174/1568011033482242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.2174%2F1568011033482242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=14529450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotFOns7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=421-429&author=E.+Rudolfauthor=M.+Cervinka&title=Topoisomerases+and+tubulin+inhibitors%3A+a+promising+combination+for+cancer+treatment&doi=10.2174%2F1568011033482242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Topoisomerases and tubulin inhibitors: A promising combination for cancer treatment</span></div><div class="casAuthors">Rudolf, E.; Cervinka, M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry: Anti-Cancer Agents</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">421-429</span>CODEN:
                <span class="NLM_cas:coden">CMCACI</span>;
        ISSN:<span class="NLM_cas:issn">1568-0118</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Modern approaches to treatment of cancer seek to activate the internal suicide program in the malignant cells, and thereby effectively eliminate them without engaging most of other bodily systems.  Many currently used cytostatics are known to induce apoptosis and efforts are being paid to develop new ones with better and more effective proapoptotic potential.  Nevertheless, despite recent developments in this field, there are still numerous malignancies showing a varying degree of resistance to cell death due to the corrupted signaling pathways and genetic alterations, often in conjunction with expansive proliferation rate.  It has been shown that topoisomerase inhibiting agents such as etoposide, camptothecin and others represent a powerful and dynamic group of cytostatic chems. used in exptl. and clin. conditions.  So, it is a group of microtubule targeting poisons comprising classical colchicines on the one hand and new taxanes on the other hand.  Since several members of both groups have been evidenced as apoptosis inducers operating via distinct mechanism, their combination should theor. enhance the final therapeutic outcome.  This minireview focuses on the possibilities of such a combinational approach with respect to possible benefits and hazards of this strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJiCqrOtqGHLVg90H21EOLACvtfcHk0lhXn3cXJr64yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotFOns7s%253D&md5=2ecc33565f5b54921de17a2fac21e916</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.2174%2F1568011033482242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568011033482242%26sid%3Dliteratum%253Aachs%26aulast%3DRudolf%26aufirst%3DE.%26aulast%3DCervinka%26aufirst%3DM.%26atitle%3DTopoisomerases%2520and%2520tubulin%2520inhibitors%253A%2520a%2520promising%2520combination%2520for%2520cancer%2520treatment%26jtitle%3DCurr.%2520Med.%2520Chem.%253A%2520Anti-Cancer%2520Agents%26date%3D2003%26volume%3D3%26spage%3D421%26epage%3D429%26doi%3D10.2174%2F1568011033482242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathi, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathi, M. K.</span></span> <span> </span><span class="NLM_article-title">Mechanisms regulating resistance to inhibitors of topoisomerase II</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">89</span>, <span class="refDoi"> DOI: 10.3389/fphar.2013.00089</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.3389%2Ffphar.2013.00089" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=23914174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A280%3ADC%252BC3sfmslWqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=89&author=R.+N.+Ganapathiauthor=M.+K.+Ganapathi&title=Mechanisms+regulating+resistance+to+inhibitors+of+topoisomerase+II&doi=10.3389%2Ffphar.2013.00089"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms regulating resistance to inhibitors of topoisomerase II</span></div><div class="casAuthors">Ganapathi Ram N; Ganapathi Mahrukh K</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">89</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">Inhibitors of topoisomerase II (topo II) are clinically effective in the management of hematological malignancies and solid tumors.  The efficacy of anti-tumor drugs targeting topo II is often limited by resistance and studies with in vitro cell culture models have provided several insights on potential mechanisms.  Multidrug transporters that are involved in the efflux and consequently reduced cytotoxicity of diverse anti-tumor agents suggest that they play an important role in resistance to clinically active drugs.  However, in clinical trials, modulating the multidrug-resistant phenotype with agents that inhibit the efflux pump has not had an impact.  Since reduced drug accumulation per se is insufficient to explain tumor cell resistance to topo II inhibitors several studies have focused on characterizing mechanisms that impact on DNA damage mediated by drugs that target the enzyme.  Mammalian topo IIα and topo IIβ isozymes exhibit similar catalytic, but different biologic, activities.  Whereas topo IIα is associated with cell division, topo IIβ is involved in differentiation.  In addition to site specific mutations that can affect drug-induced topo II-mediated DNA damage, post-translation modification of topo II primarily by phosphorylation can potentially affect enzyme-mediated DNA damage and the downstream cytotoxic response of drugs targeting topo II.  Signaling pathways that can affect phosphorylation and changes in intracellular calcium levels/calcium dependent signaling that can regulate site-specific phosphorylation of topoisomerase have an impact on downstream cytotoxic effects of topo II inhibitors.  Overall, tumor cell resistance to inhibitors of topo II is a complex process that is orchestrated not only by cellular pharmacokinetics but more importantly by enzymatic alterations that govern the intrinsic drug sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR-P0PWb68VA8ScOqQTSkOffW6udTcc2eYf7x-PXr0aibntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sfmslWqtQ%253D%253D&md5=7828c568fa64b072dd47e8dee2ce767c</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2013.00089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2013.00089%26sid%3Dliteratum%253Aachs%26aulast%3DGanapathi%26aufirst%3DR.%2BN.%26aulast%3DGanapathi%26aufirst%3DM.%2BK.%26atitle%3DMechanisms%2520regulating%2520resistance%2520to%2520inhibitors%2520of%2520topoisomerase%2520II%26jtitle%3DFront.%2520Pharmacol.%26date%3D2013%26volume%3D4%26spage%3D89%26doi%3D10.3389%2Ffphar.2013.00089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perez, E. A.</span></span> <span> </span><span class="NLM_article-title">Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2086</span>– <span class="NLM_lpage">2095</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1158%2F1535-7163.MCT-09-0366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=19671735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpvFCnurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=2086-2095&author=E.+A.+Perez&title=Microtubule+inhibitors%3A+Differentiating+tubulin-inhibiting+agents+based+on+mechanisms+of+action%2C+clinical+activity%2C+and+resistance&doi=10.1158%2F1535-7163.MCT-09-0366"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance</span></div><div class="casAuthors">Perez, Edith A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2086-2095</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Microtubules are important cellular targets for anticancer therapy because of their key role in mitosis.  Microtubule inhibitors (MTI) such as taxanes, vinca alkaloids, and epothilones stabilize or destabilize microtubules, thereby suppressing microtubule dynamics required for proper mitotic function, effectively blocking cell cycle progression and resulting in apoptosis.  In spite of their antitumor activity, innate or acquired drug resistance to MTIs such as the taxanes is common, limiting their overall clin. efficacy.  Further insight into the mechanisms of action of microtubule-targeting drugs has lead to the discovery of novel agents that may provide higher efficacy with limited toxicity and help overcome resistance to conventional MTIs.  This review will focus on the different mechanisms of action of MTIs, potential factors related to resistance and tolerability, and will discuss the recent approval as well as the development of new antineoplastic agents. [Mol Cancer Ther 2009;8(8):2086-95].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1HM8JP4QG8LVg90H21EOLACvtfcHk0lhCXRbmrELvKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpvFCnurw%253D&md5=1d8dec9ed6c0f061032cec57c96c833e</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0366%26sid%3Dliteratum%253Aachs%26aulast%3DPerez%26aufirst%3DE.%2BA.%26atitle%3DMicrotubule%2520inhibitors%253A%2520Differentiating%2520tubulin-inhibiting%2520agents%2520based%2520on%2520mechanisms%2520of%2520action%252C%2520clinical%2520activity%252C%2520and%2520resistance%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D2086%26epage%3D2095%26doi%3D10.1158%2F1535-7163.MCT-09-0366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diéras, V.</span></span> <span> </span><span class="NLM_article-title">Review of docetaxel/doxorubicin combination in metastatic breast cancer</span>. <i>Oncology (Williston Park)</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">33</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=9364539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A280%3ADyaK1c%252FjtFWhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1997&pages=31-33&author=V.+Di%C3%A9ras&title=Review+of+docetaxel%2Fdoxorubicin+combination+in+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Review of docetaxel/doxorubicin combination in metastatic breast cancer</span></div><div class="casAuthors">Dieras V</div><div class="citationInfo"><span class="NLM_cas:title">Oncology (Williston Park, N.Y.)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8 Suppl 8</span>),
    <span class="NLM_cas:pages">31-3</span>
        ISSN:<span class="NLM_cas:issn">0890-9091</span>.
    </div><div class="casAbstract">Docetaxel (Taxotere) and doxorubicin (Adriamycin) have each demonstrated significant activity in metastatic breast cancer.  Thus, the combination of docetaxel and doxorubicin has been evaluated in phase I trials to establish the dose-limiting toxicity, maximum tolerated dose, recommended dose for future phase II and III studies, and toxicity profile of the two agents used in combination.  Results from phase I trials in patients with metastatic breast cancer indicate that the docetaxel/doxorubicin combination is well tolerated.  The recommended dose for the combination regimen is either 50 mg/m2 of doxorubicin followed by 75 mg/m2 of docetaxel or 60 mg/m2 of both drugs, without granulocyte colony-stimulating factor (G-CSF) support.  Febrile neutropenia complicated by grade 3 infection was the dose-limiting effect at the maximum tolerated dose.  The response rate at this dose level was 90%.  Based on the preliminary results of phase I studies, further phase II and III studies of a docetaxel/doxorubicin combination regimen are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRugEZYQeiChWGmni0r9GoKfW6udTcc2eYf7x-PXr0aibntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c%252FjtFWhsA%253D%253D&md5=d352b42637b90485d1e996c70fc833e6</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDi%25C3%25A9ras%26aufirst%3DV.%26atitle%3DReview%2520of%2520docetaxel%252Fdoxorubicin%2520combination%2520in%2520metastatic%2520breast%2520cancer%26jtitle%3DOncology%2520%2528Williston%2520Park%2529%26date%3D1997%26volume%3D11%26spage%3D31%26epage%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hao, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, L.</span></span> <span> </span><span class="NLM_article-title">Novel conjugates of podophyllotoxin and coumarin: synthesis, cytotoxicities, cell cycle arrest, binding CT DNA and inhibition of Topo IIβ</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">2129</span>– <span class="NLM_lpage">2135</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.06.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.bmcl.2019.06.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=31278032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlejs77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=2129-2135&author=S.+Y.+Haoauthor=S.+L.+Fengauthor=X.+R.+Wangauthor=Z.+Wangauthor=S.+W.+Chenauthor=L.+Hui&title=Novel+conjugates+of+podophyllotoxin+and+coumarin%3A+synthesis%2C+cytotoxicities%2C+cell+cycle+arrest%2C+binding+CT+DNA+and+inhibition+of+Topo+II%CE%B2&doi=10.1016%2Fj.bmcl.2019.06.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Novel conjugates of podophyllotoxin and coumarin: Synthesis, cytotoxicities, cell cycle arrest, binding CT DNA and inhibition of Topo IIβ</span></div><div class="casAuthors">Hao, Shu-Yi; Feng, Shi-Liang; Wang, Xing-Rong; Wang, Zhichao; Chen, Shi-Wu; Hui, Ling</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2129-2135</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of conjugates of podophyllotoxin and coumarin, I (X = O, NH, R1 = H, Me, Br, OMe, R2 = H, Br, OMe), were prepd. using the click reaction, and their cytotoxicities against A549, HepG2, HeLa, and LoVo cells were evaluated.  Among them, compd. I (X = NH, R1 = OMe, R2 = H) (II) exhibited the strongest cytotoxicities against these cancer cells with IC50 values of 4.9-17.5 μM.  Furthermore, II disrupted microtubules and induced cell cycle arrest at G1 phase by regulating P21 and Cyclin D1 in LoVo cells.  In addn., II bound CT DNA and selectively inhibited Topo IIβ over Topo IIα.  Mol. docking model showed that II appeared to form stable hydrogen bonds with several DNA bases and residue Gln778.  Taken together, these conjugates have the potential to be developed as anti-tumor drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-st5yLtlaqrVg90H21EOLACvtfcHk0ljtAr-jc6lybw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlejs77N&md5=5e9deabb0c6d9ad91c5ec1e9eedde56c</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.06.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.06.063%26sid%3Dliteratum%253Aachs%26aulast%3DHao%26aufirst%3DS.%2BY.%26aulast%3DFeng%26aufirst%3DS.%2BL.%26aulast%3DWang%26aufirst%3DX.%2BR.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DS.%2BW.%26aulast%3DHui%26aufirst%3DL.%26atitle%3DNovel%2520conjugates%2520of%2520podophyllotoxin%2520and%2520coumarin%253A%2520synthesis%252C%2520cytotoxicities%252C%2520cell%2520cycle%2520arrest%252C%2520binding%2520CT%2520DNA%2520and%2520inhibition%2520of%2520Topo%2520II%25CE%25B2%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D2129%26epage%3D2135%26doi%3D10.1016%2Fj.bmcl.2019.06.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hernández, A.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Díez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Andrés, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jambrina, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Díez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuentes, M.</span></span> <span> </span><span class="NLM_article-title">A novel cytotoxic conjugate derived from the natural product podophyllotoxin as a direct-target protein dual inhibitor</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">4258</span>, <span class="refDoi"> DOI: 10.3390/molecules25184258</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.3390%2Fmolecules25184258" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2020&pages=4258&author=A.-P.+Hern%C3%A1ndezauthor=P.+D%C3%ADezauthor=P.+A.+Garc%C3%ADaauthor=M.+P%C3%A9rez-Andr%C3%A9sauthor=P.+Ortegaauthor=P.+G.+Jambrinaauthor=D.+D%C3%ADezauthor=M.+Castroauthor=M.+Fuentes&title=A+novel+cytotoxic+conjugate+derived+from+the+natural+product+podophyllotoxin+as+a+direct-target+protein+dual+inhibitor&doi=10.3390%2Fmolecules25184258"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.3390%2Fmolecules25184258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules25184258%26sid%3Dliteratum%253Aachs%26aulast%3DHern%25C3%25A1ndez%26aufirst%3DA.-P.%26aulast%3DD%25C3%25ADez%26aufirst%3DP.%26aulast%3DGarc%25C3%25ADa%26aufirst%3DP.%2BA.%26aulast%3DP%25C3%25A9rez-Andr%25C3%25A9s%26aufirst%3DM.%26aulast%3DOrtega%26aufirst%3DP.%26aulast%3DJambrina%26aufirst%3DP.%2BG.%26aulast%3DD%25C3%25ADez%26aufirst%3DD.%26aulast%3DCastro%26aufirst%3DM.%26aulast%3DFuentes%26aufirst%3DM.%26atitle%3DA%2520novel%2520cytotoxic%2520conjugate%2520derived%2520from%2520the%2520natural%2520product%2520podophyllotoxin%2520as%2520a%2520direct-target%2520protein%2520dual%2520inhibitor%26jtitle%3DMolecules%26date%3D2020%26volume%3D25%26spage%3D4258%26doi%3D10.3390%2Fmolecules25184258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yi, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huan, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Q. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z. H.</span></span> <span> </span><span class="NLM_article-title">Dual targeting of microtubule and topoisomerase II by α-carboline derivative YCH337 for tumor proliferation and growth inhibition</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">8960</span>– <span class="NLM_lpage">8973</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.3264</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.18632%2Foncotarget.3264" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=25840421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjgs1Oltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=8960-8973&author=J.+M.+Yiauthor=X.+F.+Zhangauthor=X.+J.+Huanauthor=S.+S.+Songauthor=W.+Wangauthor=Q.+T.+Tianauthor=Y.+M.+Sunauthor=Y.+Chenauthor=J.+Dingauthor=Y.+Q.+Wangauthor=C.+H.+Yangauthor=Z.+H.+Miao&title=Dual+targeting+of+microtubule+and+topoisomerase+II+by+%CE%B1-carboline+derivative+YCH337+for+tumor+proliferation+and+growth+inhibition&doi=10.18632%2Foncotarget.3264"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Dual targeting of microtubule and topoisomerase II by α-carboline derivative YCH337 for tumor proliferation and growth inhibition</span></div><div class="casAuthors">Yi Jun-Mei; Huan Xia-Juan; Song Shan-Shan; Wang Wei; Tian Qian-Ting; Sun Yi-Ming; Chen Yi; Ding Jian; Wang Ying-Qing; Miao Ze-Hong; Zhang Xiao-Fei; Yang Chun-Hao</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">8960-73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Both microtubule and topoisomerase II (Top2) are important anticancer targets and their respective inhibitors are widely used in combination for cancer therapy.  However, some combinations could be mutually antagonistic and drug resistance further limits their therapeutic efficacy.  Here we report YCH337, a novel α-carboline derivative that targets both microtubule and Top2, eliciting tumor proliferation and growth inhibition and overcoming drug resistance.  YCH337 inhibited microtubule polymerization by binding to the colchicine site and subsequently led to mitotic arrest.  It also suppressed Top2 and caused DNA double-strand breaks.  It disrupted microtubule more potently than Top2.  YCH337 induced reversible mitotic arrest at low concentrations but persistent DNA damage.  YCH337 caused intrinsic and extrinsic apoptosis and decreased MCL-1, cIAP1 and XIAP proteins.  In this aspect, YCH337 behaved differently from the combination of vincristine and etoposide.  YCH337 inhibited proliferation of tumor cells with an averaged IC50 of 0.3 μM.  It significantly suppressed the growth of HT-29 xenografts in nude mice too.  Importantly, YCH337 nearly equally killed different-mechanism-mediated resistant tumor cells and corresponding parent cells.  Together with the novelty of its chemical structure, YCH337 could serve as a promising lead for drug development and a prototype for a dual microtubule/Top2 targeting strategy for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSG7_gaQunNwoJKJbLTgsvCfW6udTcc2eZIe1wXPV5BdLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjgs1Oltw%253D%253D&md5=bd05960113eda9a65fa6626a8277ca20</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.3264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.3264%26sid%3Dliteratum%253Aachs%26aulast%3DYi%26aufirst%3DJ.%2BM.%26aulast%3DZhang%26aufirst%3DX.%2BF.%26aulast%3DHuan%26aufirst%3DX.%2BJ.%26aulast%3DSong%26aufirst%3DS.%2BS.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DTian%26aufirst%3DQ.%2BT.%26aulast%3DSun%26aufirst%3DY.%2BM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%2BQ.%26aulast%3DYang%26aufirst%3DC.%2BH.%26aulast%3DMiao%26aufirst%3DZ.%2BH.%26atitle%3DDual%2520targeting%2520of%2520microtubule%2520and%2520topoisomerase%2520II%2520by%2520%25CE%25B1-carboline%2520derivative%2520YCH337%2520for%2520tumor%2520proliferation%2520and%2520growth%2520inhibition%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D8960%26epage%3D8973%26doi%3D10.18632%2Foncotarget.3264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Podolski-Renić, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banković, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinić, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ríos-Luci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovačević-Grujičić, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martín, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padrón, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pešić, M.</span></span> <span> </span><span class="NLM_article-title">DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">168</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2017.05.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejps.2017.05.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=28502672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotVCmtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2017&pages=159-168&author=A.+Podolski-Reni%C4%87author=J.+Bankovi%C4%87author=J.+Dini%C4%87author=C.+R%C3%ADos-Luciauthor=M.+X.+Fernandesauthor=N.+Ortegaauthor=N.+Kova%C4%8Devi%C4%87-Gruji%C4%8Di%C4%87author=V.+S.+Mart%C3%ADnauthor=J.+M.+Padr%C3%B3nauthor=M.+Pe%C5%A1i%C4%87&title=DTA0100%2C+dual+topoisomerase+II+and+microtubule+inhibitor%2C+evades+paclitaxel+resistance+in+P-glycoprotein+overexpressing+cancer+cells&doi=10.1016%2Fj.ejps.2017.05.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells</span></div><div class="casAuthors">Podolski-Renic, Ana; Bankovic, Jasna; Dinic, Jelena; Rios-Luci, Carla; Fernandes, Miguel X.; Ortega, Nuria; Kovacevic-Grujicic, Natasa; Martin, Victor S.; Padron, Jose M.; Pesic, Milica</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">159-168</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The efficacy of microtubule targeting agents in cancer treatment has been compromised by the development of drug resistance that may involve both, P-glycoprotein overexpression and the changes in β-tubulin isoforms' expression.  The anti-Topoisomerase II activity of Me 4-((E)-2-(methoxycarbonyl)vinyloxy)oct-2-ynoate (DTA0100) was recently reported.  Herein, we further evaluated this propargylic enol ether deriv. and found that it exerts inhibitory effect on tubulin polymn. by binding to colchicine binding site.  DTA0100 mitotic arrest properties were investigated in two multi-drug resistant cancer cell lines with P-glycoprotein overexpression (colorectal carcinoma and glioblastoma).  The sensitivity of multi-drug resistant cancer cell lines to DTA0100 was not significantly changed in contrast to microtubule targeting agents such as paclitaxel, vinblastine and colchicine.  DTA0100 clearly induced microtubule depolymn., leading to disturbance of cell cycle kinetics and subsequent apoptosis.  The fine-tuning in β-tubulin isoforms expression obsd. in multi-drug resistant cancer cells may influence the efficacy of DTA0100.  Importantly, DTA0100 blocked the P-glycoprotein function in both multi-drug resistant cancer cell lines without inducing the increase in P-glycoprotein expression.  Therefore, DTA0100 acting as dual inhibitor of Topoisomerase II and microtubule formation could be considered as multi-potent anticancer agent.  Besides, it is able to overcome the problem of drug resistance that emerges in the therapeutic approaches with either Topoisomerase II or microtubule targeting agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3Yr0A5xxeibVg90H21EOLACvtfcHk0lgkPM2Lc6I2Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotVCmtr4%253D&md5=415d67d933dd9d2933cb3b4f5dd37b45</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2017.05.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2017.05.011%26sid%3Dliteratum%253Aachs%26aulast%3DPodolski-Reni%25C4%2587%26aufirst%3DA.%26aulast%3DBankovi%25C4%2587%26aufirst%3DJ.%26aulast%3DDini%25C4%2587%26aufirst%3DJ.%26aulast%3DR%25C3%25ADos-Luci%26aufirst%3DC.%26aulast%3DFernandes%26aufirst%3DM.%2BX.%26aulast%3DOrtega%26aufirst%3DN.%26aulast%3DKova%25C4%258Devi%25C4%2587-Gruji%25C4%258Di%25C4%2587%26aufirst%3DN.%26aulast%3DMart%25C3%25ADn%26aufirst%3DV.%2BS.%26aulast%3DPadr%25C3%25B3n%26aufirst%3DJ.%2BM.%26aulast%3DPe%25C5%25A1i%25C4%2587%26aufirst%3DM.%26atitle%3DDTA0100%252C%2520dual%2520topoisomerase%2520II%2520and%2520microtubule%2520inhibitor%252C%2520evades%2520paclitaxel%2520resistance%2520in%2520P-glycoprotein%2520overexpressing%2520cancer%2520cells%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2017%26volume%3D105%26spage%3D159%26epage%3D168%26doi%3D10.1016%2Fj.ejps.2017.05.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verma, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fatima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudi, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabassum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luqman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mondhe, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negi, A. S.</span></span> <span> </span><span class="NLM_article-title">Antiproliferative activity of diarylnaphthylpyrrolidine derivative via dual target inhibition</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>188</i></span>,  <span class="NLM_fpage">111986</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111986</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejmech.2019.111986" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=31884407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFOltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=2020&pages=111986&author=A.+K.+Vermaauthor=K.+Fatimaauthor=R.+K.+Dudiauthor=M.+Tabassumauthor=H.+Iqbalauthor=Y.+Kumarauthor=S.+Luqmanauthor=D.+M.+Mondheauthor=D.+Chandaauthor=F.+Khanauthor=K.+Shankerauthor=A.+S.+Negi&title=Antiproliferative+activity+of+diarylnaphthylpyrrolidine+derivative+via+dual+target+inhibition&doi=10.1016%2Fj.ejmech.2019.111986"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Antiproliferative activity of diarylnaphthylpyrrolidine derivative via dual target inhibition</span></div><div class="casAuthors">Verma, Amit Kumar; Fatima, Kaneez; Dudi, Rajesh Kumar; Tabassum, Misbah; Iqbal, Hina; Kumar, Yogesh; Luqman, Suaib; Mondhe, D. M.; Chanda, Debabrata; Khan, Feroz; Shanker, Karuna; Negi, Arvind S.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">188</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111986</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Breast cancer is the second leading cause of deaths in women globally.  Present communication deals with design and synthesis of a few diarylnaphthyls as possible anti-breast cancer agents.  Among the thirteen thirty three representatives with significant antiproliferative activity compds. 23 and 50 were quite efficacious against human breast cancer cells.  Compd. 50 induced apoptosis in both MCF-7 and MDA-MB-231 cells and exerted S phase and G2/M phase arrest resp. via distinct mechanistic pathways.  It showed moderate microtubule destabilization.  Further, it exhibited DNA topoisomerase-II inhibition effect in MCF-7 cells.  It was well tolerable and found safe up to 300 mg/kg dose in Swiss albino mice.  The dual action antiproliferative effect of compd. 50 is quite interesting and warrants for future development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAodPaPs01bLVg90H21EOLACvtfcHk0lgkPM2Lc6I2Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFOltw%253D%253D&md5=5476a0e2326bf6dad0850d898406fb35</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111986&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111986%26sid%3Dliteratum%253Aachs%26aulast%3DVerma%26aufirst%3DA.%2BK.%26aulast%3DFatima%26aufirst%3DK.%26aulast%3DDudi%26aufirst%3DR.%2BK.%26aulast%3DTabassum%26aufirst%3DM.%26aulast%3DIqbal%26aufirst%3DH.%26aulast%3DKumar%26aufirst%3DY.%26aulast%3DLuqman%26aufirst%3DS.%26aulast%3DMondhe%26aufirst%3DD.%2BM.%26aulast%3DChanda%26aufirst%3DD.%26aulast%3DKhan%26aufirst%3DF.%26aulast%3DShanker%26aufirst%3DK.%26aulast%3DNegi%26aufirst%3DA.%2BS.%26atitle%3DAntiproliferative%2520activity%2520of%2520diarylnaphthylpyrrolidine%2520derivative%2520via%2520dual%2520target%2520inhibition%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D188%26spage%3D111986%26doi%3D10.1016%2Fj.ejmech.2019.111986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Scaffold diversity inspired by the natural product evodiamine: Discovery of highly potent and multitargeting antitumor agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6678</span>– <span class="NLM_lpage">6696</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00910</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00910" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Gms7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6678-6696&author=S.+Wangauthor=K.+Fangauthor=G.+Dongauthor=S.+Chenauthor=N.+Liuauthor=Z.+Miaoauthor=J.+Yaoauthor=J.+Liauthor=W.+Zhangauthor=C.+Sheng&title=Scaffold+diversity+inspired+by+the+natural+product+evodiamine%3A+Discovery+of+highly+potent+and+multitargeting+antitumor+agents&doi=10.1021%2Facs.jmedchem.5b00910"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Scaffold diversity inspired by the natural product evodiamine: discovery of highly potent and multitargeting antitumor agents</span></div><div class="casAuthors">Wang, Shengzheng; Fang, Kun; Dong, Guoqiang; Chen, Shuqiang; Liu, Na; Miao, Zhenyuan; Yao, Jianzhong; Li, Jian; Zhang, Wannian; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6678-6696</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A crit. question in natural product-based drug discovery is how to translate the product into drug-like mols. with optimal pharmacol. properties.  The generation of natural product-inspired scaffold diversity is an effective but challenging strategy to investigate the broader chem. space and identify promising drug leads.  Extending the efforts to the natural product evodiamine, a diverse library contg. 11 evodiamine-inspired novel scaffolds and their derivs. were designed and synthesized.  Most of them showed good to excellent antitumor activity against various human cancer cell lines.  In particular, 3-chloro-10-hydroxyl thio-evodiamine I showed excellent in vitro and in vivo antitumor efficacy with good tolerability and low toxicity.  Antitumor mechanism and target profiling studies indicate that compd. I is the first-in-class triple topoisomerase I/topoisomerase II/tubulin inhibitor.  Overall, this study provided an effective strategy for natural product-based drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFmWoZPbDbVrVg90H21EOLACvtfcHk0lhduJFNUjiyiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Gms7%252FO&md5=eac1cb75b532b53aada4cbc25c0de4bf</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00910%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DFang%26aufirst%3DK.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DYao%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DScaffold%2520diversity%2520inspired%2520by%2520the%2520natural%2520product%2520evodiamine%253A%2520Discovery%2520of%2520highly%2520potent%2520and%2520multitargeting%2520antitumor%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6678%26epage%3D6696%26doi%3D10.1021%2Facs.jmedchem.5b00910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Scaffold hopping of natural product evodiamine: Discovery of a novel antitumor scaffold with excellent potency against colon cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">696</span>– <span class="NLM_lpage">713</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01626</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01626" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3cXosFOi" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=696-713&author=L.+Wangauthor=K.+Fangauthor=J.+Chengauthor=Y.+Liauthor=Y.+Huangauthor=S.+Chenauthor=G.+Dongauthor=S.+Wuauthor=C.+Sheng&title=Scaffold+hopping+of+natural+product+evodiamine%3A+Discovery+of+a+novel+antitumor+scaffold+with+excellent+potency+against+colon+cancer&doi=10.1021%2Facs.jmedchem.9b01626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Scaffold Hopping of Natural Product Evodiamine: Discovery of a Novel Antitumor Scaffold with Excellent Potency against Colon Cancer</span></div><div class="casAuthors">Wang, Lei; Fang, Kun; Cheng, Junfei; Li, Yu; Huang, Yahui; Chen, Shuqiang; Dong, Guoqiang; Wu, Shanchao; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">696-713</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inspired by the natural product evodiamine, a novel antitumor indolopyrazinoquinazolinone scaffold was designed by scaffold hopping.  Structure-activity relationship studies led to the discovery of compd. 15j, which shows low nanomolar inhibitory activity against the HCT116 cell line.  Further antitumor mechanism studies indicated that compd. 15j acted by the dual inhibition of topoisomerase 1 and tubulin and induced apoptosis with G2 cell-cycle arrest.  The quaternary ammonium salt of compd. 15j (compd. 15js) exhibited excellent in vivo antitumor activity (TGI = 66.6%) in the HCT116 xenograft model with low toxicity.  Indolopyrazinoquinazolinone derivs. represent promising multitargeting antitumor leads for the development of novel antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdvRim1Ho107Vg90H21EOLACvtfcHk0lhduJFNUjiyiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXosFOi&md5=7d9556dcd1d5aaf92c7eccfcc09b862c</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01626%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DFang%26aufirst%3DK.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DScaffold%2520hopping%2520of%2520natural%2520product%2520evodiamine%253A%2520Discovery%2520of%2520a%2520novel%2520antitumor%2520scaffold%2520with%2520excellent%2520potency%2520against%2520colon%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D696%26epage%3D713%26doi%3D10.1021%2Facs.jmedchem.9b01626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ceramella, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caruso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Occhiuzzi, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacopetta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbarossa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzuti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallemagne, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rault, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kashef, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saturnino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grande, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinicropi, M. S.</span></span> <span> </span><span class="NLM_article-title">Benzothienoquinazolinones as new multi-target scaffolds: Dual inhibition of human Topoisomerase I and tubulin polymerization</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">111583</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejmech.2019.111583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=31400710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFGjt7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2019&pages=111583&author=J.+Ceramellaauthor=A.+Carusoauthor=M.+A.+Occhiuzziauthor=D.+Iacopettaauthor=A.+Barbarossaauthor=B.+Rizzutiauthor=P.+Dallemagneauthor=S.+Raultauthor=H.+El-Kashefauthor=C.+Saturninoauthor=F.+Grandeauthor=M.+S.+Sinicropi&title=Benzothienoquinazolinones+as+new+multi-target+scaffolds%3A+Dual+inhibition+of+human+Topoisomerase+I+and+tubulin+polymerization&doi=10.1016%2Fj.ejmech.2019.111583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Benzothienoquinazolinones as new multi-target scaffolds: Dual inhibition of human Topoisomerase I and tubulin polymerization</span></div><div class="casAuthors">Ceramella, Jessica; Caruso, Anna; Occhiuzzi, Maria Antonietta; Iacopetta, Domenico; Barbarossa, Alexia; Rizzuti, Bruno; Dallemagne, Patrick; Rault, Sylvain; El-Kashef, Hussein; Saturnino, Carmela; Grande, Fedora; Sinicropi, Maria Stefania</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111583pp.</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">3-(Alkyl(dialkyl)amino)benzothieno[2,3-f]quinazolin-1(2H)-ones I [R = H, Pr, n-pentyl; R1 = Pr, Bu, n-pentyl, cyclopentyl; RR1 = morpholin-1-yl] were designed using Ellipticine structure as a model, replacing the carbazole core and the pyridine ring with a dibenzothiophene and a pyrimidine moiety, resp.  New benzothienoquinazolinones I were synthesized by a simple one-pot reaction employing 3-aminodibenzothiophene as starting material.  The benzothienoquinazolinones obtained I were evaluated for their anticancer activity against two breast cancer cell lines, MDA-MB-231 and MCF-7.  The results revealed that compds. I [R = H, R1 = n-propyl; R = R1 = n-propyl] presented a good antitumor activity toward the triple neg. MDA-MB-231, without cytotoxicity against non-tumoral cells.  Furthermore, the compds. I [R = H, R1 = n-propyl; R = R1 = n-propyl] can be considered important mol. multi-target tools for their dual inhibition of different cellular proteins, i.e. tubulin and human topoisomerase I, involved in relevant cellular processes, as predicted by in-silico studies and demonstrated by in-vitro assays (for compd. I [R = H, R1 = n-propyl]).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRYyLuCUV5MLVg90H21EOLACvtfcHk0liMSMKXicJ1Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFGjt7zE&md5=d83067a2da6624e77f2d8174556eed70</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111583%26sid%3Dliteratum%253Aachs%26aulast%3DCeramella%26aufirst%3DJ.%26aulast%3DCaruso%26aufirst%3DA.%26aulast%3DOcchiuzzi%26aufirst%3DM.%2BA.%26aulast%3DIacopetta%26aufirst%3DD.%26aulast%3DBarbarossa%26aufirst%3DA.%26aulast%3DRizzuti%26aufirst%3DB.%26aulast%3DDallemagne%26aufirst%3DP.%26aulast%3DRault%26aufirst%3DS.%26aulast%3DEl-Kashef%26aufirst%3DH.%26aulast%3DSaturnino%26aufirst%3DC.%26aulast%3DGrande%26aufirst%3DF.%26aulast%3DSinicropi%26aufirst%3DM.%2BS.%26atitle%3DBenzothienoquinazolinones%2520as%2520new%2520multi-target%2520scaffolds%253A%2520Dual%2520inhibition%2520of%2520human%2520Topoisomerase%2520I%2520and%2520tubulin%2520polymerization%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D181%26spage%3D111583%26doi%3D10.1016%2Fj.ejmech.2019.111583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noha, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdelhameid, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismail, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammed, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salwa, E.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and screening of benzimidazole containing compounds with methoxylated aryl radicals as cytotoxic molecules on (HCT-116) colon cancer cells</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>209</i></span>,  <span class="NLM_fpage">112870</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112870</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejmech.2020.112870" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=33158579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3cXit1GqsbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=209&publication_year=2021&pages=112870&author=R.+M.+Nohaauthor=M.+K.+Abdelhameidauthor=M.+M.+Ismailauthor=M.+R.+Mohammedauthor=E.+Salwa&title=Design%2C+synthesis+and+screening+of+benzimidazole+containing+compounds+with+methoxylated+aryl+radicals+as+cytotoxic+molecules+on+%28HCT-116%29+colon+cancer+cells&doi=10.1016%2Fj.ejmech.2020.112870"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and screening of benzimidazole containing compounds with methoxylated aryl radicals as cytotoxic molecules on (HCT-116) colon cancer cells</span></div><div class="casAuthors">Noha, Ryad M.; Abdelhameid, Mohammed. K.; Ismail, M. Mohsen; Mohammed, Manal. R.; Salwa, Elmeligie</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">209</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112870</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A novel series of benzimidazole derivs. I [R = NH2, NO2; R1 = H, OMe; R2 = OH, OMe, Cl, etc.; R3 = H, OMe] and II [R4 = NO2, NHC(O)CH3] with methoxylated aryl groups was designed and synthesized as mols. with potential cytotoxic activity.  In vitro cytotoxic activity over HCT-116 cells showed that N-(benzimidazothiazolone)acetamides II [R1 = H, R2 = OH, R3 = OMe, R4 = NHC(O)Me; R1 = R2 = R3 = OMe, R4 = NHC(O)Me; R1 = H, R2 = Me, R3 = H, R4 = NHC(O)Me] were found to be the most cytotoxic compds. compared camptothecin (CPT).  The tested compds. had a dual topoisomerase I-β (Topo I-β) and tubulin inhibiting activities when compared to CPT and Podophyllotoxin (Podo) where, compds. II [R1 = H, R2 = OH, R3 = OMe, R4 = NO2; R1 = H, R2 = OH, R3 = OMe, R4 = NO2; R1 = H, R2 = OH, R3 = OMe, R4 = NHC(O)Me; R1 = R2 = R3 = OMe, R4 = NHC(O)Me] exhibited a potent inhibitory activity on Topo I-β enzyme in nano-molar concn., on the other hand, compds. I [R = NO2, R1 = R2 = R3 = OMe; R = NH2, R1 = R2 = R3 = OMe] exhibited the best inhibitory activity β-tubulin polymn.  Results of the cell cycle anal. as well as the results of annexin-V on HCT-116 cells showed that benzimidazothiazoles I [R = NO2, R1 = R2 = R3 = OMe; R = NH2, R1 = R2 = R3 = OMe] had a pro-apoptotic activity higher than CPT by 1.33- and 1.30-folds, resp.  Moreover, the concn. of p53, Bax/Bcl-2 ratio and caspase 3/7 increased in compds. I [R = NO2, R1 = R2 = R3 = OMe; R = NH2, R1 = R2 = R3 = OMe] and II [R1 = R2 = R3 = OMe, R4 = NHC(O)Me; R1 = R2 = R3 = OMe, R4 = NO2].  Finally, compd. II [R1 = R2 = R3 = OMe, R4 = NHC(O)Me] regulated the radiosensitizing activity of the HCT-116 cells by modulating the chromosomal instability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiKHAgzedL8bVg90H21EOLACvtfcHk0liMSMKXicJ1Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXit1GqsbvL&md5=9c8eecc14ebbe75abdb1a1c17601e744</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112870%26sid%3Dliteratum%253Aachs%26aulast%3DNoha%26aufirst%3DR.%2BM.%26aulast%3DAbdelhameid%26aufirst%3DM.%2BK.%26aulast%3DIsmail%26aufirst%3DM.%2BM.%26aulast%3DMohammed%26aufirst%3DM.%2BR.%26aulast%3DSalwa%26aufirst%3DE.%26atitle%3DDesign%252C%2520synthesis%2520and%2520screening%2520of%2520benzimidazole%2520containing%2520compounds%2520with%2520methoxylated%2520aryl%2520radicals%2520as%2520cytotoxic%2520molecules%2520on%2520%2528HCT-116%2529%2520colon%2520cancer%2520cells%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D209%26spage%3D112870%26doi%3D10.1016%2Fj.ejmech.2020.112870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span> <span> </span><span class="NLM_article-title">Role of IDO and TDO in cancers and related diseases and the therapeutic implications</span>. <i>J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2771</span>– <span class="NLM_lpage">2782</span>, <span class="refDoi"> DOI: 10.7150/jca.31727</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.7150%2Fjca.31727" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=31258785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjsFeisLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=2771-2782&author=Z.+Yeauthor=L.+Yueauthor=J.+Shiauthor=M.+Shaoauthor=T.+Wu&title=Role+of+IDO+and+TDO+in+cancers+and+related+diseases+and+the+therapeutic+implications&doi=10.7150%2Fjca.31727"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Role of IDO and TDO in cancers and related diseases and the therapeutic implications</span></div><div class="casAuthors">Ye, Zixiang; Yue, Linxiu; Shi, Jiachen; Shao, Mingmei; Wu, Tao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cancer (Wyoming, Australia)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2771-2782</span>CODEN:
                <span class="NLM_cas:coden">JCWAAL</span>;
        ISSN:<span class="NLM_cas:issn">1837-9664</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher Pty Ltd.</span>)
        </div><div class="casAbstract">Kynurenine (Kyn) pathway is a significant metabolic pathway of tryptophan (Trp).  The metabolites of the Kyn pathway are closely correlated with numerous diseases.  Two main enzymes, indoleamine-2,3-dioxygenase (IDO) and tryptophan-2,3-dioxygenase (TDO or TDO2), regulate the first and rate-limiting step of the Kyn pathway.  These enzymes are directly or indirectly involved in various diseases, including inflammatory diseases, cancer, diabetes, and mental disorders.  Presently, an increasing no. of potential mechanisms have been revealed.  In the present review, we depict the structure of IDO and TDO and explicate their functions in various diseases to facilitate a better understanding of them and to indicate new therapeutic plans to target them.  Moreover, we summarize the inhibitors of IDO/TDO that are currently under development and their efficacy in the treatment of cancer and other diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGZfh-B1VYnrVg90H21EOLACvtfcHk0lgm1yuKXvasMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjsFeisLY%253D&md5=36feb2b7de3d8252e8f13da7bdeb9801</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.7150%2Fjca.31727&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fjca.31727%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DZ.%26aulast%3DYue%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DT.%26atitle%3DRole%2520of%2520IDO%2520and%2520TDO%2520in%2520cancers%2520and%2520related%2520diseases%2520and%2520the%2520therapeutic%2520implications%26jtitle%3DJ.%2520Cancer%26date%3D2019%26volume%3D10%26spage%3D2771%26epage%3D2782%26doi%3D10.7150%2Fjca.31727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuHadaway, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donover, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutanto-Ward, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span> <span> </span><span class="NLM_article-title">Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">312</span>– <span class="NLM_lpage">319</span>, <span class="refDoi"> DOI: 10.1038/nm1196</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1038%2Fnm1196" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=15711557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A280%3ADC%252BD2M7hs1Wiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=312-319&author=A.+J.+Mullerauthor=J.+B.+DuHadawayauthor=P.+S.+Donoverauthor=E.+Sutanto-Wardauthor=G.+C.+Prendergast&title=Inhibition+of+indoleamine+2%2C3-dioxygenase%2C+an+immunoregulatory+target+of+the+cancer+suppression+gene+Bin1%2C+potentiates+cancer+chemotherapy&doi=10.1038%2Fnm1196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy</span></div><div class="casAuthors">Muller Alexander J; DuHadaway James B; Donover P Scott; Sutanto-Ward Erika; Prendergast George C</div><div class="citationInfo"><span class="NLM_cas:title">Nature medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">312-9</span>
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    </div><div class="casAbstract">Immune escape is a crucial feature of cancer progression about which little is known.  Elevation of the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO) in tumor cells can facilitate immune escape.  Not known is how IDO becomes elevated or whether IDO inhibitors will be useful for cancer treatment.  Here we show that IDO is under genetic control of Bin1, which is attenuated in many human malignancies.  Mouse knockout studies indicate that Bin1 loss elevates the STAT1- and NF-kappaB-dependent expression of IDO, driving escape of oncogenically transformed cells from T cell-dependent antitumor immunity.  In MMTV-Neu mice, an established breast cancer model, we show that small-molecule inhibitors of IDO cooperate with cytotoxic agents to elicit regression of established tumors refractory to single-agent therapy.  Our findings suggest that Bin1 loss promotes immune escape in cancer by deregulating IDO and that IDO inhibitors may improve responses to cancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSmoMRy8m8ZDAyMywPm6HgQfW6udTcc2eYG8mXCja2KRbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M7hs1Wiuw%253D%253D&md5=2871eb26a11432381462091144b227f1</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1038%2Fnm1196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1196%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26aulast%3DDuHadaway%26aufirst%3DJ.%2BB.%26aulast%3DDonover%26aufirst%3DP.%2BS.%26aulast%3DSutanto-Ward%26aufirst%3DE.%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26atitle%3DInhibition%2520of%2520indoleamine%25202%252C3-dioxygenase%252C%2520an%2520immunoregulatory%2520target%2520of%2520the%2520cancer%2520suppression%2520gene%2520Bin1%252C%2520potentiates%2520cancer%2520chemotherapy%26jtitle%3DNat.%2520Med.%26date%3D2005%26volume%3D11%26spage%3D312%26epage%3D319%26doi%3D10.1038%2Fnm1196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pilotte, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrieu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroobant, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolusic, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frédérick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Plaen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uyttenhove, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wouters, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masereel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den Eynde, B. J.</span></span> <span> </span><span class="NLM_article-title">Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">2497</span>– <span class="NLM_lpage">2502</span>, <span class="refDoi"> DOI: 10.1073/pnas.1113873109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1073%2Fpnas.1113873109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=22308364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC38XivVKnt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=2497-2502&author=L.+Pilotteauthor=P.+Larrieuauthor=V.+Stroobantauthor=D.+Colauauthor=E.+Dolusicauthor=R.+Fr%C3%A9d%C3%A9rickauthor=E.+De+Plaenauthor=C.+Uyttenhoveauthor=J.+Woutersauthor=B.+Masereelauthor=B.+J.+Van+den+Eynde&title=Reversal+of+tumoral+immune+resistance+by+inhibition+of+tryptophan+2%2C3-dioxygenase&doi=10.1073%2Fpnas.1113873109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase</span></div><div class="casAuthors">Pilotte, Luc; Larrieu, Pierre; Stroobant, Vincent; Colau, Didier; Dolusic, Eduard; Frederick, Raphael; De Plaen, Etienne; Uyttenhove, Catherine; Wouters, Johan; Masereel, Bernard; Vand den Eynde, Benoit</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2497-2502, S2497/1-S2497/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Tryptophan catabolism mediated by indoleamine 2,3-dioxygenase (IDO1) is an important mechanism of peripheral immune tolerance contributing to tumoral immune resistance, and IDO1 inhibition is an active area of drug development.  Tryptophan 2,3-dioxygenase (TDO) is an unrelated hepatic enzyme that also degrades tryptophan along the kynurenine pathway.  Here, we show that enzymically active TDO is expressed in a significant proportion of human tumors.  In a preclin. model, TDO expression by tumors prevented their rejection by immunized mice.  We developed a TDO inhibitor, which, upon systemic treatment, restored the ability of mice to reject TDO-expressing tumors.  Our results describe a mechanism of tumoral immune resistance based on TDO expression and establish proof-of-concept for the use of TDO inhibitors in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUOPsopvoi1LVg90H21EOLACvtfcHk0lgm1yuKXvasMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivVKnt7o%253D&md5=e29b0d7a9180526a2b79173c75765e6c</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1113873109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1113873109%26sid%3Dliteratum%253Aachs%26aulast%3DPilotte%26aufirst%3DL.%26aulast%3DLarrieu%26aufirst%3DP.%26aulast%3DStroobant%26aufirst%3DV.%26aulast%3DColau%26aufirst%3DD.%26aulast%3DDolusic%26aufirst%3DE.%26aulast%3DFr%25C3%25A9d%25C3%25A9rick%26aufirst%3DR.%26aulast%3DDe%2BPlaen%26aufirst%3DE.%26aulast%3DUyttenhove%26aufirst%3DC.%26aulast%3DWouters%26aufirst%3DJ.%26aulast%3DMasereel%26aufirst%3DB.%26aulast%3DVan%2Bden%2BEynde%26aufirst%3DB.%2BJ.%26atitle%3DReversal%2520of%2520tumoral%2520immune%2520resistance%2520by%2520inhibition%2520of%2520tryptophan%25202%252C3-dioxygenase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3D2497%26epage%3D2502%26doi%3D10.1073%2Fpnas.1113873109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Awuah, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemann, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">A Pt(IV) pro-drug preferentially targets indoleamine-2,3-dioxygenase, providing enhanced ovarian cancer immuno-chemotherapy</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">14854</span>– <span class="NLM_lpage">14857</span>, <span class="refDoi"> DOI: 10.1021/jacs.5b10182</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.5b10182" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVahtrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=14854-14857&author=S.+G.+Awuahauthor=Y.+R.+Zhengauthor=P.+M.+Brunoauthor=M.+T.+Hemannauthor=S.+J.+Lippard&title=A+Pt%28IV%29+pro-drug+preferentially+targets+indoleamine-2%2C3-dioxygenase%2C+providing+enhanced+ovarian+cancer+immuno-chemotherapy&doi=10.1021%2Fjacs.5b10182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy</span></div><div class="casAuthors">Awuah, Samuel G.; Zheng, Yao-Rong; Bruno, Peter M.; Hemann, Michael T.; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">14854-14857</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Expression of indoleamine-2,3-dioxygenase (IDO), an immunosuppressive enzyme in human tumors, leads to immune evasion and tumor tolerance.  IDO is therefore a tumor immunotherapeutic target, and several IDO inhibitors are currently undergoing clin. trials.  IDO inhibitors can enhance the efficacy of common cancer chemotherapeutics.  Here the authors investigate Pt(IV)-(D)-1-methyltryptophan conjugates cis,cis,trans-[Pt(NH3)2Cl2(O2C-D-1-MT)2] (1) and cis,cis,trans-[Pt(NH3)2Cl2(O2CC2H4OCNHC2H4O2C-D-1MT)(O2CNHC16H33)] (2) for combined immunomodulation and DNA crosslink-triggered apoptosis for cancer "immuno-chemotherapy".  Compd. (2) effectively kills hormone-dependent, cisplatin-resistant human ovarian cancer cells, inhibiting IDO by transcriptional deregulation of the autocrine-signaling loop IDO-AHR-IL6, which blocks kynurenine prodn. and promotes T-cell proliferation.  Addnl., (1) and (2) display low toxicity in mice and are stable in blood.  To the authors' knowledge, this construct is the first Pt drug candidate with immune checkpoint blockade properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjz_KgWt-JOLVg90H21EOLACvtfcHk0ljVE_usYhcohg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVahtrbI&md5=04851d0bb481296b00294bc985190c28</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1021%2Fjacs.5b10182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.5b10182%26sid%3Dliteratum%253Aachs%26aulast%3DAwuah%26aufirst%3DS.%2BG.%26aulast%3DZheng%26aufirst%3DY.%2BR.%26aulast%3DBruno%26aufirst%3DP.%2BM.%26aulast%3DHemann%26aufirst%3DM.%2BT.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DA%2520Pt%2528IV%2529%2520pro-drug%2520preferentially%2520targets%2520indoleamine-2%252C3-dioxygenase%252C%2520providing%2520enhanced%2520ovarian%2520cancer%2520immuno-chemotherapy%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2015%26volume%3D137%26spage%3D14854%26epage%3D14857%26doi%3D10.1021%2Fjacs.5b10182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hua, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span> <span> </span><span class="NLM_article-title">Multifunctional platinum(IV) complexes as immunostimulatory agents to promote cancer immunochemotherapy by inhibiting tryptophan-2,3-dioxygenase</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>169</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">41</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.02.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejmech.2019.02.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=30852385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1MXks12itrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2019&pages=29-41&author=S.+Huaauthor=F.+Chenauthor=G.+Xuauthor=S.+Gou&title=Multifunctional+platinum%28IV%29+complexes+as+immunostimulatory+agents+to+promote+cancer+immunochemotherapy+by+inhibiting+tryptophan-2%2C3-dioxygenase&doi=10.1016%2Fj.ejmech.2019.02.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Multifunctional platinum(IV) complexes as immunostimulatory agents to promote cancer immunochemotherapy by inhibiting tryptophan-2,3-dioxygenase</span></div><div class="casAuthors">Hua, Shixian; Chen, Feihong; Xu, Gang; Gou, Shaohua</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">29-41</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Increasing evidences suggested that cisplatin can be involved in a tumor-specific immune response as an immunomodulator to improve antitumor immunity, but the designation and development are limited.  Here, we report a series of novel Pt(IV) complexes derived from the conjugation of platinum(II) anticancer agents with an immune checkpoint TDO inhibitor.  These complexes not only showed significant cytotoxic effects on the tested cancer cell lines, but also could enhance antitumor immune response.  Particularly, complex T2, the mono-conjugate of oxoplatin and (E)-4-oxo-4-(3-(2-(pyridin-3-yl)vinyl)-1H-indol-1-yl)butanoic acid, displayed 35-fold more potency than cisplatin against TDO-overexpressed HepG-2 cancer cells.  Further study indicated that T2 could inhibit TDO via releasing a deriv. of a TDO inhibitor and block kynurenine prodn., resulting in T-cell activation and proliferation in vitro.  In vivo tests proved that T2 as a potent immunomodulator could highly promote the antitumor activity of cisplatin and effectively suppress the expression of TDO.  This immunochemotherapeutic strategy can be promisingly applied to treat with TDO-overexpressed cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraJ66nUl2NzbVg90H21EOLACvtfcHk0ljVE_usYhcohg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXks12itrc%253D&md5=c2abc299a2d18a2bffed504df3e24a4f</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.02.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.02.063%26sid%3Dliteratum%253Aachs%26aulast%3DHua%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DGou%26aufirst%3DS.%26atitle%3DMultifunctional%2520platinum%2528IV%2529%2520complexes%2520as%2520immunostimulatory%2520agents%2520to%2520promote%2520cancer%2520immunochemotherapy%2520by%2520inhibiting%2520tryptophan-2%252C3-dioxygenase%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D169%26spage%3D29%26epage%3D41%26doi%3D10.1016%2Fj.ejmech.2019.02.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hua, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span> <span> </span><span class="NLM_article-title">Microtubule inhibitors containing immunostimulatory agents promote cancer immunochemotherapy by inhibiting tubulin polymerization and tryptophan-2,3-dioxygenase</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>187</i></span>,  <span class="NLM_fpage">111949</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111949</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejmech.2019.111949" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=31830637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlGhu7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=2020&pages=111949&author=S.+Huaauthor=F.+Chenauthor=S.+Gou&title=Microtubule+inhibitors+containing+immunostimulatory+agents+promote+cancer+immunochemotherapy+by+inhibiting+tubulin+polymerization+and+tryptophan-2%2C3-dioxygenase&doi=10.1016%2Fj.ejmech.2019.111949"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule inhibitors containing immunostimulatory agents promote cancer immunochemotherapy by inhibiting tubulin polymerization and tryptophan-2,3-dioxygenase</span></div><div class="casAuthors">Hua, Shixian; Chen, Feihong; Gou, Shaohua</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111949</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A combination therapeutic regimen via introducing tryptophan 2,3-dioxygenase inhibitors into microtubule inhibitors was performed and evaluated for their antitumor activity.  Thereinto, HT2, composed of combretastatin A-4 (CA-4) and tryptophan-2,3-dioxygenase (TDO) inhibitor by a linker, displayed the most potent activity with 10-fold higher than its parent CA-4 against HepG2, A549 and HCT-116 cancer cell lines.  Mechanism studies suggested that HT2 inhibited tubulin polymn. and cell migration, caused G2 phase arrest, induced apoptosis by mitochondrial mediated apoptotic pathway, concurrent depolarized the mitochondria membrane potentials and caused reactive oxygen species (ROS) prodn. in HepG2 cells.  Moreover, HT2 could enhance T-cell immune responses in vitro by releasing a TDO inhibitor to suppress TDO expression and blockade kynurenine prodn.  As expected, HT2 could remarkably promote the antitumor activity of CA-4 in either immunocompetent H22 or immunodeficient A549 tumor xenograft models without observable toxic effects.  More importantly, HT2 increased the level of splenic and tumor-infiltrated T cells and in turn effectively boosted the inhibition effect in H22 xenografted tumor growth.  Collectively, this immunochemotherapeutic strategy can be applied to promote chemotherapeutic effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaKG5W_QhNz7Vg90H21EOLACvtfcHk0lhRMQQoJHV1XA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlGhu7zJ&md5=a8d8e6f33d2ad2f5dd02c4403ba2ed94</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111949%26sid%3Dliteratum%253Aachs%26aulast%3DHua%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DGou%26aufirst%3DS.%26atitle%3DMicrotubule%2520inhibitors%2520containing%2520immunostimulatory%2520agents%2520promote%2520cancer%2520immunochemotherapy%2520by%2520inhibiting%2520tubulin%2520polymerization%2520and%2520tryptophan-2%252C3-dioxygenase%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D187%26spage%3D111949%26doi%3D10.1016%2Fj.ejmech.2019.111949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hua, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span> <span> </span><span class="NLM_article-title">Dual-functional conjugates improving cancer immunochemotherapy by inhibiting tubulin polymerization and indoleamine-2,3-dioxygenase</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>189</i></span>,  <span class="NLM_fpage">112041</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejmech.2020.112041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=31954880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFGjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2020&pages=112041&author=S.+Huaauthor=F.+Chenauthor=X.+Wangauthor=S.+Gou&title=Dual-functional+conjugates+improving+cancer+immunochemotherapy+by+inhibiting+tubulin+polymerization+and+indoleamine-2%2C3-dioxygenase&doi=10.1016%2Fj.ejmech.2020.112041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-functional conjugates improving cancer immunochemotherapy by inhibiting tubulin polymerization and indoleamine-2,3-dioxygenase</span></div><div class="casAuthors">Hua, Shixian; Chen, Feihong; Wang, Xinyi; Gou, Shaohua</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">189</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112041</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of novel conjugates comprising tublin and IDO inhibitors were designed, synthesized and evaluated for their antiproliferative activity.  Among them, HI5, composed of combretastatin A-4 (CA-4) and (D)-1-methyltryptophan (D-MT) by a linker, exhibited the most potent antitumor activity, in particular with higher IC50 value (0.07 μM) than CA-4 (0.21 μM) against HeLa cancer cell line.  Mechanism studies indicated that HI5 can inhibit tubulin polymn. and cell migration, cause G2/M phase arrest, concurrent induce apoptosis via the mitochondrial dependent apoptosis pathway and cause reactive oxidative stress generation in HeLa cells.  Furthermore, HI5 can inhibit IDO expression and decrease kynurenine prodn., leading to stimulating T cells activation and proliferation to enhance antitumor immunity in vitro.  Interestingly, HI5 can effectively limit the tumor growth in the HeLa xenograft mice models without causing significant loss of body wt.  Consequently, such a conjugation can be a potent and safe immunochemotherapeutic method for improving cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK6mjQcEaBRbVg90H21EOLACvtfcHk0lhRMQQoJHV1XA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFGjt7Y%253D&md5=f6e05a7ba52c4112d0d767f0f1f7f1f3</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112041%26sid%3Dliteratum%253Aachs%26aulast%3DHua%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGou%26aufirst%3DS.%26atitle%3DDual-functional%2520conjugates%2520improving%2520cancer%2520immunochemotherapy%2520by%2520inhibiting%2520tubulin%2520polymerization%2520and%2520indoleamine-2%252C3-dioxygenase%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D189%26spage%3D112041%26doi%3D10.1016%2Fj.ejmech.2020.112041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dasgupta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luthra, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awasthi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nag, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakrabarti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakrabarti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sen, S.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of a novel library of antimitotic C(2)-aroyl/arylimino tryptamine derivatives that are also potent inhibitors of indoleamine-2, 3-dioxygenase (IDO)</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">249</span>– <span class="NLM_lpage">265</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2018.08.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejps.2018.08.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=30170210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1GqtL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2018&pages=249-265&author=J.+Chauhanauthor=M.+Dasguptaauthor=T.+Luthraauthor=A.+Awasthiauthor=S.+Tripathyauthor=A.+Banerjeeauthor=S.+Paulauthor=D.+Nagauthor=S.+Chakrabartiauthor=G.+Chakrabartiauthor=S.+Sen&title=Design%2C+synthesis+and+biological+evaluation+of+a+novel+library+of+antimitotic+C%282%29-aroyl%2Farylimino+tryptamine+derivatives+that+are+also+potent+inhibitors+of+indoleamine-2%2C+3-dioxygenase+%28IDO%29&doi=10.1016%2Fj.ejps.2018.08.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of a novel library of antimitotic C2-aroyl/arylimino tryptamine derivatives that are also potent inhibitors of indoleamine-2, 3-dioxygenase (IDO)</span></div><div class="casAuthors">Chauhan, Jyoti; Dasgupta, Moumita; Luthra, Tania; Awasthi, Akanksha; Tripathy, Sayantan; Banerjee, Anindyajit; Paul, Santanu; Nag, Debasish; Chakrabarti, Saikat; Chakrabarti, Gopal; Sen, Subhabrata</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">249-265</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel library of C2-substituted tryptamines (based on diverse C2-aroyl/arylimino indoles and indole-diketopiperazine hybrids) possessing antimitotic properties were designed, synthesized and screened for their inhibitory activity against tubulin polymn., and against proliferation of A549 lung cancer, HeLa cervical cancer, MCF7 breast cancer and HePG2 liver cancer cell lines.  The design of mols. were inspired from known antimitotic compds. and natural products.  The mol. docking of the designed compds. indicated that they bind to the colchicin binding site of tubulin.  They were synthesized by a unique iodine catalyzed oxidative ring opening reaction of 1-aryltetrahydro-β-carbolines.  Among the compds. synthesized quite a few compds. induced cytotoxicity on the cancer cells by disrupting the tubulin polymn.  They were found to be non-toxic for healthy cells.  Immuno Fluorescence study for the most active mols. (between ~ 6μM concn.) against A549 and HeLa cells demonstrated complete disruption and shrinkage of the microtubule structures.  These compds. also inhibited indoleamine-2, 3-dioxygenase with low micromolar IC50.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3TM5khkpf-rVg90H21EOLACvtfcHk0ljsHM6PG5ZVmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1GqtL3N&md5=01a650de48f157b4bc97873f4d6314fa</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2018.08.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2018.08.033%26sid%3Dliteratum%253Aachs%26aulast%3DChauhan%26aufirst%3DJ.%26aulast%3DDasgupta%26aufirst%3DM.%26aulast%3DLuthra%26aufirst%3DT.%26aulast%3DAwasthi%26aufirst%3DA.%26aulast%3DTripathy%26aufirst%3DS.%26aulast%3DBanerjee%26aufirst%3DA.%26aulast%3DPaul%26aufirst%3DS.%26aulast%3DNag%26aufirst%3DD.%26aulast%3DChakrabarti%26aufirst%3DS.%26aulast%3DChakrabarti%26aufirst%3DG.%26aulast%3DSen%26aufirst%3DS.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520a%2520novel%2520library%2520of%2520antimitotic%2520C%25282%2529-aroyl%252Farylimino%2520tryptamine%2520derivatives%2520that%2520are%2520also%2520potent%2520inhibitors%2520of%2520indoleamine-2%252C%25203-dioxygenase%2520%2528IDO%2529%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2018%26volume%3D124%26spage%3D249%26epage%3D265%26doi%3D10.1016%2Fj.ejps.2018.08.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meegan, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lloyd, D. G.</span></span> <span> </span><span class="NLM_article-title">Advances in the science of estrogen receptor modulation</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.2174/0929867033368501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.2174%2F0929867033368501" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=12570707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlt1Ghtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2003&pages=181-210&author=M.+J.+Meeganauthor=D.+G.+Lloyd&title=Advances+in+the+science+of+estrogen+receptor+modulation&doi=10.2174%2F0929867033368501"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the science of estrogen receptor modulation</span></div><div class="casAuthors">Meegan, M. J.; Lloyd, D. G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">181-210</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers</span>)
        </div><div class="casAbstract">A review.  This work details recent advances in the science of estrogen receptor (ER) modulation, with emphasis on the discovery of novel ligands for the ER ligand binding domain (LBD).  A detailed examn. of structural studies of the ERs is presented with anal. of the impact of such works on contemporary ligand design and the mol. pharmacol. of the ER.  The various classes of ER modulators are discussed on the basis of structural similarities including selective estrogen receptor modulators (SERMs) and pure nonsteroidal antiestrogens.  Addnl. the authors review the emergence of a novel selective class of modulator - which is termed the selective estrogen receptor subtype modulators (SERSMs) and, in a departure from LBD strategies the authors examine the discovery of novel peptide inhibitors of the ER which inhibit transcriptional activation of agonist liganded receptor through interaction with coactivator recruitment proteins, and offer unique insight to the mechanism of action of all classes of ER modulators.  Through examn. of patent and classical literature the authors present a thorough and informative cross-section of the contemporary state of the art in this exciting field of pharmaceutical research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjk0iqK7f-9rVg90H21EOLACvtfcHk0ljsHM6PG5ZVmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlt1Ghtw%253D%253D&md5=c84e9564c709148ca17206fa6ce6ada9</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.2174%2F0929867033368501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867033368501%26sid%3Dliteratum%253Aachs%26aulast%3DMeegan%26aufirst%3DM.%2BJ.%26aulast%3DLloyd%26aufirst%3DD.%2BG.%26atitle%3DAdvances%2520in%2520the%2520science%2520of%2520estrogen%2520receptor%2520modulation%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2003%26volume%3D10%26spage%3D181%26epage%3D210%26doi%3D10.2174%2F0929867033368501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ershler, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brawley, O. W.</span></span> <span> </span><span class="NLM_article-title">Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1023/A:1020299707510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1023%2FA%3A1020299707510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=12408373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD38XntVKjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2002&pages=27-36&author=W.+F.+Andersonauthor=N.+Chatterjeeauthor=W.+B.+Ershlerauthor=O.+W.+Brawley&title=Estrogen+receptor+breast+cancer+phenotypes+in+the+Surveillance%2C+Epidemiology%2C+and+End+Results+database&doi=10.1023%2FA%3A1020299707510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results Database</span></div><div class="casAuthors">Anderson, William F.; Chatterjee, Nilanjan; Ershler, William B.; Brawley, Otis W.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-36</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">Researchers question whether estrogen receptor α-neg. (ERN) and -pos. (ERP) represent different stages of one disease or different breast cancer types.  To further examine ERα phenotypes, the authors stratified incident tumor characteristics in the Surveillance, Epidemiol., and End Results (SEER) Database (n = 82,488) by ERN and ERP.  Study variables included black-white race, age-at-diagnosis, and std. incident tumor characteristics.  These characteristics were arbitrarily dichotomized into good vs. poor prognostic factor groups, for example, good (tumor size ≤ 2.0 cm, neg. axillary lymph nodes, and good histol. grade) vs. poor (tumor size > 2.0 cm, pos. nodes, and poor grade).  Age frequency d. plots were generated from the corresponding age-at-diagnosis frequency histograms.  Av. annual age-specific incidence rates (or risks) were adjusted to the 1970 United States std. female population.  Age frequency d. plots demonstrated bimodal premenopausal and postmenopausal breast cancer populations.  ERN was correlated with premenopausal disease, black race, and poor prognostic factor groups, whereas ERP was assocd. with postmenopausal disease, white race, and favorable tumor characteristics.  ERN rates increased premenopausally and then flattened to a nearly const. level after 50 yr of age.  ERP risk rose for most of a woman's lifetime with the greatest risk occurring between 75 and 79 yr.  ERα exhibited bimodal age frequency distribution with a dichotomous pattern for age-specific rates, racial, and prognostic factor profiles.  Menopause had a greater effect on ERN than ERP.  Possible implications for breast carcinogenesis and cancer prevention are discussed in the text.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrREH2KVZKrbVg90H21EOLACvtfcHk0ljsHM6PG5ZVmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntVKjtbo%253D&md5=a40a50fe92135da539717096d1722e01</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1023%2FA%3A1020299707510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1020299707510%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DW.%2BF.%26aulast%3DChatterjee%26aufirst%3DN.%26aulast%3DErshler%26aufirst%3DW.%2BB.%26aulast%3DBrawley%26aufirst%3DO.%2BW.%26atitle%3DEstrogen%2520receptor%2520breast%2520cancer%2520phenotypes%2520in%2520the%2520Surveillance%252C%2520Epidemiology%252C%2520and%2520End%2520Results%2520database%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2002%26volume%3D76%26spage%3D27%26epage%3D36%26doi%3D10.1023%2FA%3A1020299707510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berd, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mastrangelo, M. J.</span></span> <span> </span><span class="NLM_article-title">Paclitaxel and tamoxifen: An active regimen for patients with metastatic melanoma</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">87</span>, <span class="refDoi"> DOI: 10.1002/(SICI)1097-0142(20000101)88:1<79::AID-CNCR12>3.0.CO;2-L</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1002%2F%28SICI%291097-0142%2820000101%2988%3A1%3C79%3A%3AAID-CNCR12%3E3.0.CO%3B2-L" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10618609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmtV2gsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2000&pages=79-87&author=F.+E.+Nathanauthor=D.+Berdauthor=T.+Satoauthor=M.+J.+Mastrangelo&title=Paclitaxel+and+tamoxifen%3A+An+active+regimen+for+patients+with+metastatic+melanoma&doi=10.1002%2F%28SICI%291097-0142%2820000101%2988%3A1%3C79%3A%3AAID-CNCR12%3E3.0.CO%3B2-L"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Paclitaxel and tamoxifen: An active regimen for patients with metastatic melanoma</span></div><div class="casAuthors">Nathan, Faith E.; Berd, David; Sato, Takami; Mastrangelo, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (New York)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">79-87</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">In early trials of paclitaxel administered as a 24-h infusion, an overall response rate of 16% was reported for patients with metastatic melanoma.  Paclitaxel is a natural product-based agent and is thus subject to the problem of multidrug resistance (MDR).  Tamoxifen is an agent that can abrogate MDR and potentially enhance the effect of paclitaxel.  A Phase II trial of the combination was undertaken with previously treated patients.  Patients with metastatic cutaneous or mucosal melanoma who were previously treated with the Dartmouth chemotherapy regimen (dacarbazine, carmustine, cisplatin, and tamoxifen) were evaluated.  Paclitaxel was administered at a dose of 225 mg/m2 i.v. over 3 h every 3 wk.  All patients also took tamoxifen 40 mg orally daily.  Treatment continued until disease progression.  Twenty-one patients completed at least two cycles of paclitaxel and were evaluable for response.  Five responses were obsd., 1 complete response, and 4 partial responses, for an overall response rate of 24%.  The combination was well tolerated.  The most common nonhematol. side effects were myalgia and paresthesia.  Hematol. toxicity was mild.  No patients developed neutropenic fever.  This is the first report of a Phase II trial evaluating paclitaxel as a 3-h infusion in melanoma patients.  The 3-h infusion is well tolerated and results in little myelosuppression and minimal neurotoxicity.  The contribution of tamoxifen is difficult to evaluate because plasma levels were not measured.  It is possible that a higher response rate might be obsd. with larger doses of tamoxifen.  Further investigation of paclitaxel in the treatment of patients with metastatic melanoma is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjfS5pgcF2zLVg90H21EOLACvtfcHk0lgz7kEP0uv1PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmtV2gsw%253D%253D&md5=d7bb071cfb264c8ea70801dd7009867a</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291097-0142%2820000101%2988%3A1%3C79%3A%3AAID-CNCR12%3E3.0.CO%3B2-L&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291097-0142%252820000101%252988%253A1%253C79%253A%253AAID-CNCR12%253E3.0.CO%253B2-L%26sid%3Dliteratum%253Aachs%26aulast%3DNathan%26aufirst%3DF.%2BE.%26aulast%3DBerd%26aufirst%3DD.%26aulast%3DSato%26aufirst%3DT.%26aulast%3DMastrangelo%26aufirst%3DM.%2BJ.%26atitle%3DPaclitaxel%2520and%2520tamoxifen%253A%2520An%2520active%2520regimen%2520for%2520patients%2520with%2520metastatic%2520melanoma%26jtitle%3DCancer%26date%3D2000%26volume%3D88%26spage%3D79%26epage%3D87%26doi%3D10.1002%2F%28SICI%291097-0142%2820000101%2988%3A1%3C79%3A%3AAID-CNCR12%3E3.0.CO%3B2-L" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Boyle, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knox, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathwani, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caboni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zisterer, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meegan, M. J.</span></span> <span> </span><span class="NLM_article-title">β-Lactam estrogen receptor antagonists and a dual-targeting estrogen receptor/tubulin ligand</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">9370</span>– <span class="NLM_lpage">9382</span>, <span class="refDoi"> DOI: 10.1021/jm500670d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500670d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGls7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=9370-9382&author=N.+M.+O%E2%80%99Boyleauthor=J.+K.+Pollockauthor=M.+Carrauthor=A.+J.+Knoxauthor=S.+M.+Nathwaniauthor=S.+Wangauthor=L.+Caboniauthor=D.+M.+Zistererauthor=M.+J.+Meegan&title=%CE%B2-Lactam+estrogen+receptor+antagonists+and+a+dual-targeting+estrogen+receptor%2Ftubulin+ligand&doi=10.1021%2Fjm500670d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">β-Lactam Estrogen Receptor Antagonists and a Dual-Targeting Estrogen Receptor/Tubulin Ligand</span></div><div class="casAuthors">O'Boyle, Niamh M.; Pollock, Jade K.; Carr, Miriam; Knox, Andrew J. S.; Nathwani, Seema M.; Wang, Shu; Caboni, Laura; Zisterer, Daniela M.; Meegan, Mary J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9370-9382</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Twelve novel β-lactams were synthesized and their antiproliferative effects and binding affinity for the predominant isoforms of the estrogen receptor (ER), ERα and ERβ, were detd.  β-Lactams I and II had the strongest binding affinities for ERα (IC50 values: 40 and 8 nM, resp.) and ERβ (IC50 values: 19 and 15 nM).  β-Lactam II was the most potent in antiproliferative assays using MCF-7 breast cancer cells; and further biochem. anal. showed that it caused accumulation of cells in G2/M phase (mitotic blockade) and depolymn. of tubulin in MCF-7 cells.  Compd. II also induced apoptosis and down-regulation of the expression of pro-survival proteins Bcl-2 and Mcl-1.  Computational modeling predicted binding preferences for the dual ER/tubulin ligand II.  This series is an important addn. to the known pool of ER antagonists and β-lactam II is the first reported compd. that has dual-targeting properties for both the ER and tubulin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtrx6ltjEnGrVg90H21EOLACvtfcHk0lgxGe8ZxUeXCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGls7nJ&md5=f28caec3db6b9a8fad76d1abe5007f78</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1021%2Fjm500670d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500670d%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DN.%2BM.%26aulast%3DPollock%26aufirst%3DJ.%2BK.%26aulast%3DCarr%26aufirst%3DM.%26aulast%3DKnox%26aufirst%3DA.%2BJ.%26aulast%3DNathwani%26aufirst%3DS.%2BM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DCaboni%26aufirst%3DL.%26aulast%3DZisterer%26aufirst%3DD.%2BM.%26aulast%3DMeegan%26aufirst%3DM.%2BJ.%26atitle%3D%25CE%25B2-Lactam%2520estrogen%2520receptor%2520antagonists%2520and%2520a%2520dual-targeting%2520estrogen%2520receptor%252Ftubulin%2520ligand%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D9370%26epage%3D9382%26doi%3D10.1021%2Fjm500670d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span> <span> </span><span class="NLM_article-title">The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism</span>. <i>Nat. Rev. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">606</span>– <span class="NLM_lpage">619</span>, <span class="refDoi"> DOI: 10.1038/nrg1879</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1038%2Fnrg1879" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=16847462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFCnu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=606-619&author=J.+A.+Engelmanauthor=J.+Luoauthor=L.+C.+Cantley&title=The+evolution+of+phosphatidylinositol+3-kinases+as+regulators+of+growth+and+metabolism&doi=10.1038%2Fnrg1879"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism</span></div><div class="casAuthors">Engelman, Jeffrey A.; Luo, Ji; Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Genetics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">606-619</span>CODEN:
                <span class="NLM_cas:coden">NRGAAM</span>;
        ISSN:<span class="NLM_cas:issn">1471-0056</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Phosphatidylinositol 3-kinases (PI3Ks) evolved from a single enzyme that regulates vesicle trafficking in unicellular eukaryotes into a family of enzymes that regulate cellular metab. and growth in multicellular organisms.  In this review, we examine how the PI3K pathway has evolved to control these fundamental processes, and how this pathway is in turn regulated by intricate feedback and crosstalk mechanisms.  In light of the recent advances in our understanding of the function of PI3Ks in the pathogenesis of diabetes and cancer, we discuss the exciting therapeutic opportunities for targeting this pathway to treat these diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphucxYJIwcQLVg90H21EOLACvtfcHk0lgxGe8ZxUeXCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFCnu7Y%253D&md5=cd9eb85158710db6b33336af4e0a8cfe</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1038%2Fnrg1879&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrg1879%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DThe%2520evolution%2520of%2520phosphatidylinositol%25203-kinases%2520as%2520regulators%2520of%2520growth%2520and%2520metabolism%26jtitle%3DNat.%2520Rev.%2520Genet.%26date%3D2006%26volume%3D7%26spage%3D606%26epage%3D619%26doi%3D10.1038%2Fnrg1879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pons-Tostivint, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thibault, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillermet-Guibert, J.</span></span> <span> </span><span class="NLM_article-title">Targeting PI3K signaling in combination cancer therapy</span>. <i>Trends Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">454</span>– <span class="NLM_lpage">469</span>, <span class="refDoi"> DOI: 10.1016/j.trecan.2017.04.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.trecan.2017.04.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=28718419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1MXksVOksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=454-469&author=E.+Pons-Tostivintauthor=B.+Thibaultauthor=J.+Guillermet-Guibert&title=Targeting+PI3K+signaling+in+combination+cancer+therapy&doi=10.1016%2Fj.trecan.2017.04.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting PI3K Signaling in Combination Cancer Therapy</span></div><div class="casAuthors">Pons-Tostivint, Elvire; Thibault, Benoit; Guillermet-Guibert, Julie</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">454-469</span>CODEN:
                <span class="NLM_cas:coden">TCRAB5</span>;
        ISSN:<span class="NLM_cas:issn">2405-8033</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Targeting upstream phosphatidylinositol-3-kinases (PI3Ks) in the PI3K/Akt/mTOR pathway appears to be a promising therapy in solid cancers; however, first early clin. trials with PI3K inhibitors in monotherapy have been disappointing.  A massive array of preclin. and clin. trials are currently evaluating combinations of PI3K inhibitors in targeted therapies.  These combinations include co-treatments with drugs directed against other intra-/extracellular signaling mols., nuclear hormone receptors, DNA damage repair enzymes, and immune modulators.  We review the literature and pinpoint mechanisms of action in different genomic and organ contexts.  Combinatorial approaches are potentially superior to monotherapies and should become alternative clin. strategies to treat cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotS0vLAVeC87Vg90H21EOLACvtfcHk0lh4wjFGu4-t_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXksVOksQ%253D%253D&md5=3b905f4d00de4428b52078434ad11f12</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.trecan.2017.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.trecan.2017.04.002%26sid%3Dliteratum%253Aachs%26aulast%3DPons-Tostivint%26aufirst%3DE.%26aulast%3DThibault%26aufirst%3DB.%26aulast%3DGuillermet-Guibert%26aufirst%3DJ.%26atitle%3DTargeting%2520PI3K%2520signaling%2520in%2520combination%2520cancer%2520therapy%26jtitle%3DTrends%2520Cancer%26date%3D2017%26volume%3D3%26spage%3D454%26epage%3D469%26doi%3D10.1016%2Fj.trecan.2017.04.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosokawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanimura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohno, M.</span></span> <span> </span><span class="NLM_article-title">Blockade of the phosphatidylinositol-3-kinase-Akt signaling pathway enhances the induction of apoptosis by microtubule-destabilizing agents in tumor cells in which the pathway is constitutively activated</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1133</span>– <span class="NLM_lpage">1142</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-06-0639</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1158%2F1535-7163.MCT-06-0639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=17363506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2ntL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=1133-1142&author=Y.+Fujiwaraauthor=Y.+Hosokawaauthor=K.+Watanabeauthor=S.+Tanimuraauthor=K.+Ozakiauthor=M.+Kohno&title=Blockade+of+the+phosphatidylinositol-3-kinase-Akt+signaling+pathway+enhances+the+induction+of+apoptosis+by+microtubule-destabilizing+agents+in+tumor+cells+in+which+the+pathway+is+constitutively+activated&doi=10.1158%2F1535-7163.MCT-06-0639"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of the phosphatidylinositol-3-kinase-Akt signaling pathway enhances the induction of apoptosis by microtubule-destabilizing agents in tumor cells in which the pathway is constitutively activated</span></div><div class="casAuthors">Fujiwara, Yusuke; Hosokawa, Yoshihisa; Watanabe, Kazushi; Tanimura, Susumu; Ozaki, Kei-Ichi; Kohno, Michiaki</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1133-1142</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Constitutive activation of the phosphatidylinositol-3-kinase (PI3K)-Akt signaling pathway is assocd. with the neoplastic phenotype in many human tumor cell types.  Given the antiapoptotic role of this pathway, we examd. whether its specific blockade might sensitize human tumor cells to the induction of apoptosis by various anticancer drugs.  Although specific blockade of the PI3K-Akt pathway alone with inhibitors such as LY294002 did not induce cell death, it resulted in marked and selective enhancement of the induction of apoptosis by microtubule-destabilizing agents such as vincristine.  This effect was apparent only in tumor cells in which the PI3K-Akt pathway is constitutively activated.  Blockade of the PI3K-Akt pathway induced the activation of glycogen synthase kinase-3β, which phosphorylates microtubule-assocd. proteins such as tau and thereby reduces their ability to bind and stabilize microtubules.  The consequent destabilization of microtubules induced by the inhibition of PI3K-Akt signaling appeared to increase their sensitivity to low concns. of microtubule-destabilizing agents that alone do not lead to the disruption of cytoplasmic microtubules in tumor cells.  Such a synergistic effect on microtubule integrity was not apparent for stable microtubules in the neurites of neuronal cells.  These results suggest that the administration of a combination of a PI3K-Akt pathway inhibitor and a microtubule-destabilizing agent is a potential chemotherapeutic strategy for the treatment of tumor cells in which this signaling pathway is constitutively activated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcCv9iTqdlvbVg90H21EOLACvtfcHk0lh4wjFGu4-t_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2ntL0%253D&md5=ed8077b440c71649160eb7b63c7e6656</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0639%26sid%3Dliteratum%253Aachs%26aulast%3DFujiwara%26aufirst%3DY.%26aulast%3DHosokawa%26aufirst%3DY.%26aulast%3DWatanabe%26aufirst%3DK.%26aulast%3DTanimura%26aufirst%3DS.%26aulast%3DOzaki%26aufirst%3DK.%26aulast%3DKohno%26aufirst%3DM.%26atitle%3DBlockade%2520of%2520the%2520phosphatidylinositol-3-kinase-Akt%2520signaling%2520pathway%2520enhances%2520the%2520induction%2520of%2520apoptosis%2520by%2520microtubule-destabilizing%2520agents%2520in%2520tumor%2520cells%2520in%2520which%2520the%2520pathway%2520is%2520constitutively%2520activated%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D1133%26epage%3D1142%26doi%3D10.1158%2F1535-7163.MCT-06-0639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sekino, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawaguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teishima, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiota, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasui, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsubara, A.</span></span> <span> </span><span class="NLM_article-title">TUBB3 reverses resistance to docetaxel and cabazitaxel in prostate cancer</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">3936</span>, <span class="refDoi"> DOI: 10.3390/ijms20163936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.3390%2Fijms20163936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVCmtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=3936&author=Y.+Sekinoauthor=X.+Hanauthor=T.+Kawaguchiauthor=T.+Babasakiauthor=K.+Gotoauthor=S.+Inoueauthor=T.+Hayashiauthor=J.+Teishimaauthor=M.+Shiotaauthor=W.+Yasuiauthor=A.+Matsubara&title=TUBB3+reverses+resistance+to+docetaxel+and+cabazitaxel+in+prostate+cancer&doi=10.3390%2Fijms20163936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">TUBB3 reverses resistance to docetaxel and cabazitaxel in prostate cancer</span></div><div class="casAuthors">Sekino, Yohei; Han, Xiangrui; Kawaguchi, Takafumi; Babasaki, Takashi; Goto, Keisuke; Inoue, Shogo; Hayashi, Tetsutaro; Teishima, Jun; Shiota, Masaki; Yasui, Wataru; Matsubara, Akio</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3936</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Recent studies have reported that TUBB3 overexpression is involved in docetaxel (DTX) resistance in prostate cancer (PCa).  The aim of this study was to clarify the role of TUBB3 in DTX and cabazitaxel (CBZ) resistance, and cross-resistance between DTX and CBZ in PCa.  We analyzed the effect of TUBB3 knockdown on DTX and CBZ resistance and examd. the interaction between TUBB3 and PTEN.  We also investigated the role of phosphoinositide 3-kinases (PI3K) inhibitor (LY294002) in DTX and CBZ resistance.  TUBB3 expression was upregulated in DTX-resistant and CBZ-resistant cells.  TUBB3 knockdown re-sensitized DTX-resistant cells to DTX and CBZ-resistant cells to CBZ.  Addnl., TUBB3 knockdown re-sensitized DTX-resistant cell lines to CBZ, indicating that TUBB3 mediates cross-resistance between DTX and CBZ.  Knockdown of TUBB3 enhanced PTEN expression, and PTEN knockout enhanced TUBB3 expression.  LY294002 suppressed TUBB3 expression in DTX-resistant and CBZ-resistant cell lines.  LY294002 re-sensitized DTX-resistant cell lines to DTX and CBZ-resistant cell lines to CBZ.  These results suggest that TUBB3 is involved in DTX resistance and CBZ resistance.  A combination of LY294002/DTX and that of LY294002/CBZ could be potential strategies for PCa treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1sLyEntEtXbVg90H21EOLACvtfcHk0lh4wjFGu4-t_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVCmtr0%253D&md5=bcb7c3966eddd83b32cb0107623873a3</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.3390%2Fijms20163936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20163936%26sid%3Dliteratum%253Aachs%26aulast%3DSekino%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DKawaguchi%26aufirst%3DT.%26aulast%3DBabasaki%26aufirst%3DT.%26aulast%3DGoto%26aufirst%3DK.%26aulast%3DInoue%26aufirst%3DS.%26aulast%3DHayashi%26aufirst%3DT.%26aulast%3DTeishima%26aufirst%3DJ.%26aulast%3DShiota%26aufirst%3DM.%26aulast%3DYasui%26aufirst%3DW.%26aulast%3DMatsubara%26aufirst%3DA.%26atitle%3DTUBB3%2520reverses%2520resistance%2520to%2520docetaxel%2520and%2520cabazitaxel%2520in%2520prostate%2520cancer%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D3936%26doi%3D10.3390%2Fijms20163936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maira, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sterker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guthy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brachmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chène, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Pover, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martiny-Baron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlegel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Echeverría, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voliva, C. F.</span></span> <span> </span><span class="NLM_article-title">Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">317</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0474</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1158%2F1535-7163.MCT-11-0474" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=22188813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFWltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=317-328&author=S.+M.+Mairaauthor=S.+Pecchiauthor=A.+Huangauthor=M.+Burgerauthor=M.+Knappauthor=D.+Sterkerauthor=C.+Schnellauthor=D.+Guthyauthor=T.+Nagelauthor=M.+Wiesmannauthor=S.+Brachmannauthor=C.+Fritschauthor=M.+Dorschauthor=P.+Ch%C3%A8neauthor=K.+Shoemakerauthor=A.+De+Poverauthor=D.+Menezesauthor=G.+Martiny-Baronauthor=D.+Fabbroauthor=C.+J.+Wilsonauthor=R.+Schlegelauthor=F.+Hofmannauthor=C.+Garc%C3%ADa-Echeverr%C3%ADaauthor=W.+R.+Sellersauthor=C.+F.+Voliva&title=Identification+and+characterization+of+NVP-BKM120%2C+an+orally+available+pan-class+I+PI3-kinase+inhibitor&doi=10.1158%2F1535-7163.MCT-11-0474"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor</span></div><div class="casAuthors">Maira, Sauveur-Michel; Pecchi, Sabina; Huang, Alan; Burger, Matthew; Knapp, Mark; Sterker, Dario; Schnell, Christian; Guthy, Daniel; Nagel, Tobi; Wiesmann, Marion; Brachmann, Saskia; Fritsch, Christine; Dorsch, Marion; Chene, Patrick; Shoemaker, Kevin; De Pover, Alain; Menezes, Daniel; Martiny-Baron, Georg; Fabbro, Doriano; Wilson, Christopher J.; Schlegel, Robert; Hofmann, Francesco; Garcia-Echeverria, Carlos; Sellers, William R.; Voliva, Charles F.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">317-328</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Following the discovery of NVP-BEZ235, our first dual pan-PI3K/mTOR clin. compd., we sought to identify addnl. phosphoinositide 3-kinase (PI3K) inhibitors from different chem. classes with a different selectivity profile.  The key to achieve these objectives was to couple a structure-based design approach with intensive pharmacol. evaluation of selected compds. during the medicinal chem. optimization process.  Here, we report on the biol. characterization of the 2-morpholino pyrimidine deriv. pan-PI3K inhibitor NVP-BKM120.  This compd. inhibits all four class I PI3K isoforms in biochem. assays with at least 50-fold selectivity against other protein kinases.  The compd. is also active against the most common somatic PI3Kα mutations but does not significantly inhibit the related class III (Vps34) and class IV (mTOR, DNA-PK) PI3K kinases.  Consistent with its mechanism of action, NVP-BKM120 decreases the cellular levels of p-Akt in mechanistic models and relevant tumor cell lines, as well as downstream effectors in a concn.-dependent and pathway-specific manner.  Tested in a panel of 353 cell lines, NVP-BKM120 exhibited preferential inhibition of tumor cells bearing PIK3CA mutations, in contrast to either KRAS or PTEN mutant models.  NVP-BKM120 shows dose-dependent in vivo pharmacodynamic activity as measured by significant inhibition of p-Akt and tumor growth inhibition in mechanistic xenograft models.  NVP-BKM120 behaves synergistically when combined with either targeted agents such as MEK or HER2 inhibitors or with cytotoxic agents such as docetaxel or temozolomide.  The pharmacol., biol., and preclin. safety profile of NVP-BKM120 supports its clin. development and the compd. is undergoing phase II clin. trials in patients with cancer.  Mol Cancer Ther; 11(2); 317-28.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps2mNHzJneaLVg90H21EOLACvtfcHk0ljGqmEFcYlOSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFWltb8%253D&md5=4c3b225d45591e9cd49800baa06e8152</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0474&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0474%26sid%3Dliteratum%253Aachs%26aulast%3DMaira%26aufirst%3DS.%2BM.%26aulast%3DPecchi%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DA.%26aulast%3DBurger%26aufirst%3DM.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DSterker%26aufirst%3DD.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DGuthy%26aufirst%3DD.%26aulast%3DNagel%26aufirst%3DT.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DBrachmann%26aufirst%3DS.%26aulast%3DFritsch%26aufirst%3DC.%26aulast%3DDorsch%26aufirst%3DM.%26aulast%3DCh%25C3%25A8ne%26aufirst%3DP.%26aulast%3DShoemaker%26aufirst%3DK.%26aulast%3DDe%2BPover%26aufirst%3DA.%26aulast%3DMenezes%26aufirst%3DD.%26aulast%3DMartiny-Baron%26aufirst%3DG.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DC.%2BJ.%26aulast%3DSchlegel%26aufirst%3DR.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DGarc%25C3%25ADa-Echeverr%25C3%25ADa%26aufirst%3DC.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DVoliva%26aufirst%3DC.%2BF.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520NVP-BKM120%252C%2520an%2520orally%2520available%2520pan-class%2520I%2520PI3-kinase%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D317%26epage%3D328%26doi%3D10.1158%2F1535-7163.MCT-11-0474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bohnacker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prota, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inglis, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sele, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargsten, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhmanova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Díaz, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvelebil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">14683</span>, <span class="refDoi"> DOI: 10.1038/ncomms14683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1038%2Fncomms14683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=28276440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A280%3ADC%252BC1czksV2ruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=14683&author=T.+Bohnackerauthor=A.+E.+Protaauthor=F.+Beaufilsauthor=J.+E.+Burkeauthor=A.+Meloneauthor=A.+J.+Inglisauthor=D.+Rageotauthor=A.+M.+Seleauthor=V.+Cmiljanovicauthor=N.+Cmiljanovicauthor=K.+Bargstenauthor=A.+Aherauthor=A.+Akhmanovaauthor=J.+F.+D%C3%ADazauthor=D.+Fabbroauthor=M.+Zvelebilauthor=R.+L.+Williamsauthor=M.+O.+Steinmetzauthor=M.+P.+Wymann&title=Deconvolution+of+Buparlisib%E2%80%99s+mechanism+of+action+defines+specific+PI3K+and+tubulin+inhibitors+for+therapeutic+intervention&doi=10.1038%2Fncomms14683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention</span></div><div class="casAuthors">Bohnacker Thomas; Beaufils Florent; Melone Anna; Rageot Denise; Sele Alexander M; Cmiljanovic Vladimir; Cmiljanovic Natasa; Wymann Matthias P; Prota Andrea E; Bargsten Katja; Steinmetz Michel O; Burke John E; Inglis Alison J; Williams Roger L; Aher Amol; Akhmanova Anna; Diaz J Fernando; Fabbro Doriano; Zvelebil Marketa</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14683</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BKM120 (Buparlisib) is one of the most advanced phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer, but it interferes as an off-target effect with microtubule polymerization.  Here, we developed two chemical derivatives that differ from BKM120 by only one atom.  We show that these minute changes separate the dual activity of BKM120 into discrete PI3K and tubulin inhibitors.  Analysis of the compounds cellular growth arrest phenotypes and microtubule dynamics suggest that the antiproliferative activity of BKM120 is mainly due to microtubule-dependent cytotoxicity rather than through inhibition of PI3K.  Crystal structures of BKM120 and derivatives in complex with tubulin and PI3K provide insights into the selective mode of action of this class of drugs.  Our results raise concerns over BKM120's generally accepted mode of action, and provide a unique mechanistic basis for next-generation PI3K inhibitors with improved safety profiles and flexibility for use in combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRzPPj8gFbG6HWEEzDrymxmfW6udTcc2eZXSzLAA8Z9o7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czksV2ruw%253D%253D&md5=97d27a7d83bf6ab6094a587565f82bf6</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1038%2Fncomms14683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms14683%26sid%3Dliteratum%253Aachs%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DBurke%26aufirst%3DJ.%2BE.%26aulast%3DMelone%26aufirst%3DA.%26aulast%3DInglis%26aufirst%3DA.%2BJ.%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DSele%26aufirst%3DA.%2BM.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DCmiljanovic%26aufirst%3DN.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DAher%26aufirst%3DA.%26aulast%3DAkhmanova%26aufirst%3DA.%26aulast%3DD%25C3%25ADaz%26aufirst%3DJ.%2BF.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DZvelebil%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DDeconvolution%2520of%2520Buparlisib%25E2%2580%2599s%2520mechanism%2520of%2520action%2520defines%2520specific%2520PI3K%2520and%2520tubulin%2520inhibitors%2520for%2520therapeutic%2520intervention%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D14683%26doi%3D10.1038%2Fncomms14683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agoni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basu, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfieri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gambino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guha, C.</span></span> <span> </span><span class="NLM_article-title">Rigosertib is a more effective radiosensitizer than cisplatin in concurrent chemoradiation treatment of cervical carcinoma, in vitro and in vivo</span>. <i>Int. J. Radiat. Oncol., Biol., Phys.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">1180</span>– <span class="NLM_lpage">1187</span>, <span class="refDoi"> DOI: 10.1016/j.ijrobp.2013.12.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ijrobp.2013.12.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=24529717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFejur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2014&pages=1180-1187&author=L.+Agoniauthor=I.+Basuauthor=S.+Guptaauthor=A.+Alfieriauthor=A.+Gambinoauthor=G.+L.+Goldbergauthor=E.+P.+Reddyauthor=C.+Guha&title=Rigosertib+is+a+more+effective+radiosensitizer+than+cisplatin+in+concurrent+chemoradiation+treatment+of+cervical+carcinoma%2C+in+vitro+and+in+vivo&doi=10.1016%2Fj.ijrobp.2013.12.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Rigosertib Is a More Effective Radiosensitizer Than Cisplatin in Concurrent Chemoradiation Treatment of Cervical Carcinoma, In Vitro and In Vivo</span></div><div class="casAuthors">Agoni, Lorenzo; Basu, Indranil; Gupta, Seema; Alfieri, Alan; Gambino, Angela; Goldberg, Gary L.; Reddy, E. Premkumar; Guha, Chandan</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Radiation Oncology, Biology, Physics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1180-1187</span>CODEN:
                <span class="NLM_cas:coden">IOBPD3</span>;
        ISSN:<span class="NLM_cas:issn">0360-3016</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">To compare rigosertib vs. cisplatin as an effective radiosensitizing agent for cervical malignancies.  Rigosertib and cisplatin were tested in cervical cancer cell lines, HeLa and C33A.  A 24-h incubation with rigosertib and cisplatin, before irradn. (2-8 Gy), was used for clonogenic survival assays.  Cell cycle anal. (propidium iodide staining) and DNA damage (γ-H2AX expression) were evaluated by fluorescence-activated cell sorter cytometry.  Rigosertib was also tested in vivo in tumor growth expts. on cervical cancer xenografts.Rigosertib was demonstrated to induce a G2/M block in cancer cells.  Survival curve comparison revealed a dose modification factor, as index of radiosensitization effect, of 1.1-1.3 for cisplatin and 1.4-2.2 for rigosertib.  With 6-Gy irradn., an increase in DNA damage of 15%-25% was achieved in both HeLa and C33A cells with cisplatin pretreatment, and a 71-108% increase with rigosertib pretreatment.  In vivo tumor growth studies demonstrated higher performance of rigosertib when compared with cisplatin, with 53% longer tumor growth delay.Rigosertib was more effective than cisplatin when combined with radiation and caused minimal toxicity.  These data support the need for clin. trials with rigosertib in combination therapy for patients with cervical carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp4WxezwzrXrVg90H21EOLACvtfcHk0ljD1WJ9vFbHKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFejur4%253D&md5=e44b7983b086c8d87800c9761b2579bc</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2Fj.ijrobp.2013.12.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijrobp.2013.12.051%26sid%3Dliteratum%253Aachs%26aulast%3DAgoni%26aufirst%3DL.%26aulast%3DBasu%26aufirst%3DI.%26aulast%3DGupta%26aufirst%3DS.%26aulast%3DAlfieri%26aufirst%3DA.%26aulast%3DGambino%26aufirst%3DA.%26aulast%3DGoldberg%26aufirst%3DG.%2BL.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26aulast%3DGuha%26aufirst%3DC.%26atitle%3DRigosertib%2520is%2520a%2520more%2520effective%2520radiosensitizer%2520than%2520cisplatin%2520in%2520concurrent%2520chemoradiation%2520treatment%2520of%2520cervical%2520carcinoma%252C%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DInt.%2520J.%2520Radiat.%2520Oncol.%252C%2520Biol.%252C%2520Phys.%26date%3D2014%26volume%3D88%26spage%3D1180%26epage%3D1187%26doi%3D10.1016%2Fj.ijrobp.2013.12.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatapuram, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallireddigari, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallela, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosenza, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robell, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akula, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, E. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2′,4′,6′-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910. Na): synthesis, structure-activity relationship, and biological activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6254</span>– <span class="NLM_lpage">6276</span>, <span class="refDoi"> DOI: 10.1021/jm200570p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200570p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVegt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6254-6276&author=M.+V.+Reddyauthor=P.+Venkatapuramauthor=M.+R.+Mallireddigariauthor=V.+R.+Pallelaauthor=S.+C.+Cosenzaauthor=K.+A.+Robellauthor=B.+Akulaauthor=B.+S.+Hoffmanauthor=E.+P.+Reddy&title=Discovery+of+a+clinical+stage+multi-kinase+inhibitor+sodium+%28E%29-2-%7B2-methoxy-5-%5B%282%E2%80%B2%2C4%E2%80%B2%2C6%E2%80%B2-trimethoxystyrylsulfonyl%29methyl%5Dphenylamino%7Dacetate+%28ON+01910.+Na%29%3A+synthesis%2C+structure-activity+relationship%2C+and+biological+activity&doi=10.1021%2Fjm200570p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Clinical Stage Multi-Kinase Inhibitor Sodium (E)-2-{2-Methoxy-5-[(2',4',6'-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): Synthesis, Structure-Activity Relationship, and Biological Activity</span></div><div class="casAuthors">Reddy, M. V. Ramana; Venkatapuram, Padmavathi; Mallireddigari, Muralidhar R.; Pallela, Venkat R.; Cosenza, Stephen C.; Robell, Kimberly A.; Akula, Balaiah; Hoffman, Benjamin S.; Reddy, E. Premkumar</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6254-6276</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin D proteins are elevated in many cancer cells, and targeted deletion of cyclin D1 gene in the mammary tissues protects mice from breast cancer.  Accordingly, there is an increasing awareness of this novel nonenzymic target for cancer therapeutics.  We have developed novel, nonalkylating styrylbenzylsulfones that induce cell death in wide variety of cancer cells without affecting the proliferation and survival of normal cells.  The development of styrylbenzylsulfone derivs. followed logically from a tumor cell cytotoxicity screen performed in our lab. that did not have an a priori target profile.  Modifications of some of the precursor mols. led to lead optimization with regard to tumor cell cytotoxicity.  In this report we describe the synthesis and structure-activity relationships of novel, nonalkylating (E)-styrylbenzylsulfones and the development of the novel anticancer agent sodium (E)-2-{2-methoxy-5-[(2',4',6'-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (I) (ON 01910.Na), which is in phase III trials for myelodysplastic syndromes (MDS) assocd. with aberrant expression of cyclin D proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXyWp-VIWe7rVg90H21EOLACvtfcHk0likLWdNUmmOQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVegt7vP&md5=216de055e27dc53794018fc1416bc62f</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1021%2Fjm200570p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200570p%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DM.%2BV.%26aulast%3DVenkatapuram%26aufirst%3DP.%26aulast%3DMallireddigari%26aufirst%3DM.%2BR.%26aulast%3DPallela%26aufirst%3DV.%2BR.%26aulast%3DCosenza%26aufirst%3DS.%2BC.%26aulast%3DRobell%26aufirst%3DK.%2BA.%26aulast%3DAkula%26aufirst%3DB.%26aulast%3DHoffman%26aufirst%3DB.%2BS.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DDiscovery%2520of%2520a%2520clinical%2520stage%2520multi-kinase%2520inhibitor%2520sodium%2520%2528E%2529-2-%257B2-methoxy-5-%255B%25282%25E2%2580%25B2%252C4%25E2%2580%25B2%252C6%25E2%2580%25B2-trimethoxystyrylsulfonyl%2529methyl%255Dphenylamino%257Dacetate%2520%2528ON%252001910.%2520Na%2529%253A%2520synthesis%252C%2520structure-activity%2520relationship%252C%2520and%2520biological%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6254%26epage%3D6276%26doi%3D10.1021%2Fjm200570p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Athuluri-Divakar, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasquez-Del Carpio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosenza, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basu, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogt, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulholland, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guha, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, E. P.</span></span> <span> </span><span class="NLM_article-title">A small molecule RAS-mimetic disrupts RAS association with effector proteins to block signaling</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">643</span>– <span class="NLM_lpage">655</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2016.03.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.cell.2016.03.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=27104980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC28XmslShtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2016&pages=643-655&author=S.+K.+Athuluri-Divakarauthor=R.+Vasquez-Del+Carpioauthor=K.+Duttaauthor=S.+J.+Bakerauthor=S.+C.+Cosenzaauthor=I.+Basuauthor=Y.+K.+Guptaauthor=M.+V.+Reddyauthor=L.+Uenoauthor=J.+R.+Hartauthor=P.+K.+Vogtauthor=D.+Mulhollandauthor=C.+Guhaauthor=A.+K.+Aggarwalauthor=E.+P.+Reddy&title=A+small+molecule+RAS-mimetic+disrupts+RAS+association+with+effector+proteins+to+block+signaling&doi=10.1016%2Fj.cell.2016.03.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling</span></div><div class="casAuthors">Athuluri-Divakar, Sai Krishna; Vasquez-Del Carpio, Rodrigo; Dutta, Kaushik; Baker, Stacey J.; Cosenza, Stephen C.; Basu, Indranil; Gupta, Yogesh K.; Reddy, M. V. Ramana; Ueno, Lynn; Hart, Jonathan R.; Vogt, Peter K.; Mulholland, David; Guha, Chandan; Aggarwal, Aneel K.; Reddy, E. Premkumar</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">643-655</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Oncogenic activation of RAS genes via point mutations occurs in 20%-30% of human cancers.  The development of effective RAS inhibitors has been challenging, necessitating new approaches to inhibit this oncogenic protein.  Functional studies have shown that the switch region of RAS interacts with a large no. of effector proteins contg. a common RAS-binding domain (RBD).  Because RBD-mediated interactions are essential for RAS signaling, blocking RBD assocn. with small mols. constitutes an attractive therapeutic approach.  Here, the authors present evidence that rigosertib, a styryl-benzyl sulfone, acts as a RAS-mimetic and interacts with the RBDs of RAF kinases, resulting in their inability to bind to RAS, disruption of RAF activation, and inhibition of the RAS-RAF-MEK pathway.  The authors also find that ribosertib binds to the RBDs of Ral-GDS and PI3Ks.  These results suggest that targeting of RBDs across multiple signaling pathways by rigosertib may represent an effective strategy for inactivation of RAS signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoa5skbfbqCQrVg90H21EOLACvtfcHk0likLWdNUmmOQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmslShtbs%253D&md5=c79482e4a9cc6819034dd9117348b8bc</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2016.03.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2016.03.045%26sid%3Dliteratum%253Aachs%26aulast%3DAthuluri-Divakar%26aufirst%3DS.%2BK.%26aulast%3DVasquez-Del%2BCarpio%26aufirst%3DR.%26aulast%3DDutta%26aufirst%3DK.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DCosenza%26aufirst%3DS.%2BC.%26aulast%3DBasu%26aufirst%3DI.%26aulast%3DGupta%26aufirst%3DY.%2BK.%26aulast%3DReddy%26aufirst%3DM.%2BV.%26aulast%3DUeno%26aufirst%3DL.%26aulast%3DHart%26aufirst%3DJ.%2BR.%26aulast%3DVogt%26aufirst%3DP.%2BK.%26aulast%3DMulholland%26aufirst%3DD.%26aulast%3DGuha%26aufirst%3DC.%26aulast%3DAggarwal%26aufirst%3DA.%2BK.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DA%2520small%2520molecule%2520RAS-mimetic%2520disrupts%2520RAS%2520association%2520with%2520effector%2520proteins%2520to%2520block%2520signaling%26jtitle%3DCell%26date%3D2016%26volume%3D165%26spage%3D643%26epage%3D655%26doi%3D10.1016%2Fj.cell.2016.03.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jost, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horlbeck, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krenning, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menchon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stern, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prota, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kampmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhmanova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanenbaum, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissman, J. S.</span></span> <span> </span><span class="NLM_article-title">Combined CRISPRi/a-based chemical genetic screens reveal that rigosertib is a microtubule-destabilizing agent</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">210</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2017.09.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.molcel.2017.09.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=28985505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Wqs77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2017&pages=210-223&author=M.+Jostauthor=Y.+Chenauthor=L.+A.+Gilbertauthor=M.+A.+Horlbeckauthor=L.+Krenningauthor=G.+Menchonauthor=A.+Raiauthor=M.+Y.+Choauthor=J.+J.+Sternauthor=A.+E.+Protaauthor=M.+Kampmannauthor=A.+Akhmanovaauthor=M.+O.+Steinmetzauthor=M.+E.+Tanenbaumauthor=J.+S.+Weissman&title=Combined+CRISPRi%2Fa-based+chemical+genetic+screens+reveal+that+rigosertib+is+a+microtubule-destabilizing+agent&doi=10.1016%2Fj.molcel.2017.09.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent</span></div><div class="casAuthors">Jost, Marco; Chen, Yuwen; Gilbert, Luke A.; Horlbeck, Max A.; Krenning, Lenno; Menchon, Gregory; Rai, Ankit; Cho, Min Y.; Stern, Jacob J.; Prota, Andrea E.; Kampmann, Martin; Akhmanova, Anna; Steinmetz, Michel O.; Tanenbaum, Marvin E.; Weissman, Jonathan S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">210-223.e6</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Chem. libraries paired with phenotypic screens can now readily identify compds. with therapeutic potential.  A central limitation to exploiting these compds., however, has been in identifying their relevant cellular targets.  Here, we present a two-tiered CRISPR-mediated chem.-genetic strategy for target identification: combined genome-wide knockdown and overexpression screening as well as focused, comparative chem.-genetic profiling.  Application of these strategies to rigosertib, a drug in phase 3 clin. trials for high-risk myelodysplastic syndrome whose mol. target had remained controversial, pointed singularly to microtubules as rigosertib's target.  We showed that rigosertib indeed directly binds to and destabilizes microtubules using cell biol., in vitro, and structural approaches.  Finally, expression of tubulin with a structure-guided mutation in the rigosertib-binding pocket conferred resistance to rigosertib, establishing that rigosertib kills cancer cells by destabilizing microtubules.  These results demonstrate the power of our chem.-genetic screening strategies for pinpointing the physiol. relevant targets of chem. agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBsbZCZePrwLVg90H21EOLACvtfcHk0ljdFhgpU51VoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Wqs77L&md5=115f89a6cc9eef8c3709c06b74109c51</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2017.09.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2017.09.012%26sid%3Dliteratum%253Aachs%26aulast%3DJost%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DGilbert%26aufirst%3DL.%2BA.%26aulast%3DHorlbeck%26aufirst%3DM.%2BA.%26aulast%3DKrenning%26aufirst%3DL.%26aulast%3DMenchon%26aufirst%3DG.%26aulast%3DRai%26aufirst%3DA.%26aulast%3DCho%26aufirst%3DM.%2BY.%26aulast%3DStern%26aufirst%3DJ.%2BJ.%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DKampmann%26aufirst%3DM.%26aulast%3DAkhmanova%26aufirst%3DA.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26aulast%3DTanenbaum%26aufirst%3DM.%2BE.%26aulast%3DWeissman%26aufirst%3DJ.%2BS.%26atitle%3DCombined%2520CRISPRi%252Fa-based%2520chemical%2520genetic%2520screens%2520reveal%2520that%2520rigosertib%2520is%2520a%2520microtubule-destabilizing%2520agent%26jtitle%3DMol.%2520Cell%26date%3D2017%26volume%3D68%26spage%3D210%26epage%3D223%26doi%3D10.1016%2Fj.molcel.2017.09.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, G. S.</span></span> <span> </span><span class="NLM_article-title">The hunting of the Src</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">475</span>, <span class="refDoi"> DOI: 10.1038/35073094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1038%2F35073094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=11389470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD3MXks1agsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=467-475&author=G.+S.+Martin&title=The+hunting+of+the+Src&doi=10.1038%2F35073094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">The hunting of the Src</span></div><div class="casAuthors">Martin, G. Steven</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">467-475</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review, with 120 refs.  The non-receptor tyrosine kinase Src is important for many aspects of cell physiol.  The viral src gene was the 1st retroviral oncogene to be identified, and its cellular counterpart was the 1st protooncogene to be discovered in the vertebrate genome.  Src has been important, not only as an object of study in itself, but also as an entry point into the mol. genetics of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqId3YlI11q77Vg90H21EOLACvtfcHk0ljdFhgpU51VoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXks1agsLw%253D&md5=36cad805c8b312f84b692efc42b16094</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1038%2F35073094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35073094%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DG.%2BS.%26atitle%3DThe%2520hunting%2520of%2520the%2520Src%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2001%26volume%3D2%26spage%3D467%26epage%3D475%26doi%3D10.1038%2F35073094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frame, M. C.</span></span> <span> </span><span class="NLM_article-title">Src in cancer: deregulation and consequences for cell behaviour</span>. <i>Biochim. Biophys. Acta, Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1602</i></span>,  <span class="NLM_fpage">114</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.1016/S0304-419X(02)00040-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2FS0304-419X%2802%2900040-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=12020799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvVeitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1602&publication_year=2002&pages=114-130&author=M.+C.+Frame&title=Src+in+cancer%3A+deregulation+and+consequences+for+cell+behaviour&doi=10.1016%2FS0304-419X%2802%2900040-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Src in cancer: deregulation and consequences for cell behavior</span></div><div class="casAuthors">Frame, Margaret C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Reviews on Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1602</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">114-130</span>CODEN:
                <span class="NLM_cas:coden">BBACEU</span>;
        ISSN:<span class="NLM_cas:issn">0304-419X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Considerable evidence now implicates elevated expression and/or activity of Src in cancer development.  In cells, endogenous Src is switched from an inactive to an active state by a variety of mechanisms that simultaneously relieve constraints on the kinase and protein-interacting Src homol. (SH) domains.  As a result, Src is translocated to the cell periphery, often to sites of cell adhesion, where myristylation mediates attachment to the inner surface of the plasma membrane.  From these peripheral sites, Src's catalytic activity initiates intracellular signal transduction pathways that influence cell growth and adhesion strength, the latter contributing to control of cell migration.  De-regulation in cancer cells may therefore enhance tumor growth and/or stimulate migratory or invasive potential in cells that would normally be relatively non-motile.  Evidence now exists to suggest that Src may also influence the life or death decisions that cells make during many biol. processes.  Thus, Src modulation in cancer cells can alter cell responses that are often perturbed in cancer.  Consequently, there is optimism that drugs which inhibit Src's kinase activity, or the activity of its downstream effectors, might have profound effects on cancer cell behavior and be useful therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4PUbbCfYCTrVg90H21EOLACvtfcHk0ljdFhgpU51VoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvVeitLs%253D&md5=ac3f4d59c7979798349ea7f0db807d67</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1016%2FS0304-419X%2802%2900040-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0304-419X%252802%252900040-9%26sid%3Dliteratum%253Aachs%26aulast%3DFrame%26aufirst%3DM.%2BC.%26atitle%3DSrc%2520in%2520cancer%253A%2520deregulation%2520and%2520consequences%2520for%2520cell%2520behaviour%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Rev.%2520Cancer%26date%3D2002%26volume%3D1602%26spage%3D114%26epage%3D130%26doi%3D10.1016%2FS0304-419X%2802%2900040-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smolinski, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clements, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelman, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegab, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutler, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, J. W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fetterly, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnett, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J. Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D. G.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel dual mechanism of action Src signaling and tubulin polymerization inhibitors (KX2–391 and KX2–361)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4704</span>– <span class="NLM_lpage">4719</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00164</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00164" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVCmt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4704-4719&author=M.+P.+Smolinskiauthor=Y.+Buauthor=J.+Clementsauthor=I.+H.+Gelmanauthor=T.+Hegabauthor=D.+L.+Cutlerauthor=J.+W.+S.+Fangauthor=G.+Fetterlyauthor=R.+Kwanauthor=A.+Barnettauthor=J.+Y.+N.+Lauauthor=D.+G.+Hangauer&title=Discovery+of+novel+dual+mechanism+of+action+Src+signaling+and+tubulin+polymerization+inhibitors+%28KX2%E2%80%93391+and+KX2%E2%80%93361%29&doi=10.1021%2Facs.jmedchem.8b00164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361)</span></div><div class="casAuthors">Smolinski, Michael P.; Bu, Yahao; Clements, James; Gelman, Irwin H.; Hegab, Taher; Cutler, David L.; Fang, Jane W. S.; Fetterly, Gerald; Kwan, Rudolf; Barnett, Allen; Lau, Johnson Y. N.; Hangauer, David G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4704-4719</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of potent, peptide site directed, tyrosine kinase inhibitors has remained an elusive goal.  Herein we describe the discovery of two such clin. candidates that inhibit the tyrosine kinase Src.  Compd. 1 is a phase 3 clin. trial candidate that is likely to provide a first in class topical treatment for actinic keratosis (AK) with good efficacy and dramatically less toxicity compared to existing std. therapy.  Compd. 2 is a phase 1 clin. trial candidate that is likely to provide a first in class treatment of malignant glioblastoma and induces 30% long-term complete tumor remission in animal models.  The discovery strategy for these compds. iteratively utilized mol. modeling, along with the synthesis and testing of increasingly elaborated proof of concept compds., until the final clin. candidates were arrived at.  This was followed with mechanism of action (MOA) studies that revealed tubulin polymn. inhibition as the second MOA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY6WD_5NG6-7Vg90H21EOLACvtfcHk0lhw1r1622NRMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVCmt7k%253D&md5=b35b9fb022675d3d4c37e3ac8225ab67</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00164%26sid%3Dliteratum%253Aachs%26aulast%3DSmolinski%26aufirst%3DM.%2BP.%26aulast%3DBu%26aufirst%3DY.%26aulast%3DClements%26aufirst%3DJ.%26aulast%3DGelman%26aufirst%3DI.%2BH.%26aulast%3DHegab%26aufirst%3DT.%26aulast%3DCutler%26aufirst%3DD.%2BL.%26aulast%3DFang%26aufirst%3DJ.%2BW.%2BS.%26aulast%3DFetterly%26aufirst%3DG.%26aulast%3DKwan%26aufirst%3DR.%26aulast%3DBarnett%26aufirst%3DA.%26aulast%3DLau%26aufirst%3DJ.%2BY.%2BN.%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26atitle%3DDiscovery%2520of%2520novel%2520dual%2520mechanism%2520of%2520action%2520Src%2520signaling%2520and%2520tubulin%2520polymerization%2520inhibitors%2520%2528KX2%25E2%2580%2593391%2520and%2520KX2%25E2%2580%2593361%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4704%26epage%3D4719%26doi%3D10.1021%2Facs.jmedchem.8b00164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padmanabha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moquin, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doweyko, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Fex, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuster, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behnia, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schieven, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wityak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span> <span> </span><span class="NLM_article-title">2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">6819</span>– <span class="NLM_lpage">6832</span>, <span class="refDoi"> DOI: 10.1021/jm060727j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060727j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFSlsLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6819-6832&author=J.+Dasauthor=P.+Chenauthor=D.+Norrisauthor=R.+Padmanabhaauthor=J.+Linauthor=R.+V.+Moquinauthor=Z.+Shenauthor=L.+S.+Cookauthor=A.+M.+Doweykoauthor=S.+Pittauthor=S.+Pangauthor=D.+R.+Shenauthor=Q.+Fangauthor=H.+F.+de+Fexauthor=K.+W.+McIntyreauthor=D.+J.+Shusterauthor=K.+M.+Gilloolyauthor=K.+Behniaauthor=G.+L.+Schievenauthor=J.+Wityakauthor=J.+C.+Barrish&title=2-aminothiazole+as+a+novel+kinase+inhibitor+template.+Structure-activity+relationship+studies+toward+the+discovery+of+N-%282-chloro-6-methylphenyl%29-2-%5B%5B6-%5B4-%282-hydroxyethyl%29-1-+piperazinyl%29%5D-2-methyl-4-pyrimidinyl%5Damino%29%5D-1%2C3-thiazole-5-carboxamide+%28dasatinib%2C+BMS-354825%29+as+a+potent+pan-Src+kinase+inhibitor&doi=10.1021%2Fjm060727j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">2-Aminothiazole as a Novel Kinase Inhibitor Template. Structure-Activity Relationship Studies toward the Discovery of N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a Potent pan-Src Kinase Inhibitor</span></div><div class="casAuthors">Das, Jagabandhu; Chen, Ping; Norris, Derek; Padmanabha, Ramesh; Lin, James; Moquin, Robert V.; Shen, Zhongqi; Cook, Lynda S.; Doweyko, Arthur M.; Pitt, Sidney; Pang, Suhong; Shen, Ding Ren; Fang, Qiong; de Fex, Henry F.; McIntyre, Kim W.; Shuster, David J.; Gillooly, Kathleen M.; Behnia, Kamelia; Schieven, Gary L.; Wityak, John; Barrish, Joel C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6819-6832</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">2-Aminothiazole was discovered as a novel Src family kinase inhibitor template through screening of our internal compd. collection.  Optimization through successive structure-activity relationship iterations identified analogs I [R = 4-(2-hydroxyethyl)piperazino, Q] (Dasatinib, BMS-354825) and I [R = Me]as pan-Src inhibitors with nanomolar to subnanomolar potencies in biochem. and cellular assays.  Mol. modeling was used to construct a putative binding model for Lck inhibition by this class of compds.  The framework of key hydrogen-bond interactions proposed by this model was in agreement with the subsequent, published crystal structure of I [R = Q] bound to structurally similar Abl kinase.  The oral efficacy of this class of inhibitors was demonstrated with I [R = Me] in inhibiting the proinflammatory cytokine IL-2 ex vivo in mice (ED50 ∼ 5 mg/kg) and in reducing TNF levels in an acute murine model of inflammation (90% inhibition in LPS-induced TNFα prodn. when dosed orally at 60 mg/kg, 2 h prior to LPS administration).  The oral efficacy of I [R = Me] was further demonstrated in a chronic model of adjuvant arthritis in rats with established disease when administered orally at 0.3 and 3 mg/kg twice daily.  I [R = Q] is currently in clin. trials for the treatment of chronic myelogenous leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrbDd3Qks9cLVg90H21EOLACvtfcHk0lhw1r1622NRMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFSlsLrI&md5=9eed66048de7ab90b8a8015385d6f581</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1021%2Fjm060727j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060727j%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DPadmanabha%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DMoquin%26aufirst%3DR.%2BV.%26aulast%3DShen%26aufirst%3DZ.%26aulast%3DCook%26aufirst%3DL.%2BS.%26aulast%3DDoweyko%26aufirst%3DA.%2BM.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DPang%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DFang%26aufirst%3DQ.%26aulast%3Dde%2BFex%26aufirst%3DH.%2BF.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DShuster%26aufirst%3DD.%2BJ.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DBehnia%26aufirst%3DK.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DWityak%26aufirst%3DJ.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26atitle%3D2-aminothiazole%2520as%2520a%2520novel%2520kinase%2520inhibitor%2520template.%2520Structure-activity%2520relationship%2520studies%2520toward%2520the%2520discovery%2520of%2520N-%25282-chloro-6-methylphenyl%2529-2-%255B%255B6-%255B4-%25282-hydroxyethyl%2529-1-%2520piperazinyl%2529%255D-2-methyl-4-pyrimidinyl%255Damino%2529%255D-1%252C3-thiazole-5-carboxamide%2520%2528dasatinib%252C%2520BMS-354825%2529%2520as%2520a%2520potent%2520pan-Src%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6819%26epage%3D6832%26doi%3D10.1021%2Fjm060727j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, I.</span></span> <span> </span><span class="NLM_article-title">Photoaffinity labeling in target- and binding-site identification</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">183</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.4155%2Ffmc.14.152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=25686004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivVegu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=159-183&author=E.+Smithauthor=I.+Collins&title=Photoaffinity+labeling+in+target-+and+binding-site+identification&doi=10.4155%2Ffmc.14.152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Photoaffinity labeling in target- and binding-site identification</span></div><div class="casAuthors">Smith, Ewan; Collins, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">159-183</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Photoaffinity labeling (PAL) using a chem. probe to covalently bind its target in response to activation by light has become a frequently used tool in drug discovery for identifying new drug targets and mol. interactions, and for probing the location and structure of binding sites.  Methods to identify the specific target proteins of hit mols. from phenotypic screens are highly valuable in early drug discovery.  In this review, we summarize the principles of PAL including probe design and exptl. techniques for in vitro and live cell investigations.  We emphasize the need to optimize and validate probes and highlight examples of the successful application of PAL across multiple disease areas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpIXjEh35goLVg90H21EOLACvtfcHk0lhiBhB_2inTjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivVegu7c%253D&md5=ca00880405324587a542f19f8bd10d6c</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.152%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DE.%26aulast%3DCollins%26aufirst%3DI.%26atitle%3DPhotoaffinity%2520labeling%2520in%2520target-%2520and%2520binding-site%2520identification%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2015%26volume%3D7%26spage%3D159%26epage%3D183%26doi%3D10.4155%2Ffmc.14.152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Reversible binding of the anticancer drug KXO1 (tirbanibulin) to the colchicine-binding site of β-tubulin explains KXO1’s low clinical toxicity</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>294</i></span>,  <span class="NLM_fpage">18099</span>– <span class="NLM_lpage">18108</span>, <span class="refDoi"> DOI: 10.1074/jbc.RA119.010732</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1074%2Fjbc.RA119.010732" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=31628188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A280%3ADC%252BB3MnpsVaksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=2019&pages=18099-18108&author=L.+Niuauthor=J.+Yangauthor=W.+Yanauthor=Y.+Yuauthor=Y.+Zhengauthor=H.+Yeauthor=Q.+Chenauthor=L.+Chen&title=Reversible+binding+of+the+anticancer+drug+KXO1+%28tirbanibulin%29+to+the+colchicine-binding+site+of+%CE%B2-tubulin+explains+KXO1%E2%80%99s+low+clinical+toxicity&doi=10.1074%2Fjbc.RA119.010732"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Reversible binding of the anticancer drug KXO1 (tirbanibulin) to the colchicine-binding site of β-tubulin explains KXO1's low clinical toxicity</span></div><div class="casAuthors">Niu Lu; Yang Jianhong; Yan Wei; Yu Yamei; Zheng Yunhua; Ye Haoyu; Chen Qiang; Chen Lijuan</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of biological chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">18099-18108</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">KXO1 (tirbanibulin or KX2-391) is as a non-ATP-competitive inhibitor of SRC proto-oncogene nonreceptor tyrosine kinase (SRC) and is being clinically investigated for the management of various cancers and actinic keratosis.  Recently, KXO1 has also been shown to strongly inhibit tubulin.  Interestingly, unlike conventional tubulin-targeting drugs, KXO1 has exhibited low toxicity in preclinical and clinical studies, but the reason for this remains elusive, as are the KXO1-binding site and other details of the interaction of KXO1 with tubulin.  Here, cell-based experiments revealed that KXO1 induces tubulin depolymerization and G2/M phase cell cycle arrest at low nanomolar concentrations, similar to colchicine, used as a positive control.  Results from biochemical experiments, including an N,N-ethylenebis(iodoacetamide) competition assay, disclosed that KXO1 binds to the colchicine-binding site on β-tubulin, further confirmed by the crystal structure of the tubulin-KXO1 complex at 2.5-ÅA resolution.  A high-quality electron density map of the crystallographic data enabled us to unambiguously determine the position and orientation of KXO1 in the colchicine-binding site, revealing the detailed interactions between KXO1 and tubulin.  We also found that KXO1 binds reversibly to purified tubulin, induces a totally reversible cellular effect (G2/M cell cycle arrest), and possesses no cellular toxicity 5 days after drug washout, explaining KXO1's low toxicity.  In summary, we show that KXO1 binds to the colchicine-binding site of tubulin and resolved the crystal structure of the tubulin-KXO1 complex.  Importantly, KXO1's reversible binding to tubulin explains its clinically low toxicity, an insight that could guide further clinical applications of KXO1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQhfWQ2BlTvKJZoeNcnHOQ9fW6udTcc2eYs16svQsyGfbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnpsVaksA%253D%253D&md5=b3eac35ef261149a46a2531ff014ced1</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1074%2Fjbc.RA119.010732&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.RA119.010732%26sid%3Dliteratum%253Aachs%26aulast%3DNiu%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DW.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DReversible%2520binding%2520of%2520the%2520anticancer%2520drug%2520KXO1%2520%2528tirbanibulin%2529%2520to%2520the%2520colchicine-binding%2520site%2520of%2520%25CE%25B2-tubulin%2520explains%2520KXO1%25E2%2580%2599s%2520low%2520clinical%2520toxicity%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2019%26volume%3D294%26spage%3D18099%26epage%3D18108%26doi%3D10.1074%2Fjbc.RA119.010732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anbalagan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsden, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowan, B. G.</span></span> <span> </span><span class="NLM_article-title">Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1936</span>– <span class="NLM_lpage">1947</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-0146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1158%2F1535-7163.MCT-12-0146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=22784709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlWhsrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1936-1947&author=M.+Anbalaganauthor=A.+Aliauthor=R.+K.+Jonesauthor=C.+G.+Marsdenauthor=M.+Shengauthor=L.+Carrierauthor=Y.+Buauthor=D.+Hangauerauthor=B.+G.+Rowan&title=Peptidomimetic+Src%2Fpretubulin+inhibitor+KX-01+alone+and+in+combination+with+paclitaxel+suppresses+growth%2C+metastasis+in+human+ER%2FPR%2FHER2-negative+tumor+xenografts&doi=10.1158%2F1535-7163.MCT-12-0146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Peptidomimetic Src/Pretubulin Inhibitor KX-01 Alone and in Combination with Paclitaxel Suppresses Growth, Metastasis in Human ER/PR/HER2-Negative Tumor Xenografts</span></div><div class="casAuthors">Anbalagan, Muralidharan; Ali, Alaa; Jones, Ryan K.; Marsden, Carolyn G.; Sheng, Mei; Carrier, Latonya; Bu, Yahao; Hangauer, David; Rowan, Brian G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1936-1947</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Src kinase is elevated in breast tumors that are ER/PR neg. and do not overexpress HER2, but clin. trials with Src inhibitors have shown little activity.  The present study evaluated preclin. efficacy of a novel peptidomimetic compd., KX-01 (KX2-391), that exhibits dual action as an Src and pretubulin inhibitor.  KX-01 was evaluated as a single-agent and in combination with paclitaxel in MDA-MB-231, MDA-MB-157, and MDA-MB-468 human ER/PR/HER2-neg. breast cancer cells.  Treatments were evaluated by growth/apoptosis, isobologram anal., migration/invasion assays, tumor xenograft vol., metastasis, and measurement of Src, focal adhesion kinase (FAK), microtubules, Ki67, and microvessel d.  KX-01 inhibited cell growth in vitro and in combination with paclitaxel resulted in synergistic growth inhibition.  KX-01 resulted in a dose-dependent inhibition of MDA-MB-231 and MDA-MB-157 tumor xenografts (1 and 5 mg/kg, twice daily).  KX-01 inhibited activity of Src and downstream mediator FAK in tumors that was coincident with reduced proliferation and angiogenesis and increased apoptosis.  KX01 also resulted in microtubule disruption in tumors.  Combination of KX-01 with paclitaxel resulted in significant regression of MDA-MB-231 tumors and reduced metastasis to mouse lung and liver.  KX-01 is a potently active Src/pretubulin inhibitor that inhibits breast tumor growth and metastasis.  As ER/PR/HER2-neg. patients are candidates for paclitaxel therapy, combination with KX-01 may potentiate antitumor efficacy in management of this aggressive breast cancer subtype.  Mol Cancer Ther; 11(9); 1936-47. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTPQgufjmNZ7Vg90H21EOLACvtfcHk0lippRiZm-_Q1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlWhsrrI&md5=dd688323209801ec45284d3dc86ead48</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0146%26sid%3Dliteratum%253Aachs%26aulast%3DAnbalagan%26aufirst%3DM.%26aulast%3DAli%26aufirst%3DA.%26aulast%3DJones%26aufirst%3DR.%2BK.%26aulast%3DMarsden%26aufirst%3DC.%2BG.%26aulast%3DSheng%26aufirst%3DM.%26aulast%3DCarrier%26aufirst%3DL.%26aulast%3DBu%26aufirst%3DY.%26aulast%3DHangauer%26aufirst%3DD.%26aulast%3DRowan%26aufirst%3DB.%2BG.%26atitle%3DPeptidomimetic%2520Src%252Fpretubulin%2520inhibitor%2520KX-01%2520alone%2520and%2520in%2520combination%2520with%2520paclitaxel%2520suppresses%2520growth%252C%2520metastasis%2520in%2520human%2520ER%252FPR%252FHER2-negative%2520tumor%2520xenografts%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D1936%26epage%3D1947%26doi%3D10.1158%2F1535-7163.MCT-12-0146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, S. A.</span></span> <span> </span><span class="NLM_article-title">Antitumor effect of KX-01 through inhibiting Src family kinases and mitosis</span>. <i>Cancer Res. Treat</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">643</span>– <span class="NLM_lpage">655</span>, <span class="refDoi"> DOI: 10.4143/crt.2016.168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.4143%2Fcrt.2016.168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=27737538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmvF2rt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2017&pages=643-655&author=S.+Kimauthor=A.+Minauthor=K.+H.+Leeauthor=Y.+Yangauthor=T.+Y.+Kimauthor=J.+M.+Limauthor=S.+J.+Parkauthor=H.+J.+Namauthor=J.+E.+Kimauthor=S.+H.+Songauthor=S.+W.+Hanauthor=D.+Y.+Ohauthor=J.+H.+Kimauthor=T.+Y.+Kimauthor=D.+Hangauerauthor=J.+Y.+Lauauthor=K.+Imauthor=D.+S.+Leeauthor=Y.+J.+Bangauthor=S.+A.+Im&title=Antitumor+effect+of+KX-01+through+inhibiting+Src+family+kinases+and+mitosis&doi=10.4143%2Fcrt.2016.168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor effect of KX-01 through inhibiting Src family kinases and mitosis</span></div><div class="casAuthors">Kim, Seongyeong; Min, Ahrum; Lee, Kyung-Hun; Yang, Yaewon; Kim, Tae-Yong; Lim, Jee Min; Park, So Jung; Nam, Hyun-Jin; Kim, Jung Eun; Song, Sang-Hyun; Han, Sae-Won; Oh, Do-Youn; Kim, Jee Hyun; Kim, Tae-You; Hangauer, David; Lau, Johnson Yiu-Nam; Im, Kyongok; Lee, Dong Soon; Bang, Yung-Jue; Im, Seock-Ah</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">643-655</span>CODEN:
                <span class="NLM_cas:coden">CRTAC2</span>;
        ISSN:<span class="NLM_cas:issn">2005-9256</span>.
    
            (<span class="NLM_cas:orgname">Korean Cancer Association</span>)
        </div><div class="casAbstract">Purpose KX-01 is a novel dual inhibitor of Src and tubulin.  Unlike previous Src inhibitors that failed to show clin. benefit during treatment of breast cancer, KX-01 can potentially overcome the therapeutic limitations of current Src inhibitors through inhibition of both Src and tubulin.  The present study further evaluates the activity and mechanism of KX-01 in vitro and in vivo.  Materials and Methods The antitumor effect of KX-01 in triple neg. breast cancer (TNBC) cell lines was detd. by MTT assay.  Wound healing and immunofluorescence assays were performed to evaluate the action mechanisms of KX-01.  Changes in the cell cycle and mol. changes induced by KX-01 were also evaluated.  A MDA-MB-231 mouse xenograft model was used to demonstrate the in vivo effects.  Results KX-01 effectively inhibited the growth of breast cancer cell lines.  The expression of phospho-Src and proliferative-signaling mols. were down-regulated in KX-01-sensitive TNBC cell lines.  In addn., migration inhibition was obsd. by wound healing assay.  KX-01-induced G2/M cell cycle arrest and increased the aneuploid cell population in KX-01-sensitive cell lines.  Multi-nucleated cells were significantly increased after KX-01 treatment.  Furthermore, KX-01 effectively delayed tumor growth in a MDA-MB-231 mouse xenograft model.  Conclusion KX-01 effectively inhibited cell growth and migration of TNBC cells.  Moreover, this study demonstrated that KX-01 showed antitumor effects through the inhibition of Src signaling and the induction of mitotic catastrophe.  The antitumor effects of KX-01 were also demonstrated in vivo using a mouse xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmHqWoyrQksbVg90H21EOLACvtfcHk0lippRiZm-_Q1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmvF2rt7k%253D&md5=936b6a9d11d1b626394fb0605cdbdf4a</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.4143%2Fcrt.2016.168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4143%252Fcrt.2016.168%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%26aulast%3DMin%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DT.%2BY.%26aulast%3DLim%26aufirst%3DJ.%2BM.%26aulast%3DPark%26aufirst%3DS.%2BJ.%26aulast%3DNam%26aufirst%3DH.%2BJ.%26aulast%3DKim%26aufirst%3DJ.%2BE.%26aulast%3DSong%26aufirst%3DS.%2BH.%26aulast%3DHan%26aufirst%3DS.%2BW.%26aulast%3DOh%26aufirst%3DD.%2BY.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DT.%2BY.%26aulast%3DHangauer%26aufirst%3DD.%26aulast%3DLau%26aufirst%3DJ.%2BY.%26aulast%3DIm%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DD.%2BS.%26aulast%3DBang%26aufirst%3DY.%2BJ.%26aulast%3DIm%26aufirst%3DS.%2BA.%26atitle%3DAntitumor%2520effect%2520of%2520KX-01%2520through%2520inhibiting%2520Src%2520family%2520kinases%2520and%2520mitosis%26jtitle%3DCancer%2520Res.%2520Treat%26date%3D2017%26volume%3D49%26spage%3D643%26epage%3D655%26doi%3D10.4143%2Fcrt.2016.168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradeep, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecot, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottsford-Miller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zand, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennings, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallick, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baggerly, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frumovitz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sood, A. K.</span></span> <span> </span><span class="NLM_article-title">Targeting SRC and tubulin in mucinous ovarian carcinoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">6532</span>– <span class="NLM_lpage">6543</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-1305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1158%2F1078-0432.CCR-13-1305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=24100628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVOitbzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=6532-6543&author=T.+Liuauthor=W.+Huauthor=H.+J.+Daltonauthor=H.+J.+Choiauthor=J.+Huangauthor=Y.+Kangauthor=S.+Pradeepauthor=T.+Miyakeauthor=J.+H.+Songauthor=Y.+Wenauthor=C.+Luauthor=C.+V.+Pecotauthor=J.+Bottsford-Millerauthor=B.+Zandauthor=N.+B.+Jenningsauthor=C.+Ivanauthor=G.+E.+Gallickauthor=K.+A.+Baggerlyauthor=D.+G.+Hangauerauthor=R.+L.+Colemanauthor=M.+Frumovitzauthor=A.+K.+Sood&title=Targeting+SRC+and+tubulin+in+mucinous+ovarian+carcinoma&doi=10.1158%2F1078-0432.CCR-13-1305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Src and Tubulin in Mucinous Ovarian Carcinoma</span></div><div class="casAuthors">Liu, Tao; Hu, Wei; Dalton, Heather J.; Choi, Hyun Jin; Huang, Jie; Kang, Yu; Pradeep, Sunila; Miyake, Takahito; Song, Jian H.; Wen, Yunfei; Lu, Chunhua; Pecot, Chad V.; Bottsford-Miller, Justin; Zand, Behrouz; Jennings, Nicholas B.; Ivan, Cristina; Gallick, Gary E.; Baggerly, Keith A.; Hangauer, David G.; Coleman, Robert L.; Frumovitz, Michael; Sood, Anil K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6532-6543</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: To investigate the antitumor effects of targeting Src and tubulin in mucinous ovarian carcinoma.  Exptl. Design: The in vitro and in vivo effects and mol. mechanisms of KX-01, which inhibits Src pathway and tubulin polymn., were examd. in mucinous ovarian cancer models.  Results: In vitro studies using RMUG-S and RMUG-L cell lines showed that KX-01 inhibited cell proliferation, induced apoptosis, arrested the cell cycle at the G2-M phase, and enhanced the cytotoxicity of oxaliplatin in the KX-01-sensitive cell line, RMUG-S.  In vivo studies showed that KX-01 significantly decreased tumor burden in RMUG-S and RMUG-L mouse models relative to untreated controls, and the effects were greater when KX-01 was combined with oxaliplatin.  KX-01 alone and in combination with oxaliplatin significantly inhibited tumor growth by reducing cell proliferation and inducing apoptosis in vivo.  PTEN knock-in expts. in RMUG-L cells showed improved response to KX-01.  Reverse phase protein array anal. showed that in addn. to blocking downstream mols. of Src family kinases, KX-01 also activated acute stress-inducing mols.  Conclusion: Our results showed that targeting both the Src pathway and tubulin with KX-01 significantly inhibited tumor growth in preclin. mucinous ovarian cancer models, suggesting that this may be a promising therapeutic approach for patients with mucinous ovarian carcinoma.  Clin Cancer Res; 19(23); 6532-43. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGph-wBwf5SGhLVg90H21EOLACvtfcHk0liTCfuz2nSiLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVOitbzM&md5=cea052b1774b6850f996f05a5d02d10b</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-1305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-1305%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DDalton%26aufirst%3DH.%2BJ.%26aulast%3DChoi%26aufirst%3DH.%2BJ.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DY.%26aulast%3DPradeep%26aufirst%3DS.%26aulast%3DMiyake%26aufirst%3DT.%26aulast%3DSong%26aufirst%3DJ.%2BH.%26aulast%3DWen%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DPecot%26aufirst%3DC.%2BV.%26aulast%3DBottsford-Miller%26aufirst%3DJ.%26aulast%3DZand%26aufirst%3DB.%26aulast%3DJennings%26aufirst%3DN.%2BB.%26aulast%3DIvan%26aufirst%3DC.%26aulast%3DGallick%26aufirst%3DG.%2BE.%26aulast%3DBaggerly%26aufirst%3DK.%2BA.%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26aulast%3DColeman%26aufirst%3DR.%2BL.%26aulast%3DFrumovitz%26aufirst%3DM.%26aulast%3DSood%26aufirst%3DA.%2BK.%26atitle%3DTargeting%2520SRC%2520and%2520tubulin%2520in%2520mucinous%2520ovarian%2520carcinoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D6532%26epage%3D6543%26doi%3D10.1158%2F1078-0432.CCR-13-1305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anbalagan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glodowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowan, B. G.</span></span> <span> </span><span class="NLM_article-title">KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">391</span>– <span class="NLM_lpage">409</span>, <span class="refDoi"> DOI: 10.1007/s10549-011-1513-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1007%2Fs10549-011-1513-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=21509526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC38XktFOjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2012&pages=391-409&author=M.+Anbalaganauthor=L.+Carrierauthor=S.+Glodowskiauthor=D.+Hangauerauthor=B.+Shanauthor=B.+G.+Rowan&title=KX-01%2C+a+novel+Src+kinase+inhibitor+directed+toward+the+peptide+substrate+site%2C+synergizes+with+tamoxifen+in+estrogen+receptor+%CE%B1+positive+breast+cancer&doi=10.1007%2Fs10549-011-1513-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer</span></div><div class="casAuthors">Anbalagan, Muralidharan; Carrier, Latonya; Glodowski, Seth; Hangauer, David; Shan, Bin; Rowan, Brian G.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">391-409</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">KX-01 is the first clin. Src inhibitor of the novel peptidomimetic class that targets the peptide substrate site of Src providing more specificity toward Src kinase.  The present study was designed to evaluate the effects of KX-01 as a single agent and in combination with tamoxifen (TAM) on cell growth and apoptosis of ERα pos. breast cancer in vitro and in vivo.  Flow cytometry demonstrated that KX-01 induced cell cycle arrest in G2/M phase.  Immunofluorescent staining for mitotic phase markers and TUNEL staining indicated that cells had arrested in the mitotic phase and mitotic arrested cells were undergoing apoptosis.  KX-01 induced nuclear accumulation of cyclin B1, and activation of CDK1, MPM2, and Cdc25C that is required for progression past the G2/M checkpoint.  Apoptosis resulted from activation of caspases 6, 7, 8, and 9.  Combinational index anal. revealed that combinations of KX-01 with TAM resulted in synergistic growth inhibition of breast cancer cell lines.  KX-01 combined with TAM resulted in decreased ERα phosphorylation at Src-regulated phosphorylation sites serines 118 and 167 that were assocd. with reduced ERα transcriptional activity.  Orally administered KX-01 resulted in a dose dependent growth inhibition of MCF-7 tumor xenografts, and in combination with TAM exhibited synergistic growth inhibition.  Immunohistochem. anal. revealed that combinational treatment reduced angiogenesis, and ERα signaling in tumors compared to either drug alone that may underlie the synergistic tumor growth inhibition.  Combinations of KX-01 with endocrine therapy present a promising new strategy for clin. management of ERα pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDjBSgfh5qJbVg90H21EOLACvtfcHk0liTCfuz2nSiLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktFOjt7Y%253D&md5=e55cc94c076cfd5f38a715c4b55b15dd</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1007%2Fs10549-011-1513-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-011-1513-3%26sid%3Dliteratum%253Aachs%26aulast%3DAnbalagan%26aufirst%3DM.%26aulast%3DCarrier%26aufirst%3DL.%26aulast%3DGlodowski%26aufirst%3DS.%26aulast%3DHangauer%26aufirst%3DD.%26aulast%3DShan%26aufirst%3DB.%26aulast%3DRowan%26aufirst%3DB.%2BG.%26atitle%3DKX-01%252C%2520a%2520novel%2520Src%2520kinase%2520inhibitor%2520directed%2520toward%2520the%2520peptide%2520substrate%2520site%252C%2520synergizes%2520with%2520tamoxifen%2520in%2520estrogen%2520receptor%2520%25CE%25B1%2520positive%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2012%26volume%3D132%26spage%3D391%26epage%3D409%26doi%3D10.1007%2Fs10549-011-1513-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ciesielski, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munich, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teegarden, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smolinski, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clements, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J. Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangauer, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenstermaker, R. A.</span></span> <span> </span><span class="NLM_article-title">KX2–361: a novel orally bioavailable small molecule dual Src/tubulin inhibitor that provides long term survival in a murine model of glioblastoma</span>. <i>J. Neuro-Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">519</span>– <span class="NLM_lpage">527</span>, <span class="refDoi"> DOI: 10.1007/s11060-018-2992-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1007%2Fs11060-018-2992-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=30238350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslOjsrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2018&pages=519-527&author=M.+J.+Ciesielskiauthor=Y.+Buauthor=S.+A.+Munichauthor=P.+Teegardenauthor=M.+P.+Smolinskiauthor=J.+L.+Clementsauthor=J.+Y.+N.+Lauauthor=D.+G.+Hangauerauthor=R.+A.+Fenstermaker&title=KX2%E2%80%93361%3A+a+novel+orally+bioavailable+small+molecule+dual+Src%2Ftubulin+inhibitor+that+provides+long+term+survival+in+a+murine+model+of+glioblastoma&doi=10.1007%2Fs11060-018-2992-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">KX2-361: a novel orally bioavailable small molecule dual Src/tubulin inhibitor that provides long term survival in a murine model of glioblastoma</span></div><div class="casAuthors">Ciesielski, Michael J.; Bu, Yahao; Munich, Stephan A.; Teegarden, Paola; Smolinski, Michael P.; Clements, James L.; Lau, Johnson Y. N.; Hangauer, David G.; Fenstermaker, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuro-Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">519-527</span>CODEN:
                <span class="NLM_cas:coden">JNODD2</span>;
        ISSN:<span class="NLM_cas:issn">0167-594X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: A major challenge to developing new therapies for patients with malignant brain tumors is that relatively few small mol. anticancer drugs penetrate the blood-brain barrier (BBB) well enough to provide therapeutically effective concns. in brain tissue before drug exposure in non-CNS tissues results in unacceptable toxicity.  Methods: KX2-361, a member of a novel family of compds. with Src-kinase and tubulin polymn. inhibitory activity, demonstrates good oral bioavailability and readily crosses the BBB in mice.  The objective of this study was to investigate the activity of KX2-361 against human and murine glioma cells and assess its therapeutic effect in a syngeneic orthotopic model of glioblastoma.  Results: In addn. to reducing the level of Src autophosphorylation in the GL261 murine glioblastoma cell line, KX2-361 binds directly to tubulin and disrupts microtubule architecture in glioma cells maintained in culture.  Conclusions: The drug is active in vivo against orthotopic GL261 gliomas in syngeneic C57BL/6 mice.  Long term survival is not obsd. in mice lacking an adaptive immune system, indicating that KX2-361 works in concert with the host immune system to control tumor growth and promote long-term survival in the GL261 glioma model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIImeMoLHmy7Vg90H21EOLACvtfcHk0liVKVPk1aqs1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslOjsrjM&md5=df3e383df04e08671bd7fc4df6e5d824</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1007%2Fs11060-018-2992-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11060-018-2992-4%26sid%3Dliteratum%253Aachs%26aulast%3DCiesielski%26aufirst%3DM.%2BJ.%26aulast%3DBu%26aufirst%3DY.%26aulast%3DMunich%26aufirst%3DS.%2BA.%26aulast%3DTeegarden%26aufirst%3DP.%26aulast%3DSmolinski%26aufirst%3DM.%2BP.%26aulast%3DClements%26aufirst%3DJ.%2BL.%26aulast%3DLau%26aufirst%3DJ.%2BY.%2BN.%26aulast%3DHangauer%26aufirst%3DD.%2BG.%26aulast%3DFenstermaker%26aufirst%3DR.%2BA.%26atitle%3DKX2%25E2%2580%2593361%253A%2520a%2520novel%2520orally%2520bioavailable%2520small%2520molecule%2520dual%2520Src%252Ftubulin%2520inhibitor%2520that%2520provides%2520long%2520term%2520survival%2520in%2520a%2520murine%2520model%2520of%2520glioblastoma%26jtitle%3DJ.%2520Neuro-Oncol.%26date%3D2018%26volume%3D140%26spage%3D519%26epage%3D527%26doi%3D10.1007%2Fs11060-018-2992-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tainsky, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huebner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croce, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vande
Woude, G. F.</span></span> <span> </span><span class="NLM_article-title">Molecular cloning of a new transforming gene from a chemically transformed human cell line</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>311</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1038/311029a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1038%2F311029a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=6590967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADyaL2cXmt1ersbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=1984&pages=29-33&author=C.+S.+Cooperauthor=M.+Parkauthor=D.+G.+Blairauthor=M.+A.+Tainskyauthor=K.+Huebnerauthor=C.+M.+Croceauthor=G.+F.+Vande%0AWoude&title=Molecular+cloning+of+a+new+transforming+gene+from+a+chemically+transformed+human+cell+line&doi=10.1038%2F311029a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular cloning of a new transforming gene from a chemically transformed human cell line</span></div><div class="casAuthors">Cooper, Colin S.; Park, Morag; Blair, Donald G.; Tainsky, Michael A.; Huebner, Kay; Croce, Carlo M.; Vande Woude, George F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">311</span>
        (<span class="NLM_cas:issue">5981</span>),
    <span class="NLM_cas:pages">29-33</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">Mol. cloning of the transforming gene from a chem. transformed human osteosarcoma-derived cell line enables the gene to be mapped to chromosome 7 (7p11.4-7qter) and by this criterion and by direct hybridization to be unrelated to known oncogenes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP9IGyWhLtabVg90H21EOLACvtfcHk0liVKVPk1aqs1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXmt1ersbk%253D&md5=7cf32881870e75ecabce2c8206b31c20</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1038%2F311029a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F311029a0%26sid%3Dliteratum%253Aachs%26aulast%3DCooper%26aufirst%3DC.%2BS.%26aulast%3DPark%26aufirst%3DM.%26aulast%3DBlair%26aufirst%3DD.%2BG.%26aulast%3DTainsky%26aufirst%3DM.%2BA.%26aulast%3DHuebner%26aufirst%3DK.%26aulast%3DCroce%26aufirst%3DC.%2BM.%26aulast%3DVande%2BWoude%26aufirst%3DG.%2BF.%26atitle%3DMolecular%2520cloning%2520of%2520a%2520new%2520transforming%2520gene%2520from%2520a%2520chemically%2520transformed%2520human%2520cell%2520line%26jtitle%3DNature%26date%3D1984%26volume%3D311%26spage%3D29%26epage%3D33%26doi%3D10.1038%2F311029a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Danilkovitch-Miagkova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zbar, B.</span></span> <span> </span><span class="NLM_article-title">Dysregulation of Met receptor tyrosine kinase activity in invasive tumors</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">863</span>– <span class="NLM_lpage">867</span>, <span class="refDoi"> DOI: 10.1172/JCI0215418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1172%2FJCI0215418" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=11927612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD38Xis1Kju74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2002&pages=863-867&author=A.+Danilkovitch-Miagkovaauthor=B.+Zbar&title=Dysregulation+of+Met+receptor+tyrosine+kinase+activity+in+invasive+tumors&doi=10.1172%2FJCI0215418"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Dysregulation of met receptor tyrosine kinase activity in invasive tumors</span></div><div class="casAuthors">Danilkovitch-Miagkova, Alla; Zbar, Berton</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">863-867</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  The oncogenic Met has the ability to mediate chem. induced transformation of a human osteogenic sarcoma cell line.  Met expression has been found in papillary carcinomas of the thyroid gland, in carcinomas of colon, pancreas, and ovary, in osteogenic sarcomas, and in other types of cancer.  Several exptl. and clin. data showed the role of HGF and Met in tumor invasive growth, a stage of tumor progression resulting in metastases.  Dysregulation of Met activity in cells is thought to be a key event underlying tumor metastasis, and Met overexpression and hyperactivation correlated with metastatic ability of the tumor cells.  The mechanisms resulting in dysregulation in tumor cells and the consequences of Met dysregulation by various mechanisms are discussed.  The dysregulated cell motility and the resulting tumor metastasis that follow from inappropriate Met activation involve collaborations with many other receptors and multiple signaling pathways.  Met can function as part of other receptor complexes and can respond to stimuli that do not impinge on it directly.  On the other hand, dysregulated Met may promote activation of these other receptors.  Both kinds of interactions have profound consequences for the invasive growth of tumors and, indeed, of healthy cells and tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2BsZnOEEDt7Vg90H21EOLACvtfcHk0liVKVPk1aqs1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xis1Kju74%253D&md5=58373f3f2bf58ce5be1702d7580ba20e</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1172%2FJCI0215418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI0215418%26sid%3Dliteratum%253Aachs%26aulast%3DDanilkovitch-Miagkova%26aufirst%3DA.%26aulast%3DZbar%26aufirst%3DB.%26atitle%3DDysregulation%2520of%2520Met%2520receptor%2520tyrosine%2520kinase%2520activity%2520in%2520invasive%2520tumors%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2002%26volume%3D109%26spage%3D863%26epage%3D867%26doi%3D10.1172%2FJCI0215418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">France, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashwell, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moussa, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leggett, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. J.</span></span> <span> </span><span class="NLM_article-title">ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1544</span>– <span class="NLM_lpage">1553</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-1173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1158%2F1535-7163.MCT-09-1173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=20484018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntFGgsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=1544-1553&author=N.+Munshiauthor=S.+Jeayauthor=Y.+Liauthor=C.+R.+Chenauthor=D.+S.+Franceauthor=M.+A.+Ashwellauthor=J.+Hillauthor=M.+M.+Moussaauthor=D.+S.+Leggettauthor=C.+J.+Li&title=ARQ+197%2C+a+novel+and+selective+inhibitor+of+the+human+c-Met+receptor+tyrosine+kinase+with+antitumor+activity&doi=10.1158%2F1535-7163.MCT-09-1173"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity</span></div><div class="casAuthors">Munshi, Neru; Jeay, Sebastien; Li, Youzhi; Chen, Chang-Rung; France, Dennis S.; Ashwell, Mark A.; Hill, Jason; Moussa, Magdi M.; Leggett, David S.; Li, Chiang J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1544-1553</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The met proto-oncogene is functionally linked with tumorigenesis and metastatic progression.  Validation of the receptor tyrosine kinase c-Met as a selective anticancer target has awaited the emergence of selective c-Met inhibitors.  Herein, we report ARQ 197 as the first non-ATP-competitive small mol. that selectively targets the c-Met receptor tyrosine kinase.  Exposure to ARQ 197 resulted in the inhibition of proliferation of c-Met-expressing cancer cell lines as well as the induction of caspase-dependent apoptosis in cell lines with constitutive c-Met activity.  These cellular responses to ARQ 197 were phenocopied by RNAi-mediated c-Met depletion and further demonstrated by the growth inhibition of human tumors following oral administration of ARQ 197 in multiple mouse xenograft efficacy studies.  Cumulatively, these data suggest that ARQ 197, currently in phase II clin. trials, is a promising agent for targeting cancers in which c-Met-driven signaling is important for their survival and proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxYa8M1T1wfLVg90H21EOLACvtfcHk0lifFTOMKkVsoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntFGgsL0%253D&md5=2fd9c4ad5be6e1a119f2aa9699bb9519</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-1173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-1173%26sid%3Dliteratum%253Aachs%26aulast%3DMunshi%26aufirst%3DN.%26aulast%3DJeay%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DC.%2BR.%26aulast%3DFrance%26aufirst%3DD.%2BS.%26aulast%3DAshwell%26aufirst%3DM.%2BA.%26aulast%3DHill%26aufirst%3DJ.%26aulast%3DMoussa%26aufirst%3DM.%2BM.%26aulast%3DLeggett%26aufirst%3DD.%2BS.%26aulast%3DLi%26aufirst%3DC.%2BJ.%26atitle%3DARQ%2520197%252C%2520a%2520novel%2520and%2520selective%2520inhibitor%2520of%2520the%2520human%2520c-Met%2520receptor%2520tyrosine%2520kinase%2520with%2520antitumor%2520activity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D1544%26epage%3D1553%26doi%3D10.1158%2F1535-7163.MCT-09-1173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adjei, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garmey, E.</span></span> <span> </span><span class="NLM_article-title">Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">788</span>– <span class="NLM_lpage">799</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.2010-0380</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1634%2Ftheoncologist.2010-0380" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=21632449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlSkt7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=788-799&author=A.+A.+Adjeiauthor=B.+Schwartzauthor=E.+Garmey&title=Early+clinical+development+of+ARQ+197%2C+a+selective%2C+non-ATP-competitive+inhibitor+targeting+MET+tyrosine+kinase+for+the+treatment+of+advanced+cancers&doi=10.1634%2Ftheoncologist.2010-0380"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers</span></div><div class="casAuthors">Adjei, Alex A.; Schwartz, Brian; Garmey, Edward</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">788-799</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">A review.  Expression of the receptor tyrosine kinase c-MET (MET, mesenchymal-epithelial transition factor) in many cancers, and its participation in multiple signal transduction pathways involved in malignant tumor growth, suggest a wide therapeutic potential for MET inhibition in human cancer.  Here we describe the discovery and early clin. development of ARQ 197, a novel, selective, non-ATP-competitive inhibitor of MET.  Phase I studies demonstrate that ARQ 197 has a predictable pharmacokinetics and favorable safety profile, making it a potentially ideal partner for combination with cytotoxic chemotherapies and targeted anticancer agents.  Results from phase I and phase II trials demonstrate preliminary evidence of anticancer activity.  New data from a global phase II randomized trial comparing a combination of ARQ 197 plus erlotinib with erlotinib/placebo, in endothelial growth factor receptor inhibitor-naive patients with locally advanced/metastatic non-small cell lung cancer, demonstrate improvement in progression-free and overall survival with combined therapy.  Results were esp. pronounced for patients with non-squamous lung cancer histologies, and in particular molecularly defined subgroups including KRAS mutations.  These and other data from ARQ 197 clin. trials in hepatocellular, germ-cell, pancreatic (in combination with gemcitabine), and colorectal (in combination with cetuximab and irinotecan) cancers further highlight the potential role of ARQ 197 in existing and emerging anticancer therapeutic regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqjgY3d_H9lrVg90H21EOLACvtfcHk0lifFTOMKkVsoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlSkt7nK&md5=d2c0a70dcb044937bbb938e5d9f8b5d4</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2010-0380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2010-0380%26sid%3Dliteratum%253Aachs%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DGarmey%26aufirst%3DE.%26atitle%3DEarly%2520clinical%2520development%2520of%2520ARQ%2520197%252C%2520a%2520selective%252C%2520non-ATP-competitive%2520inhibitor%2520targeting%2520MET%2520tyrosine%2520kinase%2520for%2520the%2520treatment%2520of%2520advanced%2520cancers%26jtitle%3DOncologist%26date%3D2011%26volume%3D16%26spage%3D788%26epage%3D799%26doi%3D10.1634%2Ftheoncologist.2010-0380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laux, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savage, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garmey, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Just, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, L. S.</span></span> <span> </span><span class="NLM_article-title">Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">5903</span>– <span class="NLM_lpage">5911</span>, <span class="refDoi"> DOI: 10.1002/cncr.27575</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1002%2Fcncr.27575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=22605616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs12itLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2012&pages=5903-5911&author=J.+W.+Goldmanauthor=I.+Lauxauthor=F.+Chaiauthor=R.+E.+Savageauthor=D.+Ferrariauthor=E.+G.+Garmeyauthor=R.+G.+Justauthor=L.+S.+Rosen&title=Phase+1+dose-escalation+trial+evaluating+the+combination+of+the+selective+MET+%28mesenchymal-epithelial+transition+factor%29+inhibitor+tivantinib+%28ARQ+197%29+plus+erlotinib&doi=10.1002%2Fcncr.27575"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib</span></div><div class="casAuthors">Goldman, Jonathan W.; Laux, Isett; Chai, Feng; Savage, Ronald E.; Ferrari, Dora; Garmey, Edward G.; Just, Richard G.; Rosen, Lee S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5903-5911</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">BACKGROUND: : Amplification of the mesenchymal-epithelial transition factor (MET) gene can promote tumor resistance to epidermal growth factor receptor (EGFR) inhibition.  Dual EGFR-MET inhibition may overcome this resistance.  Tivantinib (ARQ 197) is a selective, oral, non-ATP-competitive, small-mol. inhibitor of the MET receptor tyrosine kinase.  This phase 1 trial assessed the safety, pharmacokinetics, and preliminary antitumor activity of tivantinib combined with the EGFR inhibitor erlotinib.  METHODS: : Patients with advanced solid malignancies were administered oral tivantinib at escalating doses of 120, 240, 360, and 480 mg twice daily (BID) plus 150 mg erlotinib once daily (QD).  Single or multiple intrapatient dose escalation was planned in the absence of dose-limiting toxicity in the first cycle of therapy (21 days).  RESULTS: : Thirty-two patients received combination treatment.  Tivantinib serum concns. were not dose-proportional.  The most common (≥20%) adverse events (AEs) regardless of causality included rash (n = 17), fatigue (n = 12), nausea (n = 10), abdominal pain (n = 10), diarrhea (n = 9), bradycardia (n = 9), and anemia (n = 7).  AEs considered related to study treatment occurred in 28 patients (87.5%), and 5 patients (15.6%) had treatment-related serious AEs, including neutropenia, leukopenia, syncope, sinus bradycardia, and sick sinus syndrome.  Fifteen of 32 patients (46.8%) had a partial response (n = 1) or stable disease (n = 14) as assessed by Response Evaluation Criteria in Solid Tumors.  Six of 8 patients with nonsmall cell lung cancer achieved stable disease.  The recommended phase 2 dose is tivantinib 360 mg BID plus erlotinib 150 mg QD.  CONCLUSIONS: : Tivantinib plus erlotinib was well tolerated with encouraging clin. activity, esp. in patients with nonsmall cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGos__Hafq2fDLVg90H21EOLACvtfcHk0lg9PR9bBQIfqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs12itLnL&md5=22a89a1273b9c4919236a0bc689f28a3</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1002%2Fcncr.27575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.27575%26sid%3Dliteratum%253Aachs%26aulast%3DGoldman%26aufirst%3DJ.%2BW.%26aulast%3DLaux%26aufirst%3DI.%26aulast%3DChai%26aufirst%3DF.%26aulast%3DSavage%26aufirst%3DR.%2BE.%26aulast%3DFerrari%26aufirst%3DD.%26aulast%3DGarmey%26aufirst%3DE.%2BG.%26aulast%3DJust%26aufirst%3DR.%2BG.%26aulast%3DRosen%26aufirst%3DL.%2BS.%26atitle%3DPhase%25201%2520dose-escalation%2520trial%2520evaluating%2520the%2520combination%2520of%2520the%2520selective%2520MET%2520%2528mesenchymal-epithelial%2520transition%2520factor%2529%2520inhibitor%2520tivantinib%2520%2528ARQ%2520197%2529%2520plus%2520erlotinib%26jtitle%3DCancer%26date%3D2012%26volume%3D118%26spage%3D5903%26epage%3D5911%26doi%3D10.1002%2Fcncr.27575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoyama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh-Hara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, N.</span></span> <span> </span><span class="NLM_article-title">Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">3087</span>– <span class="NLM_lpage">3096</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-12-3256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1158%2F0008-5472.CAN-12-3256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=23598276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsFejsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=3087-3096&author=R.+Katayamaauthor=A.+Aoyamaauthor=T.+Yamoriauthor=J.+Qiauthor=T.+Oh-Haraauthor=Y.+Songauthor=J.+A.+Engelmanauthor=N.+Fujita&title=Cytotoxic+activity+of+tivantinib+%28ARQ+197%29+is+not+due+solely+to+c-MET+inhibition&doi=10.1158%2F0008-5472.CAN-12-3256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition</span></div><div class="casAuthors">Katayama, Ryohei; Aoyama, Aki; Yamori, Takao; Qi, Jie; Oh-hara, Tomoko; Song, Youngchul; Engelman, Jeffrey A.; Fujita, Naoya</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3087-3096</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase c-MET is the high-affinity receptor for the hepatocyte growth factor (HGF).  The HGF/c-MET axis is often dysregulated in tumors. c-MET activation can be caused by MET gene amplification, activating mutations, and auto- or paracrine mechanisms.  Thus, c-MET inhibitors are under development as anticancer drugs.  Tivantinib (ARQ 197) was reported as a small-mol. c-MET inhibitor and early clin. studies suggest antitumor activity.  To assess whether the antitumor activity of tivantinib was due to inhibition of c-MET, we compared the activity of tivantinib with other c-MET inhibitors in both c-MET-addicted and nonaddicted cancer cells.  As expected, other c-MET inhibitors, crizotinib and PHA-665752, suppressed the growth of c-MET-addicted cancers, but not the growth of cancers that are not addicted to c-MET.  In contrast, tivantinib inhibited cell viability with similar potency in both c-MET-addicted and nonaddicted cells.  These results suggest that tivantinib exhibits its antitumor activity in a manner independent of c-MET status.  Tivantinib treatment induced a G2-M cell-cycle arrest in EBC1 cells similarly to vincristine treatment, whereas PHA-665752 or crizotinib treatment markedly induced G0-G1 cell-cycle arrest.  To identify the addnl. mol. target of tivantinib, we conducted COMPARE anal., an in silico screening of a database of drug sensitivities across 39 cancer cell lines (JFCR39), and identified microtubule as a target of tivantinib.  Tivantinib-treated cells showed typical microtubule disruption similar to vincristine and inhibited microtubule assembly in vitro.  These results suggest that tivantinib inhibits microtubule polymn. in addn. to inhibiting c-MET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTD-_8Jg3bHbVg90H21EOLACvtfcHk0lg9PR9bBQIfqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsFejsb4%253D&md5=dea0d14f1c5e1739064899f2f7e85257</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-12-3256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-12-3256%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DAoyama%26aufirst%3DA.%26aulast%3DYamori%26aufirst%3DT.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DOh-Hara%26aufirst%3DT.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DFujita%26aufirst%3DN.%26atitle%3DCytotoxic%2520activity%2520of%2520tivantinib%2520%2528ARQ%2520197%2529%2520is%2520not%2520due%2520solely%2520to%2520c-MET%2520inhibition%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D3087%26epage%3D3096%26doi%3D10.1158%2F0008-5472.CAN-12-3256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gigant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery</span>. <i>FEBS J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">102</span>– <span class="NLM_lpage">111</span>, <span class="refDoi"> DOI: 10.1111/febs.13555</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1111%2Ffebs.13555" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=26462166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKktrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2016&pages=102-111&author=Y.+Wangauthor=H.+Zhangauthor=B.+Gigantauthor=Y.+Yuauthor=Y.+Wuauthor=X.+Chenauthor=Q.+Laiauthor=Z.+Yangauthor=Q.+Chenauthor=J.+Yang&title=Structures+of+a+diverse+set+of+colchicine+binding+site+inhibitors+in+complex+with+tubulin+provide+a+rationale+for+drug+discovery&doi=10.1111%2Ffebs.13555"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery</span></div><div class="casAuthors">Wang, Yuxi; Zhang, Hang; Gigant, Benoit; Yu, Yamei; Wu, Yangping; Chen, Xiangzheng; Lai, Qinhuai; Yang, Zhaoya; Chen, Qiang; Yang, Jinliang</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">102-111</span>CODEN:
                <span class="NLM_cas:coden">FJEOAC</span>;
        ISSN:<span class="NLM_cas:issn">1742-464X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Microtubules are dynamic assemblies of αβ-tubulin heterodimers and have been recognized as highly attractive targets for cancer chemotherapy.  A broad range of agents bind to tubulin and interfere with microtubule assembly.  Despite having a long history of characterization, colchicine binding site inhibitors (CBSIs) have not yet reached the com. phase as anti-cancer drugs to date.  We detd. the structures of tubulin complexed with a set of structurally diverse CBSIs (lexibulin, nocodazole, plinabulin and tivantinib), among which nocodazole and tivantinib are both binary-function inhibitors targeting cancer-related kinases and microtubules simultaneously.  High resoln. structures revealed the detailed interactions between these ligands and tubulin.  Our results showed that the binding modes of the CBSIs were different from previous docking models, highlighting the importance of crystal structure information in structure-based drug design.  A real structure-based pharmacophore was proposed to rationalize key common interactions of the CBSIs at the colchicine domain.  Our studies provide a solid structural basis for developing new anti-cancer agents for the colchicine binding site.  Database : The at. coordinates and structure factors for tubulin complexed with lexibulin, nocodazole, plinabulin and tivantinib have been deposited in the Protein Data Bank under accession codes , , and , resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSIAVSS_EsIbVg90H21EOLACvtfcHk0liMW0W40Xu29Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKktrzP&md5=d5a17d9a3ac54d8eda44d0543ffa5fbd</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1111%2Ffebs.13555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Ffebs.13555%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DGigant%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLai%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DStructures%2520of%2520a%2520diverse%2520set%2520of%2520colchicine%2520binding%2520site%2520inhibitors%2520in%2520complex%2520with%2520tubulin%2520provide%2520a%2520rationale%2520for%2520drug%2520discovery%26jtitle%3DFEBS%2520J.%26date%3D2016%26volume%3D283%26spage%3D102%26epage%3D111%26doi%3D10.1111%2Ffebs.13555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eathiraj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volckova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirschi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">France, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashwell, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, T. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>286</i></span>,  <span class="NLM_fpage">20666</span>– <span class="NLM_lpage">20676</span>, <span class="refDoi"> DOI: 10.1074/jbc.M110.213801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1074%2Fjbc.M110.213801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=21454604" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFCgtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=20666-20676&author=S.+Eathirajauthor=R.+Palmaauthor=E.+Volckovaauthor=M.+Hirschiauthor=D.+S.+Franceauthor=M.+A.+Ashwellauthor=T.+C.+Chan&title=Discovery+of+a+novel+mode+of+protein+kinase+inhibition+characterized+by+the+mechanism+of+inhibition+of+human+mesenchymal-epithelial+transition+factor+%28c-Met%29+protein+autophosphorylation+by+ARQ+197&doi=10.1074%2Fjbc.M110.213801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel Mode of Protein Kinase Inhibition Characterized by the Mechanism of Inhibition of Human Mesenchymal-epithelial Transition Factor (c-Met) Protein Autophosphorylation by ARQ 197</span></div><div class="casAuthors">Eathiraj, Sudharshan; Palma, Rocio; Volckova, Erika; Hirschi, Marscha; France, Dennis S.; Ashwell, Mark A.; Chan, Thomas C. K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">20666-20676</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A no. of human malignancies exhibit sustained stimulation, mutation, or gene amplification of the receptor tyrosine kinase human mesenchymal-epithelial transition factor c-Met.  ARQ 197 is a clin. advanced, selective, orally bioavailable, and well tolerated c-Met inhibitor, currently in Phase 3 clin. testing in non-small cell lung cancer patients.  Herein, the authors describe the mol. and structural basis by which ARQ 197 selectively targets c-Met.  Through the authors' anal. the authors reveal a previously undisclosed, novel inhibitory mechanism that utilizes distinct regulatory elements of the c-Met kinase.  The structure of ARQ 197 in complex with the c-Met kinase domain shows that the inhibitor binds a conformation that is distinct from published kinase structures.  ARQ 197 inhibits c-Met autophosphorylation and is highly selective for the inactive or unphosphorylated form of c-Met.  Through the authors' anal. of the interplay between the regulatory and catalytic residues of c-Met, and by comparison between the autoinhibited canonical conformation of c-Met bound by ARQ 197 to previously described kinase domains of type III receptor tyrosine kinases, the authors believe this to be the basis of a powerful new in silico approach for the design of similar inhibitors for other protein kinases of therapeutic interest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY0thp4qAFF7Vg90H21EOLACvtfcHk0liMW0W40Xu29Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFCgtbo%253D&md5=e7cf95b0bd6893514fd9a1c726ad71b9</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M110.213801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M110.213801%26sid%3Dliteratum%253Aachs%26aulast%3DEathiraj%26aufirst%3DS.%26aulast%3DPalma%26aufirst%3DR.%26aulast%3DVolckova%26aufirst%3DE.%26aulast%3DHirschi%26aufirst%3DM.%26aulast%3DFrance%26aufirst%3DD.%2BS.%26aulast%3DAshwell%26aufirst%3DM.%2BA.%26aulast%3DChan%26aufirst%3DT.%2BC.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520mode%2520of%2520protein%2520kinase%2520inhibition%2520characterized%2520by%2520the%2520mechanism%2520of%2520inhibition%2520of%2520human%2520mesenchymal-epithelial%2520transition%2520factor%2520%2528c-Met%2529%2520protein%2520autophosphorylation%2520by%2520ARQ%2520197%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26spage%3D20666%26epage%3D20676%26doi%3D10.1074%2Fjbc.M110.213801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ye, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choueiri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logothetis, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu-Lee, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. H.</span></span> <span> </span><span class="NLM_article-title">Aberrant expression of katanin p60 in prostate cancer bone metastasis</span>. <i>Prostate</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">291</span>– <span class="NLM_lpage">300</span>, <span class="refDoi"> DOI: 10.1002/pros.21431</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1002%2Fpros.21431" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=21681775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjsl2itA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=291-300&author=X.+Yeauthor=Y.+C.+Leeauthor=M.+Choueiriauthor=K.+Chuauthor=C.+F.+Huangauthor=W.+W.+Tsaiauthor=R.+Kobayashiauthor=C.+J.+Logothetisauthor=L.+Y.+Yu-Leeauthor=S.+H.+Lin&title=Aberrant+expression+of+katanin+p60+in+prostate+cancer+bone+metastasis&doi=10.1002%2Fpros.21431"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Aberrant expression of katanin p60 in prostate cancer bone metastasis</span></div><div class="casAuthors">Ye, Xiangcang; Lee, Yu-Chen; Choueiri, Michel; Chu, Khoi; Huang, Chih-Fen; Tsai, Wen-Wei; Kobayashi, Ryuji; Logothetis, Christopher J.; Yu-Lee, Li-Yuan; Lin, Sue-Hwa</div><div class="citationInfo"><span class="NLM_cas:title">Prostate (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">291-300</span>CODEN:
                <span class="NLM_cas:coden">PRSTDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-4137</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Katanin p60 is a microtubule-severing protein and is involved in microtubule cytoskeleton organization in both mitotic and non-mitotic processes.  Its role in cancer metastasis is unknown.  Differential protein profiles of bone marrow aspirates were analyzed by chromatog., electrophoresis, and mass spectrometry.  Expression of katanin p60 in primary and metastatic prostate cancer was examd. by immunohistochem.  Cellular function of katanin p60 was further examd. in prostate cell lines.  In a proteomic profiling of bone marrow aspirates from men with prostate cancer, we found that katanin p60 was one of the proteins differentially expressed in bone metastasis samples.  Immunohistochem. staining showed that katanin p60 was expressed in the basal cells in normal human prostate glands.  In prostatic adenocarcinomas, in which the basal cells were absent, katanin p60 was expressed in the prostate cancer cells.  In the specimens from bone metastasis, katanin p60 was detectable in the metastatic cancer cells.  Strikingly, some of the metastatic cancer cells also co-expressed basal cell biomarkers including the tumor suppressor p53-homologous protein p63 and the high mol. wt. cytokeratins, suggesting that the metastatic prostate cancer cells may have a basal cell-like phenotype.  Moreover, overexpression of katanin p60 inhibited prostate cancer cell proliferation but enhanced cell migration activity.  Katanin p60 was aberrantly expressed during prostate cancer progression.  Its expression in the metastatic cells in bone was assocd. with the re-emergence of a basal cell-like phenotype.  The elevated katanin p60 expression may contribute to cancer cell metastasis via a stimulatory effect on cell motility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9sgS_WA-2CbVg90H21EOLACvtfcHk0limGaZr3LEK_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjsl2itA%253D%253D&md5=f1d4077463247cff8591da9126e1adc7</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1002%2Fpros.21431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpros.21431%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DX.%26aulast%3DLee%26aufirst%3DY.%2BC.%26aulast%3DChoueiri%26aufirst%3DM.%26aulast%3DChu%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DC.%2BF.%26aulast%3DTsai%26aufirst%3DW.%2BW.%26aulast%3DKobayashi%26aufirst%3DR.%26aulast%3DLogothetis%26aufirst%3DC.%2BJ.%26aulast%3DYu-Lee%26aufirst%3DL.%2BY.%26aulast%3DLin%26aufirst%3DS.%2BH.%26atitle%3DAberrant%2520expression%2520of%2520katanin%2520p60%2520in%2520prostate%2520cancer%2520bone%2520metastasis%26jtitle%3DProstate%26date%3D2012%26volume%3D72%26spage%3D291%26epage%3D300%26doi%3D10.1002%2Fpros.21431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sudo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maru, Y.</span></span> <span> </span><span class="NLM_article-title">LAPSER1 is a putative cytokinetic tumor suppressor that shows the same centrosome and midbody subcellular localization pattern as p80 katanin</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2086</span>– <span class="NLM_lpage">2100</span>, <span class="refDoi"> DOI: 10.1096/fj.06-7254com</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1096%2Ffj.06-7254com" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=17351128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnvVagsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=2086-2100&author=H.+Sudoauthor=Y.+Maru&title=LAPSER1+is+a+putative+cytokinetic+tumor+suppressor+that+shows+the+same+centrosome+and+midbody+subcellular+localization+pattern+as+p80+katanin&doi=10.1096%2Ffj.06-7254com"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">LAPSER1 is a putative cytokinetic tumor suppressor that shows the same centrosome and midbody subcellular localization pattern as p80 katanin</span></div><div class="casAuthors">Sudo, Haruka; Maru, Yoshiro</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2086-2100, 10.1096/fj.06-7254com</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Prostate cancer is one of the most common cancers in men, with more than 500,000 new worldwide cases reported annually, resulting in 200,000 deaths of mainly older men in developed countries.  Existing treatments have not proved very effective in managing prostate cancer, and continuing efforts therefore are ongoing to explore novel targets and strategies for future therapies.  LAPSER1 has been identified as a candidate tumor suppressor gene in prostate cancer, but its true functions remain unknown.  We report here that LAPSER1 colocalizes to the centrosomes and mid-bodies in mitotic cells with γ-tubulin, MKLP1, and p80 katanin, and is involved in cytokinesis.  Moreover, RNAi-mediated disruption of LAPSER1, which is accompanied by the mislocalization of p80 katanin, results in malformation of the central spindle.  Significantly, the enhanced expression of LAPSER1 induces binucleation and renders the cells resistant to oncogenic transformation.  In cells transformed by the v-Fps oncogene, overexpressed LAPSER1 induces abortive cytokinesis, followed by mitotic catastrophe in a p80 katanin-dependent manner.  Cells that are rescued from this apoptotic pathway with Z-VAD-fmk display karyokinesis.  These results suggest that LAPSER1 participates in cytokinesis by interacting with p80 katanin, the disruption of which may potentially cause genetic instability and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6HEJ2ibPbU7Vg90H21EOLACvtfcHk0limGaZr3LEK_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnvVagsL8%253D&md5=d615348025024af922cb3d487f08e641</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1096%2Ffj.06-7254com&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.06-7254com%26sid%3Dliteratum%253Aachs%26aulast%3DSudo%26aufirst%3DH.%26aulast%3DMaru%26aufirst%3DY.%26atitle%3DLAPSER1%2520is%2520a%2520putative%2520cytokinetic%2520tumor%2520suppressor%2520that%2520shows%2520the%2520same%2520centrosome%2520and%2520midbody%2520subcellular%2520localization%2520pattern%2520as%2520p80%2520katanin%26jtitle%3DFASEB%2520J.%26date%3D2007%26volume%3D21%26spage%3D2086%26epage%3D2100%26doi%3D10.1096%2Ffj.06-7254com" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. C.</span></span> <span> </span><span class="NLM_article-title">Purine-type compounds induce microtubule fragmentation and lung cancer cell death through interaction with katanin</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8521</span>– <span class="NLM_lpage">8534</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00797</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00797" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOgtrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8521-8534&author=T.+C.+Kuoauthor=L.+W.+Liauthor=S.+H.+Panauthor=J.+M.+Fangauthor=J.+H.+Liuauthor=T.+J.+Chengauthor=C.+J.+Wangauthor=P.+F.+Hungauthor=H.+Y.+Chenauthor=T.+M.+Hongauthor=Y.+L.+Hsuauthor=C.+H.+Wongauthor=P.+C.+Yang&title=Purine-type+compounds+induce+microtubule+fragmentation+and+lung+cancer+cell+death+through+interaction+with+katanin&doi=10.1021%2Facs.jmedchem.6b00797"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Purine-Type Compounds Induce Microtubule Fragmentation and Lung Cancer Cell Death through Interaction with Katanin</span></div><div class="casAuthors">Kuo, Ting-Chun; Li, Ling-Wei; Pan, Szu-Hua; Fang, Jim-Min; Liu, Jyung-Hurng; Cheng, Ting-Jen; Wang, Chia-Jen; Hung, Pei-Fang; Chen, Hsuan-Yu; Hong, Tse-Ming; Hsu, Yuan-Ling; Wong, Chi-Huey; Yang, Pan-Chyr</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8521-8534</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Microtubule targeting agents (MTAs) constitute a class of drugs for cancer treatment.  Despite many MTAs have been proven to significantly improve the treatment outcomes of various malignancies, resistance has usually occurred.  By selection from a 2-million entry chem. library based on the efficacy and safety, the authors identified purine-type compds. that were active against lung small cell lung cancer (NSCLC).  The purine compd. I (GRC0321) was an MTA with good effects against NSCLC.  Lung cancer cells H1975 treated with I could induce microtubule fragmentation, leading to G2/M cell cycle arrest and intrinsic apoptosis.  Compd. I directly targeted katanin and regulated the severing activity of katanin, which cut the cellular microtubules into short pieces and activated c-Jun N-terminal kinases (JNK).  The microtubule fragmenting effect of I is a unique mechanism in MTAs.  It might overcome the resistance problems that most of the MTAs have faced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHYxyvm45m4bVg90H21EOLACvtfcHk0limGaZr3LEK_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOgtrnI&md5=069f8498e6fd14cac3f86324b77e09cb</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00797%26sid%3Dliteratum%253Aachs%26aulast%3DKuo%26aufirst%3DT.%2BC.%26aulast%3DLi%26aufirst%3DL.%2BW.%26aulast%3DPan%26aufirst%3DS.%2BH.%26aulast%3DFang%26aufirst%3DJ.%2BM.%26aulast%3DLiu%26aufirst%3DJ.%2BH.%26aulast%3DCheng%26aufirst%3DT.%2BJ.%26aulast%3DWang%26aufirst%3DC.%2BJ.%26aulast%3DHung%26aufirst%3DP.%2BF.%26aulast%3DChen%26aufirst%3DH.%2BY.%26aulast%3DHong%26aufirst%3DT.%2BM.%26aulast%3DHsu%26aufirst%3DY.%2BL.%26aulast%3DWong%26aufirst%3DC.%2BH.%26aulast%3DYang%26aufirst%3DP.%2BC.%26atitle%3DPurine-type%2520compounds%2520induce%2520microtubule%2520fragmentation%2520and%2520lung%2520cancer%2520cell%2520death%2520through%2520interaction%2520with%2520katanin%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8521%26epage%3D8534%26doi%3D10.1021%2Facs.jmedchem.6b00797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, antitumor activities and biological studies of novel diaryl substituted fused heterocycles as dual ligands targeting tubulin and katanin</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>178</i></span>,  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">194</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.05.072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.ejmech.2019.05.072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=31185410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFKqs7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2019&pages=177-194&author=F.+Gaoauthor=Y.+Liangauthor=P.+Zhouauthor=J.+Chengauthor=K.+Dingauthor=Y.+Wang&title=Design%2C+synthesis%2C+antitumor+activities+and+biological+studies+of+novel+diaryl+substituted+fused+heterocycles+as+dual+ligands+targeting+tubulin+and+katanin&doi=10.1016%2Fj.ejmech.2019.05.072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, antitumor activities and biological studies of novel diaryl substituted fused heterocycles as dual ligands targeting tubulin and katanin</span></div><div class="casAuthors">Gao, Feng; Liang, Yuru; Zhou, Pengfei; Cheng, Jiayi; Ding, Kuiling; Wang, Yang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">177-194</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Microtubule is one of the important targets for cancer treatment.  A novel class of diaryl substituted imidazo[4,5-c]pyridin-2-ones and imidazo[4,5-c]pyridines were designed based on combination principles by merging the structures of β-lactams and purine-type compds. known as tubulin polymn. inhibitor and katanin activity up-regulator, resp.  Their antitumor activities were evaluated in vitro and the mechanism was elucidated, leading to the identification of 1,6-diaryl-1H-imidazo[4,5-c]pyridin-2(3H)-one I as the first bifunctional agent that can target both tubulin and katanin simultaneously.  The in vivo assays verified that compd. I significantly inhibited xenograft tumor growth with good pharmacokinetic characteristics, demonstrating a promising potential for further development into anti-tumor drug candidates with a unique mechanism of dual-targeting microtubule.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmwI1A_To45rVg90H21EOLACvtfcHk0lghqistu9qADA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFKqs7fI&md5=4b71536c807d513c707371370dd966a0</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.05.072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.05.072%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DF.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DP.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%252C%2520antitumor%2520activities%2520and%2520biological%2520studies%2520of%2520novel%2520diaryl%2520substituted%2520fused%2520heterocycles%2520as%2520dual%2520ligands%2520targeting%2520tubulin%2520and%2520katanin%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D178%26spage%3D177%26epage%3D194%26doi%3D10.1016%2Fj.ejmech.2019.05.072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of quinazolin-4(3 H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">156</span>– <span class="NLM_lpage">180</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2020.06.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.apsb.2020.06.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=33532187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3MXhtVOms7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2021&pages=156-180&author=X.+Changauthor=D.+Sunauthor=D.+Shiauthor=G.+Wangauthor=Y.+Chenauthor=K.+Zhangauthor=H.+Tanauthor=J.+Liuauthor=B.+Liuauthor=L.+Ouyang&title=Design%2C+synthesis%2C+and+biological+evaluation+of+quinazolin-4%283+H%29-one+derivatives+co-targeting+poly%28ADP-ribose%29+polymerase-1+and+bromodomain+containing+protein+4+for+breast+cancer+therapy&doi=10.1016%2Fj.apsb.2020.06.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy</span></div><div class="casAuthors">Chang, Xiaosa; Sun, Dejuan; Shi, Danfeng; Wang, Guan; Chen, Yanmei; Zhang, Kai; Tan, Huidan; Liu, Jie; Liu, Bo; Ouyang, Liang</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmaceutica Sinica B</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">156-180</span>CODEN:
                <span class="NLM_cas:coden">APSBCW</span>;
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This study was aimed to design the first dual-target small-mol. inhibitor co-targeting poly (ADP-ribose) polymerase-1 (PARP1) and bromodomain contg. protein 4 (BRD4), which had important cross relation in the global network of breast cancer, reflecting the synthetic lethal effect.  A series of new BRD4 and PARP1 dual-target inhibitors were discovered and synthesized by fragment-based combinatorial screening and activity assays that together led to the chem. optimization.  Among these compds., 19d was selected and exhibited micromole enzymic potencies against BRD4 and PARP1, resp.  Compd. 19d was further shown to efficiently modulate the expression of BRD4 and PARP1.  Subsequently, compd. 19d was found to induce breast cancer cell apoptosis and stimulate cell cycle arrest at G1 phase.  Following pharmacokinetic studies, compd. 19d showed its antitumor activity in breast cancer susceptibility gene 1/2 (BRCA1/2) wild-type MDA-MB-468 and MCF-7 xenograft models without apparent toxicity and loss of body wt.  These results together demonstrated that a highly potent dual-targeted inhibitor was successfully synthesized and indicated that co-targeting of BRD4 and PARP1 based on the concept of synthetic lethality would be a promising therapeutic strategy for breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDduOqn_KYnLVg90H21EOLACvtfcHk0lghqistu9qADA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXhtVOms7bF&md5=1b99b491690caa69d35863bf0b99a615</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2020.06.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2020.06.003%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DShi%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DTan%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DOuyang%26aufirst%3DL.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520quinazolin-4%25283%2520H%2529-one%2520derivatives%2520co-targeting%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520and%2520bromodomain%2520containing%2520protein%25204%2520for%2520breast%2520cancer%2520therapy%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2021%26volume%3D11%26spage%3D156%26epage%3D180%26doi%3D10.1016%2Fj.apsb.2020.06.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fong, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boss, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tutt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mergui-Roelvink, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortimer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaisland, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmichael, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bono, J. S.</span></span> <span> </span><span class="NLM_article-title">Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>361</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa0900212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1056%2FNEJMoa0900212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=19553641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVKrtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=123-134&author=P.+C.+Fongauthor=D.+S.+Bossauthor=T.+A.+Yapauthor=A.+Tuttauthor=P.+Wuauthor=M.+Mergui-Roelvinkauthor=P.+Mortimerauthor=H.+Swaislandauthor=A.+Lauauthor=M.+J.+O%E2%80%99Connorauthor=A.+Ashworthauthor=J.+Carmichaelauthor=S.+B.+Kayeauthor=J.+H.+Schellensauthor=J.+S.+de+Bono&title=Inhibition+of+poly%28ADP-ribose%29+polymerase+in+tumors+from+BRCA+mutation+carriers&doi=10.1056%2FNEJMoa0900212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers</span></div><div class="casAuthors">Fong, Peter C.; Boss, David S.; Yap, Timothy A.; Tutt, Andrew; Wu, Peijun; Mergui-Roelvink, Marja; Mortimer, Peter; Swaisland, Helen; Lau, Alan; O'Connor, Mark J.; Ashworth, Alan; Carmichael, James; Kaye, Stan B.; Schellens, Jan H. M.; de Bono, Johann S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-134</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The inhibition of poly(ADP-ribose) polymerase (PARP) is a potential synthetic lethal therapeutic strategy for the treatment of cancers with specific DNA-repair defects, including those arising in carriers of a BRCA1 or BRCA2 mutation.  We conducted a clin. evaluation in humans of olaparib (AZD2281), a novel, potent, orally active PARP inhibitor.  This was a phase 1 trial that included the anal. of pharmacokinetic and pharmacodynamic characteristics of olaparib.  Selection was aimed at having a study population enriched in carriers of a BRCA1 or BRCA2 mutation.  We enrolled and treated 60 patients; 22 were carriers of a BRCA1 or BRCA2 mutation and 1 had a strong family history of BRCA-assocd. cancer but declined to undergo mutational testing.  The olaparib dose and schedule were increased from 10 mg daily for 2 of every 3 wk to 600 mg twice daily continuously.  Reversible dose-limiting toxicity was seen in one of eight patients receiving 400 mg twice daily (grade 3 mood alteration and fatigue) and two of five patients receiving 600 mg twice daily (grade 4 thrombocytopenia and grade 3 somnolence).  This led us to enroll another cohort, consisting only of carriers of a BRCA1 or BRCA2 mutation, to receive olaparib at a dose of 200 mg twice daily.  Other adverse effects included mild gastrointestinal symptoms.  There was no obvious increase in adverse effects seen in the mutation carriers.  Pharmacokinetic data indicated rapid absorption and elimination; pharmacodynamic studies confirmed PARP inhibition in surrogate samples (of peripheral-blood mononuclear cells and plucked eyebrow-hair follicles) and tumor tissue.  Objective antitumor activity was reported only in mutation carriers, all of whom had ovarian, breast, or prostate cancer and had received multiple treatment regimens.  Olaparib has few of the adverse effects of conventional chemotherapy, inhibits PARP, and has antitumor activity in cancer assocd. with the BRCA1 or BRCA2 mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCT49Hz0HbW7Vg90H21EOLACvtfcHk0ljE6L96lADVNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVKrtrw%253D&md5=aec7dcffe3d3cf614362a4f38bbb369a</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0900212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0900212%26sid%3Dliteratum%253Aachs%26aulast%3DFong%26aufirst%3DP.%2BC.%26aulast%3DBoss%26aufirst%3DD.%2BS.%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DTutt%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DMergui-Roelvink%26aufirst%3DM.%26aulast%3DMortimer%26aufirst%3DP.%26aulast%3DSwaisland%26aufirst%3DH.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DAshworth%26aufirst%3DA.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DKaye%26aufirst%3DS.%2BB.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26atitle%3DInhibition%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%2520in%2520tumors%2520from%2520BRCA%2520mutation%2520carriers%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D123%26epage%3D134%26doi%3D10.1056%2FNEJMoa0900212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brodie, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khuri, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vertino, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandes, J. C.</span></span> <span> </span><span class="NLM_article-title">Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">30773</span>– <span class="NLM_lpage">30786</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.5040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.18632%2Foncotarget.5040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=26356822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A280%3ADC%252BC283htVantA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=30773-30786&author=S.+A.+Brodieauthor=G.+Liauthor=D.+Harveyauthor=F.+R.+Khuriauthor=P.+M.+Vertinoauthor=J.+C.+Brandes&title=Small+molecule+inhibition+of+the+CHFR-PARP1+interaction+as+novel+approach+to+overcome+intrinsic+taxane+resistance+in+cancer&doi=10.18632%2Foncotarget.5040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer</span></div><div class="casAuthors">Brodie Seth A; Li Ge; Harvey Donald; Khuri Fadlo R; Brandes Johann C; Brodie Seth A; Li Ge; Harvey Donald; Khuri Fadlo R; Vertino Paula M; Brandes Johann C; Vertino Paula M; Brandes Johann C</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">30773-86</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The mitotic checkpoint protein CHFR has emerged as a major mediator of taxane resistance in cancer.  Here we show that CHFR's PAR-binding zinc finger domain (PBZ) mediates a protein interaction with poly-ADP ribosylated PARP1 leading to stabilization of CHFR.  Disruption of the CHFR-PARP1 interaction through either PARP1 shRNA-mediated knockdown or overexpression of a PBZ domain peptide induces loss of CHFR protein expression.  In an attempt to exploit this observation therapeutically, and to develop compounds with synthetic lethality in combination with taxanes, we performed a high-throughput computational screen of 5,256,508 chemical structures against the published crystal structure of the CHFR PBZ domain to identify candidate small molecule CHFR protein-protein interaction inhibitors.  The 10 compounds with the best docking scores (< -9.7) were used for further in vitro testing.  One lead compound in particular, termed 'A3', completely disrupted the protein-protein interaction between CHFR and PARP1, resulting in the inhibition of mitotic checkpoint function, and led to therapeutic synergy with docetaxel in cell viability and colony formation assays.  In mouse xenografts, i.p. administration of 'A3' led to a significant reduction in nuclear CHFR protein expression with a maximal effect 4 hours after administration, confirming relevant pharmacodynamics following the peak of 'A3' plasma concentration in vivo.  Furthermore, combination of A3 and taxane led to significant reduction of implanted tumor size without increase in hematological, hepatic or renal toxicity.  These findings provide a proof-of-principle that small molecule inhibition of CHFR PBZ domain interaction is a novel potential therapeutic approach to increase the efficacy of taxane-based chemotherapy in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSEPbu_Txv-kO2mnZh2OgS0fW6udTcc2ealtO2Zj_lhcLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283htVantA%253D%253D&md5=6d0355b7f95c6e2fa33443d7853717e0</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.5040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.5040%26sid%3Dliteratum%253Aachs%26aulast%3DBrodie%26aufirst%3DS.%2BA.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DHarvey%26aufirst%3DD.%26aulast%3DKhuri%26aufirst%3DF.%2BR.%26aulast%3DVertino%26aufirst%3DP.%2BM.%26aulast%3DBrandes%26aufirst%3DJ.%2BC.%26atitle%3DSmall%2520molecule%2520inhibition%2520of%2520the%2520CHFR-PARP1%2520interaction%2520as%2520novel%2520approach%2520to%2520overcome%2520intrinsic%2520taxane%2520resistance%2520in%2520cancer%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D30773%26epage%3D30786%26doi%3D10.18632%2Foncotarget.5040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dent, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindeman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemons, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wildiers, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmichael, J.</span></span> <span> </span><span class="NLM_article-title">Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">R88</span>, <span class="refDoi"> DOI: 10.1186/bcr3484</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1186%2Fbcr3484" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=24063698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFOhsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=R88&author=R.+A.+Dentauthor=G.+J.+Lindemanauthor=M.+Clemonsauthor=H.+Wildiersauthor=A.+Chanauthor=N.+J.+McCarthyauthor=C.+F.+Singerauthor=E.+S.+Loweauthor=C.+L.+Watkinsauthor=J.+Carmichael&title=Phase+I+trial+of+the+oral+PARP+inhibitor+olaparib+in+combination+with+paclitaxel+for+first-+or+second-line+treatment+of+patients+with+metastatic+triple-negative+breast+cancer&doi=10.1186%2Fbcr3484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer</span></div><div class="casAuthors">Dent, Rebecca A.; Lindeman, Geoffrey J.; Clemons, Mark; Wildiers, Hans; Chan, Arlene; McCarthy, Nicole J.; Singer, Christian F.; Lowe, Elizabeth S.; Watkins, Claire L.; Carmichael, James</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">R88/1-R88/8, 8 pp.</span>CODEN:
                <span class="NLM_cas:coden">BRCRFS</span>;
        ISSN:<span class="NLM_cas:issn">1465-542X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Introduction: This Phase I study evaluated the safety, tolerability and efficacy of olaparib, a potent oral poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with paclitaxel in patients with metastatic triple-neg. breast cancer (mTNBC).  Methods: Eligible patients who had received ≤1 prior cytotoxic regimen for mTNBC were treated with olaparib 200 mg bid continuously plus weekly paclitaxel 90 mg/m2 for three weeks per four-week cycle.  Dose modifications in a large proportion of patients due to neutropenia resulted in enrollment of a second cohort of patients who, if they experienced grade ≥2 neutropenia in cycle 1, received granulocyte-colony stimulating factor, which was continued prophylactically in subsequent cycles.  All patients had measurable disease; tumor responses were evaluated according to RECIST (version 1.0).  Results: Nineteen patients (cohort 1, n = 9; cohort 2, n = 10) received treatment; 15 had received prior taxane chemotherapy.  The most frequent adverse events were diarrhea (n = 12, 63%), nausea (n = 11, 58%) and neutropenia (n = 11, 58%).  Seven neutropenia events were reported in cohort 1 (four grade ≥3) and four in cohort 2 (two grade ≥3, including one event of febrile neutropenia).  The median (range) dose intensity of paclitaxel was 57% (26 to 100%) in cohort 1 and 73% (29 to 100%) in cohort 2.  Seven patients (37%) had a confirmed partial response; one patient remains on olaparib monotherapy without progression.  Conclusions: The combination of olaparib and weekly paclitaxel was complicated by a significant clin. interaction, with higher-than-expected rates of neutropenia despite secondary prophylaxis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFe81cPlJPr7Vg90H21EOLACvtfcHk0ljE6L96lADVNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFOhsb8%253D&md5=1da261cd68c4d2cd5b8eb222dc61db9c</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1186%2Fbcr3484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fbcr3484%26sid%3Dliteratum%253Aachs%26aulast%3DDent%26aufirst%3DR.%2BA.%26aulast%3DLindeman%26aufirst%3DG.%2BJ.%26aulast%3DClemons%26aufirst%3DM.%26aulast%3DWildiers%26aufirst%3DH.%26aulast%3DChan%26aufirst%3DA.%26aulast%3DMcCarthy%26aufirst%3DN.%2BJ.%26aulast%3DSinger%26aufirst%3DC.%2BF.%26aulast%3DLowe%26aufirst%3DE.%2BS.%26aulast%3DWatkins%26aufirst%3DC.%2BL.%26aulast%3DCarmichael%26aufirst%3DJ.%26atitle%3DPhase%2520I%2520trial%2520of%2520the%2520oral%2520PARP%2520inhibitor%2520olaparib%2520in%2520combination%2520with%2520paclitaxel%2520for%2520first-%2520or%2520second-line%2520treatment%2520of%2520patients%2520with%2520metastatic%2520triple-negative%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2013%26volume%3D15%26spage%3DR88%26doi%3D10.1186%2Fbcr3484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poruchynsky, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komlodi-Pasztor, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trostel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkerson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regairaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar Maity, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burotto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sackett, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guha, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fojo, A. T.</span></span> <span> </span><span class="NLM_article-title">Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">1571</span>– <span class="NLM_lpage">1576</span>, <span class="refDoi"> DOI: 10.1073/pnas.1416418112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1073%2Fpnas.1416418112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=25605897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOhu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=1571-1576&author=M.+S.+Poruchynskyauthor=E.+Komlodi-Pasztorauthor=S.+Trostelauthor=J.+Wilkersonauthor=M.+Regairazauthor=Y.+Pommierauthor=X.+Zhangauthor=T.+Kumar+Maityauthor=R.+Robeyauthor=M.+Burottoauthor=D.+Sackettauthor=U.+Guhaauthor=A.+T.+Fojo&title=Microtubule-targeting+agents+augment+the+toxicity+of+DNA-damaging+agents+by+disrupting+intracellular+trafficking+of+DNA+repair+proteins&doi=10.1073%2Fpnas.1416418112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins</span></div><div class="casAuthors">Poruchynsky, Marianne S.; Komlodi-Pasztor, Edina; Trostel, Shana; Wilkerson, Julia; Regairaz, Marie; Pommier, Yves; Zhang, Xu; Maity, Tapan Kumar; Robey, Robert; Burotto, Mauricio; Sackett, Dan; Guha, Udayan; Fojo, Antonio Tito</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1571-1576</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The paradigm that microtubule-targeting agents (MTAs) cause cell death via mitotic arrest applies to rapidly dividing cells but cannot explain MTA activity in slowly growing human cancers.  Many preferred cancer regimens combine a MTA with a DNA-damaging agent (DDA).  We hypothesized that MTAs synergize with DDAs by interfering with trafficking of DNA repair proteins on interphase microtubules.  We investigated nine proteins involved in DNA repair: ATM, ATR, DNA-PK, Rad50, Mre11, p95/NBS1, p53, 53BP1, and p63.  The proteins were sequestered in the cytoplasm by vincristine and paclitaxel but not by an aurora kinase inhibitor, colocalized with tubulin by confocal microscopy and coimmunopptd. with the microtubule motor dynein.  Furthermore, adding MTAs to radiation, doxorubicin, or etoposide led to more sustained γ-H2AX levels.  We conclude DNA damage-repair proteins traffic on microtubules and addn. of MTAs sequesters them in the cytoplasm, explaining why MTA/DDA combinations are common anticancer regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4RzUulWoZyLVg90H21EOLACvtfcHk0ljLB6AmNsfg6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOhu74%253D&md5=f7f94679f54bf5859c18437a40076aae</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1416418112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1416418112%26sid%3Dliteratum%253Aachs%26aulast%3DPoruchynsky%26aufirst%3DM.%2BS.%26aulast%3DKomlodi-Pasztor%26aufirst%3DE.%26aulast%3DTrostel%26aufirst%3DS.%26aulast%3DWilkerson%26aufirst%3DJ.%26aulast%3DRegairaz%26aufirst%3DM.%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DKumar%2BMaity%26aufirst%3DT.%26aulast%3DRobey%26aufirst%3DR.%26aulast%3DBurotto%26aufirst%3DM.%26aulast%3DSackett%26aufirst%3DD.%26aulast%3DGuha%26aufirst%3DU.%26aulast%3DFojo%26aufirst%3DA.%2BT.%26atitle%3DMicrotubule-targeting%2520agents%2520augment%2520the%2520toxicity%2520of%2520DNA-damaging%2520agents%2520by%2520disrupting%2520intracellular%2520trafficking%2520of%2520DNA%2520repair%2520proteins%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D1571%26epage%3D1576%26doi%3D10.1073%2Fpnas.1416418112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemjabbar-Alaoui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peto, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jablons, D. M.</span></span> <span> </span><span class="NLM_article-title">AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers</span>. <i>Am. J. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2649</span>– <span class="NLM_lpage">2676</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=32905466" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFant77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=2649-2676&author=H.+Lemjabbar-Alaouiauthor=C.+J.+Petoauthor=Y.+W.+Yangauthor=D.+M.+Jablons&title=AMXI-5001%2C+a+novel+dual+parp1%2F2+and+microtubule+polymerization+inhibitor+for+the+treatment+of+human+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers</span></div><div class="casAuthors">Lemjabbar-Alaoui, Hassan; Peto, Csaba J.; Yang, Yi-Wei; Jablons, David M.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Cancer Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2649-2676</span>CODEN:
                <span class="NLM_cas:coden">AJCRFT</span>;
        ISSN:<span class="NLM_cas:issn">2156-6976</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">Poly (ADP-ribose) polymerase (PARP) has recently emerged as a central mediator in cancer resistance against numerous anticancer agents to include chemotherapeutic agents such as microtubule targeting agents and DNA damaging agents.  Here, we describe AMXI-5001, a novel, highly potent dual PARP1/2 and microtubule polymn. inhibitor with favorable metabolic stability, oral bioavailability, and pharmacokinetic properties.  The potency and selectivity of AMXI-5001 were detd. by biochem. assays.  Anticancer activity either as a singleagent or in combination with other antitumor agents was evaluated in vitro.  In vivo antitumor activity as a singleagent was assessed in a triple-neg. breast cancer (TNBC) model.  AMXI-5001 demonstrates comparable IC50 inhibition against PARP and microtubule polymn. as clin. PARP inhibitors (Olaparib, Rucaparib, Niraparib, and Talazoparib) and the potent polymn. inhibitor (Vinblastine), resp.  In vitro, AMXI-5001 exhibited selective antitumor cytotoxicity across a wide variety of human cancer cells with much lower IC50s than existing clin. PARP1/2 inhibitors.  AMXI-5001 is highly active in both BRCA mutated and wild type cancers.  AMXI-5001 is orally bioavailable.  AMXI-5001 elicited a remarkable In vivo preclin. anti-tumor activity in a BRCA mutated TNBC model.  Oral administration of AMXI-5001 induced complete regression of established tumors, including exceedingly large tumors.  AMXI-5001 resulted in superior anti-tumor effects compared to either single agent (PARP or microtubule) inhibitor or combination with both agents.  AMXI-5001 will enter clin. trial testing soon and represents a promising, novel first in class dual PARP1/2 and microtubule polymn. inhibitor that delivers continuous and synchronous one-two punch cancer therapy with one mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ3bQO97CJV7Vg90H21EOLACvtfcHk0ljLB6AmNsfg6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFant77P&md5=eece5fd2fe270f97cb9c0d7f0ec907db</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLemjabbar-Alaoui%26aufirst%3DH.%26aulast%3DPeto%26aufirst%3DC.%2BJ.%26aulast%3DYang%26aufirst%3DY.%2BW.%26aulast%3DJablons%26aufirst%3DD.%2BM.%26atitle%3DAMXI-5001%252C%2520a%2520novel%2520dual%2520parp1%252F2%2520and%2520microtubule%2520polymerization%2520inhibitor%2520for%2520the%2520treatment%2520of%2520human%2520cancers%26jtitle%3DAm.%2520J.%2520Cancer%2520Res.%26date%3D2020%26volume%3D10%26spage%3D2649%26epage%3D2676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hengst, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegde, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geffert, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kester, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loughran, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulson, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claxton, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, J. K.</span></span> <span> </span><span class="NLM_article-title">SKI-178: A multitargeted inhibitor of sphingosine kinase and microtubule dynamics demonstrating therapeutic efficacy in acute myeloid leukemia models</span>. <i>Cancer Transl Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">121</span>, <span class="refDoi"> DOI: 10.4103/ctm.ctm_7_17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.4103%2Fctm.ctm_7_17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=28890935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFOhtL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=109-121&author=J.+A.+Hengstauthor=T.+E.+Dickauthor=A.+Sharmaauthor=K.+Doiauthor=S.+Hegdeauthor=S.+F.+Tanauthor=L.+M.+Geffertauthor=T.+E.+Foxauthor=A.+K.+Sharmaauthor=D.+Desaiauthor=S.+Aminauthor=M.+Kesterauthor=T.+P.+Loughranauthor=R.+F.+Paulsonauthor=D.+F.+Claxtonauthor=H.+G.+Wangauthor=J.+K.+Yun&title=SKI-178%3A+A+multitargeted+inhibitor+of+sphingosine+kinase+and+microtubule+dynamics+demonstrating+therapeutic+efficacy+in+acute+myeloid+leukemia+models&doi=10.4103%2Fctm.ctm_7_17"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">SKI-178: a multitargeted inhibitor of sphingosine kinase and microtubule dynamics demonstrating therapeutic efficacy in acute myeloid leukemia models</span></div><div class="casAuthors">Hengst, Jeremy A.; Dick, Taryn E.; Sharma, Arati; Doi, Kenichiro; Hegde, Shailaja; Tan, Su-Fern; Geffert, Laura M.; Fox, Todd E.; Sharma, Arun K.; Desai, Dhimant; Amin, Shantu; Kester, Mark; Loughran, Thomas P.; Paulson, Robert F.; Claxton, David F.; Wang, Hong-Gang; Yun, Jong K.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Translational Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">109-121, S1</span>CODEN:
                <span class="NLM_cas:coden">CTMABE</span>;
        ISSN:<span class="NLM_cas:issn">2395-3012</span>.
    
            (<span class="NLM_cas:orgname">Medknow Publications</span>)
        </div><div class="casAbstract">Aim: To further characterize the selectivity, mechanism of action, and therapeutic efficacy of the novel small mol. inhibitor, SKI-178.  Methods: We used the state-of-the-art cellular thermal shift assay technique to detect "direct target engagement" of proteins in intact cells.  In vitro and in vivo assays, pharmacol. assays, and multiple mouse models of acute myeloid leukemia (AML) were also used.  Results: Herein, we demonstrate that SKI-178 directly target engages both sphingosine kinase 1 and 2 (SphK1 and 2).  We also present evidence that, in addn. to its actions as a sphingosine kinase inhibitor, SKI-178 functions as a microtubule network disrupting agent both in vitro and in intact cells.  Interestingly, we sep. demonstrate that simultaneous SphK inhibition and microtubule disruption synergistically induce apoptosis in AML cell lines.  Furthermore, we demonstrate that SKI-178 is well tolerated in normal healthy mice.  Most importantly, we demonstrate that SKI-178 has therapeutic efficacy in several mouse models of AML.  Conclusion: SKI-178 is a multitargeted agent that functions both as an inhibitor of the SphKs as well as a disruptor of the microtubule network.  SKI-178-induced apoptosis arises from a synergistic interaction of these two activities.  SKI-178 is safe and effective in mouse models of AML, supporting its further development as a multitargeted anticancer therapeutic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4CVSGc0jL9LVg90H21EOLACvtfcHk0ljLB6AmNsfg6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFOhtL7I&md5=ef8a162ad34dbdc947433d302cced3d7</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.4103%2Fctm.ctm_7_17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252Fctm.ctm_7_17%26sid%3Dliteratum%253Aachs%26aulast%3DHengst%26aufirst%3DJ.%2BA.%26aulast%3DDick%26aufirst%3DT.%2BE.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DDoi%26aufirst%3DK.%26aulast%3DHegde%26aufirst%3DS.%26aulast%3DTan%26aufirst%3DS.%2BF.%26aulast%3DGeffert%26aufirst%3DL.%2BM.%26aulast%3DFox%26aufirst%3DT.%2BE.%26aulast%3DSharma%26aufirst%3DA.%2BK.%26aulast%3DDesai%26aufirst%3DD.%26aulast%3DAmin%26aufirst%3DS.%26aulast%3DKester%26aufirst%3DM.%26aulast%3DLoughran%26aufirst%3DT.%2BP.%26aulast%3DPaulson%26aufirst%3DR.%2BF.%26aulast%3DClaxton%26aufirst%3DD.%2BF.%26aulast%3DWang%26aufirst%3DH.%2BG.%26aulast%3DYun%26aufirst%3DJ.%2BK.%26atitle%3DSKI-178%253A%2520A%2520multitargeted%2520inhibitor%2520of%2520sphingosine%2520kinase%2520and%2520microtubule%2520dynamics%2520demonstrating%2520therapeutic%2520efficacy%2520in%2520acute%2520myeloid%2520leukemia%2520models%26jtitle%3DCancer%2520Transl%2520Med.%26date%3D2017%26volume%3D3%26spage%3D109%26epage%3D121%26doi%3D10.4103%2Fctm.ctm_7_17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hengst, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegde, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulson, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, J. K.</span></span> <span> </span><span class="NLM_article-title">Development of SKI-349, a dual-targeted inhibitor of sphingosine kinase and microtubule polymerization</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">127453</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127453</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.bmcl.2020.127453" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=32736077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFGls7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127453&author=J.+A.+Hengstauthor=S.+Hegdeauthor=R.+F.+Paulsonauthor=J.+K.+Yun&title=Development+of+SKI-349%2C+a+dual-targeted+inhibitor+of+sphingosine+kinase+and+microtubule+polymerization&doi=10.1016%2Fj.bmcl.2020.127453"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Development of SKI-349, a dual-targeted inhibitor of sphingosine kinase and microtubule polymerization</span></div><div class="casAuthors">Hengst, Jeremy A.; Hegde, Shailaja; Paulson, Robert F.; Yun, Jong K.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">127453</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Our sphingosine kinase inhibitor (SKI) optimization studies originated with the optimization of the SKI-I chemotype by replacement of the substituted benzyl rings with substituted Ph rings giving rise to the discovery of SKI-178.  We have recently reported that SKI-178 is a dual-targeted inhibitor of both sphingosine kinase isoforms (SphK1/2) and a microtubule disrupting agent (MDA).  In mechanism-of-action studies, we have shown that these two sep. actions synergize to induce cancer cell death in acute myeloid leukemia (AML) cell and animal models.  Owning to the effectiveness of SKI-178, we sought to further refine the chemotype while maintaining "on-target" SKI and MDA activities.  Herein, we modified the "linker region" between the substituted Ph rings of SKI-178 through a structure guided approach.  These studies have yielded the discovery of an SKI-178 congener, SKI-349, with log-fold enhancements in both SphK inhibition and cytotoxic potency.  Importantly, SKI-349 also demonstrates log-fold improvements in therapeutic efficacy in a retro-viral transduction model of MLL-AF9 AML as compared to previous studies with SKI-178.  Together, our results strengthen the hypothesis that simultaneous targeting of the sphingosine kinases (SphK1/2) and the induction of mitotic spindle assembly checkpoint arrest, via microtubule disruption, might be an effective therapeutic strategy for hematol. malignancies including AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7z_h5g2BX0bVg90H21EOLACvtfcHk0lhvx91ERyPpcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFGls7bM&md5=e9393ea1c84933ace638edb892ca1fd6</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127453%26sid%3Dliteratum%253Aachs%26aulast%3DHengst%26aufirst%3DJ.%2BA.%26aulast%3DHegde%26aufirst%3DS.%26aulast%3DPaulson%26aufirst%3DR.%2BF.%26aulast%3DYun%26aufirst%3DJ.%2BK.%26atitle%3DDevelopment%2520of%2520SKI-349%252C%2520a%2520dual-targeted%2520inhibitor%2520of%2520sphingosine%2520kinase%2520and%2520microtubule%2520polymerization%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26spage%3D127453%26doi%3D10.1016%2Fj.bmcl.2020.127453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khandelwal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merfeld, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munthali, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matts, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, B. S. J.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibition of the Hsp90α Isoform</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">10547</span>– <span class="NLM_lpage">10551</span>, <span class="refDoi"> DOI: 10.1002/anie.202015422</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1002%2Fanie.202015422" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3MXnt1Oms7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2021&pages=10547-10551&author=S.+J.+Mishraauthor=A.+Khandelwalauthor=M.+Banerjeeauthor=M.+Balchauthor=S.+Pengauthor=R.+E.+Davisauthor=T.+Merfeldauthor=V.+Munthaliauthor=J.+Dengauthor=R.+L.+Mattsauthor=B.+S.+J.+Blagg&title=Selective+Inhibition+of+the+Hsp90%CE%B1+Isoform&doi=10.1002%2Fanie.202015422"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of the Hsp90α Isoform</span></div><div class="casAuthors">Mishra, Sanket J.; Khandelwal, Anuj; Banerjee, Monimoy; Balch, Maurie; Peng, Shuxia; Davis, Rachel E.; Merfeld, Taylor; Munthali, Vitumbiko; Deng, Junpeng; Matts, Robert L.; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">10547-10551</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The 90 kDa heat shock protein (Hsp90) is a mol. chaperone that processes nascent polypeptides into their biol. active conformations.  Many of these proteins contribute to the progression of cancer, and consequently, inhibition of the Hsp90 protein folding machinery represents an innovative approach toward cancer chemotherapy.  However, clin. trials with Hsp90 N-terminal inhibitors have encountered deleterious side effects and toxicities, which appear to result from the pan-inhibition of all four Hsp90 isoforms.  Therefore, the development of isoform-selective Hsp90 inhibitors is sought to delineate the pathol. role played by each isoform.  Herein, we describe a structure-based approach that was used to design the first Hsp90α-selective inhibitors, which exhibit >50-fold selectivity vs. other Hsp90 isoforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf_-tPiVfjqLVg90H21EOLACvtfcHk0lhvx91ERyPpcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXnt1Oms7w%253D&md5=a13fa7b40d3c2cd467bcc67e47358b85</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1002%2Fanie.202015422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.202015422%26sid%3Dliteratum%253Aachs%26aulast%3DMishra%26aufirst%3DS.%2BJ.%26aulast%3DKhandelwal%26aufirst%3DA.%26aulast%3DBanerjee%26aufirst%3DM.%26aulast%3DBalch%26aufirst%3DM.%26aulast%3DPeng%26aufirst%3DS.%26aulast%3DDavis%26aufirst%3DR.%2BE.%26aulast%3DMerfeld%26aufirst%3DT.%26aulast%3DMunthali%26aufirst%3DV.%26aulast%3DDeng%26aufirst%3DJ.%26aulast%3DMatts%26aufirst%3DR.%2BL.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DSelective%2520Inhibition%2520of%2520the%2520Hsp90%25CE%25B1%2520Isoform%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2021%26volume%3D60%26spage%3D10547%26epage%3D10551%26doi%3D10.1002%2Fanie.202015422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Echeverría, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernthaler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupuis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picard, D.</span></span> <span> </span><span class="NLM_article-title">An interaction network predicted from public data as a discovery tool: application to the Hsp90 molecular chaperone machine</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">e26044</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0026044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1371%2Fjournal.pone.0026044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=22022502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtl2lsrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=e26044&author=P.+C.+Echeverr%C3%ADaauthor=A.+Bernthalerauthor=P.+Dupuisauthor=B.+Mayerauthor=D.+Picard&title=An+interaction+network+predicted+from+public+data+as+a+discovery+tool%3A+application+to+the+Hsp90+molecular+chaperone+machine&doi=10.1371%2Fjournal.pone.0026044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">An interaction network predicted from public data as a discovery tool: application to the Hsp90 molecular chaperone machine</span></div><div class="casAuthors">Echeverria, Pablo C.; Bernthaler, Andreas; Dupuis, Pierre; Mayer, Bernd; Picard, Didier</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e26044</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Understanding the functions of proteins requires information about their protein-protein interactions (PPI).  The collective effort of the scientific community generates far more data on any given protein than individual exptl. approaches.  The latter are often too limited to reveal an interactome comprehensively.  We developed a workflow for parallel mining of all major PPI databases, contg. data from several model organisms, and to integrate data from the literature for a protein of interest.  We applied this novel approach to build the PPI network of the human Hsp90 mol. chaperone machine (Hsp90Int) for which previous efforts have yielded limited and poorly overlapping sets of interactors.  We demonstrate the power of the Hsp90Int database as a discovery tool by validating the prediction that the Hsp90 co-chaperone Aha1 is involved in nucleocytoplasmic transport.  Thus, we both describe how to build a custom database and introduce a powerful new resource for the scientific community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR31go7KI5lLVg90H21EOLACvtfcHk0lhvx91ERyPpcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtl2lsrrL&md5=e1908fb96cd467c7e315e1ca93c00391</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0026044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0026044%26sid%3Dliteratum%253Aachs%26aulast%3DEcheverr%25C3%25ADa%26aufirst%3DP.%2BC.%26aulast%3DBernthaler%26aufirst%3DA.%26aulast%3DDupuis%26aufirst%3DP.%26aulast%3DMayer%26aufirst%3DB.%26aulast%3DPicard%26aufirst%3DD.%26atitle%3DAn%2520interaction%2520network%2520predicted%2520from%2520public%2520data%2520as%2520a%2520discovery%2520tool%253A%2520application%2520to%2520the%2520Hsp90%2520molecular%2520chaperone%2520machine%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26spage%3De26044%26doi%3D10.1371%2Fjournal.pone.0026044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knox, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawlak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golfis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flood, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fayne, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meegan, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lloyd, D. G.</span></span> <span> </span><span class="NLM_article-title">Integration of ligand and structure-based virtual screening for the identification of the first dual targeting agent for heat shock protein 90 (Hsp90) and tubulin</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">2177</span>– <span class="NLM_lpage">2180</span>, <span class="refDoi"> DOI: 10.1021/jm801569z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801569z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktFGrt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2177-2180&author=A.+J.+Knoxauthor=T.+Priceauthor=M.+Pawlakauthor=G.+Golfisauthor=C.+T.+Floodauthor=D.+Fayneauthor=D.+C.+Williamsauthor=M.+J.+Meeganauthor=D.+G.+Lloyd&title=Integration+of+ligand+and+structure-based+virtual+screening+for+the+identification+of+the+first+dual+targeting+agent+for+heat+shock+protein+90+%28Hsp90%29+and+tubulin&doi=10.1021%2Fjm801569z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Integration of Ligand and Structure-Based Virtual Screening for the Identification of the First Dual Targeting Agent for Heat Shock Protein 90 (Hsp90) and Tubulin</span></div><div class="casAuthors">Knox, Andrew J. S.; Price, Trevor; Pawlak, Michal; Golfis, Georgia; Flood, Christopher T.; Fayne, Darren; Williams, D. Clive; Meegan, Mary J.; Lloyd, David G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2177-2180</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We describe the discovery of a novel indazole-based scaffold that represents the "first-in-class" dual Hsp90/tubulin binding compd.  Individual known ligands for both targets shared similar 3',4',5'-trimethoxyphenyl cores, and from this it was hypothesized that application of an integrated ligand and structure-based virtual screening (VS) workflow could yield a single scaffold with dual binding affinity.  Following validation of the VS protocol, we successfully identified a novel dual inhibitor, sourced from a com. screening collection of 160 000 compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRptEHjoTCsLVg90H21EOLACvtfcHk0lh46XtO2O2u2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktFGrt70%253D&md5=c8268f36a0da627404be37696c5afe4b</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1021%2Fjm801569z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801569z%26sid%3Dliteratum%253Aachs%26aulast%3DKnox%26aufirst%3DA.%2BJ.%26aulast%3DPrice%26aufirst%3DT.%26aulast%3DPawlak%26aufirst%3DM.%26aulast%3DGolfis%26aufirst%3DG.%26aulast%3DFlood%26aufirst%3DC.%2BT.%26aulast%3DFayne%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DD.%2BC.%26aulast%3DMeegan%26aufirst%3DM.%2BJ.%26aulast%3DLloyd%26aufirst%3DD.%2BG.%26atitle%3DIntegration%2520of%2520ligand%2520and%2520structure-based%2520virtual%2520screening%2520for%2520the%2520identification%2520of%2520the%2520first%2520dual%2520targeting%2520agent%2520for%2520heat%2520shock%2520protein%252090%2520%2528Hsp90%2529%2520and%2520tubulin%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2177%26epage%3D2180%26doi%3D10.1021%2Fjm801569z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, B.</span></span> <span> </span><span class="NLM_article-title">Anti-tumor selectivity of a novel tubulin and HSP90 dual-targeting inhibitor in non-small cell lung cancer models</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">351</span>– <span class="NLM_lpage">360</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2013.05.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.bcp.2013.05.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=23743233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVWgtb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2013&pages=351-360&author=Q.+Zhangauthor=S.+Zhaiauthor=L.+Liauthor=X.+Liauthor=H.+Zhouauthor=A.+Liuauthor=G.+Suauthor=Q.+Muauthor=Y.+Duauthor=B.+Yan&title=Anti-tumor+selectivity+of+a+novel+tubulin+and+HSP90+dual-targeting+inhibitor+in+non-small+cell+lung+cancer+models&doi=10.1016%2Fj.bcp.2013.05.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-tumor selectivity of a novel Tubulin and HSP90 dual-targeting inhibitor in non-small cell lung cancer models</span></div><div class="casAuthors">Zhang, Qiu; Zhai, Shumei; Li, Liwen; Li, Xiue; Zhou, Hongyu; Liu, Aifeng; Su, Gaoxing; Mu, Qingxin; Du, Yuhong; Yan, Bing</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">351-360</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Dose-limiting toxicity is a main road blocker for successful cancer chemotherapy.  By phenotype screening, a novel chem. agent 2-(2-Chlorophenylimino)-5-(4-dimethylamino-benzylidene) thiazolidin-4-one (CDBT) was found to strongly inhibit the proliferation of non-small cell lung cancer (NSCLC) cells H460 and H322 while displaying no obvious toxicity to normal fast-dividing fibroblast cells NHFB and WI-38 at a concn. 100-fold higher than its EC50 to NSCLC cells.  CDBT targets microtubule and heat shock protein 90 (HSP90) simultaneously with moderate affinities compared to microtubule targeting Colchicine and HSP90 inhibitor 17-dimethylaminoethylamino-17-demethoxygaldanamcyin (17-DMAG).  CDBT blocks microtubule formation, decreases cancer-essential proteins CRAF-1, ERBB2 and phosphorylated AKT, and causes G2/M arrest and apoptosis.  The moderate inhibitory effects of CDBT on targets require a higher cellular concn. of targets, a situation only exist in cancer cells.  This accounts for its good cancer selectivity.  Furthermore, CDBT effectively inhibits tumor growth by 62.4% relative to the vehicle control after i.p. administration at 30 mg/kg for 11 days while showing no toxicity to normal tissues in NSCLC H460 xenograft mouse model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr435e-wAVfCrVg90H21EOLACvtfcHk0lh46XtO2O2u2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVWgtb3N&md5=13bdd37754a95a1352ba70b611d74d88</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2013.05.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2013.05.019%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DZhai%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DA.%26aulast%3DSu%26aufirst%3DG.%26aulast%3DMu%26aufirst%3DQ.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DB.%26atitle%3DAnti-tumor%2520selectivity%2520of%2520a%2520novel%2520tubulin%2520and%2520HSP90%2520dual-targeting%2520inhibitor%2520in%2520non-small%2520cell%2520lung%2520cancer%2520models%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2013%26volume%3D86%26spage%3D351%26epage%3D360%26doi%3D10.1016%2Fj.bcp.2013.05.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, B.</span></span> <span> </span><span class="NLM_article-title">P-glycoprotein-evading anti-tumor activity of a novel tubulin and HSP90 dual inhibitor in a non-small-cell lung cancer model</span>. <i>J. Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">66</span>– <span class="NLM_lpage">76</span>, <span class="refDoi"> DOI: 10.1254/jphs.14050FP</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1254%2Fjphs.14050FP" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=25185500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1OgsLzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2014&pages=66-76&author=Q.+Zhangauthor=S.+Zhaiauthor=L.+Liauthor=X.+Liauthor=C.+Jiangauthor=C.+Zhangauthor=B.+Yan&title=P-glycoprotein-evading+anti-tumor+activity+of+a+novel+tubulin+and+HSP90+dual+inhibitor+in+a+non-small-cell+lung+cancer+model&doi=10.1254%2Fjphs.14050FP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">P-glycoprotein-evading anti-tumor activity of a novel tubulin and HSP90 dual inhibitor in a non-small-cell lung cancer model</span></div><div class="casAuthors">Zhang, Qiu; Zhai, Shumei; Li, Liwen; Li, Xiue; Jiang, Cuijuan; Zhang, Chengke; Yan, Bing</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological Sciences (Tokyo, Japan)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">66-76</span>CODEN:
                <span class="NLM_cas:coden">JPSTGJ</span>;
        ISSN:<span class="NLM_cas:issn">1347-8613</span>.
    
            (<span class="NLM_cas:orgname">Japanese Pharmacological Society</span>)
        </div><div class="casAbstract">P-glycoprotein (P-gp)-induced drug resistance is a major road block for successful cancer chemotherapy.  Through phenotypic screening, the compd. 2-(2-chlorophenylimino)-5-(4-dimethylaminobenzylidene) thiazolidin-4-one (CDBT) was discovered to have potent anti-tumor activity in P-gp over-expressing drug-resistant non-small-cell lung cancer (NSCLC) H460TaxR cells.  Here, we report mechanistic investigations of the P-gp-evading anti-tumor activity of CDBT.  CDBT is evidently not a P-gp substrate and escapes the P-gp efflux pump.  As a novel microtubule and heat shock protein 90 (HSP90) dual targeting inhibitor, CDBT causes the destabilization of microtubules and degrdn. of HSP90 client proteins CRAF-1 and ERBB2, resulting in cell cycle arrest at the G2/M phase and apoptosis.  Furthermore, CDBT effectively inhibits tumor growth by 60.4% relative to the vehicle control after i.p. administration at 30 mg/kg for 11 days and shows no toxicity in normal tissues in the NSCLC H460TaxR xenograft mouse model.  Our data suggest a novel drug discovery strategy to combat P-gp over-expressing drug-resistant NSCLC cancer cells with a single therapeutic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozWR0jNMTVmbVg90H21EOLACvtfcHk0lh46XtO2O2u2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1OgsLzP&md5=03be83b93e7235ba627900687da66a14</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1254%2Fjphs.14050FP&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1254%252Fjphs.14050FP%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DZhai%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DYan%26aufirst%3DB.%26atitle%3DP-glycoprotein-evading%2520anti-tumor%2520activity%2520of%2520a%2520novel%2520tubulin%2520and%2520HSP90%2520dual%2520inhibitor%2520in%2520a%2520non-small-cell%2520lung%2520cancer%2520model%26jtitle%3DJ.%2520Pharmacol.%2520Sci.%26date%3D2014%26volume%3D126%26spage%3D66%26epage%3D76%26doi%3D10.1254%2Fjphs.14050FP" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nepali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. Y.</span></span> <span> </span><span class="NLM_article-title">2-Aroylquinoline-5,8-diones as potent anticancer agents displaying tubulin and heat shock protein 90 (HSP90) inhibition</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">716</span>– <span class="NLM_lpage">723</span>, <span class="refDoi"> DOI: 10.1039/C5OB02100F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1039%2FC5OB02100F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=26694589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyqs7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=716-723&author=K.+Nepaliauthor=S.+Kumarauthor=H.+L.+Huangauthor=F.+C.+Kuoauthor=C.+H.+Leeauthor=C.+C.+Kuoauthor=T.+K.+Yehauthor=Y.+H.+Liauthor=J.+Y.+Changauthor=J.+P.+Liouauthor=H.+Y.+Lee&title=2-Aroylquinoline-5%2C8-diones+as+potent+anticancer+agents+displaying+tubulin+and+heat+shock+protein+90+%28HSP90%29+inhibition&doi=10.1039%2FC5OB02100F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">2-Aroylquinoline-5,8-diones as potent anticancer agents displaying tubulin and heat shock protein 90 (HSP90) inhibition</span></div><div class="casAuthors">Nepali, Kunal; Kumar, Sunil; Huang, Hsiang-Ling; Kuo, Fei-Chiao; Lee, Cheng-Hsin; Kuo, Ching-Chuan; Yeh, Teng-Kuang; Li, Yu-Hsuan; Chang, Jang-Yang; Liou, Jing-Ping; Lee, Hsueh-Yun</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">716-723</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Amine-substituted aroylquinolinediones I [R = MeO, Me2N, EtNH, H2C:CHCH2NH, Me2CH2CH2NH, 2-(4-morpholinyl)ethyl, PhNH, 1-pyrrolidinyl, 4-morpholinyl, 4-Me-1-piperazinyl, H; R1 = H, 4-morpholinyl, Me2N, 1-pyrrolidinyl] were prepd. and tested for inhibition of human cancer cell lines; selected compds. were tested for inhibition of tubulin polymn. and for binding to the colchicine tubulin binding site and for the inhibition of HSP90 activity (and consequent induction of HSP70 and degrdn. of Akt).  I were prepd. in seven steps from 1,2,4-trimethoxybenzene, crotonaldehyde, 3,4,5-trimethoxyphenylmagnesium bromide, and amines.  The use of 6-methoxy-substituted quinolinedione intermediates allowed regioselective prepn. of the corresponding 6-aminated products and assisted in detn. of product regiochem.  Among the compds. prepd., I (R = Me2N; R1 = H) and I (R = H; R1 = 1-pyrrolidinyl) exhibited antiproliferative activity against human cancer cell lines, with mean IC50 values of 0.14 μM and 0.27 μM, resp.  I (R = H; R1 = 1-pyrrolidinyl) inhibited tubulin polymn. with an IC50 value of 5.9 μM.  I (R = H; R1 = 1-pyrrolidinyl) caused induction of HSP70 and degrdn. of Akt consistent with inhibition of HSP90.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr76oB0EPM7kLVg90H21EOLACvtfcHk0lgqZjVR3-rD7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyqs7fO&md5=f57c77b0ea7d4d8a78225f8fcbebd81f</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1039%2FC5OB02100F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5OB02100F%26sid%3Dliteratum%253Aachs%26aulast%3DNepali%26aufirst%3DK.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DH.%2BL.%26aulast%3DKuo%26aufirst%3DF.%2BC.%26aulast%3DLee%26aufirst%3DC.%2BH.%26aulast%3DKuo%26aufirst%3DC.%2BC.%26aulast%3DYeh%26aufirst%3DT.%2BK.%26aulast%3DLi%26aufirst%3DY.%2BH.%26aulast%3DChang%26aufirst%3DJ.%2BY.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26aulast%3DLee%26aufirst%3DH.%2BY.%26atitle%3D2-Aroylquinoline-5%252C8-diones%2520as%2520potent%2520anticancer%2520agents%2520displaying%2520tubulin%2520and%2520heat%2520shock%2520protein%252090%2520%2528HSP90%2529%2520inhibition%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2016%26volume%3D14%26spage%3D716%26epage%3D723%26doi%3D10.1039%2FC5OB02100F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span> <span> </span><span class="NLM_article-title">Discovery of a dual tubulin polymerization and cell division cycle 20 homologue inhibitor via structural modification on apcin</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">4685</span>– <span class="NLM_lpage">4700</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b02097</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b02097" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntFCnur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=4685-4700&author=P.+Huangauthor=X.+Leauthor=F.+Huangauthor=J.+Yangauthor=H.+Yangauthor=J.+Maauthor=G.+Huauthor=Q.+Liauthor=Z.+Chen&title=Discovery+of+a+dual+tubulin+polymerization+and+cell+division+cycle+20+homologue+inhibitor+via+structural+modification+on+apcin&doi=10.1021%2Facs.jmedchem.9b02097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Dual Tubulin Polymerization and Cell Division Cycle 20 Homologue Inhibitor via Structural Modification on Apcin</span></div><div class="casAuthors">Huang, Pan; Le, Xiangyang; Huang, Fei; Yang, Jie; Yang, Haofeng; Ma, Junlong; Hu, Gaoyun; Li, Qianbin; Chen, Zhuo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4685-4700</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Apcin is one of the few compds. that have been previously reported as a Cdc20 specific inhibitor, although Cdc20 is a very promising drug target.  We reported here the design, synthesis, and biol. evaluations of 2,2,2-trichloro-1-aryl carbamate derivs. as Cdc20 inhibitors.  Among these derivs., compd. 9f(I) was much more efficient than the pos. compd. apcin in inhibiting cancer cell growth, but it had approx. the same binding affinity with apcin in SPR assays.  It is possible that another mechanism of action might exist.  Further evidence demonstrated that compd. 9f also inhibited tubulin polymn., disorganized the microtubule network, and blocked the cell cycle at the M phase with changes in the expression of cyclins.  Thus, it induced apoptosis through the activation of caspase-3 and PARP.  In addn., compd. 9f inhibited cell migration and invasion in a concn.-dependent manner.  These results provide guidance for developing the current series as potential new anticancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTMpILvY9XMbVg90H21EOLACvtfcHk0lgqZjVR3-rD7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntFCnur0%253D&md5=4757f94005b5221e7f837981d4a27194</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b02097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b02097%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DP.%26aulast%3DLe%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DZ.%26atitle%3DDiscovery%2520of%2520a%2520dual%2520tubulin%2520polymerization%2520and%2520cell%2520division%2520cycle%252020%2520homologue%2520inhibitor%2520via%2520structural%2520modification%2520on%2520apcin%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D4685%26epage%3D4700%26doi%3D10.1021%2Facs.jmedchem.9b02097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghinet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuru, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floquet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubois, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farce, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigo, B.</span></span> <span> </span><span class="NLM_article-title">Enhanced antitumor potential induced by chloroacetate-loaded benzophenones acting as fused tubulin-pyruvate dehydrogenase kinase 1 (PDHK1) ligands</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">103643</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2020.103643</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.bioorg.2020.103643" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=32035298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisV2ntbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2020&pages=103643&author=A.+Ghinetauthor=X.+Thuruauthor=E.+Floquetauthor=J.+Duboisauthor=A.+Farceauthor=B.+Rigo&title=Enhanced+antitumor+potential+induced+by+chloroacetate-loaded+benzophenones+acting+as+fused+tubulin-pyruvate+dehydrogenase+kinase+1+%28PDHK1%29+ligands&doi=10.1016%2Fj.bioorg.2020.103643"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced antitumor potential induced by chloroacetate-loaded benzophenones acting as fused tubulin-pyruvate dehydrogenase kinase 1 (PDHK1) ligands</span></div><div class="casAuthors">Ghinet, Alina; Thuru, Xavier; Floquet, Emilie; Dubois, Joelle; Farce, Amaury; Rigo, Benoit</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103643</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The majority of cancers detected every year are treated with anti-cancer compds.  Unfortunately, many tumors become resistant to antineoplastic drugs.  One option is to use cocktails of compds. acting on different targets to try to overcome the resistant cells.  This type of approach can produce good results, but is often accompanied by a sharp increase of assocd. side effects.  The strategy presented herein focuses on the use of a single compd. acting on two different biol. targets enhancing potency and lowering the toxicity of the chemotherapy.  In this light, the approach presented in the current study involves the dual inhibition of human pyruvate dehydrogenase kinase-1 (PDHK1) and tubulin polymn. using mono-, di- and tri-chloroacetate-loaded benzophenones and benzothiophenones.  Synthesized mols. were evaluated in vitro on tubulin polymn. and on pyruvate dehydrogenase kinase 1.  The cell cycle distribution after treatment of DA1-3b leukemic cells with active compds. was tested.  Twenty-two benzo(thio)phenones have been selected by the National Cancer Institute (USA) for evaluation of their anti-proliferative potential against NCI-60 cancer cell lines including multidrug-resistant tumor cell lines.  Seventeen mols. proved to be very effective in combating the growth of tumor cells exhibiting inhibitory activities up to nanomolar range.  The mol. docking of best antitumor mols. in the study was realized with GOLD in the tubulin and PDHK1 binding sites, and allowed to understand the positioning of active mols.  Chloroacetate-loaded benzo(thio)phenones are dual targeted tubulin- and pyruvate dehydrogenase kinase 1 (PDHK1)-binding antitumor agents and exhibited superior antitumor activity compared to non-chlorinated congeners particularly on leukemia, colon, melanoma and breast cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqM4jINFrNYU7Vg90H21EOLACvtfcHk0lgqZjVR3-rD7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisV2ntbc%253D&md5=1045b4b0a47ec2dced17dec680bc50dc</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2020.103643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2020.103643%26sid%3Dliteratum%253Aachs%26aulast%3DGhinet%26aufirst%3DA.%26aulast%3DThuru%26aufirst%3DX.%26aulast%3DFloquet%26aufirst%3DE.%26aulast%3DDubois%26aufirst%3DJ.%26aulast%3DFarce%26aufirst%3DA.%26aulast%3DRigo%26aufirst%3DB.%26atitle%3DEnhanced%2520antitumor%2520potential%2520induced%2520by%2520chloroacetate-loaded%2520benzophenones%2520acting%2520as%2520fused%2520tubulin-pyruvate%2520dehydrogenase%2520kinase%25201%2520%2528PDHK1%2529%2520ligands%26jtitle%3DBioorg.%2520Chem.%26date%3D2020%26volume%3D96%26spage%3D103643%26doi%3D10.1016%2Fj.bioorg.2020.103643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malik, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krohn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saleem, R. S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faisal, A.</span></span> <span> </span><span class="NLM_article-title">Natural and semisynthetic chalcones as dual FLT3 and microtubule polymerization inhibitors</span>. <i>J. Nat. Prod.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">3111</span>– <span class="NLM_lpage">3121</span>, <span class="refDoi"> DOI: 10.1021/acs.jnatprod.0c00699</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jnatprod.0c00699" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFShtbrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2020&pages=3111-3121&author=H.+S.+Malikauthor=A.+Bilalauthor=R.+Ullahauthor=M.+Iqbalauthor=S.+Khanauthor=I.+Ahmedauthor=K.+Krohnauthor=R.+S.+Z.+Saleemauthor=H.+Hussainauthor=A.+Faisal&title=Natural+and+semisynthetic+chalcones+as+dual+FLT3+and+microtubule+polymerization+inhibitors&doi=10.1021%2Facs.jnatprod.0c00699"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Natural and Semisynthetic Chalcones as Dual FLT3 and Microtubule Polymerization Inhibitors</span></div><div class="casAuthors">Malik, Haleema Sadia; Bilal, Aishah; Ullah, Rahim; Iqbal, Maheen; Khan, Sardraz; Ahmed, Ishtiaq; Krohn, Karsten; Saleem, Rahman Shah Zaib; Hussain, Hidayat; Faisal, Amir</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Natural Products</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3111-3121</span>CODEN:
                <span class="NLM_cas:coden">JNPRDF</span>;
        ISSN:<span class="NLM_cas:issn">0163-3864</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society-American Society of Pharmacognosy</span>)
        </div><div class="casAbstract">Activating mutations in FLT3 receptor tyrosine kinase are found in a third of acute myeloid leukemia (AML) patients and are assocd. with disease relapse and a poor prognosis.  The majority of these mutations are internal tandem duplications (ITDs) in the juxtamembrane domain of FLT3, which have been validated as a therapeutic target.  The clin. success of selective inhibitors targeting oncogenic FLT3, however, has been limited due to the acquisition of drug resistance.  Herein the identification of a dual FLT3/microtubule polymn. inhibitor, chalcone 4 (2'-allyloxy-4,4'-dimethoxychalcone), is reported through screening of 15 related chalcones for differential antiproliferative activity in leukemia cell lines dependent on FLT3-ITD (MV-4-11) or BCR-ABL (K562) oncogenes and by subsequent screening for mitotic inducers in the HCT116 cell line.  Three natural chalcones (1-3) were found to be differentially more potent toward the MV-4-11 (FLT3-ITD) cell line compared to the K562 (BCR-ABL) cell line.  Notably, the new semisynthetic chalcone 4, which is a 2'-O-allyl analog of the natural chalcone 3, was found to be more potent toward the FLT3-ITD+ cell line and inhibited FLT3 signaling in FLT3-dependent cells.  An in vitro kinase assay confirmed that chalcone 4 directly inhibited FLT3.  Moreover, chalcone 4 induced mitotic arrest in these cells and inhibited tubulin polymn. in both cellular and biochem. assays.  Treatment of MV-4-11 cells with this inhibitor for 24 and 48 h resulted in apoptotic cell death.  Finally, chalcone 4 was able to overcome TKD mutation-mediated acquired resistance to FLT3 inhibitors in a MOLM-13 cell line expressing FLT3-ITD with the D835Y mutation.  Chalcone 4 is, therefore, a promising lead for the discovery of dual-target FLT3 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTRPjcQDcXK7Vg90H21EOLACvtfcHk0lgRd3Aki4cKGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFShtbrO&md5=f6849db4f55a74fe7e54bced928c7a3a</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1021%2Facs.jnatprod.0c00699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jnatprod.0c00699%26sid%3Dliteratum%253Aachs%26aulast%3DMalik%26aufirst%3DH.%2BS.%26aulast%3DBilal%26aufirst%3DA.%26aulast%3DUllah%26aufirst%3DR.%26aulast%3DIqbal%26aufirst%3DM.%26aulast%3DKhan%26aufirst%3DS.%26aulast%3DAhmed%26aufirst%3DI.%26aulast%3DKrohn%26aufirst%3DK.%26aulast%3DSaleem%26aufirst%3DR.%2BS.%2BZ.%26aulast%3DHussain%26aufirst%3DH.%26aulast%3DFaisal%26aufirst%3DA.%26atitle%3DNatural%2520and%2520semisynthetic%2520chalcones%2520as%2520dual%2520FLT3%2520and%2520microtubule%2520polymerization%2520inhibitors%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D2020%26volume%3D83%26spage%3D3111%26epage%3D3121%26doi%3D10.1021%2Facs.jnatprod.0c00699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moise, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bîcu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farce, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubois, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghinet, A.</span></span> <span> </span><span class="NLM_article-title">Indolizine-phenothiazine hybrids as the first dual inhibitors of tubulin polymerization and farnesyltransferase with synergistic antitumor activity</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">104184</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2020.104184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.bioorg.2020.104184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=32891861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVSnu7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2020&pages=104184&author=I.+M.+Moiseauthor=E.+B%C3%AEcuauthor=A.+Farceauthor=J.+Duboisauthor=A.+Ghinet&title=Indolizine-phenothiazine+hybrids+as+the+first+dual+inhibitors+of+tubulin+polymerization+and+farnesyltransferase+with+synergistic+antitumor+activity&doi=10.1016%2Fj.bioorg.2020.104184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Indolizine-phenothiazine hybrids as the first dual inhibitors of tubulin polymerization and farnesyltransferase with synergistic antitumor activity</span></div><div class="casAuthors">Moise, Iuliana-Monica; Bicu, Elena; Farce, Amaury; Dubois, Joelle; Ghinet, Alina</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104184</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of indolizine-phenothiazine hybrids amides I [R = 8-Me, 7-OMe, 6-Br] and ketones such as II [R = H, 5-Me, 7-Me, etc.; R1 = H, Me] was obtained in a 4-step procedure.  The combination of the two heterocycles provided potent tubulin polymn. inhibitors with similar efficiency as the ref. phenstatin and (-)-desoxypodophyllotoxin.  Ketones II were also able to inhibit human farnesyltransferase (FTase) in vitro.  Interestingly, three mols. II [R = 5-Me, 7-Me, 7-OMe, R1 = H] were very effective against both considered biol. targets.  Nine indolizine-phenothiazine hybrids I [R = 8-Me, 7-OMe], II [R = H, 5-Me, 5-Me, 7-Me, 6,8-di-Me, 7-OMe, R1 = H] and bis-(5-methylindolizin-1-yl)carbonyl(10H-phenothiazin-3,7-diyl) were evaluated for their cell growth inhibition potential on the NCI-60 cancer cell lines panel.  Ketones II [R = H, 5-Me, 5-Me, 7-Me, 6,8-di-Me, 7-OMe, R1 = H] were the most active and arrested the cell growth of almost all tested cancer cells, also displayed cytotoxicity potential with GI50 values in the low nanomolar range.  The most sensitive cell lines upon treatment with indolizine-phenothiazine hybrids I and II were NCI-H522 (lung cancer), COLO-205 and HT29 (colon cancer), SF-539 (human glioblastoma), OVCAR-3 (ovarian cancer), A498 (renal cancer) and esp. MDA-MB-435 (melanoma).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXqREImYNM-rVg90H21EOLACvtfcHk0lgRd3Aki4cKGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVSnu7nK&md5=0ba0dadcda1f2b30bf0c8a3d684bf15f</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2020.104184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2020.104184%26sid%3Dliteratum%253Aachs%26aulast%3DMoise%26aufirst%3DI.%2BM.%26aulast%3DB%25C3%25AEcu%26aufirst%3DE.%26aulast%3DFarce%26aufirst%3DA.%26aulast%3DDubois%26aufirst%3DJ.%26aulast%3DGhinet%26aufirst%3DA.%26atitle%3DIndolizine-phenothiazine%2520hybrids%2520as%2520the%2520first%2520dual%2520inhibitors%2520of%2520tubulin%2520polymerization%2520and%2520farnesyltransferase%2520with%2520synergistic%2520antitumor%2520activity%26jtitle%3DBioorg.%2520Chem.%26date%3D2020%26volume%3D103%26spage%3D104184%26doi%3D10.1016%2Fj.bioorg.2020.104184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gurgis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Åkerfeldt, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemin, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johns, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chircop, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, L.</span></span> <span> </span><span class="NLM_article-title">Cytotoxic activity of the MK2 inhibitor CMPD1 in glioblastoma cells is independent of MK2</span>. <i>Cell Death Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">15028</span>, <span class="refDoi"> DOI: 10.1038/cddiscovery.2015.28</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1038%2Fcddiscovery.2015.28" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=27551460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1aisrnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=15028&author=F.+Gurgisauthor=M.+C.+%C3%85kerfeldtauthor=B.+Hengauthor=C.+Wongauthor=S.+Adamsauthor=G.+J.+Guilleminauthor=T.+G.+Johnsauthor=M.+Chircopauthor=L.+Munoz&title=Cytotoxic+activity+of+the+MK2+inhibitor+CMPD1+in+glioblastoma+cells+is+independent+of+MK2&doi=10.1038%2Fcddiscovery.2015.28"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Cytotoxic activity of the MK2 inhibitor CMPD1 in glioblastoma cells is independent of MK2</span></div><div class="casAuthors">Gurgis, F. M. S.; Akerfeldt, M. C.; Heng, B.; Wong, C.; Adams, S.; Guillemin, G. J.; Johns, T. G.; Chircop, M.; Munoz, L.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15028</span>CODEN:
                <span class="NLM_cas:coden">CDDEB5</span>;
        ISSN:<span class="NLM_cas:issn">2058-7716</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">MAPK-activated protein kinase 2 (MK2) is a checkpoint kinase involved in the DNA damage response.  MK2 inhibition enhances the efficacy of chemotherapeutic agents; however, whether MK2 inhibition alone, without concurrent chemotherapy, would attenuate survival of cancer cells has not been investigated.  CMPD1 is a widely used non-ATP competitive inhibitor that prevents MK2 phosphorylation.  We employed CMPD1 together with MK2 knock-down and ATP-competitive MK2 inhibitor III (MK2i) in a panel of glioblastoma cells to assess whether MK2 inhibition could induce cancer cell death.  While CMPD1 was effective at selective killing of cancer cells, MK2i and MK2 knock-down had no effect on viability of glioblastoma cells.  CMPD1 treatment induced a significant G2/M arrest but MK2i-treated cells were only minimally arrested at G1 phase.  Intriguingly, at doses that were cytotoxic to glioblastoma cells, CMPD1 did not inhibit phosphorylation of MK2 and of its downstream substrate Hsp27.  These results suggest that CMPD1 exhibits cytotoxic activity independently of MK2 inhibition.  Indeed, we identified tubulin as a primary target of the CMPD1 cytotoxic activity.  This study demonstrates how functional and mechanistic studies with appropriate selection of test compds., combining genetic knock-down and pharmacol. inhibition, coordinating timing and dose levels enabled us to uncover the primary target of an MK2 inhibitor commonly used in the research community.  Tubulin is emerging as one of the most common non-kinase targets for kinase inhibitors and we propose that potential tubulin-targeting activity should be assessed in preclin. pharmacol. studies of all novel kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSxasb1evR3bVg90H21EOLACvtfcHk0lgRd3Aki4cKGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1aisrnP&md5=9648be4c4664b6b7360e6c05a1714217</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1038%2Fcddiscovery.2015.28&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcddiscovery.2015.28%26sid%3Dliteratum%253Aachs%26aulast%3DGurgis%26aufirst%3DF.%26aulast%3D%25C3%2585kerfeldt%26aufirst%3DM.%2BC.%26aulast%3DHeng%26aufirst%3DB.%26aulast%3DWong%26aufirst%3DC.%26aulast%3DAdams%26aufirst%3DS.%26aulast%3DGuillemin%26aufirst%3DG.%2BJ.%26aulast%3DJohns%26aufirst%3DT.%2BG.%26aulast%3DChircop%26aufirst%3DM.%26aulast%3DMunoz%26aufirst%3DL.%26atitle%3DCytotoxic%2520activity%2520of%2520the%2520MK2%2520inhibitor%2520CMPD1%2520in%2520glioblastoma%2520cells%2520is%2520independent%2520of%2520MK2%26jtitle%3DCell%2520Death%2520Discovery%26date%3D2015%26volume%3D1%26spage%3D15028%26doi%3D10.1038%2Fcddiscovery.2015.28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tripodi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliarin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fumagalli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fusi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frattini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coccetti, P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of 1,4-diaryl-2-azetidinones as specific anticancer agents: activation of adenosine monophosphate activated protein kinase and induction of apoptosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">2112</span>– <span class="NLM_lpage">2124</span>, <span class="refDoi"> DOI: 10.1021/jm201344a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201344a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFCjsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2112-2124&author=F.+Tripodiauthor=R.+Pagliarinauthor=G.+Fumagalliauthor=A.+Bigiauthor=P.+Fusiauthor=F.+Orsiniauthor=M.+Frattiniauthor=P.+Coccetti&title=Synthesis+and+biological+evaluation+of+1%2C4-diaryl-2-azetidinones+as+specific+anticancer+agents%3A+activation+of+adenosine+monophosphate+activated+protein+kinase+and+induction+of+apoptosis&doi=10.1021%2Fjm201344a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of 1,4-diaryl-2-azetidinones as specific anticancer agents: Activation of adenosine monophosphate activated protein kinase and induction of apoptosis</span></div><div class="casAuthors">Tripodi, Farida; Pagliarin, Roberto; Fumagalli, Gabriele; Bigi, Alessandra; Fusi, Paola; Orsini, Fulvia; Frattini, Milo; Coccetti, Paola</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2112-2124</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 1,4-diaryl-2-azetidinones, e.g., I, were synthesized and evaluated for antiproliferative activity, cell cycle effects, and apoptosis induction.  Strong cytotoxicity was obsd. with the best compds. (±)-trans-20, (±)-trans-21, and enantiomers (+)-trans-20 and (+)-trans-21, which exhibited IC50 values of 3-13 nM against duodenal adenocarcinoma cells.  They induced inhibition of tubulin polymn. and subsequent G2/M arrest.  This effect was accompanied by activation of AMP-activated protein kinase, activation of caspase-3, and induction of apoptosis.  Addnl., the most potent compds. displayed antiproliferative activity against different colon cancer cell lines, opening the route to a new class of potential therapeutic agents against colon cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrunWqTtiFUv7Vg90H21EOLACvtfcHk0lguqIKmlhWpOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFCjsb8%253D&md5=728ba8ed7433a73953bc3afe6f944aeb</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1021%2Fjm201344a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201344a%26sid%3Dliteratum%253Aachs%26aulast%3DTripodi%26aufirst%3DF.%26aulast%3DPagliarin%26aufirst%3DR.%26aulast%3DFumagalli%26aufirst%3DG.%26aulast%3DBigi%26aufirst%3DA.%26aulast%3DFusi%26aufirst%3DP.%26aulast%3DOrsini%26aufirst%3DF.%26aulast%3DFrattini%26aufirst%3DM.%26aulast%3DCoccetti%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%25201%252C4-diaryl-2-azetidinones%2520as%2520specific%2520anticancer%2520agents%253A%2520activation%2520of%2520adenosine%2520monophosphate%2520activated%2520protein%2520kinase%2520and%2520induction%2520of%2520apoptosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2112%26epage%3D2124%26doi%3D10.1021%2Fjm201344a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lötsch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geisslinger, G.</span></span> <span> </span><span class="NLM_article-title">Low-dose drug combinations along molecular pathways could maximize therapeutic effectiveness while minimizing collateral adverse effects</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1001</span>– <span class="NLM_lpage">1006</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2011.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.drudis.2011.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=22016087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A280%3ADC%252BC38%252FjtVygtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=1001-1006&author=J.+L%C3%B6tschauthor=G.+Geisslinger&title=Low-dose+drug+combinations+along+molecular+pathways+could+maximize+therapeutic+effectiveness+while+minimizing+collateral+adverse+effects&doi=10.1016%2Fj.drudis.2011.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Low-dose drug combinations along molecular pathways could maximize therapeutic effectiveness while minimizing collateral adverse effects</span></div><div class="casAuthors">Lotsch Jorn; Geisslinger Gerd</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">23-24</span>),
    <span class="NLM_cas:pages">1001-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Increasing knowledge of molecular signaling processes has enabled the identification of drug targets that synergistically address multifactorial symptoms along several contributing pathways.  The idea behind 'polypills' is that minor doses of pharmacodynamically interacting drugs would selectively achieve intended clinical effects.  Analogously, monofactorial symptoms could be addressed vertically along their main pathway.  Clinical selectivity follows from successive incomplete inhibitions of the pathological pathway at several steps.  Here, we discuss and exemplify of how successive inhibitions in the prostaglandin E2 (PGE(2)) signaling pathway could achieve anti-inflammatory and analgesic effects while preserving physiological PGE(2) signaling in organs of major toxicity.  Intentionally using intelligent low-dose drug combinations might provide an innovative therapeutic concept that directs combined small-drug effects towards a large, selective clinical effect with minor collateral damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQRu7M3C_0-j-dfST00W0BcfW6udTcc2ebVej8LGnvViLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252FjtVygtg%253D%253D&md5=f88337f88016a3736e13e493dc064089</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B6tsch%26aufirst%3DJ.%26aulast%3DGeisslinger%26aufirst%3DG.%26atitle%3DLow-dose%2520drug%2520combinations%2520along%2520molecular%2520pathways%2520could%2520maximize%2520therapeutic%2520effectiveness%2520while%2520minimizing%2520collateral%2520adverse%2520effects%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26spage%3D1001%26epage%3D1006%26doi%3D10.1016%2Fj.drudis.2011.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doak, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobritzsch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kihlberg, J.</span></span> <span> </span><span class="NLM_article-title">How beyond rule of 5 drugs and clinical candidates bind to their targets</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2312</span>– <span class="NLM_lpage">2327</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01286</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Cgu77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2312-2327&author=B.+C.+Doakauthor=J.+Zhengauthor=D.+Dobritzschauthor=J.+Kihlberg&title=How+beyond+rule+of+5+drugs+and+clinical+candidates+bind+to+their+targets&doi=10.1021%2Facs.jmedchem.5b01286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets</span></div><div class="casAuthors">Doak, Bradley C.; Zheng, Jie; Dobritzsch, Doreen; Kihlberg, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2312-2327</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To improve discovery of drugs for difficult targets, the opportunities of chem. space beyond the rule of 5 (bRo5) were examd. by retrospective anal. of a comprehensive set of structures for complexes between drugs and clin. candidates and their targets.  The anal. illustrates the potential of compds. far beyond rule of 5 space to modulate novel and difficult target classes that have large, flat, and groove-shaped binding sites.  However, ligand efficiencies are significantly reduced for flat- and groove-shape binding sites, suggesting that adjustments of how to use such metrics are required.  Ligands bRo5 appear to benefit from an appropriate balance between rigidity and flexibility to bind with sufficient affinity to their targets, with macrocycles and nonmacrocycles being found to have similar flexibility.  However, macrocycles were more disk- and spherelike, which may contribute to their superior binding to flat sites, while rigidification of nonmacrocycles lead to rodlike ligands that bind well to groove-shaped binding sites.  These insights should contribute to altering perceptions of what targets are considered "druggable" and provide support for drug design in beyond rule of 5 space.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZD-h9VodiPLVg90H21EOLACvtfcHk0ljkTI9Rg8D1kQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Cgu77F&md5=a417b605d1a3ffbc7ee84706401f01f4</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01286%26sid%3Dliteratum%253Aachs%26aulast%3DDoak%26aufirst%3DB.%2BC.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DDobritzsch%26aufirst%3DD.%26aulast%3DKihlberg%26aufirst%3DJ.%26atitle%3DHow%2520beyond%2520rule%2520of%25205%2520drugs%2520and%2520clinical%2520candidates%2520bind%2520to%2520their%2520targets%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2312%26epage%3D2327%26doi%3D10.1021%2Facs.jmedchem.5b01286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">The physicochemical challenges of designing multiple ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">4961</span>– <span class="NLM_lpage">4970</span>, <span class="refDoi"> DOI: 10.1021/jm0603015</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0603015" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFejtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4961-4970&author=R.+Morphyauthor=Z.+Rankovic&title=The+physicochemical+challenges+of+designing+multiple+ligands&doi=10.1021%2Fjm0603015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">The Physicochemical Challenges of Designing Multiple Ligands</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4961-4970</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Compds. designed to bind more than one target can provide a therapeutic benefit relative to highly target-selective ligands.  The physicochem. properties of designed multiple ligands were found to be less druglike than those for preclin. compds. in general.  These properties are controlled by the superfamily to which the targets belong and the lead discovery strategy that was followed.  The properties for peptide G-protein-coupled receptor (GPCR) ligands were the least favorable for oral delivery, whereas transporter, monoamine GPCR, and oxidase ligands were the most druglike.  The lead discovery strategy, framework combination or screening, exerts a profound influence on the property values.  Combining the frameworks from two selective ligands often results in large, complex dual ligands, but druglike ligands can be achieved if the degree of framework overlap is maximized and the size of the selective ligands minimized.  For some target combinations, a screening approach may provide a route to smaller, less complex leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonGHbXyxgv4LVg90H21EOLACvtfcHk0ljkTI9Rg8D1kQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFejtL4%253D&md5=c7a227848516d0aa58ed037a582943fe</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1021%2Fjm0603015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0603015%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DThe%2520physicochemical%2520challenges%2520of%2520designing%2520multiple%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4961%26epage%3D4970%26doi%3D10.1021%2Fjm0603015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engkvist, O.</span>; <span class="NLM_string-name">Chen, H.</span>; <span class="NLM_string-name">Bauer, U.</span></span> <i>Merged multiple ligands</i>; <span class="NLM_publisher-name">Wiley-VCH Verlag</span>, <span class="NLM_year">2017</span>; pp  <span class="NLM_fpage">247</span>– <span class="NLM_lpage">274</span>, <span class="refDoi"> DOI: 10.1002/9783527674381.ch9</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1002%2F9783527674381.ch9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=247-274&author=O.+Engkvist&author=H.+Chen&author=U.+Bauer&title=Merged+multiple+ligands"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1002%2F9783527674381.ch9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783527674381.ch9%26sid%3Dliteratum%253Aachs%26aulast%3DEngkvist%26aufirst%3DO.%26btitle%3DMerged%2520multiple%2520ligands%26pub%3DWiley-VCH%2520Verlag%26date%3D2017%26spage%3D247%26epage%3D274%26doi%3D10.1002%2F9783527674381.ch9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, A. M.</span></span> <span> </span><span class="NLM_article-title">Artificial intelligence in drug design-the storm before the calm?</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1150</span>– <span class="NLM_lpage">1152</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00500</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00500" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVKktL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1150-1152&author=A.+M.+Jordan&title=Artificial+intelligence+in+drug+design-the+storm+before+the+calm%3F&doi=10.1021%2Facsmedchemlett.8b00500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Artificial Intelligence in Drug Design-The Storm Before the Calm?</span></div><div class="casAuthors">Jordan, Allan M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1150-1152</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Artificial intelligence in drug design in experiencing a wave of excitement not seen since the emergence of computational chem. in the late 1980s and early 1990s.  Apparently failing to learn the lessons of recent history, we are promised imminent and pervasive solns. to the ills of drug design and significant increases in productivity as we seek to deliver innovative new therapeutics.  However, do significant issues remain to be answered before AI enters the day-to-day toolbox of the practicing medicinal chemist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBn1rYzHOJi7Vg90H21EOLACvtfcHk0liWoWd6fWqXNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVKktL7I&md5=b0a7a61b5046a024891b034f413fe894</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00500%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DA.%2BM.%26atitle%3DArtificial%2520intelligence%2520in%2520drug%2520design-the%2520storm%2520before%2520the%2520calm%253F%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D1150%26epage%3D1152%26doi%3D10.1021%2Facsmedchemlett.8b00500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hessler, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baringhaus, K. H.</span></span> <span> </span><span class="NLM_article-title">Artificial intelligence in drug design</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2520</span>, <span class="refDoi"> DOI: 10.3390/molecules23102520</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.3390%2Fmolecules23102520" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1ygurfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=2520&author=G.+Hesslerauthor=K.+H.+Baringhaus&title=Artificial+intelligence+in+drug+design&doi=10.3390%2Fmolecules23102520"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Artificial intelligence in drug design</span></div><div class="casAuthors">Hessler, Gerhard; Baringhaus, Karl-Heinz</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2520/1-2520/13</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Artificial Intelligence (AI) plays a pivotal role in drug discovery.  In particular artificial neural networks such as deep neural networks or recurrent networks drive this area.  Numerous applications in property or activity predictions like physicochem. and ADMET properties have recently appeared and underpin the strength of this technol. in quant. structure-property relationships (QSPR) or quant. structure-activity relationships (QSAR).  Artificial intelligence in de novo design drives the generation of meaningful new biol. active mols. towards desired properties.  Several examples establish the strength of artificial intelligence in this field.  Combination with synthesis planning and ease of synthesis is feasible and more and more automated drug discovery by computers is expected in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO50YM96eg57Vg90H21EOLACvtfcHk0lh_YwL0hkexVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1ygurfE&md5=7f01179fe4fdd97570aedcd1ad817c7f</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.3390%2Fmolecules23102520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules23102520%26sid%3Dliteratum%253Aachs%26aulast%3DHessler%26aufirst%3DG.%26aulast%3DBaringhaus%26aufirst%3DK.%2BH.%26atitle%3DArtificial%2520intelligence%2520in%2520drug%2520design%26jtitle%3DMolecules%26date%3D2018%26volume%3D23%26spage%3D2520%26doi%3D10.3390%2Fmolecules23102520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Du, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. H.</span></span> <span> </span><span class="NLM_article-title">New techniques and strategies in drug discovery</span>. <i>Chin. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1695</span>– <span class="NLM_lpage">1708</span>, <span class="refDoi"> DOI: 10.1016/j.cclet.2020.03.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.cclet.2020.03.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsVaqs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2020&pages=1695-1708&author=J.+T.+Duauthor=J.+Guoauthor=D.+W.+Kangauthor=Z.+H.+Liauthor=G.+Wangauthor=J.+B.+Wuauthor=Z.+Zhangauthor=H.+Fangauthor=X.+B.+Houauthor=Z.+J.+Huangauthor=G.+B.+Liauthor=X.+Y.+Luauthor=X.+Y.+Liuauthor=L.+Ouyangauthor=L.+Raoauthor=P.+Zhanauthor=X.+J.+Zhangauthor=Y.+H.+Zhang&title=New+techniques+and+strategies+in+drug+discovery&doi=10.1016%2Fj.cclet.2020.03.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">New techniques and strategies in drug discovery</span></div><div class="casAuthors">Du, Jintong; Guo, Jing; Kang, Dongwei; Li, Zhihong; Wang, Guan; Wu, Jianbing; Zhang, Zhen; Fang, Hao; Hou, Xuben; Huang, Zhangjian; Li, Guobo; Lu, Xiaoyun; Liu, Xinyong; Ouyang, Liang; Rao, Li; Zhan, Peng; Zhang, Xiaojin; Zhang, Yihua</div><div class="citationInfo"><span class="NLM_cas:title">Chinese Chemical Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1695-1708</span>CODEN:
                <span class="NLM_cas:coden">CCLEE7</span>;
        ISSN:<span class="NLM_cas:issn">1001-8417</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review. Perspective.  Great success has been witnessed in last decades, some new techniques and strategies have been widely used in drug discovery.  In this roadmap, several representative techniques and strategies are highlighted to show recent advances in this filed.  (A) A DOX protocol has been developed for accurate protein-ligand binding structure prediction, in which first principle method was used to rank the binding poses.  Validation against crystal structures have found that DOX prediction achieved an impressive success rate of 99%, indicating significant improvement over mol. docking method.  (B) Virtual target profiling is a compd.-centric strategy enabling a parallel implementation of interrogating compds. against various targets in a single screen, which has been used in hit/lead identification, drug repositioning, and mechanism-of-action studies.  Current and emerging methods for virtual target profiling are briefly summarized herein.  (C) Research on targeted autophagy to treat diseases has received encouraging progress.  However, due to the complexity of autophagy and disease, exptl. and in silico methods should be performed synergistically for the entire process.  This part focuses on in silico methods in autophagy research to promote their use in medicinal research.  (D) Histone deacetylases (HDACs) play important roles in various biol. functions through the deacetylation of lysine residues.  Recent studies demonstrated that HDACs, which possess low deacetylase activities, exhibited more efficient defatty-acylase activities.  Here, we review the defatty-acylase activity of HDACs and describe examples for the design of isoform selective HDAC inhibitor.  (E) The FDA approval of three kinase allosteric inhibitors and some others entering clin. study has spurred considerable interests in this targeted drug discovery area.  (F) Recent advances are reviewed in structure-based design of novel antiviral agents to combat drug resistance.  (G) Since nitric oxide (NO) exerts anticancer activity depending on its concn., optimal levels of NO in cancer cells is desirable.  In this minireview, we briefly describe recent advances in the research of NO-based anticancer agents by our group and present some opinions on the future development of these agents.  (H) The field of photoactivation strategies have been extensively developed for controlling chem. and biol. processes with light.  This review will summarize and provide insight into recent research advances in the understanding of photoactivatable mols. including photoactivatable caged prodrugs and photoswitchable mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp60y_k9ZgfoLVg90H21EOLACvtfcHk0lh_YwL0hkexVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsVaqs7s%253D&md5=1b37a0ea77ee3e77dfd974ebf16f3e24</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1016%2Fj.cclet.2020.03.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cclet.2020.03.028%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DJ.%2BT.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DD.%2BW.%26aulast%3DLi%26aufirst%3DZ.%2BH.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DWu%26aufirst%3DJ.%2BB.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DFang%26aufirst%3DH.%26aulast%3DHou%26aufirst%3DX.%2BB.%26aulast%3DHuang%26aufirst%3DZ.%2BJ.%26aulast%3DLi%26aufirst%3DG.%2BB.%26aulast%3DLu%26aufirst%3DX.%2BY.%26aulast%3DLiu%26aufirst%3DX.%2BY.%26aulast%3DOuyang%26aufirst%3DL.%26aulast%3DRao%26aufirst%3DL.%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DX.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%2BH.%26atitle%3DNew%2520techniques%2520and%2520strategies%2520in%2520drug%2520discovery%26jtitle%3DChin.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D31%26spage%3D1695%26epage%3D1708%26doi%3D10.1016%2Fj.cclet.2020.03.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abola, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span> <span> </span><span class="NLM_article-title">Serial crystallography for structure-based drug discovery</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">830</span>– <span class="NLM_lpage">839</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2020.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=10.1016%2Fj.tips.2020.08.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=32950259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVeqtL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2020&pages=830-839&author=L.+Zhuauthor=X.+Chenauthor=E.+E.+Abolaauthor=L.+Jingauthor=W.+Liu&title=Serial+crystallography+for+structure-based+drug+discovery&doi=10.1016%2Fj.tips.2020.08.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Serial Crystallography for Structure-Based Drug Discovery</span></div><div class="casAuthors">Zhu, Lan; Chen, Xiaoyu; Abola, Enrique E.; Jing, Liang; Liu, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">830-839</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Rational drug discovery has greatly accelerated the development of safer and more efficacious therapeutics, assisted significantly by insights from exptl. detd. 3D structures of ligands in complex with their targets.  Serial crystallog. (SX) with X-ray free-electron lasers has enabled structural detd. using micrometer- or nanometer-size crystals.  This technol. applied in the past decade to solve structures of notoriously difficult-to-study drug targets at room temps., has now been adapted for use in synchrotron radiation facilities.  Ultrashort time scales allow time-resolved characterization of dynamic structural changes and pave the road to study the mol. mechanisms by 'mol. movie'.  This article summarizes the latest progress in SX technol. and deliberates its demanding applications in future structure-based drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohfNLnXuV617Vg90H21EOLACvtfcHk0lh-GPRs7fLBEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVeqtL%252FE&md5=8b180cb643b51b35fb929aa834bb547b</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2020.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2020.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DAbola%26aufirst%3DE.%2BE.%26aulast%3DJing%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26atitle%3DSerial%2520crystallography%2520for%2520structure-based%2520drug%2520discovery%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2020%26volume%3D41%26spage%3D830%26epage%3D839%26doi%3D10.1016%2Fj.tips.2020.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5M7E" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5M7E','PDB','5M7E'); return false;">PDB: 5M7E</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3SD5" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3SD5','PDB','3SD5'); return false;">PDB: 3SD5</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OV7" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OV7','PDB','5OV7'); return false;">PDB: 5OV7</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5J18" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5J18','PDB','5J18'); return false;">PDB: 5J18</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5J2R" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5J2R','PDB','5J2R'); return false;">PDB: 5J2R</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6KNZ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6KNZ','PDB','6KNZ'); return false;">PDB: 6KNZ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CB4" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CB4','PDB','5CB4'); return false;">PDB: 5CB4</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3RHK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3RHK','PDB','3RHK'); return false;">PDB: 3RHK</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00100&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-12%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00100%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00100" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                14MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a98966ea13dd7","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
